"Molecule ChEMBL ID";"Molecule Name";"Molecule Max Phase";"Molecular Weight";"#RO5 Violations";"AlogP";"Compound Key";"Smiles";"Standard Type";"Standard Relation";"Standard Value";"Standard Units";"pChEMBL Value";"Data Validity Comment";"Comment";"Uo Units";"Ligand Efficiency BEI";"Ligand Efficiency LE";"Ligand Efficiency LLE";"Ligand Efficiency SEI";"Potential Duplicate";"Assay ChEMBL ID";"Assay Description";"Assay Type";"BAO Format ID";"BAO Label";"Assay Organism";"Assay Tissue ChEMBL ID";"Assay Tissue Name";"Assay Cell Type";"Assay Subcellular Fraction";"Assay Parameters";"Assay Variant Accession";"Assay Variant Mutation";"Target ChEMBL ID";"Target Name";"Target Organism";"Target Type";"Document ChEMBL ID";"Source ID";"Source Description";"Document Journal";"Document Year";"Cell ChEMBL ID";"Properties";"Action Type";"Standard Text Value"
"CHEMBL2348984";"";"None";"355.32";"0";"4.55";"51";"FC(F)(F)c1cccc(Nc2ccc3nnc(-c4ccccc4)n3n2)c1";"IC50";"'>'";"100000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL2351468";"Inhibition of LRRK2 G2019S mutant (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348982";"";"None";"450.47";"1";"5.20";"49";"CCOC(=O)c1cc(Sc2cccc(C(F)(F)F)c2)nn2c(-c3cccs3)nnc12";"IC50";"'>'";"100000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL2351468";"Inhibition of LRRK2 G2019S mutant (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348967";"";"None";"395.39";"0";"4.30";"33";"FC(F)(F)Oc1cccc(Sc2ccc3nnc(-c4cncs4)n3n2)c1";"IC50";"'='";"67.0";"nM";"7.17";"";"";"UO_0000065";"18.14";"0.38";"2.87";"11.00";"0";"CHEMBL2351468";"Inhibition of LRRK2 G2019S mutant (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348962";"";"None";"390.29";"0";"4.16";"28";"Brc1cccc(Sc2ccc3nnc(-c4cncs4)n3n2)c1";"IC50";"'='";"6.0";"nM";"8.22";"";"";"UO_0000065";"21.07";"0.51";"4.06";"14.69";"0";"CHEMBL2351468";"Inhibition of LRRK2 G2019S mutant (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348956";"";"None";"336.34";"0";"4.17";"21";"FC(F)(F)c1cccc(Sc2ccc3nnc(C4CC4)n3n2)c1";"IC50";"'='";"309.0";"nM";"6.51";"";"";"UO_0000065";"19.36";"0.39";"2.34";"15.11";"0";"CHEMBL2351468";"Inhibition of LRRK2 G2019S mutant (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348955";"";"None";"390.37";"1";"5.10";"20";"Fc1ccc(-c2nnc3ccc(Sc4cccc(C(F)(F)F)c4)nn23)cc1";"IC50";"'='";"179.0";"nM";"6.75";"";"";"UO_0000065";"17.28";"0.34";"1.65";"15.66";"0";"CHEMBL2351468";"Inhibition of LRRK2 G2019S mutant (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348943";"";"None";"319.41";"0";"3.11";"8";"COC(=O)C(C)Sc1ccc2ncc(-c3cccs3)n2n1";"IC50";"'='";"10.0";"nM";"8.00";"";"";"UO_0000065";"25.05";"0.52";"4.89";"14.16";"0";"CHEMBL2351468";"Inhibition of LRRK2 G2019S mutant (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348983";"";"None";"356.31";"0";"4.60";"50";"FC(F)(F)c1cccc(Oc2ccc3nnc(-c4ccccc4)n3n2)c1";"IC50";"'>'";"4000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL2351467";"Inhibition of wild type LRRK2 (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348962";"";"None";"390.29";"0";"4.16";"28";"Brc1cccc(Sc2ccc3nnc(-c4cncs4)n3n2)c1";"IC50";"'='";"32.0";"nM";"7.50";"";"";"UO_0000065";"19.20";"0.47";"3.33";"13.39";"0";"CHEMBL2351467";"Inhibition of wild type LRRK2 (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348961";"";"None";"372.38";"0";"4.96";"27";"FC(F)(F)c1ccccc1Sc1ccc2nnc(-c3ccccc3)n2n1";"IC50";"'='";"3168.0";"nM";"5.50";"";"";"UO_0000065";"14.77";"0.29";"0.54";"12.77";"0";"CHEMBL2351467";"Inhibition of wild type LRRK2 (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348960";"";"None";"372.38";"0";"4.96";"26";"FC(F)(F)c1ccc(Sc2ccc3nnc(-c4ccccc4)n3n2)cc1";"IC50";"'='";"5897.0";"nM";"5.23";"";"";"UO_0000065";"14.04";"0.27";"0.27";"12.14";"0";"CHEMBL2351467";"Inhibition of wild type LRRK2 (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348942";"";"None";"377.42";"1";"5.63";"7";"FC(F)(F)c1cccc(Sc2cn3c(-c4cccs4)cnc3cn2)c1";"IC50";"'='";"3400.0";"nM";"5.47";"";"";"UO_0000065";"14.49";"0.30";"-0.16";"18.11";"0";"CHEMBL2351467";"Inhibition of wild type LRRK2 (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL3326139";"";"None";"350.38";"0";"2.13";"27";"COc1ccc(OC)c(Cc2ccc3nnc(-c4cnn(C)c4)n3n2)c1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL3367451";"Inhibition of phosphorylation at S935 residue of wild-type full-length LRRK2 kinase (unknown origin) expressed in HEK 293 cells after 90 mins by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"CHEMBL3307715";"";"";""
"CHEMBL3326134";"";"None";"377.26";"0";"3.98";"21";"Cn1cc(-c2nnc3ccc(Sc4cc(Cl)ccc4Cl)nn23)cn1";"IC50";"'='";"1800.0";"nM";"5.75";"";"";"UO_0000065";"15.23";"0.33";"1.76";"9.43";"0";"CHEMBL3367451";"Inhibition of phosphorylation at S935 residue of wild-type full-length LRRK2 kinase (unknown origin) expressed in HEK 293 cells after 90 mins by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"CHEMBL3307715";"";"";""
"CHEMBL3326130";"";"None";"334.40";"0";"3.95";"17";"COc1ccccc1Sc1ccc2nnc(-c3ccccc3)n2n1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL3367451";"Inhibition of phosphorylation at S935 residue of wild-type full-length LRRK2 kinase (unknown origin) expressed in HEK 293 cells after 90 mins by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"CHEMBL3307715";"";"";""
"CHEMBL3326145";"";"None";"382.45";"0";"3.00";"33";"COc1ccc(OC)c(Sc2cc(C)c3nnc(-c4cnn(C)c4)n3n2)c1";"IC50";"'='";"32000.0";"nM";"4.50";"";"";"UO_0000065";"11.75";"0.23";"1.49";"5.66";"0";"CHEMBL3367450";"Inhibition of GST-tagged truncated LRRK2 (unknown origin) using fluorescein-labeled peptide LRRKtide as substrate by LANTHA screen assay in presence of 1 mM ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL3326140";"";"None";"366.38";"0";"1.62";"28";"COc1ccc(OC)c(C(O)c2ccc3nnc(-c4cnn(C)c4)n3n2)c1";"IC50";"'='";"9124.0";"nM";"5.04";"";"";"UO_0000065";"13.76";"0.25";"3.42";"5.06";"0";"CHEMBL3367450";"Inhibition of GST-tagged truncated LRRK2 (unknown origin) using fluorescein-labeled peptide LRRKtide as substrate by LANTHA screen assay in presence of 1 mM ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL3326135";"";"None";"380.48";"0";"3.81";"22";"COc1ccc(C(C)C)cc1Sc1ccc2nnc(-c3cnn(C)c3)n2n1";"IC50";"'='";"1350.0";"nM";"5.87";"";"";"UO_0000065";"15.43";"0.30";"2.06";"8.37";"0";"CHEMBL3367450";"Inhibition of GST-tagged truncated LRRK2 (unknown origin) using fluorescein-labeled peptide LRRKtide as substrate by LANTHA screen assay in presence of 1 mM ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL3326128";"";"None";"368.42";"0";"2.69";"15";"COc1ccc(OC)c(Sc2ccc3nnc(-c4cnn(C)c4)n3n2)c1";"IC50";"'='";"64.0";"nM";"7.19";"";"";"UO_0000065";"19.53";"0.38";"4.50";"9.06";"0";"CHEMBL3367450";"Inhibition of GST-tagged truncated LRRK2 (unknown origin) using fluorescein-labeled peptide LRRKtide as substrate by LANTHA screen assay in presence of 1 mM ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL3326118";"";"None";"366.41";"0";"2.75";"5";"COc1ccc(OC)c(Sc2ccc3nnc(-c4cnccn4)n3n2)c1";"IC50";"'='";"880.0";"nM";"6.06";"";"";"UO_0000065";"16.53";"0.32";"3.31";"6.93";"0";"CHEMBL3367450";"Inhibition of GST-tagged truncated LRRK2 (unknown origin) using fluorescein-labeled peptide LRRKtide as substrate by LANTHA screen assay in presence of 1 mM ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL3326117";"";"None";"365.42";"0";"3.35";"4";"COc1ccc(OC)c(Sc2ccc3nnc(-c4ccncc4)n3n2)c1";"IC50";"'='";"349.0";"nM";"6.46";"";"";"UO_0000065";"17.67";"0.34";"3.11";"8.68";"0";"CHEMBL3367450";"Inhibition of GST-tagged truncated LRRK2 (unknown origin) using fluorescein-labeled peptide LRRKtide as substrate by LANTHA screen assay in presence of 1 mM ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL3326149";"";"None";"368.42";"0";"2.72";"37";"COc1ccc(OC)c(Sc2ccc3nnn(-c4cnn(C)c4)c3n2)c1";"IC50";"'='";"5240.0";"nM";"5.28";"";"";"UO_0000065";"14.33";"0.28";"2.56";"6.61";"0";"CHEMBL3367451";"Inhibition of phosphorylation at S935 residue of wild-type full-length LRRK2 kinase (unknown origin) expressed in HEK 293 cells after 90 mins by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"CHEMBL3307715";"";"";""
"CHEMBL3326153";"";"None";"381.46";"0";"3.61";"41";"COc1ccc(OC)c(Sc2ccn3nc(C)c(-c4cnn(C)c4)c3n2)c1";"IC50";"'='";"759.0";"nM";"6.12";"";"";"UO_0000065";"16.04";"0.31";"2.51";"9.21";"0";"CHEMBL3367451";"Inhibition of phosphorylation at S935 residue of wild-type full-length LRRK2 kinase (unknown origin) expressed in HEK 293 cells after 90 mins by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"CHEMBL3307715";"";"";""
"CHEMBL2347817";"";"None";"391.50";"0";"4.39";"31";"C[C@@H](Nc1c(C#N)cnc2cc(-c3ccc(S(C)(=O)=O)cc3)ccc12)C1CC1";"IC50";"'='";"39.0";"nM";"7.41";"";"";"UO_0000065";"18.92";"0.36";"3.02";"8.94";"0";"CHEMBL2352557";"Inhibition of GST-tagged LRRK2 G2019S mutant (970-2527 amino acids) (unknown origin) assessed as inhibition of LRRKtide phosphorylation by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346515";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2347804";"";"None";"420.54";"0";"4.38";"18";"CC(C)Nc1c(C#N)cnc2cc(-c3ccc(S(=O)(=O)N4CCCC4)cc3)ccc12";"IC50";"'='";"19.0";"nM";"7.72";"";"";"UO_0000065";"18.36";"0.35";"3.34";"8.97";"0";"CHEMBL2352557";"Inhibition of GST-tagged LRRK2 G2019S mutant (970-2527 amino acids) (unknown origin) assessed as inhibition of LRRKtide phosphorylation by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346515";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2347821";"";"None";"408.53";"0";"3.48";"4";"CC(C)Nc1c(C2=NCCN2)cnc2cc(-c3ccc(S(C)(=O)=O)cc3)ccc12";"IC50";"'='";"88597.0";"nM";"4.05";"";"";"UO_0000065";"9.92";"0.19";"0.57";"4.86";"0";"CHEMBL2352557";"Inhibition of GST-tagged LRRK2 G2019S mutant (970-2527 amino acids) (unknown origin) assessed as inhibition of LRRKtide phosphorylation by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346515";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2347813";"";"None";"406.51";"0";"2.93";"27";"CN1CCN(c2c(C#N)cnc3cc(-c4ccc(S(C)(=O)=O)cc4)ccc23)CC1";"IC50";"'='";"281.0";"nM";"6.55";"";"";"UO_0000065";"16.12";"0.31";"3.62";"8.48";"0";"CHEMBL2352558";"Inhibition of wild type GST-tagged LRRK2 (970-2527 amino acids)(unknown origin) assessed as inhibition of LRRKtide phosphorylation by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346515";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2347812";"";"None";"391.50";"0";"4.17";"26";"CS(=O)(=O)c1ccc(-c2ccc3c(N4CCCCC4)c(C#N)cnc3c2)cc1";"IC50";"'='";"52.0";"nM";"7.28";"";"";"UO_0000065";"18.61";"0.36";"3.11";"9.84";"0";"CHEMBL2352558";"Inhibition of wild type GST-tagged LRRK2 (970-2527 amino acids)(unknown origin) assessed as inhibition of LRRKtide phosphorylation by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346515";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2347823";"";"None";"365.46";"0";"4.00";"6";"CC(C)Nc1c(C#N)cnc2cc(-c3ccc(S(C)(=O)=O)cc3)ccc12";"IC50";"'='";"31.0";"nM";"7.51";"";"";"UO_0000065";"20.55";"0.39";"3.51";"9.06";"0";"CHEMBL2352558";"Inhibition of wild type GST-tagged LRRK2 (970-2527 amino acids)(unknown origin) assessed as inhibition of LRRKtide phosphorylation by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346515";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2347819";"";"None";"382.49";"0";"4.33";"2";"CC(=O)c1cnc2cc(-c3ccc(S(C)(=O)=O)cc3)ccc2c1NC(C)C";"IC50";"'='";"66.0";"nM";"7.18";"";"";"UO_0000065";"18.77";"0.36";"2.85";"9.43";"0";"CHEMBL2352558";"Inhibition of wild type GST-tagged LRRK2 (970-2527 amino acids)(unknown origin) assessed as inhibition of LRRKtide phosphorylation by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346515";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2349090";"";"None";"379.35";"0";"4.47";"53";"N#CC(c1cccc(C(F)(F)F)c1)c1ccc2nnc(-c3ccccc3)n2n1";"IC50";"'='";"26000.0";"nM";"4.58";"";"";"UO_0000065";"12.09";"0.22";"0.12";"6.86";"0";"CHEMBL2351467";"Inhibition of wild type LRRK2 (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348967";"";"None";"395.39";"0";"4.30";"33";"FC(F)(F)Oc1cccc(Sc2ccc3nnc(-c4cncs4)n3n2)c1";"IC50";"'='";"281.0";"nM";"6.55";"";"";"UO_0000065";"16.57";"0.34";"2.25";"10.05";"0";"CHEMBL2351467";"Inhibition of wild type LRRK2 (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348964";"";"None";"329.38";"0";"3.54";"30";"Fc1cccc(Sc2ccc3nnc(-c4cncs4)n3n2)c1";"IC50";"'='";"169.0";"nM";"6.77";"";"";"UO_0000065";"20.56";"0.42";"3.23";"12.10";"0";"CHEMBL2351467";"Inhibition of wild type LRRK2 (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348946";"";"None";"379.39";"0";"4.42";"11";"FC(F)(F)c1cccc(Sc2ccc3nnc(-c4nccs4)n3n2)c1";"IC50";"'='";"88.0";"nM";"7.06";"";"";"UO_0000065";"18.60";"0.39";"2.64";"12.61";"0";"CHEMBL2351467";"Inhibition of wild type LRRK2 (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL4567108";"";"None";"225.25";"0";"2.40";"5";"Cc1n[nH]c2ccnc(Nc3cccnc3)c12";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL4331900";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant catalytic domain (970 to 2527 residues) expressed in baculovirus expression system by radiometric assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330096";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4098877";"MLi-2";"None";"379.46";"0";"3.56";"1; MLi-2";"C[C@@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@H](C)O1";"IC50";"'='";"0.76";"nM";"9.12";"";"";"UO_0000065";"24.03";"0.44";"5.56";"11.97";"0";"CHEMBL4010109";"Inhibition of recombinant human GST-tagged LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus using fluorescein-ERM as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007454";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL3928102";"";"None";"339.40";"0";"2.64";"24";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCOCC4)ncn3)c2c1";"IC50";"'='";"96.0";"nM";"7.02";"";"";"UO_0000065";"20.68";"0.38";"4.38";"9.21";"1";"CHEMBL4010117";"Inhibition of recombinant human GST-tagged LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus using fluorescein-ERM as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr in presence of 5 mM ATP by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007454";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL2012582";"";"None";"570.70";"1";"3.44";"LRRK2IN1";"COc1cc(C(=O)N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2C";"IC50";"'='";"6.0";"nM";"8.22";"";"";"UO_0000065";"14.41";"0.27";"4.78";"8.44";"1";"CHEMBL2398946";"Inhibition of GST-tagged LRRK2 (1326 to 2527 amino acids) G2019S mutant (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2396520";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL3326135";"";"None";"380.48";"0";"3.81";"22";"COc1ccc(C(C)C)cc1Sc1ccc2nnc(-c3cnn(C)c3)n2n1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL3367451";"Inhibition of phosphorylation at S935 residue of wild-type full-length LRRK2 kinase (unknown origin) expressed in HEK 293 cells after 90 mins by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"CHEMBL3307715";"";"";""
"CHEMBL3326124";"";"None";"355.38";"0";"2.95";"11";"COc1ccc(OC)c(Sc2ccc3nnc(-c4ccon4)n3n2)c1";"IC50";"'='";"4330.0";"nM";"5.36";"";"";"UO_0000065";"15.09";"0.29";"2.41";"6.12";"0";"CHEMBL3367451";"Inhibition of phosphorylation at S935 residue of wild-type full-length LRRK2 kinase (unknown origin) expressed in HEK 293 cells after 90 mins by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"CHEMBL3307715";"";"";""
"CHEMBL3326150";"";"None";"367.43";"0";"3.32";"38";"COc1ccc(OC)c(Sc2ccc3ncn(-c4cnn(C)c4)c3n2)c1";"IC50";"'='";"661.0";"nM";"6.18";"";"";"UO_0000065";"16.82";"0.32";"2.86";"9.22";"0";"CHEMBL3367450";"Inhibition of GST-tagged truncated LRRK2 (unknown origin) using fluorescein-labeled peptide LRRKtide as substrate by LANTHA screen assay in presence of 1 mM ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL3326144";"";"None";"382.45";"0";"3.00";"32";"COc1ccc(OC)c(Sc2nn3c(-c4cnn(C)c4)nnc3cc2C)c1";"IC50";"'='";"32000.0";"nM";"4.50";"";"";"UO_0000065";"11.75";"0.23";"1.49";"5.66";"0";"CHEMBL3367450";"Inhibition of GST-tagged truncated LRRK2 (unknown origin) using fluorescein-labeled peptide LRRKtide as substrate by LANTHA screen assay in presence of 1 mM ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL3326143";"";"None";"365.40";"0";"2.31";"31";"COc1ccc(OC)c(N(C)c2ccc3nnc(-c4cnn(C)c4)n3n2)c1";"IC50";"'='";"21858.0";"nM";"4.66";"";"";"UO_0000065";"12.75";"0.24";"2.35";"5.64";"0";"CHEMBL3367450";"Inhibition of GST-tagged truncated LRRK2 (unknown origin) using fluorescein-labeled peptide LRRKtide as substrate by LANTHA screen assay in presence of 1 mM ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL3326127";"";"None";"368.42";"0";"2.69";"14";"COc1ccc(OC)c(Sc2ccc3nnc(-c4ccn(C)n4)n3n2)c1";"IC50";"'='";"224.0";"nM";"6.65";"";"";"UO_0000065";"18.05";"0.35";"3.96";"8.38";"0";"CHEMBL3367450";"Inhibition of GST-tagged truncated LRRK2 (unknown origin) using fluorescein-labeled peptide LRRKtide as substrate by LANTHA screen assay in presence of 1 mM ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL3975665";"";"None";"389.42";"0";"2.32";"BDBM239479";"COc1cncc(-c2ccc3[nH]nc(-c4cc(N5CCOCC5)ncn4)c3c2)n1";"IC50";"'='";"18.3";"nM";"7.74";"";"417944";"UO_0000065";"19.87";"0.36";"5.42";"7.59";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3922699";"";"None";"405.46";"0";"2.37";"BDBM239484";"COCCn1cc(-c2ccc3[nH]nc(-c4cc(N5CCOCC5)ncn4)c3c2)cn1";"IC50";"'='";"1.5";"nM";"8.82";"";"417949";"UO_0000065";"21.76";"0.40";"6.45";"9.39";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3946757";"";"None";"386.46";"0";"3.70";"BDBM239492";"C[C@@H]1CN(c2cc(-c3n[nH]c4ccc(-c5ccncc5)cc34)ncn2)C[C@H](C)O1";"IC50";"'='";"49.5";"nM";"7.30";"";"417957";"UO_0000065";"18.90";"0.34";"3.61";"9.15";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3929219";"";"None";"410.48";"0";"4.17";"BDBM239505";"C[C@@H]1CN(c2cc(-c3n[nH]c4ccc(-c5cccc(C#N)c5)cc34)ncn2)C[C@H](C)O1";"IC50";"'='";"47.9";"nM";"7.32";"";"417970";"UO_0000065";"17.83";"0.32";"3.15";"8.07";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3894116";"";"None";"335.41";"0";"3.28";"BDBM239513";"CC(C)=Cc1ccc2[nH]nc(-c3cc(N4CCOCC4)ncn3)c2c1";"IC50";"'='";"16.4";"nM";"7.79";"";"417977";"UO_0000065";"23.21";"0.43";"4.51";"11.63";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3984439";"";"None";"396.45";"0";"3.63";"BDBM239519";"FC1(F)CCN(c2cc(-c3n[nH]c4ccc(C5=CCNCC5)cc34)ncn2)CC1";"IC50";"'='";"119.7";"nM";"6.92";"";"417982";"UO_0000065";"17.46";"0.33";"3.29";"9.93";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3927749";"";"None";"381.39";"0";"3.65";"BDBM239522";"FC1(F)CCN(c2cc(-c3n[nH]c4ccc(-c5cc[nH]n5)cc34)ncn2)CC1";"IC50";"'='";"2.16";"nM";"8.67";"";"417985";"UO_0000065";"22.72";"0.42";"5.02";"10.03";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3972368";"";"None";"403.49";"0";"3.63";"BDBM239527";"CC1(C)CC(=O)C=C(c2ccc3[nH]nc(-c4cc(N5CCOCC5)ncn4)c3c2)C1";"IC50";"'='";"1.63";"nM";"8.79";"";"417990";"UO_0000065";"21.78";"0.40";"5.16";"10.46";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3919142";"";"None";"375.44";"0";"2.86";"BDBM239535";"Cc1n[nH]c(C)c1-c1ccc2[nH]nc(-c3cc(N4CCOCC4)ncn3)c2c1";"IC50";"'='";"2.58";"nM";"8.59";"";"417998";"UO_0000065";"22.88";"0.42";"5.73";"8.98";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3915861";"";"None";"388.48";"0";"2.94";"BDBM239540";"CC(C)N1CCN(c2cc(-c3n[nH]c4ccc(-c5cn[nH]c5)cc34)ncn2)CC1";"IC50";"'='";"0.96";"nM";"9.02";"";"418003";"UO_0000065";"23.21";"0.42";"6.08";"10.06";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3943811";"";"None";"388.48";"0";"2.94";"BDBM239541";"CC(C)N1CCN(c2cc(-c3n[nH]c4ccc(-c5ccn[nH]5)cc34)ncn2)CC1";"IC50";"'='";"2.34";"nM";"8.63";"";"418004";"UO_0000065";"22.22";"0.41";"5.69";"9.63";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3967326";"";"None";"460.54";"0";"2.56";"BDBM239247";"CC(C)Oc1cc2c(-c3cc(N4CCN(S(=O)(=O)C5CC5)CC4)ncn3)n[nH]c2cc1F";"IC50";"'='";"4.17";"nM";"8.38";"";"417708";"UO_0000065";"18.20";"0.36";"5.82";"8.03";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3902574";"";"None";"352.40";"0";"1.70";"BDBM239268";"CCN1CCN(c2cc(-c3n[nH]c4ccc(OC)cc34)ncn2)CC1=O";"IC50";"'='";"78.3";"nM";"7.11";"";"417727";"UO_0000065";"20.17";"0.37";"5.41";"8.15";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3892058";"";"None";"394.48";"0";"2.33";"BDBM239288";"COCCOc1ccc2[nH]nc(-c3cc(N4CCN(C5CC5)CC4)ncn3)c2c1";"IC50";"'='";"97.04";"nM";"7.01";"";"417747";"UO_0000065";"17.78";"0.33";"4.68";"8.83";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3893371";"";"None";"436.52";"0";"2.54";"BDBM239306";"COC[C@H](C)Oc1ccc2[nH]nc(-c3cc(N4CCC5(CC4)CNC(=O)C5)ncn3)c2c1";"IC50";"'='";"2.85";"nM";"8.54";"";"417766";"UO_0000065";"19.58";"0.36";"6.01";"8.12";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4114340";"";"None";"383.45";"0";"2.66";"BDBM239312";"COC[C@H](C)Oc1ccc2[nH]nc(-c3cc(N4CCO[C@H](C)C4)ncn3)c2c1";"IC50";"'='";"2.79";"nM";"8.55";"";"417772";"UO_0000065";"22.31";"0.42";"5.89";"10.02";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3895621";"";"None";"430.53";"0";"2.28";"BDBM239326";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCCN(S(C)(=O)=O)CC4)ncn3)c2c1";"IC50";"'='";"51.3";"nM";"7.29";"";"417795";"UO_0000065";"16.93";"0.33";"5.01";"6.99";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4113764";"";"None";"339.40";"0";"2.64";"BDBM239282";"CCOc1ccc2[nH]nc(-c3cc(N4CCO[C@H](C)C4)ncn3)c2c1";"IC50";"'='";"10.5";"nM";"7.98";"";"417741";"UO_0000065";"23.51";"0.44";"5.34";"10.48";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3966383";"";"None";"382.47";"0";"2.19";"BDBM239291";"CCN1CCN(c2cc(-c3n[nH]c4ccc(OCCOC)cc34)ncn2)CC1";"IC50";"'='";"96.99";"nM";"7.01";"";"417750";"UO_0000065";"18.34";"0.34";"4.82";"8.83";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4108658";"";"None";"369.43";"0";"2.27";"BDBM239293";"COCCOc1ccc2[nH]nc(-c3cc(N4CCO[C@H](C)C4)ncn3)c2c1";"IC50";"'='";"42.84";"nM";"7.37";"";"417752";"UO_0000065";"19.94";"0.37";"5.10";"8.63";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3949950";"";"None";"381.44";"0";"2.41";"BDBM239295";"COCCOc1ccc2[nH]nc(-c3cc(N4CC5CCC(C4)O5)ncn3)c2c1";"IC50";"'='";"154.0";"nM";"6.81";"";"417754";"UO_0000065";"17.86";"0.33";"4.40";"7.98";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3939048";"";"None";"395.42";"0";"3.66";"BDBM239392";"Cn1cc(-c2ccc3[nH]nc(-c4cc(N5CCCC(F)(F)C5)ncn4)c3c2)cn1";"IC50";"'='";"2.2";"nM";"8.66";"";"417858";"UO_0000065";"21.89";"0.41";"5.00";"11.46";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3980373";"";"None";"393.48";"0";"1.99";"BDBM239401";"Cn1cc(-c2ccc3[nH]nc(-c4cc(N5CC[S+]([O-])CC5)ncn4)c3c2)cn1";"IC50";"'='";"26.8";"nM";"7.57";"";"417867";"UO_0000065";"19.24";"0.37";"5.58";"7.68";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3939844";"";"None";"398.42";"0";"3.78";"BDBM239435";"CC(C)Oc1cc2c(-c3cc(N4CCC(F)(C#N)CC4)ncn3)n[nH]c2cc1F";"IC50";"'='";"17.7";"nM";"7.75";"";"417901";"UO_0000065";"19.46";"0.37";"3.97";"8.55";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3924185";"";"None";"389.41";"0";"2.93";"BDBM239457";"COC[C@H](C)Oc1ccc2[nH]nc(-c3cc(N4C[C@H](F)[C@@H](F)C4)ncn3)c2c1";"IC50";"'='";"7.9";"nM";"8.10";"";"417922";"UO_0000065";"20.81";"0.40";"5.17";"10.64";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4466696";"";"None";"325.38";"0";"0.83";"32";"Cn1cc(-c2cc3nccnc3c(NC[C@@H]3CNCCO3)n2)cn1";"IC50";"'='";"251.19";"nM";"6.60";"";"";"UO_0000065";"20.28";"0.38";"5.77";"7.35";"0";"CHEMBL4433048";"Inhibition of LRRK2 (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4431389";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2016";"None";"";"";""
"CHEMBL3326115";"";"None";"365.42";"0";"3.35";"2";"COc1ccc(OC)c(Sc2ccc3nnc(-c4ccccn4)n3n2)c1";"IC50";"'='";"1310.0";"nM";"5.88";"";"";"UO_0000065";"16.10";"0.31";"2.53";"7.90";"0";"CHEMBL3367451";"Inhibition of phosphorylation at S935 residue of wild-type full-length LRRK2 kinase (unknown origin) expressed in HEK 293 cells after 90 mins by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"CHEMBL3307715";"";"";""
"CHEMBL3326130";"";"None";"334.40";"0";"3.95";"17";"COc1ccccc1Sc1ccc2nnc(-c3ccccc3)n2n1";"IC50";"'='";"1070.0";"nM";"5.97";"";"";"UO_0000065";"17.85";"0.34";"2.02";"11.41";"0";"CHEMBL3367450";"Inhibition of GST-tagged truncated LRRK2 (unknown origin) using fluorescein-labeled peptide LRRKtide as substrate by LANTHA screen assay in presence of 1 mM ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL3326148";"";"None";"367.43";"0";"3.30";"36";"COc1ccc(OC)c(Sc2ccn3ncc(-c4cnn(C)c4)c3n2)c1";"IC50";"'='";"488.0";"nM";"6.31";"";"";"UO_0000065";"17.18";"0.33";"3.01";"9.50";"0";"CHEMBL3367451";"Inhibition of phosphorylation at S935 residue of wild-type full-length LRRK2 kinase (unknown origin) expressed in HEK 293 cells after 90 mins by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"CHEMBL3307715";"";"";""
"CHEMBL3326132";"";"None";"363.41";"0";"2.56";"19";"COc1ccc(C#N)cc1Sc1ccc2nnc(-c3cnn(C)c3)n2n1";"IC50";"'='";"2070.0";"nM";"5.68";"";"";"UO_0000065";"15.64";"0.30";"3.12";"6.05";"0";"CHEMBL3367451";"Inhibition of phosphorylation at S935 residue of wild-type full-length LRRK2 kinase (unknown origin) expressed in HEK 293 cells after 90 mins by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"CHEMBL3307715";"";"";""
"CHEMBL3326131";"";"None";"334.40";"0";"3.95";"18";"COc1cccc(Sc2ccc3nnc(-c4ccccc4)n3n2)c1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL3367451";"Inhibition of phosphorylation at S935 residue of wild-type full-length LRRK2 kinase (unknown origin) expressed in HEK 293 cells after 90 mins by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"CHEMBL3307715";"";"";""
"CHEMBL3326123";"";"None";"382.45";"0";"2.62";"10";"COc1ccc(OC)c(Sc2ccc3nnc(Cc4cnn(C)c4)n3n2)c1";"IC50";"'='";"32000.0";"nM";"4.50";"";"";"UO_0000065";"11.75";"0.23";"1.87";"5.66";"0";"CHEMBL3367450";"Inhibition of GST-tagged truncated LRRK2 (unknown origin) using fluorescein-labeled peptide LRRKtide as substrate by LANTHA screen assay in presence of 1 mM ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL4560505";"";"None";"296.38";"0";"3.10";"26";"Cn1cc(-c2n[nH]c3ccnc(NC4CCCCC4)c23)cn1";"IC50";"'='";"130.0";"nM";"6.89";"";"";"UO_0000065";"23.23";"0.43";"3.79";"9.64";"0";"CHEMBL4331900";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant catalytic domain (970 to 2527 residues) expressed in baculovirus expression system by radiometric assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330096";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4473011";"";"None";"352.44";"0";"3.53";"28";"c1cc2[nH]nc(-c3cnn(C4CCCC4)c3)c2c(NC2CCOCC2)n1";"IC50";"'='";"170.0";"nM";"6.77";"";"";"UO_0000065";"19.21";"0.36";"3.24";"8.39";"0";"CHEMBL4331900";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant catalytic domain (970 to 2527 residues) expressed in baculovirus expression system by radiometric assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330096";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4442480";"";"None";"229.33";"0";"3.62";"38";"Cc1c[nH]c2ccnc(NC3CCCCC3)c12";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL4331900";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant catalytic domain (970 to 2527 residues) expressed in baculovirus expression system by radiometric assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330096";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL2333120";"";"None";"315.38";"0";"1.39";"33";"CC(C)Nc1c(C(N)=O)nnc2cc(N3CCOCC3)ccc12";"IC50";"'='";"12.0";"nM";"7.92";"";"";"UO_0000065";"25.12";"0.47";"6.53";"8.48";"0";"CHEMBL2345527";"Inhibition of GST-tagged LRRK2 G2019S mutant (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2333115";"";"None";"296.33";"0";"1.94";"28";"CC(C)Nc1c(C(N)=O)nnc2ccc(-c3cn[nH]c3)cc12";"IC50";"'='";"5.0";"nM";"8.30";"";"";"UO_0000065";"28.01";"0.52";"6.36";"7.58";"0";"CHEMBL2345527";"Inhibition of GST-tagged LRRK2 G2019S mutant (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2333114";"";"None";"307.36";"0";"2.61";"27";"CC(C)Nc1c(C(N)=O)nnc2ccc(-c3ccncc3)cc12";"IC50";"'='";"66.0";"nM";"7.18";"";"";"UO_0000065";"23.36";"0.43";"4.57";"7.66";"0";"CHEMBL2345527";"Inhibition of GST-tagged LRRK2 G2019S mutant (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL4871959";"";"None";"507.45";"1";"4.19";"8.7";"O=S1(=O)CC(N2CCC(c3cc4nc(Nc5cnn(C6CC6)c5Cl)ncc4cc3Cl)CC2)C1";"IC50";"'<'";"0.631";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL4827623";"Inhibition of Kinase tracer 236 binding to GST-tagged truncated human LRRK2 G2019S (970 to 2527 residues) mutant using fluorescein labeled LRRKtide peptide as substrate preincubated for 15 mins followed by substrate addition measured after 90 mins in presence of ATP at Km concentration by TR-FRET Lanthascreen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4825716";"1";"Scientific Literature";"ACS Med Chem Lett";"2021";"None";"TIME = 1.75 hr";"";""
"CHEMBL1673053";"";"None";"513.65";"1";"4.65";"XMD10-76";"COc1cc(N2CCN(C)CC2)ccc1Nc1ncc2c(n1)N(C1CCCC1)c1ccccc1C(=O)N2C";"IC50";"'='";"421.0";"nM";"6.38";"";"";"UO_0000065";"12.41";"0.23";"1.73";"8.27";"0";"CHEMBL4612965";"Inhibition of recombinant human GST-tagged LRRK2 catalytic domain (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate measured after 1 hr by Alexa fluor-647 ADP tracer-based ADAPTA assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4610122";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL4645267";"";"None";"535.65";"1";"4.91";"XMD11-32";"COc1cc(N2CCN(C)CC2)ccc1Nc1ncc2c(n1)N(Cc1ccccc1)c1ccccc1C(=O)N2C";"IC50";"'='";"141.0";"nM";"6.85";"";"";"UO_0000065";"12.79";"0.23";"1.94";"8.89";"0";"CHEMBL4612965";"Inhibition of recombinant human GST-tagged LRRK2 catalytic domain (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate measured after 1 hr by Alexa fluor-647 ADP tracer-based ADAPTA assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4610122";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL1771411";"";"None";"262.32";"0";"3.38";"4";"Cc1cc(N/N=C/c2ccncc2)nc2ccccc12";"IC50";"'='";"4100.0";"nM";"5.39";"";"";"UO_0000065";"20.54";"0.37";"2.01";"10.74";"0";"CHEMBL1772599";"Inhibition of purified N-terminal GST-tagged LRRK2 G2019S mutant autophosphorylation activity using myelin basic protein as substrate";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1770059";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2011";"None";"";"";""
"CHEMBL4780638";"";"None";"436.52";"0";"3.03";"21";"CCOc1nc(Nc2ccc(C(=O)N3CCN4CCC[C@H]4C3)cc2OC)nc2[nH]ccc12";"IC50";"'='";"79.43";"nM";"7.10";"";"";"UO_0000065";"16.27";"0.30";"4.07";"7.43";"0";"CHEMBL4721244";"Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins by Alpha Screen assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4715821";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2018";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL4784139";"";"None";"424.51";"0";"2.89";"8";"CCOc1cc(C(=O)N2CCN(C)CC2)ccc1Nc1nc(OCC)c2cc[nH]c2n1";"IC50";"'='";"125.89";"nM";"6.90";"";"";"UO_0000065";"16.25";"0.30";"4.01";"7.22";"0";"CHEMBL4721244";"Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins by Alpha Screen assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4715821";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2018";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL2326710";"";"None";"272.23";"0";"2.01";"2";"CNc1nc(Nc2ccn(C)n2)ncc1C(F)(F)F";"IC50";"'='";"170.0";"nM";"6.77";"";"";"UO_0000065";"24.87";"0.49";"4.76";"10.01";"0";"CHEMBL2328175";"Inhibition of LRRK2 (unknown origin) autophosphorylation by cell-based assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2321736";"1";"Scientific Literature";"ACS Med Chem Lett";"2013";"None";"";"";""
"CHEMBL3326140";"";"None";"366.38";"0";"1.62";"28";"COc1ccc(OC)c(C(O)c2ccc3nnc(-c4cnn(C)c4)n3n2)c1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL3367451";"Inhibition of phosphorylation at S935 residue of wild-type full-length LRRK2 kinase (unknown origin) expressed in HEK 293 cells after 90 mins by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"CHEMBL3307715";"";"";""
"CHEMBL3326128";"";"None";"368.42";"0";"2.69";"15";"COc1ccc(OC)c(Sc2ccc3nnc(-c4cnn(C)c4)n3n2)c1";"IC50";"'='";"387.0";"nM";"6.41";"";"";"UO_0000065";"17.40";"0.34";"3.72";"8.08";"0";"CHEMBL3367451";"Inhibition of phosphorylation at S935 residue of wild-type full-length LRRK2 kinase (unknown origin) expressed in HEK 293 cells after 90 mins by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"CHEMBL3307715";"";"";""
"CHEMBL1982880";"";"None";"347.38";"0";"3.55";"25";"COc1ccc(OC)c(Nc2ccc3nnc(-c4ccccc4)n3n2)c1";"IC50";"'='";"22265.0";"nM";"4.65";"";"";"UO_0000065";"13.39";"0.24";"1.10";"6.32";"0";"CHEMBL3367450";"Inhibition of GST-tagged truncated LRRK2 (unknown origin) using fluorescein-labeled peptide LRRKtide as substrate by LANTHA screen assay in presence of 1 mM ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL3122106";"";"None";"314.27";"0";"2.01";"4";"CNc1nc(Nc2cnn3c2COCC3)ncc1C(F)(F)F";"IC50";"'='";"18.0";"nM";"7.75";"";"";"UO_0000065";"24.64";"0.48";"5.73";"10.07";"0";"CHEMBL3124215";"Inhibition of LRRK2 (unknown origin) phosphorylation by cell-based assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3120096";"1";"Scientific Literature";"J Med Chem";"2014";"None";"";"";""
"CHEMBL3122112";"";"None";"439.36";"0";"3.20";"10";"CNc1nc(Nc2cn(C(C)(C)C(=O)NCC(F)(F)F)nc2C)ncc1C(F)(F)F";"IC50";"'='";"53.0";"nM";"7.28";"";"";"UO_0000065";"16.56";"0.33";"4.08";"7.52";"0";"CHEMBL3124215";"Inhibition of LRRK2 (unknown origin) phosphorylation by cell-based assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3120096";"1";"Scientific Literature";"J Med Chem";"2014";"None";"";"";""
"CHEMBL3122107";"";"None";"342.33";"0";"2.96";"5";"CNc1nc(Nc2cnn3c2C(C)O[C@@H](C)C3)ncc1C(F)(F)F";"IC50";"'='";"49.0";"nM";"7.31";"";"";"UO_0000065";"21.35";"0.42";"4.35";"9.51";"0";"CHEMBL3124215";"Inhibition of LRRK2 (unknown origin) phosphorylation by cell-based assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3120096";"1";"Scientific Literature";"J Med Chem";"2014";"None";"";"";""
"CHEMBL2333139";"";"None";"309.33";"0";"1.19";"24";"NC(=O)c1nnc2cc(-c3ccncc3)ccc2c1NCCO";"IC50";"'='";"264.0";"nM";"6.58";"";"";"UO_0000065";"21.27";"0.39";"5.39";"5.77";"0";"CHEMBL2345527";"Inhibition of GST-tagged LRRK2 G2019S mutant (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2333131";"";"None";"370.43";"0";"2.23";"16";"CCNc1c(C(N)=O)nnc2cc(-c3ccc(S(C)(=O)=O)cc3)ccc12";"IC50";"'='";"55.0";"nM";"7.26";"";"";"UO_0000065";"19.60";"0.38";"5.03";"6.31";"0";"CHEMBL2345527";"Inhibition of GST-tagged LRRK2 G2019S mutant (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL3335329";"";"None";"271.70";"0";"3.54";"15c";"O=C1Nc2ccc(Cl)cc2/C1=C\c1ccc(O)cc1";"IC50";"'='";"12000.0";"nM";"4.92";"";"";"UO_0000065";"18.11";"0.35";"1.38";"9.98";"0";"CHEMBL3390652";"Inhibition of recombinant LRRK2 (unknown origin) using gamma-32P-ATP assessed as LRRKtide substrate phosphorylation level by autoradiography";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352815";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL3335331";"";"None";"342.83";"0";"3.77";"15e";"CN(C)CCOc1ccc(/C=C2/C(=O)Nc3ccc(Cl)cc32)cc1";"IC50";"'='";"466.0";"nM";"6.33";"";"";"UO_0000065";"18.47";"0.36";"2.56";"15.23";"0";"CHEMBL3390652";"Inhibition of recombinant LRRK2 (unknown origin) using gamma-32P-ATP assessed as LRRKtide substrate phosphorylation level by autoradiography";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352815";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL4103716";"";"None";"291.31";"0";"3.17";"38";"Cc1nnc(-c2cc(-c3ccc4[nH]ccc4c3)cnc2N)o1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL4045604";"Inhibition of recombinant human wild type GST-tagged LRRK2 (970 to 2527 residues) preincubated for 30 mins followed by fluorescein-LRRKtide substrate addition after 2 hrs by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4043168";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL1771409";"";"None";"293.33";"0";"3.40";"1";"Cc1cc(N/N=C/c2ccc(O)c(O)c2)nc2ccccc12";"IC50";"'='";"13200.0";"nM";"4.88";"";"";"UO_0000065";"16.63";"0.30";"1.48";"6.28";"0";"CHEMBL1772597";"Inhibition of purified N-terminal GST-tagged LRRK2 G2019S mutant autophosphorylation activity using [gamma32-P]ATP";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1770059";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2011";"None";"";"";""
"CHEMBL4060747";"";"None";"292.34";"0";"3.57";"32";"Cc1ccc(-c2cnc(N)c(-c3nnc(C4CC4)o3)c2)cc1";"IC50";"'='";"2300.0";"nM";"5.64";"";"";"UO_0000065";"19.29";"0.35";"2.07";"7.24";"0";"CHEMBL4045604";"Inhibition of recombinant human wild type GST-tagged LRRK2 (970 to 2527 residues) preincubated for 30 mins followed by fluorescein-LRRKtide substrate addition after 2 hrs by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4043168";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL2348966";"";"None";"367.50";"0";"4.70";"32";"CC(C)(C)c1cccc(Sc2ccc3nnc(-c4cncs4)n3n2)c1";"IC50";"'='";"1393.0";"nM";"5.86";"";"";"UO_0000065";"15.93";"0.32";"1.16";"10.46";"0";"CHEMBL2351460";"Inhibition of LRRK2 G2019S mutant (unknown origin) transfected in HEK293 cells assessed decrease in S935 autophosphorylation";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"CHEMBL3307715";"";"";""
"CHEMBL2348944";"";"None";"362.34";"0";"3.68";"9";"FC(F)(F)c1cccc(Sc2ccc3nnc(-c4ccn[nH]4)n3n2)c1";"IC50";"'='";"1016.0";"nM";"5.99";"";"";"UO_0000065";"16.54";"0.33";"2.31";"8.35";"0";"CHEMBL2351460";"Inhibition of LRRK2 G2019S mutant (unknown origin) transfected in HEK293 cells assessed decrease in S935 autophosphorylation";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"CHEMBL3307715";"";"";""
"CHEMBL4527314";"";"None";"364.33";"0";"3.02";"18";"FC(F)(F)c1cc(-c2n[nH]c3ccnc(NC4CCOCC4)c23)ncn1";"IC50";"'='";"24.0";"nM";"7.62";"";"";"UO_0000065";"20.91";"0.40";"4.60";"8.60";"0";"CHEMBL4331199";"Inhibition of LRRK2 G2019S mutant (unknown origin) by cell based assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330074";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4553487";"";"None";"306.75";"0";"4.34";"20";"O=C(Nc1nc2ccc(F)cc2s1)c1ccc(Cl)cc1";"IC50";"'='";"4460.0";"nM";"5.35";"";"";"UO_0000065";"17.44";"0.37";"1.01";"12.74";"0";"CHEMBL4403862";"Inhibition of wild type human GST-tagged LRRK2 (970 to 2527 residues) expressed in baculovirus expression system assessed as reduction in ADP formation using LRRKtide as substrate measured after 1 hr in presence of ATP by Adapta assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4402549";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL2178127";"";"None";"459.86";"0";"3.81";"11";"CCNc1nc(Nc2cc(OC)c(C(=O)N3CCOCC3)cc2Cl)ncc1C(F)(F)F";"IC50";"'='";"27.0";"nM";"7.57";"";"";"UO_0000065";"16.46";"0.33";"3.76";"8.54";"0";"CHEMBL2188381";"Inhibition of autophosphorylation of LRRK2 in human HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2176933";"1";"Scientific Literature";"J Med Chem";"2012";"CHEMBL3307715";"";"";""
"CHEMBL4780229";"";"None";"411.46";"0";"2.97";"15";"CCOc1nc(Nc2ccc(C(=O)N3CCOC[C@@H]3C)cc2OC)nc2[nH]ccc12";"IC50";"'='";"7.943";"nM";"8.10";"";"";"UO_0000065";"19.69";"0.37";"5.13";"7.97";"0";"CHEMBL4721243";"Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs in presence of ATP by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4715821";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2018";"None";"TIME = 2.5 hr";"INHIBITOR";""
"CHEMBL4465653";"";"None";"324.43";"0";"4.15";"27";"CC(C)n1cc(-c2n[nH]c3ccnc(NC4CCCCC4)c23)cn1";"IC50";"'='";"110.0";"nM";"6.96";"";"";"UO_0000065";"21.45";"0.40";"2.81";"9.74";"0";"CHEMBL4331900";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant catalytic domain (970 to 2527 residues) expressed in baculovirus expression system by radiometric assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330096";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4454874";"";"None";"381.50";"0";"4.51";"17";"CC(C)c1ccc2nc(NC(=O)c3ccc(N4CCOCC4)cc3)sc2c1";"IC50";"'='";"2500.0";"nM";"5.60";"";"";"UO_0000065";"14.68";"0.28";"1.09";"10.29";"0";"CHEMBL4403862";"Inhibition of wild type human GST-tagged LRRK2 (970 to 2527 residues) expressed in baculovirus expression system assessed as reduction in ADP formation using LRRKtide as substrate measured after 1 hr in presence of ATP by Adapta assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4402549";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL3981708";"";"None";"411.47";"0";"2.13";"BDBM239371";"Cn1cc(-c2cc3c(-c4cc(N5CC[S+]([O-])CC5)ncn4)n[nH]c3cc2F)cn1";"IC50";"'='";"130.7";"nM";"6.88";"";"417838";"UO_0000065";"16.73";"0.32";"4.75";"6.98";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3959252";"";"None";"393.43";"0";"2.78";"BDBM239375";"C[C@H]1CN(c2cc(-c3n[nH]c4cc(F)c(-c5cnn(C)c5)cc34)ncn2)CCO1";"IC50";"'='";"26.5";"nM";"7.58";"";"417842";"UO_0000065";"19.26";"0.36";"4.80";"8.94";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3981913";"";"None";"419.46";"0";"3.32";"BDBM239378";"Cn1cc(-c2cc3c(-c4cc(N5CCCC6(CCO6)C5)ncn4)n[nH]c3cc2F)cn1";"IC50";"'='";"398.1";"nM";"6.40";"";"417845";"UO_0000065";"15.26";"0.28";"3.08";"7.55";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3932528";"";"None";"398.43";"0";"2.57";"BDBM239470";"c1nc(-c2n[nH]c3ccc(-c4ccc5ncnn5c4)cc23)cc(N2CCOCC2)n1";"IC50";"'='";"192.7";"nM";"6.71";"";"417935";"UO_0000065";"16.85";"0.31";"4.15";"6.91";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3906334";"";"None";"391.44";"0";"3.10";"BDBM239337";"Cc1noc(C2CN(c3cc(-c4n[nH]c5ccc(OC(C)C)cc45)ncn3)C2)n1";"IC50";"'='";"9.3";"nM";"8.03";"";"417806";"UO_0000065";"20.52";"0.38";"4.93";"7.59";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3914976";"";"None";"385.44";"0";"3.56";"BDBM239088";"CC(C)Oc1cc2c(-c3cc(N4C[C@@H](C)O[C@@H](C)C4)ncn3)n[nH]c2cc1F";"IC50";"'='";"22.0";"nM";"7.66";"";"417372";"UO_0000065";"19.87";"0.37";"4.10";"10.05";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3959075";"";"None";"387.45";"0";"2.79";"BDBM239185";"Cn1cc(-c2ccc3[nH]nc(-c4cc(N5CC6CCC(C5)O6)ncn4)c3c2)cn1";"IC50";"'='";"5.18";"nM";"8.29";"";"417644";"UO_0000065";"21.39";"0.39";"5.50";"9.78";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3928102";"";"None";"339.40";"0";"2.64";"BDBM239084";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCOCC4)ncn3)c2c1";"IC50";"'='";"7.12";"nM";"8.15";"";"417660";"UO_0000065";"24.01";"0.45";"5.51";"10.70";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3942829";"";"None";"410.48";"0";"2.10";"BDBM239208";"COCCN1CCN(c2cc(-c3n[nH]c4ccc(OC(C)C)cc34)ncn2)CC1=O";"IC50";"'='";"5.59";"nM";"8.25";"";"417669";"UO_0000065";"20.10";"0.38";"6.15";"8.55";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3335348";"";"None";"313.78";"0";"4.46";"26c";"COc1c(C)cc(/C=C2/C(=O)Nc3ccc(Cl)cc32)cc1C";"IC50";"'='";"1500.0";"nM";"5.82";"";"";"UO_0000065";"18.56";"0.36";"1.36";"15.19";"0";"CHEMBL3390652";"Inhibition of recombinant LRRK2 (unknown origin) using gamma-32P-ATP assessed as LRRKtide substrate phosphorylation level by autoradiography";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352815";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL3335328";"";"None";"307.68";"0";"3.82";"15a";"O=C1Nc2ccc(Cl)cc2/C1=C\c1cc(F)c(O)c(F)c1";"IC50";"'='";"261.0";"nM";"6.58";"";"";"UO_0000065";"21.40";"0.43";"2.76";"13.35";"0";"CHEMBL3390652";"Inhibition of recombinant LRRK2 (unknown origin) using gamma-32P-ATP assessed as LRRKtide substrate phosphorylation level by autoradiography";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352815";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL3393444";"";"None";"319.37";"0";"2.72";"33";"C[C@H]1CN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)CCO1";"IC50";"'='";"122.0";"nM";"6.91";"";"";"UO_0000065";"21.65";"0.39";"4.19";"8.88";"0";"CHEMBL3395728";"Inhibition of full length LRRK2 (unknown origin) expressed in HEK293 cells assessed as reduction in S935 phosphorylation incubated for 90 mins by ELISA method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL3393443";"";"None";"319.37";"0";"2.72";"32";"C[C@@H]1CN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)CCO1";"IC50";"'='";"377.0";"nM";"6.42";"";"";"UO_0000065";"20.11";"0.37";"3.70";"8.25";"0";"CHEMBL3395728";"Inhibition of full length LRRK2 (unknown origin) expressed in HEK293 cells assessed as reduction in S935 phosphorylation incubated for 90 mins by ELISA method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL3393344";"";"None";"289.34";"0";"3.10";"10";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCCC4)c23)c1";"IC50";"'='";"64.0";"nM";"7.19";"";"";"UO_0000065";"24.86";"0.45";"4.09";"10.49";"0";"CHEMBL3395727";"Inhibition of GST-tagged truncated human recombinant LRRK2 G2019S mutant using fluorescein-labeled LRRKtide peptide substrate incubated for 90 mins";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3122114";"";"None";"339.33";"0";"3.04";"12";"CNc1nc(Nc2cnn(C(C)(C)C#N)c2C)ncc1C(F)(F)F";"IC50";"'='";"5.0";"nM";"8.30";"";"";"UO_0000065";"24.46";"0.47";"5.26";"9.08";"0";"CHEMBL3124215";"Inhibition of LRRK2 (unknown origin) phosphorylation by cell-based assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3120096";"1";"Scientific Literature";"J Med Chem";"2014";"None";"";"";""
"CHEMBL3122110";"";"None";"385.39";"0";"2.66";"8";"CCNC(=O)C(C)(C)n1cc(Nc2ncc(C(F)(F)F)c(NC)n2)c(C)n1";"IC50";"'='";"99.0";"nM";"7.00";"";"";"UO_0000065";"18.17";"0.35";"4.34";"7.24";"0";"CHEMBL3124215";"Inhibition of LRRK2 (unknown origin) phosphorylation by cell-based assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3120096";"1";"Scientific Literature";"J Med Chem";"2014";"None";"";"";""
"CHEMBL1673051";"";"None";"473.58";"0";"3.73";"XMD10-39";"CCN1c2ccccc2C(=O)N(C)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3OC)nc21";"IC50";"'='";"57.0";"nM";"7.24";"";"";"UO_0000065";"15.30";"0.28";"3.51";"9.40";"0";"CHEMBL4612965";"Inhibition of recombinant human GST-tagged LRRK2 catalytic domain (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate measured after 1 hr by Alexa fluor-647 ADP tracer-based ADAPTA assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4610122";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL4649318";"";"None";"487.61";"0";"4.12";"FMF-03-149-1";"COc1cc(N2CCN(C)CC2)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2C(C)C";"IC50";"'='";"1900.0";"nM";"5.72";"";"";"UO_0000065";"11.73";"0.22";"1.60";"7.42";"0";"CHEMBL4612965";"Inhibition of recombinant human GST-tagged LRRK2 catalytic domain (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate measured after 1 hr by Alexa fluor-647 ADP tracer-based ADAPTA assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4610122";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL3409473";"";"None";"455.00";"1";"5.13";"32";"CC(=O)Nc1ccc(Nc2ccc(C(=O)N3CCC(N4CCCCC4)CC3)cc2Cl)cc1";"IC50";"'>'";"1000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL3412556";"Inhibition of LRRK2 G2019S mutant (1326 to 252 aa) (unknown origin) stably expressed in HEK293 cell lysate using [gamma-32P] after 15 mins by Cerenkov counting method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3407393";"1";"Scientific Literature";"Eur J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL4759051";"";"None";"423.52";"0";"2.55";"13";"CCOc1nc(Nc2ccc(C(=O)N3CCN(C)CC3)cc2N(C)C)nc2[nH]ccc12";"IC50";"'='";"199.53";"nM";"6.70";"";"";"UO_0000065";"15.82";"0.30";"4.15";"7.48";"0";"CHEMBL4721243";"Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs in presence of ATP by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4715821";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2018";"None";"TIME = 2.5 hr";"INHIBITOR";""
"CHEMBL4795075";"";"None";"409.45";"0";"2.58";"19";"CCOc1nc(Nc2ccc(C(=O)N3CC4(COC4)C3)cc2OC)nc2[nH]ccc12";"IC50";"'='";"158.49";"nM";"6.80";"";"";"UO_0000065";"16.61";"0.31";"4.22";"6.69";"0";"CHEMBL4721244";"Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins by Alpha Screen assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4715821";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2018";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL4753216";"";"None";"438.53";"0";"3.28";"10";"CCOc1nc(Nc2ccc(C(=O)N3CCN(C)CC3)cc2OC(C)C)nc2[nH]ccc12";"IC50";"'='";"398.11";"nM";"6.40";"";"";"UO_0000065";"14.59";"0.27";"3.12";"6.69";"0";"CHEMBL4721244";"Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins by Alpha Screen assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4715821";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2018";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL2178129";"";"None";"429.83";"0";"3.71";"13";"CNc1nc(Nc2cc(C)c(C(=O)N3CCOCC3)cc2Cl)ncc1C(F)(F)F";"IC50";"'='";"43.0";"nM";"7.37";"";"";"UO_0000065";"17.14";"0.35";"3.66";"9.28";"0";"CHEMBL2188381";"Inhibition of autophosphorylation of LRRK2 in human HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2176933";"1";"Scientific Literature";"J Med Chem";"2012";"CHEMBL3307715";"";"";""
"CHEMBL2170016";"";"None";"377.83";"0";"2.40";"SID174006364";"CNc1nc(Nc2ccc(C(=O)N3CCOCC3)cc2OC)ncc1Cl";"IC50";"'='";"95.9";"nM";"7.02";"";"";"UO_0000065";"18.57";"0.37";"4.62";"7.92";"0";"CHEMBL2173831";"Inhibition of LRRK2 G2019S/A2016T mutant expressed in HEK293 cells using nictide as substrate and [gamma32P]ATP after 15 mins by Cerenkov counting method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S,A2016T";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169803";"1";"Scientific Literature";"ACS Med Chem Lett";"2012";"CHEMBL3307715";"";"";""
"CHEMBL3393453";"";"None";"331.38";"0";"2.72";"42";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CC5CCOC5C4)c23)c1";"IC50";"'='";"3694.0";"nM";"5.43";"";"";"UO_0000065";"16.39";"0.30";"2.71";"6.98";"0";"CHEMBL3395728";"Inhibition of full length LRRK2 (unknown origin) expressed in HEK293 cells assessed as reduction in S935 phosphorylation incubated for 90 mins by ELISA method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL3393445";"";"None";"330.35";"0";"2.23";"34";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCOC(C#N)C4)c23)c1";"IC50";"'='";"1331.0";"nM";"5.88";"";"";"UO_0000065";"17.79";"0.32";"3.65";"5.78";"0";"CHEMBL3395728";"Inhibition of full length LRRK2 (unknown origin) expressed in HEK293 cells assessed as reduction in S935 phosphorylation incubated for 90 mins by ELISA method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL3393354";"";"None";"310.36";"0";"2.47";"20";"COc1cccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"882.0";"nM";"6.05";"";"";"UO_0000065";"19.51";"0.36";"3.58";"9.57";"0";"CHEMBL3395728";"Inhibition of full length LRRK2 (unknown origin) expressed in HEK293 cells assessed as reduction in S935 phosphorylation incubated for 90 mins by ELISA method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL3393439";"";"None";"284.32";"0";"1.19";"28";"Cn1cc(-c2c[nH]c3ncnc(N4CCOCC4)c23)cn1";"IC50";"'='";"12.0";"nM";"7.92";"";"";"UO_0000065";"27.86";"0.52";"6.73";"11.02";"0";"CHEMBL3395726";"Inhibition of GST-tagged truncated human recombinant LRRK2 using fluorescein-labeled LRRKtide peptide substrate incubated for 2 hrs";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3393361";"";"None";"306.33";"0";"1.73";"27";"N#Cc1cncc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"2243.0";"nM";"5.65";"";"";"UO_0000065";"18.44";"0.34";"3.92";"6.23";"0";"CHEMBL3395726";"Inhibition of GST-tagged truncated human recombinant LRRK2 using fluorescein-labeled LRRKtide peptide substrate incubated for 2 hrs";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3393355";"";"None";"314.78";"0";"3.11";"21";"Clc1cccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"8.0";"nM";"8.10";"";"";"UO_0000065";"25.72";"0.50";"4.99";"14.98";"0";"CHEMBL3395726";"Inhibition of GST-tagged truncated human recombinant LRRK2 using fluorescein-labeled LRRKtide peptide substrate incubated for 2 hrs";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3393346";"";"None";"263.30";"0";"2.56";"12";"CN(C)c1ncnc2[nH]cc(-c3cccc(C#N)c3)c12";"IC50";"'='";"5.0";"nM";"8.30";"";"";"UO_0000065";"31.53";"0.57";"5.74";"12.10";"0";"CHEMBL3395726";"Inhibition of GST-tagged truncated human recombinant LRRK2 using fluorescein-labeled LRRKtide peptide substrate incubated for 2 hrs";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3393343";"";"None";"303.37";"0";"3.49";"9";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCCCC4)c23)c1";"IC50";"'='";"6.0";"nM";"8.22";"";"";"UO_0000065";"27.10";"0.49";"4.73";"11.99";"0";"CHEMBL3395726";"Inhibition of GST-tagged truncated human recombinant LRRK2 using fluorescein-labeled LRRKtide peptide substrate incubated for 2 hrs";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3393351";"";"None";"333.40";"0";"3.11";"17";"COC1CCN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)CC1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL3395728";"Inhibition of full length LRRK2 (unknown origin) expressed in HEK293 cells assessed as reduction in S935 phosphorylation incubated for 90 mins by ELISA method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL3393341";"";"None";"317.40";"0";"3.73";"7";"C[C@H]1CCCN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)C1";"IC50";"'='";"16.0";"nM";"7.80";"";"";"UO_0000065";"24.56";"0.44";"4.07";"11.36";"0";"CHEMBL3395726";"Inhibition of GST-tagged truncated human recombinant LRRK2 using fluorescein-labeled LRRKtide peptide substrate incubated for 2 hrs";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3393346";"";"None";"263.30";"0";"2.56";"12";"CN(C)c1ncnc2[nH]cc(-c3cccc(C#N)c3)c12";"IC50";"'='";"42.0";"nM";"7.38";"";"";"UO_0000065";"28.02";"0.50";"4.82";"10.75";"0";"CHEMBL3395731";"Inhibition of LRRK2 in human PBMCs by ActivX KiNativ method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3393361";"";"None";"306.33";"0";"1.73";"27";"N#Cc1cncc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL3395728";"Inhibition of full length LRRK2 (unknown origin) expressed in HEK293 cells assessed as reduction in S935 phosphorylation incubated for 90 mins by ELISA method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL2348948";"";"None";"457.30";"1";"5.79";"13";"FC(F)(F)c1cccc(Sc2ccc3nnc(-c4sccc4Br)n3n2)c1";"IC50";"'='";"134.0";"nM";"6.87";"";"";"UO_0000065";"15.03";"0.36";"1.08";"15.95";"0";"CHEMBL2351468";"Inhibition of LRRK2 G2019S mutant (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348941";"";"None";"376.43";"1";"6.23";"6";"FC(F)(F)c1cccc(Sc2ccc3ncc(-c4cccs4)n3c2)c1";"IC50";"'='";"1313.0";"nM";"5.88";"";"";"UO_0000065";"15.63";"0.32";"-0.35";"34.00";"0";"CHEMBL2351468";"Inhibition of LRRK2 G2019S mutant (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348963";"";"None";"345.84";"0";"4.05";"29";"Clc1cccc(Sc2ccc3nnc(-c4cncs4)n3n2)c1";"IC50";"'='";"31.0";"nM";"7.51";"";"";"UO_0000065";"21.71";"0.47";"3.46";"13.42";"0";"CHEMBL2351467";"Inhibition of wild type LRRK2 (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL4746922";"";"None";"450.54";"0";"3.28";"20";"CCOc1nc(Nc2ccc(C(=O)N3CCC4(CC3)CN(C)C4)cc2OC)nc2[nH]ccc12";"IC50";"'='";"6.31";"nM";"8.20";"";"";"UO_0000065";"18.20";"0.34";"4.92";"8.58";"0";"CHEMBL4721243";"Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs in presence of ATP by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4715821";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2018";"None";"TIME = 2.5 hr";"INHIBITOR";""
"CHEMBL4648454";"";"None";"542.69";"1";"3.80";"XMD8-90";"COc1cc(N2CCN(C3CCN(C)CC3)CC2)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2C";"IC50";"'='";"16.0";"nM";"7.80";"";"";"UO_0000065";"14.37";"0.27";"4.00";"9.71";"0";"CHEMBL4612965";"Inhibition of recombinant human GST-tagged LRRK2 catalytic domain (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate measured after 1 hr by Alexa fluor-647 ADP tracer-based ADAPTA assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4610122";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL4649424";"";"None";"430.51";"0";"3.54";"XMD12-1";"CN1C(=O)c2ccccc2N(C)c2nc(Nc3ccc(N4CCC(O)CC4)cc3)ncc21";"IC50";"'='";"30.0";"nM";"7.52";"";"";"UO_0000065";"17.47";"0.32";"3.98";"8.87";"0";"CHEMBL4612965";"Inhibition of recombinant human GST-tagged LRRK2 catalytic domain (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate measured after 1 hr by Alexa fluor-647 ADP tracer-based ADAPTA assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4610122";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL3335349";"";"None";"350.60";"0";"4.30";"26d";"O=C1Nc2ccc(Cl)cc2/C1=C\c1ccc(O)c(Br)c1";"IC50";"'='";"46.0";"nM";"7.34";"";"";"UO_0000065";"20.93";"0.50";"3.04";"14.87";"0";"CHEMBL3390652";"Inhibition of recombinant LRRK2 (unknown origin) using gamma-32P-ATP assessed as LRRKtide substrate phosphorylation level by autoradiography";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352815";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL2206014";"";"None";"429.50";"1";"5.06";"15b";"O=C1Nc2ccc(Cl)cc2/C1=C/c1cc(Br)c(O)c(Br)c1";"IC50";"'='";"15.0";"nM";"7.82";"";"";"UO_0000065";"18.22";"0.51";"2.76";"15.86";"0";"CHEMBL3390652";"Inhibition of recombinant LRRK2 (unknown origin) using gamma-32P-ATP assessed as LRRKtide substrate phosphorylation level by autoradiography";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352815";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL3335347";"";"None";"443.52";"1";"5.37";"26b";"COc1c(Br)cc(/C=C2/C(=O)Nc3ccc(Cl)cc32)cc1Br";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL3390652";"Inhibition of recombinant LRRK2 (unknown origin) using gamma-32P-ATP assessed as LRRKtide substrate phosphorylation level by autoradiography";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352815";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL3951477";"";"None";"332.41";"0";"3.74";"BDBM185401";"C[C@H]1CCCN(c2ncnc3[nH]cc(-c4ccc5[nH]ncc5c4)c23)C1";"IC50";"'='";"66.0";"nM";"7.18";"";"334576";"UO_0000065";"21.60";"0.39";"3.44";"9.77";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3971055";"";"None";"305.34";"0";"2.33";"BDBM185434";"N#Cc1ccccc1-c1c[nH]c2ncnc(N3CCOCC3)c12";"IC50";"'='";"148.0";"nM";"6.83";"";"334613";"UO_0000065";"22.37";"0.41";"4.50";"8.78";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3393358";"";"None";"323.33";"0";"2.47";"24";"N#Cc1cc(F)cc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"80.0";"nM";"7.10";"";"";"UO_0000065";"21.95";"0.40";"4.63";"9.12";"0";"CHEMBL3395726";"Inhibition of GST-tagged truncated human recombinant LRRK2 using fluorescein-labeled LRRKtide peptide substrate incubated for 2 hrs";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3393359";"";"None";"306.33";"0";"1.73";"BDBM50059314";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)n1";"IC50";"'='";"9.0";"nM";"8.05";"";"334322";"UO_0000065";"26.27";"0.48";"6.32";"8.87";"1";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3393343";"";"None";"303.37";"0";"3.49";"BDBM50059353";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCCCC4)c23)c1";"IC50";"'='";"6.0";"nM";"8.22";"";"334331";"UO_0000065";"27.10";"0.49";"4.73";"11.99";"1";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3906554";"";"None";"319.37";"0";"2.46";"BDBM185372";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCC[C@H](O)C4)c23)c1";"IC50";"'='";"17.0";"nM";"7.77";"";"334333";"UO_0000065";"24.33";"0.44";"5.31";"8.75";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3986026";"";"None";"347.42";"0";"4.42";"BDBM185380";"[C-]#[N+]c1ccc(OC)c(-c2c[nH]c3ncnc(N4CCCC(C)C4)c23)c1";"IC50";"'='";"25.0";"nM";"7.60";"";"334342";"UO_0000065";"21.88";"0.40";"3.18";"13.02";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3986410";"";"None";"308.39";"0";"3.57";"BDBM185412";"C[C@H]1CCCN(c2ncnc3[nH]cc(-c4ccc(O)cc4)c23)C1";"IC50";"'='";"26.0";"nM";"7.58";"";"334376";"UO_0000065";"24.60";"0.45";"4.02";"11.66";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3941219";"";"None";"371.40";"0";"2.80";"BDBM185392";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCOC(c5cc[nH]n5)C4)c23)c1";"IC50";"'='";"23.0";"nM";"7.64";"";"334396";"UO_0000065";"20.57";"0.37";"4.84";"7.17";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3972118";"";"None";"300.34";"0";"2.30";"BDBM185433";"Cn1cc(-c2c[nH]c3ncnc(N4CCC(F)CC4)c23)cn1";"IC50";"'='";"36.0";"nM";"7.44";"";"334401";"UO_0000065";"24.78";"0.46";"5.14";"11.89";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3929926";"";"None";"360.22";"0";"2.62";"BDBM185454";"Brc1cncc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"14.0";"nM";"7.85";"";"334636";"UO_0000065";"21.80";"0.49";"5.23";"11.73";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3917998";"";"None";"300.34";"0";"2.30";"BDBM185470";"Cn1cc(-c2c[nH]c3ncnc(N4CCCC(F)C4)c23)cn1";"IC50";"'='";"27.0";"nM";"7.57";"";"334654";"UO_0000065";"25.20";"0.47";"5.27";"12.08";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3963430";"";"None";"413.44";"0";"3.33";"BDBM185482";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCOC(c5noc(C6CC6)n5)C4)c23)c1";"IC50";"'='";"19.0";"nM";"7.72";"";"334455";"UO_0000065";"18.68";"0.34";"4.39";"6.61";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3913219";"";"None";"333.40";"0";"3.11";"BDBM185487";"CCC1CN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)CCO1";"IC50";"'='";"61.0";"nM";"7.21";"";"334460";"UO_0000065";"21.64";"0.39";"4.10";"9.27";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3907468";"";"None";"311.37";"0";"2.39";"BDBM185552";"N#Cc1ccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)s1";"IC50";"'='";"21.9";"nM";"7.66";"";"334522";"UO_0000065";"24.60";"0.48";"5.27";"9.84";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3393439";"";"None";"284.32";"0";"1.19";"BDBM50059307";"Cn1cc(-c2c[nH]c3ncnc(N4CCOCC4)c23)cn1";"IC50";"'='";"36.0";"nM";"7.44";"";"334531";"UO_0000065";"26.18";"0.48";"6.25";"10.36";"1";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3968566";"";"None";"331.42";"0";"4.12";"BDBM185370";"CC1(C)CCCN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)C1";"IC50";"'='";"325.0";"nM";"6.49";"";"334541";"UO_0000065";"19.58";"0.35";"2.37";"9.46";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3918244";"";"None";"321.36";"0";"3.43";"BDBM185388";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCC(F)CC4)c23)c1";"IC50";"'='";"56.0";"nM";"7.25";"";"334564";"UO_0000065";"22.57";"0.41";"3.82";"10.57";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3941219";"";"None";"371.40";"0";"2.80";"BDBM185392";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCOC(c5cc[nH]n5)C4)c23)c1";"IC50";"'='";"238.0";"nM";"6.62";"";"334567";"UO_0000065";"17.83";"0.32";"3.82";"6.22";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3912951";"";"None";"233.27";"0";"3.41";"BDBM254919";"Cc1cccc(-c2ccnc3[nH]cc(C#N)c23)c1";"IC50";"'='";"195.0";"nM";"6.71";"";"443702";"UO_0000065";"28.76";"0.51";"3.30";"12.79";"0";"CHEMBL3889252";"Homogeneous Time Resolved-fluorescence Resonance Energy Transfer (TR-FRET) Assay: LRRK2 kinase activity is measured using a LanthaScreen kinase activity assay available from Invitrogen (Life Technologies Corporation). The assay is a homogeneous time resolved-fluorescence resonance energy transfer (TR-FRET) assay that measures phosphorylation of a fluorescein-labelled peptide substrate (fluorescein-LRRKtide, fluorescein-GAGRLGRDKYKTLRQIRQ) (SEQ ID NO 1) as a result of LRRK2 kinase activity. The phosphorylated peptide is recognized by a terbium-labelled phospho-specific anti-LRRKtide antibody and, subsequently, the phosphorylated LRRKtide can be quantified by the extent of TR-FRET between the terbium donor and fluorescein acceptor.The LRRK2 kinase is obtained from Invitrogen (Life Technologies Corporation) and comprises residues 970 to 2527 of the full length human wild-type LRRK2 kinase or a similar sequence with the G2019S mutation. As discussed above, this mutation increases the kinase activity relative to the wild-type. The kinase reactions are performed in a 20 uL volume in 384-well plates. The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT.Â  In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 uM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 uM fluorescein-LRRKtide. The reaction mixture (20 ul total volume) is incubated for 2 hours at 30° C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 ul). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 us) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 us. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 us time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3887011";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3122108";"";"None";"328.30";"0";"2.57";"6";"CNc1nc(Nc2cnn3c2C(C)OCC3)ncc1C(F)(F)F";"IC50";"'='";"42.0";"nM";"7.38";"";"";"UO_0000065";"22.47";"0.44";"4.81";"9.59";"0";"CHEMBL3124215";"Inhibition of LRRK2 (unknown origin) phosphorylation by cell-based assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3120096";"1";"Scientific Literature";"J Med Chem";"2014";"None";"";"";""
"CHEMBL3393442";"";"None";"282.31";"0";"1.25";"31";"c1cnc(-c2c[nH]c3ncnc(N4CCOCC4)c23)cn1";"IC50";"'='";"1199.0";"nM";"5.92";"";"";"UO_0000065";"20.97";"0.39";"4.67";"7.42";"0";"CHEMBL3395727";"Inhibition of GST-tagged truncated human recombinant LRRK2 G2019S mutant using fluorescein-labeled LRRKtide peptide substrate incubated for 90 mins";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3393349";"";"None";"318.38";"0";"2.25";"15";"CN1CCN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)CC1";"IC50";"'='";"5223.0";"nM";"5.28";"";"";"UO_0000065";"16.59";"0.30";"3.03";"7.35";"0";"CHEMBL3395727";"Inhibition of GST-tagged truncated human recombinant LRRK2 G2019S mutant using fluorescein-labeled LRRKtide peptide substrate incubated for 90 mins";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3393448";"";"None";"387.40";"0";"2.77";"37";"Cc1noc(C2CN(c3ncnc4[nH]cc(-c5cccc(C#N)c5)c34)CCO2)n1";"IC50";"'='";"20.0";"nM";"7.70";"";"";"UO_0000065";"19.87";"0.36";"4.93";"6.59";"0";"CHEMBL3395726";"Inhibition of GST-tagged truncated human recombinant LRRK2 using fluorescein-labeled LRRKtide peptide substrate incubated for 2 hrs";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL2348938";"";"None";"378.40";"1";"5.02";"3";"FC(F)(F)c1cccc(Sc2ccc3nnc(-c4cccs4)n3n2)c1";"IC50";"'='";"1656.0";"nM";"5.78";"";"";"UO_0000065";"15.28";"0.32";"0.76";"13.42";"0";"CHEMBL2351460";"Inhibition of LRRK2 G2019S mutant (unknown origin) transfected in HEK293 cells assessed decrease in S935 autophosphorylation";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"CHEMBL3307715";"";"";""
"CHEMBL3409475";"";"None";"442.00";"1";"5.05";"34";"COc1cccc(CNc2ccc(C(=O)N3CCC(N4CCCCC4)CC3)cc2Cl)c1";"IC50";"'>'";"1000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL3412556";"Inhibition of LRRK2 G2019S mutant (1326 to 252 aa) (unknown origin) stably expressed in HEK293 cell lysate using [gamma-32P] after 15 mins by Cerenkov counting method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3407393";"1";"Scientific Literature";"Eur J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL3326129";"";"None";"382.45";"0";"3.00";"16";"COc1ccc(OC)c(Sc2ccc3nnc(-c4cn(C)nc4C)n3n2)c1";"IC50";"'='";"323.0";"nM";"6.49";"";"";"UO_0000065";"16.97";"0.33";"3.49";"8.18";"0";"CHEMBL3367450";"Inhibition of GST-tagged truncated LRRK2 (unknown origin) using fluorescein-labeled peptide LRRKtide as substrate by LANTHA screen assay in presence of 1 mM ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL3326115";"";"None";"365.42";"0";"3.35";"2";"COc1ccc(OC)c(Sc2ccc3nnc(-c4ccccn4)n3n2)c1";"IC50";"'='";"496.0";"nM";"6.30";"";"";"UO_0000065";"17.25";"0.33";"2.95";"8.47";"0";"CHEMBL3367450";"Inhibition of GST-tagged truncated LRRK2 (unknown origin) using fluorescein-labeled peptide LRRKtide as substrate by LANTHA screen assay in presence of 1 mM ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL388978";"STAUROSPORINE";"None";"466.54";"0";"4.35";"Staurosporine";"CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4";"IC50";"'='";"1.0";"nM";"9.00";"";"";"UO_0000065";"19.29";"0.35";"4.65";"12.96";"0";"CHEMBL2398947";"Inhibition of human N-terminal GST-tagged LRRK2 after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2396520";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL3954450";"";"None";"319.37";"0";"2.72";"BDBM185499";"C[C@H]1COCCN1c1ncnc2[nH]cc(-c3cccc(C#N)c3)c12";"IC50";"'='";"165.0";"nM";"6.78";"";"334684";"UO_0000065";"21.24";"0.39";"4.06";"8.71";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3910711";"";"None";"337.36";"0";"2.78";"BDBM185500";"Cc1nc(N2CCOCC2)c2c(-c3cccc(C#N)c3F)c[nH]c2n1";"IC50";"'='";"365.0";"nM";"6.44";"";"334685";"UO_0000065";"19.08";"0.35";"3.66";"8.27";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3925893";"";"None";"405.39";"0";"2.90";"BDBM185512";"Cc1noc(C2CN(c3ncnc4[nH]cc(-c5cccc(C#N)c5F)c34)CCO2)n1";"IC50";"'='";"95.7";"nM";"7.02";"";"334735";"UO_0000065";"17.31";"0.32";"4.12";"6.01";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3893023";"";"None";"323.36";"0";"1.56";"BDBM185556";"NC(=O)c1cccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"79.3";"nM";"7.10";"";"334736";"UO_0000065";"21.96";"0.40";"5.54";"7.31";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3966500";"";"None";"335.41";"0";"2.96";"BDBM185416";"C[C@H]1CCCN(c2ncnc3[nH]cc(-c4cccc(C(N)=O)c4)c23)C1";"IC50";"'='";"58.0";"nM";"7.24";"";"334591";"UO_0000065";"21.58";"0.40";"4.28";"8.23";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL378695";"";"None";"252.27";"0";"2.77";"2, E:Z Mixture (83:17)";"COc1ccc(/N=C2\C(=O)Nc3ccccc32)cc1";"IC50";"'='";"2330.0";"nM";"5.63";"";"";"UO_0000065";"22.33";"0.40";"2.86";"11.11";"0";"CHEMBL4192179";"Inhibition of recombinant catalytic human GST-tagged LLRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4190250";"1";"Scientific Literature";"Eur J Med Chem";"2017";"None";"";"";""
"CHEMBL4084769";"";"None";"329.37";"0";"3.28";"28";"Cc1cccc(-c2cc(Nc3ccn(C)n3)nc3[nH]cc(C#N)c23)n1";"IC50";"'='";"41.0";"nM";"7.39";"";"";"UO_0000065";"22.43";"0.40";"4.11";"7.76";"0";"CHEMBL4031821";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus using fluorescein-LRRKtide as substrate after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL3961481";"";"None";"343.39";"0";"3.59";"31";"Cc1cccc(-c2cc(Nc3nn(C)cc3C)nc3[nH]cc(C#N)c23)n1";"IC50";"'='";"130.0";"nM";"6.89";"";"";"UO_0000065";"20.05";"0.36";"3.30";"7.23";"0";"CHEMBL4031825";"Inhibition of human wild type LRRK2 phosphorylation at ser935 expressed in BacMam transduced HEK293 cells after 48 hrs by in-cell Western assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"CHEMBL3307715";"";"";""
"CHEMBL4065198";"";"None";"329.37";"0";"3.28";"25";"Cc1ccnc(-c2cc(Nc3ccn(C)n3)nc3[nH]cc(C#N)c23)c1";"IC50";"'='";"205.0";"nM";"6.69";"";"";"UO_0000065";"20.31";"0.37";"3.41";"7.02";"0";"CHEMBL4031820";"Inhibition of wild type recombinant human GST-tagged LRRK2 (970 to 2527 residues) expressed in baculovirus using fluorescein-LRRKtide as substrate after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL3912951";"";"None";"233.27";"0";"3.41";"18";"Cc1cccc(-c2ccnc3[nH]cc(C#N)c23)c1";"IC50";"'='";"195.0";"nM";"6.71";"";"";"UO_0000065";"28.76";"0.51";"3.30";"12.79";"1";"CHEMBL4031821";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus using fluorescein-LRRKtide as substrate after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL3979676";"";"None";"249.27";"0";"3.11";"20";"COc1cccc(-c2ccnc3[nH]cc(C#N)c23)c1";"IC50";"'='";"354.0";"nM";"6.45";"";"";"UO_0000065";"25.88";"0.46";"3.34";"10.46";"0";"CHEMBL4031821";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus using fluorescein-LRRKtide as substrate after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL3961632";"";"None";"248.29";"0";"2.99";"22";"Cc1cccc(-c2cc(N)nc3[nH]cc(C#N)c23)c1";"IC50";"'='";"39.81";"nM";"7.40";"";"";"UO_0000065";"29.80";"0.53";"4.41";"9.43";"0";"CHEMBL4031823";"Inhibition of human LRRK2 G2019S mutant phosphorylation at ser935 transfected in HEK293 cells after 48 hrs by in-cell Western assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"CHEMBL3307715";"";"";""
"CHEMBL3961481";"";"None";"343.39";"0";"3.59";"31";"Cc1cccc(-c2cc(Nc3nn(C)cc3C)nc3[nH]cc(C#N)c23)n1";"IC50";"'='";"170.0";"nM";"6.77";"";"";"UO_0000065";"19.71";"0.36";"3.18";"7.11";"0";"CHEMBL4031826";"Inhibition of human LRRK2 G2019S mutant phosphorylation at ser935 expressed in BacMam transduced HEK293 cells after 48 hrs by in-cell Western assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"CHEMBL3307715";"";"";""
"CHEMBL3919118";"";"None";"238.29";"0";"2.69";"BDBM185424";"CN(C)c1ncnc2[nH]cc(-c3ccccc3)c12";"IC50";"'='";"39.0";"nM";"7.41";"";"334599";"UO_0000065";"31.09";"0.56";"4.72";"16.53";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3393346";"";"None";"263.30";"0";"2.56";"12";"CN(C)c1ncnc2[nH]cc(-c3cccc(C#N)c3)c12";"IC50";"'='";"89.0";"nM";"7.05";"";"";"UO_0000065";"26.78";"0.48";"4.49";"10.28";"0";"CHEMBL3395728";"Inhibition of full length LRRK2 (unknown origin) expressed in HEK293 cells assessed as reduction in S935 phosphorylation incubated for 90 mins by ELISA method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL3393352";"";"None";"347.42";"0";"3.36";"18";"COCC1CCCN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)C1";"IC50";"'='";"219.0";"nM";"6.66";"";"";"UO_0000065";"19.17";"0.35";"3.30";"8.56";"0";"CHEMBL3395727";"Inhibition of GST-tagged truncated human recombinant LRRK2 G2019S mutant using fluorescein-labeled LRRKtide peptide substrate incubated for 90 mins";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3393351";"";"None";"333.40";"0";"3.11";"17";"COC1CCN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)CC1";"IC50";"'='";"393.0";"nM";"6.41";"";"";"UO_0000065";"19.21";"0.35";"3.30";"8.23";"0";"CHEMBL3395726";"Inhibition of GST-tagged truncated human recombinant LRRK2 using fluorescein-labeled LRRKtide peptide substrate incubated for 2 hrs";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3590142";"";"None";"295.26";"0";"2.38";"Z-8205";"N#Cc1ccc(Nc2ccc3[nH]c(=O)[nH]c3c2)c([N+](=O)[O-])c1";"IC50";"'='";"450.0";"nM";"6.35";"";"";"UO_0000065";"21.50";"0.39";"3.97";"4.97";"0";"CHEMBL3592570";"Inhibition of LRRK2 G2019S mutant (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3588794";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2015";"None";"";"";""
"CHEMBL3590143";"";"None";"418.88";"0";"4.42";"F-0025a";"O=C(NCCO)c1ccc(Nc2nc(-c3ccccc3)c3cc(Cl)ccc3n2)cc1";"IC50";"'='";"2000.0";"nM";"5.70";"";"";"UO_0000065";"13.61";"0.26";"1.28";"6.54";"0";"CHEMBL3592570";"Inhibition of LRRK2 G2019S mutant (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3588794";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2015";"None";"";"";""
"CHEMBL3122111";"";"None";"399.42";"0";"3.05";"9";"CNc1nc(Nc2cn(C(C)(C)C(=O)NC(C)C)nc2C)ncc1C(F)(F)F";"IC50";"'='";"140.0";"nM";"6.85";"";"";"UO_0000065";"17.16";"0.33";"3.80";"7.08";"0";"CHEMBL3124215";"Inhibition of LRRK2 (unknown origin) phosphorylation by cell-based assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3120096";"1";"Scientific Literature";"J Med Chem";"2014";"None";"";"";""
"CHEMBL2347817";"";"None";"391.50";"0";"4.39";"31";"C[C@@H](Nc1c(C#N)cnc2cc(-c3ccc(S(C)(=O)=O)cc3)ccc12)C1CC1";"IC50";"'='";"46.0";"nM";"7.34";"";"";"UO_0000065";"18.74";"0.36";"2.95";"8.86";"0";"CHEMBL2352558";"Inhibition of wild type GST-tagged LRRK2 (970-2527 amino acids)(unknown origin) assessed as inhibition of LRRKtide phosphorylation by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346515";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2347805";"";"None";"394.50";"0";"3.84";"19";"CC(C)Nc1c(C#N)cnc2cc(-c3ccc(S(=O)(=O)N(C)C)cc3)ccc12";"IC50";"'='";"37.0";"nM";"7.43";"";"";"UO_0000065";"18.84";"0.36";"3.59";"8.63";"0";"CHEMBL2352558";"Inhibition of wild type GST-tagged LRRK2 (970-2527 amino acids)(unknown origin) assessed as inhibition of LRRKtide phosphorylation by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346515";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL3971067";"";"None";"378.48";"0";"3.00";"45";"CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)cc3)cnc2N)nn1";"IC50";"'='";"920.0";"nM";"6.04";"";"";"UO_0000065";"15.95";"0.29";"3.04";"7.35";"0";"CHEMBL4045621";"Inhibition LRRK2 G2019S mutant (unknown origin) Ser935 phosphorylation in HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4043168";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL2348946";"";"None";"379.39";"0";"4.42";"11";"FC(F)(F)c1cccc(Sc2ccc3nnc(-c4nccs4)n3n2)c1";"IC50";"'='";"1727.0";"nM";"5.76";"";"";"UO_0000065";"15.19";"0.31";"1.34";"10.30";"0";"CHEMBL2351460";"Inhibition of LRRK2 G2019S mutant (unknown origin) transfected in HEK293 cells assessed decrease in S935 autophosphorylation";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"CHEMBL3307715";"";"";""
"CHEMBL3326124";"";"None";"355.38";"0";"2.95";"11";"COc1ccc(OC)c(Sc2ccc3nnc(-c4ccon4)n3n2)c1";"IC50";"'='";"804.0";"nM";"6.09";"";"";"UO_0000065";"17.15";"0.33";"3.14";"6.96";"0";"CHEMBL3367450";"Inhibition of GST-tagged truncated LRRK2 (unknown origin) using fluorescein-labeled peptide LRRKtide as substrate by LANTHA screen assay in presence of 1 mM ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL3326120";"";"None";"328.40";"0";"3.17";"7";"COc1ccc(OC)c(Sc2ccc3nnc(C4CC4)n3n2)c1";"IC50";"'='";"2290.0";"nM";"5.64";"";"";"UO_0000065";"17.17";"0.33";"2.47";"9.17";"0";"CHEMBL3367450";"Inhibition of GST-tagged truncated LRRK2 (unknown origin) using fluorescein-labeled peptide LRRKtide as substrate by LANTHA screen assay in presence of 1 mM ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL4103352";"";"None";"358.39";"0";"3.91";"22";"CC(C)Oc1ccc2[nH]nc(-c3ccnc(N4C[C@@H](F)[C@H](F)C4)c3)c2c1";"IC50";"'='";"341.0";"nM";"6.47";"";"";"UO_0000065";"18.05";"0.34";"2.56";"11.97";"0";"CHEMBL4010118";"Inhibition LRRK2 G2019S mutant Ser935 phosphorylation in human SH-SY5Y cells after 90 mins by Western blot analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007454";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4100265";"";"None";"363.81";"0";"3.94";"32";"Cc1cncc(-c2cc(Nc3nn(C)cc3Cl)nc3[nH]cc(C#N)c23)c1";"IC50";"'='";"68.0";"nM";"7.17";"";"";"UO_0000065";"19.70";"0.38";"3.23";"7.53";"0";"CHEMBL4031821";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus using fluorescein-LRRKtide as substrate after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL2204495";"";"None";"399.43";"1";"5.11";"2";"O=C(Nc1cccnc1)c1cc(-c2ccnc(F)c2)ccc1OCc1ccccc1";"IC50";"'='";"8.9";"nM";"8.05";"";"";"UO_0000065";"20.16";"0.37";"2.94";"12.56";"1";"CHEMBL4018178";"Inhibition of LRRK2 G2019S mutant (unknown origin) using biotinylated ezrin/radaxin/meosin peptide as substrate measured after 1 hr";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4017473";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL4463940";"";"None";"231.30";"0";"3.28";"37";"Cc1noc2ccnc(NC3CCCCC3)c12";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL4331900";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant catalytic domain (970 to 2527 residues) expressed in baculovirus expression system by radiometric assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330096";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4588446";"";"None";"281.34";"0";"3.62";"7, 19";"Cc1n[nH]c2ccnc(Nc3ccc4ncsc4c3)c12";"IC50";"'='";"130.0";"nM";"6.89";"";"";"UO_0000065";"24.48";"0.47";"3.27";"10.36";"0";"CHEMBL4331900";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant catalytic domain (970 to 2527 residues) expressed in baculovirus expression system by radiometric assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330096";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL2012582";"";"None";"570.70";"1";"3.44";"LRRK2-IN-1";"COc1cc(C(=O)N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2C";"IC50";"'='";"2450.0";"nM";"5.61";"";"";"UO_0000065";"9.83";"0.18";"2.17";"5.76";"0";"CHEMBL2015543";"Inhibition of LRRK2 A2016T mutant expressed in HEK293 cells using nictide and ATP as substrate";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"A2016T";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2010643";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2012";"CHEMBL3307715";"";"";""
"CHEMBL3966314";"";"None";"416.50";"0";"3.79";"BDBM234862";"COc1cc2ncnc(Nc3cccc(NS(=O)(=O)CC(C)C)c3)c2cc1OC";"IC50";"'='";"241.0";"nM";"6.62";"";"409340";"UO_0000065";"15.89";"0.31";"2.83";"6.46";"0";"CHEMBL3888566";"In vitro Kinase Assay: In vitro kinase assays using LRRK WT and LRRK G2019S.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886763";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3916001";"";"None";"388.45";"0";"3.15";"BDBM234869";"CCS(=O)(=O)Nc1cccc(Nc2ncnc3cc(OC)c(OC)cc23)c1";"IC50";"'='";"121.0";"nM";"6.92";"";"409352";"UO_0000065";"17.81";"0.35";"3.77";"6.75";"0";"CHEMBL3888567";"In vitro Kinase Assay: In vitro kinase assays using LRRK WT and LRRK G2019S.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886763";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3393352";"";"None";"347.42";"0";"3.36";"BDBM50059420";"COCC1CCCN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)C1";"IC50";"'='";"95.0";"nM";"7.02";"";"334346";"UO_0000065";"20.21";"0.37";"3.66";"9.02";"1";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3942403";"";"None";"348.41";"0";"2.24";"BDBM185398";"N#Cc1cccc(-c2c[nH]c3ncnc(NCCN4CCOCC4)c23)c1";"IC50";"'='";"89.0";"nM";"7.05";"";"334362";"UO_0000065";"20.24";"0.37";"4.81";"7.85";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3891128";"";"None";"347.42";"0";"3.10";"BDBM185406";"C[C@H]1CCCN(c2ncnc3[nH]cc(-c4ccc5c(c4)CNC5=O)c23)C1";"IC50";"'='";"33.0";"nM";"7.48";"";"334370";"UO_0000065";"21.53";"0.39";"4.38";"10.12";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3966500";"";"None";"335.41";"0";"2.96";"BDBM185416";"C[C@H]1CCCN(c2ncnc3[nH]cc(-c4cccc(C(N)=O)c4)c23)C1";"IC50";"'='";"86.0";"nM";"7.07";"";"334380";"UO_0000065";"21.07";"0.39";"4.11";"8.04";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3393344";"";"None";"289.34";"0";"3.10";"BDBM50059350";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCCC4)c23)c1";"IC50";"'='";"8.0";"nM";"8.10";"";"334390";"UO_0000065";"27.98";"0.50";"5.00";"11.80";"1";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3942521";"";"None";"323.33";"0";"3.15";"BDBM185432";"[C-]#[N+]c1ccc(F)c(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"49.0";"nM";"7.31";"";"334400";"UO_0000065";"22.61";"0.42";"4.16";"12.52";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3905428";"";"None";"310.41";"0";"2.84";"BDBM185379";"C[C@@H]1C[C@H](C)CN(c2ncnc3[nH]cc(-c4cnn(C)c4)c23)C1";"IC50";"'='";"16.0";"nM";"7.80";"";"334341";"UO_0000065";"25.11";"0.46";"4.96";"12.45";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3954258";"";"None";"310.36";"0";"1.95";"BDBM185449";"OCc1cccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"12.0";"nM";"7.92";"";"334420";"UO_0000065";"25.52";"0.47";"5.97";"10.66";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3948963";"";"None";"281.32";"0";"1.86";"BDBM185452";"c1cncc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"35.0";"nM";"7.46";"";"334423";"UO_0000065";"26.50";"0.48";"5.60";"11.14";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3964190";"";"None";"335.37";"0";"3.02";"BDBM185462";"[C-]#[N+]c1ccc(OC)c(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"48.0";"nM";"7.32";"";"334435";"UO_0000065";"21.82";"0.40";"4.30";"10.82";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL4112240";"";"None";"319.37";"0";"2.46";"BDBM185501";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCC[C@@H](O)C4)c23)c1";"IC50";"'='";"8.0";"nM";"8.10";"";"334475";"UO_0000065";"25.35";"0.46";"5.64";"9.12";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3916889";"";"None";"342.37";"0";"2.73";"BDBM185510";"COc1cc(F)cc(-c2c[nH]c3ncnc(N4CCCC(O)C4)c23)c1";"IC50";"'='";"29.0";"nM";"7.54";"";"334483";"UO_0000065";"22.02";"0.41";"4.81";"10.15";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3931267";"";"None";"298.32";"0";"2.98";"BDBM185514";"COc1ccc(F)cc1-c1c[nH]c2ncnc(N3CCC3)c12";"IC50";"'='";"85.0";"nM";"7.07";"";"334487";"UO_0000065";"23.70";"0.44";"4.09";"13.08";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3903295";"";"None";"309.37";"0";"2.55";"BDBM185515";"Cc1cncc(-c2c[nH]c3ncnc(N4CCO[C@@H](C)C4)c23)c1";"IC50";"'='";"99.0";"nM";"7.00";"";"334488";"UO_0000065";"22.64";"0.42";"4.45";"10.47";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3901378";"";"None";"309.33";"0";"1.07";"BDBM185560";"Cn1cc(-c2c[nH]c3ncnc(N4CCOCC4)c23)nc1C#N";"IC50";"'='";"7.47";"nM";"8.13";"";"334530";"UO_0000065";"26.27";"0.48";"7.06";"8.50";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3928018";"";"None";"303.37";"0";"3.34";"BDBM185426";"CC1CCN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)C1";"IC50";"'='";"158.0";"nM";"6.80";"";"334608";"UO_0000065";"22.42";"0.40";"3.46";"9.91";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3393353";"";"None";"280.33";"0";"2.46";"BDBM50059347";"c1ccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)cc1";"IC50";"'='";"14.0";"nM";"7.85";"";"334624";"UO_0000065";"28.02";"0.51";"5.39";"14.53";"1";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3907778";"";"None";"319.37";"0";"2.64";"BDBM185458";"Cc1cc(C#N)cc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"64.0";"nM";"7.19";"";"334642";"UO_0000065";"22.53";"0.41";"4.55";"9.24";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL2347825";"";"None";"380.47";"0";"3.50";"15";"CNS(=O)(=O)c1ccc(-c2ccc3c(NC(C)C)c(C#N)cnc3c2)cc1";"IC50";"'='";"9.0";"nM";"8.05";"";"";"UO_0000065";"21.15";"0.41";"4.55";"8.48";"0";"CHEMBL2352558";"Inhibition of wild type GST-tagged LRRK2 (970-2527 amino acids)(unknown origin) assessed as inhibition of LRRKtide phosphorylation by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346515";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2178799";"";"None";"387.23";"0";"3.69";"8";"Cn1cc(NC(=O)c2cnn3cccnc23)c(-c2cc(Cl)ccc2Cl)n1";"IC50";"'='";"400.0";"nM";"6.40";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL4666938";"Inhibition of recombinant human GST-tagged LRRK2 (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate incubated for 60 mins by Adapta assay";"A";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4665643";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL4764019";"";"None";"496.21";"0";"3.58";"47";"O=C(Nc1c[nH]nc1-c1cc(I)ccc1OC(F)F)c1cnn2cccnc12";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL4666938";"Inhibition of recombinant human GST-tagged LRRK2 (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate incubated for 60 mins by Adapta assay";"A";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4665643";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"TIME = 1.0 hr";"";""
"CHEMBL509032";"TAE-684";"None";"614.22";"2";"5.02";"TAE684";"COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1";"IC50";"'='";"93.3";"nM";"7.03";"";"";"UO_0000065";"11.45";"0.23";"2.01";"6.83";"0";"CHEMBL2015543";"Inhibition of LRRK2 A2016T mutant expressed in HEK293 cells using nictide and ATP as substrate";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"A2016T";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2010643";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2012";"CHEMBL3307715";"";"";""
"CHEMBL2012582";"";"None";"570.70";"1";"3.44";"23; LRRK2-IN-1";"COc1cc(C(=O)N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2C";"IC50";"'='";"6.0";"nM";"8.22";"";"";"UO_0000065";"14.41";"0.27";"4.78";"8.44";"1";"CHEMBL4668319";"Inhibition of GST-LRRK2 (1326 to 2527 residues) G2019S mutant (unknown origin) expressed in HEK293 cells incubated for 15 mins by cerenkov counting method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4665673";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 0.25 hr";"DEGRADER";""
"CHEMBL3414584";"";"None";"350.43";"0";"2.41";"11";"NC(=O)c1ncc(N[C@@H]2CCCC[C@@H]2N)nc1-c1cc2ccccc2[nH]1";"IC50";"'='";"30.0";"nM";"7.52";"";"";"UO_0000065";"21.47";"0.40";"5.11";"6.13";"1";"CHEMBL3865679";"Inhibition of GST-tagged recombinant human LRRK2 (970 to 2527 residues) expressed in baculovirus";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3864189";"1";"Scientific Literature";"ACS Med Chem Lett";"2016";"None";"";"";""
"CHEMBL3884319";"";"None";"386.45";"0";"4.24";"33";"CC1(C)C(=O)N([C@H]2CCc3c(O)cccc32)c2nc(Nc3ccccc3)ncc21";"IC50";"'='";"167.0";"nM";"6.78";"";"";"UO_0000065";"17.54";"0.32";"2.54";"8.65";"0";"CHEMBL3876040";"Inhibition of human full length wild type DYKDDDDK-tagged LRRK2 expressed in baculovirus expression system";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3875183";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL3901487";"";"None";"309.37";"0";"2.29";"BDBM185508";"Cc1cncc(-c2c[nH]c3ncnc(N4CCCC(O)C4)c23)c1";"IC50";"'='";"36.0";"nM";"7.44";"";"334481";"UO_0000065";"24.06";"0.44";"5.15";"9.55";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3977855";"";"None";"334.38";"0";"2.39";"BDBM185386";"CN(C)C(=O)CCNc1ncnc2[nH]cc(-c3cccc(C#N)c3)c12";"IC50";"'='";"248.0";"nM";"6.61";"";"334561";"UO_0000065";"19.75";"0.36";"4.22";"6.76";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3940203";"";"None";"332.41";"0";"3.00";"BDBM185395";"CN1CCCC(Nc2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)C1";"IC50";"'='";"243.0";"nM";"6.61";"";"334570";"UO_0000065";"19.90";"0.36";"3.61";"8.20";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3910647";"";"None";"371.47";"0";"2.51";"BDBM185402";"C[C@H]1CCCN(c2ncnc3[nH]cc(-c4cccc(S(N)(=O)=O)c4)c23)C1";"IC50";"'='";"33.0";"nM";"7.48";"";"334577";"UO_0000065";"20.14";"0.39";"4.97";"7.13";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3393454";"";"None";"331.38";"0";"2.58";"43";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CC5COCC5C4)c23)c1";"IC50";"'='";"3363.0";"nM";"5.47";"";"";"UO_0000065";"16.52";"0.30";"2.89";"7.03";"0";"CHEMBL3395728";"Inhibition of full length LRRK2 (unknown origin) expressed in HEK293 cells assessed as reduction in S935 phosphorylation incubated for 90 mins by ELISA method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL3393358";"";"None";"323.33";"0";"2.47";"24";"N#Cc1cc(F)cc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"2082.0";"nM";"5.68";"";"";"UO_0000065";"17.57";"0.32";"3.21";"7.30";"0";"CHEMBL3395728";"Inhibition of full length LRRK2 (unknown origin) expressed in HEK293 cells assessed as reduction in S935 phosphorylation incubated for 90 mins by ELISA method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL3393439";"";"None";"284.32";"0";"1.19";"28";"Cn1cc(-c2c[nH]c3ncnc(N4CCOCC4)c23)cn1";"IC50";"'='";"36.0";"nM";"7.44";"";"";"UO_0000065";"26.18";"0.48";"6.25";"10.36";"0";"CHEMBL3395727";"Inhibition of GST-tagged truncated human recombinant LRRK2 G2019S mutant using fluorescein-labeled LRRKtide peptide substrate incubated for 90 mins";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3393346";"";"None";"263.30";"0";"2.56";"12";"CN(C)c1ncnc2[nH]cc(-c3cccc(C#N)c3)c12";"IC50";"'='";"15.0";"nM";"7.82";"";"";"UO_0000065";"29.71";"0.53";"5.26";"11.41";"0";"CHEMBL3395727";"Inhibition of GST-tagged truncated human recombinant LRRK2 G2019S mutant using fluorescein-labeled LRRKtide peptide substrate incubated for 90 mins";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3393441";"";"None";"295.35";"0";"2.16";"30";"Cc1cncc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"18.0";"nM";"7.75";"";"";"UO_0000065";"26.22";"0.48";"5.58";"11.57";"0";"CHEMBL3395726";"Inhibition of GST-tagged truncated human recombinant LRRK2 using fluorescein-labeled LRRKtide peptide substrate incubated for 2 hrs";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3393357";"";"None";"323.33";"0";"2.47";"23";"N#Cc1cc(-c2c[nH]c3ncnc(N4CCOCC4)c23)ccc1F";"IC50";"'='";"117.0";"nM";"6.93";"";"";"UO_0000065";"21.44";"0.39";"4.46";"8.91";"0";"CHEMBL3395726";"Inhibition of GST-tagged truncated human recombinant LRRK2 using fluorescein-labeled LRRKtide peptide substrate incubated for 2 hrs";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3393352";"";"None";"347.42";"0";"3.36";"18";"COCC1CCCN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)C1";"IC50";"'='";"95.0";"nM";"7.02";"";"";"UO_0000065";"20.21";"0.37";"3.66";"9.02";"0";"CHEMBL3395726";"Inhibition of GST-tagged truncated human recombinant LRRK2 using fluorescein-labeled LRRKtide peptide substrate incubated for 2 hrs";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3393348";"";"None";"305.34";"0";"2.33";"14";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"3.0";"nM";"8.52";"";"";"UO_0000065";"27.91";"0.51";"6.19";"10.95";"0";"CHEMBL3395726";"Inhibition of GST-tagged truncated human recombinant LRRK2 using fluorescein-labeled LRRKtide peptide substrate incubated for 2 hrs";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3415610";"";"None";"382.42";"0";"1.26";"57";"COc1cccc2[nH]c(-c3nc(N[C@@H]4CCOC[C@@H]4N)cnc3C(N)=O)cc12";"IC50";"'='";"33.0";"nM";"7.48";"";"";"UO_0000065";"19.56";"0.36";"6.22";"5.30";"0";"CHEMBL3418522";"Inhibition of LRRK2 (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3414497";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3393440";"";"None";"284.32";"0";"1.19";"29";"Cn1ccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)n1";"IC50";"'='";"2570.0";"nM";"5.59";"";"";"UO_0000065";"19.66";"0.36";"4.40";"7.78";"0";"CHEMBL3395728";"Inhibition of full length LRRK2 (unknown origin) expressed in HEK293 cells assessed as reduction in S935 phosphorylation incubated for 90 mins by ELISA method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL3393351";"";"None";"333.40";"0";"3.11";"17";"COC1CCN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)CC1";"IC50";"'='";"950.0";"nM";"6.02";"";"";"UO_0000065";"18.06";"0.33";"2.91";"7.74";"0";"CHEMBL3395727";"Inhibition of GST-tagged truncated human recombinant LRRK2 G2019S mutant using fluorescein-labeled LRRKtide peptide substrate incubated for 90 mins";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3393341";"";"None";"317.40";"0";"3.73";"7";"C[C@H]1CCCN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)C1";"IC50";"'='";"49.0";"nM";"7.31";"";"";"UO_0000065";"23.03";"0.42";"3.58";"10.66";"0";"CHEMBL3395727";"Inhibition of GST-tagged truncated human recombinant LRRK2 G2019S mutant using fluorescein-labeled LRRKtide peptide substrate incubated for 90 mins";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3961632";"";"None";"248.29";"0";"2.99";"22";"Cc1cccc(-c2cc(N)nc3[nH]cc(C#N)c23)c1";"IC50";"'='";"471.0";"nM";"6.33";"";"";"UO_0000065";"25.48";"0.45";"3.34";"8.06";"0";"CHEMBL4031824";"Inhibition of human LRRK2 A2016T mutant phosphorylation at ser935 transfected in HEK293 cells after 48 hrs by in-cell Western assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"A2016T";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"CHEMBL3307715";"";"";""
"CHEMBL4065198";"";"None";"329.37";"0";"3.28";"25";"Cc1ccnc(-c2cc(Nc3ccn(C)n3)nc3[nH]cc(C#N)c23)c1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL4031825";"Inhibition of human wild type LRRK2 phosphorylation at ser935 expressed in BacMam transduced HEK293 cells after 48 hrs by in-cell Western assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"CHEMBL3307715";"";"";""
"CHEMBL4100265";"";"None";"363.81";"0";"3.94";"32";"Cc1cncc(-c2cc(Nc3nn(C)cc3Cl)nc3[nH]cc(C#N)c23)c1";"IC50";"'='";"93.0";"nM";"7.03";"";"";"UO_0000065";"19.33";"0.37";"3.09";"7.39";"0";"CHEMBL4031825";"Inhibition of human wild type LRRK2 phosphorylation at ser935 expressed in BacMam transduced HEK293 cells after 48 hrs by in-cell Western assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"CHEMBL3307715";"";"";""
"CHEMBL4207019";"";"None";"265.32";"0";"2.83";"13, E:Z Mixture (76:24)";"CN(C)c1ccc(N=C2C(=O)Nc3ccccc32)cc1";"IC50";"'='";"3790.0";"nM";"5.42";"";"";"UO_0000065";"20.43";"0.37";"2.59";"12.13";"0";"CHEMBL4192178";"Inhibition of recombinant catalytic human GST-tagged LLRK2 (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4190250";"1";"Scientific Literature";"Eur J Med Chem";"2017";"None";"";"";""
"CHEMBL3937482";"";"None";"402.48";"0";"3.54";"BDBM234865";"CCCS(=O)(=O)Nc1cccc(Nc2ncnc3cc(OC)c(OC)cc23)c1";"IC50";"'='";"334.0";"nM";"6.48";"";"409339";"UO_0000065";"16.09";"0.32";"2.94";"6.32";"0";"CHEMBL3888566";"In vitro Kinase Assay: In vitro kinase assays using LRRK WT and LRRK G2019S.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886763";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3975770";"";"None";"442.52";"0";"4.25";"BDBM234867";"COc1cc2ncnc(Nc3cccc(NS(=O)(=O)c4cccs4)c3)c2cc1OC";"IC50";"'='";"329.0";"nM";"6.48";"";"409342";"UO_0000065";"14.65";"0.30";"2.23";"6.33";"0";"CHEMBL3888566";"In vitro Kinase Assay: In vitro kinase assays using LRRK WT and LRRK G2019S.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886763";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3951753";"";"None";"386.43";"0";"3.28";"BDBM234860";"C=CS(=O)(=O)Nc1cccc(Nc2ncnc3cc(OC)c(OC)cc23)c1";"IC50";"'='";"45.5";"nM";"7.34";"";"409345";"UO_0000065";"19.00";"0.37";"4.06";"7.17";"0";"CHEMBL3888567";"In vitro Kinase Assay: In vitro kinase assays using LRRK WT and LRRK G2019S.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886763";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL2347819";"";"None";"382.49";"0";"4.33";"2";"CC(=O)c1cnc2cc(-c3ccc(S(C)(=O)=O)cc3)ccc2c1NC(C)C";"IC50";"'='";"71.0";"nM";"7.15";"";"";"UO_0000065";"18.69";"0.36";"2.82";"9.39";"0";"CHEMBL2352557";"Inhibition of GST-tagged LRRK2 G2019S mutant (970-2527 amino acids) (unknown origin) assessed as inhibition of LRRKtide phosphorylation by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346515";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL4784139";"";"None";"424.51";"0";"2.89";"8";"CCOc1cc(C(=O)N2CCN(C)CC2)ccc1Nc1nc(OCC)c2cc[nH]c2n1";"IC50";"'='";"10.0";"nM";"8.00";"";"";"UO_0000065";"18.85";"0.35";"5.11";"8.37";"0";"CHEMBL4721243";"Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs in presence of ATP by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4715821";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2018";"None";"TIME = 2.5 hr";"INHIBITOR";""
"CHEMBL4448579";"";"None";"447.54";"0";"3.08";"23";"COCCN1CCN(c2ccc(OCc3ccccc3)c(C(=O)Nc3ccnnc3)c2)CC1";"IC50";"'='";"398.11";"nM";"6.40";"";"";"UO_0000065";"14.30";"0.26";"3.32";"8.02";"0";"CHEMBL4372262";"Inhibition of human lymphoblastoid cell-derived LRRK2";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4371037";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4457647";"";"None";"390.44";"0";"3.14";"18";"O=C(Nc1ccnnc1)c1cc(N2CCOCC2)ccc1OCc1ccccc1";"IC50";"'='";"158.49";"nM";"6.80";"";"";"UO_0000065";"17.42";"0.32";"3.66";"8.88";"0";"CHEMBL4372262";"Inhibition of human lymphoblastoid cell-derived LRRK2";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4371037";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL3409462";"";"None";"321.85";"0";"3.01";"21";"Nc1ccc(C(=O)N2CCC(N3CCCCC3)CC2)cc1Cl";"IC50";"'='";"654.0";"nM";"6.18";"";"";"UO_0000065";"19.22";"0.38";"3.17";"12.48";"0";"CHEMBL3412556";"Inhibition of LRRK2 G2019S mutant (1326 to 252 aa) (unknown origin) stably expressed in HEK293 cell lysate using [gamma-32P] after 15 mins by Cerenkov counting method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3407393";"1";"Scientific Literature";"Eur J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL3409464";"";"None";"399.93";"0";"3.96";"23";"O=C(c1ccc(Nc2cncnc2)c(Cl)c1)N1CCC(N2CCCCC2)CC1";"IC50";"'>'";"1000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL3412556";"Inhibition of LRRK2 G2019S mutant (1326 to 252 aa) (unknown origin) stably expressed in HEK293 cell lysate using [gamma-32P] after 15 mins by Cerenkov counting method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3407393";"1";"Scientific Literature";"Eur J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL3409469";"";"None";"442.95";"1";"5.08";"28";"O=C(c1ccc(Nc2ccccc2[N+](=O)[O-])c(Cl)c1)N1CCC(N2CCCCC2)CC1";"IC50";"'>'";"1000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL3412556";"Inhibition of LRRK2 G2019S mutant (1326 to 252 aa) (unknown origin) stably expressed in HEK293 cell lysate using [gamma-32P] after 15 mins by Cerenkov counting method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3407393";"1";"Scientific Literature";"Eur J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL3409471";"";"None";"442.95";"1";"5.08";"30";"O=C(c1ccc(Nc2ccc([N+](=O)[O-])cc2)c(Cl)c1)N1CCC(N2CCCCC2)CC1";"IC50";"'>'";"1000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL3412556";"Inhibition of LRRK2 G2019S mutant (1326 to 252 aa) (unknown origin) stably expressed in HEK293 cell lysate using [gamma-32P] after 15 mins by Cerenkov counting method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3407393";"1";"Scientific Literature";"Eur J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL2326712";"";"None";"272.23";"0";"2.01";"4";"CNc1nc(Nc2cnn(C)c2)ncc1C(F)(F)F";"IC50";"'='";"99.0";"nM";"7.00";"";"";"UO_0000065";"25.73";"0.50";"4.99";"10.35";"0";"CHEMBL2328175";"Inhibition of LRRK2 (unknown origin) autophosphorylation by cell-based assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2321736";"1";"Scientific Literature";"ACS Med Chem Lett";"2013";"None";"";"";""
"CHEMBL3393452";"";"None";"317.35";"0";"2.33";"41";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CC5(COC5)C4)c23)c1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL3395728";"Inhibition of full length LRRK2 (unknown origin) expressed in HEK293 cells assessed as reduction in S935 phosphorylation incubated for 90 mins by ELISA method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL3393444";"";"None";"319.37";"0";"2.72";"33";"C[C@H]1CN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)CCO1";"IC50";"'='";"7.0";"nM";"8.15";"";"";"UO_0000065";"25.53";"0.46";"5.43";"10.48";"0";"CHEMBL3395726";"Inhibition of GST-tagged truncated human recombinant LRRK2 using fluorescein-labeled LRRKtide peptide substrate incubated for 2 hrs";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3393348";"";"None";"305.34";"0";"2.33";"14";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"15.0";"nM";"7.82";"";"";"UO_0000065";"25.62";"0.46";"5.49";"10.05";"0";"CHEMBL3395731";"Inhibition of LRRK2 in human PBMCs by ActivX KiNativ method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3393439";"";"None";"284.32";"0";"1.19";"28";"Cn1cc(-c2c[nH]c3ncnc(N4CCOCC4)c23)cn1";"IC50";"'='";"50.0";"nM";"7.30";"";"";"UO_0000065";"25.68";"0.47";"6.11";"10.16";"0";"CHEMBL3395731";"Inhibition of LRRK2 in human PBMCs by ActivX KiNativ method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL4091885";"";"None";"410.46";"0";"3.12";"16";"CN(C)S(=O)(=O)c1ccc(C(=O)Nc2nc3ccccc3n2-c2ccccc2)o1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL4018178";"Inhibition of LRRK2 G2019S mutant (unknown origin) using biotinylated ezrin/radaxin/meosin peptide as substrate measured after 1 hr";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4017473";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL4071415";"";"None";"358.41";"0";"2.92";"11";"c1cnnc(-c2ccc3[nH]nc(-c4ccnc(N5CCOCC5)c4)c3c2)c1";"IC50";"'='";"6.4";"nM";"8.19";"";"";"UO_0000065";"22.86";"0.41";"5.27";"10.27";"0";"CHEMBL4010109";"Inhibition of recombinant human GST-tagged LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus using fluorescein-ERM as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007454";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL3961632";"";"None";"248.29";"0";"2.99";"22";"Cc1cccc(-c2cc(N)nc3[nH]cc(C#N)c23)c1";"IC50";"'='";"40.0";"nM";"7.40";"";"";"UO_0000065";"29.80";"0.53";"4.41";"9.43";"0";"CHEMBL4031823";"Inhibition of human LRRK2 G2019S mutant phosphorylation at ser935 transfected in HEK293 cells after 48 hrs by in-cell Western assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"CHEMBL3307715";"";"";""
"CHEMBL4062430";"";"None";"401.24";"0";"4.81";"6c";"O=C(Nc1cccnc1)c1cc(Br)ccc1OCc1cccc(F)c1";"IC50";"'='";"15.85";"nM";"7.80";"";"";"UO_0000065";"19.44";"0.43";"2.99";"15.23";"0";"CHEMBL4058537";"Inhibition of LRRK2 (unknown origin) by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4052807";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL4756244";"";"None";"410.48";"0";"2.50";"6";"CCOc1nc(Nc2ccc(C(=O)N3CCN(C)CC3)cc2OC)nc2[nH]ccc12";"IC50";"'='";"15.85";"nM";"7.80";"";"";"UO_0000065";"19.00";"0.36";"5.30";"8.16";"0";"CHEMBL4721243";"Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs in presence of ATP by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4715821";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2018";"None";"TIME = 2.5 hr";"INHIBITOR";""
"CHEMBL4756758";"";"None";"380.45";"0";"2.49";"3";"CCOc1nc(Nc2ccc(C(=O)N3CCN(C)CC3)cc2)nc2[nH]ccc12";"IC50";"'='";"12.59";"nM";"7.90";"";"";"UO_0000065";"20.76";"0.39";"5.41";"9.15";"0";"CHEMBL4721243";"Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs in presence of ATP by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4715821";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2018";"None";"TIME = 2.5 hr";"INHIBITOR";""
"CHEMBL4759051";"";"None";"423.52";"0";"2.55";"13";"CCOc1nc(Nc2ccc(C(=O)N3CCN(C)CC3)cc2N(C)C)nc2[nH]ccc12";"IC50";"'='";"3162.28";"nM";"5.50";"";"";"UO_0000065";"12.99";"0.24";"2.95";"6.14";"0";"CHEMBL4721244";"Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins by Alpha Screen assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4715821";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2018";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL4794578";"";"None";"397.44";"0";"2.58";"7";"CCOc1nc(Nc2ccc(C(=O)N3CCOCC3)cc2OC)nc2[nH]ccc12";"IC50";"'='";"31.62";"nM";"7.50";"";"";"UO_0000065";"18.87";"0.35";"4.92";"7.38";"0";"CHEMBL4721259";"Inhibition of LRRK2 in human AHE cells assessed as reduction in Ser935 phosphorylation";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"Lymphoblastoid cell";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4715821";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2018";"None";"";"INHIBITOR";""
"CHEMBL4743843";"";"None";"425.49";"0";"3.36";"11";"CCOc1nc(Nc2ccc(C(=O)N3CCOCC3)cc2OC(C)C)nc2[nH]ccc12";"IC50";"'='";"630.96";"nM";"6.20";"";"";"UO_0000065";"14.57";"0.27";"2.84";"6.10";"0";"CHEMBL4721244";"Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins by Alpha Screen assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4715821";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2018";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL4795075";"";"None";"409.45";"0";"2.58";"19";"CCOc1nc(Nc2ccc(C(=O)N3CC4(COC4)C3)cc2OC)nc2[nH]ccc12";"IC50";"'='";"63.1";"nM";"7.20";"";"";"UO_0000065";"17.58";"0.33";"4.62";"7.09";"0";"CHEMBL4721243";"Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs in presence of ATP by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4715821";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2018";"None";"TIME = 2.5 hr";"INHIBITOR";""
"CHEMBL2347813";"";"None";"406.51";"0";"2.93";"27";"CN1CCN(c2c(C#N)cnc3cc(-c4ccc(S(C)(=O)=O)cc4)ccc23)CC1";"IC50";"'='";"120.0";"nM";"6.92";"";"";"UO_0000065";"17.02";"0.33";"3.99";"8.95";"0";"CHEMBL2352557";"Inhibition of GST-tagged LRRK2 G2019S mutant (970-2527 amino acids) (unknown origin) assessed as inhibition of LRRKtide phosphorylation by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346515";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2347818";"";"None";"396.45";"0";"4.73";"32";"C[C@@H](Nc1c(C#N)cnc2cc(-c3ccc(-n4ccoc4=O)cc3)ccc12)C1CC1";"IC50";"'='";"48.0";"nM";"7.32";"";"";"UO_0000065";"18.46";"0.33";"2.59";"8.73";"0";"CHEMBL2352558";"Inhibition of wild type GST-tagged LRRK2 (970-2527 amino acids)(unknown origin) assessed as inhibition of LRRKtide phosphorylation by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346515";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2347807";"";"None";"327.84";"1";"5.31";"21";"CC(C)Nc1c(C#N)cnc2cc(-c3ccc(Cl)s3)ccc12";"IC50";"'='";"109.0";"nM";"6.96";"";"";"UO_0000065";"21.24";"0.43";"1.65";"14.29";"0";"CHEMBL2352558";"Inhibition of wild type GST-tagged LRRK2 (970-2527 amino acids)(unknown origin) assessed as inhibition of LRRKtide phosphorylation by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346515";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL3409460";"";"None";"274.71";"0";"2.49";"11";"CN1C(=O)c2ccccc2N(C)c2nc(Cl)ncc21";"IC50";"'>'";"1000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL3412556";"Inhibition of LRRK2 G2019S mutant (1326 to 252 aa) (unknown origin) stably expressed in HEK293 cell lysate using [gamma-32P] after 15 mins by Cerenkov counting method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3407393";"1";"Scientific Literature";"Eur J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL3949980";"";"None";"332.41";"0";"3.66";"41";"CC(C)n1cc(-c2cc(-c3ccc4c(ccn4C)c3)cnc2N)nn1";"IC50";"'='";"550.0";"nM";"6.26";"";"";"UO_0000065";"18.83";"0.34";"2.60";"8.40";"1";"CHEMBL4045604";"Inhibition of recombinant human wild type GST-tagged LRRK2 (970 to 2527 residues) preincubated for 30 mins followed by fluorescein-LRRKtide substrate addition after 2 hrs by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4043168";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL3921258";"";"None";"364.45";"0";"3.01";"43";"CC(C)n1cc(-c2cc(-c3ccc(N4CCOCC4)cc3)cnc2N)nn1";"IC50";"'='";"340.0";"nM";"6.47";"";"";"UO_0000065";"17.75";"0.33";"3.46";"7.88";"1";"CHEMBL4045604";"Inhibition of recombinant human wild type GST-tagged LRRK2 (970 to 2527 residues) preincubated for 30 mins followed by fluorescein-LRRKtide substrate addition after 2 hrs by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4043168";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL4064894";"";"None";"264.33";"0";"3.04";"31";"Cc1ccc(-c2cnc(N)c(-c3cn(C)cn3)c2)cc1";"IC50";"'='";"57000.0";"nM";"4.24";"";"";"UO_0000065";"16.06";"0.29";"1.20";"7.48";"0";"CHEMBL4045603";"Inhibition of recombinant human LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus preincubated for 30 mins followed by fluorescein-LRRKtide substrate addition after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4043168";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL4100328";"";"None";"289.34";"0";"3.21";"36";"Cn1cc(-c2cc(-c3ccc4[nH]ccc4c3)cnc2N)cn1";"IC50";"'='";"13000.0";"nM";"4.89";"";"";"UO_0000065";"16.89";"0.30";"1.68";"6.74";"0";"CHEMBL4045603";"Inhibition of recombinant human LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus preincubated for 30 mins followed by fluorescein-LRRKtide substrate addition after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4043168";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL3040018";"";"None";"479.59";"0";"4.25";"F-0193";"Cc1ccc(NC(=O)c2ccc(CN3CCNCC3)cc2)cc1Nc1nccc(-c2cccnc2)n1";"IC50";"'='";"3300.0";"nM";"5.48";"";"";"UO_0000065";"11.43";"0.21";"1.23";"5.77";"0";"CHEMBL3592570";"Inhibition of LRRK2 G2019S mutant (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3588794";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2015";"None";"";"";""
"CHEMBL4069384";"";"None";"265.32";"0";"2.53";"16";"Cc1ccc(-c2cnc(N)c(-n3cc(C)nn3)c2)cc1";"IC50";"'='";"9100.0";"nM";"5.04";"";"";"UO_0000065";"19.00";"0.34";"2.51";"7.24";"0";"CHEMBL4045603";"Inhibition of recombinant human LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus preincubated for 30 mins followed by fluorescein-LRRKtide substrate addition after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4043168";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL4098856";"";"None";"303.37";"0";"3.22";"42";"Cn1cc(-c2cc(-c3ccc4c(ccn4C)c3)cnc2N)cn1";"IC50";"'='";"5800.0";"nM";"5.24";"";"";"UO_0000065";"17.26";"0.31";"2.02";"8.49";"0";"CHEMBL4045603";"Inhibition of recombinant human LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus preincubated for 30 mins followed by fluorescein-LRRKtide substrate addition after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4043168";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL4060616";"";"None";"177.59";"0";"2.09";"11";"N#Cc1c[nH]c2nccc(Cl)c12";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL4031820";"Inhibition of wild type recombinant human GST-tagged LRRK2 (970 to 2527 residues) expressed in baculovirus using fluorescein-LRRKtide as substrate after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4070845";"";"None";"375.43";"0";"3.61";"8f";"CN(C)C(=O)c1ccc(OCc2ccccc2)c(C(=O)Nc2cccnc2)c1";"IC50";"'='";"199.53";"nM";"6.70";"";"";"UO_0000065";"17.85";"0.33";"3.09";"9.37";"0";"CHEMBL4058537";"Inhibition of LRRK2 (unknown origin) by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4052807";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL4066777";"";"None";"334.38";"0";"3.92";"8d";"COc1ccc(OCc2ccccc2)c(C(=O)Nc2cccnc2)c1";"IC50";"'='";"15.85";"nM";"7.80";"";"";"UO_0000065";"23.33";"0.43";"3.88";"12.90";"0";"CHEMBL4058537";"Inhibition of LRRK2 (unknown origin) by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4052807";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL4104344";"";"None";"264.33";"0";"3.04";"3a";"Cc1ccc(-c2cnc(N)c(-c3cnn(C)c3)c2)cc1";"IC50";"'='";"16000.0";"nM";"4.80";"";"";"UO_0000065";"18.14";"0.33";"1.76";"8.45";"0";"CHEMBL4045604";"Inhibition of recombinant human wild type GST-tagged LRRK2 (970 to 2527 residues) preincubated for 30 mins followed by fluorescein-LRRKtide substrate addition after 2 hrs by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4043168";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL2333128";"";"None";"410.50";"0";"3.01";"13";"C[C@@H](Nc1c(C(N)=O)nnc2cc(-c3ccc(S(C)(=O)=O)cc3)ccc12)C1CC1";"IC50";"'='";"7.0";"nM";"8.15";"";"";"UO_0000065";"19.87";"0.38";"5.14";"7.09";"0";"CHEMBL2345527";"Inhibition of GST-tagged LRRK2 G2019S mutant (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL1434292";"";"None";"240.24";"0";"2.90";"10, E:Z Mixture (67:33)";"O=C1Nc2ccccc2C1=Nc1ccc(F)cc1";"IC50";"'='";"3690.0";"nM";"5.43";"";"";"UO_0000065";"22.61";"0.41";"2.53";"13.10";"0";"CHEMBL4192179";"Inhibition of recombinant catalytic human GST-tagged LLRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4190250";"1";"Scientific Literature";"Eur J Med Chem";"2017";"None";"";"";""
"CHEMBL4207019";"";"None";"265.32";"0";"2.83";"13, E:Z Mixture (76:24)";"CN(C)c1ccc(N=C2C(=O)Nc3ccccc32)cc1";"IC50";"'='";"3110.0";"nM";"5.51";"";"";"UO_0000065";"20.76";"0.38";"2.68";"12.32";"0";"CHEMBL4192179";"Inhibition of recombinant catalytic human GST-tagged LLRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4190250";"1";"Scientific Literature";"Eur J Med Chem";"2017";"None";"";"";""
"CHEMBL1311313";"";"None";"231.25";"0";"0.68";"20, E:Z Mixture (88:12)";"O=C1Nc2ccccc2C1=NN1CCOCC1";"IC50";"'='";"6680.0";"nM";"5.17";"";"";"UO_0000065";"22.38";"0.42";"4.50";"9.60";"0";"CHEMBL4192179";"Inhibition of recombinant catalytic human GST-tagged LLRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4190250";"1";"Scientific Literature";"Eur J Med Chem";"2017";"None";"";"";""
"CHEMBL4215437";"";"None";"265.70";"0";"1.33";"44, E:Z Mixture (26:74)";"O=C1Nc2ccc(Cl)cc2C1=NN1CCOCC1";"IC50";"'='";"1460.0";"nM";"5.84";"";"";"UO_0000065";"21.96";"0.44";"4.51";"10.82";"0";"CHEMBL4192179";"Inhibition of recombinant catalytic human GST-tagged LLRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4190250";"1";"Scientific Literature";"Eur J Med Chem";"2017";"None";"";"";""
"CHEMBL4216488";"";"None";"357.15";"0";"1.28";"50, E:Z Mixture (30:70)";"O=C1Nc2ccc(I)cc2C1=NN1CCOCC1";"IC50";"'='";"550.0";"nM";"6.26";"";"";"UO_0000065";"17.53";"0.47";"4.98";"11.61";"0";"CHEMBL4192178";"Inhibition of recombinant catalytic human GST-tagged LLRK2 (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4190250";"1";"Scientific Literature";"Eur J Med Chem";"2017";"None";"";"";""
"CHEMBL4210498";"";"None";"249.24";"0";"0.81";"45, E:Z Mixture (30:70)";"O=C1Nc2ccc(F)cc2C1=NN1CCOCC1";"IC50";"'='";"5400.0";"nM";"5.27";"";"";"UO_0000065";"21.13";"0.40";"4.46";"9.77";"0";"CHEMBL4192179";"Inhibition of recombinant catalytic human GST-tagged LLRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4190250";"1";"Scientific Literature";"Eur J Med Chem";"2017";"None";"";"";""
"CHEMBL4203202";"";"None";"240.24";"0";"2.90";"8, E:Z Mixture (67:33)";"O=C1Nc2ccccc2C1=Nc1ccccc1F";"IC50";"'='";"3290.0";"nM";"5.48";"";"";"UO_0000065";"22.82";"0.42";"2.58";"13.22";"0";"CHEMBL4192179";"Inhibition of recombinant catalytic human GST-tagged LLRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4190250";"1";"Scientific Literature";"Eur J Med Chem";"2017";"None";"";"";""
"CHEMBL3978913";"";"None";"353.43";"0";"3.03";"BDBM239272";"CCOc1ccc2[nH]nc(-c3cc(N4C[C@@H](C)O[C@@H](C)C4)ncn3)c2c1";"IC50";"'='";"12.75";"nM";"7.89";"";"417731";"UO_0000065";"22.34";"0.41";"4.86";"10.37";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3979762";"";"None";"361.41";"0";"2.26";"BDBM239080";"Cn1cc(-c2ccc3[nH]nc(-c4cc(N5CCOCC5)ncn4)c3c2)cn1";"IC50";"'='";"41.0";"nM";"7.39";"";"417363";"UO_0000065";"20.44";"0.37";"5.13";"8.72";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3890426";"";"None";"388.48";"0";"2.56";"BDBM239082";"CCN1CCN(c2cc(-c3n[nH]c4ccc(-c5cnn(C)c5)cc34)ncn2)CC1";"IC50";"'='";"14.0";"nM";"7.85";"";"417365";"UO_0000065";"20.22";"0.37";"5.29";"9.97";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3953967";"";"None";"373.41";"0";"4.04";"BDBM239195";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCC(F)(F)CC4)ncn3)c2c1";"IC50";"'='";"14.8";"nM";"7.83";"";"417653";"UO_0000065";"20.97";"0.40";"3.79";"11.70";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3933109";"";"None";"371.42";"0";"3.17";"BDBM239223";"CC(C)Oc1cc2c(-c3cc(N4CCO[C@@H](C)C4)ncn3)n[nH]c2cc1F";"IC50";"'='";"5.01";"nM";"8.30";"";"417684";"UO_0000065";"22.35";"0.42";"5.13";"10.90";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3897231";"";"None";"448.52";"0";"2.42";"BDBM239252";"CCS(=O)(=O)N1CCN(c2cc(-c3n[nH]c4cc(F)c(OC(C)C)cc34)ncn2)CC1";"IC50";"'='";"2.24";"nM";"8.65";"";"417713";"UO_0000065";"19.29";"0.38";"6.23";"8.29";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3967517";"";"None";"382.47";"0";"1.92";"BDBM239318";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCN(CCO)CC4)ncn3)c2c1";"IC50";"'='";"7.4";"nM";"8.13";"";"417786";"UO_0000065";"21.26";"0.40";"6.21";"8.99";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3955983";"";"None";"437.55";"0";"2.45";"BDBM239343";"CC(C)NC(=O)CN1CCN(c2cc(-c3n[nH]c4ccc(OC(C)C)cc34)ncn2)CC1";"IC50";"'='";"5.1";"nM";"8.29";"";"417811";"UO_0000065";"18.95";"0.35";"5.84";"8.35";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4107947";"";"None";"375.44";"0";"2.65";"BDBM239391";"CO[C@@H]1CCN(c2cc(-c3n[nH]c4ccc(-c5cnn(C)c5)cc34)ncn2)C1";"IC50";"'='";"4.0";"nM";"8.40";"";"417857";"UO_0000065";"22.37";"0.41";"5.75";"9.91";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3975424";"";"None";"409.48";"0";"1.66";"BDBM239408";"Cn1cc(-c2ccc3[nH]nc(-c4cc(N5CCS(=O)(=O)CC5)ncn4)c3c2)cn1";"IC50";"'='";"22.4";"nM";"7.65";"";"417874";"UO_0000065";"18.68";"0.36";"5.99";"6.98";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3957537";"";"None";"381.39";"0";"3.27";"BDBM239416";"Cn1cc(-c2ccc3[nH]nc(-c4cc(N5CCC(F)(F)C5)ncn4)c3c2)cn1";"IC50";"'='";"3.7";"nM";"8.43";"";"417882";"UO_0000065";"22.11";"0.41";"5.16";"11.16";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3946153";"";"None";"385.44";"0";"3.56";"BDBM239444";"CC(C)Oc1cc2c(-c3cc(N4[C@H](C)COC[C@@H]4C)ncn3)n[nH]c2cc1F";"IC50";"'='";"5.4";"nM";"8.27";"";"417910";"UO_0000065";"21.45";"0.40";"4.71";"10.86";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3984092";"";"None";"390.45";"0";"3.60";"BDBM239491";"Cc1nocc1-c1ccc2[nH]nc(-c3cc(N4C[C@@H](C)O[C@@H](C)C4)ncn3)c2c1";"IC50";"'='";"40.0";"nM";"7.40";"";"417956";"UO_0000065";"18.95";"0.35";"3.80";"7.96";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3898946";"";"None";"318.38";"0";"2.42";"BDBM185476";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCCC(N)C4)c23)c1";"IC50";"'='";"21.0";"nM";"7.68";"";"334660";"UO_0000065";"24.12";"0.44";"5.26";"8.11";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3901157";"";"None";"436.48";"0";"3.65";"BDBM185484";"N#Cc1cccc(OCC2CN(c3ncnc4[nH]cc(-c5cccc(C#N)c5)c34)CCO2)c1";"IC50";"'='";"51.0";"nM";"7.29";"";"334668";"UO_0000065";"16.71";"0.30";"3.64";"6.58";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3986654";"";"None";"346.39";"0";"2.20";"BDBM185486";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCCC(C(N)=O)C4)c23)c1";"IC50";"'='";"136.0";"nM";"6.87";"";"334670";"UO_0000065";"19.82";"0.36";"4.67";"6.15";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL4112240";"";"None";"319.37";"0";"2.46";"BDBM185501";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCC[C@@H](O)C4)c23)c1";"IC50";"'='";"37.0";"nM";"7.43";"";"334686";"UO_0000065";"23.27";"0.42";"4.97";"8.37";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3931267";"";"None";"298.32";"0";"2.98";"BDBM185514";"COc1ccc(F)cc1-c1c[nH]c2ncnc(N3CCC3)c12";"IC50";"'='";"75.0";"nM";"7.12";"";"334698";"UO_0000065";"23.88";"0.44";"4.14";"13.18";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3979426";"";"None";"268.32";"0";"2.70";"BDBM185519";"COc1ccccc1-c1c[nH]c2ncnc(N(C)C)c12";"IC50";"'='";"29.0";"nM";"7.54";"";"334700";"UO_0000065";"28.09";"0.51";"4.84";"13.95";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3962415";"";"None";"312.35";"0";"3.18";"BDBM185521";"COc1ccccc1-c1c[nH]c2ncnc(N3CC[C@H](F)C3)c12";"IC50";"'='";"54.0";"nM";"7.27";"";"334701";"UO_0000065";"23.27";"0.43";"4.09";"13.45";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3948344";"";"None";"342.37";"0";"3.00";"BDBM185525";"COc1ccc(F)cc1-c1c[nH]c2ncnc(N3CCO[C@@H](C)C3)c12";"IC50";"'='";"30.0";"nM";"7.52";"";"334705";"UO_0000065";"21.97";"0.41";"4.52";"11.89";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3935730";"";"None";"387.40";"0";"2.77";"BDBM185459";"Cc1nc(C2CN(c3ncnc4[nH]cc(-c5cccc(C#N)c5)c34)CCO2)no1";"IC50";"'='";"73.0";"nM";"7.14";"";"334718";"UO_0000065";"18.42";"0.34";"4.37";"6.11";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3981043";"";"None";"321.34";"0";"1.50";"BDBM185553";"c1cnn2c(-c3c[nH]c4ncnc(N5CCOCC5)c34)cnc2c1";"IC50";"'='";"12.3";"nM";"7.91";"";"334734";"UO_0000065";"24.62";"0.45";"6.41";"9.39";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3946203";"";"None";"310.38";"0";"4.00";"BDBM185403";"C[C@H]1CCCN(c2ncnc3[nH]cc(-c4ccccc4F)c23)C1";"IC50";"'='";"97.0";"nM";"7.01";"";"334367";"UO_0000065";"22.60";"0.42";"3.01";"15.65";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3914712";"";"None";"314.78";"0";"3.11";"BDBM185445";"Clc1ccccc1-c1c[nH]c2ncnc(N3CCOCC3)c12";"IC50";"'='";"21.0";"nM";"7.68";"";"334415";"UO_0000065";"24.39";"0.48";"4.57";"14.21";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3952215";"";"None";"331.38";"0";"3.01";"BDBM185453";"c1ccc2c(-c3c[nH]c4ncnc(N5CCOCC5)c34)cncc2c1";"IC50";"'='";"27.0";"nM";"7.57";"";"334424";"UO_0000065";"22.84";"0.41";"4.56";"11.31";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3905907";"";"None";"298.35";"0";"1.32";"BDBM185467";"Cn1cc(-c2c[nH]c3ncnc(N4CCCC(O)C4)c23)cn1";"IC50";"'='";"44.0";"nM";"7.36";"";"334440";"UO_0000065";"24.66";"0.46";"6.04";"8.88";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL4448579";"";"None";"447.54";"0";"3.08";"23";"COCCN1CCN(c2ccc(OCc3ccccc3)c(C(=O)Nc3ccnnc3)c2)CC1";"IC50";"'='";"251.19";"nM";"6.60";"";"";"UO_0000065";"14.75";"0.27";"3.52";"8.27";"0";"CHEMBL4372261";"Inhibition of parkinson's patient-derived LRRK2 G2019S mutant";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4371037";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4439028";"";"None";"188.23";"0";"1.84";"13";"Cc1n[nH]c2ccnc(NC3CC3)c12";"IC50";"'='";"4700.0";"nM";"5.33";"";"";"UO_0000065";"28.31";"0.52";"3.49";"9.94";"0";"CHEMBL4331900";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant catalytic domain (970 to 2527 residues) expressed in baculovirus expression system by radiometric assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330096";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4077034";"";"None";"363.81";"0";"3.94";"33";"Cc1cc(-c2cc(Nc3nn(C)cc3Cl)nc3[nH]cc(C#N)c23)ccn1";"IC50";"'='";"1300.0";"nM";"5.89";"";"";"UO_0000065";"16.18";"0.31";"1.95";"6.18";"0";"CHEMBL4031825";"Inhibition of human wild type LRRK2 phosphorylation at ser935 expressed in BacMam transduced HEK293 cells after 48 hrs by in-cell Western assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"CHEMBL3307715";"";"";""
"CHEMBL4092521";"";"None";"363.81";"0";"3.94";"34";"Cc1cccc(-c2cc(Nc3nn(C)cc3Cl)nc3[nH]cc(C#N)c23)n1";"IC50";"'='";"110.0";"nM";"6.96";"";"";"UO_0000065";"19.13";"0.37";"3.02";"7.31";"0";"CHEMBL4031825";"Inhibition of human wild type LRRK2 phosphorylation at ser935 expressed in BacMam transduced HEK293 cells after 48 hrs by in-cell Western assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"CHEMBL3307715";"";"";""
"CHEMBL4473326";"";"None";"357.41";"0";"3.52";"10";"O=C(Nc1nc2ccc(F)cc2s1)c1ccc(N2CCOCC2)cc1";"IC50";"'='";"170.0";"nM";"6.77";"";"";"UO_0000065";"18.94";"0.37";"3.25";"12.43";"0";"CHEMBL4403862";"Inhibition of wild type human GST-tagged LRRK2 (970 to 2527 residues) expressed in baculovirus expression system assessed as reduction in ADP formation using LRRKtide as substrate measured after 1 hr in presence of ATP by Adapta assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4402549";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL4543902";"";"None";"397.50";"0";"4.17";"16";"CCCOc1ccc2nc(NC(=O)c3ccc(N4CCOCC4)cc3)sc2c1";"IC50";"'='";"1120.0";"nM";"5.95";"";"";"UO_0000065";"14.97";"0.29";"1.78";"9.34";"0";"CHEMBL4403864";"Inhibition of human GST-tagged LRRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus expression system assessed as reduction in ADP formation using LRRKtide as substrate measured after 1 hr in presence of ATP by Adapta assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4402549";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL4553487";"";"None";"306.75";"0";"4.34";"20";"O=C(Nc1nc2ccc(F)cc2s1)c1ccc(Cl)cc1";"IC50";"'='";"5640.0";"nM";"5.25";"";"";"UO_0000065";"17.11";"0.36";"0.91";"12.50";"0";"CHEMBL4403864";"Inhibition of human GST-tagged LRRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus expression system assessed as reduction in ADP formation using LRRKtide as substrate measured after 1 hr in presence of ATP by Adapta assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4402549";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL3909904";"";"None";"375.44";"0";"2.65";"BDBM239402";"C[C@H]1CN(c2cc(-c3n[nH]c4ccc(-c5cnn(C)c5)cc34)ncn2)CCO1";"IC50";"'='";"2.2";"nM";"8.66";"";"417868";"UO_0000065";"23.06";"0.42";"6.01";"10.22";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3911917";"";"None";"395.42";"0";"3.66";"BDBM239411";"Cn1cc(-c2ccc3[nH]nc(-c4cc(N5CCC(F)(F)CC5)ncn4)c3c2)cn1";"IC50";"'='";"4.6";"nM";"8.34";"";"417877";"UO_0000065";"21.08";"0.39";"4.68";"11.04";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3968354";"";"None";"383.43";"0";"3.31";"BDBM239430";"CC(C)Oc1cc2c(-c3cc(N4C5CCC4COC5)ncn3)n[nH]c2cc1F";"IC50";"'='";"18.2";"nM";"7.74";"";"417896";"UO_0000065";"20.19";"0.38";"4.43";"10.16";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3890426";"";"None";"388.48";"0";"2.56";"BDBM239082";"CCN1CCN(c2cc(-c3n[nH]c4ccc(-c5cnn(C)c5)cc34)ncn2)CC1";"IC50";"'='";"0.76";"nM";"9.12";"";"312514";"UO_0000065";"23.47";"0.43";"6.56";"11.58";"0";"CHEMBL3887174";"LanthaScreen™ Assay (Km ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 184 μM ATP solution in 1× assay buffer to all wells. d) After a 60 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3967186";"";"None";"384.46";"0";"2.90";"BDBM239085";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCN(CCF)CC4)ncn3)c2c1";"IC50";"'='";"5.5";"nM";"8.26";"";"312517";"UO_0000065";"21.48";"0.40";"5.36";"11.77";"0";"CHEMBL3887174";"LanthaScreen™ Assay (Km ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 184 μM ATP solution in 1× assay buffer to all wells. d) After a 60 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4202514";"";"None";"261.28";"0";"0.68";"49, E:Z Mixture (38:62)";"COc1ccc2c(c1)C(=NN1CCOCC1)C(=O)N2";"IC50";"'='";"5930.0";"nM";"5.23";"";"";"UO_0000065";"20.01";"0.38";"4.55";"8.28";"0";"CHEMBL4192179";"Inhibition of recombinant catalytic human GST-tagged LLRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4190250";"1";"Scientific Literature";"Eur J Med Chem";"2017";"None";"";"";""
"CHEMBL3393347";"";"None";"291.36";"0";"3.34";"13";"CCN(CC)c1ncnc2[nH]cc(-c3cccc(C#N)c3)c12";"IC50";"'='";"20.0";"nM";"7.70";"";"";"UO_0000065";"26.42";"0.48";"4.36";"11.22";"0";"CHEMBL3395726";"Inhibition of GST-tagged truncated human recombinant LRRK2 using fluorescein-labeled LRRKtide peptide substrate incubated for 2 hrs";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL2333113";"";"None";"333.40";"0";"3.00";"8";"C[C@@H](Nc1c(C(N)=O)nnc2cc(-c3ccncc3)ccc12)C1CC1";"IC50";"'<='";"6.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL4018177";"Inhibition of full length wild-type LRRK2 (unknown origin) using biotinylated ezrin/radaxin/meosin peptide as substrate measured after 1 hr";"A";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4017473";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL4634025";"";"None";"444.54";"0";"3.85";"XMD12-68";"Cc1cc(N2CCC(O)CC2)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2C";"IC50";"'='";"35.0";"nM";"7.46";"";"";"UO_0000065";"16.77";"0.31";"3.61";"8.79";"0";"CHEMBL4612965";"Inhibition of recombinant human GST-tagged LRRK2 catalytic domain (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate measured after 1 hr by Alexa fluor-647 ADP tracer-based ADAPTA assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4610122";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL4634326";"";"None";"473.58";"0";"3.73";"FMF-03-055-1";"CCN1C(=O)c2ccccc2N(C)c2nc(Nc3ccc(N4CCN(C)CC4)cc3OC)ncc21";"IC50";"'='";"62.0";"nM";"7.21";"";"";"UO_0000065";"15.22";"0.28";"3.48";"9.35";"0";"CHEMBL4612965";"Inhibition of recombinant human GST-tagged LRRK2 catalytic domain (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate measured after 1 hr by Alexa fluor-647 ADP tracer-based ADAPTA assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4610122";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL3933899";"";"None";"329.37";"0";"3.28";"26";"Cc1cncc(-c2cc(Nc3ccn(C)n3)nc3[nH]cc(C#N)c23)c1";"IC50";"'='";"27.0";"nM";"7.57";"";"";"UO_0000065";"22.98";"0.41";"4.29";"7.95";"1";"CHEMBL4031820";"Inhibition of wild type recombinant human GST-tagged LRRK2 (970 to 2527 residues) expressed in baculovirus using fluorescein-LRRKtide as substrate after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL2397014";"";"None";"488.55";"0";"3.32";"1, CZC-25146";"COc1cc(N2CCOCC2)ccc1Nc1ncc(F)c(Nc2ccccc2NS(C)(=O)=O)n1";"IC50";"'='";"7.0";"nM";"8.15";"";"";"UO_0000065";"16.69";"0.33";"4.83";"6.93";"1";"CHEMBL3607919";"Inhibition of LRRK2 (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3603772";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3604124";"";"None";"402.50";"0";"3.66";"10b, BMPPB-32";"CN1CCN(c2ccc(OCc3ccccc3)c(C(=O)Nc3cccnc3)c2)CC1";"IC50";"'='";"94.0";"nM";"7.03";"";"";"UO_0000065";"17.46";"0.32";"3.37";"12.18";"0";"CHEMBL3607924";"Inhibition of LRRK2 G2019S mutant in human HEK293 cells assessed as phosphorylation at Ser935";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3603772";"1";"Scientific Literature";"J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL2012582";"";"None";"570.70";"1";"3.44";"LRRK2-IN-1";"COc1cc(C(=O)N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2C";"IC50";"'='";"3080.0";"nM";"5.51";"";"";"UO_0000065";"9.66";"0.18";"2.07";"5.66";"0";"CHEMBL2015770";"Inhibition of LRRK2 G2019S and A2016T mutant expressed in HEK293 cells using nictide and ATP as substrate";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S,A2016T";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2010643";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2012";"CHEMBL3307715";"";"";""
"CHEMBL4745837";"";"None";"402.50";"0";"3.40";"12.3";"CC1(N2CCC(c3cc4c(cnn4-c4cnn(C5CC5)c4)cc3C#N)CC2)COC1";"IC50";"'<'";"0.625";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL4714711";"Inhibition of recombinant human GST tagged LRRK2 G2019S mutant catalytic domain (970 to 2527 residues) expressed in baculovirus expression system using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 90 mins by TR-FRET based Lanthascreen assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4706723";"1";"Scientific Literature";"ACS Med Chem Lett";"2021";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL3914976";"";"None";"385.44";"0";"3.56";"BDBM239088";"CC(C)Oc1cc2c(-c3cc(N4C[C@@H](C)O[C@@H](C)C4)ncn3)n[nH]c2cc1F";"IC50";"'='";"2.89";"nM";"8.54";"";"312521";"UO_0000065";"22.15";"0.42";"4.98";"11.21";"0";"CHEMBL3887174";"LanthaScreen™ Assay (Km ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 184 μM ATP solution in 1× assay buffer to all wells. d) After a 60 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3917138";"";"None";"392.41";"0";"4.32";"BDBM62320";"FC1(F)CCN(c2cc(-c3n[nH]c4ccc(-c5cccnc5)cc34)ncn2)CC1";"IC50";"'='";"11.1";"nM";"7.96";"";"312523";"UO_0000065";"20.27";"0.37";"3.63";"11.27";"0";"CHEMBL3887174";"LanthaScreen™ Assay (Km ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 184 μM ATP solution in 1× assay buffer to all wells. d) After a 60 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4634634";"";"None";"365.44";"0";"1.44";"29";"C[C@@H]1C[C@H]1C(=O)N1CCN(c2cnc(C#N)c(-c3cnn(C)c3)n2)C[C@H]1C";"IC50";"'>'";"100000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL4603518";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant catalytic domain (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate measured after 1 hr in presence of ATP by ADAPTA assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4602617";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2020";"None";"";"";""
"CHEMBL4071886";"";"None";"378.46";"0";"3.80";"2";"CN(c1cccc(S(C)(=O)=O)c1)c1ccc2[nH]nc(-c3ccncc3)c2c1";"IC50";"'='";"44.0";"nM";"7.36";"";"";"UO_0000065";"19.44";"0.37";"3.56";"9.32";"0";"CHEMBL4010150";"Inhibition of wild type human recombinant LRRK2 expressed in baculovirus using fluorescein-ERM as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007454";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4093185";"";"None";"351.45";"0";"3.16";"19";"CC(C)Oc1ccc2[nH]nc(-c3ccnc(N4CCN(C)CC4)c3)c2c1";"IC50";"'='";"52.0";"nM";"7.28";"";"";"UO_0000065";"20.73";"0.38";"4.12";"12.72";"0";"CHEMBL4010118";"Inhibition LRRK2 G2019S mutant Ser935 phosphorylation in human SH-SY5Y cells after 90 mins by Western blot analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007454";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4076248";"";"None";"233.27";"0";"3.41";"17";"Cc1ccccc1-c1ccnc2[nH]cc(C#N)c12";"IC50";"'='";"26163.0";"nM";"4.58";"";"";"UO_0000065";"19.64";"0.35";"1.17";"8.73";"0";"CHEMBL4031820";"Inhibition of wild type recombinant human GST-tagged LRRK2 (970 to 2527 residues) expressed in baculovirus using fluorescein-LRRKtide as substrate after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4077186";"";"None";"219.25";"0";"3.10";"12";"N#Cc1c[nH]c2nccc(-c3ccccc3)c12";"IC50";"'='";"1178.0";"nM";"5.93";"";"";"UO_0000065";"27.04";"0.48";"2.83";"11.30";"0";"CHEMBL4031821";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus using fluorescein-LRRKtide as substrate after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL3896115";"";"None";"234.26";"0";"2.68";"21";"N#Cc1c[nH]c2nc(N)cc(-c3ccccc3)c12";"IC50";"'='";"176.0";"nM";"6.75";"";"";"UO_0000065";"28.83";"0.51";"4.07";"8.61";"0";"CHEMBL4031821";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus using fluorescein-LRRKtide as substrate after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4106502";"";"None";"409.43";"0";"1.76";"BDBM239383";"CO[C@@H]1CN(c2cc(-c3n[nH]c4cc(F)c(-c5cnn(C)c5)cc34)ncn2)C[C@H]1O";"IC50";"'='";"36.2";"nM";"7.44";"";"417850";"UO_0000065";"18.17";"0.34";"5.68";"7.09";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3890121";"";"None";"383.45";"0";"2.25";"BDBM239451";"COC[C@H](C)Oc1ccc2[nH]nc(-c3cc(N4CC[C@H](CO)C4)ncn3)c2c1";"IC50";"'='";"6.0";"nM";"8.22";"";"417916";"UO_0000065";"21.44";"0.40";"5.97";"8.53";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3980002";"";"None";"383.45";"0";"2.25";"BDBM239452";"COC[C@H](C)Oc1ccc2[nH]nc(-c3cc(N4CC[C@@H](CO)C4)ncn3)c2c1";"IC50";"'='";"3.6";"nM";"8.44";"";"417917";"UO_0000065";"22.02";"0.41";"6.19";"8.76";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL2178134";"";"None";"443.40";"0";"3.29";"2a; GNE-7915";"CCNc1nc(Nc2cc(F)c(C(=O)N3CCOCC3)cc2OC)ncc1C(F)(F)F";"IC50";"'='";"97.0";"nM";"7.01";"";"";"UO_0000065";"15.82";"0.31";"3.72";"7.91";"0";"CHEMBL4045604";"Inhibition of recombinant human wild type GST-tagged LRRK2 (970 to 2527 residues) preincubated for 30 mins followed by fluorescein-LRRKtide substrate addition after 2 hrs by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4043168";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL2348947";"";"None";"379.39";"0";"4.42";"12";"FC(F)(F)c1cccc(Sc2ccc3nnc(-c4cscn4)n3n2)c1";"IC50";"'='";"35.0";"nM";"7.46";"";"";"UO_0000065";"19.65";"0.41";"3.04";"13.32";"0";"CHEMBL2351468";"Inhibition of LRRK2 G2019S mutant (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348942";"";"None";"377.42";"1";"5.63";"7";"FC(F)(F)c1cccc(Sc2cn3c(-c4cccs4)cnc3cn2)c1";"IC50";"'='";"2168.0";"nM";"5.66";"";"";"UO_0000065";"15.01";"0.31";"0.03";"18.76";"0";"CHEMBL2351468";"Inhibition of LRRK2 G2019S mutant (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348957";"";"None";"380.40";"0";"4.19";"23";"FC(F)(F)c1cccc(Sc2ccc3nnc(C4CCOCC4)n3n2)c1";"IC50";"'='";"5329.0";"nM";"5.27";"";"";"UO_0000065";"13.86";"0.28";"1.08";"10.08";"0";"CHEMBL2351467";"Inhibition of wild type LRRK2 (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348953";"";"None";"406.82";"1";"5.61";"18";"FC(F)(F)c1cccc(Sc2ccc3nnc(-c4cccc(Cl)c4)n3n2)c1";"IC50";"'='";"265.0";"nM";"6.58";"";"";"UO_0000065";"16.17";"0.33";"0.97";"15.27";"0";"CHEMBL2351467";"Inhibition of wild type LRRK2 (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL5283711";"";"None";"324.35";"0";"1.30";"13";"CCC1=C(C(=O)Nc2ccc3[nH]ncc3c2)Cn2nnnc2N1C";"IC50";"'='";"534.0";"nM";"6.27";"";"";"UO_0000065";"19.34";"0.36";"4.97";"6.00";"0";"CHEMBL5246745";"Inhibition of N-terminal GST-fused human wild type LRRK2 using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5279765";"";"None";"338.38";"0";"1.78";"24";"CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)[C@H](C)n2nnnc2N1C";"IC50";"'='";"1220.0";"nM";"5.91";"";"";"UO_0000065";"17.48";"0.32";"4.13";"5.65";"0";"CHEMBL5246745";"Inhibition of N-terminal GST-fused human wild type LRRK2 using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5286893";"";"None";"401.43";"0";"2.53";"25";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4ccncc4)c3c2)[C@@H](C)n2nnnc2N1C";"IC50";"'<'";"0.2";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5246745";"Inhibition of N-terminal GST-fused human wild type LRRK2 using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5277051";"";"None";"353.34";"0";"0.48";"41";"CC1=C(C(=O)Nc2ccc3c(c2)C(=O)NC3=O)[C@@H](C)n2nnnc2N1C";"IC50";"'='";"2840.0";"nM";"5.55";"";"";"UO_0000065";"15.70";"0.29";"5.07";"4.54";"0";"CHEMBL5246745";"Inhibition of N-terminal GST-fused human wild type LRRK2 using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5271931";"";"None";"389.22";"0";"1.67";"8";"CC1=C(C(=O)Nc2ccc3[nH]nc(Br)c3c2)Cn2nnnc2N1C";"IC50";"'='";"2.4";"nM";"8.62";"";"";"UO_0000065";"22.15";"0.49";"6.95";"8.24";"0";"CHEMBL5246746";"Inhibition of N-terminal GST-fused human LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5269009";"";"None";"409.45";"0";"0.61";"15";"CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)Cn2nnnc2N1CCN1CCOCC1";"IC50";"'='";"4650.0";"nM";"5.33";"";"";"UO_0000065";"13.02";"0.24";"4.72";"4.55";"0";"CHEMBL5246746";"Inhibition of N-terminal GST-fused human LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5281154";"";"None";"486.54";"0";"2.37";"26";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4ccnc(N5CCOCC5)c4)c3c2)[C@@H](C)n2nnnc2N1C";"IC50";"'<'";"0.2";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5246746";"Inhibition of N-terminal GST-fused human LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5285625";"";"None";"324.35";"0";"0.99";"35";"CC1=C(C(=O)Nc2ccc3cnc(C)n3c2)Cn2nnnc2N1C";"IC50";"'='";"3120.0";"nM";"5.51";"";"";"UO_0000065";"16.98";"0.31";"4.52";"5.91";"0";"CHEMBL5246746";"Inhibition of N-terminal GST-fused human LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL4098877";"MLi-2";"None";"379.46";"0";"3.56";"5; MLi-2";"C[C@@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@H](C)O1";"IC50";"'='";"0.5";"nM";"9.30";"";"";"UO_0000065";"24.51";"0.45";"5.74";"12.21";"0";"CHEMBL5239655";"Inhibition of GST20-tagged human LRRK2 G2019S mutant using LRRKtide peptide preincubated for 15 mins followed by substrate addition and measured after 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5236618";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL5289513";"";"None";"324.35";"0";"1.47";"21";"CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)[C@@H](C)n2nnnc2N1C";"IC50";"'='";"2180.0";"nM";"5.66";"";"";"UO_0000065";"17.46";"0.32";"4.19";"5.41";"0";"CHEMBL5246754";"Inhibition of human wild type LRRK2 expressed in HEK293 cells assessed as reduction in pS1292 phosphorylation incubated for 2 hrs by MSD analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL5282880";"";"None";"326.32";"0";"0.21";"38";"CC1=C(C(=O)Nc2ccc3[nH]c(=O)[nH]c3c2)Cn2nnnc2N1C";"IC50";"'='";"240.0";"nM";"6.62";"";"";"UO_0000065";"20.29";"0.38";"6.41";"5.31";"0";"CHEMBL5246746";"Inhibition of N-terminal GST-fused human LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5279816";"";"None";"338.38";"0";"1.78";"23";"CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)[C@@H](C)n2nnnc2N1C";"IC50";"'='";"106.0";"nM";"6.97";"";"";"UO_0000065";"20.61";"0.38";"5.19";"6.67";"0";"CHEMBL5246752";"Inhibition of human LRRK2 G2019S mutant expressed in HEK293 cells assessed as reduction in pSer935 phosphorylation incubated for 2 hrs by immunoblotting analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL4791349";"";"None";"399.93";"0";"3.86";"7.4";"CCn1cc(-n2ncc3cc(Cl)c(C4CCN(C5(C)COC5)CC4)cc32)cn1";"IC50";"'='";"0.8";"nM";"9.10";"";"";"UO_0000065";"22.75";"0.44";"5.24";"18.91";"0";"CHEMBL4714711";"Inhibition of recombinant human GST tagged LRRK2 G2019S mutant catalytic domain (970 to 2527 residues) expressed in baculovirus expression system using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 90 mins by TR-FRET based Lanthascreen assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4706723";"1";"Scientific Literature";"ACS Med Chem Lett";"2021";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL3973394";"";"None";"286.31";"0";"2.84";"BDBM185523";"COc1cc(F)cc(-c2c[nH]c3ncnc(N(C)C)c23)c1";"IC50";"'='";"41.0";"nM";"7.39";"";"334492";"UO_0000065";"25.80";"0.48";"4.55";"13.67";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3893561";"";"None";"286.31";"0";"2.84";"BDBM185529";"COc1ccc(F)cc1-c1c[nH]c2ncnc(N(C)C)c12";"IC50";"'='";"13.0";"nM";"7.89";"";"334498";"UO_0000065";"27.54";"0.51";"5.05";"14.59";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3951523";"";"None";"319.37";"0";"2.64";"BDBM185544";"Cc1c(C#N)cccc1-c1c[nH]c2ncnc(N3CCOCC3)c12";"IC50";"'='";"13.2";"nM";"7.88";"";"334514";"UO_0000065";"24.67";"0.45";"5.24";"10.12";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3897065";"";"None";"369.43";"0";"3.60";"BDBM185383";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCC(c5ncc[nH]5)CC4)c23)c1";"IC50";"'='";"230.0";"nM";"6.64";"";"334556";"UO_0000065";"17.97";"0.32";"3.04";"6.82";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3963791";"";"None";"369.43";"0";"3.60";"BDBM185390";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCC(c5cc[nH]n5)CC4)c23)c1";"IC50";"'='";"136.0";"nM";"6.87";"";"334565";"UO_0000065";"18.59";"0.33";"3.27";"7.06";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3974547";"";"None";"325.39";"0";"3.70";"BDBM185405";"Cc1cc(-c2c[nH]c3ncnc(N4CCC[C@H](C)C4)c23)cnc1F";"IC50";"'='";"65.0";"nM";"7.19";"";"334580";"UO_0000065";"22.09";"0.41";"3.49";"12.46";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3954258";"";"None";"310.36";"0";"1.95";"BDBM185449";"OCc1cccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"19.0";"nM";"7.72";"";"334631";"UO_0000065";"24.88";"0.46";"5.77";"10.40";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3957480";"";"None";"328.80";"0";"3.42";"BDBM185455";"Cc1ccc(Cl)c(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"44.0";"nM";"7.36";"";"334637";"UO_0000065";"22.37";"0.44";"3.94";"13.61";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3968498";"";"None";"319.37";"0";"2.46";"BDBM185457";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCC(O)CC4)c23)c1";"IC50";"'='";"109.0";"nM";"6.96";"";"334640";"UO_0000065";"21.80";"0.40";"4.50";"7.84";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3942875";"";"None";"317.35";"0";"2.47";"BDBM185460";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CC5CC(C4)O5)c23)c1";"IC50";"'='";"523.0";"nM";"6.28";"";"334644";"UO_0000065";"19.79";"0.36";"3.81";"8.07";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3942416";"";"None";"314.35";"0";"0.56";"BDBM185471";"Cn1cc(-c2c[nH]c3ncnc(N4CCOC(CO)C4)c23)cn1";"IC50";"'='";"80.0";"nM";"7.10";"";"334655";"UO_0000065";"22.58";"0.42";"6.54";"7.71";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3896507";"";"None";"268.32";"0";"1.96";"BDBM185474";"CN(c1ncnc2[nH]cc(-c3cnn(C)c3)c12)C1CC1";"IC50";"'='";"37.0";"nM";"7.43";"";"334658";"UO_0000065";"27.70";"0.51";"5.47";"11.87";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL535";"SUNITINIB";"4.0";"398.48";"0";"3.33";"sunitinib";"CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C";"IC50";"'='";"15.0";"nM";"7.82";"";"";"UO_0000065";"19.63";"0.37";"4.49";"10.13";"0";"CHEMBL2398947";"Inhibition of human N-terminal GST-tagged LRRK2 after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2396520";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL4542888";"";"None";"233.27";"0";"1.82";"4";"Cc1n[nH]c2ccnc(OC3CCOCC3)c12";"IC50";"'='";"301.0";"nM";"6.52";"";"";"UO_0000065";"27.96";"0.52";"4.70";"10.86";"0";"CHEMBL4331199";"Inhibition of LRRK2 G2019S mutant (unknown origin) by cell based assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330074";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4466051";"";"None";"328.38";"0";"2.42";"10";"CC(C)c1n[nH]c(-c2n[nH]c3ccnc(OC4CCOCC4)c23)n1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL4331199";"Inhibition of LRRK2 G2019S mutant (unknown origin) by cell based assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330074";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL5270706";"";"None";"500.57";"1";"2.55";"30";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4ccnc(N5CCOCC5)c4)c3c2)C(C)(C)n2nnnc2N1C";"IC50";"'='";"1.5";"nM";"8.82";"";"";"UO_0000065";"17.63";"0.33";"6.27";"6.79";"0";"CHEMBL5246752";"Inhibition of human LRRK2 G2019S mutant expressed in HEK293 cells assessed as reduction in pSer935 phosphorylation incubated for 2 hrs by immunoblotting analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL5282583";"";"None";"389.46";"0";"2.80";"13";"CC(C)(O)[C@@H]1CCN(c2cc(-n3ncc4ccc(-c5ccn[nH]5)cc43)ncn2)C1";"IC50";"'='";"6.0";"nM";"8.22";"";"";"UO_0000065";"21.11";"0.39";"5.42";"8.59";"0";"CHEMBL5239655";"Inhibition of GST20-tagged human LRRK2 G2019S mutant using LRRKtide peptide preincubated for 15 mins followed by substrate addition and measured after 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5236618";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL5278535";"";"None";"375.48";"0";"2.80";"16";"C[C@@H]1CN(c2cc(-n3ncc4ccc(CCC#N)cc43)ncn2)C[C@H](C)N1C";"IC50";"'='";"990.0";"nM";"6.00";"";"";"UO_0000065";"15.99";"0.29";"3.20";"8.13";"0";"CHEMBL5239655";"Inhibition of GST20-tagged human LRRK2 G2019S mutant using LRRKtide peptide preincubated for 15 mins followed by substrate addition and measured after 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5236618";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL4757048";"";"None";"462.99";"0";"4.25";"7.11";"CC1(N2CCC(c3cc4c(cnn4-c4cnn(C56CC(C#N)(C5)C6)c4)cc3Cl)CC2)COC1";"IC50";"'<'";"0.625";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL4714711";"Inhibition of recombinant human GST tagged LRRK2 G2019S mutant catalytic domain (970 to 2527 residues) expressed in baculovirus expression system using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 90 mins by TR-FRET based Lanthascreen assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4706723";"1";"Scientific Literature";"ACS Med Chem Lett";"2021";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL4571409";"";"None";"326.40";"0";"2.51";"16";"CCc1cc(-c2n[nH]c3ccnc(NC4CCOCC4)c23)n(C)n1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL4331199";"Inhibition of LRRK2 G2019S mutant (unknown origin) by cell based assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330074";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4460272";"";"None";"381.44";"0";"2.41";"6";"c1cc(-c2n[nH]c3ccnc(OC4CCOCC4)c23)cc(N2CCOCC2)n1";"IC50";"'='";"24.0";"nM";"7.62";"";"";"UO_0000065";"19.98";"0.37";"5.21";"8.92";"0";"CHEMBL4331199";"Inhibition of LRRK2 G2019S mutant (unknown origin) by cell based assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330074";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL5280273";"";"None";"395.43";"0";"1.65";"11";"CCCC(=O)Nc1n[nH]c2ccc(NC(=O)C3=C(C)N(C)c4nnnn4C3)cc12";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5246745";"Inhibition of N-terminal GST-fused human wild type LRRK2 using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"";""
"CHEMBL5280528";"";"None";"323.36";"0";"1.83";"33";"CC1=C(C(=O)Nc2ccc3[nH]cc(C)c3c2)Cn2nnnc2N1C";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5246745";"Inhibition of N-terminal GST-fused human wild type LRRK2 using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"";""
"CHEMBL5267350";"";"None";"388.48";"0";"3.64";"7";"C[C@@H]1CN(c2cc(-c3n[nH]c4ccc(-c5cnn(C)c5)cc34)ccn2)C[C@H](C)O1";"IC50";"'='";"0.3";"nM";"9.52";"";"";"UO_0000065";"24.51";"0.45";"5.88";"13.25";"0";"CHEMBL5239655";"Inhibition of GST20-tagged human LRRK2 G2019S mutant using LRRKtide peptide preincubated for 15 mins followed by substrate addition and measured after 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5236618";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL2347827";"";"None";"308.41";"0";"4.36";"17";"Cc1ncc(-c2ccc3c(NC(C)C)c(C#N)cnc3c2)s1";"IC50";"'='";"16.0";"nM";"7.80";"";"";"UO_0000065";"25.28";"0.48";"3.44";"12.66";"0";"CHEMBL2352557";"Inhibition of GST-tagged LRRK2 G2019S mutant (970-2527 amino acids) (unknown origin) assessed as inhibition of LRRKtide phosphorylation by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346515";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348978";"";"None";"356.84";"0";"4.02";"45";"CC(Sc1ccc2nnc(-c3cccc(Cl)c3)n2n1)c1ccn[nH]1";"IC50";"'='";"798.0";"nM";"6.10";"";"";"UO_0000065";"17.09";"0.35";"2.08";"8.50";"0";"CHEMBL2351468";"Inhibition of LRRK2 G2019S mutant (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348965";"";"None";"341.42";"0";"3.41";"31";"COc1cccc(Sc2ccc3nnc(-c4cncs4)n3n2)c1";"IC50";"'='";"26.0";"nM";"7.58";"";"";"UO_0000065";"22.22";"0.45";"4.18";"11.63";"0";"CHEMBL2351468";"Inhibition of LRRK2 G2019S mutant (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348952";"";"None";"406.82";"1";"5.61";"17";"FC(F)(F)c1cccc(Sc2ccc3nnc(-c4ccccc4Cl)n3n2)c1";"IC50";"'='";"1023.0";"nM";"5.99";"";"";"UO_0000065";"14.72";"0.30";"0.38";"13.90";"0";"CHEMBL2351468";"Inhibition of LRRK2 G2019S mutant (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348951";"";"None";"373.36";"0";"4.36";"16";"FC(F)(F)c1cccc(Sc2ccc3nnc(-c4ccncc4)n3n2)c1";"IC50";"'='";"253.0";"nM";"6.60";"";"";"UO_0000065";"17.67";"0.35";"2.24";"11.79";"0";"CHEMBL2351468";"Inhibition of LRRK2 G2019S mutant (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348974";"";"None";"334.43";"0";"2.90";"41";"CCC(Sc1ccc2nnc(-c3cccs3)n2n1)C(=O)OC";"IC50";"'='";"338.0";"nM";"6.47";"";"";"UO_0000065";"19.35";"0.40";"3.57";"9.33";"0";"CHEMBL2351467";"Inhibition of wild type LRRK2 (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348972";"";"None";"320.40";"0";"2.51";"39";"COC(=O)[C@H](C)Sc1ccc2nnc(-c3cccs3)n2n1";"IC50";"'='";"458.0";"nM";"6.34";"";"";"UO_0000065";"19.79";"0.41";"3.83";"9.14";"0";"CHEMBL2351467";"Inhibition of wild type LRRK2 (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348952";"";"None";"406.82";"1";"5.61";"17";"FC(F)(F)c1cccc(Sc2ccc3nnc(-c4ccccc4Cl)n3n2)c1";"IC50";"'='";"3305.0";"nM";"5.48";"";"";"UO_0000065";"13.47";"0.28";"-0.13";"12.72";"0";"CHEMBL2351467";"Inhibition of wild type LRRK2 (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348941";"";"None";"376.43";"1";"6.23";"6";"FC(F)(F)c1cccc(Sc2ccc3ncc(-c4cccs4)n3c2)c1";"IC50";"'='";"4215.0";"nM";"5.38";"";"";"UO_0000065";"14.28";"0.29";"-0.85";"31.07";"0";"CHEMBL2351467";"Inhibition of wild type LRRK2 (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL4075970";"";"None";"143.15";"0";"1.43";"10";"N#Cc1c[nH]c2ncccc12";"IC50";"'='";"101080.0";"nM";"";"Outside typical range";"";"UO_0000065";"";"";"";"";"0";"CHEMBL4031820";"Inhibition of wild type recombinant human GST-tagged LRRK2 (970 to 2527 residues) expressed in baculovirus using fluorescein-LRRKtide as substrate after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4077186";"";"None";"219.25";"0";"3.10";"12";"N#Cc1c[nH]c2nccc(-c3ccccc3)c12";"IC50";"'='";"954.0";"nM";"6.02";"";"";"UO_0000065";"27.46";"0.48";"2.92";"11.47";"0";"CHEMBL4031820";"Inhibition of wild type recombinant human GST-tagged LRRK2 (970 to 2527 residues) expressed in baculovirus using fluorescein-LRRKtide as substrate after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4066167";"";"None";"253.69";"0";"3.75";"16";"N#Cc1c[nH]c2nccc(-c3ccc(Cl)cc3)c12";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL4031820";"Inhibition of wild type recombinant human GST-tagged LRRK2 (970 to 2527 residues) expressed in baculovirus using fluorescein-LRRKtide as substrate after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL3961632";"";"None";"248.29";"0";"2.99";"22";"Cc1cccc(-c2cc(N)nc3[nH]cc(C#N)c23)c1";"IC50";"'='";"69.18";"nM";"7.16";"";"";"UO_0000065";"28.84";"0.51";"4.17";"9.12";"0";"CHEMBL4031826";"Inhibition of human LRRK2 G2019S mutant phosphorylation at ser935 expressed in BacMam transduced HEK293 cells after 48 hrs by in-cell Western assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"CHEMBL3307715";"";"";""
"CHEMBL3969077";"";"None";"328.38";"0";"3.89";"23";"Cc1cccc(-c2cc(Nc3ccn(C)n3)nc3[nH]cc(C#N)c23)c1";"IC50";"'='";"18.0";"nM";"7.75";"";"";"UO_0000065";"23.58";"0.42";"3.85";"9.41";"0";"CHEMBL4031826";"Inhibition of human LRRK2 G2019S mutant phosphorylation at ser935 expressed in BacMam transduced HEK293 cells after 48 hrs by in-cell Western assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"CHEMBL3307715";"";"";""
"CHEMBL4067104";"";"None";"315.76";"0";"2.51";"7";"Clc1c[nH]c2ncc(-c3cncc(N4CCOCC4)n3)cc12";"IC50";"'<='";"500.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL4018178";"Inhibition of LRRK2 G2019S mutant (unknown origin) using biotinylated ezrin/radaxin/meosin peptide as substrate measured after 1 hr";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4017473";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL3393446";"";"None";"344.38";"0";"2.62";"35";"N#CCC1CN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)CCO1";"IC50";"'='";"5.0";"nM";"8.30";"";"";"UO_0000065";"24.10";"0.44";"5.68";"8.17";"0";"CHEMBL3395726";"Inhibition of GST-tagged truncated human recombinant LRRK2 using fluorescein-labeled LRRKtide peptide substrate incubated for 2 hrs";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3393445";"";"None";"330.35";"0";"2.23";"34";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCOC(C#N)C4)c23)c1";"IC50";"'='";"42.0";"nM";"7.38";"";"";"UO_0000065";"22.33";"0.40";"5.15";"7.26";"0";"CHEMBL3395726";"Inhibition of GST-tagged truncated human recombinant LRRK2 using fluorescein-labeled LRRKtide peptide substrate incubated for 2 hrs";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3393350";"";"None";"333.40";"0";"3.11";"16";"COC1CCCN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)C1";"IC50";"'='";"79.0";"nM";"7.10";"";"";"UO_0000065";"21.30";"0.39";"3.99";"9.13";"0";"CHEMBL3395726";"Inhibition of GST-tagged truncated human recombinant LRRK2 using fluorescein-labeled LRRKtide peptide substrate incubated for 2 hrs";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3335346";"";"None";"299.76";"0";"4.16";"26a";"Cc1cc(/C=C2/C(=O)Nc3ccc(Cl)cc32)cc(C)c1O";"IC50";"'='";"194.0";"nM";"6.71";"";"";"UO_0000065";"22.39";"0.44";"2.55";"13.61";"0";"CHEMBL3390652";"Inhibition of recombinant LRRK2 (unknown origin) using gamma-32P-ATP assessed as LRRKtide substrate phosphorylation level by autoradiography";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352815";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL4745472";"";"None";"399.93";"0";"3.77";"15.4-1";"Cn1cc(-n2ncc3cc(Cl)c(C4CCN(C5(C)CCOC5)CC4)cc32)cn1";"IC50";"'<'";"0.625";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL4714711";"Inhibition of recombinant human GST tagged LRRK2 G2019S mutant catalytic domain (970 to 2527 residues) expressed in baculovirus expression system using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 90 mins by TR-FRET based Lanthascreen assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4706723";"1";"Scientific Literature";"ACS Med Chem Lett";"2021";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL3896115";"";"None";"234.26";"0";"2.68";"BDBM254928";"N#Cc1c[nH]c2nc(N)cc(-c3ccccc3)c12";"IC50";"'='";"240.0";"nM";"6.62";"";"443711";"UO_0000065";"28.26";"0.50";"3.94";"8.43";"0";"CHEMBL3889252";"Homogeneous Time Resolved-fluorescence Resonance Energy Transfer (TR-FRET) Assay: LRRK2 kinase activity is measured using a LanthaScreen kinase activity assay available from Invitrogen (Life Technologies Corporation). The assay is a homogeneous time resolved-fluorescence resonance energy transfer (TR-FRET) assay that measures phosphorylation of a fluorescein-labelled peptide substrate (fluorescein-LRRKtide, fluorescein-GAGRLGRDKYKTLRQIRQ) (SEQ ID NO 1) as a result of LRRK2 kinase activity. The phosphorylated peptide is recognized by a terbium-labelled phospho-specific anti-LRRKtide antibody and, subsequently, the phosphorylated LRRKtide can be quantified by the extent of TR-FRET between the terbium donor and fluorescein acceptor.The LRRK2 kinase is obtained from Invitrogen (Life Technologies Corporation) and comprises residues 970 to 2527 of the full length human wild-type LRRK2 kinase or a similar sequence with the G2019S mutation. As discussed above, this mutation increases the kinase activity relative to the wild-type. The kinase reactions are performed in a 20 uL volume in 384-well plates. The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT.Â  In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 uM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 uM fluorescein-LRRKtide. The reaction mixture (20 ul total volume) is incubated for 2 hours at 30° C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 ul). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 us) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 us. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 us time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3887011";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3951135";"";"None";"351.41";"0";"2.86";"BDBM223547";"COc1cccc(-c2cnc(N)c(-c3nnc(C4CCNCC4)o3)c2)c1";"IC50";"'='";"1000.0";"nM";"6.00";"";"390803";"UO_0000065";"17.07";"0.32";"3.14";"6.06";"0";"CHEMBL3888345";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3955954";"";"None";"408.51";"0";"3.01";"BDBM223558";"COc1cc(-c2cnc(N)c(-c3cn(C(C)C)nn3)c2)ccc1CN1CCOCC1";"IC50";"'='";"93.0";"nM";"7.03";"";"390843";"UO_0000065";"17.21";"0.32";"4.02";"7.70";"0";"CHEMBL3888346";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3910377";"";"None";"377.45";"0";"3.09";"BDBM223569";"Nc1ncc(-c2cccc(CN3CCOCC3)c2)cc1-c1nnc(C2CC2)o1";"IC50";"'='";"900.0";"nM";"6.05";"";"390854";"UO_0000065";"16.02";"0.29";"2.96";"6.70";"0";"CHEMBL3888346";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3932856";"";"None";"436.52";"0";"2.63";"BDBM239348";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCN(C(=O)C5CCCO5)CC4)ncn3)c2c1";"IC50";"'='";"58.1";"nM";"7.24";"";"417816";"UO_0000065";"16.58";"0.31";"4.61";"7.50";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3985770";"";"None";"396.45";"0";"2.70";"BDBM239351";"COC(=O)N1CCN(c2cc(-c3n[nH]c4ccc(OC(C)C)cc34)ncn2)CC1";"IC50";"'='";"10.2";"nM";"7.99";"";"417819";"UO_0000065";"20.16";"0.38";"5.29";"8.28";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4107416";"";"None";"406.47";"0";"2.70";"BDBM239387";"CN(C)[C@@H]1CCN(c2cc(-c3n[nH]c4cc(F)c(-c5cnn(C)c5)cc34)ncn2)C1";"IC50";"'='";"58.0";"nM";"7.24";"";"417854";"UO_0000065";"17.80";"0.33";"4.54";"9.19";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3932912";"";"None";"358.41";"0";"2.92";"BDBM239514";"c1cncc(-c2ccc3[nH]nc(-c4cc(N5CCOCC5)ncn4)c3c2)c1";"IC50";"'='";"5.5";"nM";"8.26";"";"417978";"UO_0000065";"23.05";"0.42";"5.34";"10.35";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3936325";"";"None";"437.49";"1";"5.03";"BDBM239521";"CC1(C)CC(=O)C=C(c2ccc3[nH]nc(-c4cc(N5CCC(F)(F)CC5)ncn4)c3c2)C1";"IC50";"'='";"7.08";"nM";"8.15";"";"417984";"UO_0000065";"18.63";"0.35";"3.12";"10.90";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3937634";"";"None";"348.41";"0";"2.94";"BDBM254927";"COc1cc(-c2ccnc3[nH]cc(C#N)c23)ccc1CN1CCOCC1";"IC50";"'='";"154.0";"nM";"6.81";"";"443710";"UO_0000065";"19.55";"0.36";"3.87";"9.18";"0";"CHEMBL3889252";"Homogeneous Time Resolved-fluorescence Resonance Energy Transfer (TR-FRET) Assay: LRRK2 kinase activity is measured using a LanthaScreen kinase activity assay available from Invitrogen (Life Technologies Corporation). The assay is a homogeneous time resolved-fluorescence resonance energy transfer (TR-FRET) assay that measures phosphorylation of a fluorescein-labelled peptide substrate (fluorescein-LRRKtide, fluorescein-GAGRLGRDKYKTLRQIRQ) (SEQ ID NO 1) as a result of LRRK2 kinase activity. The phosphorylated peptide is recognized by a terbium-labelled phospho-specific anti-LRRKtide antibody and, subsequently, the phosphorylated LRRKtide can be quantified by the extent of TR-FRET between the terbium donor and fluorescein acceptor.The LRRK2 kinase is obtained from Invitrogen (Life Technologies Corporation) and comprises residues 970 to 2527 of the full length human wild-type LRRK2 kinase or a similar sequence with the G2019S mutation. As discussed above, this mutation increases the kinase activity relative to the wild-type. The kinase reactions are performed in a 20 uL volume in 384-well plates. The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT.Â  In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 uM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 uM fluorescein-LRRKtide. The reaction mixture (20 ul total volume) is incubated for 2 hours at 30° C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 ul). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 us) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 us. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 us time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3887011";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3907032";"";"None";"314.35";"0";"3.58";"BDBM254933";"Cn1cc(Nc2cc(-c3ccccc3)c3c(C#N)c[nH]c3n2)cn1";"IC50";"'='";"164.0";"nM";"6.79";"";"443716";"UO_0000065";"21.58";"0.39";"3.21";"8.24";"0";"CHEMBL3889252";"Homogeneous Time Resolved-fluorescence Resonance Energy Transfer (TR-FRET) Assay: LRRK2 kinase activity is measured using a LanthaScreen kinase activity assay available from Invitrogen (Life Technologies Corporation). The assay is a homogeneous time resolved-fluorescence resonance energy transfer (TR-FRET) assay that measures phosphorylation of a fluorescein-labelled peptide substrate (fluorescein-LRRKtide, fluorescein-GAGRLGRDKYKTLRQIRQ) (SEQ ID NO 1) as a result of LRRK2 kinase activity. The phosphorylated peptide is recognized by a terbium-labelled phospho-specific anti-LRRKtide antibody and, subsequently, the phosphorylated LRRKtide can be quantified by the extent of TR-FRET between the terbium donor and fluorescein acceptor.The LRRK2 kinase is obtained from Invitrogen (Life Technologies Corporation) and comprises residues 970 to 2527 of the full length human wild-type LRRK2 kinase or a similar sequence with the G2019S mutation. As discussed above, this mutation increases the kinase activity relative to the wild-type. The kinase reactions are performed in a 20 uL volume in 384-well plates. The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT.Â  In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 uM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 uM fluorescein-LRRKtide. The reaction mixture (20 ul total volume) is incubated for 2 hours at 30° C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 ul). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 us) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 us. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 us time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3887011";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3923178";"";"None";"307.36";"0";"2.19";"BDBM254923";"N#Cc1c[nH]c2nccc(-c3ccn(CN4CCOCC4)c3)c12";"IC50";"'='";"3868.0";"nM";"5.41";"";"443729";"UO_0000065";"17.61";"0.32";"3.22";"7.75";"0";"CHEMBL3889253";"Homogeneous Time Resolved-fluorescence Resonance Energy Transfer (TR-FRET) Assay: LRRK2 kinase activity is measured using a LanthaScreen kinase activity assay available from Invitrogen (Life Technologies Corporation). The assay is a homogeneous time resolved-fluorescence resonance energy transfer (TR-FRET) assay that measures phosphorylation of a fluorescein-labelled peptide substrate (fluorescein-LRRKtide, fluorescein-GAGRLGRDKYKTLRQIRQ) (SEQ ID NO 1) as a result of LRRK2 kinase activity. The phosphorylated peptide is recognized by a terbium-labelled phospho-specific anti-LRRKtide antibody and, subsequently, the phosphorylated LRRKtide can be quantified by the extent of TR-FRET between the terbium donor and fluorescein acceptor.The LRRK2 kinase is obtained from Invitrogen (Life Technologies Corporation) and comprises residues 970 to 2527 of the full length human wild-type LRRK2 kinase or a similar sequence with the G2019S mutation. As discussed above, this mutation increases the kinase activity relative to the wild-type. The kinase reactions are performed in a 20 uL volume in 384-well plates. The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT.Â  In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 uM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 uM fluorescein-LRRKtide. The reaction mixture (20 ul total volume) is incubated for 2 hours at 30° C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 ul). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 us) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 us. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 us time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3887011";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3964405";"";"None";"312.35";"0";"2.73";"BDBM185502";"OC1CCCN(c2ncnc3[nH]cc(-c4cccc(F)c4)c23)C1";"IC50";"'='";"86.0";"nM";"7.07";"";"334687";"UO_0000065";"22.62";"0.42";"4.34";"10.86";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3890691";"";"None";"295.35";"0";"2.16";"BDBM185534";"Cc1ccnc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"43.0";"nM";"7.37";"";"334502";"UO_0000065";"24.94";"0.46";"5.21";"11.01";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3892682";"";"None";"328.35";"0";"2.61";"BDBM185536";"COc1cccc(F)c1-c1c[nH]c2ncnc(N3CCOCC3)c12";"IC50";"'='";"25.0";"nM";"7.60";"";"334504";"UO_0000065";"23.15";"0.43";"4.99";"12.02";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3942469";"";"None";"322.41";"0";"3.35";"BDBM185571";"C[C@H]1CCCN(c2ncnc3[nH]cc(-c4cccc(CO)c4)c23)C1";"IC50";"'='";"18.0";"nM";"7.75";"";"334537";"UO_0000065";"24.02";"0.44";"4.39";"11.91";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3966408";"";"None";"369.43";"0";"3.60";"BDBM185394";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCCC(c5ncc[nH]5)C4)c23)c1";"IC50";"'='";"331.0";"nM";"6.48";"";"334569";"UO_0000065";"17.54";"0.32";"2.88";"6.66";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3393356";"";"None";"323.33";"0";"2.47";"BDBM50059318";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1F";"IC50";"'='";"7.0";"nM";"8.15";"";"334609";"UO_0000065";"25.22";"0.46";"5.68";"10.48";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3905434";"";"None";"405.46";"0";"2.35";"BDBM185472";"Cc1ccc(OCC2CN(c3ncnc4[nH]cc(-c5cnn(C)c5)c34)CCO2)cn1";"IC50";"'='";"87.0";"nM";"7.06";"";"334656";"UO_0000065";"17.41";"0.32";"4.71";"7.51";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3393439";"";"None";"284.32";"0";"1.19";"BDBM50059307";"Cn1cc(-c2c[nH]c3ncnc(N4CCOCC4)c23)cn1";"IC50";"'='";"13.0";"nM";"7.89";"";"334320";"UO_0000065";"27.74";"0.51";"6.70";"10.97";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL4075407";"";"None";"233.27";"0";"3.41";"19";"Cc1ccc(-c2ccnc3[nH]cc(C#N)c23)cc1";"IC50";"'='";"4135.0";"nM";"5.38";"";"";"UO_0000065";"23.08";"0.41";"1.97";"10.26";"0";"CHEMBL4031820";"Inhibition of wild type recombinant human GST-tagged LRRK2 (970 to 2527 residues) expressed in baculovirus using fluorescein-LRRKtide as substrate after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL3979676";"";"None";"249.27";"0";"3.11";"20";"COc1cccc(-c2ccnc3[nH]cc(C#N)c23)c1";"IC50";"'='";"247.0";"nM";"6.61";"";"";"UO_0000065";"26.51";"0.47";"3.50";"10.71";"1";"CHEMBL4031820";"Inhibition of wild type recombinant human GST-tagged LRRK2 (970 to 2527 residues) expressed in baculovirus using fluorescein-LRRKtide as substrate after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL3961481";"";"None";"343.39";"0";"3.59";"31";"Cc1cccc(-c2cc(Nc3nn(C)cc3C)nc3[nH]cc(C#N)c23)n1";"IC50";"'='";"36.0";"nM";"7.44";"";"";"UO_0000065";"21.68";"0.39";"3.85";"7.82";"1";"CHEMBL4031820";"Inhibition of wild type recombinant human GST-tagged LRRK2 (970 to 2527 residues) expressed in baculovirus using fluorescein-LRRKtide as substrate after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL3969077";"";"None";"328.38";"0";"3.89";"23";"Cc1cccc(-c2cc(Nc3ccn(C)n3)nc3[nH]cc(C#N)c23)c1";"IC50";"'='";"8.0";"nM";"8.10";"";"";"UO_0000065";"24.66";"0.44";"4.21";"9.84";"0";"CHEMBL4031821";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus using fluorescein-LRRKtide as substrate after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4101218";"";"None";"343.39";"0";"3.59";"29";"Cc1cncc(-c2cc(Nc3nn(C)cc3C)nc3[nH]cc(C#N)c23)c1";"IC50";"'='";"48.0";"nM";"7.32";"";"";"UO_0000065";"21.31";"0.38";"3.73";"7.69";"0";"CHEMBL4031821";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus using fluorescein-LRRKtide as substrate after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL3961481";"";"None";"343.39";"0";"3.59";"31";"Cc1cccc(-c2cc(Nc3nn(C)cc3C)nc3[nH]cc(C#N)c23)n1";"IC50";"'='";"50.0";"nM";"7.30";"";"";"UO_0000065";"21.26";"0.38";"3.71";"7.67";"1";"CHEMBL4031821";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus using fluorescein-LRRKtide as substrate after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL3961632";"";"None";"248.29";"0";"2.99";"22";"Cc1cccc(-c2cc(N)nc3[nH]cc(C#N)c23)c1";"IC50";"'='";"24.0";"nM";"7.62";"";"";"UO_0000065";"30.69";"0.55";"4.63";"9.71";"0";"CHEMBL4031822";"Inhibition of human wild type LRRK2 phosphorylation at ser935 transfected in HEK293 cells after 48 hrs by in-cell Western assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"CHEMBL3307715";"";"";""
"CHEMBL4065198";"";"None";"329.37";"0";"3.28";"25";"Cc1ccnc(-c2cc(Nc3ccn(C)n3)nc3[nH]cc(C#N)c23)c1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL4031826";"Inhibition of human LRRK2 G2019S mutant phosphorylation at ser935 expressed in BacMam transduced HEK293 cells after 48 hrs by in-cell Western assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"CHEMBL3307715";"";"";""
"CHEMBL3933899";"";"None";"329.37";"0";"3.28";"26";"Cc1cncc(-c2cc(Nc3ccn(C)n3)nc3[nH]cc(C#N)c23)c1";"IC50";"'='";"90.0";"nM";"7.05";"";"";"UO_0000065";"21.39";"0.38";"3.77";"7.40";"0";"CHEMBL4031826";"Inhibition of human LRRK2 G2019S mutant phosphorylation at ser935 expressed in BacMam transduced HEK293 cells after 48 hrs by in-cell Western assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"CHEMBL3307715";"";"";""
"CHEMBL2403368";"";"None";"404.43";"0";"3.01";"4";"COc1ccc2c(c1)/C(=C/c1cc3c([nH]1)CCN(C(=O)c1cnoc1C)C3)C(=O)N2";"IC50";"'='";"7.0";"nM";"8.15";"";"";"UO_0000065";"20.16";"0.37";"5.14";"8.12";"0";"CHEMBL2406186";"Inhibition of human LRRK2 (1885 to 2132) using 5-Fluo-Ahx-RLGRDKYKTLRQIRQGNTK-OH as substrate after 60 mins by fluorescence assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2401634";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL4099618";"";"None";"340.39";"0";"2.33";"14";"CCOc1ccc(Nc2nc(N3CCOCC3)c3nc[nH]c3n2)cc1";"IC50";"'='";"355.0";"nM";"6.45";"";"";"UO_0000065";"18.95";"0.35";"4.12";"7.31";"0";"CHEMBL4018178";"Inhibition of LRRK2 G2019S mutant (unknown origin) using biotinylated ezrin/radaxin/meosin peptide as substrate measured after 1 hr";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4017473";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL4093670";"";"None";"283.33";"0";"3.00";"9";"Cc1ncc(/C=C2\C(=O)Nc3ccc(OC(C)C)cc32)[nH]1";"IC50";"'='";"1.2";"nM";"8.92";"";"";"UO_0000065";"31.49";"0.58";"5.92";"13.31";"0";"CHEMBL4018178";"Inhibition of LRRK2 G2019S mutant (unknown origin) using biotinylated ezrin/radaxin/meosin peptide as substrate measured after 1 hr";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4017473";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL4091885";"";"None";"410.46";"0";"3.12";"16";"CN(C)S(=O)(=O)c1ccc(C(=O)Nc2nc3ccccc3n2-c2ccccc2)o1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL4018177";"Inhibition of full length wild-type LRRK2 (unknown origin) using biotinylated ezrin/radaxin/meosin peptide as substrate measured after 1 hr";"A";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4017473";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL3924132";"";"None";"446.56";"0";"4.73";"36; BOS172722";"CCOc1cc(-c2nncn2C)ccc1Nc1ncc2cc(C)nc(NCC(C)(C)C)c2n1";"IC50";"'='";"48.0";"nM";"7.32";"";"";"UO_0000065";"16.39";"0.30";"2.59";"7.13";"0";"CHEMBL4236806";"Inhibition of recombinant human GST-tagged LRRK2 (970 to 2527 residues) expressed in baculovirus expression system by Z'-LYTE assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4229562";"1";"Scientific Literature";"J Med Chem";"2018";"None";"";"";""
"CHEMBL3335330";"";"None";"414.89";"0";"3.55";"15d";"COc1cc(/C=C2/C(=O)Nc3ccc(Cl)cc32)ccc1OCCN1CCOCC1";"IC50";"'='";"163.0";"nM";"6.79";"";"";"UO_0000065";"16.36";"0.32";"3.24";"11.31";"0";"CHEMBL3390652";"Inhibition of recombinant LRRK2 (unknown origin) using gamma-32P-ATP assessed as LRRKtide substrate phosphorylation level by autoradiography";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352815";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL3335332";"";"None";"255.70";"0";"3.83";"15f";"O=C1Nc2ccc(Cl)cc2/C1=C\c1ccccc1";"IC50";"'='";"10000.0";"nM";"5.00";"";"";"UO_0000065";"19.55";"0.38";"1.17";"17.18";"0";"CHEMBL3390652";"Inhibition of recombinant LRRK2 (unknown origin) using gamma-32P-ATP assessed as LRRKtide substrate phosphorylation level by autoradiography";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352815";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL3335349";"";"None";"350.60";"0";"4.30";"26d";"O=C1Nc2ccc(Cl)cc2/C1=C\c1ccc(O)c(Br)c1";"IC50";"'='";"64.0";"nM";"7.19";"";"";"UO_0000065";"20.52";"0.49";"2.89";"14.58";"0";"CHEMBL3390653";"Inhibition of recombinant LRRK2 G2019S mutant (unknown origin) using gamma-32P-ATP assessed as LRRKtide substrate phosphorylation level by autoradiography";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352815";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL3326143";"";"None";"365.40";"0";"2.31";"31";"COc1ccc(OC)c(N(C)c2ccc3nnc(-c4cnn(C)c4)n3n2)c1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL3367451";"Inhibition of phosphorylation at S935 residue of wild-type full-length LRRK2 kinase (unknown origin) expressed in HEK 293 cells after 90 mins by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"CHEMBL3307715";"";"";""
"CHEMBL3326150";"";"None";"367.43";"0";"3.32";"38";"COc1ccc(OC)c(Sc2ccc3ncn(-c4cnn(C)c4)c3n2)c1";"IC50";"'='";"5850.0";"nM";"5.23";"";"";"UO_0000065";"14.24";"0.27";"1.91";"7.81";"0";"CHEMBL3367451";"Inhibition of phosphorylation at S935 residue of wild-type full-length LRRK2 kinase (unknown origin) expressed in HEK 293 cells after 90 mins by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"CHEMBL3307715";"";"";""
"CHEMBL3326122";"";"None";"371.47";"0";"2.71";"9";"COc1ccc(OC)c(Sc2ccc3nnc(C4CCN(C)C4)n3n2)c1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL3367451";"Inhibition of phosphorylation at S935 residue of wild-type full-length LRRK2 kinase (unknown origin) expressed in HEK 293 cells after 90 mins by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"CHEMBL3307715";"";"";""
"CHEMBL3326146";"";"None";"367.43";"0";"3.30";"34";"COc1ccc(OC)c(Sc2ccc3nnc(-c4cnn(C)c4)n3c2)c1";"IC50";"'='";"1461.0";"nM";"5.83";"";"";"UO_0000065";"15.88";"0.31";"2.54";"8.78";"0";"CHEMBL3367450";"Inhibition of GST-tagged truncated LRRK2 (unknown origin) using fluorescein-labeled peptide LRRKtide as substrate by LANTHA screen assay in presence of 1 mM ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL2347807";"";"None";"327.84";"1";"5.31";"21";"CC(C)Nc1c(C#N)cnc2cc(-c3ccc(Cl)s3)ccc12";"IC50";"'='";"65.0";"nM";"7.19";"";"";"UO_0000065";"21.92";"0.45";"1.88";"14.75";"0";"CHEMBL2352557";"Inhibition of GST-tagged LRRK2 G2019S mutant (970-2527 amino acids) (unknown origin) assessed as inhibition of LRRKtide phosphorylation by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346515";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2347820";"";"None";"423.56";"1";"5.25";"3";"CC(C)Nc1c(-c2nccs2)cnc2cc(-c3ccc(S(C)(=O)=O)cc3)ccc12";"IC50";"'='";"1747.0";"nM";"5.76";"";"";"UO_0000065";"13.59";"0.27";"0.51";"8.00";"0";"CHEMBL2352558";"Inhibition of wild type GST-tagged LRRK2 (970-2527 amino acids)(unknown origin) assessed as inhibition of LRRKtide phosphorylation by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346515";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL3959637";"";"None";"247.30";"0";"3.66";"BDBM254920";"CCc1cccc(-c2ccnc3[nH]cc(C#N)c23)c1";"IC50";"'='";"252.0";"nM";"6.60";"";"443703";"UO_0000065";"26.68";"0.47";"2.94";"12.58";"0";"CHEMBL3889252";"Homogeneous Time Resolved-fluorescence Resonance Energy Transfer (TR-FRET) Assay: LRRK2 kinase activity is measured using a LanthaScreen kinase activity assay available from Invitrogen (Life Technologies Corporation). The assay is a homogeneous time resolved-fluorescence resonance energy transfer (TR-FRET) assay that measures phosphorylation of a fluorescein-labelled peptide substrate (fluorescein-LRRKtide, fluorescein-GAGRLGRDKYKTLRQIRQ) (SEQ ID NO 1) as a result of LRRK2 kinase activity. The phosphorylated peptide is recognized by a terbium-labelled phospho-specific anti-LRRKtide antibody and, subsequently, the phosphorylated LRRKtide can be quantified by the extent of TR-FRET between the terbium donor and fluorescein acceptor.The LRRK2 kinase is obtained from Invitrogen (Life Technologies Corporation) and comprises residues 970 to 2527 of the full length human wild-type LRRK2 kinase or a similar sequence with the G2019S mutation. As discussed above, this mutation increases the kinase activity relative to the wild-type. The kinase reactions are performed in a 20 uL volume in 384-well plates. The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT.Â  In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 uM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 uM fluorescein-LRRKtide. The reaction mixture (20 ul total volume) is incubated for 2 hours at 30° C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 ul). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 us) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 us. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 us time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3887011";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4204060";"";"None";"327.39";"0";"4.21";"22, E:Z Mixture (91:9)";"CN1C(=O)C(=NN(c2ccccc2)c2ccccc2)c2ccccc21";"IC50";"'='";"5760.0";"nM";"5.24";"";"";"UO_0000065";"16.00";"0.29";"1.03";"14.59";"0";"CHEMBL4192178";"Inhibition of recombinant catalytic human GST-tagged LLRK2 (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4190250";"1";"Scientific Literature";"Eur J Med Chem";"2017";"None";"";"";""
"CHEMBL4214200";"";"None";"315.25";"0";"1.57";"48, E:Z Mixture (12:88)";"O=C1Nc2ccc(OC(F)(F)F)cc2C1=NN1CCOCC1";"IC50";"'='";"8740.0";"nM";"5.06";"";"";"UO_0000065";"16.05";"0.31";"3.49";"8.01";"0";"CHEMBL4192178";"Inhibition of recombinant catalytic human GST-tagged LLRK2 (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4190250";"1";"Scientific Literature";"Eur J Med Chem";"2017";"None";"";"";""
"CHEMBL3966624";"";"None";"405.39";"0";"2.90";"BDBM185532";"Cc1nc(C2CN(c3ncnc4[nH]cc(-c5cccc(C#N)c5F)c34)CCO2)no1";"IC50";"'='";"90.0";"nM";"7.05";"";"334712";"UO_0000065";"17.38";"0.32";"4.15";"6.03";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3979061";"";"None";"362.79";"0";"3.26";"BDBM185539";"COc1ccc(F)c(Cl)c1-c1c[nH]c2ncnc(N3CCOCC3)c12";"IC50";"'='";"51.0";"nM";"7.29";"";"334717";"UO_0000065";"20.10";"0.40";"4.03";"11.53";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3934716";"";"None";"386.42";"0";"3.37";"BDBM185579";"Cc1cc(C2CN(c3ncnc4[nH]cc(-c5cccc(C#N)c5)c34)CCO2)on1";"IC50";"'='";"350.0";"nM";"6.46";"";"334724";"UO_0000065";"16.71";"0.30";"3.09";"6.22";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3946246";"";"None";"326.39";"0";"2.17";"BDBM185546";"c1nc(N2CCOCC2)c2c(-c3cnc4sccn34)c[nH]c2n1";"IC50";"'='";"60.5";"nM";"7.22";"";"334727";"UO_0000065";"22.12";"0.43";"5.05";"10.12";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3969635";"";"None";"333.40";"0";"3.11";"BDBM185551";"CC1(C)CN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)CCO1";"IC50";"'='";"304.0";"nM";"6.52";"";"334732";"UO_0000065";"19.55";"0.36";"3.41";"8.37";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3976897";"";"None";"340.41";"0";"2.48";"BDBM185559";"Cc1nc2sccn2c1-c1c[nH]c2ncnc(N3CCOCC3)c12";"IC50";"'='";"135.0";"nM";"6.87";"";"334739";"UO_0000065";"20.18";"0.39";"4.39";"9.63";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3980330";"";"None";"335.39";"0";"3.87";"BDBM185423";"C[C@H]1CCCN(c2ncnc3[nH]cc(-c4cccc(C#N)c4F)c23)C1";"IC50";"'='";"35.0";"nM";"7.46";"";"334598";"UO_0000065";"22.23";"0.41";"3.59";"10.87";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3942521";"";"None";"323.33";"0";"3.15";"BDBM185432";"[C-]#[N+]c1ccc(F)c(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"393.0";"nM";"6.41";"";"334611";"UO_0000065";"19.81";"0.36";"3.26";"10.97";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3965800";"";"None";"328.35";"0";"2.61";"BDBM185444";"COc1ccc(F)cc1-c1c[nH]c2ncnc(N3CCOCC3)c12";"IC50";"'='";"10.0";"nM";"8.00";"";"334625";"UO_0000065";"24.36";"0.46";"5.39";"12.64";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL4079468";"";"None";"291.31";"0";"3.17";"24";"Cc1noc(-c2cc(-c3ccc4[nH]ccc4c3)cnc2N)n1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL4045604";"Inhibition of recombinant human wild type GST-tagged LRRK2 (970 to 2527 residues) preincubated for 30 mins followed by fluorescein-LRRKtide substrate addition after 2 hrs by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4043168";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL3971067";"";"None";"378.48";"0";"3.00";"45";"CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)cc3)cnc2N)nn1";"IC50";"'='";"300.0";"nM";"6.52";"";"";"UO_0000065";"17.23";"0.32";"3.52";"7.95";"1";"CHEMBL4045604";"Inhibition of recombinant human wild type GST-tagged LRRK2 (970 to 2527 residues) preincubated for 30 mins followed by fluorescein-LRRKtide substrate addition after 2 hrs by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4043168";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL3921258";"";"None";"364.45";"0";"3.01";"43";"CC(C)n1cc(-c2cc(-c3ccc(N4CCOCC4)cc3)cnc2N)nn1";"IC50";"'='";"280.0";"nM";"6.55";"";"";"UO_0000065";"17.98";"0.33";"3.54";"7.98";"1";"CHEMBL4045603";"Inhibition of recombinant human LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus preincubated for 30 mins followed by fluorescein-LRRKtide substrate addition after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4043168";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL4645565";"";"None";"446.54";"0";"3.25";"12f";"CC(O)(C#Cc1ccc(N2CCOCC2)c(Nc2ncnc3[nH]ccc23)c1)c1nccs1";"IC50";"'='";"94.6";"nM";"7.02";"";"";"UO_0000065";"15.73";"0.30";"3.77";"7.08";"0";"CHEMBL4618350";"Inhibition of human LRRK2 using [RLGRDKYKTLRQIRQ] as substrate in presence of [gamma33P]ATP by hotspot assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4616671";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL4082856";"";"None";"365.44";"0";"3.18";"26";"C[C@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)CCO1";"IC50";"'='";"5.8";"nM";"8.24";"";"";"UO_0000065";"22.54";"0.42";"5.06";"10.81";"0";"CHEMBL4010109";"Inhibition of recombinant human GST-tagged LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus using fluorescein-ERM as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007454";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4074145";"";"None";"336.40";"0";"3.00";"18";"c1cc(-c2n[nH]c3ccc(OC4CC4)cc23)cc(N2CCOCC2)n1";"IC50";"'='";"41.0";"nM";"7.39";"";"";"UO_0000065";"21.96";"0.40";"4.39";"11.68";"0";"CHEMBL4010109";"Inhibition of recombinant human GST-tagged LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus using fluorescein-ERM as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007454";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL2347809";"";"None";"289.34";"0";"2.72";"23";"Cn1cc(-c2ccc3c(N4CCC4)c(C#N)cnc3c2)cn1";"IC50";"'='";"13.0";"nM";"7.89";"";"";"UO_0000065";"27.26";"0.49";"5.17";"13.66";"0";"CHEMBL2352557";"Inhibition of GST-tagged LRRK2 G2019S mutant (970-2527 amino acids) (unknown origin) assessed as inhibition of LRRKtide phosphorylation by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346515";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2347811";"";"None";"351.43";"0";"3.24";"25";"CN(C)c1c(C#N)cnc2cc(-c3ccc(S(C)(=O)=O)cc3)ccc12";"IC50";"'='";"20.0";"nM";"7.70";"";"";"UO_0000065";"21.91";"0.42";"4.46";"10.40";"0";"CHEMBL2352558";"Inhibition of wild type GST-tagged LRRK2 (970-2527 amino acids)(unknown origin) assessed as inhibition of LRRKtide phosphorylation by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346515";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2347806";"";"None";"366.45";"0";"3.39";"20";"CC(C)Nc1c(C#N)cnc2cc(-c3ccc(S(C)(=O)=O)nc3)ccc12";"IC50";"'='";"64.0";"nM";"7.19";"";"";"UO_0000065";"19.63";"0.38";"3.80";"7.51";"0";"CHEMBL2352558";"Inhibition of wild type GST-tagged LRRK2 (970-2527 amino acids)(unknown origin) assessed as inhibition of LRRKtide phosphorylation by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346515";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL3326121";"";"None";"358.42";"0";"2.80";"8";"COc1ccc(OC)c(Sc2ccc3nnc(C4CCOC4)n3n2)c1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL3367451";"Inhibition of phosphorylation at S935 residue of wild-type full-length LRRK2 kinase (unknown origin) expressed in HEK 293 cells after 90 mins by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"CHEMBL3307715";"";"";""
"CHEMBL3949016";"";"None";"355.35";"0";"3.27";"BDBM185575";"N#Cc1cccc(-c2c(C(F)F)[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"127.0";"nM";"6.90";"";"334509";"UO_0000065";"19.41";"0.36";"3.63";"8.86";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3985170";"";"None";"316.31";"0";"2.74";"BDBM185437";"Fc1ccc(F)c(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"145.0";"nM";"6.84";"";"334617";"UO_0000065";"21.62";"0.41";"4.10";"12.65";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3957480";"";"None";"328.80";"0";"3.42";"BDBM185455";"Cc1ccc(Cl)c(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"22.0";"nM";"7.66";"";"334426";"UO_0000065";"23.29";"0.45";"4.24";"14.17";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL1673042";"";"None";"445.53";"0";"3.00";"XMD13-44";"COc1cc(N2CCNCC2)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2C";"IC50";"'='";"23.0";"nM";"7.64";"";"";"UO_0000065";"17.14";"0.32";"4.64";"8.90";"0";"CHEMBL4612965";"Inhibition of recombinant human GST-tagged LRRK2 catalytic domain (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate measured after 1 hr by Alexa fluor-647 ADP tracer-based ADAPTA assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4610122";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL1673048";"";"None";"501.59";"1";"3.41";"XMD11-52";"COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2C";"IC50";"'='";"8.2";"nM";"8.09";"";"";"UO_0000065";"16.12";"0.30";"4.68";"7.86";"0";"CHEMBL4612965";"Inhibition of recombinant human GST-tagged LRRK2 catalytic domain (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate measured after 1 hr by Alexa fluor-647 ADP tracer-based ADAPTA assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4610122";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL4648947";"";"None";"501.64";"1";"4.51";"JWG-070";"CCC(C)N1c2ccccc2C(=O)N(C)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3OC)nc21";"IC50";"'='";"743.0";"nM";"6.13";"";"";"UO_0000065";"12.22";"0.23";"1.62";"7.95";"0";"CHEMBL4612965";"Inhibition of recombinant human GST-tagged LRRK2 catalytic domain (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate measured after 1 hr by Alexa fluor-647 ADP tracer-based ADAPTA assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4610122";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL3393355";"";"None";"314.78";"0";"3.11";"21";"Clc1cccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"144.0";"nM";"6.84";"";"";"UO_0000065";"21.73";"0.42";"3.73";"12.66";"0";"CHEMBL3395728";"Inhibition of full length LRRK2 (unknown origin) expressed in HEK293 cells assessed as reduction in S935 phosphorylation incubated for 90 mins by ELISA method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL3393341";"";"None";"317.40";"0";"3.73";"7";"C[C@H]1CCCN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)C1";"IC50";"'='";"210.0";"nM";"6.68";"";"";"UO_0000065";"21.04";"0.38";"2.95";"9.73";"0";"CHEMBL3395728";"Inhibition of full length LRRK2 (unknown origin) expressed in HEK293 cells assessed as reduction in S935 phosphorylation incubated for 90 mins by ELISA method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL3393361";"";"None";"306.33";"0";"1.73";"27";"N#Cc1cncc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"6599.0";"nM";"5.18";"";"";"UO_0000065";"16.91";"0.31";"3.45";"5.71";"0";"CHEMBL3395727";"Inhibition of GST-tagged truncated human recombinant LRRK2 G2019S mutant using fluorescein-labeled LRRKtide peptide substrate incubated for 90 mins";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3979676";"";"None";"249.27";"0";"3.11";"BDBM254918";"COc1cccc(-c2ccnc3[nH]cc(C#N)c23)c1";"IC50";"'='";"201.0";"nM";"6.70";"";"443701";"UO_0000065";"26.87";"0.48";"3.59";"10.85";"0";"CHEMBL3889252";"Homogeneous Time Resolved-fluorescence Resonance Energy Transfer (TR-FRET) Assay: LRRK2 kinase activity is measured using a LanthaScreen kinase activity assay available from Invitrogen (Life Technologies Corporation). The assay is a homogeneous time resolved-fluorescence resonance energy transfer (TR-FRET) assay that measures phosphorylation of a fluorescein-labelled peptide substrate (fluorescein-LRRKtide, fluorescein-GAGRLGRDKYKTLRQIRQ) (SEQ ID NO 1) as a result of LRRK2 kinase activity. The phosphorylated peptide is recognized by a terbium-labelled phospho-specific anti-LRRKtide antibody and, subsequently, the phosphorylated LRRKtide can be quantified by the extent of TR-FRET between the terbium donor and fluorescein acceptor.The LRRK2 kinase is obtained from Invitrogen (Life Technologies Corporation) and comprises residues 970 to 2527 of the full length human wild-type LRRK2 kinase or a similar sequence with the G2019S mutation. As discussed above, this mutation increases the kinase activity relative to the wild-type. The kinase reactions are performed in a 20 uL volume in 384-well plates. The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT.Â  In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 uM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 uM fluorescein-LRRKtide. The reaction mixture (20 ul total volume) is incubated for 2 hours at 30° C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 ul). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 us) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 us. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 us time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3887011";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL2012582";"";"None";"570.70";"1";"3.44";"2, LRRK2-IN-1";"COc1cc(C(=O)N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2C";"IC50";"'='";"3.5";"nM";"8.46";"";"";"UO_0000065";"14.82";"0.27";"5.02";"8.68";"0";"CHEMBL3390652";"Inhibition of recombinant LRRK2 (unknown origin) using gamma-32P-ATP assessed as LRRKtide substrate phosphorylation level by autoradiography";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352815";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL4087313";"";"None";"425.33";"1";"5.35";"7j";"CN(C)c1cccc(NC(=O)c2cc(Br)ccc2OCc2ccccc2)c1";"IC50";"'='";"15848.93";"nM";"4.80";"";"";"UO_0000065";"11.29";"0.24";"-0.55";"11.55";"0";"CHEMBL4058537";"Inhibition of LRRK2 (unknown origin) by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4052807";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL4063006";"";"None";"384.44";"0";"4.31";"8j";"Cn1nccc1-c1ccc(OCc2ccccc2)c(C(=O)Nc2cccnc2)c1";"IC50";"'='";"12.59";"nM";"7.90";"";"";"UO_0000065";"20.55";"0.37";"3.59";"11.44";"0";"CHEMBL4058537";"Inhibition of LRRK2 (unknown origin) by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4052807";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL4083136";"";"None";"411.48";"0";"3.16";"8g";"CN(C)S(=O)(=O)c1ccc(OCc2ccccc2)c(C(=O)Nc2cccnc2)c1";"IC50";"'='";"1258.93";"nM";"5.90";"";"";"UO_0000065";"14.34";"0.28";"2.74";"6.66";"0";"CHEMBL4058537";"Inhibition of LRRK2 (unknown origin) by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4052807";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL4077034";"";"None";"363.81";"0";"3.94";"33";"Cc1cc(-c2cc(Nc3nn(C)cc3Cl)nc3[nH]cc(C#N)c23)ccn1";"IC50";"'='";"158.0";"nM";"6.80";"";"";"UO_0000065";"18.69";"0.36";"2.86";"7.14";"0";"CHEMBL4031821";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus using fluorescein-LRRKtide as substrate after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4092521";"";"None";"363.81";"0";"3.94";"34";"Cc1cccc(-c2cc(Nc3nn(C)cc3Cl)nc3[nH]cc(C#N)c23)n1";"IC50";"'='";"57.0";"nM";"7.24";"";"";"UO_0000065";"19.91";"0.38";"3.30";"7.61";"0";"CHEMBL4031821";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus using fluorescein-LRRKtide as substrate after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4084769";"";"None";"329.37";"0";"3.28";"28";"Cc1cccc(-c2cc(Nc3ccn(C)n3)nc3[nH]cc(C#N)c23)n1";"IC50";"'='";"160.0";"nM";"6.80";"";"";"UO_0000065";"20.63";"0.37";"3.52";"7.14";"0";"CHEMBL4031826";"Inhibition of human LRRK2 G2019S mutant phosphorylation at ser935 expressed in BacMam transduced HEK293 cells after 48 hrs by in-cell Western assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"CHEMBL3307715";"";"";""
"CHEMBL4066983";"";"None";"351.41";"0";"2.79";"25";"CC1(Oc2ccc3[nH]nc(-c4cc(N5CCOCC5)ncn4)c3c2)CC1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL4010118";"Inhibition LRRK2 G2019S mutant Ser935 phosphorylation in human SH-SY5Y cells after 90 mins by Western blot analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007454";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4065697";"";"None";"365.44";"0";"3.18";"27";"C[C@@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)CCO1";"IC50";"'='";"13.0";"nM";"7.89";"";"";"UO_0000065";"21.58";"0.40";"4.71";"10.35";"0";"CHEMBL4010117";"Inhibition of recombinant human GST-tagged LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus using fluorescein-ERM as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr in presence of 5 mM ATP by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007454";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL2347809";"";"None";"289.34";"0";"2.72";"23";"Cn1cc(-c2ccc3c(N4CCC4)c(C#N)cnc3c2)cn1";"IC50";"'='";"10.0";"nM";"8.00";"";"";"UO_0000065";"27.65";"0.50";"5.28";"13.86";"0";"CHEMBL2352558";"Inhibition of wild type GST-tagged LRRK2 (970-2527 amino acids)(unknown origin) assessed as inhibition of LRRKtide phosphorylation by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346515";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2347826";"";"None";"436.54";"0";"3.61";"16";"CC(C)Nc1c(C#N)cnc2cc(-c3ccc(S(=O)(=O)N4CCOCC4)cc3)ccc12";"IC50";"'='";"14.0";"nM";"7.85";"";"";"UO_0000065";"17.99";"0.35";"4.24";"8.24";"0";"CHEMBL2352558";"Inhibition of wild type GST-tagged LRRK2 (970-2527 amino acids)(unknown origin) assessed as inhibition of LRRKtide phosphorylation by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346515";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348954";"";"None";"456.50";"0";"4.37";"19";"FC(F)(F)c1cccc(Sc2ccc3nnc(-c4cccc(N5CCNCC5)c4)n3n2)c1";"IC50";"'='";"55.0";"nM";"7.26";"";"";"UO_0000065";"15.90";"0.31";"2.89";"12.44";"0";"CHEMBL2351468";"Inhibition of LRRK2 G2019S mutant (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348940";"";"None";"377.42";"1";"5.63";"5";"FC(F)(F)c1cccc(Sc2ccc3cnc(-c4cccs4)n3n2)c1";"IC50";"'='";"7270.0";"nM";"5.14";"";"";"UO_0000065";"13.61";"0.28";"-0.49";"17.02";"0";"CHEMBL2351468";"Inhibition of LRRK2 G2019S mutant (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348938";"";"None";"378.40";"1";"5.02";"3";"FC(F)(F)c1cccc(Sc2ccc3nnc(-c4cccs4)n3n2)c1";"IC50";"'='";"23.0";"nM";"7.64";"";"";"UO_0000065";"20.19";"0.42";"2.62";"17.73";"0";"CHEMBL2351468";"Inhibition of LRRK2 G2019S mutant (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348969";"";"None";"381.37";"0";"3.21";"35";"FC(F)(F)c1ccnc(Sc2ccc3nnc(-c4cncs4)n3n2)n1";"IC50";"'='";"183.0";"nM";"6.74";"";"";"UO_0000065";"17.67";"0.37";"3.53";"8.24";"0";"CHEMBL2351467";"Inhibition of wild type LRRK2 (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL4072721";"";"None";"332.37";"0";"2.89";"15; Z606357948";"CCn1c(NC(=O)c2ccnc(-n3ccnc3)c2)nc2ccccc21";"IC50";"'='";"274.0";"nM";"6.56";"";"";"UO_0000065";"19.74";"0.36";"3.67";"8.45";"0";"CHEMBL4018178";"Inhibition of LRRK2 G2019S mutant (unknown origin) using biotinylated ezrin/radaxin/meosin peptide as substrate measured after 1 hr";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4017473";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL4093185";"";"None";"351.45";"0";"3.16";"19";"CC(C)Oc1ccc2[nH]nc(-c3ccnc(N4CCN(C)CC4)c3)c2c1";"IC50";"'='";"22.0";"nM";"7.66";"";"";"UO_0000065";"21.79";"0.40";"4.50";"13.37";"0";"CHEMBL4010117";"Inhibition of recombinant human GST-tagged LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus using fluorescein-ERM as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr in presence of 5 mM ATP by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007454";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL3326120";"";"None";"328.40";"0";"3.17";"7";"COc1ccc(OC)c(Sc2ccc3nnc(C4CC4)n3n2)c1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL3367451";"Inhibition of phosphorylation at S935 residue of wild-type full-length LRRK2 kinase (unknown origin) expressed in HEK 293 cells after 90 mins by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"CHEMBL3307715";"";"";""
"CHEMBL3326151";"";"None";"366.45";"0";"3.90";"39";"COc1ccc(OC)c(Sc2ccc3ncc(-c4cnn(C)c4)n3c2)c1";"IC50";"'='";"1145.0";"nM";"5.94";"";"";"UO_0000065";"16.21";"0.31";"2.04";"11.09";"0";"CHEMBL3367450";"Inhibition of GST-tagged truncated LRRK2 (unknown origin) using fluorescein-labeled peptide LRRKtide as substrate by LANTHA screen assay in presence of 1 mM ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL2178124";"";"None";"445.83";"0";"3.42";"8";"CNc1nc(Nc2cc(Cl)c(C(=O)N3CCOCC3)cc2OC)ncc1C(F)(F)F";"IC50";"'='";"7.0";"nM";"8.15";"";"";"UO_0000065";"18.29";"0.37";"4.73";"9.20";"0";"CHEMBL2188381";"Inhibition of autophosphorylation of LRRK2 in human HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2176933";"1";"Scientific Literature";"J Med Chem";"2012";"CHEMBL3307715";"";"";""
"CHEMBL2178141";"";"None";"439.44";"0";"3.41";"25";"CCNc1nc(Nc2cc3c(cc2OC)C(=O)N(CC(C)(C)O)C3)ncc1C(F)(F)F";"IC50";"'='";"22.0";"nM";"7.66";"";"";"UO_0000065";"17.43";"0.34";"4.25";"7.69";"0";"CHEMBL2188381";"Inhibition of autophosphorylation of LRRK2 in human HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2176933";"1";"Scientific Literature";"J Med Chem";"2012";"CHEMBL3307715";"";"";""
"CHEMBL2348963";"";"None";"345.84";"0";"4.05";"29";"Clc1cccc(Sc2ccc3nnc(-c4cncs4)n3n2)c1";"IC50";"'='";"1397.0";"nM";"5.86";"";"";"UO_0000065";"16.93";"0.36";"1.80";"10.46";"0";"CHEMBL2351460";"Inhibition of LRRK2 G2019S mutant (unknown origin) transfected in HEK293 cells assessed decrease in S935 autophosphorylation";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"CHEMBL3307715";"";"";""
"CHEMBL3961632";"";"None";"248.29";"0";"2.99";"22";"Cc1cccc(-c2cc(N)nc3[nH]cc(C#N)c23)c1";"IC50";"'='";"67.0";"nM";"7.17";"";"";"UO_0000065";"28.89";"0.52";"4.18";"9.14";"0";"CHEMBL4031825";"Inhibition of human wild type LRRK2 phosphorylation at ser935 expressed in BacMam transduced HEK293 cells after 48 hrs by in-cell Western assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"CHEMBL3307715";"";"";""
"CHEMBL3905887";"";"None";"397.36";"0";"4.30";"BDBM254938";"Cc1cccc(-c2cc(Nc3nn(C)cc3C(F)(F)F)nc3[nH]cc(C#N)c23)n1";"IC50";"'='";"575.0";"nM";"6.24";"";"443721";"UO_0000065";"15.70";"0.29";"1.94";"6.55";"0";"CHEMBL3889252";"Homogeneous Time Resolved-fluorescence Resonance Energy Transfer (TR-FRET) Assay: LRRK2 kinase activity is measured using a LanthaScreen kinase activity assay available from Invitrogen (Life Technologies Corporation). The assay is a homogeneous time resolved-fluorescence resonance energy transfer (TR-FRET) assay that measures phosphorylation of a fluorescein-labelled peptide substrate (fluorescein-LRRKtide, fluorescein-GAGRLGRDKYKTLRQIRQ) (SEQ ID NO 1) as a result of LRRK2 kinase activity. The phosphorylated peptide is recognized by a terbium-labelled phospho-specific anti-LRRKtide antibody and, subsequently, the phosphorylated LRRKtide can be quantified by the extent of TR-FRET between the terbium donor and fluorescein acceptor.The LRRK2 kinase is obtained from Invitrogen (Life Technologies Corporation) and comprises residues 970 to 2527 of the full length human wild-type LRRK2 kinase or a similar sequence with the G2019S mutation. As discussed above, this mutation increases the kinase activity relative to the wild-type. The kinase reactions are performed in a 20 uL volume in 384-well plates. The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT.Â  In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 uM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 uM fluorescein-LRRKtide. The reaction mixture (20 ul total volume) is incubated for 2 hours at 30° C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 ul). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 us) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 us. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 us time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3887011";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3959637";"";"None";"247.30";"0";"3.66";"BDBM254920";"CCc1cccc(-c2ccnc3[nH]cc(C#N)c23)c1";"IC50";"'='";"266.0";"nM";"6.58";"";"443726";"UO_0000065";"26.59";"0.47";"2.92";"12.53";"0";"CHEMBL3889253";"Homogeneous Time Resolved-fluorescence Resonance Energy Transfer (TR-FRET) Assay: LRRK2 kinase activity is measured using a LanthaScreen kinase activity assay available from Invitrogen (Life Technologies Corporation). The assay is a homogeneous time resolved-fluorescence resonance energy transfer (TR-FRET) assay that measures phosphorylation of a fluorescein-labelled peptide substrate (fluorescein-LRRKtide, fluorescein-GAGRLGRDKYKTLRQIRQ) (SEQ ID NO 1) as a result of LRRK2 kinase activity. The phosphorylated peptide is recognized by a terbium-labelled phospho-specific anti-LRRKtide antibody and, subsequently, the phosphorylated LRRKtide can be quantified by the extent of TR-FRET between the terbium donor and fluorescein acceptor.The LRRK2 kinase is obtained from Invitrogen (Life Technologies Corporation) and comprises residues 970 to 2527 of the full length human wild-type LRRK2 kinase or a similar sequence with the G2019S mutation. As discussed above, this mutation increases the kinase activity relative to the wild-type. The kinase reactions are performed in a 20 uL volume in 384-well plates. The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT.Â  In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 uM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 uM fluorescein-LRRKtide. The reaction mixture (20 ul total volume) is incubated for 2 hours at 30° C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 ul). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 us) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 us. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 us time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3887011";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3980700";"";"None";"427.51";"0";"3.72";"BDBM254932";"Cc1cc(-c2cc(Nc3ccn(C)n3)nc3[nH]cc(C#N)c23)ccc1CN1CCOCC1";"IC50";"'='";"4.0";"nM";"8.40";"";"443738";"UO_0000065";"19.64";"0.36";"4.68";"8.86";"0";"CHEMBL3889253";"Homogeneous Time Resolved-fluorescence Resonance Energy Transfer (TR-FRET) Assay: LRRK2 kinase activity is measured using a LanthaScreen kinase activity assay available from Invitrogen (Life Technologies Corporation). The assay is a homogeneous time resolved-fluorescence resonance energy transfer (TR-FRET) assay that measures phosphorylation of a fluorescein-labelled peptide substrate (fluorescein-LRRKtide, fluorescein-GAGRLGRDKYKTLRQIRQ) (SEQ ID NO 1) as a result of LRRK2 kinase activity. The phosphorylated peptide is recognized by a terbium-labelled phospho-specific anti-LRRKtide antibody and, subsequently, the phosphorylated LRRKtide can be quantified by the extent of TR-FRET between the terbium donor and fluorescein acceptor.The LRRK2 kinase is obtained from Invitrogen (Life Technologies Corporation) and comprises residues 970 to 2527 of the full length human wild-type LRRK2 kinase or a similar sequence with the G2019S mutation. As discussed above, this mutation increases the kinase activity relative to the wild-type. The kinase reactions are performed in a 20 uL volume in 384-well plates. The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT.Â  In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 uM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 uM fluorescein-LRRKtide. The reaction mixture (20 ul total volume) is incubated for 2 hours at 30° C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 ul). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 us) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 us. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 us time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3887011";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3905887";"";"None";"397.36";"0";"4.30";"BDBM254938";"Cc1cccc(-c2cc(Nc3nn(C)cc3C(F)(F)F)nc3[nH]cc(C#N)c23)n1";"IC50";"'='";"393.0";"nM";"6.41";"";"443744";"UO_0000065";"16.12";"0.30";"2.11";"6.73";"0";"CHEMBL3889253";"Homogeneous Time Resolved-fluorescence Resonance Energy Transfer (TR-FRET) Assay: LRRK2 kinase activity is measured using a LanthaScreen kinase activity assay available from Invitrogen (Life Technologies Corporation). The assay is a homogeneous time resolved-fluorescence resonance energy transfer (TR-FRET) assay that measures phosphorylation of a fluorescein-labelled peptide substrate (fluorescein-LRRKtide, fluorescein-GAGRLGRDKYKTLRQIRQ) (SEQ ID NO 1) as a result of LRRK2 kinase activity. The phosphorylated peptide is recognized by a terbium-labelled phospho-specific anti-LRRKtide antibody and, subsequently, the phosphorylated LRRKtide can be quantified by the extent of TR-FRET between the terbium donor and fluorescein acceptor.The LRRK2 kinase is obtained from Invitrogen (Life Technologies Corporation) and comprises residues 970 to 2527 of the full length human wild-type LRRK2 kinase or a similar sequence with the G2019S mutation. As discussed above, this mutation increases the kinase activity relative to the wild-type. The kinase reactions are performed in a 20 uL volume in 384-well plates. The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT.Â  In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 uM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 uM fluorescein-LRRKtide. The reaction mixture (20 ul total volume) is incubated for 2 hours at 30° C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 ul). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 us) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 us. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 us time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3887011";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3975770";"";"None";"442.52";"0";"4.25";"BDBM234867";"COc1cc2ncnc(Nc3cccc(NS(=O)(=O)c4cccs4)c3)c2cc1OC";"IC50";"'='";"57.7";"nM";"7.24";"";"409350";"UO_0000065";"16.36";"0.33";"2.99";"7.07";"0";"CHEMBL3888567";"In vitro Kinase Assay: In vitro kinase assays using LRRK WT and LRRK G2019S.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886763";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3981493";"";"None";"331.38";"0";"2.58";"BDBM185548";"N#Cc1cccc(-c2c[nH]c3ncnc(N4C[C@H]5COC[C@H]5C4)c23)c1";"IC50";"'='";"687.0";"nM";"6.16";"";"334729";"UO_0000065";"18.60";"0.34";"3.58";"7.92";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL2178131";"";"None";"429.37";"0";"2.90";"15";"CNc1nc(Nc2cc(OC)c(C(=O)N3CCOCC3)cc2F)ncc1C(F)(F)F";"IC50";"'='";"63.0";"nM";"7.20";"";"";"UO_0000065";"16.77";"0.33";"4.30";"8.13";"0";"CHEMBL2188381";"Inhibition of autophosphorylation of LRRK2 in human HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2176933";"1";"Scientific Literature";"J Med Chem";"2012";"CHEMBL3307715";"";"";""
"CHEMBL2333129";"";"None";"396.47";"0";"2.76";"14";"CS(=O)(=O)c1ccc(-c2ccc3c(NC4CCC4)c(C(N)=O)nnc3c2)cc1";"IC50";"'='";"19.0";"nM";"7.72";"";"";"UO_0000065";"19.47";"0.38";"4.96";"6.71";"0";"CHEMBL2345527";"Inhibition of GST-tagged LRRK2 G2019S mutant (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2333116";"";"None";"296.33";"0";"1.94";"29";"CC(C)Nc1c(C(N)=O)nnc2cc(-c3cn[nH]c3)ccc12";"IC50";"'='";"12.0";"nM";"7.92";"";"";"UO_0000065";"26.73";"0.49";"5.98";"7.23";"0";"CHEMBL2345528";"Inhibition of wild type GST-tagged LRRK2 (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL3978722";"";"None";"392.51";"0";"3.04";"BDBM223554";"CC(C)n1cc(-c2cc(-c3ccc(CCN4CCOCC4)cc3)cnc2N)nn1";"IC50";"'='";"600.0";"nM";"6.22";"";"390839";"UO_0000065";"15.85";"0.29";"3.18";"7.58";"0";"CHEMBL3888346";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3973194";"";"None";"286.34";"0";"1.60";"BDBM185576";"C1=C(c2c[nH]c3ncnc(N4CCOCC4)c23)COCC1";"IC50";"'='";"97.8";"nM";"7.01";"";"334510";"UO_0000065";"24.48";"0.46";"5.41";"11.08";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3946246";"";"None";"326.39";"0";"2.17";"BDBM185546";"c1nc(N2CCOCC2)c2c(-c3cnc4sccn34)c[nH]c2n1";"IC50";"'='";"15.8";"nM";"7.80";"";"334516";"UO_0000065";"23.90";"0.46";"5.63";"10.94";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3975005";"";"None";"347.42";"0";"3.10";"BDBM185410";"C[C@H]1CCCN(c2ncnc3[nH]cc(-c4ccc5c(c4)C(=O)NC5)c23)C1";"IC50";"'='";"59.0";"nM";"7.23";"";"334585";"UO_0000065";"20.81";"0.38";"4.13";"9.78";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3904113";"";"None";"332.41";"0";"3.74";"BDBM185411";"C[C@H]1CCCN(c2ncnc3[nH]cc(-c4cnc5cc[nH]c5c4)c23)C1";"IC50";"'='";"50.0";"nM";"7.30";"";"334586";"UO_0000065";"21.96";"0.40";"3.56";"9.93";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3986410";"";"None";"308.39";"0";"3.57";"BDBM185412";"C[C@H]1CCCN(c2ncnc3[nH]cc(-c4ccc(O)cc4)c23)C1";"IC50";"'='";"28.0";"nM";"7.55";"";"334587";"UO_0000065";"24.49";"0.45";"3.98";"11.61";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3891060";"";"None";"281.29";"0";"2.70";"BDBM185425";"CN(C)c1ncnc2[nH]cc(-c3cccc(C#N)c3F)c12";"IC50";"'='";"17.0";"nM";"7.77";"";"334600";"UO_0000065";"27.62";"0.51";"5.07";"11.33";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3895606";"";"None";"316.31";"0";"2.74";"BDBM185443";"Fc1cc(F)cc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"238.0";"nM";"6.62";"";"334623";"UO_0000065";"20.94";"0.39";"3.88";"12.26";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3943641";"";"None";"310.36";"0";"2.47";"BDBM185450";"COc1ccccc1-c1c[nH]c2ncnc(N3CCOCC3)c12";"IC50";"'='";"23.0";"nM";"7.64";"";"334632";"UO_0000065";"24.61";"0.45";"5.17";"12.07";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3914899";"";"None";"339.79";"0";"2.99";"BDBM185461";"N#Cc1cc(Cl)cc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"406.0";"nM";"6.39";"";"334645";"UO_0000065";"18.81";"0.36";"3.40";"8.21";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3964190";"";"None";"335.37";"0";"3.02";"BDBM185462";"[C-]#[N+]c1ccc(OC)c(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"121.0";"nM";"6.92";"";"334646";"UO_0000065";"20.63";"0.38";"3.90";"10.23";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3922710";"";"None";"298.35";"0";"1.58";"BDBM185468";"C[C@H]1CN(c2ncnc3[nH]cc(-c4cnn(C)c4)c23)CCO1";"IC50";"'='";"59.0";"nM";"7.23";"";"334652";"UO_0000065";"24.23";"0.45";"5.65";"10.06";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3934683";"";"None";"317.35";"0";"2.67";"BDBM185479";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCC(=O)CC4)c23)c1";"IC50";"'='";"223.0";"nM";"6.65";"";"334663";"UO_0000065";"20.96";"0.38";"3.98";"7.76";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3948671";"";"None";"365.44";"0";"3.17";"BDBM239197";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CC5CCC(C4)O5)ncn3)c2c1";"IC50";"'='";"29.2";"nM";"7.54";"";"417655";"UO_0000065";"20.62";"0.38";"4.36";"9.89";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3906572";"";"None";"352.44";"0";"2.73";"BDBM239236";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4C[C@H](N)C[C@@H]4C)ncn3)c2c1";"IC50";"'='";"11.1";"nM";"7.96";"";"417697";"UO_0000065";"22.57";"0.42";"5.22";"8.56";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3975433";"";"None";"383.45";"0";"2.66";"BDBM239308";"COC[C@H](C)Oc1ccc2[nH]nc(-c3cc(N4CC[C@H](OC)C4)ncn3)c2c1";"IC50";"'='";"5.27";"nM";"8.28";"";"417777";"UO_0000065";"21.59";"0.40";"5.62";"9.69";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3948696";"";"None";"367.45";"0";"3.42";"BDBM239322";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4C[C@@H](C)O[C@@H](C)C4)ncn3)c2c1";"IC50";"'='";"7.8";"nM";"8.11";"";"417790";"UO_0000065";"22.07";"0.41";"4.69";"10.65";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3968954";"";"None";"380.45";"0";"2.48";"BDBM239347";"CC(=O)N1CCN(c2cc(-c3n[nH]c4ccc(OC(C)C)cc34)ncn2)CC1";"IC50";"'='";"11.2";"nM";"7.95";"";"417815";"UO_0000065";"20.90";"0.39";"5.47";"9.11";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3922687";"";"None";"416.49";"0";"3.30";"BDBM239360";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCn5nc(C6CC6)nc5C4)ncn3)c2c1";"IC50";"'='";"18.2";"nM";"7.74";"";"417828";"UO_0000065";"18.58";"0.34";"4.44";"7.93";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3962713";"";"None";"367.45";"0";"3.42";"BDBM239193";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCOC(C)(C)C4)ncn3)c2c1";"IC50";"'='";"6.37";"nM";"8.20";"";"417651";"UO_0000065";"22.30";"0.41";"4.78";"10.76";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3986028";"";"None";"371.47";"0";"2.38";"BDBM239194";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CC[S+]([O-])CC4)ncn3)c2c1";"IC50";"'='";"11.5";"nM";"7.94";"";"417652";"UO_0000065";"21.37";"0.42";"5.56";"8.82";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3960371";"";"None";"370.43";"0";"2.70";"BDBM239211";"CC(C)Oc1cc2c(-c3cc(N4CCN(C)CC4)ncn3)n[nH]c2cc1F";"IC50";"'='";"4.35";"nM";"8.36";"";"417672";"UO_0000065";"22.57";"0.42";"5.66";"11.92";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3971462";"";"None";"353.45";"0";"3.83";"BDBM239213";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4C=CSCC4)ncn3)c2c1";"IC50";"'='";"6.08";"nM";"8.22";"";"417674";"UO_0000065";"23.25";"0.45";"4.39";"12.28";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3952858";"";"None";"389.46";"0";"3.46";"BDBM239352";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCC(n5ccnc5)C4)ncn3)c2c1";"IC50";"'='";"11.3";"nM";"7.95";"";"417820";"UO_0000065";"20.40";"0.37";"4.49";"9.38";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3901579";"";"None";"395.51";"0";"3.79";"BDBM239354";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCCC(C(C)(C)O)C4)ncn3)c2c1";"IC50";"'='";"6.9";"nM";"8.16";"";"417822";"UO_0000065";"20.63";"0.38";"4.37";"9.36";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3933792";"";"None";"422.44";"0";"4.33";"BDBM239520";"COc1ccncc1-c1ccc2[nH]nc(-c3cc(N4CCC(F)(F)CC4)ncn3)c2c1";"IC50";"'='";"6.66";"nM";"8.18";"";"417983";"UO_0000065";"19.36";"0.36";"3.85";"10.24";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3973695";"";"None";"407.45";"0";"3.59";"BDBM239432";"CC(C)Oc1cc2c(-c3cc(N4CCC(n5cccn5)C4)ncn3)n[nH]c2cc1F";"IC50";"'='";"6.1";"nM";"8.21";"";"417898";"UO_0000065";"20.16";"0.37";"4.62";"9.69";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3933018";"";"None";"424.46";"0";"2.07";"BDBM239465";"COC[C@H](C)Oc1ccc2[nH]nc(-c3cc(N4CCN5C(=O)OCC5C4)ncn3)c2c1";"IC50";"'='";"8.8";"nM";"8.06";"";"417930";"UO_0000065";"18.98";"0.35";"5.99";"7.62";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3940938";"";"None";"358.41";"0";"2.92";"BDBM239471";"c1cc(-c2ccc3[nH]nc(-c4cc(N5CCOCC5)ncn4)c3c2)ccn1";"IC50";"'='";"96.7";"nM";"7.01";"";"417936";"UO_0000065";"19.57";"0.35";"4.09";"8.79";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3925427";"";"None";"376.42";"0";"3.13";"BDBM239472";"Cc1noc(C)c1-c1ccc2[nH]nc(-c3cc(N4CCOCC4)ncn3)c2c1";"IC50";"'='";"48.7";"nM";"7.31";"";"417937";"UO_0000065";"19.43";"0.36";"4.18";"7.87";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3926502";"";"None";"382.43";"0";"3.40";"BDBM239475";"N#Cc1cccc(-c2ccc3[nH]nc(-c4cc(N5CCOCC5)ncn4)c3c2)c1";"IC50";"'='";"81.3";"nM";"7.09";"";"417940";"UO_0000065";"18.54";"0.33";"3.69";"7.82";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3928556";"";"None";"325.37";"0";"2.25";"BDBM239270";"COc1ccc2[nH]nc(-c3cc(N4CCO[C@@H](C)C4)ncn3)c2c1";"IC50";"'='";"76.9";"nM";"7.11";"";"417729";"UO_0000065";"21.86";"0.40";"4.86";"9.34";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3915967";"";"None";"345.35";"0";"2.91";"BDBM239273";"CCOc1ccc2[nH]nc(-c3cc(N4C[C@H](F)[C@@H](F)C4)ncn3)c2c1";"IC50";"'='";"26.56";"nM";"7.58";"";"417732";"UO_0000065";"21.94";"0.41";"4.67";"11.32";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4113360";"";"None";"369.43";"0";"2.27";"BDBM239297";"COC[C@@H](C)Oc1ccc2[nH]nc(-c3cc(N4CCOCC4)ncn3)c2c1";"IC50";"'='";"56.2";"nM";"7.25";"";"417756";"UO_0000065";"19.63";"0.37";"4.98";"8.49";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3393448";"";"None";"387.40";"0";"2.77";"37";"Cc1noc(C2CN(c3ncnc4[nH]cc(-c5cccc(C#N)c5)c34)CCO2)n1";"IC50";"'='";"390.0";"nM";"6.41";"";"";"UO_0000065";"16.54";"0.30";"3.64";"5.49";"0";"CHEMBL3395728";"Inhibition of full length LRRK2 (unknown origin) expressed in HEK293 cells assessed as reduction in S935 phosphorylation incubated for 90 mins by ELISA method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL3393345";"";"None";"275.32";"0";"2.71";"11";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCC4)c23)c1";"IC50";"'='";"7687.0";"nM";"5.11";"";"";"UO_0000065";"18.58";"0.33";"2.40";"7.46";"0";"CHEMBL3395728";"Inhibition of full length LRRK2 (unknown origin) expressed in HEK293 cells assessed as reduction in S935 phosphorylation incubated for 90 mins by ELISA method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL2347816";"";"None";"379.44";"0";"3.16";"30";"CC(=O)N(C)c1c(C#N)cnc2cc(-c3ccc(S(C)(=O)=O)cc3)ccc12";"IC50";"'='";"1177.0";"nM";"5.93";"";"";"UO_0000065";"15.63";"0.30";"2.77";"6.51";"0";"CHEMBL2352557";"Inhibition of GST-tagged LRRK2 G2019S mutant (970-2527 amino acids) (unknown origin) assessed as inhibition of LRRKtide phosphorylation by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346515";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2347808";"";"None";"211.27";"0";"2.93";"22";"CC(C)Nc1c(C#N)cnc2ccccc12";"IC50";"'='";"288.0";"nM";"6.54";"";"";"UO_0000065";"30.96";"0.56";"3.61";"13.43";"0";"CHEMBL2352557";"Inhibition of GST-tagged LRRK2 G2019S mutant (970-2527 amino acids) (unknown origin) assessed as inhibition of LRRKtide phosphorylation by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346515";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2333125";"";"None";"383.47";"0";"3.22";"1";"CC(C)Nc1c(C(N)=O)cnc2cc(-c3ccc(S(C)(=O)=O)cc3)ccc12";"IC50";"'='";"39.0";"nM";"7.41";"";"";"UO_0000065";"19.32";"0.37";"4.19";"7.25";"0";"CHEMBL2352558";"Inhibition of wild type GST-tagged LRRK2 (970-2527 amino acids)(unknown origin) assessed as inhibition of LRRKtide phosphorylation by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346515";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348968";"";"None";"313.37";"0";"2.19";"34";"c1cnc(Sc2ccc3nnc(-c4cncs4)n3n2)nc1";"IC50";"'='";"117.0";"nM";"6.93";"";"";"UO_0000065";"22.12";"0.45";"4.74";"8.48";"0";"CHEMBL2351467";"Inhibition of wild type LRRK2 (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348954";"";"None";"456.50";"0";"4.37";"19";"FC(F)(F)c1cccc(Sc2ccc3nnc(-c4cccc(N5CCNCC5)c4)n3n2)c1";"IC50";"'='";"314.0";"nM";"6.50";"";"";"UO_0000065";"14.25";"0.28";"2.13";"11.14";"0";"CHEMBL2351467";"Inhibition of wild type LRRK2 (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348977";"";"None";"330.40";"0";"3.09";"44";"CC(Sc1ccc2nnc(-c3cccs3)n2n1)c1nnco1";"IC50";"'='";"162.0";"nM";"6.79";"";"";"UO_0000065";"20.55";"0.42";"3.70";"8.28";"0";"CHEMBL2351468";"Inhibition of LRRK2 G2019S mutant (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348961";"";"None";"372.38";"0";"4.96";"27";"FC(F)(F)c1ccccc1Sc1ccc2nnc(-c3ccccc3)n2n1";"IC50";"'='";"2470.0";"nM";"5.61";"";"";"UO_0000065";"15.06";"0.29";"0.65";"13.02";"0";"CHEMBL2351468";"Inhibition of LRRK2 G2019S mutant (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL3891365";"";"None";"366.43";"0";"2.09";"BDBM239279";"CCOc1ccc2[nH]nc(-c3cc(N4CCN(CC)C(=O)C4)ncn3)c2c1";"IC50";"'='";"16.7";"nM";"7.78";"";"417738";"UO_0000065";"21.22";"0.39";"5.69";"8.91";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3931403";"";"None";"425.44";"0";"2.86";"BDBM239386";"Cn1cc(-c2cc3c(-c4cc(N5CCC(F)(CO)CC5)ncn4)n[nH]c3cc2F)cn1";"IC50";"'='";"15.3";"nM";"7.82";"";"417853";"UO_0000065";"18.37";"0.34";"4.96";"8.16";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3972322";"";"None";"404.48";"0";"1.53";"BDBM239407";"CN(C)[C@H]1CN(c2cc(-c3n[nH]c4ccc(-c5cnn(C)c5)cc34)ncn2)C[C@@H]1O";"IC50";"'='";"13.5";"nM";"7.87";"";"417873";"UO_0000065";"19.46";"0.36";"6.34";"7.95";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3981493";"";"None";"331.38";"0";"2.58";"BDBM185548";"N#Cc1cccc(-c2c[nH]c3ncnc(N4C[C@H]5COC[C@H]5C4)c23)c1";"IC50";"'='";"223.0";"nM";"6.65";"";"334518";"UO_0000065";"20.07";"0.36";"4.07";"8.55";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3983291";"";"None";"413.44";"0";"3.33";"BDBM185489";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCOC(c5nc(C6CC6)no5)C4)c23)c1";"IC50";"'='";"84.0";"nM";"7.08";"";"334673";"UO_0000065";"17.11";"0.31";"3.75";"6.06";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3926809";"";"None";"298.35";"0";"1.50";"BDBM185498";"Cc1nn(C)cc1-c1c[nH]c2ncnc(N3CCOCC3)c12";"IC50";"'='";"91.0";"nM";"7.04";"";"334683";"UO_0000065";"23.60";"0.44";"5.54";"9.80";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL2403375";"";"None";"365.43";"0";"3.20";"11";"CC(=O)N1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(OC(C)C)cc43)cc2C1";"IC50";"'='";"4.0";"nM";"8.40";"";"";"UO_0000065";"22.98";"0.42";"5.20";"11.28";"0";"CHEMBL2406186";"Inhibition of human LRRK2 (1885 to 2132) using 5-Fluo-Ahx-RLGRDKYKTLRQIRQGNTK-OH as substrate after 60 mins by fluorescence assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2401634";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2333121";"";"None";"313.39";"0";"2.67";"34";"CC(C)Nc1c(C(N)=O)nnc2cc(-c3cnsc3)ccc12";"IC50";"'='";"20.0";"nM";"7.70";"";"";"UO_0000065";"24.57";"0.48";"5.03";"8.21";"0";"CHEMBL2345527";"Inhibition of GST-tagged LRRK2 G2019S mutant (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2333118";"";"None";"310.36";"0";"1.95";"31";"CC(C)Nc1c(C(N)=O)nnc2cc(-c3cnn(C)c3)ccc12";"IC50";"'='";"12.0";"nM";"7.92";"";"";"UO_0000065";"25.52";"0.47";"5.97";"8.02";"0";"CHEMBL2345527";"Inhibition of GST-tagged LRRK2 G2019S mutant (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL3908109";"";"None";"388.45";"0";"1.11";"BDBM239261";"COc1ccc2[nH]nc(-c3cc(N4CCN(S(C)(=O)=O)CC4)ncn3)c2c1";"IC50";"'='";"35.4";"nM";"7.45";"";"417720";"UO_0000065";"19.18";"0.38";"6.34";"7.14";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4111764";"";"None";"325.37";"0";"2.25";"BDBM239269";"COc1ccc2[nH]nc(-c3cc(N4CCO[C@H](C)C4)ncn3)c2c1";"IC50";"'='";"28.5";"nM";"7.54";"";"417728";"UO_0000065";"23.19";"0.43";"5.30";"9.91";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3975412";"";"None";"351.41";"0";"2.79";"BDBM239280";"CCOc1ccc2[nH]nc(-c3cc(N4CC5CCC(C4)O5)ncn3)c2c1";"IC50";"'='";"32.69";"nM";"7.49";"";"417739";"UO_0000065";"21.30";"0.39";"4.70";"9.83";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3924286";"";"None";"387.42";"0";"2.14";"BDBM239436";"CO[C@H]1CN(c2cc(-c3n[nH]c4cc(F)c(OC(C)C)cc34)ncn2)C[C@@H]1O";"IC50";"'='";"7.7";"nM";"8.11";"";"417902";"UO_0000065";"20.94";"0.40";"5.97";"8.42";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3917046";"";"None";"428.47";"0";"3.22";"BDBM239440";"CCOC(=O)N1CCN(c2cc(-c3n[nH]c4cc(F)c(OC(C)C)cc34)ncn2)CC1";"IC50";"'='";"6.1";"nM";"8.21";"";"417906";"UO_0000065";"19.17";"0.36";"4.99";"8.52";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL2171746";"";"None";"368.40";"0";"1.61";"6";"CNc1nc(Nc2ccc(C(=O)N3CCOCC3)cc2OC)ncc1C#N";"IC50";"'='";"105.0";"nM";"6.98";"";"";"UO_0000065";"18.94";"0.35";"5.37";"6.21";"0";"CHEMBL2188381";"Inhibition of autophosphorylation of LRRK2 in human HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2176933";"1";"Scientific Literature";"J Med Chem";"2012";"CHEMBL3307715";"";"";""
"CHEMBL2441273";"";"None";"459.62";"1";"5.70";"13";"CCc1ccc2nc(Nc3cc(Cc4ccccc4)nc(N[C@H]4CC[C@H](O)CC4)n3)sc2c1";"IC50";"'='";"398.11";"nM";"6.40";"";"";"UO_0000065";"13.92";"0.26";"0.70";"7.71";"0";"CHEMBL2446675";"Inhibition of LRRK2 (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2440060";"1";"Scientific Literature";"ACS Med Chem Lett";"2013";"None";"";"";""
"CHEMBL3961632";"";"None";"248.29";"0";"2.99";"22";"Cc1cccc(-c2cc(N)nc3[nH]cc(C#N)c23)c1";"IC50";"'='";"24.55";"nM";"7.61";"";"";"UO_0000065";"30.65";"0.55";"4.62";"9.70";"0";"CHEMBL4031822";"Inhibition of human wild type LRRK2 phosphorylation at ser935 transfected in HEK293 cells after 48 hrs by in-cell Western assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"CHEMBL3307715";"";"";""
"CHEMBL4104344";"";"None";"264.33";"0";"3.04";"3a";"Cc1ccc(-c2cnc(N)c(-c3cnn(C)c3)c2)cc1";"IC50";"'='";"6700.0";"nM";"5.17";"";"";"UO_0000065";"19.57";"0.35";"2.13";"9.12";"0";"CHEMBL4045603";"Inhibition of recombinant human LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus preincubated for 30 mins followed by fluorescein-LRRKtide substrate addition after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4043168";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL3936985";"";"None";"333.40";"0";"3.25";"35";"CN1CCc2cc(-c3cnc(N)c(-c4nnc(C5CC5)o4)c3)ccc21";"IC50";"'='";"710.0";"nM";"6.15";"";"";"UO_0000065";"18.44";"0.34";"2.90";"7.58";"1";"CHEMBL4045603";"Inhibition of recombinant human LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus preincubated for 30 mins followed by fluorescein-LRRKtide substrate addition after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4043168";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL3954783";"";"None";"365.44";"0";"3.20";"BDBM223548";"COc1cccc(-c2cnc(N)c(-c3nnc(C4CCN(C)CC4)o3)c2)c1";"IC50";"'='";"880.0";"nM";"6.06";"";"390804";"UO_0000065";"16.57";"0.31";"2.86";"6.71";"0";"CHEMBL3888345";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3984578";"";"None";"396.47";"0";"3.14";"BDBM223559";"CC(C)n1cc(-c2cc(-c3ccc(F)c(CN4CCOCC4)c3)cnc2N)nn1";"IC50";"'='";"1000.0";"nM";"6.00";"";"390844";"UO_0000065";"15.13";"0.28";"2.86";"7.31";"0";"CHEMBL3888346";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3893023";"";"None";"323.36";"0";"1.56";"BDBM185556";"NC(=O)c1cccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"30.6";"nM";"7.51";"";"334525";"UO_0000065";"23.24";"0.43";"5.95";"7.74";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3909357";"";"None";"328.35";"0";"2.09";"BDBM185447";"OCc1cc(-c2c[nH]c3ncnc(N4CCOCC4)c23)ccc1F";"IC50";"'='";"70.0";"nM";"7.16";"";"334418";"UO_0000065";"21.79";"0.41";"5.06";"9.63";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3906353";"";"None";"298.32";"0";"2.60";"BDBM185448";"Fc1ccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)cc1";"IC50";"'='";"95.0";"nM";"7.02";"";"334419";"UO_0000065";"23.54";"0.44";"4.42";"12.99";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3973146";"";"None";"326.43";"0";"3.18";"BDBM185451";"CSc1cccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"52.0";"nM";"7.28";"";"334422";"UO_0000065";"22.31";"0.43";"4.10";"13.48";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3899731";"";"None";"385.43";"0";"3.57";"BDBM185493";"Cc1nnc(C2CCCN(c3ncnc4[nH]cc(-c5cccc(C#N)c5)c34)C2)o1";"IC50";"'='";"96.0";"nM";"7.02";"";"334466";"UO_0000065";"18.21";"0.33";"3.45";"6.53";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3930005";"";"None";"333.40";"0";"3.01";"BDBM185377";"[C-]#[N+]C1CCCN(c2ncnc3[nH]cc(-c4cccc(CO)c4)c23)C1";"IC50";"'='";"31.0";"nM";"7.51";"";"334550";"UO_0000065";"22.52";"0.41";"4.50";"10.82";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3896369";"";"None";"372.43";"0";"2.60";"BDBM185396";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCCC5(CNC(=O)C5)C4)c23)c1";"IC50";"'='";"119.0";"nM";"6.92";"";"334571";"UO_0000065";"18.59";"0.34";"4.32";"7.09";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3966226";"";"None";"360.42";"0";"2.60";"BDBM185400";"CC(=O)NC1CCN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)CC1";"IC50";"'='";"190.0";"nM";"6.72";"";"334575";"UO_0000065";"18.65";"0.34";"4.12";"6.88";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3899731";"";"None";"385.43";"0";"3.57";"BDBM185493";"Cc1nnc(C2CCCN(c3ncnc4[nH]cc(-c5cccc(C#N)c5)c34)C2)o1";"IC50";"'='";"217.0";"nM";"6.66";"";"334677";"UO_0000065";"17.29";"0.31";"3.09";"6.20";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3931788";"";"None";"410.41";"0";"3.04";"BDBM185503";"COc1ccc(F)cc1-c1c[nH]c2ncnc(N3CCOC(c4noc(C)n4)C3)c12";"IC50";"'='";"46.0";"nM";"7.34";"";"334688";"UO_0000065";"17.88";"0.33";"4.30";"7.18";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL4112166";"";"None";"345.41";"0";"3.25";"BDBM185549";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCO[C@H]5CCC[C@H]54)c23)c1";"IC50";"'='";"186.0";"nM";"6.73";"";"334730";"UO_0000065";"19.49";"0.35";"3.48";"8.65";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3898442";"";"None";"330.35";"0";"2.58";"BDBM185550";"[C-]#[N+]C1CN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)CCO1";"IC50";"'='";"336.0";"nM";"6.47";"";"334731";"UO_0000065";"19.60";"0.35";"3.89";"7.88";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3977201";"";"None";"461.60";"0";"4.36";"BDBM239499";"C[C@@H]1CN(c2cc(-c3n[nH]c4ccc(-c5cnc(N6CCCC6)s5)cc34)ncn2)C[C@H](C)O1";"IC50";"'='";"7.6";"nM";"8.12";"";"417964";"UO_0000065";"17.59";"0.34";"3.76";"9.78";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3952380";"";"None";"472.55";"0";"3.02";"BDBM239503";"C[C@@H]1CN(c2cc(-c3n[nH]c4ccc(-c5ccc(C(=O)NCCO)cc5)cc34)ncn2)C[C@H](C)O1";"IC50";"'='";"77.0";"nM";"7.11";"";"417968";"UO_0000065";"15.05";"0.28";"4.09";"6.12";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3895440";"";"None";"484.60";"0";"4.78";"BDBM239506";"CCN(CC)C(=O)c1ccc(-c2ccc3[nH]nc(-c4cc(N5C[C@@H](C)O[C@@H](C)C5)ncn4)c3c2)cc1";"IC50";"'='";"847.1";"nM";"6.07";"";"417971";"UO_0000065";"12.53";"0.23";"1.29";"6.96";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL2436976";"";"None";"377.40";"0";"3.29";"12";"COc1cc(-c2cnc3[nH]cc(-c4cnc(N)nc4)c3c2)cc(OC)c1OC";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL2439119";"Inhibition of human wild type LRRK2 by qPCR analysis";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2434948";"1";"Scientific Literature";"J Med Chem";"2013";"None";"";"";""
"CHEMBL2326711";"";"None";"272.23";"0";"2.01";"3";"CNc1nc(Nc2ccnn2C)ncc1C(F)(F)F";"IC50";"'='";"130.0";"nM";"6.89";"";"";"UO_0000065";"25.29";"0.49";"4.88";"10.18";"0";"CHEMBL2328175";"Inhibition of LRRK2 (unknown origin) autophosphorylation by cell-based assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2321736";"1";"Scientific Literature";"ACS Med Chem Lett";"2013";"None";"";"";""
"CHEMBL3934683";"";"None";"317.35";"0";"2.67";"BDBM185479";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCC(=O)CC4)c23)c1";"IC50";"'='";"66.0";"nM";"7.18";"";"334452";"UO_0000065";"22.63";"0.41";"4.51";"8.38";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3911449";"";"None";"397.44";"0";"3.78";"BDBM185481";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCOC(c5cccc(O)c5)C4)c23)c1";"IC50";"'='";"91.0";"nM";"7.04";"";"334454";"UO_0000065";"17.72";"0.32";"3.26";"7.18";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3947266";"";"None";"294.36";"0";"3.23";"BDBM185522";"COc1ccccc1-c1c[nH]c2ncnc(N3CCCC3)c12";"IC50";"'='";"54.0";"nM";"7.27";"";"334491";"UO_0000065";"24.69";"0.45";"4.04";"13.45";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3942400";"";"None";"319.37";"0";"3.99";"BDBM223541";"CC(C)c1nnc(-c2cc(-c3ccc4[nH]ccc4c3)cnc2N)o1";"IC50";"'='";"910.0";"nM";"6.04";"";"390797";"UO_0000065";"18.92";"0.34";"2.05";"6.45";"0";"CHEMBL3888345";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3984578";"";"None";"396.47";"0";"3.14";"BDBM223559";"CC(C)n1cc(-c2cc(-c3ccc(F)c(CN4CCOCC4)c3)cnc2N)nn1";"IC50";"'='";"880.0";"nM";"6.06";"";"390815";"UO_0000065";"15.27";"0.29";"2.92";"7.38";"0";"CHEMBL3888345";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3981561";"";"None";"374.41";"0";"1.36";"BDBM239189";"Cn1cc(-c2ccc3[nH]nc(-c4cc(N5CCNC(=O)C5)ncn4)c3c2)cn1";"IC50";"'='";"2.84";"nM";"8.55";"";"417648";"UO_0000065";"22.83";"0.42";"7.19";"8.17";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3922487";"";"None";"430.45";"0";"3.42";"BDBM239380";"Cc1nc2c(o1)CCN(c1cc(-c3n[nH]c4cc(F)c(-c5cnn(C)c5)cc34)ncn1)C2";"IC50";"'='";"53.4";"nM";"7.27";"";"417847";"UO_0000065";"16.90";"0.31";"3.85";"7.16";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3894658";"";"None";"381.39";"0";"2.92";"BDBM239403";"Cn1cc(-c2ccc3[nH]nc(-c4cc(N5C[C@H](F)[C@@H](F)C5)ncn4)c3c2)cn1";"IC50";"'='";"3.8";"nM";"8.42";"";"417869";"UO_0000065";"22.08";"0.41";"5.50";"11.15";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3897651";"";"None";"368.44";"0";"1.70";"BDBM239239";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4C[C@H](O)[C@@H](N)[C@@H]4C)ncn3)c2c1";"IC50";"'='";"14.4";"nM";"7.84";"";"417700";"UO_0000065";"21.28";"0.40";"6.14";"6.93";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3934167";"";"None";"428.47";"0";"2.24";"BDBM239255";"COCCN1CCN(c2cc(-c3n[nH]c4cc(F)c(OC(C)C)cc34)ncn2)CC1=O";"IC50";"'='";"1.63";"nM";"8.79";"";"417716";"UO_0000065";"20.51";"0.39";"6.55";"9.11";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3914638";"";"None";"338.42";"0";"2.17";"BDBM239265";"CCN1CCN(c2cc(-c3n[nH]c4ccc(OC)cc34)ncn2)CC1";"IC50";"'='";"24.3";"nM";"7.61";"";"417724";"UO_0000065";"22.50";"0.42";"5.44";"10.85";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3964546";"";"None";"450.54";"0";"2.88";"BDBM239310";"COC[C@H](C)Oc1ccc2[nH]nc(-c3cc(N4CCC5(CCN(C)C5=O)CC4)ncn3)c2c1";"IC50";"'='";"3.71";"nM";"8.43";"";"417779";"UO_0000065";"18.71";"0.35";"5.55";"8.74";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3950409";"";"None";"385.44";"0";"3.11";"BDBM239361";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCC(F)(CO)CC4)ncn3)c2c1";"IC50";"'='";"6.3";"nM";"8.20";"";"417829";"UO_0000065";"21.28";"0.40";"5.09";"9.41";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3928101";"";"None";"422.52";"0";"2.99";"BDBM239362";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCN(c5nncs5)CC4)ncn3)c2c1";"IC50";"'='";"17.0";"nM";"7.77";"";"417830";"UO_0000065";"18.39";"0.35";"4.78";"8.10";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4113317";"";"None";"393.43";"0";"2.78";"BDBM239376";"C[C@@H]1CN(c2cc(-c3n[nH]c4cc(F)c(-c5cnn(C)c5)cc34)ncn2)CCO1";"IC50";"'='";"20.5";"nM";"7.69";"";"417843";"UO_0000065";"19.54";"0.36";"4.91";"9.07";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3897407";"";"None";"418.51";"0";"1.92";"BDBM239415";"Cn1cc(-c2ccc3[nH]nc(-c4cc(N5CCN(CCCO)CC5)ncn4)c3c2)cn1";"IC50";"'='";"3.0";"nM";"8.52";"";"417881";"UO_0000065";"20.36";"0.38";"6.60";"8.61";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3942757";"";"None";"378.46";"0";"3.29";"BDBM239526";"Cc1ncc(-c2ccc3[nH]nc(-c4cc(N5CCOCC5)ncn4)c3c2)s1";"IC50";"'='";"2.2";"nM";"8.66";"";"417989";"UO_0000065";"22.88";"0.44";"5.37";"10.85";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3980700";"";"None";"427.51";"0";"3.72";"BDBM254932";"Cc1cc(-c2cc(Nc3ccn(C)n3)nc3[nH]cc(C#N)c23)ccc1CN1CCOCC1";"IC50";"'='";"1.0";"nM";"9.00";"";"443715";"UO_0000065";"21.05";"0.38";"5.28";"9.49";"0";"CHEMBL3889252";"Homogeneous Time Resolved-fluorescence Resonance Energy Transfer (TR-FRET) Assay: LRRK2 kinase activity is measured using a LanthaScreen kinase activity assay available from Invitrogen (Life Technologies Corporation). The assay is a homogeneous time resolved-fluorescence resonance energy transfer (TR-FRET) assay that measures phosphorylation of a fluorescein-labelled peptide substrate (fluorescein-LRRKtide, fluorescein-GAGRLGRDKYKTLRQIRQ) (SEQ ID NO 1) as a result of LRRK2 kinase activity. The phosphorylated peptide is recognized by a terbium-labelled phospho-specific anti-LRRKtide antibody and, subsequently, the phosphorylated LRRKtide can be quantified by the extent of TR-FRET between the terbium donor and fluorescein acceptor.The LRRK2 kinase is obtained from Invitrogen (Life Technologies Corporation) and comprises residues 970 to 2527 of the full length human wild-type LRRK2 kinase or a similar sequence with the G2019S mutation. As discussed above, this mutation increases the kinase activity relative to the wild-type. The kinase reactions are performed in a 20 uL volume in 384-well plates. The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT.Â  In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 uM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 uM fluorescein-LRRKtide. The reaction mixture (20 ul total volume) is incubated for 2 hours at 30° C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 ul). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 us) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 us. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 us time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3887011";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3939513";"";"None";"314.35";"0";"3.58";"BDBM254930";"Cn1ccc(Nc2cc(-c3ccccc3)c3c(C#N)c[nH]c3n2)n1";"IC50";"'='";"48.0";"nM";"7.32";"";"443736";"UO_0000065";"23.28";"0.42";"3.74";"8.89";"0";"CHEMBL3889253";"Homogeneous Time Resolved-fluorescence Resonance Energy Transfer (TR-FRET) Assay: LRRK2 kinase activity is measured using a LanthaScreen kinase activity assay available from Invitrogen (Life Technologies Corporation). The assay is a homogeneous time resolved-fluorescence resonance energy transfer (TR-FRET) assay that measures phosphorylation of a fluorescein-labelled peptide substrate (fluorescein-LRRKtide, fluorescein-GAGRLGRDKYKTLRQIRQ) (SEQ ID NO 1) as a result of LRRK2 kinase activity. The phosphorylated peptide is recognized by a terbium-labelled phospho-specific anti-LRRKtide antibody and, subsequently, the phosphorylated LRRKtide can be quantified by the extent of TR-FRET between the terbium donor and fluorescein acceptor.The LRRK2 kinase is obtained from Invitrogen (Life Technologies Corporation) and comprises residues 970 to 2527 of the full length human wild-type LRRK2 kinase or a similar sequence with the G2019S mutation. As discussed above, this mutation increases the kinase activity relative to the wild-type. The kinase reactions are performed in a 20 uL volume in 384-well plates. The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT.Â  In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 uM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 uM fluorescein-LRRKtide. The reaction mixture (20 ul total volume) is incubated for 2 hours at 30° C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 ul). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 us) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 us. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 us time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3887011";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL2178137";"";"None";"394.35";"0";"2.83";"21";"CNc1nc(Nc2cc(F)c(S(C)(=O)=O)cc2OC)ncc1C(F)(F)F";"IC50";"'='";"27.0";"nM";"7.57";"";"";"UO_0000065";"19.19";"0.40";"4.74";"8.12";"0";"CHEMBL2188381";"Inhibition of autophosphorylation of LRRK2 in human HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2176933";"1";"Scientific Literature";"J Med Chem";"2012";"CHEMBL3307715";"";"";""
"CHEMBL2170016";"";"None";"377.83";"0";"2.40";"1";"CNc1nc(Nc2ccc(C(=O)N3CCOCC3)cc2OC)ncc1Cl";"IC50";"'='";"29.0";"nM";"7.54";"";"";"UO_0000065";"19.95";"0.40";"5.14";"8.51";"0";"CHEMBL2188381";"Inhibition of autophosphorylation of LRRK2 in human HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2176933";"1";"Scientific Literature";"J Med Chem";"2012";"CHEMBL3307715";"";"";""
"CHEMBL2348979";"";"None";"392.43";"1";"5.33";"46";"Cc1cc2nnc(-c3cccs3)n2nc1Sc1cccc(C(F)(F)F)c1";"IC50";"'>'";"4000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL2351467";"Inhibition of wild type LRRK2 (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2347805";"";"None";"394.50";"0";"3.84";"19";"CC(C)Nc1c(C#N)cnc2cc(-c3ccc(S(=O)(=O)N(C)C)cc3)ccc12";"IC50";"'='";"28.0";"nM";"7.55";"";"";"UO_0000065";"19.15";"0.37";"3.71";"8.77";"0";"CHEMBL2352557";"Inhibition of GST-tagged LRRK2 G2019S mutant (970-2527 amino acids) (unknown origin) assessed as inhibition of LRRKtide phosphorylation by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346515";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2333125";"";"None";"383.47";"0";"3.22";"1";"CC(C)Nc1c(C(N)=O)cnc2cc(-c3ccc(S(C)(=O)=O)cc3)ccc12";"IC50";"'='";"41.0";"nM";"7.39";"";"";"UO_0000065";"19.26";"0.37";"4.17";"7.23";"0";"CHEMBL2352557";"Inhibition of GST-tagged LRRK2 G2019S mutant (970-2527 amino acids) (unknown origin) assessed as inhibition of LRRKtide phosphorylation by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346515";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2347816";"";"None";"379.44";"0";"3.16";"30";"CC(=O)N(C)c1c(C#N)cnc2cc(-c3ccc(S(C)(=O)=O)cc3)ccc12";"IC50";"'='";"2333.0";"nM";"5.63";"";"";"UO_0000065";"14.84";"0.28";"2.47";"6.18";"0";"CHEMBL2352558";"Inhibition of wild type GST-tagged LRRK2 (970-2527 amino acids)(unknown origin) assessed as inhibition of LRRKtide phosphorylation by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346515";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2347824";"";"None";"291.36";"0";"3.33";"14";"CC(C)Nc1c(C#N)cnc2cc(-c3cnn(C)c3)ccc12";"IC50";"'='";"7.0";"nM";"8.15";"";"";"UO_0000065";"27.99";"0.51";"4.82";"12.26";"0";"CHEMBL2352558";"Inhibition of wild type GST-tagged LRRK2 (970-2527 amino acids)(unknown origin) assessed as inhibition of LRRKtide phosphorylation by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346515";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2171743";"";"None";"422.28";"0";"2.51";"3";"CNc1nc(Nc2ccc(C(=O)N3CCOCC3)cc2OC)ncc1Br";"IC50";"'='";"13.0";"nM";"7.89";"";"";"UO_0000065";"18.67";"0.41";"5.38";"8.90";"0";"CHEMBL2188381";"Inhibition of autophosphorylation of LRRK2 in human HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2176933";"1";"Scientific Literature";"J Med Chem";"2012";"CHEMBL3307715";"";"";""
"CHEMBL2170016";"";"None";"377.83";"0";"2.40";"4, HG-10-102-01";"CNc1nc(Nc2ccc(C(=O)N3CCOCC3)cc2OC)ncc1Cl";"IC50";"'='";"3.2";"nM";"8.49";"";"";"UO_0000065";"22.48";"0.45";"6.09";"9.59";"0";"CHEMBL2173829";"Inhibition of LRRK2 G2019S mutant expressed in HEK293 cells using nictide as substrate and [gamma32P]ATP after 15 mins by Cerenkov counting method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169803";"1";"Scientific Literature";"ACS Med Chem Lett";"2012";"CHEMBL3307715";"";"";""
"CHEMBL2348946";"";"None";"379.39";"0";"4.42";"11";"FC(F)(F)c1cccc(Sc2ccc3nnc(-c4nccs4)n3n2)c1";"IC50";"'='";"25.0";"nM";"7.60";"";"";"UO_0000065";"20.04";"0.42";"3.18";"13.58";"0";"CHEMBL2351468";"Inhibition of LRRK2 G2019S mutant (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2349091";"";"None";"388.37";"0";"3.98";"54";"[O-][S+](c1cccc(C(F)(F)F)c1)c1ccc2nnc(-c3ccccc3)n2n1";"IC50";"'='";"2580.0";"nM";"5.59";"";"";"UO_0000065";"14.39";"0.28";"1.61";"8.45";"0";"CHEMBL2351467";"Inhibition of wild type LRRK2 (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL3915904";"";"None";"325.32";"0";"3.34";"BDBM185483";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCC(F)(F)C4)c23)c1";"IC50";"'='";"74.0";"nM";"7.13";"";"334456";"UO_0000065";"21.92";"0.41";"3.79";"10.39";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3951102";"";"None";"315.76";"0";"2.51";"BDBM185496";"Clc1cncc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"28.0";"nM";"7.55";"";"334470";"UO_0000065";"23.92";"0.47";"5.04";"11.28";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3931788";"";"None";"410.41";"0";"3.04";"BDBM185503";"COc1ccc(F)cc1-c1c[nH]c2ncnc(N3CCOC(c4noc(C)n4)C3)c12";"IC50";"'='";"44.0";"nM";"7.36";"";"334477";"UO_0000065";"17.92";"0.33";"4.32";"7.20";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL2348974";"";"None";"334.43";"0";"2.90";"41";"CCC(Sc1ccc2nnc(-c3cccs3)n2n1)C(=O)OC";"IC50";"'='";"167.0";"nM";"6.78";"";"";"UO_0000065";"20.27";"0.42";"3.88";"9.77";"0";"CHEMBL2351468";"Inhibition of LRRK2 G2019S mutant (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348968";"";"None";"313.37";"0";"2.19";"34";"c1cnc(Sc2ccc3nnc(-c4cncs4)n3n2)nc1";"IC50";"'='";"101.0";"nM";"7.00";"";"";"UO_0000065";"22.32";"0.45";"4.81";"8.56";"0";"CHEMBL2351468";"Inhibition of LRRK2 G2019S mutant (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL3904113";"";"None";"332.41";"0";"3.74";"BDBM185411";"C[C@H]1CCCN(c2ncnc3[nH]cc(-c4cnc5cc[nH]c5c4)c23)C1";"IC50";"'='";"53.0";"nM";"7.28";"";"334375";"UO_0000065";"21.89";"0.40";"3.54";"9.90";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL2333122";"";"None";"398.49";"0";"2.88";"35";"CNC(=O)c1nnc2cc(-c3ccc(S(C)(=O)=O)cc3)ccc2c1NC(C)C";"IC50";"'='";"418.0";"nM";"6.38";"";"";"UO_0000065";"16.01";"0.31";"3.50";"6.31";"0";"CHEMBL2345527";"Inhibition of GST-tagged LRRK2 G2019S mutant (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2333116";"";"None";"296.33";"0";"1.94";"29";"CC(C)Nc1c(C(N)=O)nnc2cc(-c3cn[nH]c3)ccc12";"IC50";"'='";"18.0";"nM";"7.75";"";"";"UO_0000065";"26.14";"0.48";"5.80";"7.07";"0";"CHEMBL2345527";"Inhibition of GST-tagged LRRK2 G2019S mutant (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2333129";"";"None";"396.47";"0";"2.76";"14";"CS(=O)(=O)c1ccc(-c2ccc3c(NC4CCC4)c(C(N)=O)nnc3c2)cc1";"IC50";"'='";"10.0";"nM";"8.00";"";"";"UO_0000065";"20.18";"0.39";"5.24";"6.95";"0";"CHEMBL2345528";"Inhibition of wild type GST-tagged LRRK2 (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2333127";"";"None";"398.49";"0";"3.01";"12";"CC[C@@H](C)Nc1c(C(N)=O)nnc2cc(-c3ccc(S(C)(=O)=O)cc3)ccc12";"IC50";"'='";"1.0";"nM";"9.00";"";"";"UO_0000065";"22.59";"0.44";"5.99";"7.82";"0";"CHEMBL2345528";"Inhibition of wild type GST-tagged LRRK2 (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL250364";"";"None";"417.49";"0";"4.15";"1";"CS(=O)(=O)c1ccc(-c2ccc3c(Nc4ccccc4)c(C(N)=O)cnc3c2)cc1";"IC50";"'='";"781.0";"nM";"6.11";"";"";"UO_0000065";"14.63";"0.28";"1.96";"5.98";"0";"CHEMBL2345528";"Inhibition of wild type GST-tagged LRRK2 (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL3906216";"";"None";"381.39";"0";"4.52";"BDBM239517";"FC1(F)CCN(c2cc(-c3n[nH]c4ccc(-c5ccoc5)cc34)ncn2)CC1";"IC50";"'='";"86.2";"nM";"7.06";"";"417980";"UO_0000065";"18.52";"0.34";"2.54";"9.97";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3946347";"";"None";"389.42";"0";"2.32";"BDBM239478";"COc1cnc(-c2ccc3[nH]nc(-c4cc(N5CCOCC5)ncn4)c3c2)cn1";"IC50";"'='";"271.5";"nM";"6.57";"";"417943";"UO_0000065";"16.86";"0.31";"4.25";"6.44";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3968941";"";"None";"362.44";"0";"2.23";"BDBM239528";"C1=C(c2ccc3[nH]nc(-c4cc(N5CCOCC5)ncn4)c3c2)CCNC1";"IC50";"'='";"71.6";"nM";"7.14";"";"417991";"UO_0000065";"19.71";"0.36";"4.92";"9.05";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3946947";"";"None";"392.85";"0";"3.57";"BDBM239534";"Clc1cc(-c2ccc3[nH]nc(-c4cc(N5CCOCC5)ncn4)c3c2)ccn1";"IC50";"'='";"266.5";"nM";"6.57";"";"417997";"UO_0000065";"16.73";"0.32";"3.00";"8.24";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4114275";"";"None";"337.43";"0";"3.06";"BDBM239546";"CC(C)Cc1ccc2[nH]nc(-c3cc(N4CCOCC4)ncn3)c2c1";"IC50";"'='";"56.0";"nM";"7.25";"";"418009";"UO_0000065";"21.49";"0.40";"4.19";"10.83";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3903923";"";"None";"423.52";"0";"3.58";"BDBM239309";"COC[C@H](C)Oc1ccc2[nH]nc(-c3cc(N4CCC5(CCCO5)CC4)ncn3)c2c1";"IC50";"'='";"2.02";"nM";"8.70";"";"417769";"UO_0000065";"20.53";"0.38";"5.11";"10.18";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3939653";"";"None";"436.52";"0";"2.54";"BDBM239311";"COC[C@H](C)Oc1ccc2[nH]nc(-c3cc(N4CCC5(CCNC5=O)CC4)ncn3)c2c1";"IC50";"'='";"2.83";"nM";"8.55";"";"417771";"UO_0000065";"19.58";"0.36";"6.01";"8.12";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3945269";"";"None";"429.46";"0";"3.21";"BDBM239379";"Cn1cc(-c2cc3c(-c4cc(N5CCC(n6cccn6)C5)ncn4)n[nH]c3cc2F)cn1";"IC50";"'='";"73.5";"nM";"7.13";"";"417846";"UO_0000065";"16.61";"0.30";"3.92";"7.64";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3895725";"";"None";"412.46";"0";"3.28";"BDBM239404";"Cc1nc2c(o1)CCN(c1cc(-c3n[nH]c4ccc(-c5cnn(C)c5)cc34)ncn1)C2";"IC50";"'='";"2.8";"nM";"8.55";"";"417870";"UO_0000065";"20.74";"0.38";"5.27";"8.42";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3923178";"";"None";"307.36";"0";"2.19";"BDBM254923";"N#Cc1c[nH]c2nccc(-c3ccn(CN4CCOCC4)c3)c12";"IC50";"'='";"650.0";"nM";"6.19";"";"443706";"UO_0000065";"20.13";"0.37";"4.00";"8.86";"0";"CHEMBL3889252";"Homogeneous Time Resolved-fluorescence Resonance Energy Transfer (TR-FRET) Assay: LRRK2 kinase activity is measured using a LanthaScreen kinase activity assay available from Invitrogen (Life Technologies Corporation). The assay is a homogeneous time resolved-fluorescence resonance energy transfer (TR-FRET) assay that measures phosphorylation of a fluorescein-labelled peptide substrate (fluorescein-LRRKtide, fluorescein-GAGRLGRDKYKTLRQIRQ) (SEQ ID NO 1) as a result of LRRK2 kinase activity. The phosphorylated peptide is recognized by a terbium-labelled phospho-specific anti-LRRKtide antibody and, subsequently, the phosphorylated LRRKtide can be quantified by the extent of TR-FRET between the terbium donor and fluorescein acceptor.The LRRK2 kinase is obtained from Invitrogen (Life Technologies Corporation) and comprises residues 970 to 2527 of the full length human wild-type LRRK2 kinase or a similar sequence with the G2019S mutation. As discussed above, this mutation increases the kinase activity relative to the wild-type. The kinase reactions are performed in a 20 uL volume in 384-well plates. The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT.Â  In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 uM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 uM fluorescein-LRRKtide. The reaction mixture (20 ul total volume) is incubated for 2 hours at 30° C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 ul). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 us) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 us. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 us time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3887011";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3961632";"";"None";"248.29";"0";"2.99";"BDBM254929";"Cc1cccc(-c2cc(N)nc3[nH]cc(C#N)c23)c1";"IC50";"'='";"17.0";"nM";"7.77";"";"443712";"UO_0000065";"31.29";"0.56";"4.78";"9.90";"0";"CHEMBL3889252";"Homogeneous Time Resolved-fluorescence Resonance Energy Transfer (TR-FRET) Assay: LRRK2 kinase activity is measured using a LanthaScreen kinase activity assay available from Invitrogen (Life Technologies Corporation). The assay is a homogeneous time resolved-fluorescence resonance energy transfer (TR-FRET) assay that measures phosphorylation of a fluorescein-labelled peptide substrate (fluorescein-LRRKtide, fluorescein-GAGRLGRDKYKTLRQIRQ) (SEQ ID NO 1) as a result of LRRK2 kinase activity. The phosphorylated peptide is recognized by a terbium-labelled phospho-specific anti-LRRKtide antibody and, subsequently, the phosphorylated LRRKtide can be quantified by the extent of TR-FRET between the terbium donor and fluorescein acceptor.The LRRK2 kinase is obtained from Invitrogen (Life Technologies Corporation) and comprises residues 970 to 2527 of the full length human wild-type LRRK2 kinase or a similar sequence with the G2019S mutation. As discussed above, this mutation increases the kinase activity relative to the wild-type. The kinase reactions are performed in a 20 uL volume in 384-well plates. The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT.Â  In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 uM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 uM fluorescein-LRRKtide. The reaction mixture (20 ul total volume) is incubated for 2 hours at 30° C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 ul). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 us) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 us. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 us time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3887011";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4090116";"";"None";"384.23";"0";"4.07";"7c";"O=C(Nc1cnccn1)c1cc(Br)ccc1OCc1ccccc1";"IC50";"'='";"1995.26";"nM";"5.70";"";"";"UO_0000065";"14.83";"0.32";"1.63";"8.89";"0";"CHEMBL4058537";"Inhibition of LRRK2 (unknown origin) by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4052807";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL4059881";"";"None";"396.28";"1";"5.59";"7f";"Cc1cccc(NC(=O)c2cc(Br)ccc2OCc2ccccc2)c1";"IC50";"'='";"63.1";"nM";"7.20";"";"";"UO_0000065";"18.17";"0.39";"1.61";"18.78";"0";"CHEMBL4058537";"Inhibition of LRRK2 (unknown origin) by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4052807";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL3393348";"";"None";"305.34";"0";"2.33";"BDBM50059277";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"3.0";"nM";"8.52";"";"334323";"UO_0000065";"27.91";"0.51";"6.19";"10.95";"1";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3939031";"";"None";"321.38";"0";"2.33";"BDBM185371";"NC(=O)C1CCCN(c2ncnc3[nH]cc(-c4ccccc4)c23)C1";"IC50";"'='";"41.0";"nM";"7.39";"";"334332";"UO_0000065";"22.99";"0.42";"5.06";"8.40";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3900115";"";"None";"332.41";"0";"3.74";"BDBM185404";"C[C@H]1CCCN(c2ncnc3[nH]cc(-c4cccc5[nH]ncc45)c23)C1";"IC50";"'='";"10.0";"nM";"8.00";"";"334368";"UO_0000065";"24.07";"0.44";"4.26";"10.89";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3393356";"";"None";"323.33";"0";"2.47";"BDBM50059318";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1F";"IC50";"'='";"2.0";"nM";"8.70";"";"334398";"UO_0000065";"26.90";"0.50";"6.23";"11.18";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3985170";"";"None";"316.31";"0";"2.74";"BDBM185437";"Fc1ccc(F)c(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"76.0";"nM";"7.12";"";"334406";"UO_0000065";"22.51";"0.42";"4.38";"13.17";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3895606";"";"None";"316.31";"0";"2.74";"BDBM185443";"Fc1cc(F)cc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"92.0";"nM";"7.04";"";"334412";"UO_0000065";"22.24";"0.42";"4.30";"13.02";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3929926";"";"None";"360.22";"0";"2.62";"BDBM185454";"Brc1cncc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"6.0";"nM";"8.22";"";"334425";"UO_0000065";"22.82";"0.51";"5.60";"12.28";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3907778";"";"None";"319.37";"0";"2.64";"BDBM185458";"Cc1cc(C#N)cc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"14.0";"nM";"7.85";"";"334431";"UO_0000065";"24.59";"0.45";"5.21";"10.09";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3935730";"";"None";"387.40";"0";"2.77";"BDBM185459";"Cc1nc(C2CN(c3ncnc4[nH]cc(-c5cccc(C#N)c5)c34)CCO2)no1";"IC50";"'='";"10.0";"nM";"8.00";"";"334432";"UO_0000065";"20.65";"0.38";"5.23";"6.85";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL4110249";"";"None";"298.35";"0";"1.58";"BDBM185469";"C[C@@H]1CN(c2ncnc3[nH]cc(-c4cnn(C)c4)c23)CCO1";"IC50";"'='";"67.0";"nM";"7.17";"";"334442";"UO_0000065";"24.05";"0.45";"5.59";"9.98";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3942416";"";"None";"314.35";"0";"0.56";"BDBM185471";"Cn1cc(-c2c[nH]c3ncnc(N4CCOC(CO)C4)c23)cn1";"IC50";"'='";"77.0";"nM";"7.11";"";"334444";"UO_0000065";"22.63";"0.42";"6.55";"7.72";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3945834";"";"None";"293.33";"0";"2.57";"BDBM185494";"COc1cc(C#N)cc(-c2c[nH]c3ncnc(N(C)C)c23)c1";"IC50";"'='";"37.0";"nM";"7.43";"";"334467";"UO_0000065";"25.34";"0.46";"4.86";"9.55";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3894326";"";"None";"367.38";"0";"2.49";"BDBM185513";"COCC1CN(c2ncnc3[nH]cc(-c4cccc(C#N)c4F)c23)CCO1";"IC50";"'='";"61.0";"nM";"7.21";"";"334486";"UO_0000065";"19.64";"0.36";"4.72";"8.29";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3957011";"";"None";"344.37";"0";"3.71";"BDBM185527";"COc1ccc(F)cc1-c1c[nH]c2ncnc(N3CCCC(F)C3)c12";"IC50";"'='";"22.0";"nM";"7.66";"";"334496";"UO_0000065";"22.24";"0.42";"3.95";"14.17";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3927167";"";"None";"312.35";"0";"2.99";"BDBM185528";"C[C@H]1CN(c2ncnc3[nH]cc(-c4cccc(F)c4)c23)CCO1";"IC50";"'='";"38.0";"nM";"7.42";"";"334497";"UO_0000065";"23.76";"0.44";"4.43";"13.73";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3943687";"";"None";"286.34";"0";"1.95";"BDBM185577";"C1=C(c2c[nH]c3ncnc(N4CCOCC4)c23)CCCO1";"IC50";"'='";"76.7";"nM";"7.12";"";"334511";"UO_0000065";"24.85";"0.46";"5.17";"11.25";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3898442";"";"None";"330.35";"0";"2.58";"BDBM185550";"[C-]#[N+]C1CN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)CCO1";"IC50";"'='";"42.2";"nM";"7.38";"";"334520";"UO_0000065";"22.32";"0.40";"4.79";"8.97";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3976897";"";"None";"340.41";"0";"2.48";"BDBM185559";"Cc1nc2sccn2c1-c1c[nH]c2ncnc(N3CCOCC3)c12";"IC50";"'='";"37.4";"nM";"7.43";"";"334528";"UO_0000065";"21.82";"0.42";"4.95";"10.41";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3924603";"";"None";"264.33";"0";"3.23";"BDBM185375";"c1ccc(-c2c[nH]c3ncnc(N4CCCC4)c23)cc1";"IC50";"'='";"47.0";"nM";"7.33";"";"334548";"UO_0000065";"27.72";"0.50";"4.10";"16.35";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3960985";"";"None";"308.39";"0";"2.83";"BDBM185376";"OCC1CCN(c2ncnc3[nH]cc(-c4ccccc4)c23)CC1";"IC50";"'='";"29.0";"nM";"7.54";"";"334549";"UO_0000065";"24.44";"0.45";"4.71";"11.59";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3918244";"";"None";"321.36";"0";"3.43";"BDBM185388";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCC(F)CC4)c23)c1";"IC50";"'='";"96.0";"nM";"7.02";"";"334563";"UO_0000065";"21.84";"0.40";"3.59";"10.23";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3890066";"";"None";"332.41";"0";"3.74";"BDBM185409";"C[C@H]1CCCN(c2ncnc3[nH]cc(-c4cnc5[nH]ccc5c4)c23)C1";"IC50";"'='";"69.0";"nM";"7.16";"";"334584";"UO_0000065";"21.54";"0.39";"3.42";"9.74";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3393354";"";"None";"310.36";"0";"2.47";"BDBM50059346";"COc1cccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"46.0";"nM";"7.34";"";"334628";"UO_0000065";"23.64";"0.44";"4.87";"11.60";"1";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3393448";"";"None";"387.40";"0";"2.77";"BDBM50059290";"Cc1noc(C2CN(c3ncnc4[nH]cc(-c5cccc(C#N)c5)c34)CCO2)n1";"IC50";"'='";"176.0";"nM";"6.75";"";"334641";"UO_0000065";"17.44";"0.32";"3.98";"5.79";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3981479";"";"None";"351.39";"0";"2.80";"BDBM185480";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCC(F)(CO)CC4)c23)c1";"IC50";"'='";"106.0";"nM";"6.97";"";"334664";"UO_0000065";"19.85";"0.37";"4.17";"7.85";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3967289";"";"None";"346.43";"0";"3.50";"BDBM254926";"CCc1cc(-c2ccnc3[nH]cc(C#N)c23)ccc1CN1CCOCC1";"IC50";"'='";"26.0";"nM";"7.58";"";"443709";"UO_0000065";"21.89";"0.40";"4.09";"11.68";"0";"CHEMBL3889252";"Homogeneous Time Resolved-fluorescence Resonance Energy Transfer (TR-FRET) Assay: LRRK2 kinase activity is measured using a LanthaScreen kinase activity assay available from Invitrogen (Life Technologies Corporation). The assay is a homogeneous time resolved-fluorescence resonance energy transfer (TR-FRET) assay that measures phosphorylation of a fluorescein-labelled peptide substrate (fluorescein-LRRKtide, fluorescein-GAGRLGRDKYKTLRQIRQ) (SEQ ID NO 1) as a result of LRRK2 kinase activity. The phosphorylated peptide is recognized by a terbium-labelled phospho-specific anti-LRRKtide antibody and, subsequently, the phosphorylated LRRKtide can be quantified by the extent of TR-FRET between the terbium donor and fluorescein acceptor.The LRRK2 kinase is obtained from Invitrogen (Life Technologies Corporation) and comprises residues 970 to 2527 of the full length human wild-type LRRK2 kinase or a similar sequence with the G2019S mutation. As discussed above, this mutation increases the kinase activity relative to the wild-type. The kinase reactions are performed in a 20 uL volume in 384-well plates. The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT.Â  In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 uM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 uM fluorescein-LRRKtide. The reaction mixture (20 ul total volume) is incubated for 2 hours at 30° C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 ul). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 us) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 us. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 us time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3887011";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3946086";"";"None";"392.51";"0";"3.31";"BDBM223561";"Cc1cc(-c2cnc(N)c(-c3cn(C(C)C)nn3)c2)ccc1CN1CCOCC1";"IC50";"'='";"260.0";"nM";"6.58";"";"390846";"UO_0000065";"16.78";"0.31";"3.28";"8.02";"0";"CHEMBL3888346";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4060747";"";"None";"292.34";"0";"3.57";"32";"Cc1ccc(-c2cnc(N)c(-c3nnc(C4CC4)o3)c2)cc1";"IC50";"'='";"2200.0";"nM";"5.66";"";"";"UO_0000065";"19.35";"0.35";"2.09";"7.27";"0";"CHEMBL4045603";"Inhibition of recombinant human LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus preincubated for 30 mins followed by fluorescein-LRRKtide substrate addition after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4043168";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL4066983";"";"None";"351.41";"0";"2.79";"25";"CC1(Oc2ccc3[nH]nc(-c4cc(N5CCOCC5)ncn4)c3c2)CC1";"IC50";"'='";"1.9";"nM";"8.72";"";"";"UO_0000065";"24.82";"0.46";"5.93";"11.45";"0";"CHEMBL4010109";"Inhibition of recombinant human GST-tagged LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus using fluorescein-ERM as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007454";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4098447";"";"None";"360.42";"0";"2.86";"12";"Cn1cc(-c2ccc3[nH]nc(-c4ccnc(N5CCOCC5)c4)c3c2)cn1";"IC50";"'<'";"0.6";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL4010109";"Inhibition of recombinant human GST-tagged LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus using fluorescein-ERM as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007454";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL3972675";"";"None";"403.49";"0";"3.85";"BDBM239355";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCC(n5cccn5)CC4)ncn3)c2c1";"IC50";"'='";"15.3";"nM";"7.82";"";"417823";"UO_0000065";"19.37";"0.36";"3.97";"9.22";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3907548";"";"None";"398.43";"0";"2.03";"BDBM239393";"Cn1cc(-c2ccc3[nH]nc(-c4cc(N5CCn6ncnc6C5)ncn4)c3c2)cn1";"IC50";"'='";"8.5";"nM";"8.07";"";"417859";"UO_0000065";"20.26";"0.37";"6.04";"7.60";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3948540";"";"None";"389.46";"0";"3.04";"BDBM239410";"Cn1cc(-c2ccc3[nH]nc(-c4cc(N5CCOC(C)(C)C5)ncn4)c3c2)cn1";"IC50";"'='";"8.9";"nM";"8.05";"";"417876";"UO_0000065";"20.67";"0.38";"5.01";"9.50";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3986234";"";"None";"402.44";"0";"3.25";"BDBM239417";"Cn1cc(-c2ccc3[nH]nc(-c4cc(N5CCC(F)(C#N)CC5)ncn4)c3c2)cn1";"IC50";"'='";"3.0";"nM";"8.52";"";"417883";"UO_0000065";"21.18";"0.39";"5.27";"8.58";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3919113";"";"None";"474.56";"0";"2.26";"BDBM239423";"CC(C)Oc1cc2c(-c3cc(N4CCN(C5CCS(=O)(=O)C5)CC4)ncn3)n[nH]c2cc1F";"IC50";"'='";"2.5";"nM";"8.60";"";"417889";"UO_0000065";"18.13";"0.36";"6.34";"8.25";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3892022";"";"None";"389.46";"0";"2.51";"BDBM239428";"CC(C)Oc1cc2c(-c3cc(N4CC[S+]([O-])CC4)ncn3)n[nH]c2cc1F";"IC50";"'='";"6.1";"nM";"8.21";"";"417894";"UO_0000065";"21.09";"0.42";"5.70";"9.13";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4093185";"";"None";"351.45";"0";"3.16";"19";"CC(C)Oc1ccc2[nH]nc(-c3ccnc(N4CCN(C)CC4)c3)c2c1";"IC50";"'='";"0.8";"nM";"9.10";"";"";"UO_0000065";"25.88";"0.48";"5.94";"15.88";"0";"CHEMBL4010109";"Inhibition of recombinant human GST-tagged LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus using fluorescein-ERM as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007454";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL3906353";"";"None";"298.32";"0";"2.60";"BDBM185448";"Fc1ccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)cc1";"IC50";"'='";"154.0";"nM";"6.81";"";"334630";"UO_0000065";"22.84";"0.42";"4.21";"12.61";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3973194";"";"None";"286.34";"0";"1.60";"BDBM185576";"C1=C(c2c[nH]c3ncnc(N4CCOCC4)c23)COCC1";"IC50";"'='";"351.0";"nM";"6.46";"";"334721";"UO_0000065";"22.54";"0.42";"4.85";"10.20";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3958543";"";"None";"321.34";"0";"1.50";"BDBM185557";"c1cnc2c(-c3c[nH]c4ncnc(N5CCOCC5)c34)cnn2c1";"IC50";"'='";"119.0";"nM";"6.92";"";"334737";"UO_0000065";"21.55";"0.39";"5.42";"8.22";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL4101218";"";"None";"343.39";"0";"3.59";"29";"Cc1cncc(-c2cc(Nc3nn(C)cc3C)nc3[nH]cc(C#N)c23)c1";"IC50";"'='";"43.0";"nM";"7.37";"";"";"UO_0000065";"21.45";"0.39";"3.78";"7.74";"0";"CHEMBL4031820";"Inhibition of wild type recombinant human GST-tagged LRRK2 (970 to 2527 residues) expressed in baculovirus using fluorescein-LRRKtide as substrate after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4100265";"";"None";"363.81";"0";"3.94";"32";"Cc1cncc(-c2cc(Nc3nn(C)cc3Cl)nc3[nH]cc(C#N)c23)c1";"IC50";"'='";"67.0";"nM";"7.17";"";"";"UO_0000065";"19.72";"0.38";"3.23";"7.53";"0";"CHEMBL4031820";"Inhibition of wild type recombinant human GST-tagged LRRK2 (970 to 2527 residues) expressed in baculovirus using fluorescein-LRRKtide as substrate after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL3924603";"";"None";"264.33";"0";"3.23";"BDBM185375";"c1ccc(-c2c[nH]c3ncnc(N4CCCC4)c23)cc1";"IC50";"'='";"71.0";"nM";"7.15";"";"334337";"UO_0000065";"27.04";"0.49";"3.92";"15.95";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3923525";"";"None";"317.40";"0";"3.73";"BDBM185397";"CC1CCCN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)C1";"IC50";"'='";"70.0";"nM";"7.16";"";"334361";"UO_0000065";"22.54";"0.41";"3.42";"10.43";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3967579";"";"None";"317.40";"0";"3.73";"BDBM185418";"CC1CCN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)CC1";"IC50";"'='";"91.0";"nM";"7.04";"";"334382";"UO_0000065";"22.18";"0.40";"3.31";"10.26";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3931012";"";"None";"298.32";"0";"2.60";"BDBM185435";"Fc1ccccc1-c1c[nH]c2ncnc(N3CCOCC3)c12";"IC50";"'='";"22.0";"nM";"7.66";"";"334404";"UO_0000065";"25.67";"0.48";"5.06";"14.17";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3975196";"";"None";"298.35";"0";"1.68";"BDBM185495";"CCn1cc(-c2c[nH]c3ncnc(N4CCOCC4)c23)cn1";"IC50";"'='";"77.0";"nM";"7.11";"";"334468";"UO_0000065";"23.84";"0.44";"5.43";"9.90";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3932988";"";"None";"344.37";"0";"3.71";"BDBM185509";"COc1ccc(F)cc1-c1c[nH]c2ncnc(N3CCC(F)CC3)c12";"IC50";"'='";"25.0";"nM";"7.60";"";"334482";"UO_0000065";"22.08";"0.42";"3.89";"14.07";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3975129";"";"None";"307.33";"0";"3.24";"BDBM185530";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCCC4)c23)c1F";"IC50";"'='";"15.0";"nM";"7.82";"";"334499";"UO_0000065";"25.46";"0.46";"4.58";"11.41";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3964393";"";"None";"268.32";"0";"2.18";"BDBM185574";"CN(C)c1ncnc2[nH]cc(-c3cccc(CO)c3)c12";"IC50";"'='";"23.0";"nM";"7.64";"";"334540";"UO_0000065";"28.47";"0.52";"5.46";"11.74";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3393343";"";"None";"303.37";"0";"3.49";"BDBM50059353";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCCCC4)c23)c1";"IC50";"'='";"28.0";"nM";"7.55";"";"334542";"UO_0000065";"24.90";"0.45";"4.06";"11.01";"1";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL4073840";"";"None";"419.23";"0";"4.95";"6h";"O=C(Nc1cccnc1)c1cc(Br)ccc1OCc1ccc(F)c(F)c1";"IC50";"'='";"19.95";"nM";"7.70";"";"";"UO_0000065";"18.37";"0.40";"2.75";"15.03";"0";"CHEMBL4058537";"Inhibition of LRRK2 (unknown origin) by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4052807";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL4078829";"";"None";"384.23";"0";"4.07";"7d";"O=C(Nc1cncnc1)c1cc(Br)ccc1OCc1ccccc1";"IC50";"'>'";"25118.86";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL4058537";"Inhibition of LRRK2 (unknown origin) by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4052807";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL2403377";"";"None";"332.36";"0";"2.28";"13";"CC(=O)N1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(C#N)cc43)cc2C1";"IC50";"'='";"7.0";"nM";"8.15";"";"";"UO_0000065";"24.54";"0.45";"5.87";"9.16";"0";"CHEMBL2406186";"Inhibition of human LRRK2 (1885 to 2132) using 5-Fluo-Ahx-RLGRDKYKTLRQIRQGNTK-OH as substrate after 60 mins by fluorescence assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2401634";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2403372";"";"None";"446.43";"0";"3.34";"8";"O=C1Nc2ccc(C(F)(F)F)cc2/C1=C/c1cc2c([nH]1)CCN(C(=O)N1CCOCC1)C2";"IC50";"'<'";"3.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL2406186";"Inhibition of human LRRK2 (1885 to 2132) using 5-Fluo-Ahx-RLGRDKYKTLRQIRQGNTK-OH as substrate after 60 mins by fluorescence assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2401634";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL3393441";"";"None";"295.35";"0";"2.16";"30";"Cc1cncc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"211.0";"nM";"6.68";"";"";"UO_0000065";"22.60";"0.41";"4.52";"9.97";"0";"CHEMBL3395728";"Inhibition of full length LRRK2 (unknown origin) expressed in HEK293 cells assessed as reduction in S935 phosphorylation incubated for 90 mins by ELISA method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL3393450";"";"None";"387.40";"0";"2.77";"39";"Cc1nc([C@H]2CN(c3ncnc4[nH]cc(-c5cccc(C#N)c5)c34)CCO2)no1";"IC50";"'='";"204.0";"nM";"6.69";"";"";"UO_0000065";"17.27";"0.32";"3.92";"5.73";"0";"CHEMBL3395726";"Inhibition of GST-tagged truncated human recombinant LRRK2 using fluorescein-labeled LRRKtide peptide substrate incubated for 2 hrs";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3393442";"";"None";"282.31";"0";"1.25";"31";"c1cnc(-c2c[nH]c3ncnc(N4CCOCC4)c23)cn1";"IC50";"'='";"914.0";"nM";"6.04";"";"";"UO_0000065";"21.39";"0.39";"4.79";"7.57";"0";"CHEMBL3395726";"Inhibition of GST-tagged truncated human recombinant LRRK2 using fluorescein-labeled LRRKtide peptide substrate incubated for 2 hrs";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL2436982";"";"None";"376.42";"0";"3.90";"10";"COc1cc(-c2cnc3[nH]cc(-c4ccc(N)nc4)c3c2)cc(OC)c1OC";"IC50";"'='";"5.0";"nM";"8.30";"";"";"UO_0000065";"22.05";"0.40";"4.40";"8.71";"0";"CHEMBL2439119";"Inhibition of human wild type LRRK2 by qPCR analysis";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2434948";"1";"Scientific Literature";"J Med Chem";"2013";"None";"";"";""
"CHEMBL3122113";"";"None";"339.33";"0";"3.04";"11, GNE-0877";"CNc1nc(Nc2cn(C(C)(C)C#N)nc2C)ncc1C(F)(F)F";"IC50";"'='";"3.0";"nM";"8.52";"";"";"UO_0000065";"25.12";"0.48";"5.48";"9.32";"0";"CHEMBL3124215";"Inhibition of LRRK2 (unknown origin) phosphorylation by cell-based assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3120096";"1";"Scientific Literature";"J Med Chem";"2014";"None";"";"";""
"CHEMBL3122109";"";"None";"371.37";"0";"2.27";"7";"CNC(=O)C(C)(C)n1cc(Nc2ncc(C(F)(F)F)c(NC)n2)c(C)n1";"IC50";"'='";"36.0";"nM";"7.44";"";"";"UO_0000065";"20.04";"0.39";"5.17";"7.69";"0";"CHEMBL3124215";"Inhibition of LRRK2 (unknown origin) phosphorylation by cell-based assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3120096";"1";"Scientific Literature";"J Med Chem";"2014";"None";"";"";""
"CHEMBL3122105";"";"None";"342.32";"0";"2.79";"3";"CNc1nc(Nc2cnn3c2COC(C)(C)C3)ncc1C(F)(F)F";"IC50";"'='";"20.0";"nM";"7.70";"";"";"UO_0000065";"22.49";"0.44";"4.91";"10.01";"0";"CHEMBL3124215";"Inhibition of LRRK2 (unknown origin) phosphorylation by cell-based assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3120096";"1";"Scientific Literature";"J Med Chem";"2014";"None";"";"";""
"CHEMBL4065525";"";"None";"415.52";"0";"2.49";"20";"CC(C)Oc1ccc2[nH]nc(-c3ccnc(N4CCN(S(C)(=O)=O)CC4)c3)c2c1";"IC50";"'='";"2.7";"nM";"8.57";"";"";"UO_0000065";"20.62";"0.40";"6.08";"9.37";"0";"CHEMBL4010109";"Inhibition of recombinant human GST-tagged LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus using fluorescein-ERM as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007454";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4060044";"";"None";"281.32";"0";"1.86";"10";"c1ccc2c(-c3cc(N4CCOCC4)ncn3)[nH]nc2c1";"IC50";"'='";"134.0";"nM";"6.87";"";"";"UO_0000065";"24.43";"0.45";"5.01";"10.27";"1";"CHEMBL4010109";"Inhibition of recombinant human GST-tagged LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus using fluorescein-ERM as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007454";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4081949";"";"None";"280.33";"0";"2.46";"9";"c1ccc2c(-c3cncc(N4CCOCC4)c3)n[nH]c2c1";"IC50";"'='";"256.0";"nM";"6.59";"";"";"UO_0000065";"23.51";"0.43";"4.13";"12.20";"0";"CHEMBL4010109";"Inhibition of recombinant human GST-tagged LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus using fluorescein-ERM as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007454";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL1234032";"";"None";"195.22";"0";"2.62";"4";"c1ccc2c(-c3ccncc3)n[nH]c2c1";"IC50";"'='";"904.0";"nM";"6.04";"";"";"UO_0000065";"30.96";"0.55";"3.42";"14.54";"0";"CHEMBL4010109";"Inhibition of recombinant human GST-tagged LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus using fluorescein-ERM as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007454";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL3957927";"";"None";"375.44";"0";"3.02";"BDBM239544";"C[C@@H]1CN(c2cc(-c3n[nH]c4ccc(-c5ccn[nH]5)cc34)ncn2)C[C@H](C)O1";"IC50";"'='";"1.44";"nM";"8.84";"";"418007";"UO_0000065";"23.55";"0.43";"5.82";"9.25";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3984695";"";"None";"389.46";"0";"2.77";"BDBM239398";"Cn1cc(-c2ccc3[nH]nc(-c4cc(N5CCCC(C)(O)C5)ncn4)c3c2)cn1";"IC50";"'='";"7.9";"nM";"8.10";"";"417864";"UO_0000065";"20.80";"0.38";"5.33";"8.46";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3973863";"";"None";"411.47";"0";"3.07";"BDBM239412";"Cn1cc(-c2ccc3[nH]nc(-c4cc(N5CCC(n6cccn6)C5)ncn4)c3c2)cn1";"IC50";"'='";"3.6";"nM";"8.44";"";"417878";"UO_0000065";"20.52";"0.37";"5.37";"9.05";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3931530";"";"None";"428.47";"0";"2.24";"BDBM239421";"COCC(=O)N1CCN(c2cc(-c3n[nH]c4cc(F)c(OC(C)C)cc34)ncn2)CC1";"IC50";"'='";"5.6";"nM";"8.25";"";"417887";"UO_0000065";"19.26";"0.36";"6.01";"8.55";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3393442";"";"None";"282.31";"0";"1.25";"31";"c1cnc(-c2c[nH]c3ncnc(N4CCOCC4)c23)cn1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL3395728";"Inhibition of full length LRRK2 (unknown origin) expressed in HEK293 cells assessed as reduction in S935 phosphorylation incubated for 90 mins by ELISA method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL3393439";"";"None";"284.32";"0";"1.19";"28";"Cn1cc(-c2c[nH]c3ncnc(N4CCOCC4)c23)cn1";"IC50";"'='";"278.0";"nM";"6.56";"";"";"UO_0000065";"23.06";"0.43";"5.37";"9.12";"0";"CHEMBL3395728";"Inhibition of full length LRRK2 (unknown origin) expressed in HEK293 cells assessed as reduction in S935 phosphorylation incubated for 90 mins by ELISA method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL3393353";"";"None";"280.33";"0";"2.46";"19";"c1ccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)cc1";"IC50";"'='";"198.0";"nM";"6.70";"";"";"UO_0000065";"23.91";"0.44";"4.24";"12.40";"0";"CHEMBL3395728";"Inhibition of full length LRRK2 (unknown origin) expressed in HEK293 cells assessed as reduction in S935 phosphorylation incubated for 90 mins by ELISA method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL3393359";"";"None";"306.33";"0";"1.73";"25";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)n1";"IC50";"'='";"26.0";"nM";"7.58";"";"";"UO_0000065";"24.76";"0.45";"5.86";"8.36";"0";"CHEMBL3395727";"Inhibition of GST-tagged truncated human recombinant LRRK2 G2019S mutant using fluorescein-labeled LRRKtide peptide substrate incubated for 90 mins";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3393356";"";"None";"323.33";"0";"2.47";"22";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1F";"IC50";"'='";"9.0";"nM";"8.05";"";"";"UO_0000065";"24.88";"0.46";"5.58";"10.34";"0";"CHEMBL3395727";"Inhibition of GST-tagged truncated human recombinant LRRK2 G2019S mutant using fluorescein-labeled LRRKtide peptide substrate incubated for 90 mins";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3651732";"";"None";"380.45";"0";"2.45";"5";"c1cc(-c2n[nH]c3ccnc(NC4CCOCC4)c23)cc(N2CCOCC2)n1";"IC50";"'='";"135.0";"nM";"6.87";"";"";"UO_0000065";"18.06";"0.34";"4.42";"7.79";"0";"CHEMBL4331199";"Inhibition of LRRK2 G2019S mutant (unknown origin) by cell based assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330074";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL378695";"";"None";"252.27";"0";"2.77";"2, E:Z Mixture (83:17)";"COc1ccc(/N=C2\C(=O)Nc3ccccc32)cc1";"IC50";"'='";"2170.0";"nM";"5.66";"";"";"UO_0000065";"22.45";"0.41";"2.89";"11.17";"0";"CHEMBL4192178";"Inhibition of recombinant catalytic human GST-tagged LLRK2 (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4190250";"1";"Scientific Literature";"Eur J Med Chem";"2017";"None";"";"";""
"CHEMBL4208935";"";"None";"403.49";"1";"5.78";"23, E:Z Mixture (80:20)";"O=C1C(=NN(c2ccccc2)c2ccccc2)c2ccccc2N1Cc1ccccc1";"IC50";"'='";"6980.0";"nM";"5.16";"";"";"UO_0000065";"12.78";"0.23";"-0.62";"14.36";"0";"CHEMBL4192178";"Inhibition of recombinant catalytic human GST-tagged LLRK2 (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4190250";"1";"Scientific Literature";"Eur J Med Chem";"2017";"None";"";"";""
"CHEMBL227491";"";"None";"222.25";"0";"2.76";"4, E:Z Mixture (83:17)";"O=C1Nc2ccccc2/C1=N/c1ccccc1";"IC50";"'='";"2980.0";"nM";"5.53";"";"";"UO_0000065";"24.86";"0.44";"2.77";"13.33";"0";"CHEMBL4192179";"Inhibition of recombinant catalytic human GST-tagged LLRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4190250";"1";"Scientific Literature";"Eur J Med Chem";"2017";"None";"";"";""
"CHEMBL4207078";"";"None";"310.15";"0";"1.44";"47, E:Z Mixture (17:83)";"O=C1Nc2ccc(Br)cc2C1=NN1CCOCC1";"IC50";"'='";"1020.0";"nM";"5.99";"";"";"UO_0000065";"19.32";"0.45";"4.55";"11.11";"0";"CHEMBL4192179";"Inhibition of recombinant catalytic human GST-tagged LLRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4190250";"1";"Scientific Literature";"Eur J Med Chem";"2017";"None";"";"";""
"CHEMBL4214200";"";"None";"315.25";"0";"1.57";"48, E:Z Mixture (12:88)";"O=C1Nc2ccc(OC(F)(F)F)cc2C1=NN1CCOCC1";"IC50";"'='";"7490.0";"nM";"5.13";"";"";"UO_0000065";"16.26";"0.32";"3.56";"8.12";"0";"CHEMBL4192179";"Inhibition of recombinant catalytic human GST-tagged LLRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4190250";"1";"Scientific Literature";"Eur J Med Chem";"2017";"None";"";"";""
"CHEMBL3892682";"";"None";"328.35";"0";"2.61";"BDBM185536";"COc1cccc(F)c1-c1c[nH]c2ncnc(N3CCOCC3)c12";"IC50";"'='";"34.0";"nM";"7.47";"";"334715";"UO_0000065";"22.75";"0.42";"4.86";"11.80";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL2206014";"";"None";"429.50";"1";"5.06";"15b";"O=C1Nc2ccc(Cl)cc2/C1=C/c1cc(Br)c(O)c(Br)c1";"IC50";"'='";"10.0";"nM";"8.00";"";"";"UO_0000065";"18.63";"0.52";"2.94";"16.22";"0";"CHEMBL3390653";"Inhibition of recombinant LRRK2 G2019S mutant (unknown origin) using gamma-32P-ATP assessed as LRRKtide substrate phosphorylation level by autoradiography";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352815";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL2178123";"";"None";"423.27";"0";"2.47";"4";"COc1cc(C(=O)N2CCOCC2)ccc1Nc1ncc(Br)c(OC)n1";"IC50";"'='";"53.0";"nM";"7.28";"";"";"UO_0000065";"17.19";"0.38";"4.81";"8.48";"0";"CHEMBL2188381";"Inhibition of autophosphorylation of LRRK2 in human HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2176933";"1";"Scientific Literature";"J Med Chem";"2012";"CHEMBL3307715";"";"";""
"CHEMBL3914888";"";"None";"436.49";"0";"4.19";"BDBM234866";"COc1cc2ncnc(Nc3cccc(NS(=O)(=O)c4ccccc4)c3)c2cc1OC";"IC50";"'='";"46.9";"nM";"7.33";"";"409349";"UO_0000065";"16.79";"0.32";"3.14";"7.15";"0";"CHEMBL3888567";"In vitro Kinase Assay: In vitro kinase assays using LRRK WT and LRRK G2019S.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886763";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3972503";"";"None";"319.37";"0";"2.46";"BDBM185485";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCCC(O)C4)c23)c1";"IC50";"'='";"10.0";"nM";"8.00";"";"334458";"UO_0000065";"25.05";"0.46";"5.54";"9.01";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3972882";"";"None";"388.48";"0";"2.80";"BDBM185384";"CN1CCC2(CC1)CN(c1ncnc3[nH]cc(-c4cccc(C#N)c4)c13)CCO2";"IC50";"'='";"201.0";"nM";"6.70";"";"334558";"UO_0000065";"17.24";"0.32";"3.90";"8.26";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3954837";"";"None";"326.38";"0";"3.57";"BDBM185505";"COc1ccccc1-c1c[nH]c2ncnc(N3CCC(F)CC3)c12";"IC50";"'='";"67.0";"nM";"7.17";"";"334479";"UO_0000065";"21.98";"0.41";"3.60";"13.28";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3901817";"";"None";"349.39";"0";"2.35";"BDBM185385";"COCC1CN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)CCO1";"IC50";"'='";"100.0";"nM";"7.00";"";"334605";"UO_0000065";"20.03";"0.37";"4.65";"8.04";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3956506";"";"None";"328.35";"0";"2.61";"BDBM185436";"COc1cc(F)cc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"20.0";"nM";"7.70";"";"334616";"UO_0000065";"23.45";"0.44";"5.09";"12.17";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3973248";"";"None";"332.77";"0";"3.25";"BDBM185439";"Fc1ccc(Cl)cc1-c1c[nH]c2ncnc(N3CCOCC3)c12";"IC50";"'='";"12.0";"nM";"7.92";"";"334619";"UO_0000065";"23.80";"0.47";"4.67";"14.66";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3963370";"";"None";"324.38";"0";"2.59";"BDBM185511";"COc1ccccc1-c1c[nH]c2ncnc(N3CCCC(O)C3)c12";"IC50";"'='";"62.0";"nM";"7.21";"";"334695";"UO_0000065";"22.22";"0.41";"4.62";"9.70";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3926025";"";"None";"337.36";"0";"2.86";"BDBM185526";"C[C@H]1CN(c2ncnc3[nH]cc(-c4cccc(C#N)c4F)c23)CCO1";"IC50";"'='";"62.0";"nM";"7.21";"";"334706";"UO_0000065";"21.36";"0.39";"4.35";"9.26";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3927167";"";"None";"312.35";"0";"2.99";"BDBM185528";"C[C@H]1CN(c2ncnc3[nH]cc(-c4cccc(F)c4)c23)CCO1";"IC50";"'='";"82.0";"nM";"7.09";"";"334708";"UO_0000065";"22.69";"0.42";"4.10";"13.11";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3942307";"";"None";"330.34";"0";"3.32";"BDBM185531";"COc1ccc(F)cc1-c1c[nH]c2ncnc(N3CC[C@H](F)C3)c12";"IC50";"'='";"23.0";"nM";"7.64";"";"334711";"UO_0000065";"23.12";"0.43";"4.32";"14.13";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3965683";"";"None";"286.31";"0";"2.84";"BDBM185535";"COc1cccc(F)c1-c1c[nH]c2ncnc(N(C)C)c12";"IC50";"'='";"27.0";"nM";"7.57";"";"334714";"UO_0000065";"26.44";"0.49";"4.73";"14.01";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3917780";"";"None";"348.37";"0";"2.51";"BDBM185578";"c1cc(-c2ncon2)cc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"475.0";"nM";"6.32";"";"334723";"UO_0000065";"18.15";"0.33";"3.81";"6.80";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3934301";"";"None";"408.44";"0";"3.81";"BDBM239433";"Cc1nc2c(o1)CCN(c1cc(-c3n[nH]c4cc(F)c(OC(C)C)cc34)ncn1)C2";"IC50";"'='";"6.4";"nM";"8.19";"";"417899";"UO_0000065";"20.06";"0.37";"4.38";"8.81";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3958420";"";"None";"403.43";"0";"3.25";"BDBM239439";"CC(C)Oc1cc2c(-c3cc(N4CCC(F)(CO)CC4)ncn3)n[nH]c2cc1F";"IC50";"'='";"2.3";"nM";"8.64";"";"417905";"UO_0000065";"21.41";"0.41";"5.39";"9.91";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3950303";"";"None";"385.44";"0";"3.23";"BDBM239448";"COC[C@H](C)Oc1ccc2[nH]nc(-c3cc(N4CC[C@@H](CF)C4)ncn3)c2c1";"IC50";"'='";"2.7";"nM";"8.57";"";"417913";"UO_0000065";"22.23";"0.42";"5.34";"11.25";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3909835";"";"None";"389.41";"0";"3.28";"BDBM239453";"COC[C@H](C)Oc1ccc2[nH]nc(-c3cc(N4CCC(F)(F)C4)ncn3)c2c1";"IC50";"'='";"12.6";"nM";"7.90";"";"417918";"UO_0000065";"20.29";"0.39";"4.62";"10.37";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3946914";"";"None";"425.39";"0";"3.71";"BDBM239422";"CC(C)Oc1cc2c(-c3cc(N4CCOC(C(F)(F)F)C4)ncn3)n[nH]c2cc1F";"IC50";"'='";"26.6";"nM";"7.58";"";"417888";"UO_0000065";"17.81";"0.34";"3.87";"9.95";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3966843";"";"None";"394.41";"0";"3.50";"BDBM239429";"CC(C)Oc1cc2c(-c3cc(N4CCc5oncc5C4)ncn3)n[nH]c2cc1F";"IC50";"'='";"9.8";"nM";"8.01";"";"417895";"UO_0000065";"20.31";"0.38";"4.51";"8.62";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4082856";"";"None";"365.44";"0";"3.18";"26";"C[C@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)CCO1";"IC50";"'='";"76.0";"nM";"7.12";"";"";"UO_0000065";"19.48";"0.36";"3.94";"9.35";"0";"CHEMBL4010117";"Inhibition of recombinant human GST-tagged LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus using fluorescein-ERM as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr in presence of 5 mM ATP by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007454";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL2326715";"";"None";"306.68";"0";"2.67";"7";"CNc1nc(Nc2cnn(C)c2Cl)ncc1C(F)(F)F";"IC50";"'='";"39.0";"nM";"7.41";"";"";"UO_0000065";"24.16";"0.51";"4.74";"10.95";"0";"CHEMBL2328175";"Inhibition of LRRK2 (unknown origin) autophosphorylation by cell-based assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2321736";"1";"Scientific Literature";"ACS Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2326714";"";"None";"286.26";"0";"2.32";"6";"CNc1nc(Nc2cnn(C)c2C)ncc1C(F)(F)F";"IC50";"'='";"41.0";"nM";"7.39";"";"";"UO_0000065";"25.81";"0.50";"5.07";"10.92";"0";"CHEMBL2328175";"Inhibition of LRRK2 (unknown origin) autophosphorylation by cell-based assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2321736";"1";"Scientific Literature";"ACS Med Chem Lett";"2013";"None";"";"";""
"CHEMBL3409461";"";"None";"260.73";"0";"2.85";"15";"CN1Cc2ccccc2N(C)c2nc(Cl)ncc21";"IC50";"'>'";"1000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL3412556";"Inhibition of LRRK2 G2019S mutant (1326 to 252 aa) (unknown origin) stably expressed in HEK293 cell lysate using [gamma-32P] after 15 mins by Cerenkov counting method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3407393";"1";"Scientific Literature";"Eur J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL2348971";"";"None";"305.39";"0";"1.82";"37";"CC(Sc1ccc2nnc(-c3cccs3)n2n1)C(N)=O";"IC50";"'='";"48.0";"nM";"7.32";"";"";"UO_0000065";"23.97";"0.50";"5.50";"8.49";"0";"CHEMBL2351468";"Inhibition of LRRK2 G2019S mutant (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2333115";"";"None";"296.33";"0";"1.94";"28";"CC(C)Nc1c(C(N)=O)nnc2ccc(-c3cn[nH]c3)cc12";"IC50";"'='";"1.0";"nM";"9.00";"";"";"UO_0000065";"30.37";"0.56";"7.06";"8.21";"0";"CHEMBL2345528";"Inhibition of wild type GST-tagged LRRK2 (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2333114";"";"None";"307.36";"0";"2.61";"27";"CC(C)Nc1c(C(N)=O)nnc2ccc(-c3ccncc3)cc12";"IC50";"'='";"30.0";"nM";"7.52";"";"";"UO_0000065";"24.48";"0.45";"4.91";"8.02";"0";"CHEMBL2345528";"Inhibition of wild type GST-tagged LRRK2 (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2333112";"";"None";"307.36";"0";"2.61";"25";"CC(C)Nc1c(C(N)=O)nnc2cc(-c3ccncc3)ccc12";"IC50";"'='";"15.0";"nM";"7.82";"";"";"UO_0000065";"25.46";"0.46";"5.21";"8.34";"0";"CHEMBL2345528";"Inhibition of wild type GST-tagged LRRK2 (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2333133";"";"None";"382.45";"0";"2.37";"18";"CS(=O)(=O)c1ccc(-c2ccc3c(NC4CC4)c(C(N)=O)nnc3c2)cc1";"IC50";"'='";"49.0";"nM";"7.31";"";"";"UO_0000065";"19.11";"0.37";"4.94";"6.35";"0";"CHEMBL2345528";"Inhibition of wild type GST-tagged LRRK2 (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2333131";"";"None";"370.43";"0";"2.23";"16";"CCNc1c(C(N)=O)nnc2cc(-c3ccc(S(C)(=O)=O)cc3)ccc12";"IC50";"'='";"46.0";"nM";"7.34";"";"";"UO_0000065";"19.81";"0.39";"5.11";"6.38";"0";"CHEMBL2345528";"Inhibition of wild type GST-tagged LRRK2 (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2333125";"";"None";"383.47";"0";"3.22";"2";"CC(C)Nc1c(C(N)=O)cnc2cc(-c3ccc(S(C)(=O)=O)cc3)ccc12";"IC50";"'='";"35.0";"nM";"7.46";"";"";"UO_0000065";"19.44";"0.38";"4.24";"7.30";"0";"CHEMBL2345528";"Inhibition of wild type GST-tagged LRRK2 (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2347814";"";"None";"413.50";"0";"4.94";"28";"CN(c1ccccc1)c1c(C#N)cnc2cc(-c3ccc(S(C)(=O)=O)cc3)ccc12";"IC50";"'='";"278.0";"nM";"6.56";"";"";"UO_0000065";"15.85";"0.30";"1.62";"8.85";"0";"CHEMBL2352557";"Inhibition of GST-tagged LRRK2 G2019S mutant (970-2527 amino acids) (unknown origin) assessed as inhibition of LRRKtide phosphorylation by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346515";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2347826";"";"None";"436.54";"0";"3.61";"16";"CC(C)Nc1c(C#N)cnc2cc(-c3ccc(S(=O)(=O)N4CCOCC4)cc3)ccc12";"IC50";"'='";"10.0";"nM";"8.00";"";"";"UO_0000065";"18.33";"0.35";"4.39";"8.39";"0";"CHEMBL2352557";"Inhibition of GST-tagged LRRK2 G2019S mutant (970-2527 amino acids) (unknown origin) assessed as inhibition of LRRKtide phosphorylation by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346515";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2347823";"";"None";"365.46";"0";"4.00";"6";"CC(C)Nc1c(C#N)cnc2cc(-c3ccc(S(C)(=O)=O)cc3)ccc12";"IC50";"'='";"28.0";"nM";"7.55";"";"";"UO_0000065";"20.67";"0.40";"3.55";"9.12";"0";"CHEMBL2352557";"Inhibition of GST-tagged LRRK2 G2019S mutant (970-2527 amino acids) (unknown origin) assessed as inhibition of LRRKtide phosphorylation by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346515";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2347815";"";"None";"374.43";"0";"3.36";"29";"CS(=O)(=O)c1ccc(-c2ccc3c(-n4ccnc4)c(C#N)cnc3c2)cc1";"IC50";"'='";"682.0";"nM";"6.17";"";"";"UO_0000065";"16.47";"0.31";"2.81";"6.96";"0";"CHEMBL2352558";"Inhibition of wild type GST-tagged LRRK2 (970-2527 amino acids)(unknown origin) assessed as inhibition of LRRKtide phosphorylation by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346515";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2347810";"";"None";"363.44";"0";"3.39";"24";"CS(=O)(=O)c1ccc(-c2ccc3c(N4CCC4)c(C#N)cnc3c2)cc1";"IC50";"'='";"16.0";"nM";"7.80";"";"";"UO_0000065";"21.45";"0.41";"4.41";"10.53";"0";"CHEMBL2352558";"Inhibition of wild type GST-tagged LRRK2 (970-2527 amino acids)(unknown origin) assessed as inhibition of LRRKtide phosphorylation by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346515";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2178130";"";"None";"425.41";"0";"3.07";"14";"CNc1nc(Nc2cc(C)c(C(=O)N3CCOCC3)cc2OC)ncc1C(F)(F)F";"IC50";"'='";"11.0";"nM";"7.96";"";"";"UO_0000065";"18.71";"0.36";"4.89";"8.98";"0";"CHEMBL2188381";"Inhibition of autophosphorylation of LRRK2 in human HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2176933";"1";"Scientific Literature";"J Med Chem";"2012";"CHEMBL3307715";"";"";""
"CHEMBL2171744";"";"None";"361.38";"0";"1.88";"5";"CNc1nc(Nc2ccc(C(=O)N3CCOCC3)cc2OC)ncc1F";"IC50";"'='";"418.0";"nM";"6.38";"";"";"UO_0000065";"17.65";"0.34";"4.50";"7.20";"0";"CHEMBL2188381";"Inhibition of autophosphorylation of LRRK2 in human HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2176933";"1";"Scientific Literature";"J Med Chem";"2012";"CHEMBL3307715";"";"";""
"CHEMBL4072721";"";"None";"332.37";"0";"2.89";"15; Z606357948";"CCn1c(NC(=O)c2ccnc(-n3ccnc3)c2)nc2ccccc21";"IC50";"'='";"343.0";"nM";"6.46";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL4018177";"Inhibition of full length wild-type LRRK2 (unknown origin) using biotinylated ezrin/radaxin/meosin peptide as substrate measured after 1 hr";"A";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4017473";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL4099618";"";"None";"340.39";"0";"2.33";"14";"CCOc1ccc(Nc2nc(N3CCOCC3)c3nc[nH]c3n2)cc1";"IC50";"'='";"351.0";"nM";"6.46";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL4018177";"Inhibition of full length wild-type LRRK2 (unknown origin) using biotinylated ezrin/radaxin/meosin peptide as substrate measured after 1 hr";"A";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4017473";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL2171735";"";"None";"344.42";"0";"4.77";"11";"Cc1ccccc1Nc1nc2ccc(-c3cc(C)c(O)c(C)c3)cn2n1";"IC50";"'='";"10.0";"nM";"8.00";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL4018177";"Inhibition of full length wild-type LRRK2 (unknown origin) using biotinylated ezrin/radaxin/meosin peptide as substrate measured after 1 hr";"A";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4017473";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL3915904";"";"None";"325.32";"0";"3.34";"BDBM185483";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCC(F)(F)C4)c23)c1";"IC50";"'='";"194.0";"nM";"6.71";"";"334667";"UO_0000065";"20.63";"0.38";"3.37";"9.78";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3951102";"";"None";"315.76";"0";"2.51";"BDBM185496";"Clc1cncc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"36.0";"nM";"7.44";"";"334681";"UO_0000065";"23.57";"0.46";"4.93";"11.12";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL2348980";"";"None";"392.43";"1";"5.33";"47";"Cc1cc(Sc2cccc(C(F)(F)F)c2)nn2c(-c3cccs3)nnc12";"IC50";"'>'";"100000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL2351467";"Inhibition of wild type LRRK2 (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2436981";"";"None";"325.38";"0";"4.36";"9";"Nc1ccc(-c2cnc3[nH]cc(-c4ccc5[nH]ccc5c4)c3c2)cn1";"IC50";"'='";"46.0";"nM";"7.34";"";"";"UO_0000065";"22.55";"0.40";"2.98";"8.80";"0";"CHEMBL2439119";"Inhibition of human wild type LRRK2 by qPCR analysis";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2434948";"1";"Scientific Literature";"J Med Chem";"2013";"None";"";"";""
"CHEMBL2333119";"";"None";"328.42";"0";"1.30";"32";"CC(C)Nc1c(C(N)=O)nnc2cc(N3CCN(C)CC3)ccc12";"IC50";"'='";"59.0";"nM";"7.23";"";"";"UO_0000065";"22.01";"0.41";"5.93";"8.27";"0";"CHEMBL2345527";"Inhibition of GST-tagged LRRK2 G2019S mutant (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2333123";"";"None";"424.53";"0";"3.27";"36";"CNC(=O)c1nnc2cc(-c3ccc(S(C)(=O)=O)cc3)ccc2c1N[C@H](C)C1CC1";"IC50";"'='";"168.0";"nM";"6.78";"";"";"UO_0000065";"15.96";"0.31";"3.50";"6.70";"0";"CHEMBL2345528";"Inhibition of wild type GST-tagged LRRK2 (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2333132";"";"None";"426.50";"0";"2.39";"17";"CS(=O)(=O)c1ccc(-c2ccc3c(NC4CCOCC4)c(C(N)=O)nnc3c2)cc1";"IC50";"'='";"23.0";"nM";"7.64";"";"";"UO_0000065";"17.91";"0.35";"5.25";"6.15";"0";"CHEMBL2345528";"Inhibition of wild type GST-tagged LRRK2 (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2333130";"";"None";"396.47";"0";"2.62";"15";"CS(=O)(=O)c1ccc(-c2ccc3c(NCC4CC4)c(C(N)=O)nnc3c2)cc1";"IC50";"'='";"17.0";"nM";"7.77";"";"";"UO_0000065";"19.60";"0.38";"5.15";"6.75";"0";"CHEMBL2345528";"Inhibition of wild type GST-tagged LRRK2 (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2012582";"";"None";"570.70";"1";"3.44";"LRRK2-IN-1";"COc1cc(C(=O)N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2C";"IC50";"'='";"13.0";"nM";"7.89";"";"";"UO_0000065";"13.82";"0.26";"4.45";"8.10";"0";"CHEMBL2015541";"Inhibition of wild-type LRRK2 expressed in HEK293 cells using nictide and [gamma32]ATP as substrate";"B";"BAO_0000219";"cell-based format";"None";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2010643";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2012";"CHEMBL3307715";"";"";""
"CHEMBL509032";"TAE-684";"None";"614.22";"2";"5.02";"TAE684";"COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1";"IC50";"'='";"7.8";"nM";"8.11";"";"";"UO_0000065";"13.20";"0.26";"3.09";"7.88";"0";"CHEMBL2015541";"Inhibition of wild-type LRRK2 expressed in HEK293 cells using nictide and [gamma32]ATP as substrate";"B";"BAO_0000219";"cell-based format";"None";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2010643";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2012";"CHEMBL3307715";"";"";""
"CHEMBL2403376";"";"None";"375.35";"0";"3.43";"12";"CC(=O)N1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(C(F)(F)F)cc43)cc2C1";"IC50";"'='";"31.0";"nM";"7.51";"";"";"UO_0000065";"20.00";"0.38";"4.08";"11.52";"0";"CHEMBL2406186";"Inhibition of human LRRK2 (1885 to 2132) using 5-Fluo-Ahx-RLGRDKYKTLRQIRQGNTK-OH as substrate after 60 mins by fluorescence assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2401634";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL3975433";"";"None";"383.45";"0";"2.66";"BDBM239308";"COC[C@H](C)Oc1ccc2[nH]nc(-c3cc(N4CC[C@H](OC)C4)ncn3)c2c1";"IC50";"'='";"5.27";"nM";"8.28";"";"417768";"UO_0000065";"21.59";"0.40";"5.62";"9.69";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3986028";"";"None";"371.47";"0";"2.38";"BDBM239194";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CC[S+]([O-])CC4)ncn3)c2c1";"IC50";"'='";"21.0";"nM";"7.68";"";"417797";"UO_0000065";"20.67";"0.40";"5.30";"8.53";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3891915";"";"None";"345.35";"0";"3.26";"BDBM239333";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CC(F)(F)C4)ncn3)c2c1";"IC50";"'='";"24.3";"nM";"7.61";"";"417802";"UO_0000065";"22.05";"0.42";"4.35";"11.38";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3986785";"";"None";"384.46";"0";"3.09";"BDBM239441";"CC(C)Oc1cc2c(-c3cc(N4CC[C@H](N(C)C)C4)ncn3)n[nH]c2cc1F";"IC50";"'='";"7.0";"nM";"8.15";"";"417907";"UO_0000065";"21.21";"0.40";"5.06";"11.62";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3984978";"";"None";"437.42";"0";"3.20";"BDBM239450";"COC[C@H](C)Oc1ccc2[nH]nc(-c3cc(N4CCOC(C(F)(F)F)C4)ncn3)c2c1";"IC50";"'='";"8.6";"nM";"8.07";"";"417915";"UO_0000065";"18.44";"0.36";"4.87";"9.45";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3964216";"";"None";"452.52";"0";"1.92";"BDBM239468";"COC[C@H](C)Oc1ccc2[nH]nc(-c3cc(N4CCC5(CC4)CNC(=O)CO5)ncn3)c2c1";"IC50";"'='";"3.5";"nM";"8.46";"";"417933";"UO_0000065";"18.69";"0.35";"6.54";"7.39";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3909057";"";"None";"398.43";"0";"2.57";"BDBM239480";"c1nc(-c2n[nH]c3ccc(-c4ccc5nncn5c4)cc23)cc(N2CCOCC2)n1";"IC50";"'='";"56.1";"nM";"7.25";"";"417945";"UO_0000065";"18.20";"0.33";"4.68";"7.47";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3893499";"";"None";"362.39";"0";"2.82";"BDBM239483";"Cc1nocc1-c1ccc2[nH]nc(-c3cc(N4CCOCC4)ncn3)c2c1";"IC50";"'='";"59.0";"nM";"7.23";"";"417948";"UO_0000065";"19.95";"0.37";"4.41";"7.78";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3903521";"";"None";"444.50";"0";"2.25";"BDBM239486";"O=C(NCCO)c1ccc(-c2ccc3[nH]nc(-c4cc(N5CCOCC5)ncn4)c3c2)cc1";"IC50";"'='";"153.6";"nM";"6.81";"";"417951";"UO_0000065";"15.33";"0.28";"4.56";"5.86";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3928159";"";"None";"426.48";"0";"3.34";"BDBM239502";"C[C@@H]1CN(c2cc(-c3n[nH]c4ccc(-c5ccc6nncn6c5)cc34)ncn2)C[C@H](C)O1";"IC50";"'='";"60.6";"nM";"7.22";"";"417967";"UO_0000065";"16.92";"0.31";"3.88";"7.43";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3980416";"";"None";"363.45";"0";"3.59";"BDBM239525";"c1nc(-c2n[nH]c3ccc(-c4ccsc4)cc23)cc(N2CCOCC2)n1";"IC50";"'='";"36.4";"nM";"7.44";"";"417988";"UO_0000065";"20.47";"0.39";"3.85";"11.11";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3959858";"";"None";"370.39";"0";"1.88";"BDBM239222";"CC(C)Oc1cc2c(-c3cc(N4CCNC(=O)C4)ncn3)n[nH]c2cc1F";"IC50";"'='";"2.89";"nM";"8.54";"";"417683";"UO_0000065";"23.05";"0.43";"6.66";"8.89";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3891431";"";"None";"386.43";"0";"1.84";"BDBM239245";"CC(C)Oc1cc2c(-c3cc(N4C[C@H](O)[C@@H](N)[C@@H]4C)ncn3)n[nH]c2cc1F";"IC50";"'='";"11.7";"nM";"7.93";"";"417706";"UO_0000065";"20.53";"0.39";"6.09";"7.01";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3919816";"";"None";"429.50";"0";"3.58";"BDBM239251";"COCCOC1CCN(c2cc(-c3n[nH]c4cc(F)c(OC(C)C)cc34)ncn2)CC1";"IC50";"'='";"2.1";"nM";"8.68";"";"417712";"UO_0000065";"20.20";"0.38";"5.10";"10.16";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3918740";"";"None";"398.49";"0";"3.48";"BDBM239256";"CC(C)Oc1cc2c(-c3cc(N4C[C@@H](C)N(C)[C@@H](C)C4)ncn3)n[nH]c2cc1F";"IC50";"'='";"1.33";"nM";"8.88";"";"417717";"UO_0000065";"22.27";"0.42";"5.40";"12.65";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL2436979";"";"None";"417.43";"0";"3.28";"7";"COc1cc(-c2cnc3[nH]c(=O)n(-c4ccc5[nH]ccc5c4)c3n2)cc(OC)c1OC";"IC50";"'='";"2970.0";"nM";"5.53";"";"";"UO_0000065";"13.24";"0.24";"2.25";"5.16";"0";"CHEMBL2439119";"Inhibition of human wild type LRRK2 by qPCR analysis";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2434948";"1";"Scientific Literature";"J Med Chem";"2013";"None";"";"";""
"CHEMBL2403378";"";"None";"352.35";"0";"2.32";"14";"CC(=O)N1CCc2[nH]c(/C=C3\C(=O)Nc4ccc([N+](=O)[O-])cc43)cc2C1";"IC50";"'<'";"3.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL2406186";"Inhibition of human LRRK2 (1885 to 2132) using 5-Fluo-Ahx-RLGRDKYKTLRQIRQGNTK-OH as substrate after 60 mins by fluorescence assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2401634";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL4092594";"";"None";"278.36";"0";"3.52";"30";"CCn1cc(-c2cc(-c3ccc(C)cc3)cnc2N)cn1";"IC50";"'='";"12000.0";"nM";"4.92";"";"";"UO_0000065";"17.68";"0.32";"1.40";"8.67";"0";"CHEMBL4045603";"Inhibition of recombinant human LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus preincubated for 30 mins followed by fluorescein-LRRKtide substrate addition after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4043168";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL4079468";"";"None";"291.31";"0";"3.17";"24";"Cc1noc(-c2cc(-c3ccc4[nH]ccc4c3)cnc2N)n1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL4045603";"Inhibition of recombinant human LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus preincubated for 30 mins followed by fluorescein-LRRKtide substrate addition after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4043168";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL3942400";"";"None";"319.37";"0";"3.99";"39";"CC(C)c1nnc(-c2cc(-c3ccc4[nH]ccc4c3)cnc2N)o1";"IC50";"'='";"910.0";"nM";"6.04";"";"";"UO_0000065";"18.92";"0.34";"2.05";"6.45";"1";"CHEMBL4045603";"Inhibition of recombinant human LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus preincubated for 30 mins followed by fluorescein-LRRKtide substrate addition after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4043168";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL2333138";"";"None";"323.36";"0";"1.58";"23";"NC(=O)c1nnc2cc(-c3ccncc3)ccc2c1NCCCO";"IC50";"'='";"162.0";"nM";"6.79";"";"";"UO_0000065";"21.00";"0.39";"5.21";"5.96";"0";"CHEMBL2345527";"Inhibition of GST-tagged LRRK2 G2019S mutant (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2333121";"";"None";"313.39";"0";"2.67";"34";"CC(C)Nc1c(C(N)=O)nnc2cc(-c3cnsc3)ccc12";"IC50";"'='";"14.0";"nM";"7.85";"";"";"UO_0000065";"25.06";"0.49";"5.18";"8.37";"0";"CHEMBL2345528";"Inhibition of wild type GST-tagged LRRK2 (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2333113";"";"None";"333.40";"0";"3.00";"26";"C[C@@H](Nc1c(C(N)=O)nnc2cc(-c3ccncc3)ccc12)C1CC1";"IC50";"'='";"2.0";"nM";"8.70";"";"";"UO_0000065";"26.09";"0.48";"5.70";"9.27";"0";"CHEMBL2345528";"Inhibition of wild type GST-tagged LRRK2 (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2012582";"";"None";"570.70";"1";"3.44";"SID121284524";"COc1cc(C(=O)N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2C";"IC50";"'='";"13.0";"nM";"7.89";"";"";"UO_0000065";"13.82";"0.26";"4.45";"8.10";"1";"CHEMBL2398945";"Inhibition of wild type GST-tagged LRRK2 ((1326 to 2517 amino acids) (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2396520";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2347812";"";"None";"391.50";"0";"4.17";"26";"CS(=O)(=O)c1ccc(-c2ccc3c(N4CCCCC4)c(C#N)cnc3c2)cc1";"IC50";"'='";"59.0";"nM";"7.23";"";"";"UO_0000065";"18.47";"0.35";"3.06";"9.76";"0";"CHEMBL2352557";"Inhibition of GST-tagged LRRK2 G2019S mutant (970-2527 amino acids) (unknown origin) assessed as inhibition of LRRKtide phosphorylation by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346515";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348971";"";"None";"305.39";"0";"1.82";"37";"CC(Sc1ccc2nnc(-c3cccs3)n2n1)C(N)=O";"IC50";"'='";"3032.0";"nM";"5.52";"";"";"UO_0000065";"18.07";"0.38";"3.70";"6.40";"0";"CHEMBL2351460";"Inhibition of LRRK2 G2019S mutant (unknown origin) transfected in HEK293 cells assessed decrease in S935 autophosphorylation";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"CHEMBL3307715";"";"";""
"CHEMBL2178134";"";"None";"443.40";"0";"3.29";"18, GNE-7915";"CCNc1nc(Nc2cc(F)c(C(=O)N3CCOCC3)cc2OC)ncc1C(F)(F)F";"IC50";"'='";"9.0";"nM";"8.05";"";"";"UO_0000065";"18.15";"0.35";"4.76";"9.08";"0";"CHEMBL2188381";"Inhibition of autophosphorylation of LRRK2 in human HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2176933";"1";"Scientific Literature";"J Med Chem";"2012";"CHEMBL3307715";"";"";""
"CHEMBL2178125";"";"None";"441.41";"0";"2.77";"9";"CNc1nc(Nc2cc(OC)c(C(=O)N3CCOCC3)cc2OC)ncc1C(F)(F)F";"IC50";"'='";"21.0";"nM";"7.68";"";"";"UO_0000065";"17.39";"0.34";"4.91";"7.85";"0";"CHEMBL2188381";"Inhibition of autophosphorylation of LRRK2 in human HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2176933";"1";"Scientific Literature";"J Med Chem";"2012";"CHEMBL3307715";"";"";""
"CHEMBL1673039";"";"None";"459.55";"0";"3.34";"XMD8-85";"COc1cc(N2CCN(C)CC2)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2C";"IC50";"'='";"29.0";"nM";"7.54";"";"";"UO_0000065";"16.40";"0.30";"4.20";"9.78";"0";"CHEMBL4612965";"Inhibition of recombinant human GST-tagged LRRK2 catalytic domain (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate measured after 1 hr by Alexa fluor-647 ADP tracer-based ADAPTA assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4610122";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL1933288";"";"None";"458.57";"0";"3.89";"24, BIX 02565, eutamer";"C[C@@H]1CCNC(=O)c2cc3ccc(C(=O)Nc4nc5ccccc5n4CCCN(C)C)cc3n21";"IC50";"'='";"16.0";"nM";"7.80";"";"";"UO_0000065";"17.00";"0.31";"3.91";"9.26";"0";"CHEMBL1937075";"Inhibition of human LRRK2";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1933005";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2012";"None";"";"";""
"CHEMBL4590484";"";"None";"202.26";"0";"2.23";"12";"Cc1n[nH]c2ccnc(NC3CCC3)c12";"IC50";"'='";"530.0";"nM";"6.28";"";"";"UO_0000065";"31.03";"0.57";"4.05";"11.71";"0";"CHEMBL4331900";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant catalytic domain (970 to 2527 residues) expressed in baculovirus expression system by radiometric assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330096";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4585168";"";"None";"246.31";"0";"1.74";"20";"Cc1n[nH]c2ccnc(OC3CCN(C)CC3)c12";"IC50";"'='";"1900.0";"nM";"5.72";"";"";"UO_0000065";"23.23";"0.43";"3.98";"10.59";"0";"CHEMBL4331900";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant catalytic domain (970 to 2527 residues) expressed in baculovirus expression system by radiometric assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330096";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL3942469";"";"None";"322.41";"0";"3.35";"BDBM185571";"C[C@H]1CCCN(c2ncnc3[nH]cc(-c4cccc(CO)c4)c23)C1";"IC50";"'='";"18.0";"nM";"7.75";"";"334326";"UO_0000065";"24.02";"0.44";"4.39";"11.91";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3910647";"";"None";"371.47";"0";"2.51";"BDBM185402";"C[C@H]1CCCN(c2ncnc3[nH]cc(-c4cccc(S(N)(=O)=O)c4)c23)C1";"IC50";"'='";"24.0";"nM";"7.62";"";"334366";"UO_0000065";"20.51";"0.40";"5.11";"7.26";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3928018";"";"None";"303.37";"0";"3.34";"BDBM185426";"CC1CCN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)C1";"IC50";"'='";"39.0";"nM";"7.41";"";"334397";"UO_0000065";"24.42";"0.44";"4.07";"10.80";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3956506";"";"None";"328.35";"0";"2.61";"BDBM185436";"COc1cc(F)cc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"9.0";"nM";"8.05";"";"334405";"UO_0000065";"24.50";"0.46";"5.44";"12.72";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3393440";"";"None";"284.32";"0";"1.19";"BDBM50059313";"Cn1ccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)n1";"IC50";"'='";"53.0";"nM";"7.28";"";"334428";"UO_0000065";"25.59";"0.47";"6.09";"10.12";"1";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3896507";"";"None";"268.32";"0";"1.96";"BDBM185474";"CN(c1ncnc2[nH]cc(-c3cnn(C)c3)c12)C1CC1";"IC50";"'='";"37.0";"nM";"7.43";"";"334447";"UO_0000065";"27.70";"0.51";"5.47";"11.87";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3800128";"";"None";"374.42";"0";"2.76";"BDBM234863";"COc1cc2ncnc(Nc3cccc(NS(C)(=O)=O)c3)c2cc1OC";"IC50";"'='";"353.0";"nM";"6.45";"";"409338";"UO_0000065";"17.23";"0.34";"3.69";"6.30";"0";"CHEMBL3888566";"In vitro Kinase Assay: In vitro kinase assays using LRRK WT and LRRK G2019S.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886763";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3800128";"";"None";"374.42";"0";"2.76";"BDBM234863";"COc1cc2ncnc(Nc3cccc(NS(C)(=O)=O)c3)c2cc1OC";"IC50";"'='";"100.0";"nM";"7.00";"";"409346";"UO_0000065";"18.70";"0.37";"4.24";"6.83";"0";"CHEMBL3888567";"In vitro Kinase Assay: In vitro kinase assays using LRRK WT and LRRK G2019S.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886763";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3921329";"";"None";"416.49";"0";"3.70";"BDBM239542";"COc1ccncc1-c1ccc2[nH]nc(-c3cc(N4C[C@@H](C)O[C@@H](C)C4)ncn3)c2c1";"IC50";"'='";"0.75";"nM";"9.12";"";"418005";"UO_0000065";"21.91";"0.40";"5.42";"10.25";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4111923";"";"None";"353.43";"0";"3.03";"BDBM239083";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCO[C@H](C)C4)ncn3)c2c1";"IC50";"'='";"67.0";"nM";"7.17";"";"417369";"UO_0000065";"20.30";"0.38";"4.14";"9.42";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3917266";"";"None";"369.43";"0";"2.27";"BDBM239089";"COC[C@H](C)Oc1ccc2[nH]nc(-c3cc(N4CCOCC4)ncn3)c2c1";"IC50";"'='";"33.0";"nM";"7.48";"";"417371";"UO_0000065";"20.25";"0.38";"5.21";"8.76";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3945097";"";"None";"388.44";"0";"1.70";"BDBM239181";"CN1CCN(c2cc(-c3n[nH]c4ccc(-c5cnn(C)c5)cc34)ncn2)CC1=O";"IC50";"'='";"4.91";"nM";"8.31";"";"417640";"UO_0000065";"21.39";"0.39";"6.61";"8.67";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3969038";"";"None";"380.50";"0";"3.34";"BDBM239202";"CCCN1CCN(c2cc(-c3n[nH]c4ccc(OC(C)C)cc34)ncn2)CC1";"IC50";"'='";"8.14";"nM";"8.09";"";"417663";"UO_0000065";"21.26";"0.39";"4.75";"11.53";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3896900";"";"None";"338.42";"0";"2.22";"BDBM239205";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCNCC4)ncn3)c2c1";"IC50";"'='";"12.38";"nM";"7.91";"";"417666";"UO_0000065";"23.37";"0.43";"5.69";"10.01";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3946512";"";"None";"380.45";"0";"2.48";"BDBM239214";"CCN1CCN(c2cc(-c3n[nH]c4ccc(OC(C)C)cc34)ncn2)CC1=O";"IC50";"'='";"5.6";"nM";"8.25";"";"417675";"UO_0000065";"21.69";"0.40";"5.77";"9.46";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL2397013";"";"None";"383.43";"0";"3.57";"JAK3 inhibitor VI";"CS(=O)(=O)O.O=C1Nc2ccc(-c3cccnc3)cc2/C1=C/c1ccc[nH]1";"IC50";"'='";"22.0";"nM";"7.66";"";"";"UO_0000065";"26.65";"0.48";"4.09";"13.25";"0";"CHEMBL2398947";"Inhibition of human N-terminal GST-tagged LRRK2 after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2396520";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL406821";"";"None";"319.43";"0";"1.92";"H-1152";"Cc1cncc2cccc(S(=O)(=O)N3CCCNC[C@@H]3C)c12";"IC50";"'='";"244.0";"nM";"6.61";"";"";"UO_0000065";"20.70";"0.41";"4.69";"10.61";"0";"CHEMBL2398947";"Inhibition of human N-terminal GST-tagged LRRK2 after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2396520";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL4568087";"";"None";"421.53";"0";"2.86";"19";"Cn1cc(-c2cnc3c(-c4csc(C(=O)N[C@@H]5CCCC[C@@H]5N)c4)cnn3c2)cn1";"IC50";"'='";"3.1";"nM";"8.51";"";"";"UO_0000065";"20.19";"0.39";"5.65";"8.25";"0";"CHEMBL4479740";"Inhibition of recombinant human GST-tagged LRRK2 catalytic domain expressed in baculovirus expression system by Adapta assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4477252";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2016";"None";"";"";""
"CHEMBL3964094";"";"None";"412.93";"0";"3.66";"BDBM223563";"CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)c(Cl)c3)cnc2N)nn1";"IC50";"'='";"320.0";"nM";"6.50";"";"390848";"UO_0000065";"15.73";"0.31";"2.83";"7.91";"0";"CHEMBL3888346";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL2397014";"";"None";"488.55";"0";"3.32";"10";"COc1cc(N2CCOCC2)ccc1Nc1ncc(F)c(Nc2ccccc2NS(C)(=O)=O)n1";"IC50";"'='";"1.9";"nM";"8.72";"";"";"UO_0000065";"17.85";"0.35";"5.40";"7.41";"0";"CHEMBL4018178";"Inhibition of LRRK2 G2019S mutant (unknown origin) using biotinylated ezrin/radaxin/meosin peptide as substrate measured after 1 hr";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4017473";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL4068065";"";"None";"401.24";"0";"4.81";"6b";"O=C(Nc1cccnc1)c1cc(Br)ccc1OCc1ccccc1F";"IC50";"'='";"7.943";"nM";"8.10";"";"";"UO_0000065";"20.19";"0.44";"3.29";"15.81";"0";"CHEMBL4058537";"Inhibition of LRRK2 (unknown origin) by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4052807";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL4068792";"";"None";"413.27";"0";"4.68";"6e";"COc1ccc(COc2ccc(Br)cc2C(=O)Nc2cccnc2)cc1";"IC50";"'='";"39.81";"nM";"7.40";"";"";"UO_0000065";"17.91";"0.39";"2.72";"12.24";"0";"CHEMBL4058537";"Inhibition of LRRK2 (unknown origin) by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4052807";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL4075367";"";"None";"417.69";"1";"5.33";"7e";"O=C(Nc1cncc(Cl)c1)c1cc(Br)ccc1OCc1ccccc1";"IC50";"'>'";"25118.86";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL4058537";"Inhibition of LRRK2 (unknown origin) by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4052807";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL4079429";"";"None";"388.31";"1";"5.09";"7l";"O=C(NC1CCCCC1)c1cc(Br)ccc1OCc1ccccc1";"IC50";"'>'";"25118.86";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL4058537";"Inhibition of LRRK2 (unknown origin) by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4052807";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL4211027";"";"None";"343.39";"0";"4.19";"38";"COc1ccc2c(c1)/C(=N\N(c1ccccc1)c1ccccc1)C(=O)N2";"IC50";"'='";"130.0";"nM";"6.89";"";"";"UO_0000065";"20.05";"0.36";"2.70";"12.77";"0";"CHEMBL4192178";"Inhibition of recombinant catalytic human GST-tagged LLRK2 (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4190250";"1";"Scientific Literature";"Eur J Med Chem";"2017";"None";"";"";""
"CHEMBL4203258";"";"None";"308.18";"0";"2.59";"42, E:Z Mixture (21:79)";"O=C1Nc2ccc(Br)cc2C1=NN1CCCCC1";"IC50";"'='";"490.0";"nM";"6.31";"";"";"UO_0000065";"20.47";"0.48";"3.72";"14.12";"0";"CHEMBL4192178";"Inhibition of recombinant catalytic human GST-tagged LLRK2 (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4190250";"1";"Scientific Literature";"Eur J Med Chem";"2017";"None";"";"";""
"CHEMBL2012582";"";"None";"570.70";"1";"3.44";"Lrrk2-in-1";"COc1cc(C(=O)N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2C";"IC50";"'='";"20.0";"nM";"7.70";"";"";"UO_0000065";"13.49";"0.25";"4.26";"7.91";"0";"CHEMBL4192178";"Inhibition of recombinant catalytic human GST-tagged LLRK2 (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4190250";"1";"Scientific Literature";"Eur J Med Chem";"2017";"None";"";"";""
"CHEMBL4204860";"";"None";"331.35";"0";"4.32";"34, E:Z Mixture (96:4)";"O=C1Nc2ccc(F)cc2C1=NN(c1ccccc1)c1ccccc1";"IC50";"'='";"120.0";"nM";"6.92";"";"";"UO_0000065";"20.89";"0.38";"2.60";"15.48";"0";"CHEMBL4192179";"Inhibition of recombinant catalytic human GST-tagged LLRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4190250";"1";"Scientific Literature";"Eur J Med Chem";"2017";"None";"";"";""
"CHEMBL2012582";"";"None";"570.70";"1";"3.44";"Lrrk2-in-1";"COc1cc(C(=O)N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2C";"IC50";"'='";"20.0";"nM";"7.70";"";"";"UO_0000065";"13.49";"0.25";"4.26";"7.91";"0";"CHEMBL4192179";"Inhibition of recombinant catalytic human GST-tagged LLRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4190250";"1";"Scientific Literature";"Eur J Med Chem";"2017";"None";"";"";""
"CHEMBL2348966";"";"None";"367.50";"0";"4.70";"32";"CC(C)(C)c1cccc(Sc2ccc3nnc(-c4cncs4)n3n2)c1";"IC50";"'='";"75.0";"nM";"7.12";"";"";"UO_0000065";"19.39";"0.39";"2.42";"12.73";"0";"CHEMBL2351467";"Inhibition of wild type LRRK2 (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348943";"";"None";"319.41";"0";"3.11";"8";"COC(=O)C(C)Sc1ccc2ncc(-c3cccs3)n2n1";"IC50";"'='";"76.0";"nM";"7.12";"";"";"UO_0000065";"22.29";"0.46";"4.01";"12.60";"0";"CHEMBL2351467";"Inhibition of wild type LRRK2 (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348964";"";"None";"329.38";"0";"3.54";"30";"Fc1cccc(Sc2ccc3nnc(-c4cncs4)n3n2)c1";"IC50";"'='";"77.0";"nM";"7.11";"";"";"UO_0000065";"21.60";"0.44";"3.57";"12.71";"0";"CHEMBL2351468";"Inhibition of LRRK2 G2019S mutant (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL4746726";"";"None";"410.34";"0";"2.85";"55";"O=C(Nc1c[nH]nc1-c1cc2cn[nH]c2cc1OC(F)F)c1cnn2cccnc12";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL4666938";"Inhibition of recombinant human GST-tagged LRRK2 (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate incubated for 60 mins by Adapta assay";"A";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4665643";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"TIME = 1.0 hr";"";""
"CHEMBL4634634";"";"None";"365.44";"0";"1.44";"29";"C[C@@H]1C[C@H]1C(=O)N1CCN(c2cnc(C#N)c(-c3cnn(C)c3)n2)C[C@H]1C";"IC50";"'>'";"100000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL4603517";"Inhibition of recombinant human GST-tagged LRRK2 catalytic domain (970 to 2527 amino acids) expressed in baculovirus expression system using ERM (LRRKtide) peptide as substrate incubated for 60 mins in presence of ATP by Adapta assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4602617";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2020";"None";"";"";""
"CHEMBL3966314";"";"None";"416.50";"0";"3.79";"BDBM234862";"COc1cc2ncnc(Nc3cccc(NS(=O)(=O)CC(C)C)c3)c2cc1OC";"IC50";"'='";"90.1";"nM";"7.04";"";"409348";"UO_0000065";"16.92";"0.33";"3.26";"6.88";"0";"CHEMBL3888567";"In vitro Kinase Assay: In vitro kinase assays using LRRK WT and LRRK G2019S.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886763";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3971067";"";"None";"378.48";"0";"3.00";"BDBM223552";"CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)cc3)cnc2N)nn1";"IC50";"'='";"160.0";"nM";"6.80";"";"390808";"UO_0000065";"17.96";"0.33";"3.80";"8.28";"0";"CHEMBL3888345";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3913713";"";"None";"426.91";"0";"3.30";"BDBM223562";"CC(C)n1cc(-c2cc(-c3ccc(C(=O)N4CCOCC4)c(Cl)c3)cnc2N)nn1";"IC50";"'='";"290.0";"nM";"6.54";"";"390847";"UO_0000065";"15.31";"0.30";"3.24";"6.59";"0";"CHEMBL3888346";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3944061";"";"None";"389.46";"0";"3.03";"BDBM239186";"C[C@@H]1CN(c2cc(-c3n[nH]c4ccc(-c5cnn(C)c5)cc34)ncn2)C[C@H](C)O1";"IC50";"'='";"1.4";"nM";"8.85";"";"417645";"UO_0000065";"22.73";"0.42";"5.82";"10.45";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3977858";"";"None";"416.51";"0";"1.89";"BDBM239196";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCN(S(C)(=O)=O)CC4)ncn3)c2c1";"IC50";"'='";"7.99";"nM";"8.10";"";"417654";"UO_0000065";"19.44";"0.38";"6.21";"7.76";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3910517";"";"None";"366.43";"0";"2.09";"BDBM239198";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCN(C)C(=O)C4)ncn3)c2c1";"IC50";"'='";"11.2";"nM";"7.95";"";"417658";"UO_0000065";"21.70";"0.40";"5.86";"9.11";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3895221";"";"None";"353.43";"0";"3.03";"BDBM239217";"CO[C@H]1CCN(c2cc(-c3n[nH]c4ccc(OC(C)C)cc34)ncn2)C1";"IC50";"'='";"8.79";"nM";"8.06";"";"417678";"UO_0000065";"22.79";"0.42";"5.03";"10.58";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3919519";"";"None";"436.50";"0";"3.01";"BDBM239240";"CC(C)Oc1cc2c(-c3cc(N4CCN(c5cnn(C)c5)CC4)ncn3)n[nH]c2cc1F";"IC50";"'='";"2.19";"nM";"8.66";"";"417701";"UO_0000065";"19.84";"0.37";"5.65";"9.84";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3895039";"";"None";"387.42";"0";"1.88";"BDBM239241";"CC(C)Oc1cc2c(-c3cc(N4C[C@H](O)[C@@H](O)[C@@H]4C)ncn3)n[nH]c2cc1F";"IC50";"'='";"15.5";"nM";"7.81";"";"417702";"UO_0000065";"20.16";"0.38";"5.93";"7.27";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3947673";"";"None";"412.47";"0";"3.00";"BDBM239248";"CCC(=O)N1CCN(c2cc(-c3n[nH]c4cc(F)c(OC(C)C)cc34)ncn2)CC1";"IC50";"'='";"4.32";"nM";"8.37";"";"417709";"UO_0000065";"20.28";"0.38";"5.36";"9.59";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3902480";"";"None";"424.48";"0";"3.00";"BDBM239249";"CC(C)Oc1cc2c(-c3cc(N4CCN(C(=O)C5CC5)CC4)ncn3)n[nH]c2cc1F";"IC50";"'='";"2.98";"nM";"8.53";"";"417710";"UO_0000065";"20.09";"0.38";"5.53";"9.77";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3967017";"";"None";"416.45";"0";"2.06";"BDBM239405";"Cn1cc(-c2ccc3[nH]nc(-c4cc(N5CCN6C(=O)OCC6C5)ncn4)c3c2)cn1";"IC50";"'='";"6.3";"nM";"8.20";"";"417871";"UO_0000065";"19.69";"0.36";"6.14";"7.81";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3958879";"";"None";"400.49";"0";"4.00";"BDBM239490";"Cc1cncc(-c2ccc3[nH]nc(-c4cc(N5C[C@@H](C)O[C@@H](C)C5)ncn4)c3c2)c1";"IC50";"'='";"2.2";"nM";"8.66";"";"417955";"UO_0000065";"21.62";"0.39";"4.66";"10.85";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3960093";"";"None";"417.47";"0";"3.10";"BDBM239496";"COc1cncc(-c2ccc3[nH]nc(-c4cc(N5C[C@@H](C)O[C@@H](C)C5)ncn4)c3c2)n1";"IC50";"'='";"2.4";"nM";"8.62";"";"417961";"UO_0000065";"20.65";"0.38";"5.52";"8.46";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3931039";"";"None";"348.45";"0";"3.19";"BDBM239510";"CC(C)=Cc1ccc2[nH]nc(-c3cc(N4CCN(C)CC4)ncn3)c2c1";"IC50";"'='";"32.9";"nM";"7.48";"";"417974";"UO_0000065";"21.47";"0.39";"4.29";"12.28";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3899511";"";"None";"362.44";"0";"2.72";"BDBM239511";"CC(C)=Cc1ccc2[nH]nc(-c3cc(N4CCN(C)C(=O)C4)ncn3)c2c1";"IC50";"'='";"36.2";"nM";"7.44";"";"417975";"UO_0000065";"20.53";"0.38";"4.72";"9.54";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3913219";"";"None";"333.40";"0";"3.11";"BDBM185487";"CCC1CN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)CCO1";"IC50";"'='";"95.0";"nM";"7.02";"";"334671";"UO_0000065";"21.06";"0.38";"3.91";"9.02";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3901919";"";"None";"401.43";"0";"2.64";"BDBM185492";"Cc1nc(CC2CN(c3ncnc4[nH]cc(-c5cccc(C#N)c5)c34)CCO2)no1";"IC50";"'='";"155.0";"nM";"6.81";"";"334676";"UO_0000065";"16.96";"0.31";"4.17";"5.83";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3122120";"";"None";"328.30";"0";"2.36";"16";"CNc1nc(Nc2cnn(C3COC3)c2C)ncc1C(F)(F)F";"IC50";"'='";"29.0";"nM";"7.54";"";"";"UO_0000065";"22.96";"0.45";"5.18";"9.80";"0";"CHEMBL3124215";"Inhibition of LRRK2 (unknown origin) phosphorylation by cell-based assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3120096";"1";"Scientific Literature";"J Med Chem";"2014";"None";"";"";""
"CHEMBL2397014";"";"None";"488.55";"0";"3.32";"CZC-25146";"COc1cc(N2CCOCC2)ccc1Nc1ncc(F)c(Nc2ccccc2NS(C)(=O)=O)n1";"IC50";"'='";"4.0";"nM";"8.40";"";"";"UO_0000065";"17.19";"0.34";"5.08";"7.13";"0";"CHEMBL2398944";"Inhibition of human recombinant wild type LRRK2 using biotin-LRRKtide as substrate preincubated for 15 mins prior to substrate addition measured after 60 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2396520";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL4076463";"";"None";"400.25";"1";"5.42";"7g";"O=C(Nc1cccc(F)c1)c1cc(Br)ccc1OCc1ccccc1";"IC50";"'='";"251.19";"nM";"6.60";"";"";"UO_0000065";"16.49";"0.36";"1.18";"17.22";"0";"CHEMBL4058537";"Inhibition of LRRK2 (unknown origin) by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4052807";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL4204860";"";"None";"331.35";"0";"4.32";"34, E:Z Mixture (96:4)";"O=C1Nc2ccc(F)cc2C1=NN(c1ccccc1)c1ccccc1";"IC50";"'='";"20.0";"nM";"7.70";"";"";"UO_0000065";"23.24";"0.42";"3.38";"17.22";"0";"CHEMBL4192178";"Inhibition of recombinant catalytic human GST-tagged LLRK2 (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4190250";"1";"Scientific Literature";"Eur J Med Chem";"2017";"None";"";"";""
"CHEMBL4206138";"";"None";"263.73";"0";"2.48";"39, E:Z Mixture (92:8)";"O=C1Nc2ccc(Cl)cc2C1=NN1CCCCC1";"IC50";"'='";"280.0";"nM";"6.55";"";"";"UO_0000065";"24.85";"0.50";"4.07";"14.66";"0";"CHEMBL4192178";"Inhibition of recombinant catalytic human GST-tagged LLRK2 (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4190250";"1";"Scientific Literature";"Eur J Med Chem";"2017";"None";"";"";""
"CHEMBL4217734";"";"None";"229.28";"0";"1.83";"19, E:Z Mixture (46:54)";"O=C1Nc2ccccc2C1=NN1CCCCC1";"IC50";"'='";"2210.0";"nM";"5.66";"";"";"UO_0000065";"24.67";"0.45";"3.83";"12.65";"0";"CHEMBL4192179";"Inhibition of recombinant catalytic human GST-tagged LLRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4190250";"1";"Scientific Literature";"Eur J Med Chem";"2017";"None";"";"";""
"CHEMBL4211027";"";"None";"343.39";"0";"4.19";"38";"COc1ccc2c(c1)/C(=N\N(c1ccccc1)c1ccccc1)C(=O)N2";"IC50";"'='";"310.0";"nM";"6.51";"";"";"UO_0000065";"18.95";"0.34";"2.32";"12.07";"0";"CHEMBL4192179";"Inhibition of recombinant catalytic human GST-tagged LLRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4190250";"1";"Scientific Literature";"Eur J Med Chem";"2017";"None";"";"";""
"CHEMBL4214911";"";"None";"259.31";"0";"1.84";"43, E:Z Mixture (41:59)";"COc1ccc2c(c1)C(=NN1CCCCC1)C(=O)N2";"IC50";"'='";"1110.0";"nM";"5.96";"";"";"UO_0000065";"22.96";"0.43";"4.11";"11.04";"0";"CHEMBL4192179";"Inhibition of recombinant catalytic human GST-tagged LLRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4190250";"1";"Scientific Literature";"Eur J Med Chem";"2017";"None";"";"";""
"CHEMBL4216488";"";"None";"357.15";"0";"1.28";"50, E:Z Mixture (30:70)";"O=C1Nc2ccc(I)cc2C1=NN1CCOCC1";"IC50";"'='";"510.0";"nM";"6.29";"";"";"UO_0000065";"17.62";"0.48";"5.01";"11.67";"0";"CHEMBL4192179";"Inhibition of recombinant catalytic human GST-tagged LLRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4190250";"1";"Scientific Literature";"Eur J Med Chem";"2017";"None";"";"";""
"CHEMBL2178140";"";"None";"445.42";"0";"3.32";"24";"CCNc1nc(Nc2cc(F)c(C(=O)NCC(C)(C)O)cc2OC)ncc1C(F)(F)F";"IC50";"'='";"10.0";"nM";"8.00";"";"";"UO_0000065";"17.96";"0.35";"4.68";"7.38";"0";"CHEMBL2188381";"Inhibition of autophosphorylation of LRRK2 in human HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2176933";"1";"Scientific Literature";"J Med Chem";"2012";"CHEMBL3307715";"";"";""
"CHEMBL2178142";"";"None";"378.82";"0";"2.36";"2";"COc1cc(C(=O)N2CCOCC2)ccc1Nc1ncc(Cl)c(OC)n1";"IC50";"'='";"69.0";"nM";"7.16";"";"";"UO_0000065";"18.90";"0.38";"4.80";"8.35";"0";"CHEMBL2188381";"Inhibition of autophosphorylation of LRRK2 in human HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2176933";"1";"Scientific Literature";"J Med Chem";"2012";"CHEMBL3307715";"";"";""
"CHEMBL2333135";"";"None";"356.41";"0";"1.84";"20";"CNc1c(C(N)=O)nnc2cc(-c3ccc(S(C)(=O)=O)cc3)ccc12";"IC50";"'='";"56.0";"nM";"7.25";"";"";"UO_0000065";"20.35";"0.40";"5.41";"6.30";"0";"CHEMBL2345527";"Inhibition of GST-tagged LRRK2 G2019S mutant (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2333133";"";"None";"382.45";"0";"2.37";"18";"CS(=O)(=O)c1ccc(-c2ccc3c(NC4CC4)c(C(N)=O)nnc3c2)cc1";"IC50";"'='";"52.0";"nM";"7.28";"";"";"UO_0000065";"19.05";"0.37";"4.91";"6.33";"0";"CHEMBL2345527";"Inhibition of GST-tagged LRRK2 G2019S mutant (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2333124";"";"None";"321.38";"0";"2.92";"37";"Cc1c(-c2ccncc2)ccc2c(NC(C)C)c(C(N)=O)nnc12";"IC50";"'='";"3199.0";"nM";"5.50";"";"";"UO_0000065";"17.10";"0.31";"2.57";"5.86";"0";"CHEMBL2345528";"Inhibition of wild type GST-tagged LRRK2 (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2333120";"";"None";"315.38";"0";"1.39";"33";"CC(C)Nc1c(C(N)=O)nnc2cc(N3CCOCC3)ccc12";"IC50";"'='";"9.0";"nM";"8.05";"";"";"UO_0000065";"25.51";"0.48";"6.66";"8.62";"0";"CHEMBL2345528";"Inhibition of wild type GST-tagged LRRK2 (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2333117";"";"None";"310.36";"0";"1.95";"30";"CC(C)Nc1c(C(N)=O)nnc2ccc(-c3cnn(C)c3)cc12";"IC50";"'='";"378.0";"nM";"6.42";"";"";"UO_0000065";"20.69";"0.38";"4.47";"6.51";"0";"CHEMBL2345528";"Inhibition of wild type GST-tagged LRRK2 (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2333139";"";"None";"309.33";"0";"1.19";"24";"NC(=O)c1nnc2cc(-c3ccncc3)ccc2c1NCCO";"IC50";"'='";"145.0";"nM";"6.84";"";"";"UO_0000065";"22.11";"0.41";"5.65";"6.00";"0";"CHEMBL2345528";"Inhibition of wild type GST-tagged LRRK2 (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2333135";"";"None";"356.41";"0";"1.84";"20";"CNc1c(C(N)=O)nnc2cc(-c3ccc(S(C)(=O)=O)cc3)ccc12";"IC50";"'='";"119.0";"nM";"6.92";"";"";"UO_0000065";"19.43";"0.38";"5.08";"6.02";"0";"CHEMBL2345528";"Inhibition of wild type GST-tagged LRRK2 (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2333128";"";"None";"410.50";"0";"3.01";"13";"C[C@@H](Nc1c(C(N)=O)nnc2cc(-c3ccc(S(C)(=O)=O)cc3)ccc12)C1CC1";"IC50";"'='";"1.0";"nM";"9.00";"";"";"UO_0000065";"21.92";"0.42";"5.99";"7.82";"0";"CHEMBL2345528";"Inhibition of wild type GST-tagged LRRK2 (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL3326141";"";"None";"364.37";"0";"1.77";"29";"COc1ccc(OC)c(C(=O)c2ccc3nnc(-c4cnn(C)c4)n3n2)c1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL3367451";"Inhibition of phosphorylation at S935 residue of wild-type full-length LRRK2 kinase (unknown origin) expressed in HEK 293 cells after 90 mins by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"CHEMBL3307715";"";"";""
"CHEMBL3326125";"";"None";"371.45";"0";"3.42";"12";"COc1ccc(OC)c(Sc2ccc3nnc(-c4ccsn4)n3n2)c1";"IC50";"'='";"722.0";"nM";"6.14";"";"";"UO_0000065";"16.53";"0.34";"2.72";"8.25";"0";"CHEMBL3367451";"Inhibition of phosphorylation at S935 residue of wild-type full-length LRRK2 kinase (unknown origin) expressed in HEK 293 cells after 90 mins by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"CHEMBL3307715";"";"";""
"CHEMBL3326116";"";"None";"365.42";"0";"3.35";"3";"COc1ccc(OC)c(Sc2ccc3nnc(-c4cccnc4)n3n2)c1";"IC50";"'='";"736.0";"nM";"6.13";"";"";"UO_0000065";"16.78";"0.32";"2.78";"8.24";"0";"CHEMBL3367451";"Inhibition of phosphorylation at S935 residue of wild-type full-length LRRK2 kinase (unknown origin) expressed in HEK 293 cells after 90 mins by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"CHEMBL3307715";"";"";""
"CHEMBL3326142";"";"None";"386.36";"0";"2.68";"30";"COc1ccc(OC)c(C(F)(F)c2ccc3nnc(-c4cnn(C)c4)n3n2)c1";"IC50";"'='";"763.0";"nM";"6.12";"";"";"UO_0000065";"15.83";"0.30";"3.44";"7.71";"0";"CHEMBL3367450";"Inhibition of GST-tagged truncated LRRK2 (unknown origin) using fluorescein-labeled peptide LRRKtide as substrate by LANTHA screen assay in presence of 1 mM ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL3326139";"";"None";"350.38";"0";"2.13";"27";"COc1ccc(OC)c(Cc2ccc3nnc(-c4cnn(C)c4)n3n2)c1";"IC50";"'='";"6202.0";"nM";"5.21";"";"";"UO_0000065";"14.86";"0.27";"3.08";"6.56";"0";"CHEMBL3367450";"Inhibition of GST-tagged truncated LRRK2 (unknown origin) using fluorescein-labeled peptide LRRKtide as substrate by LANTHA screen assay in presence of 1 mM ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL3326138";"";"None";"352.35";"0";"2.33";"26";"COc1ccc(OC)c(Oc2ccc3nnc(-c4cnn(C)c4)n3n2)c1";"IC50";"'='";"549.0";"nM";"6.26";"";"";"UO_0000065";"17.77";"0.33";"3.93";"7.07";"0";"CHEMBL3367450";"Inhibition of GST-tagged truncated LRRK2 (unknown origin) using fluorescein-labeled peptide LRRKtide as substrate by LANTHA screen assay in presence of 1 mM ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL3326125";"";"None";"371.45";"0";"3.42";"12";"COc1ccc(OC)c(Sc2ccc3nnc(-c4ccsn4)n3n2)c1";"IC50";"'='";"91.0";"nM";"7.04";"";"";"UO_0000065";"18.96";"0.38";"3.62";"9.46";"0";"CHEMBL3367450";"Inhibition of GST-tagged truncated LRRK2 (unknown origin) using fluorescein-labeled peptide LRRKtide as substrate by LANTHA screen assay in presence of 1 mM ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL3326145";"";"None";"382.45";"0";"3.00";"33";"COc1ccc(OC)c(Sc2cc(C)c3nnc(-c4cnn(C)c4)n3n2)c1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL3367451";"Inhibition of phosphorylation at S935 residue of wild-type full-length LRRK2 kinase (unknown origin) expressed in HEK 293 cells after 90 mins by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"CHEMBL3307715";"";"";""
"CHEMBL3326146";"";"None";"367.43";"0";"3.30";"34";"COc1ccc(OC)c(Sc2ccc3nnc(-c4cnn(C)c4)n3c2)c1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL3367451";"Inhibition of phosphorylation at S935 residue of wild-type full-length LRRK2 kinase (unknown origin) expressed in HEK 293 cells after 90 mins by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"CHEMBL3307715";"";"";""
"CHEMBL3326147";"";"None";"367.43";"0";"3.30";"35";"COc1ccc(OC)c(Sc2ccc3ncc(-c4cnn(C)c4)n3n2)c1";"IC50";"'='";"400.0";"nM";"6.40";"";"";"UO_0000065";"17.41";"0.34";"3.10";"9.63";"0";"CHEMBL3367451";"Inhibition of phosphorylation at S935 residue of wild-type full-length LRRK2 kinase (unknown origin) expressed in HEK 293 cells after 90 mins by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"CHEMBL3307715";"";"";""
"CHEMBL2348973";"";"None";"320.40";"0";"2.51";"40";"COC(=O)[C@@H](C)Sc1ccc2nnc(-c3cccs3)n2n1";"IC50";"'='";"187.0";"nM";"6.73";"";"";"UO_0000065";"21.00";"0.44";"4.22";"9.70";"0";"CHEMBL2351468";"Inhibition of LRRK2 G2019S mutant (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348958";"";"None";"379.41";"0";"3.76";"24";"FC(F)(F)c1cccc(Sc2ccc3nnc(C4CCNCC4)n3n2)c1";"IC50";"'='";"22128.0";"nM";"4.66";"";"";"UO_0000065";"12.27";"0.24";"0.90";"8.45";"0";"CHEMBL2351468";"Inhibition of LRRK2 G2019S mutant (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2349089";"";"None";"368.32";"0";"4.04";"52";"O=C(c1cccc(C(F)(F)F)c1)c1ccc2nnc(-c3ccccc3)n2n1";"IC50";"'='";"25000.0";"nM";"4.60";"";"";"UO_0000065";"12.49";"0.23";"0.56";"7.65";"0";"CHEMBL2351467";"Inhibition of wild type LRRK2 (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348984";"";"None";"355.32";"0";"4.55";"51";"FC(F)(F)c1cccc(Nc2ccc3nnc(-c4ccccc4)n3n2)c1";"IC50";"'>'";"100000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL2351467";"Inhibition of wild type LRRK2 (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348976";"";"None";"319.42";"0";"2.21";"43";"CC(C)(Sc1ccc2nnc(-c3cccs3)n2n1)C(N)=O";"IC50";"'='";"2420.0";"nM";"5.62";"";"";"UO_0000065";"17.58";"0.37";"3.41";"6.52";"0";"CHEMBL2351467";"Inhibition of wild type LRRK2 (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2346687";"";"None";"364.40";"0";"4.95";"22";"FC(F)(F)c1cccc(Sc2ccc3nnc(C4CCCC4)n3n2)c1";"IC50";"'='";"1549.0";"nM";"5.81";"";"";"UO_0000065";"15.94";"0.32";"0.86";"13.49";"0";"CHEMBL2351467";"Inhibition of wild type LRRK2 (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348947";"";"None";"379.39";"0";"4.42";"12";"FC(F)(F)c1cccc(Sc2ccc3nnc(-c4cscn4)n3n2)c1";"IC50";"'='";"140.0";"nM";"6.85";"";"";"UO_0000065";"18.07";"0.37";"2.43";"12.25";"0";"CHEMBL2351467";"Inhibition of wild type LRRK2 (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348940";"";"None";"377.42";"1";"5.63";"5";"FC(F)(F)c1cccc(Sc2ccc3cnc(-c4cccs4)n3n2)c1";"IC50";"'='";"10660.0";"nM";"4.97";"";"";"UO_0000065";"13.17";"0.27";"-0.66";"16.47";"0";"CHEMBL2351467";"Inhibition of wild type LRRK2 (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348938";"";"None";"378.40";"1";"5.02";"3";"FC(F)(F)c1cccc(Sc2ccc3nnc(-c4cccs4)n3n2)c1";"IC50";"'='";"75.0";"nM";"7.12";"";"";"UO_0000065";"18.83";"0.39";"2.10";"16.54";"0";"CHEMBL2351467";"Inhibition of wild type LRRK2 (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2436977";"";"None";"422.54";"0";"4.52";"13";"CN1CCN(Cc2ccc(-c3cnc4[nH]cc(-c5cnc6[nH]ccc6c5)c4c3)cc2)CC1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL2439119";"Inhibition of human wild type LRRK2 by qPCR analysis";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2434948";"1";"Scientific Literature";"J Med Chem";"2013";"None";"";"";""
"CHEMBL2397014";"";"None";"488.55";"0";"3.32";"CZC-25146";"COc1cc(N2CCOCC2)ccc1Nc1ncc(F)c(Nc2ccccc2NS(C)(=O)=O)n1";"IC50";"'='";"7.0";"nM";"8.15";"";"";"UO_0000065";"16.69";"0.33";"4.83";"6.93";"0";"CHEMBL2398943";"Inhibition of human recombinant LRRK2 G2019S mutant using biotin-LRRKtide as substrate preincubated for 15 mins prior to substrate addition measured after 60 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2396520";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL4088336";"";"None";"417.69";"1";"5.33";"6a";"O=C(Nc1cccnc1)c1cc(Br)ccc1OCc1ccccc1Cl";"IC50";"'='";"100.0";"nM";"7.00";"";"";"UO_0000065";"16.76";"0.38";"1.67";"13.67";"0";"CHEMBL4058537";"Inhibition of LRRK2 (unknown origin) by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4052807";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL4202671";"";"None";"247.26";"0";"2.63";"11, E:Z Mixture (64:36)";"N#Cc1ccc(N=C2C(=O)Nc3ccccc32)cc1";"IC50";"'='";"15400.0";"nM";"4.81";"";"";"UO_0000065";"19.46";"0.35";"2.18";"7.38";"0";"CHEMBL4192178";"Inhibition of recombinant catalytic human GST-tagged LLRK2 (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4190250";"1";"Scientific Literature";"Eur J Med Chem";"2017";"None";"";"";""
"CHEMBL4218856";"";"None";"313.36";"0";"4.18";"16, E:Z Mixture (95:5)";"O=C1Nc2ccccc2C1=NN(c1ccccc1)c1ccccc1";"IC50";"'='";"110.0";"nM";"6.96";"";"";"UO_0000065";"22.21";"0.40";"2.78";"15.57";"0";"CHEMBL4192178";"Inhibition of recombinant catalytic human GST-tagged LLRK2 (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4190250";"1";"Scientific Literature";"Eur J Med Chem";"2017";"None";"";"";""
"CHEMBL2349092";"";"None";"404.37";"0";"3.64";"55";"O=S(=O)(c1cccc(C(F)(F)F)c1)c1ccc2nnc(-c3ccccc3)n2n1";"IC50";"'='";"2270.0";"nM";"5.64";"";"";"UO_0000065";"13.96";"0.28";"2.00";"7.31";"0";"CHEMBL2351468";"Inhibition of LRRK2 G2019S mutant (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2347811";"";"None";"351.43";"0";"3.24";"25";"CN(C)c1c(C#N)cnc2cc(-c3ccc(S(C)(=O)=O)cc3)ccc12";"IC50";"'='";"27.0";"nM";"7.57";"";"";"UO_0000065";"21.54";"0.41";"4.33";"10.22";"0";"CHEMBL2352557";"Inhibition of GST-tagged LRRK2 G2019S mutant (970-2527 amino acids) (unknown origin) assessed as inhibition of LRRKtide phosphorylation by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346515";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2347824";"";"None";"291.36";"0";"3.33";"14";"CC(C)Nc1c(C#N)cnc2cc(-c3cnn(C)c3)ccc12";"IC50";"'='";"5.0";"nM";"8.30";"";"";"UO_0000065";"28.49";"0.52";"4.97";"12.48";"0";"CHEMBL2352557";"Inhibition of GST-tagged LRRK2 G2019S mutant (970-2527 amino acids) (unknown origin) assessed as inhibition of LRRKtide phosphorylation by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346515";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2347822";"";"None";"420.54";"0";"4.53";"5";"CC(C)Nc1c(-c2cnn(C)c2)cnc2cc(-c3ccc(S(C)(=O)=O)cc3)ccc12";"IC50";"'='";"2020.0";"nM";"5.70";"";"";"UO_0000065";"13.54";"0.26";"1.16";"7.41";"0";"CHEMBL2352558";"Inhibition of wild type GST-tagged LRRK2 (970-2527 amino acids)(unknown origin) assessed as inhibition of LRRKtide phosphorylation by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346515";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348972";"";"None";"320.40";"0";"2.51";"39";"COC(=O)[C@H](C)Sc1ccc2nnc(-c3cccs3)n2n1";"IC50";"'='";"215.0";"nM";"6.67";"";"";"UO_0000065";"20.81";"0.43";"4.16";"9.61";"0";"CHEMBL2351468";"Inhibition of LRRK2 G2019S mutant (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348957";"";"None";"380.40";"0";"4.19";"23";"FC(F)(F)c1cccc(Sc2ccc3nnc(C4CCOCC4)n3n2)c1";"IC50";"'='";"2020.0";"nM";"5.70";"";"";"UO_0000065";"14.97";"0.30";"1.50";"10.89";"0";"CHEMBL2351468";"Inhibition of LRRK2 G2019S mutant (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348982";"";"None";"450.47";"1";"5.20";"49";"CCOC(=O)c1cc(Sc2cccc(C(F)(F)F)c2)nn2c(-c3cccs3)nnc12";"IC50";"'>'";"100000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL2351467";"Inhibition of wild type LRRK2 (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2403364";"";"None";"422.49";"0";"2.35";"15";"COc1ccc2c(c1)/C(=C/c1cc3c([nH]1)CCN(C(=O)N1CCOCC1)C3)C(=O)N2C";"IC50";"'='";"150.0";"nM";"6.82";"";"";"UO_0000065";"16.15";"0.30";"4.47";"8.74";"0";"CHEMBL2406186";"Inhibition of human LRRK2 (1885 to 2132) using 5-Fluo-Ahx-RLGRDKYKTLRQIRQGNTK-OH as substrate after 60 mins by fluorescence assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2401634";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL3409459";"";"None";"546.12";"2";"5.68";"2";"CN1Cc2ccccc2N(C)c2nc(Nc3ccc(C(=O)N4CCC(N5CCCCC5)CC4)cc3Cl)ncc21";"IC50";"'='";"51.2";"nM";"7.29";"";"";"UO_0000065";"13.35";"0.26";"1.61";"10.75";"0";"CHEMBL3412556";"Inhibition of LRRK2 G2019S mutant (1326 to 252 aa) (unknown origin) stably expressed in HEK293 cell lysate using [gamma-32P] after 15 mins by Cerenkov counting method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3407393";"1";"Scientific Literature";"Eur J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL3409470";"";"None";"427.98";"1";"5.18";"29";"COc1cccc(Nc2ccc(C(=O)N3CCC(N4CCCCC4)CC3)cc2Cl)c1";"IC50";"'>'";"1000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL3412556";"Inhibition of LRRK2 G2019S mutant (1326 to 252 aa) (unknown origin) stably expressed in HEK293 cell lysate using [gamma-32P] after 15 mins by Cerenkov counting method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3407393";"1";"Scientific Literature";"Eur J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL3409476";"";"None";"456.97";"0";"4.95";"35";"O=C(c1ccc(NCc2ccc([N+](=O)[O-])cc2)c(Cl)c1)N1CCC(N2CCCCC2)CC1";"IC50";"'>'";"1000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL3412556";"Inhibition of LRRK2 G2019S mutant (1326 to 252 aa) (unknown origin) stably expressed in HEK293 cell lysate using [gamma-32P] after 15 mins by Cerenkov counting method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3407393";"1";"Scientific Literature";"Eur J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL3409458";"";"None";"560.10";"2";"5.32";"1";"CN1C(=O)c2ccccc2N(C)c2nc(Nc3ccc(C(=O)N4CCC(N5CCCCC5)CC4)cc3Cl)ncc21";"IC50";"'='";"72.0";"nM";"7.14";"";"";"UO_0000065";"12.75";"0.24";"1.82";"8.41";"0";"CHEMBL3412556";"Inhibition of LRRK2 G2019S mutant (1326 to 252 aa) (unknown origin) stably expressed in HEK293 cell lysate using [gamma-32P] after 15 mins by Cerenkov counting method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3407393";"1";"Scientific Literature";"Eur J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL3409472";"";"None";"411.98";"1";"5.48";"31";"Cc1ccc(Nc2ccc(C(=O)N3CCC(N4CCCCC4)CC3)cc2Cl)cc1";"IC50";"'>'";"1000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL3412556";"Inhibition of LRRK2 G2019S mutant (1326 to 252 aa) (unknown origin) stably expressed in HEK293 cell lysate using [gamma-32P] after 15 mins by Cerenkov counting method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3407393";"1";"Scientific Literature";"Eur J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL3393444";"";"None";"319.37";"0";"2.72";"BDBM50059281";"C[C@H]1CN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)CCO1";"IC50";"'='";"7.0";"nM";"8.15";"";"334325";"UO_0000065";"25.53";"0.46";"5.43";"10.48";"1";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3969062";"";"None";"307.33";"0";"3.04";"BDBM185391";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CC[C@H](F)C4)c23)c1";"IC50";"'='";"30.0";"nM";"7.52";"";"334355";"UO_0000065";"24.48";"0.45";"4.48";"10.97";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3393440";"";"None";"284.32";"0";"1.19";"29";"Cn1ccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)n1";"IC50";"'='";"90.0";"nM";"7.05";"";"";"UO_0000065";"24.78";"0.46";"5.86";"9.80";"0";"CHEMBL3395727";"Inhibition of GST-tagged truncated human recombinant LRRK2 G2019S mutant using fluorescein-labeled LRRKtide peptide substrate incubated for 90 mins";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3393344";"";"None";"289.34";"0";"3.10";"10";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCCC4)c23)c1";"IC50";"'='";"8.0";"nM";"8.10";"";"";"UO_0000065";"27.98";"0.50";"5.00";"11.80";"0";"CHEMBL3395726";"Inhibition of GST-tagged truncated human recombinant LRRK2 using fluorescein-labeled LRRKtide peptide substrate incubated for 2 hrs";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3908300";"";"None";"396.47";"0";"3.14";"BDBM223555";"CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)c(F)c3)cnc2N)nn1";"IC50";"'='";"200.0";"nM";"6.70";"";"390840";"UO_0000065";"16.90";"0.32";"3.56";"8.16";"0";"CHEMBL3888346";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3975429";"";"None";"406.49";"0";"2.95";"BDBM223560";"Cc1cc(-c2cnc(N)c(-c3cn(C(C)C)nn3)c2)ccc1C(=O)N1CCOCC1";"IC50";"'='";"99.0";"nM";"7.00";"";"390845";"UO_0000065";"17.23";"0.32";"4.05";"7.06";"0";"CHEMBL3888346";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3903650";"";"None";"412.93";"0";"3.66";"BDBM223567";"CC(C)n1cc(-c2cc(-c3cc(Cl)cc(CN4CCOCC4)c3)cnc2N)nn1";"IC50";"'='";"610.0";"nM";"6.21";"";"390852";"UO_0000065";"15.05";"0.29";"2.55";"7.57";"0";"CHEMBL3888346";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4068861";"";"None";"235.25";"0";"2.81";"9";"N#Cc1c[nH]c2nccc(-c3cccc(O)c3)c12";"IC50";"'='";"487.0";"nM";"6.31";"";"";"UO_0000065";"26.83";"0.48";"3.50";"8.68";"0";"CHEMBL4031820";"Inhibition of wild type recombinant human GST-tagged LRRK2 (970 to 2527 residues) expressed in baculovirus using fluorescein-LRRKtide as substrate after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL3928607";"";"None";"225.28";"0";"3.16";"13";"N#Cc1c[nH]c2nccc(-c3ccsc3)c12";"IC50";"'='";"1279.0";"nM";"5.89";"";"";"UO_0000065";"26.16";"0.50";"2.73";"11.23";"1";"CHEMBL4031820";"Inhibition of wild type recombinant human GST-tagged LRRK2 (970 to 2527 residues) expressed in baculovirus using fluorescein-LRRKtide as substrate after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4101218";"";"None";"343.39";"0";"3.59";"29";"Cc1cncc(-c2cc(Nc3nn(C)cc3C)nc3[nH]cc(C#N)c23)c1";"IC50";"'='";"160.0";"nM";"6.80";"";"";"UO_0000065";"19.79";"0.36";"3.21";"7.14";"0";"CHEMBL4031825";"Inhibition of human wild type LRRK2 phosphorylation at ser935 expressed in BacMam transduced HEK293 cells after 48 hrs by in-cell Western assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"CHEMBL3307715";"";"";""
"CHEMBL3936985";"";"None";"333.40";"0";"3.25";"35";"CN1CCc2cc(-c3cnc(N)c(-c4nnc(C5CC5)o4)c3)ccc21";"IC50";"'='";"970.0";"nM";"6.01";"";"";"UO_0000065";"18.04";"0.33";"2.76";"7.42";"1";"CHEMBL4045604";"Inhibition of recombinant human wild type GST-tagged LRRK2 (970 to 2527 residues) preincubated for 30 mins followed by fluorescein-LRRKtide substrate addition after 2 hrs by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4043168";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL3942400";"";"None";"319.37";"0";"3.99";"39";"CC(C)c1nnc(-c2cc(-c3ccc4[nH]ccc4c3)cnc2N)o1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL4045604";"Inhibition of recombinant human wild type GST-tagged LRRK2 (970 to 2527 residues) preincubated for 30 mins followed by fluorescein-LRRKtide substrate addition after 2 hrs by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4043168";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL2178134";"";"None";"443.40";"0";"3.29";"2a; GNE-7915";"CCNc1nc(Nc2cc(F)c(C(=O)N3CCOCC3)cc2OC)ncc1C(F)(F)F";"IC50";"'='";"46.0";"nM";"7.34";"";"";"UO_0000065";"16.55";"0.32";"4.05";"8.28";"0";"CHEMBL4045603";"Inhibition of recombinant human LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus preincubated for 30 mins followed by fluorescein-LRRKtide substrate addition after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4043168";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL2326713";"";"None";"286.26";"0";"2.32";"5";"CNc1nc(Nc2cn(C)nc2C)ncc1C(F)(F)F";"IC50";"'='";"52.0";"nM";"7.28";"";"";"UO_0000065";"25.45";"0.50";"4.96";"10.77";"0";"CHEMBL2328175";"Inhibition of LRRK2 (unknown origin) autophosphorylation by cell-based assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2321736";"1";"Scientific Literature";"ACS Med Chem Lett";"2013";"None";"";"";""
"CHEMBL3955954";"";"None";"408.51";"0";"3.01";"BDBM223558";"COc1cc(-c2cnc(N)c(-c3cn(C(C)C)nn3)c2)ccc1CN1CCOCC1";"IC50";"'='";"86.0";"nM";"7.07";"";"390814";"UO_0000065";"17.30";"0.32";"4.06";"7.74";"0";"CHEMBL3888345";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3968143";"";"None";"406.49";"0";"2.57";"BDBM223570";"CC(C)n1cc(-c2cc(-c3ccc(CC(=O)N4CCOCC4)cc3)cnc2N)nn1";"IC50";"'='";"520.0";"nM";"6.28";"";"390826";"UO_0000065";"15.46";"0.29";"3.71";"6.34";"0";"CHEMBL3888345";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3978210";"";"None";"412.52";"0";"2.52";"BDBM239509";"CC(C)=Cc1ccc2[nH]nc(-c3cc(N4CCN(S(C)(=O)=O)CC4)ncn3)c2c1";"IC50";"'='";"28.8";"nM";"7.54";"";"417973";"UO_0000065";"18.28";"0.36";"5.02";"7.93";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3961632";"";"None";"248.29";"0";"2.99";"22";"Cc1cccc(-c2cc(N)nc3[nH]cc(C#N)c23)c1";"IC50";"'='";"61.66";"nM";"7.21";"";"";"UO_0000065";"29.04";"0.52";"4.22";"9.19";"0";"CHEMBL4031828";"Inhibition of human LRRK2 G2019S mutant phosphorylation at ser1292 expressed in BacMam transduced HEK293 cells after 48 hrs by in-cell Western assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"CHEMBL3307715";"";"";""
"CHEMBL2348950";"";"None";"373.36";"0";"4.36";"15";"FC(F)(F)c1cccc(Sc2ccc3nnc(-c4cccnc4)n3n2)c1";"IC50";"'='";"64.0";"nM";"7.19";"";"";"UO_0000065";"19.27";"0.38";"2.83";"12.85";"0";"CHEMBL2351468";"Inhibition of LRRK2 G2019S mutant (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL3968543";"";"None";"319.37";"0";"2.64";"BDBM185570";"Cc1[nH]c2ncnc(N3CCOCC3)c2c1-c1cccc(C#N)c1";"IC50";"'='";"12.0";"nM";"7.92";"";"334321";"UO_0000065";"24.80";"0.45";"5.28";"10.18";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3393350";"";"None";"333.40";"0";"3.11";"BDBM50059422";"COC1CCCN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)C1";"IC50";"'='";"79.0";"nM";"7.10";"";"334348";"UO_0000065";"21.30";"0.39";"3.99";"9.13";"1";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3978400";"";"None";"312.35";"0";"2.91";"BDBM185446";"Cc1ccc(F)cc1-c1c[nH]c2ncnc(N3CCOCC3)c12";"IC50";"'='";"91.0";"nM";"7.04";"";"334416";"UO_0000065";"22.54";"0.42";"4.13";"13.03";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3939472";"";"None";"327.39";"0";"2.87";"BDBM239203";"COCCNc1cc(-c2n[nH]c3ccc(OC(C)C)cc23)ncn1";"IC50";"'='";"26.3";"nM";"7.58";"";"417664";"UO_0000065";"23.15";"0.43";"4.71";"8.92";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3891762";"";"None";"412.47";"0";"3.00";"BDBM239250";"CCCN1CCN(c2cc(-c3n[nH]c4cc(F)c(OC(C)C)cc34)ncn2)CC1=O";"IC50";"'='";"2.77";"nM";"8.56";"";"417711";"UO_0000065";"20.75";"0.39";"5.56";"9.81";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3937176";"";"None";"339.40";"0";"2.64";"BDBM239283";"CCOc1ccc2[nH]nc(-c3cc(N4CCO[C@@H](C)C4)ncn3)c2c1";"IC50";"'='";"41.2";"nM";"7.38";"";"417742";"UO_0000065";"21.76";"0.40";"4.75";"9.70";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3936589";"";"None";"382.42";"0";"1.32";"BDBM239290";"COCCOc1ccc2[nH]nc(-c3cc(N4CCN(C)C(=O)C4)ncn3)c2c1";"IC50";"'='";"69.01";"nM";"7.16";"";"417749";"UO_0000065";"18.73";"0.35";"5.84";"7.42";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3939653";"";"None";"436.52";"0";"2.54";"BDBM239311";"COC[C@H](C)Oc1ccc2[nH]nc(-c3cc(N4CCC5(CCNC5=O)CC4)ncn3)c2c1";"IC50";"'='";"2.83";"nM";"8.55";"";"417780";"UO_0000065";"19.58";"0.36";"6.01";"8.12";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3959561";"";"None";"436.50";"0";"1.56";"BDBM239315";"CS(=O)(=O)N1CCN(c2cc(-c3n[nH]c4ccc(-c5cnccn5)cc34)ncn2)CC1";"IC50";"'='";"19.2";"nM";"7.72";"";"417783";"UO_0000065";"17.68";"0.34";"6.16";"6.38";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3936351";"";"None";"309.37";"0";"3.02";"BDBM239320";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCC4)ncn3)c2c1";"IC50";"'='";"7.9";"nM";"8.10";"";"417788";"UO_0000065";"26.19";"0.48";"5.08";"12.11";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3960834";"";"None";"416.49";"0";"2.92";"BDBM239339";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCN(c5ccncn5)CC4)ncn3)c2c1";"IC50";"'='";"15.8";"nM";"7.80";"";"417808";"UO_0000065";"18.73";"0.34";"4.88";"8.13";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3929312";"";"None";"421.42";"0";"3.70";"BDBM239353";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCC(O)(C(F)(F)F)CC4)ncn3)c2c1";"IC50";"'='";"10.5";"nM";"7.98";"";"417821";"UO_0000065";"18.93";"0.36";"4.28";"9.15";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3918499";"";"None";"355.42";"0";"3.60";"BDBM239356";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCC(CF)C4)ncn3)c2c1";"IC50";"'='";"6.9";"nM";"8.16";"";"417824";"UO_0000065";"22.96";"0.43";"4.56";"12.19";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3926553";"";"None";"418.51";"0";"2.87";"BDBM239358";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCN(c5cnn(C)c5)CC4)ncn3)c2c1";"IC50";"'='";"5.4";"nM";"8.27";"";"417826";"UO_0000065";"19.75";"0.36";"5.40";"9.40";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3901594";"";"None";"427.47";"0";"1.79";"BDBM239385";"Cn1cc(-c2cc3c(-c4cc(N5CCS(=O)(=O)CC5)ncn4)n[nH]c3cc2F)cn1";"IC50";"'='";"145.9";"nM";"6.84";"";"417852";"UO_0000065";"15.99";"0.31";"5.05";"6.23";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3903928";"";"None";"456.55";"0";"4.01";"BDBM239476";"CCN(CC)C(=O)c1ccc(-c2ccc3[nH]nc(-c4cc(N5CCOCC5)ncn4)c3c2)cc1";"IC50";"'='";"607.5";"nM";"6.22";"";"417941";"UO_0000065";"13.62";"0.25";"2.21";"7.13";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3928607";"";"None";"225.28";"0";"3.16";"13";"N#Cc1c[nH]c2nccc(-c3ccsc3)c12";"IC50";"'='";"870.0";"nM";"6.06";"";"";"UO_0000065";"26.90";"0.52";"2.90";"11.55";"0";"CHEMBL4031821";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus using fluorescein-LRRKtide as substrate after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL2348969";"";"None";"381.37";"0";"3.21";"35";"FC(F)(F)c1ccnc(Sc2ccc3nnc(-c4cncs4)n3n2)n1";"IC50";"'='";"33.0";"nM";"7.48";"";"";"UO_0000065";"19.62";"0.41";"4.27";"9.15";"0";"CHEMBL2351468";"Inhibition of LRRK2 G2019S mutant (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348966";"";"None";"367.50";"0";"4.70";"32";"CC(C)(C)c1cccc(Sc2ccc3nnc(-c4cncs4)n3n2)c1";"IC50";"'='";"30.0";"nM";"7.52";"";"";"UO_0000065";"20.47";"0.41";"2.82";"13.44";"0";"CHEMBL2351468";"Inhibition of LRRK2 G2019S mutant (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348963";"";"None";"345.84";"0";"4.05";"29";"Clc1cccc(Sc2ccc3nnc(-c4cncs4)n3n2)c1";"IC50";"'='";"8.0";"nM";"8.10";"";"";"UO_0000065";"23.41";"0.50";"4.05";"14.47";"0";"CHEMBL2351468";"Inhibition of LRRK2 G2019S mutant (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2346687";"";"None";"364.40";"0";"4.95";"22";"FC(F)(F)c1cccc(Sc2ccc3nnc(C4CCCC4)n3n2)c1";"IC50";"'='";"511.0";"nM";"6.29";"";"";"UO_0000065";"17.27";"0.34";"1.34";"14.60";"0";"CHEMBL2351468";"Inhibition of LRRK2 G2019S mutant (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348958";"";"None";"379.41";"0";"3.76";"24";"FC(F)(F)c1cccc(Sc2ccc3nnc(C4CCNCC4)n3n2)c1";"IC50";"'>'";"20000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL2351467";"Inhibition of wild type LRRK2 (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348949";"";"None";"373.36";"0";"4.36";"14";"FC(F)(F)c1cccc(Sc2ccc3nnc(-c4ccccn4)n3n2)c1";"IC50";"'='";"164.0";"nM";"6.79";"";"";"UO_0000065";"18.17";"0.36";"2.43";"12.12";"0";"CHEMBL2351467";"Inhibition of wild type LRRK2 (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2347820";"";"None";"423.56";"1";"5.25";"3";"CC(C)Nc1c(-c2nccs2)cnc2cc(-c3ccc(S(C)(=O)=O)cc3)ccc12";"IC50";"'='";"2893.0";"nM";"5.54";"";"";"UO_0000065";"13.08";"0.26";"0.29";"7.70";"0";"CHEMBL2352557";"Inhibition of GST-tagged LRRK2 G2019S mutant (970-2527 amino acids) (unknown origin) assessed as inhibition of LRRKtide phosphorylation by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346515";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2347814";"";"None";"413.50";"0";"4.94";"28";"CN(c1ccccc1)c1c(C#N)cnc2cc(-c3ccc(S(C)(=O)=O)cc3)ccc12";"IC50";"'='";"450.0";"nM";"6.35";"";"";"UO_0000065";"15.35";"0.29";"1.41";"8.57";"0";"CHEMBL2352558";"Inhibition of wild type GST-tagged LRRK2 (970-2527 amino acids)(unknown origin) assessed as inhibition of LRRKtide phosphorylation by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346515";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2349089";"";"None";"368.32";"0";"4.04";"52";"O=C(c1cccc(C(F)(F)F)c1)c1ccc2nnc(-c3ccccc3)n2n1";"IC50";"'='";"4570.0";"nM";"5.34";"";"";"UO_0000065";"14.50";"0.27";"1.30";"8.88";"0";"CHEMBL2351468";"Inhibition of LRRK2 G2019S mutant (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348944";"";"None";"362.34";"0";"3.68";"9";"FC(F)(F)c1cccc(Sc2ccc3nnc(-c4ccn[nH]4)n3n2)c1";"IC50";"'='";"13.0";"nM";"7.89";"";"";"UO_0000065";"21.76";"0.43";"4.21";"10.99";"0";"CHEMBL2351468";"Inhibition of LRRK2 G2019S mutant (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL3393441";"";"None";"295.35";"0";"2.16";"30";"Cc1cncc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"30.0";"nM";"7.52";"";"";"UO_0000065";"25.47";"0.47";"5.36";"11.24";"0";"CHEMBL3395727";"Inhibition of GST-tagged truncated human recombinant LRRK2 G2019S mutant using fluorescein-labeled LRRKtide peptide substrate incubated for 90 mins";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL2348962";"";"None";"390.29";"0";"4.16";"28";"Brc1cccc(Sc2ccc3nnc(-c4cncs4)n3n2)c1";"IC50";"'='";"683.0";"nM";"6.17";"";"";"UO_0000065";"15.80";"0.38";"2.01";"11.02";"0";"CHEMBL2351460";"Inhibition of LRRK2 G2019S mutant (unknown origin) transfected in HEK293 cells assessed decrease in S935 autophosphorylation";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"CHEMBL3307715";"";"";""
"CHEMBL2348947";"";"None";"379.39";"0";"4.42";"12";"FC(F)(F)c1cccc(Sc2ccc3nnc(-c4cscn4)n3n2)c1";"IC50";"'='";"2112.0";"nM";"5.67";"";"";"UO_0000065";"14.96";"0.31";"1.26";"10.14";"0";"CHEMBL2351460";"Inhibition of LRRK2 G2019S mutant (unknown origin) transfected in HEK293 cells assessed decrease in S935 autophosphorylation";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"CHEMBL3307715";"";"";""
"CHEMBL2348945";"";"None";"379.39";"0";"4.42";"10";"FC(F)(F)c1cccc(Sc2ccc3nnc(-c4cncs4)n3n2)c1";"IC50";"'='";"780.0";"nM";"6.11";"";"";"UO_0000065";"16.10";"0.33";"1.69";"10.91";"0";"CHEMBL2351460";"Inhibition of LRRK2 G2019S mutant (unknown origin) transfected in HEK293 cells assessed decrease in S935 autophosphorylation";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"CHEMBL3307715";"";"";""
"CHEMBL4094362";"";"None";"300.32";"0";"1.51";"13";"COc1cccc(Nc2nc(NCCO)c3nc[nH]c3n2)c1";"IC50";"'='";"84.0";"nM";"7.08";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL4018177";"Inhibition of full length wild-type LRRK2 (unknown origin) using biotinylated ezrin/radaxin/meosin peptide as substrate measured after 1 hr";"A";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4017473";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL3894326";"";"None";"367.38";"0";"2.49";"BDBM185513";"COCC1CN(c2ncnc3[nH]cc(-c4cccc(C#N)c4F)c23)CCO1";"IC50";"'='";"372.0";"nM";"6.43";"";"334697";"UO_0000065";"17.50";"0.33";"3.94";"7.39";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3903295";"";"None";"309.37";"0";"2.55";"BDBM185515";"Cc1cncc(-c2c[nH]c3ncnc(N4CCO[C@@H](C)C4)c23)c1";"IC50";"'='";"280.0";"nM";"6.55";"";"334699";"UO_0000065";"21.18";"0.39";"4.00";"9.79";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3949016";"";"None";"355.35";"0";"3.27";"BDBM185575";"N#Cc1cccc(-c2c(C(F)F)[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"1080.0";"nM";"5.97";"";"334720";"UO_0000065";"16.79";"0.31";"2.70";"7.67";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3409463";"";"None";"399.93";"0";"3.96";"22";"O=C(c1ccc(Nc2ncccn2)c(Cl)c1)N1CCC(N2CCCCC2)CC1";"IC50";"'>'";"1000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL3412556";"Inhibition of LRRK2 G2019S mutant (1326 to 252 aa) (unknown origin) stably expressed in HEK293 cell lysate using [gamma-32P] after 15 mins by Cerenkov counting method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3407393";"1";"Scientific Literature";"Eur J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL3409468";"";"None";"427.98";"1";"5.18";"27";"COc1ccccc1Nc1ccc(C(=O)N2CCC(N3CCCCC3)CC2)cc1Cl";"IC50";"'>'";"1000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL3412556";"Inhibition of LRRK2 G2019S mutant (1326 to 252 aa) (unknown origin) stably expressed in HEK293 cell lysate using [gamma-32P] after 15 mins by Cerenkov counting method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3407393";"1";"Scientific Literature";"Eur J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL3409474";"";"None";"411.98";"1";"5.04";"33";"O=C(c1ccc(NCc2ccccc2)c(Cl)c1)N1CCC(N2CCCCC2)CC1";"IC50";"'>'";"1000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL3412556";"Inhibition of LRRK2 G2019S mutant (1326 to 252 aa) (unknown origin) stably expressed in HEK293 cell lysate using [gamma-32P] after 15 mins by Cerenkov counting method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3407393";"1";"Scientific Literature";"Eur J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL2348976";"";"None";"319.42";"0";"2.21";"43";"CC(C)(Sc1ccc2nnc(-c3cccs3)n2n1)C(N)=O";"IC50";"'='";"3117.0";"nM";"5.51";"";"";"UO_0000065";"17.24";"0.36";"3.30";"6.39";"0";"CHEMBL2351468";"Inhibition of LRRK2 G2019S mutant (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348959";"";"None";"392.43";"0";"4.95";"25";"FC(F)(F)c1cccc(Sc2ccc3nnc(Cc4cccs4)n3n2)c1";"IC50";"'='";"19542.0";"nM";"4.71";"";"";"UO_0000065";"12.00";"0.25";"-0.24";"10.93";"0";"CHEMBL2351468";"Inhibition of LRRK2 G2019S mutant (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348939";"";"None";"377.42";"1";"5.63";"4";"FC(F)(F)c1cccc(Sc2ccc3ncc(-c4cccs4)n3n2)c1";"IC50";"'='";"47.0";"nM";"7.33";"";"";"UO_0000065";"19.42";"0.40";"1.70";"24.27";"0";"CHEMBL2351468";"Inhibition of LRRK2 G2019S mutant (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348978";"";"None";"356.84";"0";"4.02";"45";"CC(Sc1ccc2nnc(-c3cccc(Cl)c3)n2n1)c1ccn[nH]1";"IC50";"'='";"1662.0";"nM";"5.78";"";"";"UO_0000065";"16.20";"0.33";"1.76";"8.05";"0";"CHEMBL2351467";"Inhibition of wild type LRRK2 (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2204495";"";"None";"399.43";"1";"5.11";"1, GSK2578215A";"O=C(Nc1cccnc1)c1cc(-c2ccnc(F)c2)ccc1OCc1ccccc1";"IC50";"'='";"10.9";"nM";"7.96";"";"";"UO_0000065";"19.93";"0.36";"2.85";"12.42";"0";"CHEMBL2215492";"Inhibition of recombinant His6-Tev-tagged LRRK2 expressed in baculovirus assessed as inhibition of LRRKtide phosphorylation by HTRF assay";"B";"BAO_0000019";"assay format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2203081";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2012";"None";"";"";""
"CHEMBL2333123";"";"None";"424.53";"0";"3.27";"36";"CNC(=O)c1nnc2cc(-c3ccc(S(C)(=O)=O)cc3)ccc2c1N[C@H](C)C1CC1";"IC50";"'='";"247.0";"nM";"6.61";"";"";"UO_0000065";"15.56";"0.30";"3.34";"6.54";"0";"CHEMBL2345527";"Inhibition of GST-tagged LRRK2 G2019S mutant (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL3393354";"";"None";"310.36";"0";"2.47";"20";"COc1cccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"46.0";"nM";"7.34";"";"";"UO_0000065";"23.64";"0.44";"4.87";"11.60";"0";"CHEMBL3395727";"Inhibition of GST-tagged truncated human recombinant LRRK2 G2019S mutant using fluorescein-labeled LRRKtide peptide substrate incubated for 90 mins";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3393454";"";"None";"331.38";"0";"2.58";"43";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CC5COCC5C4)c23)c1";"IC50";"'='";"222.0";"nM";"6.65";"";"";"UO_0000065";"20.08";"0.36";"4.07";"8.55";"0";"CHEMBL3395726";"Inhibition of GST-tagged truncated human recombinant LRRK2 using fluorescein-labeled LRRKtide peptide substrate incubated for 2 hrs";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL4636475";"";"None";"454.51";"0";"2.96";"FMF-03-047-1";"COc1cc(NS(C)(=O)=O)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2C";"IC50";"'='";"5.9";"nM";"8.23";"";"";"UO_0000065";"18.11";"0.35";"5.27";"7.05";"0";"CHEMBL4612965";"Inhibition of recombinant human GST-tagged LRRK2 catalytic domain (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate measured after 1 hr by Alexa fluor-647 ADP tracer-based ADAPTA assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4610122";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL4640016";"";"None";"569.59";"1";"4.34";"FMF-03-148-1";"COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2CC(F)(F)F";"IC50";"'='";"378.0";"nM";"6.42";"";"";"UO_0000065";"11.28";"0.21";"2.08";"6.24";"0";"CHEMBL4612965";"Inhibition of recombinant human GST-tagged LRRK2 catalytic domain (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate measured after 1 hr by Alexa fluor-647 ADP tracer-based ADAPTA assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4610122";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL4644273";"";"None";"468.54";"0";"3.35";"FMF-03-087-1";"CCN1C(=O)c2ccccc2N(C)c2nc(Nc3ccc(NS(C)(=O)=O)cc3OC)ncc21";"IC50";"'='";"23.0";"nM";"7.64";"";"";"UO_0000065";"16.30";"0.32";"4.29";"6.54";"0";"CHEMBL4612965";"Inhibition of recombinant human GST-tagged LRRK2 catalytic domain (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate measured after 1 hr by Alexa fluor-647 ADP tracer-based ADAPTA assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4610122";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL3965950";"";"None";"383.45";"0";"2.66";"BDBM239285";"COCCOc1ccc2[nH]nc(-c3cc(N4C[C@@H](C)O[C@@H](C)C4)ncn3)c2c1";"IC50";"'='";"76.57";"nM";"7.12";"";"417744";"UO_0000065";"18.56";"0.35";"4.46";"8.33";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3910461";"";"None";"406.43";"0";"1.84";"BDBM239372";"CN1CCN(c2cc(-c3n[nH]c4cc(F)c(-c5cnn(C)c5)cc34)ncn2)CC1=O";"IC50";"'='";"37.7";"nM";"7.42";"";"417839";"UO_0000065";"18.27";"0.34";"5.58";"7.75";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3948602";"";"None";"400.46";"0";"2.06";"BDBM239437";"CC(C)Oc1cc2c(-c3cc(N4C[C@H](O)[C@@H](N(C)C)C4)ncn3)n[nH]c2cc1F";"IC50";"'='";"7.9";"nM";"8.10";"";"417903";"UO_0000065";"20.23";"0.38";"6.04";"8.96";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3922591";"";"None";"403.43";"0";"3.67";"BDBM239449";"COC[C@H](C)Oc1ccc2[nH]nc(-c3cc(N4CCCC(F)(F)C4)ncn3)c2c1";"IC50";"'='";"2.8";"nM";"8.55";"";"417914";"UO_0000065";"21.20";"0.40";"4.88";"11.23";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4100904";"";"None";"338.41";"0";"3.25";"17";"CC(C)Oc1ccc2[nH]nc(-c3ccnc(N4CCOCC4)c3)c2c1";"IC50";"'='";"14.0";"nM";"7.85";"";"";"UO_0000065";"23.21";"0.43";"4.60";"12.41";"0";"CHEMBL4010117";"Inhibition of recombinant human GST-tagged LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus using fluorescein-ERM as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr in presence of 5 mM ATP by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007454";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4103352";"";"None";"358.39";"0";"3.91";"22";"CC(C)Oc1ccc2[nH]nc(-c3ccnc(N4C[C@@H](F)[C@H](F)C4)c3)c2c1";"IC50";"'='";"6.6";"nM";"8.18";"";"";"UO_0000065";"22.83";"0.43";"4.27";"15.14";"0";"CHEMBL4010109";"Inhibition of recombinant human GST-tagged LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus using fluorescein-ERM as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007454";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4075961";"";"None";"365.44";"0";"2.69";"21";"CC(C)Oc1ccc2[nH]nc(-c3ccnc(N4CCN(C)C(=O)C4)c3)c2c1";"IC50";"'='";"2.6";"nM";"8.59";"";"";"UO_0000065";"23.49";"0.43";"5.90";"11.55";"0";"CHEMBL4010109";"Inhibition of recombinant human GST-tagged LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus using fluorescein-ERM as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007454";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4100904";"";"None";"338.41";"0";"3.25";"17";"CC(C)Oc1ccc2[nH]nc(-c3ccnc(N4CCOCC4)c3)c2c1";"IC50";"'='";"0.7";"nM";"9.15";"";"";"UO_0000065";"27.05";"0.50";"5.90";"14.47";"0";"CHEMBL4010109";"Inhibition of recombinant human GST-tagged LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus using fluorescein-ERM as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007454";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4103247";"";"None";"195.22";"0";"2.62";"5";"c1cncc(-c2n[nH]c3ccccc23)c1";"IC50";"'='";"1231.0";"nM";"5.91";"";"";"UO_0000065";"30.27";"0.54";"3.29";"14.22";"0";"CHEMBL4010109";"Inhibition of recombinant human GST-tagged LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus using fluorescein-ERM as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007454";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4098877";"MLi-2";"None";"379.46";"0";"3.56";"1; MLi-2";"C[C@@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@H](C)O1";"IC50";"'='";"4.8";"nM";"8.32";"";"";"UO_0000065";"21.92";"0.41";"4.76";"10.92";"0";"CHEMBL4010118";"Inhibition LRRK2 G2019S mutant Ser935 phosphorylation in human SH-SY5Y cells after 90 mins by Western blot analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007454";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4065525";"";"None";"415.52";"0";"2.49";"20";"CC(C)Oc1ccc2[nH]nc(-c3ccnc(N4CCN(S(C)(=O)=O)CC4)c3)c2c1";"IC50";"'='";"83.0";"nM";"7.08";"";"";"UO_0000065";"17.04";"0.33";"4.59";"7.75";"0";"CHEMBL4010118";"Inhibition LRRK2 G2019S mutant Ser935 phosphorylation in human SH-SY5Y cells after 90 mins by Western blot analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007454";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4065525";"";"None";"415.52";"0";"2.49";"20";"CC(C)Oc1ccc2[nH]nc(-c3ccnc(N4CCN(S(C)(=O)=O)CC4)c3)c2c1";"IC50";"'='";"14.0";"nM";"7.85";"";"";"UO_0000065";"18.90";"0.37";"5.36";"8.59";"0";"CHEMBL4010117";"Inhibition of recombinant human GST-tagged LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus using fluorescein-ERM as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr in presence of 5 mM ATP by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007454";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL3932988";"";"None";"344.37";"0";"3.71";"BDBM185509";"COc1ccc(F)cc1-c1c[nH]c2ncnc(N3CCC(F)CC3)c12";"IC50";"'='";"29.0";"nM";"7.54";"";"334693";"UO_0000065";"21.89";"0.41";"3.83";"13.95";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3916889";"";"None";"342.37";"0";"2.73";"BDBM185510";"COc1cc(F)cc(-c2c[nH]c3ncnc(N4CCCC(O)C4)c23)c1";"IC50";"'='";"38.0";"nM";"7.42";"";"334694";"UO_0000065";"21.67";"0.41";"4.69";"9.99";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3973394";"";"None";"286.31";"0";"2.84";"BDBM185523";"COc1cc(F)cc(-c2c[nH]c3ncnc(N(C)C)c23)c1";"IC50";"'='";"49.0";"nM";"7.31";"";"334703";"UO_0000065";"25.53";"0.48";"4.47";"13.53";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3957011";"";"None";"344.37";"0";"3.71";"BDBM185527";"COc1ccc(F)cc1-c1c[nH]c2ncnc(N3CCCC(F)C3)c12";"IC50";"'='";"24.0";"nM";"7.62";"";"334707";"UO_0000065";"22.13";"0.42";"3.91";"14.10";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3901817";"";"None";"349.39";"0";"2.35";"BDBM185385";"COCC1CN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)CCO1";"IC50";"'='";"245.0";"nM";"6.61";"";"334719";"UO_0000065";"18.92";"0.35";"4.26";"7.59";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3983547";"";"None";"297.32";"0";"1.15";"BDBM185545";"O=c1cc(-c2c[nH]c3ncnc(N4CCOCC4)c23)cc[nH]1";"IC50";"'='";"32.7";"nM";"7.49";"";"334726";"UO_0000065";"25.18";"0.46";"6.34";"8.61";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL2178136";"";"None";"384.75";"0";"3.12";"20";"CNc1nc(Nc2ccc(-c3nnnn3C)cc2Cl)ncc1C(F)(F)F";"IC50";"'='";"100.0";"nM";"7.00";"";"";"UO_0000065";"18.19";"0.37";"3.88";"7.49";"0";"CHEMBL2188381";"Inhibition of autophosphorylation of LRRK2 in human HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2176933";"1";"Scientific Literature";"J Med Chem";"2012";"CHEMBL3307715";"";"";""
"CHEMBL2347822";"";"None";"420.54";"0";"4.53";"5";"CC(C)Nc1c(-c2cnn(C)c2)cnc2cc(-c3ccc(S(C)(=O)=O)cc3)ccc12";"IC50";"'='";"2229.0";"nM";"5.65";"";"";"UO_0000065";"13.44";"0.26";"1.12";"7.35";"0";"CHEMBL2352557";"Inhibition of GST-tagged LRRK2 G2019S mutant (970-2527 amino acids) (unknown origin) assessed as inhibition of LRRKtide phosphorylation by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346515";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2347808";"";"None";"211.27";"0";"2.93";"22";"CC(C)Nc1c(C#N)cnc2ccccc12";"IC50";"'='";"103.0";"nM";"6.99";"";"";"UO_0000065";"33.07";"0.60";"4.06";"14.34";"0";"CHEMBL2352558";"Inhibition of wild type GST-tagged LRRK2 (970-2527 amino acids)(unknown origin) assessed as inhibition of LRRKtide phosphorylation by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346515";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348936";"";"None";"372.38";"0";"4.96";"1";"FC(F)(F)c1cccc(Sc2ccc3nnc(-c4ccccc4)n3n2)c1";"IC50";"'='";"242.0";"nM";"6.62";"";"";"UO_0000065";"17.77";"0.35";"1.66";"15.36";"0";"CHEMBL2351467";"Inhibition of wild type LRRK2 (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL535";"SUNITINIB";"4.0";"398.48";"0";"3.33";"Sunitinib";"CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C";"IC50";"'='";"28.0";"nM";"7.55";"";"";"UO_0000065";"18.95";"0.36";"4.22";"9.78";"0";"CHEMBL2406186";"Inhibition of human LRRK2 (1885 to 2132) using 5-Fluo-Ahx-RLGRDKYKTLRQIRQGNTK-OH as substrate after 60 mins by fluorescence assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2401634";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL4213079";"";"None";"397.36";"1";"5.08";"37";"O=C1Nc2ccc(OC(F)(F)F)cc2/C1=N\N(c1ccccc1)c1ccccc1";"IC50";"'='";"21500.0";"nM";"4.67";"";"";"UO_0000065";"11.75";"0.22";"-0.41";"8.65";"0";"CHEMBL4192179";"Inhibition of recombinant catalytic human GST-tagged LLRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4190250";"1";"Scientific Literature";"Eur J Med Chem";"2017";"None";"";"";""
"CHEMBL4206654";"";"None";"247.27";"0";"1.97";"40, E:Z Mixture (30:70)";"O=C1Nc2ccc(F)cc2C1=NN1CCCCC1";"IC50";"'='";"2010.0";"nM";"5.70";"";"";"UO_0000065";"23.04";"0.43";"3.73";"12.74";"0";"CHEMBL4192179";"Inhibition of recombinant catalytic human GST-tagged LLRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4190250";"1";"Scientific Literature";"Eur J Med Chem";"2017";"None";"";"";""
"CHEMBL4218001";"";"None";"392.26";"0";"4.94";"36, E:Z Mixture (91:9)";"O=C1Nc2ccc(Br)cc2C1=NN(c1ccccc1)c1ccccc1";"IC50";"'='";"20.0";"nM";"7.70";"";"";"UO_0000065";"19.63";"0.42";"2.76";"17.22";"0";"CHEMBL4192178";"Inhibition of recombinant catalytic human GST-tagged LLRK2 (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4190250";"1";"Scientific Literature";"Eur J Med Chem";"2017";"None";"";"";""
"CHEMBL4202514";"";"None";"261.28";"0";"0.68";"49, E:Z Mixture (38:62)";"COc1ccc2c(c1)C(=NN1CCOCC1)C(=O)N2";"IC50";"'='";"6020.0";"nM";"5.22";"";"";"UO_0000065";"19.98";"0.38";"4.54";"8.27";"0";"CHEMBL4192178";"Inhibition of recombinant catalytic human GST-tagged LLRK2 (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4190250";"1";"Scientific Literature";"Eur J Med Chem";"2017";"None";"";"";""
"CHEMBL2178135";"";"None";"455.41";"0";"3.43";"19";"COc1cc(C(=O)N2CCOCC2)c(F)cc1Nc1ncc(C(F)(F)F)c(NC2CC2)n1";"IC50";"'='";"4.0";"nM";"8.40";"";"";"UO_0000065";"18.44";"0.36";"4.97";"9.48";"0";"CHEMBL2188381";"Inhibition of autophosphorylation of LRRK2 in human HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2176933";"1";"Scientific Literature";"J Med Chem";"2012";"CHEMBL3307715";"";"";""
"CHEMBL2178126";"";"None";"445.83";"0";"3.42";"10";"CNc1nc(Nc2cc(OC)c(C(=O)N3CCOCC3)cc2Cl)ncc1C(F)(F)F";"IC50";"'='";"24.0";"nM";"7.62";"";"";"UO_0000065";"17.09";"0.35";"4.20";"8.60";"0";"CHEMBL2188381";"Inhibition of autophosphorylation of LRRK2 in human HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2176933";"1";"Scientific Literature";"J Med Chem";"2012";"CHEMBL3307715";"";"";""
"CHEMBL2171745";"";"None";"411.38";"0";"2.76";"7";"CNc1nc(Nc2ccc(C(=O)N3CCOCC3)cc2OC)ncc1C(F)(F)F";"IC50";"'='";"9.0";"nM";"8.05";"";"";"UO_0000065";"19.56";"0.38";"5.29";"9.08";"0";"CHEMBL2188381";"Inhibition of autophosphorylation of LRRK2 in human HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2176933";"1";"Scientific Literature";"J Med Chem";"2012";"CHEMBL3307715";"";"";""
"CHEMBL4589029";"";"None";"258.71";"0";"3.66";"2";"Cc1n[nH]c2ccnc(Nc3ccc(Cl)cc3)c12";"IC50";"'='";"390.0";"nM";"6.41";"";"";"UO_0000065";"24.77";"0.49";"2.75";"11.96";"0";"CHEMBL4331900";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant catalytic domain (970 to 2527 residues) expressed in baculovirus expression system by radiometric assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330096";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4569508";"";"None";"529.59";"2";"5.28";"1";"O=C(NCC(F)(F)F)c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)cs1";"IC50";"'='";"14.0";"nM";"7.85";"";"";"UO_0000065";"14.83";"0.29";"2.57";"10.94";"0";"CHEMBL4479740";"Inhibition of recombinant human GST-tagged LRRK2 catalytic domain expressed in baculovirus expression system by Adapta assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4477252";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2016";"None";"";"";""
"CHEMBL2349090";"";"None";"379.35";"0";"4.47";"53";"N#CC(c1cccc(C(F)(F)F)c1)c1ccc2nnc(-c3ccccc3)n2n1";"IC50";"'='";"18000.0";"nM";"4.75";"";"";"UO_0000065";"12.51";"0.23";"0.27";"7.10";"0";"CHEMBL2351468";"Inhibition of LRRK2 G2019S mutant (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348981";"";"None";"404.50";"0";"4.50";"48";"CCOC(=O)C(C)Sc1nn2c(-c3ccccc3)nnc2cc1-c1ccccc1";"IC50";"'>'";"100000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL2351468";"Inhibition of LRRK2 G2019S mutant (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348970";"";"None";"311.40";"0";"3.40";"36";"c1ccc(Sc2ccc3nnc(-c4cncs4)n3n2)cc1";"IC50";"'='";"141.0";"nM";"6.85";"";"";"UO_0000065";"22.00";"0.45";"3.45";"12.24";"0";"CHEMBL2351468";"Inhibition of LRRK2 G2019S mutant (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348953";"";"None";"406.82";"1";"5.61";"18";"FC(F)(F)c1cccc(Sc2ccc3nnc(-c4cccc(Cl)c4)n3n2)c1";"IC50";"'='";"51.0";"nM";"7.29";"";"";"UO_0000065";"17.93";"0.37";"1.68";"16.93";"0";"CHEMBL2351468";"Inhibition of LRRK2 G2019S mutant (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348937";"";"None";"320.40";"0";"2.51";"2, 38";"COC(=O)C(C)Sc1ccc2nnc(-c3cccs3)n2n1";"IC50";"'='";"200.0";"nM";"6.70";"";"";"UO_0000065";"20.91";"0.44";"4.19";"9.66";"0";"CHEMBL2351468";"Inhibition of LRRK2 G2019S mutant (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2349092";"";"None";"404.37";"0";"3.64";"55";"O=S(=O)(c1cccc(C(F)(F)F)c1)c1ccc2nnc(-c3ccccc3)n2n1";"IC50";"'='";"4730.0";"nM";"5.33";"";"";"UO_0000065";"13.17";"0.26";"1.69";"6.90";"0";"CHEMBL2351467";"Inhibition of wild type LRRK2 (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348970";"";"None";"311.40";"0";"3.40";"36";"c1ccc(Sc2ccc3nnc(-c4cncs4)n3n2)cc1";"IC50";"'='";"159.0";"nM";"6.80";"";"";"UO_0000065";"21.83";"0.44";"3.40";"12.15";"0";"CHEMBL2351467";"Inhibition of wild type LRRK2 (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348951";"";"None";"373.36";"0";"4.36";"16";"FC(F)(F)c1cccc(Sc2ccc3nnc(-c4ccncc4)n3n2)c1";"IC50";"'='";"859.0";"nM";"6.07";"";"";"UO_0000065";"16.25";"0.32";"1.71";"10.84";"0";"CHEMBL2351467";"Inhibition of wild type LRRK2 (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348950";"";"None";"373.36";"0";"4.36";"15";"FC(F)(F)c1cccc(Sc2ccc3nnc(-c4cccnc4)n3n2)c1";"IC50";"'='";"211.0";"nM";"6.68";"";"";"UO_0000065";"17.88";"0.35";"2.32";"11.93";"0";"CHEMBL2351467";"Inhibition of wild type LRRK2 (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348945";"";"None";"379.39";"0";"4.42";"10";"FC(F)(F)c1cccc(Sc2ccc3nnc(-c4cncs4)n3n2)c1";"IC50";"'='";"74.0";"nM";"7.13";"";"";"UO_0000065";"18.80";"0.39";"2.71";"12.74";"0";"CHEMBL2351467";"Inhibition of wild type LRRK2 (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348939";"";"None";"377.42";"1";"5.63";"4";"FC(F)(F)c1cccc(Sc2ccc3ncc(-c4cccs4)n3n2)c1";"IC50";"'='";"101.0";"nM";"7.00";"";"";"UO_0000065";"18.54";"0.38";"1.37";"23.17";"0";"CHEMBL2351467";"Inhibition of wild type LRRK2 (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL3393342";"";"None";"317.40";"0";"3.73";"8";"C[C@@H]1CCCN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)C1";"IC50";"'='";"171.0";"nM";"6.77";"";"";"UO_0000065";"21.32";"0.39";"3.04";"9.86";"0";"CHEMBL3395727";"Inhibition of GST-tagged truncated human recombinant LRRK2 G2019S mutant using fluorescein-labeled LRRKtide peptide substrate incubated for 90 mins";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3393349";"";"None";"318.38";"0";"2.25";"15";"CN1CCN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)CC1";"IC50";"'='";"1830.0";"nM";"5.74";"";"";"UO_0000065";"18.02";"0.33";"3.49";"7.99";"0";"CHEMBL3395726";"Inhibition of GST-tagged truncated human recombinant LRRK2 using fluorescein-labeled LRRKtide peptide substrate incubated for 2 hrs";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3326114";"";"None";"364.43";"0";"3.96";"1";"COc1ccc(OC)c(Sc2ccc3nnc(-c4ccccc4)n3n2)c1";"IC50";"'='";"82.0";"nM";"7.09";"";"";"UO_0000065";"19.44";"0.37";"3.13";"11.51";"0";"CHEMBL3368823";"Inhibition of LRRK2 G2019S mutant (unknown origin) using fluorescein-labeled peptide LRRKtide as substrate by LANTHA screen assay in presence of 1 mM ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL2347821";"";"None";"408.53";"0";"3.48";"4";"CC(C)Nc1c(C2=NCCN2)cnc2cc(-c3ccc(S(C)(=O)=O)cc3)ccc12";"IC50";"'='";"91856.0";"nM";"4.04";"";"";"UO_0000065";"9.88";"0.19";"0.56";"4.84";"0";"CHEMBL2352558";"Inhibition of wild type GST-tagged LRRK2 (970-2527 amino acids)(unknown origin) assessed as inhibition of LRRKtide phosphorylation by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346515";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2349091";"";"None";"388.37";"0";"3.98";"54";"[O-][S+](c1cccc(C(F)(F)F)c1)c1ccc2nnc(-c3ccccc3)n2n1";"IC50";"'='";"1230.0";"nM";"5.91";"";"";"UO_0000065";"15.22";"0.30";"1.93";"8.94";"0";"CHEMBL2351468";"Inhibition of LRRK2 G2019S mutant (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348980";"";"None";"392.43";"1";"5.33";"47";"Cc1cc(Sc2cccc(C(F)(F)F)c2)nn2c(-c3cccs3)nnc12";"IC50";"'>'";"4000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL2351468";"Inhibition of LRRK2 G2019S mutant (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348960";"";"None";"372.38";"0";"4.96";"26";"FC(F)(F)c1ccc(Sc2ccc3nnc(-c4ccccc4)n3n2)cc1";"IC50";"'='";"2026.0";"nM";"5.69";"";"";"UO_0000065";"15.29";"0.30";"0.73";"13.22";"0";"CHEMBL2351468";"Inhibition of LRRK2 G2019S mutant (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348973";"";"None";"320.40";"0";"2.51";"40";"COC(=O)[C@@H](C)Sc1ccc2nnc(-c3cccs3)n2n1";"IC50";"'='";"463.0";"nM";"6.33";"";"";"UO_0000065";"19.77";"0.41";"3.82";"9.13";"0";"CHEMBL2351467";"Inhibition of wild type LRRK2 (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348965";"";"None";"341.42";"0";"3.41";"31";"COc1cccc(Sc2ccc3nnc(-c4cncs4)n3n2)c1";"IC50";"'='";"138.0";"nM";"6.86";"";"";"UO_0000065";"20.09";"0.41";"3.45";"10.52";"0";"CHEMBL2351467";"Inhibition of wild type LRRK2 (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348959";"";"None";"392.43";"0";"4.95";"25";"FC(F)(F)c1cccc(Sc2ccc3nnc(Cc4cccs4)n3n2)c1";"IC50";"'>'";"20000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL2351467";"Inhibition of wild type LRRK2 (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348956";"";"None";"336.34";"0";"4.17";"21";"FC(F)(F)c1cccc(Sc2ccc3nnc(C4CC4)n3n2)c1";"IC50";"'='";"994.0";"nM";"6.00";"";"";"UO_0000065";"17.85";"0.36";"1.83";"13.93";"0";"CHEMBL2351467";"Inhibition of wild type LRRK2 (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2333113";"";"None";"333.40";"0";"3.00";"26";"C[C@@H](Nc1c(C(N)=O)nnc2cc(-c3ccncc3)ccc12)C1CC1";"IC50";"'='";"6.0";"nM";"8.22";"";"";"UO_0000065";"24.66";"0.45";"5.22";"8.77";"0";"CHEMBL2345527";"Inhibition of GST-tagged LRRK2 G2019S mutant (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2333136";"";"None";"342.38";"0";"1.38";"21";"CS(=O)(=O)c1ccc(-c2ccc3c(N)c(C(N)=O)nnc3c2)cc1";"IC50";"'='";"298.0";"nM";"6.53";"";"";"UO_0000065";"19.06";"0.37";"5.15";"5.06";"0";"CHEMBL2345527";"Inhibition of GST-tagged LRRK2 G2019S mutant (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2333134";"";"None";"412.47";"0";"2.00";"19";"CS(=O)(=O)c1ccc(-c2ccc3c(NC4CCOC4)c(C(N)=O)nnc3c2)cc1";"IC50";"'='";"53.0";"nM";"7.28";"";"";"UO_0000065";"17.64";"0.34";"5.28";"5.85";"0";"CHEMBL2345527";"Inhibition of GST-tagged LRRK2 G2019S mutant (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2333130";"";"None";"396.47";"0";"2.62";"15";"CS(=O)(=O)c1ccc(-c2ccc3c(NCC4CC4)c(C(N)=O)nnc3c2)cc1";"IC50";"'='";"27.0";"nM";"7.57";"";"";"UO_0000065";"19.09";"0.37";"4.95";"6.58";"0";"CHEMBL2345527";"Inhibition of GST-tagged LRRK2 G2019S mutant (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2333138";"";"None";"323.36";"0";"1.58";"23";"NC(=O)c1nnc2cc(-c3ccncc3)ccc2c1NCCCO";"IC50";"'='";"121.0";"nM";"6.92";"";"";"UO_0000065";"21.39";"0.39";"5.34";"6.07";"0";"CHEMBL2345528";"Inhibition of wild type GST-tagged LRRK2 (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL3912951";"";"None";"233.27";"0";"3.41";"18";"Cc1cccc(-c2ccnc3[nH]cc(C#N)c23)c1";"IC50";"'='";"170.0";"nM";"6.77";"";"";"UO_0000065";"29.02";"0.51";"3.36";"12.90";"1";"CHEMBL4031820";"Inhibition of wild type recombinant human GST-tagged LRRK2 (970 to 2527 residues) expressed in baculovirus using fluorescein-LRRKtide as substrate after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4077034";"";"None";"363.81";"0";"3.94";"33";"Cc1cc(-c2cc(Nc3nn(C)cc3Cl)nc3[nH]cc(C#N)c23)ccn1";"IC50";"'='";"180.0";"nM";"6.75";"";"";"UO_0000065";"18.54";"0.35";"2.80";"7.08";"0";"CHEMBL4031820";"Inhibition of wild type recombinant human GST-tagged LRRK2 (970 to 2527 residues) expressed in baculovirus using fluorescein-LRRKtide as substrate after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL3961632";"";"None";"248.29";"0";"2.99";"22";"Cc1cccc(-c2cc(N)nc3[nH]cc(C#N)c23)c1";"IC50";"'='";"467.74";"nM";"6.33";"";"";"UO_0000065";"25.49";"0.46";"3.34";"8.06";"0";"CHEMBL4031824";"Inhibition of human LRRK2 A2016T mutant phosphorylation at ser935 transfected in HEK293 cells after 48 hrs by in-cell Western assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"A2016T";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"CHEMBL3307715";"";"";""
"CHEMBL3933899";"";"None";"329.37";"0";"3.28";"26";"Cc1cncc(-c2cc(Nc3ccn(C)n3)nc3[nH]cc(C#N)c23)c1";"IC50";"'='";"70.0";"nM";"7.16";"";"";"UO_0000065";"21.72";"0.39";"3.87";"7.51";"0";"CHEMBL4031825";"Inhibition of human wild type LRRK2 phosphorylation at ser935 expressed in BacMam transduced HEK293 cells after 48 hrs by in-cell Western assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"CHEMBL3307715";"";"";""
"CHEMBL4063115";"";"None";"329.37";"0";"3.28";"27";"Cc1cc(-c2cc(Nc3ccn(C)n3)nc3[nH]cc(C#N)c23)ccn1";"IC50";"'='";"130.0";"nM";"6.89";"";"";"UO_0000065";"20.91";"0.38";"3.61";"7.23";"0";"CHEMBL4031826";"Inhibition of human LRRK2 G2019S mutant phosphorylation at ser935 expressed in BacMam transduced HEK293 cells after 48 hrs by in-cell Western assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"CHEMBL3307715";"";"";""
"CHEMBL3939513";"";"None";"314.35";"0";"3.58";"24";"Cn1ccc(Nc2cc(-c3ccccc3)c3c(C#N)c[nH]c3n2)n1";"IC50";"'='";"112.0";"nM";"6.95";"";"";"UO_0000065";"22.11";"0.40";"3.37";"8.44";"0";"CHEMBL4031821";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus using fluorescein-LRRKtide as substrate after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL3969077";"";"None";"328.38";"0";"3.89";"23";"Cc1cccc(-c2cc(Nc3ccn(C)n3)nc3[nH]cc(C#N)c23)c1";"IC50";"'='";"17.0";"nM";"7.77";"";"";"UO_0000065";"23.66";"0.42";"3.88";"9.44";"0";"CHEMBL4031825";"Inhibition of human wild type LRRK2 phosphorylation at ser935 expressed in BacMam transduced HEK293 cells after 48 hrs by in-cell Western assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"CHEMBL3307715";"";"";""
"CHEMBL4215437";"";"None";"265.70";"0";"1.33";"44, E:Z Mixture (26:74)";"O=C1Nc2ccc(Cl)cc2C1=NN1CCOCC1";"IC50";"'='";"1200.0";"nM";"5.92";"";"";"UO_0000065";"22.28";"0.45";"4.59";"10.98";"0";"CHEMBL4192178";"Inhibition of recombinant catalytic human GST-tagged LLRK2 (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4190250";"1";"Scientific Literature";"Eur J Med Chem";"2017";"None";"";"";""
"CHEMBL4207078";"";"None";"310.15";"0";"1.44";"47, E:Z Mixture (17:83)";"O=C1Nc2ccc(Br)cc2C1=NN1CCOCC1";"IC50";"'='";"1330.0";"nM";"5.88";"";"";"UO_0000065";"18.95";"0.45";"4.44";"10.90";"0";"CHEMBL4192178";"Inhibition of recombinant catalytic human GST-tagged LLRK2 (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4190250";"1";"Scientific Literature";"Eur J Med Chem";"2017";"None";"";"";""
"CHEMBL4094362";"";"None";"300.32";"0";"1.51";"13";"COc1cccc(Nc2nc(NCCO)c3nc[nH]c3n2)c1";"IC50";"'='";"48.0";"nM";"7.32";"";"";"UO_0000065";"24.37";"0.45";"5.81";"6.78";"0";"CHEMBL4018178";"Inhibition of LRRK2 G2019S mutant (unknown origin) using biotinylated ezrin/radaxin/meosin peptide as substrate measured after 1 hr";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4017473";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL4203258";"";"None";"308.18";"0";"2.59";"42, E:Z Mixture (21:79)";"O=C1Nc2ccc(Br)cc2C1=NN1CCCCC1";"IC50";"'='";"540.0";"nM";"6.27";"";"";"UO_0000065";"20.34";"0.48";"3.68";"14.02";"0";"CHEMBL4192179";"Inhibition of recombinant catalytic human GST-tagged LLRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4190250";"1";"Scientific Literature";"Eur J Med Chem";"2017";"None";"";"";""
"CHEMBL4210498";"";"None";"249.24";"0";"0.81";"45, E:Z Mixture (30:70)";"O=C1Nc2ccc(F)cc2C1=NN1CCOCC1";"IC50";"'='";"3650.0";"nM";"5.44";"";"";"UO_0000065";"21.82";"0.41";"4.63";"10.08";"0";"CHEMBL4192178";"Inhibition of recombinant catalytic human GST-tagged LLRK2 (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4190250";"1";"Scientific Literature";"Eur J Med Chem";"2017";"None";"";"";""
"CHEMBL3393359";"";"None";"306.33";"0";"1.73";"25";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)n1";"IC50";"'='";"298.0";"nM";"6.53";"";"";"UO_0000065";"21.30";"0.39";"4.80";"7.19";"0";"CHEMBL3395728";"Inhibition of full length LRRK2 (unknown origin) expressed in HEK293 cells assessed as reduction in S935 phosphorylation incubated for 90 mins by ELISA method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL3393348";"";"None";"305.34";"0";"2.33";"14";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"25.0";"nM";"7.60";"";"";"UO_0000065";"24.90";"0.45";"5.27";"9.77";"0";"CHEMBL3395728";"Inhibition of full length LRRK2 (unknown origin) expressed in HEK293 cells assessed as reduction in S935 phosphorylation incubated for 90 mins by ELISA method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL3393358";"";"None";"323.33";"0";"2.47";"24";"N#Cc1cc(F)cc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"688.0";"nM";"6.16";"";"";"UO_0000065";"19.06";"0.35";"3.69";"7.92";"0";"CHEMBL3395727";"Inhibition of GST-tagged truncated human recombinant LRRK2 G2019S mutant using fluorescein-labeled LRRKtide peptide substrate incubated for 90 mins";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3393348";"";"None";"305.34";"0";"2.33";"14";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"11.0";"nM";"7.96";"";"";"UO_0000065";"26.06";"0.47";"5.63";"10.23";"0";"CHEMBL3395727";"Inhibition of GST-tagged truncated human recombinant LRRK2 G2019S mutant using fluorescein-labeled LRRKtide peptide substrate incubated for 90 mins";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3393452";"";"None";"317.35";"0";"2.33";"41";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CC5(COC5)C4)c23)c1";"IC50";"'='";"2331.0";"nM";"5.63";"";"";"UO_0000065";"17.75";"0.32";"3.30";"7.24";"0";"CHEMBL3395726";"Inhibition of GST-tagged truncated human recombinant LRRK2 using fluorescein-labeled LRRKtide peptide substrate incubated for 2 hrs";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL4638880";"";"None";"473.58";"0";"3.65";"XMD10-47";"COc1cc(N2CCN(C)CC2)ccc1Nc1nc(C)c2c(n1)N(C)c1ccccc1C(=O)N2C";"IC50";"'='";"501.0";"nM";"6.30";"";"";"UO_0000065";"13.30";"0.25";"2.65";"8.17";"0";"CHEMBL4612965";"Inhibition of recombinant human GST-tagged LRRK2 catalytic domain (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate measured after 1 hr by Alexa fluor-647 ADP tracer-based ADAPTA assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4610122";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL4639395";"";"None";"527.55";"1";"4.27";"FMF-03-146-1; DCLK1-IN-1";"COc1cc(N2CCN(C)CC2)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2CC(F)(F)F";"IC50";"'='";"7000.0";"nM";"5.16";"";"";"UO_0000065";"9.77";"0.19";"0.88";"6.69";"0";"CHEMBL4612965";"Inhibition of recombinant human GST-tagged LRRK2 catalytic domain (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate measured after 1 hr by Alexa fluor-647 ADP tracer-based ADAPTA assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4610122";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL4635720";"";"None";"482.57";"0";"3.74";"FMF-03-150-2";"COc1cc(NS(C)(=O)=O)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2C(C)C";"IC50";"'='";"683.0";"nM";"6.17";"";"";"UO_0000065";"12.78";"0.25";"2.43";"5.28";"0";"CHEMBL4612965";"Inhibition of recombinant human GST-tagged LRRK2 catalytic domain (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate measured after 1 hr by Alexa fluor-647 ADP tracer-based ADAPTA assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4610122";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL2170016";"";"None";"377.83";"0";"2.40";"4, HG-10-102-01";"CNc1nc(Nc2ccc(C(=O)N3CCOCC3)cc2OC)ncc1Cl";"IC50";"'='";"153.7";"nM";"6.81";"";"";"UO_0000065";"18.03";"0.36";"4.41";"7.69";"0";"CHEMBL2173830";"Inhibition of LRRK2 A2016T mutant expressed in HEK293 cells using nictide as substrate and [gamma32P]ATP after 15 mins by Cerenkov counting method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"A2016T";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169803";"1";"Scientific Literature";"ACS Med Chem Lett";"2012";"CHEMBL3307715";"";"";""
"CHEMBL2348981";"";"None";"404.50";"0";"4.50";"48";"CCOC(=O)C(C)Sc1nn2c(-c3ccccc3)nnc2cc1-c1ccccc1";"IC50";"'>'";"100000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL2351467";"Inhibition of wild type LRRK2 (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348975";"";"None";"333.44";"0";"2.45";"42";"CC(C)C(Sc1ccc2nnc(-c3cccs3)n2n1)C(N)=O";"IC50";"'='";"1294.0";"nM";"5.89";"";"";"UO_0000065";"17.66";"0.37";"3.44";"6.83";"0";"CHEMBL2351467";"Inhibition of wild type LRRK2 (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2333127";"";"None";"398.49";"0";"3.01";"12";"CC[C@@H](C)Nc1c(C(N)=O)nnc2cc(-c3ccc(S(C)(=O)=O)cc3)ccc12";"IC50";"'='";"4.0";"nM";"8.40";"";"";"UO_0000065";"21.07";"0.41";"5.39";"7.30";"0";"CHEMBL2345527";"Inhibition of GST-tagged LRRK2 G2019S mutant (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2333137";"";"None";"446.53";"0";"3.97";"22";"C[C@@H](Nc1c(C(N)=O)nnc2cc(-c3ccc(S(C)(=O)=O)cc3)ccc12)c1ccccc1";"IC50";"'='";"965.0";"nM";"6.01";"";"";"UO_0000065";"13.47";"0.26";"2.05";"5.23";"0";"CHEMBL2345528";"Inhibition of wild type GST-tagged LRRK2 (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL570013";"";"None";"267.24";"0";"2.67";"12, E:Z Mixture (64:36)";"O=C1Nc2ccccc2/C1=N/c1ccc([N+](=O)[O-])cc1";"IC50";"'='";"7270.0";"nM";"5.14";"";"";"UO_0000065";"19.23";"0.35";"2.47";"6.07";"0";"CHEMBL4192178";"Inhibition of recombinant catalytic human GST-tagged LLRK2 (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4190250";"1";"Scientific Literature";"Eur J Med Chem";"2017";"None";"";"";""
"CHEMBL4205499";"";"None";"327.39";"0";"4.05";"21, E:Z Mixture (44:56)";"O=C1Nc2ccccc2C1=NN(Cc1ccccc1)c1ccccc1";"IC50";"'='";"3830.0";"nM";"5.42";"";"";"UO_0000065";"16.55";"0.30";"1.37";"12.12";"0";"CHEMBL4192178";"Inhibition of recombinant catalytic human GST-tagged LLRK2 (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4190250";"1";"Scientific Literature";"Eur J Med Chem";"2017";"None";"";"";""
"CHEMBL4088961";"";"None";"253.69";"0";"3.75";"15";"N#Cc1c[nH]c2nccc(-c3cccc(Cl)c3)c12";"IC50";"'='";"784.0";"nM";"6.11";"";"";"UO_0000065";"24.07";"0.46";"2.36";"11.64";"0";"CHEMBL4031820";"Inhibition of wild type recombinant human GST-tagged LRRK2 (970 to 2527 residues) expressed in baculovirus using fluorescein-LRRKtide as substrate after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL3969077";"";"None";"328.38";"0";"3.89";"23";"Cc1cccc(-c2cc(Nc3ccn(C)n3)nc3[nH]cc(C#N)c23)c1";"IC50";"'='";"3.0";"nM";"8.52";"";"";"UO_0000065";"25.95";"0.47";"4.63";"10.35";"0";"CHEMBL4031820";"Inhibition of wild type recombinant human GST-tagged LRRK2 (970 to 2527 residues) expressed in baculovirus using fluorescein-LRRKtide as substrate after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4068861";"";"None";"235.25";"0";"2.81";"9";"N#Cc1c[nH]c2nccc(-c3cccc(O)c3)c12";"IC50";"'='";"415.0";"nM";"6.38";"";"";"UO_0000065";"27.13";"0.48";"3.57";"8.78";"0";"CHEMBL4031821";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus using fluorescein-LRRKtide as substrate after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4088961";"";"None";"253.69";"0";"3.75";"15";"N#Cc1c[nH]c2nccc(-c3cccc(Cl)c3)c12";"IC50";"'='";"1275.0";"nM";"5.89";"";"";"UO_0000065";"23.24";"0.45";"2.14";"11.23";"0";"CHEMBL4031821";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus using fluorescein-LRRKtide as substrate after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4066167";"";"None";"253.69";"0";"3.75";"16";"N#Cc1c[nH]c2nccc(-c3ccc(Cl)cc3)c12";"IC50";"'='";"1983.0";"nM";"5.70";"";"";"UO_0000065";"22.48";"0.43";"1.95";"10.87";"0";"CHEMBL4031821";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus using fluorescein-LRRKtide as substrate after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4075407";"";"None";"233.27";"0";"3.41";"19";"Cc1ccc(-c2ccnc3[nH]cc(C#N)c23)cc1";"IC50";"'='";"1639.0";"nM";"5.79";"";"";"UO_0000065";"24.80";"0.44";"2.38";"11.03";"0";"CHEMBL4031821";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus using fluorescein-LRRKtide as substrate after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL3961632";"";"None";"248.29";"0";"2.99";"22";"Cc1cccc(-c2cc(N)nc3[nH]cc(C#N)c23)c1";"IC50";"'='";"33.0";"nM";"7.48";"";"";"UO_0000065";"30.13";"0.54";"4.49";"9.53";"0";"CHEMBL4031821";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus using fluorescein-LRRKtide as substrate after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL3919901";"";"None";"377.45";"0";"3.09";"34";"Nc1ncc(-c2ccc(CN3CCOCC3)cc2)cc1-c1nnc(C2CC2)o1";"IC50";"'='";"390.0";"nM";"6.41";"";"";"UO_0000065";"16.98";"0.31";"3.32";"7.10";"1";"CHEMBL4045603";"Inhibition of recombinant human LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus preincubated for 30 mins followed by fluorescein-LRRKtide substrate addition after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4043168";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL3949980";"";"None";"332.41";"0";"3.66";"41";"CC(C)n1cc(-c2cc(-c3ccc4c(ccn4C)c3)cnc2N)nn1";"IC50";"'='";"540.0";"nM";"6.27";"";"";"UO_0000065";"18.86";"0.34";"2.61";"8.41";"1";"CHEMBL4045603";"Inhibition of recombinant human LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus preincubated for 30 mins followed by fluorescein-LRRKtide substrate addition after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4043168";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL3393450";"";"None";"387.40";"0";"2.77";"39";"Cc1nc([C@H]2CN(c3ncnc4[nH]cc(-c5cccc(C#N)c5)c34)CCO2)no1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL3395728";"Inhibition of full length LRRK2 (unknown origin) expressed in HEK293 cells assessed as reduction in S935 phosphorylation incubated for 90 mins by ELISA method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL3393449";"";"None";"387.40";"0";"2.77";"38";"Cc1nc([C@@H]2CN(c3ncnc4[nH]cc(-c5cccc(C#N)c5)c34)CCO2)no1";"IC50";"'='";"133.0";"nM";"6.88";"";"";"UO_0000065";"17.75";"0.32";"4.11";"5.89";"0";"CHEMBL3395728";"Inhibition of full length LRRK2 (unknown origin) expressed in HEK293 cells assessed as reduction in S935 phosphorylation incubated for 90 mins by ELISA method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL3393353";"";"None";"280.33";"0";"2.46";"19";"c1ccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)cc1";"IC50";"'='";"14.0";"nM";"7.85";"";"";"UO_0000065";"28.02";"0.51";"5.39";"14.53";"0";"CHEMBL3395727";"Inhibition of GST-tagged truncated human recombinant LRRK2 G2019S mutant using fluorescein-labeled LRRKtide peptide substrate incubated for 90 mins";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3393451";"";"None";"319.37";"0";"2.72";"40";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCCOCC4)c23)c1";"IC50";"'='";"111.0";"nM";"6.96";"";"";"UO_0000065";"21.78";"0.40";"4.23";"8.94";"0";"CHEMBL3395726";"Inhibition of GST-tagged truncated human recombinant LRRK2 using fluorescein-labeled LRRKtide peptide substrate incubated for 2 hrs";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3393447";"";"None";"372.39";"0";"3.06";"36";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCOC(c5ccno5)C4)c23)c1";"IC50";"'='";"37.0";"nM";"7.43";"";"";"UO_0000065";"19.96";"0.36";"4.37";"7.16";"0";"CHEMBL3395726";"Inhibition of GST-tagged truncated human recombinant LRRK2 using fluorescein-labeled LRRKtide peptide substrate incubated for 2 hrs";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL2347827";"";"None";"308.41";"0";"4.36";"17";"Cc1ncc(-c2ccc3c(NC(C)C)c(C#N)cnc3c2)s1";"IC50";"'='";"23.0";"nM";"7.64";"";"";"UO_0000065";"24.77";"0.47";"3.28";"12.40";"0";"CHEMBL2352558";"Inhibition of wild type GST-tagged LRRK2 (970-2527 amino acids)(unknown origin) assessed as inhibition of LRRKtide phosphorylation by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346515";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348937";"";"None";"320.40";"0";"2.51";"2, 38";"COC(=O)C(C)Sc1ccc2nnc(-c3cccs3)n2n1";"IC50";"'='";"535.0";"nM";"6.27";"";"";"UO_0000065";"19.57";"0.41";"3.76";"9.04";"0";"CHEMBL2351467";"Inhibition of wild type LRRK2 (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2347815";"";"None";"374.43";"0";"3.36";"29";"CS(=O)(=O)c1ccc(-c2ccc3c(-n4ccnc4)c(C#N)cnc3c2)cc1";"IC50";"'='";"498.0";"nM";"6.30";"";"";"UO_0000065";"16.83";"0.32";"2.94";"7.11";"0";"CHEMBL2352557";"Inhibition of GST-tagged LRRK2 G2019S mutant (970-2527 amino acids) (unknown origin) assessed as inhibition of LRRKtide phosphorylation by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346515";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2347806";"";"None";"366.45";"0";"3.39";"20";"CC(C)Nc1c(C#N)cnc2cc(-c3ccc(S(C)(=O)=O)nc3)ccc12";"IC50";"'='";"48.0";"nM";"7.32";"";"";"UO_0000065";"19.97";"0.38";"3.93";"7.64";"0";"CHEMBL2352557";"Inhibition of GST-tagged LRRK2 G2019S mutant (970-2527 amino acids) (unknown origin) assessed as inhibition of LRRKtide phosphorylation by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346515";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2347804";"";"None";"420.54";"0";"4.38";"18";"CC(C)Nc1c(C#N)cnc2cc(-c3ccc(S(=O)(=O)N4CCCC4)cc3)ccc12";"IC50";"'='";"12.0";"nM";"7.92";"";"";"UO_0000065";"18.83";"0.36";"3.54";"9.20";"0";"CHEMBL2352558";"Inhibition of wild type GST-tagged LRRK2 (970-2527 amino acids)(unknown origin) assessed as inhibition of LRRKtide phosphorylation by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346515";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL4440433";"";"None";"230.31";"0";"3.01";"9";"Cc1n[nH]c2ccnc(NC3CCCCC3)c12";"IC50";"'='";"390.0";"nM";"6.41";"";"";"UO_0000065";"27.83";"0.51";"3.40";"11.96";"0";"CHEMBL4331900";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant catalytic domain (970 to 2527 residues) expressed in baculovirus expression system by radiometric assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330096";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4537851";"";"None";"218.26";"0";"1.10";"8";"Cc1n[nH]c2ccnc(N3CCOCC3)c12";"IC50";"'='";"3000.0";"nM";"5.52";"";"";"UO_0000065";"25.30";"0.47";"4.42";"10.22";"0";"CHEMBL4331900";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant catalytic domain (970 to 2527 residues) expressed in baculovirus expression system by radiometric assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330096";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4566553";"";"None";"238.29";"0";"3.32";"3";"Cc1ccc(Nc2nccc3[nH]nc(C)c23)cc1";"IC50";"'='";"97.0";"nM";"7.01";"";"";"UO_0000065";"29.43";"0.53";"3.69";"13.08";"0";"CHEMBL4331900";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant catalytic domain (970 to 2527 residues) expressed in baculovirus expression system by radiometric assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330096";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4536900";"";"None";"272.74";"0";"3.53";"1";"Cc1n[nH]c2ccnc(NCc3ccc(Cl)cc3)c12";"IC50";"'='";"4900.0";"nM";"5.31";"";"";"UO_0000065";"19.47";"0.38";"1.78";"9.91";"0";"CHEMBL4331900";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant catalytic domain (970 to 2527 residues) expressed in baculovirus expression system by radiometric assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330096";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL2347818";"";"None";"396.45";"0";"4.73";"32";"C[C@@H](Nc1c(C#N)cnc2cc(-c3ccc(-n4ccoc4=O)cc3)ccc12)C1CC1";"IC50";"'='";"27.0";"nM";"7.57";"";"";"UO_0000065";"19.09";"0.34";"2.84";"9.03";"0";"CHEMBL2352557";"Inhibition of GST-tagged LRRK2 G2019S mutant (970-2527 amino acids) (unknown origin) assessed as inhibition of LRRKtide phosphorylation by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346515";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2347810";"";"None";"363.44";"0";"3.39";"24";"CS(=O)(=O)c1ccc(-c2ccc3c(N4CCC4)c(C#N)cnc3c2)cc1";"IC50";"'='";"14.0";"nM";"7.85";"";"";"UO_0000065";"21.61";"0.41";"4.46";"10.60";"0";"CHEMBL2352557";"Inhibition of GST-tagged LRRK2 G2019S mutant (970-2527 amino acids) (unknown origin) assessed as inhibition of LRRKtide phosphorylation by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346515";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2347825";"";"None";"380.47";"0";"3.50";"15";"CNS(=O)(=O)c1ccc(-c2ccc3c(NC(C)C)c(C#N)cnc3c2)cc1";"IC50";"'='";"6.0";"nM";"8.22";"";"";"UO_0000065";"21.61";"0.42";"4.72";"8.67";"0";"CHEMBL2352557";"Inhibition of GST-tagged LRRK2 G2019S mutant (970-2527 amino acids) (unknown origin) assessed as inhibition of LRRKtide phosphorylation by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346515";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348975";"";"None";"333.44";"0";"2.45";"42";"CC(C)C(Sc1ccc2nnc(-c3cccs3)n2n1)C(N)=O";"IC50";"'='";"581.0";"nM";"6.24";"";"";"UO_0000065";"18.70";"0.39";"3.79";"7.24";"0";"CHEMBL2351468";"Inhibition of LRRK2 G2019S mutant (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348936";"";"None";"372.38";"0";"4.96";"1";"FC(F)(F)c1cccc(Sc2ccc3nnc(-c4ccccc4)n3n2)c1";"IC50";"'='";"50.0";"nM";"7.30";"";"";"UO_0000065";"19.61";"0.38";"2.34";"16.95";"0";"CHEMBL2351468";"Inhibition of LRRK2 G2019S mutant (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348944";"";"None";"362.34";"0";"3.68";"9";"FC(F)(F)c1cccc(Sc2ccc3nnc(-c4ccn[nH]4)n3n2)c1";"IC50";"'='";"53.0";"nM";"7.28";"";"";"UO_0000065";"20.08";"0.40";"3.60";"10.14";"0";"CHEMBL2351467";"Inhibition of wild type LRRK2 (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL4444153";"";"None";"325.42";"0";"4.11";"31";"CC(C)n1cc(-c2n[nH]c3ccnc(OC4CCCCC4)c23)cn1";"IC50";"'='";"2.0";"nM";"8.70";"";"";"UO_0000065";"26.73";"0.50";"4.59";"12.68";"0";"CHEMBL4331900";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant catalytic domain (970 to 2527 residues) expressed in baculovirus expression system by radiometric assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330096";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4589022";"";"None";"327.39";"0";"2.96";"32";"CC(C)n1cc(-c2n[nH]c3ccnc(OC4CCOCC4)c23)cn1";"IC50";"'='";"11.0";"nM";"7.96";"";"";"UO_0000065";"24.31";"0.45";"5.00";"10.22";"0";"CHEMBL4331900";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant catalytic domain (970 to 2527 residues) expressed in baculovirus expression system by radiometric assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330096";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4561299";"";"None";"341.42";"0";"3.04";"34";"CC(C)Cn1cc(-c2n[nH]c3ccnc(OC4CCOCC4)c23)cn1";"IC50";"'='";"15.0";"nM";"7.82";"";"";"UO_0000065";"22.92";"0.43";"4.78";"10.05";"0";"CHEMBL4331900";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant catalytic domain (970 to 2527 residues) expressed in baculovirus expression system by radiometric assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330096";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4204350";"";"None";"347.80";"0";"4.83";"33, E:Z Mixture (85:15)";"O=C1Nc2ccc(Cl)cc2C1=NN(c1ccccc1)c1ccccc1";"IC50";"'='";"10.0";"nM";"8.00";"";"";"UO_0000065";"23.00";"0.44";"3.17";"17.90";"0";"CHEMBL4192178";"Inhibition of recombinant catalytic human GST-tagged LLRK2 (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4190250";"1";"Scientific Literature";"Eur J Med Chem";"2017";"None";"";"";""
"CHEMBL4641263";"";"None";"522.51";"1";"3.89";"FMF-03-147-1 P2";"COc1cc(NS(C)(=O)=O)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2CC(F)(F)F";"IC50";"'='";"8894.0";"nM";"5.05";"";"";"UO_0000065";"9.67";"0.19";"1.16";"4.33";"0";"CHEMBL4612965";"Inhibition of recombinant human GST-tagged LRRK2 catalytic domain (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate measured after 1 hr by Alexa fluor-647 ADP tracer-based ADAPTA assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4610122";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL2348949";"";"None";"373.36";"0";"4.36";"14";"FC(F)(F)c1cccc(Sc2ccc3nnc(-c4ccccn4)n3n2)c1";"IC50";"'='";"45.0";"nM";"7.35";"";"";"UO_0000065";"19.68";"0.39";"2.99";"13.13";"0";"CHEMBL2351468";"Inhibition of LRRK2 G2019S mutant (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348955";"";"None";"390.37";"1";"5.10";"20";"Fc1ccc(-c2nnc3ccc(Sc4cccc(C(F)(F)F)c4)nn23)cc1";"IC50";"'='";"674.0";"nM";"6.17";"";"";"UO_0000065";"15.81";"0.31";"1.07";"14.33";"0";"CHEMBL2351467";"Inhibition of wild type LRRK2 (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348948";"";"None";"457.30";"1";"5.79";"13";"FC(F)(F)c1cccc(Sc2ccc3nnc(-c4sccc4Br)n3n2)c1";"IC50";"'='";"613.0";"nM";"6.21";"";"";"UO_0000065";"13.59";"0.33";"0.42";"14.42";"0";"CHEMBL2351467";"Inhibition of wild type LRRK2 (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2333117";"";"None";"310.36";"0";"1.95";"30";"CC(C)Nc1c(C(N)=O)nnc2ccc(-c3cnn(C)c3)cc12";"IC50";"'='";"425.0";"nM";"6.37";"";"";"UO_0000065";"20.53";"0.38";"4.42";"6.45";"0";"CHEMBL2345527";"Inhibition of GST-tagged LRRK2 G2019S mutant (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2333132";"";"None";"426.50";"0";"2.39";"17";"CS(=O)(=O)c1ccc(-c2ccc3c(NC4CCOCC4)c(C(N)=O)nnc3c2)cc1";"IC50";"'='";"32.0";"nM";"7.50";"";"";"UO_0000065";"17.57";"0.34";"5.10";"6.03";"0";"CHEMBL2345527";"Inhibition of GST-tagged LRRK2 G2019S mutant (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL4100265";"";"None";"363.81";"0";"3.94";"32";"Cc1cncc(-c2cc(Nc3nn(C)cc3Cl)nc3[nH]cc(C#N)c23)c1";"IC50";"'='";"190.0";"nM";"6.72";"";"";"UO_0000065";"18.47";"0.35";"2.78";"7.06";"0";"CHEMBL4031826";"Inhibition of human LRRK2 G2019S mutant phosphorylation at ser935 expressed in BacMam transduced HEK293 cells after 48 hrs by in-cell Western assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"CHEMBL3307715";"";"";""
"CHEMBL4205499";"";"None";"327.39";"0";"4.05";"21, E:Z Mixture (44:56)";"O=C1Nc2ccccc2C1=NN(Cc1ccccc1)c1ccccc1";"IC50";"'='";"3670.0";"nM";"5.43";"";"";"UO_0000065";"16.60";"0.30";"1.39";"12.16";"0";"CHEMBL4192179";"Inhibition of recombinant catalytic human GST-tagged LLRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4190250";"1";"Scientific Literature";"Eur J Med Chem";"2017";"None";"";"";""
"CHEMBL2403366";"";"None";"366.42";"0";"1.75";"2";"COc1ccc2c(c1)/C(=C/c1cc3c([nH]1)CCN(C(=O)CCN)C3)C(=O)N2";"IC50";"'='";"11.0";"nM";"7.96";"";"";"UO_0000065";"21.72";"0.40";"6.21";"7.92";"0";"CHEMBL2406186";"Inhibition of human LRRK2 (1885 to 2132) using 5-Fluo-Ahx-RLGRDKYKTLRQIRQGNTK-OH as substrate after 60 mins by fluorescence assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2401634";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL1673046";"";"None";"474.57";"0";"3.94";"XMD8-92";"CCOc1cc(N2CCC(O)CC2)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2C";"IC50";"'='";"46.0";"nM";"7.34";"";"";"UO_0000065";"15.46";"0.29";"3.40";"7.80";"0";"CHEMBL4612965";"Inhibition of recombinant human GST-tagged LRRK2 catalytic domain (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate measured after 1 hr by Alexa fluor-647 ADP tracer-based ADAPTA assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4610122";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL3904942";"";"None";"410.46";"0";"2.23";"XMD17-78";"CN1C(=O)c2ccccc2N(C)c2nc(Nc3cccc(S(N)(=O)=O)c3)ncc21";"IC50";"'='";"6.1";"nM";"8.21";"";"";"UO_0000065";"20.01";"0.39";"5.98";"6.76";"0";"CHEMBL4612965";"Inhibition of recombinant human GST-tagged LRRK2 catalytic domain (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate measured after 1 hr by Alexa fluor-647 ADP tracer-based ADAPTA assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4610122";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL2436983";"";"None";"326.36";"0";"3.75";"11";"Nc1ncc(-c2cnc3[nH]cc(-c4ccc5[nH]ccc5c4)c3c2)cn1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL2439119";"Inhibition of human wild type LRRK2 by qPCR analysis";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2434948";"1";"Scientific Literature";"J Med Chem";"2013";"None";"";"";""
"CHEMBL3891016";"";"None";"411.47";"0";"3.57";"BDBM239497";"C[C@@H]1CN(c2cc(-c3n[nH]c4ccc(-c5ccnc(C#N)c5)cc34)ncn2)C[C@H](C)O1";"IC50";"'='";"171.7";"nM";"6.76";"";"417962";"UO_0000065";"16.44";"0.30";"3.20";"6.53";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3923796";"";"None";"381.39";"0";"3.65";"BDBM239523";"FC1(F)CCN(c2cc(-c3n[nH]c4ccc(-c5cn[nH]c5)cc34)ncn2)CC1";"IC50";"'='";"5.69";"nM";"8.24";"";"417986";"UO_0000065";"21.62";"0.40";"4.59";"9.54";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3932649";"";"None";"347.38";"0";"2.25";"BDBM239530";"c1cc(-c2ccc3[nH]nc(-c4cc(N5CCOCC5)ncn4)c3c2)[nH]n1";"IC50";"'='";"2.63";"nM";"8.58";"";"417993";"UO_0000065";"24.70";"0.45";"6.33";"8.97";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3931365";"";"None";"369.43";"0";"2.00";"BDBM239192";"CO[C@H]1CN(c2cc(-c3n[nH]c4ccc(OC(C)C)cc34)ncn2)C[C@@H]1O";"IC50";"'='";"9.9";"nM";"8.00";"";"417650";"UO_0000065";"21.67";"0.40";"6.00";"8.30";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3983779";"";"None";"378.48";"0";"3.09";"BDBM239199";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCN(C5CC5)CC4)ncn3)c2c1";"IC50";"'='";"8.28";"nM";"8.08";"";"417659";"UO_0000065";"21.35";"0.39";"4.99";"11.52";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3944850";"";"None";"353.43";"0";"3.03";"BDBM239201";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCOCC4C)ncn3)c2c1";"IC50";"'='";"9.82";"nM";"8.01";"";"417662";"UO_0000065";"22.66";"0.42";"4.98";"10.51";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4114530";"";"None";"353.43";"0";"3.03";"BDBM239216";"CO[C@@H]1CCN(c2cc(-c3n[nH]c4ccc(OC(C)C)cc34)ncn2)C1";"IC50";"'='";"7.47";"nM";"8.13";"";"417677";"UO_0000065";"22.99";"0.43";"5.10";"10.67";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3952806";"";"None";"402.48";"0";"1.50";"BDBM239271";"CCOc1ccc2[nH]nc(-c3cc(N4CCN(S(C)(=O)=O)CC4)ncn3)c2c1";"IC50";"'='";"15.38";"nM";"7.81";"";"417730";"UO_0000065";"19.41";"0.38";"6.31";"7.49";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3901531";"";"None";"352.40";"0";"1.70";"BDBM239277";"CCOc1ccc2[nH]nc(-c3cc(N4CCN(C)C(=O)C4)ncn3)c2c1";"IC50";"'='";"37.13";"nM";"7.43";"";"417736";"UO_0000065";"21.08";"0.39";"5.73";"8.52";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3920983";"";"None";"396.45";"0";"1.71";"BDBM239292";"CCN1CCN(c2cc(-c3n[nH]c4ccc(OCCOC)cc34)ncn2)CC1=O";"IC50";"'='";"107.1";"nM";"6.97";"";"417751";"UO_0000065";"17.58";"0.33";"5.26";"7.23";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3964546";"";"None";"450.54";"0";"2.88";"BDBM239310";"COC[C@H](C)Oc1ccc2[nH]nc(-c3cc(N4CCC5(CCN(C)C5=O)CC4)ncn3)c2c1";"IC50";"'='";"3.71";"nM";"8.43";"";"417770";"UO_0000065";"18.71";"0.35";"5.55";"8.74";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3971726";"";"None";"383.45";"0";"2.66";"BDBM239307";"COC[C@H](C)Oc1ccc2[nH]nc(-c3cc(N4CC[C@@H](OC)C4)ncn3)c2c1";"IC50";"'='";"4.8";"nM";"8.32";"";"417776";"UO_0000065";"21.69";"0.41";"5.66";"9.74";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4111097";"";"None";"395.42";"0";"3.36";"BDBM239365";"Cn1cc(-c2cc3c(-c4cc(N5CC[C@H](CF)C5)ncn4)n[nH]c3cc2F)cn1";"IC50";"'='";"13.6";"nM";"7.87";"";"417832";"UO_0000065";"19.89";"0.37";"4.51";"10.42";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3965207";"";"None";"407.45";"0";"2.91";"BDBM239370";"Cn1cc(-c2cc3c(-c4cc(N5CCCC(C)(O)C5)ncn4)n[nH]c3cc2F)cn1";"IC50";"'='";"67.5";"nM";"7.17";"";"417837";"UO_0000065";"17.60";"0.33";"4.26";"7.49";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3893775";"";"None";"418.48";"0";"2.84";"BDBM239374";"Cn1cc(-c2cc3c(-c4cc(N5CCN(C6CC6)CC5)ncn4)n[nH]c3cc2F)cn1";"IC50";"'='";"17.7";"nM";"7.75";"";"417841";"UO_0000065";"18.52";"0.34";"4.91";"9.84";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4107319";"";"None";"422.47";"0";"1.67";"BDBM239384";"CN(C)[C@@H]1CN(c2cc(-c3n[nH]c4cc(F)c(-c5cnn(C)c5)cc34)ncn2)C[C@H]1O";"IC50";"'='";"67.1";"nM";"7.17";"";"417851";"UO_0000065";"16.98";"0.32";"5.50";"7.25";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3962905";"";"None";"407.45";"0";"2.72";"BDBM239414";"Cn1cc(-c2ccc3[nH]nc(-c4cc(N5CCC(F)(CO)CC5)ncn4)c3c2)cn1";"IC50";"'='";"2.9";"nM";"8.54";"";"417880";"UO_0000065";"20.95";"0.39";"5.82";"8.92";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4106457";"";"None";"371.42";"0";"2.76";"BDBM239426";"CC(C)Oc1cc2c(-c3cc(N4CC[C@@H](CO)C4)ncn3)n[nH]c2cc1F";"IC50";"'='";"2.9";"nM";"8.54";"";"417892";"UO_0000065";"22.99";"0.43";"5.78";"9.80";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3896174";"";"None";"408.51";"0";"2.72";"BDBM239456";"COC[C@H](C)Oc1ccc2[nH]nc(-c3cc(N4CCN(C5CC5)CC4)ncn3)c2c1";"IC50";"'='";"4.1";"nM";"8.39";"";"417921";"UO_0000065";"20.53";"0.38";"5.67";"10.56";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3934457";"";"None";"369.43";"0";"3.60";"BDBM185393";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCCC(c5cc[nH]n5)C4)c23)c1";"IC50";"'='";"84.0";"nM";"7.08";"";"334357";"UO_0000065";"19.15";"0.35";"3.48";"7.27";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3968012";"";"None";"281.29";"0";"2.70";"BDBM185429";"CN(C)c1ncnc2[nH]cc(-c3cc(F)cc(C#N)c3)c12";"IC50";"'='";"396.0";"nM";"6.40";"";"334606";"UO_0000065";"22.76";"0.42";"3.70";"9.33";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3935730";"";"None";"387.40";"0";"2.77";"BDBM185459";"Cc1nc(C2CN(c3ncnc4[nH]cc(-c5cccc(C#N)c5)c34)CCO2)no1";"IC50";"'='";"41.0";"nM";"7.39";"";"334643";"UO_0000065";"19.07";"0.35";"4.62";"6.33";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3911449";"";"None";"397.44";"0";"3.78";"BDBM185481";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCOC(c5cccc(O)c5)C4)c23)c1";"IC50";"'='";"281.0";"nM";"6.55";"";"334665";"UO_0000065";"16.48";"0.30";"2.77";"6.68";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3975562";"";"None";"331.38";"0";"2.72";"BDBM185547";"N#Cc1cccc(-c2c[nH]c3ncnc(N4C[C@@H]5CCO[C@@H]5C4)c23)c1";"IC50";"'='";"139.0";"nM";"6.86";"";"334517";"UO_0000065";"20.69";"0.37";"4.14";"8.81";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3969635";"";"None";"333.40";"0";"3.11";"BDBM185551";"CC1(C)CN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)CCO1";"IC50";"'='";"35.2";"nM";"7.45";"";"334521";"UO_0000065";"22.36";"0.41";"4.34";"9.58";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3906208";"";"None";"308.35";"0";"1.67";"BDBM185558";"Cn1cc(-c2c[nH]c3ncnc(N4CCOCC4)c23)cc1C#N";"IC50";"'='";"6.37";"nM";"8.20";"";"334527";"UO_0000065";"26.58";"0.49";"6.53";"9.90";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3916251";"";"None";"293.33";"0";"3.25";"BDBM185381";"[C-]#[N+]c1ccc(OC)c(-c2c[nH]c3ncnc(N(C)C)c23)c1";"IC50";"'='";"30.0";"nM";"7.52";"";"334554";"UO_0000065";"25.65";"0.47";"4.27";"12.88";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3942403";"";"None";"348.41";"0";"2.24";"BDBM185398";"N#Cc1cccc(-c2c[nH]c3ncnc(NCCN4CCOCC4)c23)c1";"IC50";"'='";"487.0";"nM";"6.31";"";"334573";"UO_0000065";"18.12";"0.33";"4.07";"7.02";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL2403370";"";"None";"408.46";"0";"2.33";"6";"COc1ccc2c(c1)/C(=C/c1cc3c([nH]1)CCN(C(=O)N1CCOCC1)C3)C(=O)N2";"IC50";"'='";"3.0";"nM";"8.52";"";"";"UO_0000065";"20.87";"0.39";"6.19";"9.81";"0";"CHEMBL2406186";"Inhibition of human LRRK2 (1885 to 2132) using 5-Fluo-Ahx-RLGRDKYKTLRQIRQGNTK-OH as substrate after 60 mins by fluorescence assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2401634";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2403365";"";"None";"368.44";"0";"2.21";"1";"COc1ccc2c(c1)/C(=C/c1[nH]c(C)c(C(=O)NCCCN)c1C)C(=O)N2";"IC50";"'='";"46.0";"nM";"7.34";"";"";"UO_0000065";"19.91";"0.37";"5.13";"6.72";"0";"CHEMBL2406186";"Inhibition of human LRRK2 (1885 to 2132) using 5-Fluo-Ahx-RLGRDKYKTLRQIRQGNTK-OH as substrate after 60 mins by fluorescence assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2401634";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL3326152";"";"None";"381.46";"0";"3.61";"40";"COc1ccc(OC)c(Sc2ccc3nc(C)c(-c4cnn(C)c4)n3n2)c1";"IC50";"'='";"945.0";"nM";"6.03";"";"";"UO_0000065";"15.79";"0.30";"2.41";"9.06";"0";"CHEMBL3367451";"Inhibition of phosphorylation at S935 residue of wild-type full-length LRRK2 kinase (unknown origin) expressed in HEK 293 cells after 90 mins by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"CHEMBL3307715";"";"";""
"CHEMBL2403373";"";"None";"490.61";"0";"2.82";"9";"CN1CCC(Nc2ccc3c(c2)/C(=C/c2cc4c([nH]2)CCN(C(=O)N2CCOCC2)C4)C(=O)N3)CC1";"IC50";"'<'";"3.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL2406186";"Inhibition of human LRRK2 (1885 to 2132) using 5-Fluo-Ahx-RLGRDKYKTLRQIRQGNTK-OH as substrate after 60 mins by fluorescence assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2401634";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2381340";"";"None";"638.82";"2";"5.14";"XMD17-109; ERK5-IN-1";"CCOc1cc(C(=O)N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc2c(n1)N(C1CCCC1)c1ccccc1C(=O)N2C";"IC50";"'='";"171.0";"nM";"6.77";"";"";"UO_0000065";"10.59";"0.20";"1.63";"6.95";"0";"CHEMBL4612965";"Inhibition of recombinant human GST-tagged LRRK2 catalytic domain (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate measured after 1 hr by Alexa fluor-647 ADP tracer-based ADAPTA assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4610122";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL4093321";"";"None";"428.52";"0";"2.03";"28";"CC1(Oc2ccc3[nH]nc(-c4cc(N5CCN(S(C)(=O)=O)CC5)ncn4)c3c2)CC1";"IC50";"'='";"11.0";"nM";"7.96";"";"";"UO_0000065";"18.57";"0.36";"5.93";"7.63";"0";"CHEMBL4010117";"Inhibition of recombinant human GST-tagged LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus using fluorescein-ERM as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr in presence of 5 mM ATP by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007454";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL3326133";"";"None";"372.84";"0";"3.34";"20";"COc1ccc(Cl)cc1Sc1ccc2nnc(-c3cnn(C)c3)n2n1";"IC50";"'='";"245.0";"nM";"6.61";"";"";"UO_0000065";"17.73";"0.36";"3.27";"9.43";"0";"CHEMBL3367451";"Inhibition of phosphorylation at S935 residue of wild-type full-length LRRK2 kinase (unknown origin) expressed in HEK 293 cells after 90 mins by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"CHEMBL3307715";"";"";""
"CHEMBL3326117";"";"None";"365.42";"0";"3.35";"4";"COc1ccc(OC)c(Sc2ccc3nnc(-c4ccncc4)n3n2)c1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL3367451";"Inhibition of phosphorylation at S935 residue of wild-type full-length LRRK2 kinase (unknown origin) expressed in HEK 293 cells after 90 mins by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"CHEMBL3307715";"";"";""
"CHEMBL3326114";"";"None";"364.43";"0";"3.96";"1";"COc1ccc(OC)c(Sc2ccc3nnc(-c4ccccc4)n3n2)c1";"IC50";"'='";"1380.0";"nM";"5.86";"";"";"UO_0000065";"16.08";"0.31";"1.90";"9.52";"0";"CHEMBL3367451";"Inhibition of phosphorylation at S935 residue of wild-type full-length LRRK2 kinase (unknown origin) expressed in HEK 293 cells after 90 mins by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"CHEMBL3307715";"";"";""
"CHEMBL3326121";"";"None";"358.42";"0";"2.80";"8";"COc1ccc(OC)c(Sc2ccc3nnc(C4CCOC4)n3n2)c1";"IC50";"'='";"2489.0";"nM";"5.60";"";"";"UO_0000065";"15.64";"0.31";"2.80";"7.92";"0";"CHEMBL3367450";"Inhibition of GST-tagged truncated LRRK2 (unknown origin) using fluorescein-labeled peptide LRRKtide as substrate by LANTHA screen assay in presence of 1 mM ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL3919901";"";"None";"377.45";"0";"3.09";"34";"Nc1ncc(-c2ccc(CN3CCOCC3)cc2)cc1-c1nnc(C2CC2)o1";"IC50";"'='";"490.0";"nM";"6.31";"";"";"UO_0000065";"16.72";"0.31";"3.22";"6.99";"1";"CHEMBL4045604";"Inhibition of recombinant human wild type GST-tagged LRRK2 (970 to 2527 residues) preincubated for 30 mins followed by fluorescein-LRRKtide substrate addition after 2 hrs by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4043168";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL2204495";"";"None";"399.43";"1";"5.11";"1, GSK2578215A";"O=C(Nc1cccnc1)c1cc(-c2ccnc(F)c2)ccc1OCc1ccccc1";"IC50";"'='";"61.3";"nM";"7.21";"";"";"UO_0000065";"18.06";"0.33";"2.10";"11.25";"0";"CHEMBL2215489";"Inhibition of recombinant His6-Tev-tagged LRRK2 G2019S/A2016T mutant expressed in baculovirus assessed as inhibition of LRRKtide phosphorylation by HTRF assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S,A2016T";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2203081";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2012";"None";"";"";""
"CHEMBL2403371";"";"None";"371.82";"0";"3.07";"7";"COc1ccc2c(c1)/C(=C/c1[nH]c3c(c1Cl)CN(C(C)=O)CC3)C(=O)N2";"IC50";"'='";"8.0";"nM";"8.10";"";"";"UO_0000065";"21.78";"0.43";"5.03";"10.88";"0";"CHEMBL2406186";"Inhibition of human LRRK2 (1885 to 2132) using 5-Fluo-Ahx-RLGRDKYKTLRQIRQGNTK-OH as substrate after 60 mins by fluorescence assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2401634";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2333124";"";"None";"321.38";"0";"2.92";"37";"Cc1c(-c2ccncc2)ccc2c(NC(C)C)c(C(N)=O)nnc12";"IC50";"'='";"2512.0";"nM";"5.60";"";"";"UO_0000065";"17.42";"0.32";"2.68";"5.97";"0";"CHEMBL2345527";"Inhibition of GST-tagged LRRK2 G2019S mutant (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2333137";"";"None";"446.53";"0";"3.97";"22";"C[C@@H](Nc1c(C(N)=O)nnc2cc(-c3ccc(S(C)(=O)=O)cc3)ccc12)c1ccccc1";"IC50";"'='";"1495.0";"nM";"5.83";"";"";"UO_0000065";"13.05";"0.25";"1.86";"5.06";"0";"CHEMBL2345527";"Inhibition of GST-tagged LRRK2 G2019S mutant (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2333136";"";"None";"342.38";"0";"1.38";"21";"CS(=O)(=O)c1ccc(-c2ccc3c(N)c(C(N)=O)nnc3c2)cc1";"IC50";"'='";"142.0";"nM";"6.85";"";"";"UO_0000065";"20.00";"0.39";"5.47";"5.31";"0";"CHEMBL2345528";"Inhibition of wild type GST-tagged LRRK2 (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2333134";"";"None";"412.47";"0";"2.00";"19";"CS(=O)(=O)c1ccc(-c2ccc3c(NC4CCOC4)c(C(N)=O)nnc3c2)cc1";"IC50";"'='";"17.0";"nM";"7.77";"";"";"UO_0000065";"18.84";"0.37";"5.77";"6.25";"0";"CHEMBL2345528";"Inhibition of wild type GST-tagged LRRK2 (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2333126";"";"None";"384.46";"0";"2.62";"11";"CC(C)Nc1c(C(N)=O)nnc2cc(-c3ccc(S(C)(=O)=O)cc3)ccc12";"IC50";"'='";"15.0";"nM";"7.82";"";"";"UO_0000065";"20.35";"0.40";"5.20";"6.80";"0";"CHEMBL2345528";"Inhibition of wild type GST-tagged LRRK2 (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL3935728";"";"None";"376.46";"0";"2.84";"BDBM223545";"CN1CCc2cc(-c3cnc(N)c(-c4nnc(C5CCNCC5)o4)c3)ccc21";"IC50";"'='";"380.0";"nM";"6.42";"";"390801";"UO_0000065";"17.05";"0.31";"3.58";"6.90";"0";"CHEMBL3888345";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3968012";"";"None";"281.29";"0";"2.70";"BDBM185429";"CN(C)c1ncnc2[nH]cc(-c3cc(F)cc(C#N)c3)c12";"IC50";"'='";"53.0";"nM";"7.28";"";"334395";"UO_0000065";"25.87";"0.47";"4.58";"10.61";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3393443";"";"None";"319.37";"0";"2.72";"BDBM50059311";"C[C@@H]1CN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)CCO1";"IC50";"'='";"18.0";"nM";"7.75";"";"334399";"UO_0000065";"24.25";"0.44";"5.02";"9.95";"1";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3393355";"";"None";"314.78";"0";"3.11";"BDBM50059345";"Clc1cccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"8.0";"nM";"8.10";"";"334403";"UO_0000065";"25.72";"0.50";"4.99";"14.98";"1";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3983291";"";"None";"413.44";"0";"3.33";"BDBM185489";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCOC(c5nc(C6CC6)no5)C4)c23)c1";"IC50";"'='";"30.0";"nM";"7.52";"";"334462";"UO_0000065";"18.20";"0.33";"4.19";"6.44";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3901919";"";"None";"401.43";"0";"2.64";"BDBM185492";"Cc1nc(CC2CN(c3ncnc4[nH]cc(-c5cccc(C#N)c5)c34)CCO2)no1";"IC50";"'='";"55.0";"nM";"7.26";"";"334465";"UO_0000065";"18.08";"0.33";"4.62";"6.22";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3926025";"";"None";"337.36";"0";"2.86";"BDBM185526";"C[C@H]1CN(c2ncnc3[nH]cc(-c4cccc(C#N)c4F)c23)CCO1";"IC50";"'='";"10.0";"nM";"8.00";"";"334495";"UO_0000065";"23.71";"0.44";"5.14";"10.28";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3974547";"";"None";"325.39";"0";"3.70";"BDBM185405";"Cc1cc(-c2c[nH]c3ncnc(N4CCC[C@H](C)C4)c23)cnc1F";"IC50";"'='";"64.0";"nM";"7.19";"";"334369";"UO_0000065";"22.11";"0.41";"3.49";"12.47";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3889722";"";"None";"341.85";"0";"4.22";"BDBM185415";"Cc1cnc(Cl)c(-c2c[nH]c3ncnc(N4CCC[C@H](C)C4)c23)c1";"IC50";"'='";"30.0";"nM";"7.52";"";"334379";"UO_0000065";"22.01";"0.43";"3.30";"13.04";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3980330";"";"None";"335.39";"0";"3.87";"BDBM185423";"C[C@H]1CCCN(c2ncnc3[nH]cc(-c4cccc(C#N)c4F)c23)C1";"IC50";"'='";"11.0";"nM";"7.96";"";"334387";"UO_0000065";"23.73";"0.43";"4.09";"11.60";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3393341";"";"None";"317.40";"0";"3.73";"BDBM50059259";"C[C@H]1CCCN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)C1";"IC50";"'='";"16.0";"nM";"7.80";"";"334335";"UO_0000065";"24.56";"0.44";"4.07";"11.36";"1";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3960985";"";"None";"308.39";"0";"2.83";"BDBM185376";"OCC1CCN(c2ncnc3[nH]cc(-c4ccccc4)c23)CC1";"IC50";"'='";"38.0";"nM";"7.42";"";"334338";"UO_0000065";"24.06";"0.44";"4.59";"11.41";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3940203";"";"None";"332.41";"0";"3.00";"BDBM185395";"CN1CCCC(Nc2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)C1";"IC50";"'='";"78.0";"nM";"7.11";"";"334359";"UO_0000065";"21.38";"0.39";"4.11";"8.82";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3966226";"";"None";"360.42";"0";"2.60";"BDBM185400";"CC(=O)NC1CCN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)CC1";"IC50";"'='";"50.0";"nM";"7.30";"";"334364";"UO_0000065";"20.26";"0.37";"4.70";"7.47";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3975005";"";"None";"347.42";"0";"3.10";"BDBM185410";"C[C@H]1CCCN(c2ncnc3[nH]cc(-c4ccc5c(c4)C(=O)NC5)c23)C1";"IC50";"'='";"68.0";"nM";"7.17";"";"334374";"UO_0000065";"20.63";"0.38";"4.07";"9.70";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3930527";"";"None";"363.81";"0";"3.94";"BDBM254936";"Cc1ccnc(-c2cc(Nc3nn(C)cc3Cl)nc3[nH]cc(C#N)c23)c1";"IC50";"'='";"215.0";"nM";"6.67";"";"443719";"UO_0000065";"18.33";"0.35";"2.73";"7.00";"0";"CHEMBL3889252";"Homogeneous Time Resolved-fluorescence Resonance Energy Transfer (TR-FRET) Assay: LRRK2 kinase activity is measured using a LanthaScreen kinase activity assay available from Invitrogen (Life Technologies Corporation). The assay is a homogeneous time resolved-fluorescence resonance energy transfer (TR-FRET) assay that measures phosphorylation of a fluorescein-labelled peptide substrate (fluorescein-LRRKtide, fluorescein-GAGRLGRDKYKTLRQIRQ) (SEQ ID NO 1) as a result of LRRK2 kinase activity. The phosphorylated peptide is recognized by a terbium-labelled phospho-specific anti-LRRKtide antibody and, subsequently, the phosphorylated LRRKtide can be quantified by the extent of TR-FRET between the terbium donor and fluorescein acceptor.The LRRK2 kinase is obtained from Invitrogen (Life Technologies Corporation) and comprises residues 970 to 2527 of the full length human wild-type LRRK2 kinase or a similar sequence with the G2019S mutation. As discussed above, this mutation increases the kinase activity relative to the wild-type. The kinase reactions are performed in a 20 uL volume in 384-well plates. The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT.Â  In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 uM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 uM fluorescein-LRRKtide. The reaction mixture (20 ul total volume) is incubated for 2 hours at 30° C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 ul). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 us) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 us. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 us time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3887011";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3927437";"";"None";"344.80";"0";"3.12";"BDBM185463";"COc1ccc(Cl)cc1-c1c[nH]c2ncnc(N3CCOCC3)c12";"IC50";"'='";"67.0";"nM";"7.17";"";"334647";"UO_0000065";"20.81";"0.41";"4.05";"11.34";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3927997";"";"None";"339.35";"0";"3.73";"BDBM185475";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCCC(F)(F)C4)c23)c1";"IC50";"'='";"169.0";"nM";"6.77";"";"334659";"UO_0000065";"19.96";"0.37";"3.04";"9.87";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3910857";"";"None";"339.35";"0";"3.73";"BDBM185387";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCC(F)(F)CC4)c23)c1";"IC50";"'='";"67.0";"nM";"7.17";"";"334351";"UO_0000065";"21.14";"0.39";"3.44";"10.46";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3941219";"";"None";"371.40";"0";"2.80";"BDBM185392";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCOC(c5cc[nH]n5)C4)c23)c1";"IC50";"'='";"43.0";"nM";"7.37";"";"334356";"UO_0000065";"19.83";"0.36";"4.57";"6.92";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3966408";"";"None";"369.43";"0";"3.60";"BDBM185394";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCCC(c5ncc[nH]5)C4)c23)c1";"IC50";"'='";"53.0";"nM";"7.28";"";"334358";"UO_0000065";"19.69";"0.35";"3.68";"7.48";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3326129";"";"None";"382.45";"0";"3.00";"16";"COc1ccc(OC)c(Sc2ccc3nnc(-c4cn(C)nc4C)n3n2)c1";"IC50";"'='";"1260.0";"nM";"5.90";"";"";"UO_0000065";"15.43";"0.30";"2.90";"7.43";"0";"CHEMBL3367451";"Inhibition of phosphorylation at S935 residue of wild-type full-length LRRK2 kinase (unknown origin) expressed in HEK 293 cells after 90 mins by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"CHEMBL3307715";"";"";""
"CHEMBL3326126";"";"None";"371.45";"0";"3.42";"13";"COc1ccc(OC)c(Sc2ccc3nnc(-c4cncs4)n3n2)c1";"IC50";"'='";"95.0";"nM";"7.02";"";"";"UO_0000065";"18.91";"0.38";"3.60";"9.43";"0";"CHEMBL3367450";"Inhibition of GST-tagged truncated LRRK2 (unknown origin) using fluorescein-labeled peptide LRRKtide as substrate by LANTHA screen assay in presence of 1 mM ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL2178138";"";"None";"426.40";"0";"2.55";"22";"CCNc1nc(Nc2cnc(C(=O)N3CCOCC3)cc2OC)ncc1C(F)(F)F";"IC50";"'='";"17.0";"nM";"7.77";"";"";"UO_0000065";"18.22";"0.35";"5.22";"7.65";"0";"CHEMBL2188381";"Inhibition of autophosphorylation of LRRK2 in human HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2176933";"1";"Scientific Literature";"J Med Chem";"2012";"CHEMBL3307715";"";"";""
"CHEMBL2178133";"";"None";"429.37";"0";"2.90";"17";"CNc1nc(Nc2cc(F)c(C(=O)N3CCOCC3)cc2OC)ncc1C(F)(F)F";"IC50";"'='";"16.0";"nM";"7.80";"";"";"UO_0000065";"18.16";"0.35";"4.90";"8.80";"0";"CHEMBL2188381";"Inhibition of autophosphorylation of LRRK2 in human HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2176933";"1";"Scientific Literature";"J Med Chem";"2012";"CHEMBL3307715";"";"";""
"CHEMBL2178132";"";"None";"429.37";"0";"2.90";"16";"CNc1nc(Nc2ccc(C(=O)N3CCOCC3)c(F)c2OC)ncc1C(F)(F)F";"IC50";"'='";"35.0";"nM";"7.46";"";"";"UO_0000065";"17.36";"0.34";"4.56";"8.41";"0";"CHEMBL2188381";"Inhibition of autophosphorylation of LRRK2 in human HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2176933";"1";"Scientific Literature";"J Med Chem";"2012";"CHEMBL3307715";"";"";""
"CHEMBL3326137";"";"None";"348.36";"0";"3.60";"24";"COc1ccc(OC)c(Oc2ccc3nnc(-c4ccccc4)n3n2)c1";"IC50";"'='";"236.0";"nM";"6.63";"";"";"UO_0000065";"19.02";"0.35";"3.03";"9.36";"0";"CHEMBL3367450";"Inhibition of GST-tagged truncated LRRK2 (unknown origin) using fluorescein-labeled peptide LRRKtide as substrate by LANTHA screen assay in presence of 1 mM ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL3326136";"";"None";"370.40";"1";"1.48";"23";"COc1cc(Sc2ccc3nnc(-c4cnn(C)c4)n3n2)c(OC)nn1";"IC50";"'='";"12635.0";"nM";"4.90";"";"";"UO_0000065";"13.22";"0.26";"3.42";"4.66";"0";"CHEMBL3367450";"Inhibition of GST-tagged truncated LRRK2 (unknown origin) using fluorescein-labeled peptide LRRKtide as substrate by LANTHA screen assay in presence of 1 mM ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL3326133";"";"None";"372.84";"0";"3.34";"20";"COc1ccc(Cl)cc1Sc1ccc2nnc(-c3cnn(C)c3)n2n1";"IC50";"'='";"78.0";"nM";"7.11";"";"";"UO_0000065";"19.06";"0.39";"3.77";"10.14";"0";"CHEMBL3367450";"Inhibition of GST-tagged truncated LRRK2 (unknown origin) using fluorescein-labeled peptide LRRKtide as substrate by LANTHA screen assay in presence of 1 mM ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL1982880";"";"None";"347.38";"0";"3.55";"25";"COc1ccc(OC)c(Nc2ccc3nnc(-c4ccccc4)n3n2)c1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL3367451";"Inhibition of phosphorylation at S935 residue of wild-type full-length LRRK2 kinase (unknown origin) expressed in HEK 293 cells after 90 mins by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"CHEMBL3307715";"";"";""
"CHEMBL3326137";"";"None";"348.36";"0";"3.60";"24";"COc1ccc(OC)c(Oc2ccc3nnc(-c4ccccc4)n3n2)c1";"IC50";"'='";"1740.0";"nM";"5.76";"";"";"UO_0000065";"16.53";"0.30";"2.16";"8.14";"0";"CHEMBL3367451";"Inhibition of phosphorylation at S935 residue of wild-type full-length LRRK2 kinase (unknown origin) expressed in HEK 293 cells after 90 mins by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"CHEMBL3307715";"";"";""
"CHEMBL3326149";"";"None";"368.42";"0";"2.72";"37";"COc1ccc(OC)c(Sc2ccc3nnn(-c4cnn(C)c4)c3n2)c1";"IC50";"'='";"525.0";"nM";"6.28";"";"";"UO_0000065";"17.05";"0.33";"3.56";"7.86";"0";"CHEMBL3367450";"Inhibition of GST-tagged truncated LRRK2 (unknown origin) using fluorescein-labeled peptide LRRKtide as substrate by LANTHA screen assay in presence of 1 mM ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL3393360";"";"None";"306.33";"0";"1.73";"26";"N#Cc1cc(-c2c[nH]c3ncnc(N4CCOCC4)c23)ccn1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL3395728";"Inhibition of full length LRRK2 (unknown origin) expressed in HEK293 cells assessed as reduction in S935 phosphorylation incubated for 90 mins by ELISA method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL3393357";"";"None";"323.33";"0";"2.47";"23";"N#Cc1cc(-c2c[nH]c3ncnc(N4CCOCC4)c23)ccc1F";"IC50";"'='";"2460.0";"nM";"5.61";"";"";"UO_0000065";"17.35";"0.32";"3.14";"7.21";"0";"CHEMBL3395728";"Inhibition of full length LRRK2 (unknown origin) expressed in HEK293 cells assessed as reduction in S935 phosphorylation incubated for 90 mins by ELISA method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL3393344";"";"None";"289.34";"0";"3.10";"10";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCCC4)c23)c1";"IC50";"'='";"432.0";"nM";"6.37";"";"";"UO_0000065";"22.00";"0.40";"3.26";"9.28";"0";"CHEMBL3395728";"Inhibition of full length LRRK2 (unknown origin) expressed in HEK293 cells assessed as reduction in S935 phosphorylation incubated for 90 mins by ELISA method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL3393355";"";"None";"314.78";"0";"3.11";"21";"Clc1cccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"13.0";"nM";"7.89";"";"";"UO_0000065";"25.05";"0.49";"4.78";"14.59";"0";"CHEMBL3395727";"Inhibition of GST-tagged truncated human recombinant LRRK2 G2019S mutant using fluorescein-labeled LRRKtide peptide substrate incubated for 90 mins";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3590142";"";"None";"295.26";"0";"2.38";"Z-8205";"N#Cc1ccc(Nc2ccc3[nH]c(=O)[nH]c3c2)c([N+](=O)[O-])c1";"IC50";"'='";"11100.0";"nM";"4.96";"";"";"UO_0000065";"16.78";"0.31";"2.57";"3.88";"0";"CHEMBL3592569";"Inhibition of wild type LRRK2 (unknown origin) assessed as inhibition of LRRKtide phosphorylation after 120 mins by radiometric assay in presence of [gamma-33P]-ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3588794";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2015";"None";"";"";""
"CHEMBL3335333";"";"None";"384.86";"0";"3.54";"15g";"O=C1Nc2ccc(Cl)cc2/C1=C\c1ccc(OCCN2CCOCC2)cc1";"IC50";"'='";"205.0";"nM";"6.69";"";"";"UO_0000065";"17.38";"0.34";"3.15";"13.17";"0";"CHEMBL3390652";"Inhibition of recombinant LRRK2 (unknown origin) using gamma-32P-ATP assessed as LRRKtide substrate phosphorylation level by autoradiography";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352815";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL2170016";"";"None";"377.83";"0";"2.40";"4, HG-10-102-01";"CNc1nc(Nc2ccc(C(=O)N3CCOCC3)cc2OC)ncc1Cl";"IC50";"'='";"20.3";"nM";"7.69";"";"";"UO_0000065";"20.36";"0.40";"5.29";"8.68";"0";"CHEMBL2173828";"Inhibition of LRRK2 expressed in HEK293 cells using nictide as substrate and [gamma32P]ATP after 15 mins by Cerenkov counting method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169803";"1";"Scientific Literature";"ACS Med Chem Lett";"2012";"CHEMBL3307715";"";"";""
"CHEMBL3415608";"";"None";"350.43";"0";"2.41";"54";"NC(=O)c1ncc(N[C@@H]2CCCC[C@@H]2N)cc1-c1nc2ccccc2[nH]1";"IC50";"'='";"130.0";"nM";"6.89";"";"";"UO_0000065";"19.65";"0.36";"4.48";"5.61";"0";"CHEMBL3418522";"Inhibition of LRRK2 (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3414497";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL509032";"TAE-684";"None";"614.22";"2";"5.02";"SID103904598";"COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1";"IC50";"'='";"6.1";"nM";"8.21";"";"";"UO_0000065";"13.37";"0.27";"3.19";"7.98";"0";"CHEMBL2015542";"Inhibition of LRRK2 G2019S mutant expressed in HEK293 cells using nictide and ATP as substrate";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2010643";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2012";"CHEMBL3307715";"";"";""
"CHEMBL3604124";"";"None";"402.50";"0";"3.66";"10b, BMPPB-32";"CN1CCN(c2ccc(OCc3ccccc3)c(C(=O)Nc3cccnc3)c2)CC1";"IC50";"'='";"6.0";"nM";"8.22";"";"";"UO_0000065";"20.43";"0.37";"4.56";"14.25";"0";"CHEMBL3607919";"Inhibition of LRRK2 (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3603772";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3040018";"";"None";"479.59";"0";"4.25";"F-0193";"Cc1ccc(NC(=O)c2ccc(CN3CCNCC3)cc2)cc1Nc1nccc(-c2cccnc2)n1";"IC50";"'='";"4600.0";"nM";"5.34";"";"";"UO_0000065";"11.13";"0.20";"1.09";"5.61";"0";"CHEMBL3592569";"Inhibition of wild type LRRK2 (unknown origin) assessed as inhibition of LRRKtide phosphorylation after 120 mins by radiometric assay in presence of [gamma-33P]-ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3588794";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2015";"None";"";"";""
"CHEMBL3590143";"";"None";"418.88";"0";"4.42";"F-0025a";"O=C(NCCO)c1ccc(Nc2nc(-c3ccccc3)c3cc(Cl)ccc3n2)cc1";"IC50";"'='";"2800.0";"nM";"5.55";"";"";"UO_0000065";"13.26";"0.25";"1.13";"6.37";"0";"CHEMBL3592569";"Inhibition of wild type LRRK2 (unknown origin) assessed as inhibition of LRRKtide phosphorylation after 120 mins by radiometric assay in presence of [gamma-33P]-ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3588794";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2015";"None";"";"";""
"CHEMBL3122116";"";"None";"429.42";"0";"2.77";"19";"CNc1nc(Nc2cn([C@H]3CCN(C4COC4)C[C@H]3F)nc2C)ncc1C(F)(F)F";"IC50";"'='";"14.0";"nM";"7.85";"";"";"UO_0000065";"18.29";"0.36";"5.08";"9.80";"0";"CHEMBL3124215";"Inhibition of LRRK2 (unknown origin) phosphorylation by cell-based assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3120096";"1";"Scientific Literature";"J Med Chem";"2014";"None";"";"";""
"CHEMBL3393353";"";"None";"280.33";"0";"2.46";"19";"c1ccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)cc1";"IC50";"'='";"9.0";"nM";"8.05";"";"";"UO_0000065";"28.70";"0.52";"5.59";"14.89";"0";"CHEMBL3395726";"Inhibition of GST-tagged truncated human recombinant LRRK2 using fluorescein-labeled LRRKtide peptide substrate incubated for 2 hrs";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3393447";"";"None";"372.39";"0";"3.06";"36";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCOC(c5ccno5)C4)c23)c1";"IC50";"'='";"1467.0";"nM";"5.83";"";"";"UO_0000065";"15.67";"0.28";"2.77";"5.62";"0";"CHEMBL3395728";"Inhibition of full length LRRK2 (unknown origin) expressed in HEK293 cells assessed as reduction in S935 phosphorylation incubated for 90 mins by ELISA method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL3393446";"";"None";"344.38";"0";"2.62";"35";"N#CCC1CN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)CCO1";"IC50";"'='";"117.0";"nM";"6.93";"";"";"UO_0000065";"20.13";"0.36";"4.31";"6.82";"0";"CHEMBL3395728";"Inhibition of full length LRRK2 (unknown origin) expressed in HEK293 cells assessed as reduction in S935 phosphorylation incubated for 90 mins by ELISA method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL3393449";"";"None";"387.40";"0";"2.77";"38";"Cc1nc([C@@H]2CN(c3ncnc4[nH]cc(-c5cccc(C#N)c5)c34)CCO2)no1";"IC50";"'='";"8.0";"nM";"8.10";"";"";"UO_0000065";"20.90";"0.38";"5.33";"6.94";"0";"CHEMBL3395726";"Inhibition of GST-tagged truncated human recombinant LRRK2 using fluorescein-labeled LRRKtide peptide substrate incubated for 2 hrs";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL4084470";"";"None";"383.25";"0";"4.68";"6g";"O=C(Nc1cccnc1)c1cc(Br)ccc1OCc1ccccc1";"IC50";"'='";"12.59";"nM";"7.90";"";"";"UO_0000065";"20.61";"0.45";"3.22";"15.42";"0";"CHEMBL4058537";"Inhibition of LRRK2 (unknown origin) by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4052807";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL4086683";"";"None";"384.23";"0";"4.07";"7b";"O=C(Nc1cccnn1)c1cc(Br)ccc1OCc1ccccc1";"IC50";"'='";"50.12";"nM";"7.30";"";"";"UO_0000065";"19.00";"0.42";"3.23";"11.39";"0";"CHEMBL4058537";"Inhibition of LRRK2 (unknown origin) by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4052807";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL4460272";"";"None";"381.44";"0";"2.41";"35";"c1cc(-c2n[nH]c3ccnc(OC4CCOCC4)c23)cc(N2CCOCC2)n1";"IC50";"'='";"12.0";"nM";"7.92";"";"";"UO_0000065";"20.77";"0.39";"5.51";"9.28";"0";"CHEMBL4331900";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant catalytic domain (970 to 2527 residues) expressed in baculovirus expression system by radiometric assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330096";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4471414";"";"None";"216.29";"0";"2.62";"11";"Cc1n[nH]c2ccnc(NC3CCCC3)c12";"IC50";"'='";"410.0";"nM";"6.39";"";"";"UO_0000065";"29.53";"0.55";"3.77";"11.92";"0";"CHEMBL4331900";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant catalytic domain (970 to 2527 residues) expressed in baculovirus expression system by radiometric assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330096";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4206831";"";"None";"535.61";"2";"5.49";"2; FMF-03-145-1";"CCC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1";"IC50";"'='";"714.0";"nM";"6.15";"";"";"UO_0000065";"11.48";"0.21";"0.66";"5.14";"0";"CHEMBL4185649";"Inhibition of recombinant GST-tagged human LRRK2 (970 to 2527 residues) catalytic domain expressed in baculovirus expression system by ADAPTA assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4184148";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL4067228";"";"None";"338.79";"0";"4.57";"8b";"O=C(Nc1cccnc1)c1cc(Cl)ccc1OCc1ccccc1";"IC50";"'='";"15.85";"nM";"7.80";"";"";"UO_0000065";"23.02";"0.44";"3.23";"15.23";"0";"CHEMBL4058537";"Inhibition of LRRK2 (unknown origin) by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4052807";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL4103192";"";"None";"408.26";"0";"4.55";"6f";"N#Cc1ccc(COc2ccc(Br)cc2C(=O)Nc2cccnc2)cc1";"IC50";"'='";"63.1";"nM";"7.20";"";"";"UO_0000065";"17.64";"0.38";"2.65";"9.60";"0";"CHEMBL4058537";"Inhibition of LRRK2 (unknown origin) by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4052807";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL1434292";"";"None";"240.24";"0";"2.90";"10, E:Z Mixture (67:33)";"O=C1Nc2ccccc2C1=Nc1ccc(F)cc1";"IC50";"'='";"3180.0";"nM";"5.50";"";"";"UO_0000065";"22.88";"0.42";"2.60";"13.26";"0";"CHEMBL4192178";"Inhibition of recombinant catalytic human GST-tagged LLRK2 (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4190250";"1";"Scientific Literature";"Eur J Med Chem";"2017";"None";"";"";""
"CHEMBL4213079";"";"None";"397.36";"1";"5.08";"37";"O=C1Nc2ccc(OC(F)(F)F)cc2/C1=N\N(c1ccccc1)c1ccccc1";"IC50";"'='";"5350.0";"nM";"5.27";"";"";"UO_0000065";"13.27";"0.25";"0.19";"9.77";"0";"CHEMBL4192178";"Inhibition of recombinant catalytic human GST-tagged LLRK2 (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4190250";"1";"Scientific Literature";"Eur J Med Chem";"2017";"None";"";"";""
"CHEMBL3651739";"";"None";"353.43";"0";"3.49";"33";"c1cc2[nH]nc(-c3cnn(C4CCCC4)c3)c2c(OC2CCOCC2)n1";"IC50";"'='";"4.0";"nM";"8.40";"";"";"UO_0000065";"23.76";"0.44";"4.91";"10.79";"0";"CHEMBL4331900";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant catalytic domain (970 to 2527 residues) expressed in baculovirus expression system by radiometric assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330096";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL3122119";"";"None";"353.35";"0";"3.21";"15";"CCNc1nc(Nc2cc(C(C)(C)C#N)nn2C)ncc1C(F)(F)F";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL3124215";"Inhibition of LRRK2 (unknown origin) phosphorylation by cell-based assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3120096";"1";"Scientific Literature";"J Med Chem";"2014";"None";"";"";""
"CHEMBL3393350";"";"None";"333.40";"0";"3.11";"16";"COC1CCCN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)C1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL3395728";"Inhibition of full length LRRK2 (unknown origin) expressed in HEK293 cells assessed as reduction in S935 phosphorylation incubated for 90 mins by ELISA method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL3393350";"";"None";"333.40";"0";"3.11";"16";"COC1CCCN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)C1";"IC50";"'='";"154.0";"nM";"6.81";"";"";"UO_0000065";"20.43";"0.37";"3.70";"8.75";"0";"CHEMBL3395727";"Inhibition of GST-tagged truncated human recombinant LRRK2 G2019S mutant using fluorescein-labeled LRRKtide peptide substrate incubated for 90 mins";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3393360";"";"None";"306.33";"0";"1.73";"26";"N#Cc1cc(-c2c[nH]c3ncnc(N4CCOCC4)c23)ccn1";"IC50";"'='";"686.0";"nM";"6.16";"";"";"UO_0000065";"20.12";"0.37";"4.43";"6.79";"0";"CHEMBL3395726";"Inhibition of GST-tagged truncated human recombinant LRRK2 using fluorescein-labeled LRRKtide peptide substrate incubated for 2 hrs";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL4539170";"";"None";"326.40";"0";"2.51";"14";"CCc1cc(-c2n[nH]c3ccnc(NC4CCOCC4)c23)nn1C";"IC50";"'='";"4.5";"nM";"8.35";"";"";"UO_0000065";"25.57";"0.47";"5.84";"10.35";"0";"CHEMBL4331199";"Inhibition of LRRK2 G2019S mutant (unknown origin) by cell based assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330074";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL2012582";"";"None";"570.70";"1";"3.44";"LRRK2-IN-1";"COc1cc(C(=O)N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2C";"IC50";"'='";"6.0";"nM";"8.22";"";"";"UO_0000065";"14.41";"0.27";"4.78";"8.44";"0";"CHEMBL2015542";"Inhibition of LRRK2 G2019S mutant expressed in HEK293 cells using nictide and ATP as substrate";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2010643";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2012";"CHEMBL3307715";"";"";""
"CHEMBL4098877";"MLi-2";"None";"379.46";"0";"3.56";"EUB0000715";"C[C@@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@H](C)O1";"IC50";"";"1.8";"nM";"";"";"Active";"UO_0000065";"";"";"";"";"0";"CHEMBL4882637";"LRRK2 Biochemical Assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"Additional information: LanthaScreen | Assay publication: PMID: 26407721 | Target protein type: GST-tagged truncated human mutant G2019S LRRK2";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4507291";"54";"Donated Chemical Probes - SGC Frankfurt";"";"2021";"None";"";"";""
"CHEMBL3122115";"";"None";"337.31";"0";"2.80";"13";"CNc1nc(Nc2cn(C3(C#N)CC3)nc2C)ncc1C(F)(F)F";"IC50";"'='";"30.0";"nM";"7.52";"";"";"UO_0000065";"22.30";"0.43";"4.72";"8.23";"0";"CHEMBL3124215";"Inhibition of LRRK2 (unknown origin) phosphorylation by cell-based assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3120096";"1";"Scientific Literature";"J Med Chem";"2014";"None";"";"";""
"CHEMBL1673052";"";"None";"487.61";"0";"4.12";"XMD10-78";"COc1cc(N2CCN(C)CC2)ccc1Nc1ncc2c(n1)N(C(C)C)c1ccccc1C(=O)N2C";"IC50";"'='";"289.0";"nM";"6.54";"";"";"UO_0000065";"13.41";"0.25";"2.42";"8.48";"0";"CHEMBL4612965";"Inhibition of recombinant human GST-tagged LRRK2 catalytic domain (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate measured after 1 hr by Alexa fluor-647 ADP tracer-based ADAPTA assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4610122";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL3326114";"";"None";"364.43";"0";"3.96";"1";"COc1ccc(OC)c(Sc2ccc3nnc(-c4ccccc4)n3n2)c1";"IC50";"'='";"40.0";"nM";"7.40";"";"";"UO_0000065";"20.30";"0.39";"3.44";"12.02";"0";"CHEMBL3368824";"Inhibition of GST-tagged truncated LRRK2 (unknown origin) using fluorescein-labeled peptide LRRKtide as substrate by LANTHA screen assay in presence of 50 uM ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL3800405";"";"None";"319.46";"0";"3.49";"3";"C[C@H]1CNC(=O)c2c(SCC3CC3)sc(-c3cc[nH]n3)c21";"IC50";"'='";"31.0";"nM";"7.51";"";"";"UO_0000065";"23.50";"0.49";"4.02";"13.00";"0";"CHEMBL4018178";"Inhibition of LRRK2 G2019S mutant (unknown origin) using biotinylated ezrin/radaxin/meosin peptide as substrate measured after 1 hr";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4017473";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL4064135";"";"None";"349.39";"0";"2.31";"17";"NC(=O)c1ccc(Nc2nc(N3CCOCC3)c3ccccc3n2)cc1";"IC50";"'='";"825.0";"nM";"6.08";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL4018177";"Inhibition of full length wild-type LRRK2 (unknown origin) using biotinylated ezrin/radaxin/meosin peptide as substrate measured after 1 hr";"A";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4017473";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL2397014";"";"None";"488.55";"0";"3.32";"10";"COc1cc(N2CCOCC2)ccc1Nc1ncc(F)c(Nc2ccccc2NS(C)(=O)=O)n1";"IC50";"'='";"1.3";"nM";"8.89";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL4018177";"Inhibition of full length wild-type LRRK2 (unknown origin) using biotinylated ezrin/radaxin/meosin peptide as substrate measured after 1 hr";"A";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4017473";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL3961632";"";"None";"248.29";"0";"2.99";"22";"Cc1cccc(-c2cc(N)nc3[nH]cc(C#N)c23)c1";"IC50";"'='";"21.0";"nM";"7.68";"";"";"UO_0000065";"30.92";"0.55";"4.69";"9.78";"0";"CHEMBL4031820";"Inhibition of wild type recombinant human GST-tagged LRRK2 (970 to 2527 residues) expressed in baculovirus using fluorescein-LRRKtide as substrate after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4060616";"";"None";"177.59";"0";"2.09";"11";"N#Cc1c[nH]c2nccc(Cl)c12";"IC50";"'='";"37765.0";"nM";"4.42";"";"";"UO_0000065";"24.91";"0.50";"2.33";"8.43";"0";"CHEMBL4031821";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus using fluorescein-LRRKtide as substrate after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4092521";"";"None";"363.81";"0";"3.94";"34";"Cc1cccc(-c2cc(Nc3nn(C)cc3Cl)nc3[nH]cc(C#N)c23)n1";"IC50";"'='";"94.0";"nM";"7.03";"";"";"UO_0000065";"19.31";"0.37";"3.09";"7.38";"0";"CHEMBL4031826";"Inhibition of human LRRK2 G2019S mutant phosphorylation at ser935 expressed in BacMam transduced HEK293 cells after 48 hrs by in-cell Western assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"CHEMBL3307715";"";"";""
"CHEMBL3939513";"";"None";"314.35";"0";"3.58";"24";"Cn1ccc(Nc2cc(-c3ccccc3)c3c(C#N)c[nH]c3n2)n1";"IC50";"'='";"99.0";"nM";"7.00";"";"";"UO_0000065";"22.28";"0.40";"3.42";"8.51";"0";"CHEMBL4031820";"Inhibition of wild type recombinant human GST-tagged LRRK2 (970 to 2527 residues) expressed in baculovirus using fluorescein-LRRKtide as substrate after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4092537";"";"None";"253.69";"0";"3.75";"14";"N#Cc1c[nH]c2nccc(-c3ccccc3Cl)c12";"IC50";"'='";"9271.0";"nM";"5.03";"";"";"UO_0000065";"19.84";"0.38";"1.28";"9.59";"0";"CHEMBL4031821";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus using fluorescein-LRRKtide as substrate after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4076248";"";"None";"233.27";"0";"3.41";"17";"Cc1ccccc1-c1ccnc2[nH]cc(C#N)c12";"IC50";"'='";"27838.0";"nM";"4.55";"";"";"UO_0000065";"19.53";"0.35";"1.15";"8.68";"0";"CHEMBL4031821";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus using fluorescein-LRRKtide as substrate after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL2204495";"";"None";"399.43";"1";"5.11";"1, GSK2578215A";"O=C(Nc1cccnc1)c1cc(-c2ccnc(F)c2)ccc1OCc1ccccc1";"IC50";"'='";"8.9";"nM";"8.05";"";"";"UO_0000065";"20.16";"0.37";"2.94";"12.56";"0";"CHEMBL2215491";"Inhibition of recombinant His6-Tev-tagged LRRK2 G2019S mutant expressed in baculovirus assessed as inhibition of LRRKtide phosphorylation by HTRF assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2203081";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2012";"None";"";"";""
"CHEMBL4217734";"";"None";"229.28";"0";"1.83";"19, E:Z Mixture (46:54)";"O=C1Nc2ccccc2C1=NN1CCCCC1";"IC50";"'='";"1340.0";"nM";"5.87";"";"";"UO_0000065";"25.61";"0.47";"4.04";"13.14";"0";"CHEMBL4192178";"Inhibition of recombinant catalytic human GST-tagged LLRK2 (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4190250";"1";"Scientific Literature";"Eur J Med Chem";"2017";"None";"";"";""
"CHEMBL4204350";"";"None";"347.80";"0";"4.83";"33, E:Z Mixture (85:15)";"O=C1Nc2ccc(Cl)cc2C1=NN(c1ccccc1)c1ccccc1";"IC50";"'='";"50.0";"nM";"7.30";"";"";"UO_0000065";"20.99";"0.40";"2.47";"16.33";"0";"CHEMBL4192179";"Inhibition of recombinant catalytic human GST-tagged LLRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4190250";"1";"Scientific Literature";"Eur J Med Chem";"2017";"None";"";"";""
"CHEMBL4206138";"";"None";"263.73";"0";"2.48";"39, E:Z Mixture (92:8)";"O=C1Nc2ccc(Cl)cc2C1=NN1CCCCC1";"IC50";"'='";"570.0";"nM";"6.24";"";"";"UO_0000065";"23.68";"0.47";"3.76";"13.97";"0";"CHEMBL4192179";"Inhibition of recombinant catalytic human GST-tagged LLRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4190250";"1";"Scientific Literature";"Eur J Med Chem";"2017";"None";"";"";""
"CHEMBL5171585";"";"None";"393.49";"1";"5.60";"39";"Cc1cc(-c2n[nH]c3ccc(N[C@@H]4CCCc5cc(C#N)ccc54)cc23)cc(C)n1";"IC50";"'='";"4.0";"nM";"8.40";"";"";"UO_0000065";"21.34";"0.38";"2.80";"10.85";"0";"CHEMBL5157023";"Inhibition of full length LRRK2 G2019S mutant (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5171090";"";"None";"361.41";"1";"5.39";"40";"N#Cc1ccc2c(Nc3ccc4[nH]nc(-c5ccncc5)c4c3)cccc2c1";"IC50";"'='";"150.0";"nM";"6.82";"";"";"UO_0000065";"18.88";"0.33";"1.43";"8.82";"0";"CHEMBL5157023";"Inhibition of full length LRRK2 G2019S mutant (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL3590142";"";"None";"295.26";"0";"2.38";"2";"N#Cc1ccc(Nc2ccc3[nH]c(=O)[nH]c3c2)c([N+](=O)[O-])c1";"IC50";"'='";"500.0";"nM";"6.30";"";"";"UO_0000065";"21.34";"0.39";"3.92";"4.94";"0";"CHEMBL5157023";"Inhibition of full length LRRK2 G2019S mutant (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL4446892";"";"None";"520.34";"1";"3.31";"GSK8612";"Cc1nn(CC(F)(F)F)cc1Nc1ncc(Br)c(NCc2ccc(S(N)(=O)=O)cc2)n1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5046624";"Inhibition of NanoLuc-fused LRRK2 (unknown origin) expressed in HEK293 cells incubated for 2 hrs by NanoBRET assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5046221";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 2.0 hr";"";""
"CHEMBL5199715";"";"None";"485.42";"1";"5.54";"3.40";"Clc1cc2cnc(Nc3cnn(C45CC(C4)C5)c3Cl)nc2cc1N1CCC2(CCCO2)CC1";"IC50";"'='";"0.1742";"nM";"9.76";"";"";"UO_0000065";"20.10";"0.40";"4.22";"14.33";"0";"CHEMBL5135962";"Inhibition of GST-tagged truncated human LRRK2 G2019S mutant using fluorescein labeled LRRKtide peptide as substrate preincubated for 15 mins followed by substrate addition and measured after 90 mins in presence of ATP at Km concentration by TR-FRET Lanthascreen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131528";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL5177202";"";"None";"520.65";"1";"3.90";"9.20";"CCC1C(C(=O)Nc2cc3cc(N4CCN(C5(C)COCC5F)CC4)c(C)cc3cn2)C1c1cnn(C)c1";"IC50";"'='";"0.08128";"nM";"10.09";"";"";"UO_0000065";"19.38";"0.36";"6.19";"13.36";"0";"CHEMBL5126024";"Inhibition of GST-tagged truncated human LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition measured after 90 mins in presence of ATP by TR-FRET based LanthaScreen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5120951";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL5190679";"";"None";"418.38";"0";"2.33";"8";"Cn1cc(-c2cccc(C(=O)Nc3cc(N4CC(O)C4)ncc3C(F)(F)F)n2)cn1";"IC50";"'='";"4.8";"nM";"8.32";"";"";"UO_0000065";"19.88";"0.38";"5.99";"8.65";"0";"CHEMBL5108135";"Inhibition of recombinant human GST20 tagged truncated LRRK2 G2019S mutant assessed as substrate phosphorylation preincubated for 15 mins followed by substrate addition and measured after 90 mins using fluorescein-labeled LRRK2tide as substrate in presence of ATP by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5107939";"1";"Scientific Literature";"RSC Med Chem";"2021";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL5180782";"";"None";"474.49";"0";"3.75";"12";"Cn1cc(-c2cccc(C(=O)Nc3cc(N4CC[C@@H](C(C)(C)O)C4)ncc3C(F)(F)F)n2)cn1";"IC50";"'='";"1.0";"nM";"9.00";"";"";"UO_0000065";"18.97";"0.36";"5.25";"9.36";"0";"CHEMBL5108135";"Inhibition of recombinant human GST20 tagged truncated LRRK2 G2019S mutant assessed as substrate phosphorylation preincubated for 15 mins followed by substrate addition and measured after 90 mins using fluorescein-labeled LRRK2tide as substrate in presence of ATP by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5107939";"1";"Scientific Literature";"RSC Med Chem";"2021";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL5193374";"";"None";"501.51";"1";"3.06";"13";"C[C@H]1CN(c2cc(NC(=O)c3cccc(-c4cnn(C)c4)n3)c(C(F)(F)F)cn2)CCN1C1COC1";"IC50";"'='";"1.5";"nM";"8.82";"";"";"UO_0000065";"17.59";"0.33";"5.76";"9.98";"0";"CHEMBL5108135";"Inhibition of recombinant human GST20 tagged truncated LRRK2 G2019S mutant assessed as substrate phosphorylation preincubated for 15 mins followed by substrate addition and measured after 90 mins using fluorescein-labeled LRRK2tide as substrate in presence of ATP by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5107939";"1";"Scientific Literature";"RSC Med Chem";"2021";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL5172722";"";"None";"432.41";"0";"2.98";"7";"COC1CN(c2cc(NC(=O)c3cccc(-c4cnn(C)c4)n3)c(C(F)(F)F)cn2)C1";"IC50";"'='";"2.8";"nM";"8.55";"";"";"UO_0000065";"19.78";"0.38";"5.57";"10.04";"0";"CHEMBL5108136";"Inhibition of human LRRK2 G2019S mutant expressed in human SH-SY5Y cells assessed as inhibition of tetracycline induced LRRK2 phosphorylation at Ser935 residue incubated for 90 mins by MSD assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5107939";"1";"Scientific Literature";"RSC Med Chem";"2021";"None";"TIME = 1.5 hr";"INHIBITOR";""
"CHEMBL5202285";"";"None";"486.50";"0";"3.89";"11";"Cn1cc(-c2cccc(C(=O)Nc3cc(N4CC5(C(C)(C)O)CC4C5)ncc3C(F)(F)F)n2)cn1";"IC50";"'='";"2.0";"nM";"8.70";"";"";"UO_0000065";"17.88";"0.34";"4.81";"9.05";"0";"CHEMBL5108136";"Inhibition of human LRRK2 G2019S mutant expressed in human SH-SY5Y cells assessed as inhibition of tetracycline induced LRRK2 phosphorylation at Ser935 residue incubated for 90 mins by MSD assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5107939";"1";"Scientific Literature";"RSC Med Chem";"2021";"None";"TIME = 1.5 hr";"INHIBITOR";""
"CHEMBL5171071";"";"None";"421.51";"0";"2.43";"17";"Cc1nc(NC(=O)c2cccc(-c3cnn(C)c3)n2)cc(N2CC[C@@H](C(C)(C)O)C2)n1";"IC50";"'='";"42.0";"nM";"7.38";"";"";"UO_0000065";"17.50";"0.32";"4.95";"6.76";"0";"CHEMBL5108136";"Inhibition of human LRRK2 G2019S mutant expressed in human SH-SY5Y cells assessed as inhibition of tetracycline induced LRRK2 phosphorylation at Ser935 residue incubated for 90 mins by MSD assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5107939";"1";"Scientific Literature";"RSC Med Chem";"2021";"None";"TIME = 1.5 hr";"INHIBITOR";""
"CHEMBL5197547";"";"None";"542.48";"1";"4.77";"23";"CC(C)(O)[C@@H]1CCN(c2cnc(C(F)(F)F)c(NC(=O)c3cccc(-c4cnn(CC(F)(F)F)c4)n3)c2)C1";"IC50";"'='";"0.7";"nM";"9.15";"";"";"UO_0000065";"16.88";"0.33";"4.38";"9.52";"0";"CHEMBL5108136";"Inhibition of human LRRK2 G2019S mutant expressed in human SH-SY5Y cells assessed as inhibition of tetracycline induced LRRK2 phosphorylation at Ser935 residue incubated for 90 mins by MSD assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5107939";"1";"Scientific Literature";"RSC Med Chem";"2021";"None";"TIME = 1.5 hr";"INHIBITOR";""
"CHEMBL4752817";"";"None";"436.52";"0";"3.03";"22";"CCOc1nc(Nc2ccc(C(=O)N3CCN4CCC[C@@H]4C3)cc2OC)nc2[nH]ccc12";"IC50";"'='";"7.943";"nM";"8.10";"";"";"UO_0000065";"18.56";"0.35";"5.07";"8.47";"0";"CHEMBL4721243";"Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs in presence of ATP by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4715821";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2018";"None";"TIME = 2.5 hr";"INHIBITOR";""
"CHEMBL3393355";"";"None";"314.78";"0";"3.11";"6";"Clc1cccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"264.0";"nM";"6.58";"";"";"UO_0000065";"20.90";"0.41";"3.47";"12.17";"0";"CHEMBL5043428";"Displacement of K5 tracer from full length C-terminal NanoLuc fused human LRRK2 expressed in HEK293T cells incubated for 2 hrs by NanoBRET assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293T";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5042489";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL5092052";"";"None";"330.82";"0";"3.34";"27";"CC(CO)CN(C)c1ncnc2[nH]cc(-c3cccc(Cl)c3)c12";"IC50";"'='";"7140.0";"nM";"5.15";"";"";"UO_0000065";"15.56";"0.31";"1.81";"7.91";"0";"CHEMBL5043428";"Displacement of K5 tracer from full length C-terminal NanoLuc fused human LRRK2 expressed in HEK293T cells incubated for 2 hrs by NanoBRET assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293T";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5042489";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL4751816";"";"None";"413.45";"0";"3.68";"18";"CCOc1nc(Nc2ccc(C(=O)N3CCC(F)CC3)cc2OC)nc2[nH]ccc12";"IC50";"'='";"6.31";"nM";"8.20";"";"";"UO_0000065";"19.83";"0.37";"4.52";"8.88";"0";"CHEMBL4721243";"Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs in presence of ATP by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4715821";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2018";"None";"TIME = 2.5 hr";"INHIBITOR";""
"CHEMBL4861241";"";"None";"415.95";"0";"4.37";"4.45";"Cc1cc(Nc2ncc3cc(Cl)c(C4CCN(C5COC5)CC4)cc3n2)sn1";"IC50";"'<'";"0.631";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL4827623";"Inhibition of Kinase tracer 236 binding to GST-tagged truncated human LRRK2 G2019S (970 to 2527 residues) mutant using fluorescein labeled LRRKtide peptide as substrate preincubated for 15 mins followed by substrate addition measured after 90 mins in presence of ATP at Km concentration by TR-FRET Lanthascreen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4825716";"1";"Scientific Literature";"ACS Med Chem Lett";"2021";"None";"TIME = 1.75 hr";"";""
"CHEMBL5083563";"";"None";"365.45";"0";"2.20";"32";"Cc1nn(C)cc1Nc1nc(N)c2c(C#N)c(N3CCC[C@H]3C)n(C)c2n1";"IC50";"'='";"120.0";"nM";"6.92";"";"";"UO_0000065";"18.94";"0.35";"4.72";"6.09";"0";"CHEMBL5040116";"Inhibition of LRRK2-pSer935 in LRRK2 G2019S mutant expressing human HEK293 cells and measured after 48 hrs by ICW assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 48.0 hr";"INHIBITOR";""
"CHEMBL4098877";"MLi-2";"None";"379.46";"0";"3.56";"5; MLi-2";"C[C@@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@H](C)O1";"IC50";"'='";"1.2";"nM";"8.92";"";"";"UO_0000065";"23.51";"0.44";"5.36";"11.71";"0";"CHEMBL5239656";"Inhibition of GST20-tagged LRRK2 in human SH-SY5Y cells assessed as reduction in pSer935 phosphorylation incubated for 90 mins by MSD assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5236618";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 1.5 hr";"INHIBITOR";""
"CHEMBL5204372";"";"None";"404.50";"0";"4.07";"16";"Cc1cc(-c2n[nH]c(C)c2-c2ccc(-c3cccc(S(N)(=O)=O)c3)cc2)ccn1";"IC50";"'='";"6.9";"nM";"8.16";"";"";"UO_0000065";"20.18";"0.38";"4.09";"8.02";"0";"CHEMBL5136368";"Inhibition of full-length LRRK2 G2019S mutant (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5185379";"";"None";"368.44";"0";"4.52";"27";"Cc1cc(-c2c(-c3ccncc3)n[nH]c2C)ccc1-c1cccc(C(N)=O)c1";"IC50";"'='";"213.0";"nM";"6.67";"";"";"UO_0000065";"18.11";"0.33";"2.15";"7.88";"0";"CHEMBL5136368";"Inhibition of full-length LRRK2 G2019S mutant (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5286106";"";"None";"426.52";"0";"3.50";"25";"CC(C)(O)C12CC(C1)N(c1cc(-n3ncc4ccc([C@]5(C#N)CC56CC6)cc43)ncn1)C2";"IC50";"'='";"0.3";"nM";"9.52";"";"";"UO_0000065";"22.33";"0.41";"6.02";"10.48";"0";"CHEMBL5239717";"Inhibition of LRRK2 in human PBMCs assessed as reduction in Ser95 phosphorylation";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"PBMC";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5236618";"1";"Scientific Literature";"J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL3326138";"";"None";"352.35";"0";"2.33";"26";"COc1ccc(OC)c(Oc2ccc3nnc(-c4cnn(C)c4)n3n2)c1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL3367451";"Inhibition of phosphorylation at S935 residue of wild-type full-length LRRK2 kinase (unknown origin) expressed in HEK 293 cells after 90 mins by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"CHEMBL3307715";"";"";""
"CHEMBL5198878";"";"None";"404.50";"0";"4.07";"25";"Cc1cc(-c2c(-c3ccncc3)n[nH]c2C)ccc1-c1cccc(S(N)(=O)=O)c1";"IC50";"'='";"6.15";"nM";"8.21";"";"";"UO_0000065";"20.30";"0.39";"4.14";"8.07";"0";"CHEMBL5136368";"Inhibition of full-length LRRK2 G2019S mutant (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5196289";"";"None";"390.47";"0";"3.76";"7";"Cc1[nH]nc(-c2ccncc2)c1-c1ccc(-c2cccc(S(N)(=O)=O)c2)cc1";"IC50";"'='";"172.0";"nM";"6.76";"";"";"UO_0000065";"17.32";"0.33";"3.00";"6.65";"0";"CHEMBL5136367";"Inhibition of full-length wild type LRRK2 (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5191932";"";"None";"446.58";"0";"5.00";"11";"Cc1cc(-c2n[nH]c(C)c2-c2ccc(-c3ccc(S(N)(=O)=O)c(C)c3C)cc2)cc(C)n1";"IC50";"'='";"325.0";"nM";"6.49";"";"";"UO_0000065";"14.53";"0.28";"1.49";"6.38";"0";"CHEMBL5136367";"Inhibition of full-length wild type LRRK2 (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5173076";"";"None";"418.52";"0";"4.38";"15";"Cc1cc(S(N)(=O)=O)cc(-c2ccc(-c3c(-c4ccncc4)n[nH]c3C)cc2)c1C";"IC50";"'='";"1110.0";"nM";"5.96";"";"";"UO_0000065";"14.23";"0.27";"1.57";"5.85";"0";"CHEMBL5136367";"Inhibition of full-length wild type LRRK2 (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5179102";"";"None";"418.52";"0";"4.38";"23";"Cc1cc(-c2n[nH]c(C)c2-c2ccc(-c3cccc(S(N)(=O)=O)c3)cc2)cc(C)n1";"IC50";"'='";"40.2";"nM";"7.40";"";"";"UO_0000065";"17.67";"0.34";"3.02";"7.27";"0";"CHEMBL5136367";"Inhibition of full-length wild type LRRK2 (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5185379";"";"None";"368.44";"0";"4.52";"27";"Cc1cc(-c2c(-c3ccncc3)n[nH]c2C)ccc1-c1cccc(C(N)=O)c1";"IC50";"'='";"479.0";"nM";"6.32";"";"";"UO_0000065";"17.15";"0.31";"1.80";"7.46";"0";"CHEMBL5136367";"Inhibition of full-length wild type LRRK2 (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5174380";"";"None";"430.53";"0";"4.64";"37";"Cc1[nH]nc(-c2ccncc2)c1-c1ccc(-c2cccc(S(N)(=O)=O)c2)c(C2CC2)c1";"IC50";"'='";"25.4";"nM";"7.59";"";"";"UO_0000065";"17.64";"0.33";"2.96";"7.47";"0";"CHEMBL5136367";"Inhibition of full-length wild type LRRK2 (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5181966";"";"None";"444.56";"0";"4.95";"41";"Cc1cc(-c2n[nH]c(C)c2-c2ccc(-c3cccc(S(N)(=O)=O)c3)c(C3CC3)c2)ccn1";"IC50";"'='";"17.1";"nM";"7.77";"";"";"UO_0000065";"17.47";"0.33";"2.82";"7.63";"0";"CHEMBL5136367";"Inhibition of full-length wild type LRRK2 (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5194659";"";"None";"326.36";"0";"4.60";"9";"Cc1cc(C#N)ccc1Oc1ccc2[nH]nc(-c3ccncc3)c2c1";"IC50";"'='";"134.0";"nM";"6.87";"";"";"UO_0000065";"21.06";"0.38";"2.27";"9.21";"0";"CHEMBL5157022";"Inhibition of full length wild type LRRK2 (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL3326136";"";"None";"370.40";"1";"1.48";"23";"COc1cc(Sc2ccc3nnc(-c4cnn(C)c4)n3n2)c(OC)nn1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL3367451";"Inhibition of phosphorylation at S935 residue of wild-type full-length LRRK2 kinase (unknown origin) expressed in HEK 293 cells after 90 mins by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"CHEMBL3307715";"";"";""
"CHEMBL3326126";"";"None";"371.45";"0";"3.42";"13";"COc1ccc(OC)c(Sc2ccc3nnc(-c4cncs4)n3n2)c1";"IC50";"'='";"660.0";"nM";"6.18";"";"";"UO_0000065";"16.64";"0.34";"2.76";"8.30";"0";"CHEMBL3367451";"Inhibition of phosphorylation at S935 residue of wild-type full-length LRRK2 kinase (unknown origin) expressed in HEK 293 cells after 90 mins by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"CHEMBL3307715";"";"";""
"CHEMBL3326116";"";"None";"365.42";"0";"3.35";"3";"COc1ccc(OC)c(Sc2ccc3nnc(-c4cccnc4)n3n2)c1";"IC50";"'='";"242.0";"nM";"6.62";"";"";"UO_0000065";"18.11";"0.35";"3.27";"8.89";"0";"CHEMBL3367450";"Inhibition of GST-tagged truncated LRRK2 (unknown origin) using fluorescein-labeled peptide LRRKtide as substrate by LANTHA screen assay in presence of 1 mM ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL3326119";"";"None";"395.44";"0";"3.36";"6";"COc1cncc(-c2nnc3ccc(Sc4cc(OC)ccc4OC)nn23)c1";"IC50";"'='";"440.0";"nM";"6.36";"";"";"UO_0000065";"16.07";"0.31";"3.00";"7.60";"0";"CHEMBL3367451";"Inhibition of phosphorylation at S935 residue of wild-type full-length LRRK2 kinase (unknown origin) expressed in HEK 293 cells after 90 mins by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"CHEMBL3307715";"";"";""
"CHEMBL3326153";"";"None";"381.46";"0";"3.61";"41";"COc1ccc(OC)c(Sc2ccn3nc(C)c(-c4cnn(C)c4)c3n2)c1";"IC50";"'='";"110.0";"nM";"6.96";"";"";"UO_0000065";"18.24";"0.35";"3.35";"10.47";"0";"CHEMBL3367450";"Inhibition of GST-tagged truncated LRRK2 (unknown origin) using fluorescein-labeled peptide LRRKtide as substrate by LANTHA screen assay in presence of 1 mM ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL3326147";"";"None";"367.43";"0";"3.30";"35";"COc1ccc(OC)c(Sc2ccc3ncc(-c4cnn(C)c4)n3n2)c1";"IC50";"'='";"69.0";"nM";"7.16";"";"";"UO_0000065";"19.49";"0.38";"3.86";"10.77";"0";"CHEMBL3367450";"Inhibition of GST-tagged truncated LRRK2 (unknown origin) using fluorescein-labeled peptide LRRKtide as substrate by LANTHA screen assay in presence of 1 mM ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL5171071";"";"None";"421.51";"0";"2.43";"17";"Cc1nc(NC(=O)c2cccc(-c3cnn(C)c3)n2)cc(N2CC[C@@H](C(C)(C)O)C2)n1";"IC50";"'='";"4.0";"nM";"8.40";"";"";"UO_0000065";"19.92";"0.37";"5.97";"7.70";"0";"CHEMBL5108135";"Inhibition of recombinant human GST20 tagged truncated LRRK2 G2019S mutant assessed as substrate phosphorylation preincubated for 15 mins followed by substrate addition and measured after 90 mins using fluorescein-labeled LRRK2tide as substrate in presence of ATP by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5107939";"1";"Scientific Literature";"RSC Med Chem";"2021";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL5085753";"";"None";"727.91";"2";"5.95";"25";"CCc1cccc(CC)c1N1CCn2cc(-c3nc(Nc4ccc(N5CCC(C(=O)N6CC7(CN(C)C7)C6)CC5)cc4OC)nc4[nH]ccc34)cc2C1=O";"IC50";"'='";"229.0";"nM";"6.64";"";"";"UO_0000065";"9.12";"0.17";"0.69";"5.78";"0";"CHEMBL5037548";"Inhibition of LRRK2 G2019S mutant (unknown origin) by ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5036336";"1";"Scientific Literature";"J Med Chem";"2021";"None";"";"INHIBITOR";""
"CHEMBL2326726";"";"None";"364.76";"0";"2.90";"18";"CNc1nc(Nc2cnn(CC(C)(C)O)c2Cl)ncc1C(F)(F)F";"IC50";"'='";"28.0";"nM";"7.55";"";"";"UO_0000065";"20.71";"0.43";"4.65";"8.59";"0";"CHEMBL2328175";"Inhibition of LRRK2 (unknown origin) autophosphorylation by cell-based assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2321736";"1";"Scientific Literature";"ACS Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2178139";"";"None";"383.37";"0";"3.58";"23";"CNc1nc(Nc2cnc(C3CCOCC3)cc2OC)ncc1C(F)(F)F";"IC50";"'='";"51.0";"nM";"7.29";"";"";"UO_0000065";"19.02";"0.37";"3.71";"8.98";"0";"CHEMBL2188381";"Inhibition of autophosphorylation of LRRK2 in human HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2176933";"1";"Scientific Literature";"J Med Chem";"2012";"CHEMBL3307715";"";"";""
"CHEMBL4740170";"";"None";"411.46";"0";"2.97";"16";"CCOc1nc(Nc2ccc(C(=O)N3CCOC[C@H]3C)cc2OC)nc2[nH]ccc12";"IC50";"'='";"79.43";"nM";"7.10";"";"";"UO_0000065";"17.26";"0.32";"4.13";"6.99";"0";"CHEMBL4721244";"Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins by Alpha Screen assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4715821";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2018";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL4446892";"";"None";"520.34";"1";"3.31";"GSK8612";"Cc1nn(CC(F)(F)F)cc1Nc1ncc(Br)c(NCc2ccc(S(N)(=O)=O)cc2)n1";"IC50";"'='";"159.0";"nM";"6.80";"";"";"UO_0000065";"13.07";"0.30";"3.49";"5.32";"0";"CHEMBL5046600";"Inhibition of recombinant human LRRK2 (970 to end residues) using RLGRDKYKTLRQIRQ as substrate incubated for 40 mins in presence of [gamma-33P-ATP] by radiometric scintillation assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5046221";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 0.6667 hr";"INHIBITOR";""
"CHEMBL4454874";"";"None";"381.50";"0";"4.51";"17";"CC(C)c1ccc2nc(NC(=O)c3ccc(N4CCOCC4)cc3)sc2c1";"IC50";"'='";"980.0";"nM";"6.01";"";"";"UO_0000065";"15.75";"0.30";"1.50";"11.03";"0";"CHEMBL4403864";"Inhibition of human GST-tagged LRRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus expression system assessed as reduction in ADP formation using LRRKtide as substrate measured after 1 hr in presence of ATP by Adapta assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4402549";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL4093321";"";"None";"428.52";"0";"2.03";"28";"CC1(Oc2ccc3[nH]nc(-c4cc(N5CCN(S(C)(=O)=O)CC5)ncn4)c3c2)CC1";"IC50";"'='";"2.2";"nM";"8.66";"";"";"UO_0000065";"20.20";"0.39";"6.63";"8.30";"0";"CHEMBL4010109";"Inhibition of recombinant human GST-tagged LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus using fluorescein-ERM as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007454";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4065697";"";"None";"365.44";"0";"3.18";"27";"C[C@@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)CCO1";"IC50";"'='";"2.0";"nM";"8.70";"";"";"UO_0000065";"23.80";"0.44";"5.52";"11.42";"0";"CHEMBL4010109";"Inhibition of recombinant human GST-tagged LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus using fluorescein-ERM as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007454";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL3928102";"";"None";"339.40";"0";"2.64";"24";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCOCC4)ncn3)c2c1";"IC50";"'='";"7.2";"nM";"8.14";"";"";"UO_0000065";"23.99";"0.44";"5.50";"10.69";"1";"CHEMBL4010109";"Inhibition of recombinant human GST-tagged LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus using fluorescein-ERM as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007454";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4093321";"";"None";"428.52";"0";"2.03";"28";"CC1(Oc2ccc3[nH]nc(-c4cc(N5CCN(S(C)(=O)=O)CC5)ncn4)c3c2)CC1";"IC50";"'='";"7.6";"nM";"8.12";"";"";"UO_0000065";"18.95";"0.37";"6.09";"7.78";"0";"CHEMBL4010118";"Inhibition LRRK2 G2019S mutant Ser935 phosphorylation in human SH-SY5Y cells after 90 mins by Western blot analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007454";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL3326148";"";"None";"367.43";"0";"3.30";"36";"COc1ccc(OC)c(Sc2ccn3ncc(-c4cnn(C)c4)c3n2)c1";"IC50";"'='";"64.0";"nM";"7.19";"";"";"UO_0000065";"19.58";"0.38";"3.89";"10.82";"0";"CHEMBL3367450";"Inhibition of GST-tagged truncated LRRK2 (unknown origin) using fluorescein-labeled peptide LRRKtide as substrate by LANTHA screen assay in presence of 1 mM ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL3326141";"";"None";"364.37";"0";"1.77";"29";"COc1ccc(OC)c(C(=O)c2ccc3nnc(-c4cnn(C)c4)n3n2)c1";"IC50";"'='";"1211.0";"nM";"5.92";"";"";"UO_0000065";"16.24";"0.30";"4.15";"6.14";"0";"CHEMBL3367450";"Inhibition of GST-tagged truncated LRRK2 (unknown origin) using fluorescein-labeled peptide LRRKtide as substrate by LANTHA screen assay in presence of 1 mM ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL3326132";"";"None";"363.41";"0";"2.56";"19";"COc1ccc(C#N)cc1Sc1ccc2nnc(-c3cnn(C)c3)n2n1";"IC50";"'='";"64.0";"nM";"7.19";"";"";"UO_0000065";"19.80";"0.38";"4.63";"7.66";"0";"CHEMBL3367450";"Inhibition of GST-tagged truncated LRRK2 (unknown origin) using fluorescein-labeled peptide LRRKtide as substrate by LANTHA screen assay in presence of 1 mM ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL3326144";"";"None";"382.45";"0";"3.00";"32";"COc1ccc(OC)c(Sc2nn3c(-c4cnn(C)c4)nnc3cc2C)c1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL3367451";"Inhibition of phosphorylation at S935 residue of wild-type full-length LRRK2 kinase (unknown origin) expressed in HEK 293 cells after 90 mins by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"CHEMBL3307715";"";"";""
"CHEMBL3326151";"";"None";"366.45";"0";"3.90";"39";"COc1ccc(OC)c(Sc2ccc3ncc(-c4cnn(C)c4)n3c2)c1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL3367451";"Inhibition of phosphorylation at S935 residue of wild-type full-length LRRK2 kinase (unknown origin) expressed in HEK 293 cells after 90 mins by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"CHEMBL3307715";"";"";""
"CHEMBL5276942";"";"None";"354.37";"0";"0.78";"39";"CC1=C(C(=O)Nc2ccc3c(c2)[nH]c(=O)n3C)[C@@H](C)n2nnnc2N1C";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5246746";"Inhibition of N-terminal GST-fused human LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"";""
"CHEMBL5289513";"";"None";"324.35";"0";"1.47";"21";"CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)[C@@H](C)n2nnnc2N1C";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5246748";"Inhibition of human wild type LRRK2 expressed in HEK293 cells assessed as reduction in pSer935 phosphorylation incubated for 2 hrs by HTRF analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 2.0 hr";"";""
"CHEMBL5288427";"";"None";"426.44";"0";"2.46";"7";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4nc5ccccc5[nH]4)c3c2)Cn2nnnc2N1C";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL5246757";"Inhibition human wild type LRRK2 expressed in human HEK293 assessed as Rab10 substrate phosphorylation at Threonine 73 residue incubated for 2 hrs by immunoblotting analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 2.0 hr";"";""
"CHEMBL5279816";"";"None";"338.38";"0";"1.78";"23";"CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)[C@@H](C)n2nnnc2N1C";"IC50";"'='";"137.0";"nM";"6.86";"";"";"UO_0000065";"20.28";"0.37";"5.08";"6.56";"0";"CHEMBL5246758";"Inhibition human LRRK2 G2019S mutant expressed in human HEK293 assessed as Rab10 substrate phosphorylation at Threonine 73 residue incubated for 2 hrs by immunoblotting analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL4761952";"";"None";"350.30";"0";"2.77";"1";"NC(=O)c1ccc(Nc2nc(NCC(F)(F)F)c3cc[nH]c3n2)cc1";"IC50";"'='";"12.59";"nM";"7.90";"";"";"UO_0000065";"22.55";"0.43";"5.13";"7.27";"0";"CHEMBL4721243";"Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs in presence of ATP by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4715821";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2018";"None";"TIME = 2.5 hr";"INHIBITOR";""
"CHEMBL4740170";"";"None";"411.46";"0";"2.97";"16";"CCOc1nc(Nc2ccc(C(=O)N3CCOC[C@H]3C)cc2OC)nc2[nH]ccc12";"IC50";"'='";"15.85";"nM";"7.80";"";"";"UO_0000065";"18.96";"0.36";"4.83";"7.68";"0";"CHEMBL4721243";"Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs in presence of ATP by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4715821";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2018";"None";"TIME = 2.5 hr";"INHIBITOR";""
"CHEMBL4751816";"";"None";"413.45";"0";"3.68";"18";"CCOc1nc(Nc2ccc(C(=O)N3CCC(F)CC3)cc2OC)nc2[nH]ccc12";"IC50";"'='";"316.23";"nM";"6.50";"";"";"UO_0000065";"15.72";"0.30";"2.82";"7.04";"0";"CHEMBL4721244";"Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins by Alpha Screen assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4715821";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2018";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL4747186";"";"None";"446.46";"0";"3.09";"12";"CCOc1nc(Nc2ccc(C(=O)N3CCN(C)CC3)cc2OC(F)F)nc2[nH]ccc12";"IC50";"'='";"158.49";"nM";"6.80";"";"";"UO_0000065";"15.23";"0.29";"3.71";"7.11";"0";"CHEMBL4721244";"Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins by Alpha Screen assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4715821";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2018";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5092087";"";"None";"421.51";"0";"2.62";"45";"Cc1c(Nc2nc(N)c3c(C#N)c(N4CCC[C@H]4C)n(C)c3n2)cnn1[C@H]1CCOC1";"IC50";"'='";"86.0";"nM";"7.07";"";"";"UO_0000065";"16.76";"0.31";"4.45";"5.75";"0";"CHEMBL5040132";"Inhibition of LRRK2 WT expressed in human PBMCs measured by KiNativ profiling analysis";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"";"INHIBITOR";""
"CHEMBL5074799";"";"None";"448.57";"0";"3.81";"12";"Cc1c(Nc2ncc3ccc(C4CCN(C5COC5)CC4)cc3n2)cnn1C1CCOCC1";"IC50";"'='";"6800.0";"nM";"5.17";"";"";"UO_0000065";"11.52";"0.21";"1.36";"6.68";"0";"CHEMBL5044129";"Inhibition of recombinant N-terminal GST-fused LRRK2 G2109S mutant (970 to 2527 residues) (unknown origin) preincubated with enzyme for 15 mins followed by fluorescein-labeled LRRKtide peptide substrate and ATP addition for 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5042510";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL5073735";"";"None";"375.44";"0";"3.62";"8";"Cc1c(Nc2ncc3ccc(-c4ccn[nH]4)cc3n2)cnn1C1CCOCC1";"IC50";"'='";"1.7";"nM";"8.77";"";"";"UO_0000065";"23.36";"0.43";"5.15";"9.38";"0";"CHEMBL5044129";"Inhibition of recombinant N-terminal GST-fused LRRK2 G2109S mutant (970 to 2527 residues) (unknown origin) preincubated with enzyme for 15 mins followed by fluorescein-labeled LRRKtide peptide substrate and ATP addition for 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5042510";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL5092458";"";"None";"278.32";"0";"2.03";"11";"Cn1c(NCc2ccccc2)c(C#N)c2c(N)ncnc21";"IC50";"'='";"3532.0";"nM";"5.45";"";"";"UO_0000065";"19.59";"0.35";"3.42";"5.89";"0";"CHEMBL5040107";"Inhibition of recombinant human GST tagged truncated LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5190434";"";"None";"432.41";"0";"2.72";"9";"C[C@@H]1[C@@H](O)CN1c1cc(NC(=O)c2cccc(-c3cnn(C)c3)n2)c(C(F)(F)F)cn1";"IC50";"'='";"2.0";"nM";"8.70";"";"";"UO_0000065";"20.12";"0.38";"5.98";"9.05";"0";"CHEMBL5108135";"Inhibition of recombinant human GST20 tagged truncated LRRK2 G2019S mutant assessed as substrate phosphorylation preincubated for 15 mins followed by substrate addition and measured after 90 mins using fluorescein-labeled LRRK2tide as substrate in presence of ATP by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5107939";"1";"Scientific Literature";"RSC Med Chem";"2021";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL3962458";"";"None";"412.49";"0";"1.54";"BDBM239467";"COC[C@H](C)Oc1ccc2[nH]nc(-c3cc(N4C[C@H](O)[C@@H](N(C)C)C4)ncn3)c2c1";"IC50";"'='";"6.6";"nM";"8.18";"";"417932";"UO_0000065";"19.83";"0.37";"6.64";"8.21";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3894715";"";"None";"388.43";"0";"2.93";"BDBM239485";"COc1ccc(-c2ccc3[nH]nc(-c4cc(N5CCOCC5)ncn4)c3c2)cn1";"IC50";"'='";"31.2";"nM";"7.51";"";"417950";"UO_0000065";"19.32";"0.35";"4.58";"8.43";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3963980";"";"None";"403.43";"0";"3.67";"BDBM239464";"COC[C@H](C)Oc1ccc2[nH]nc(-c3cc(N4CCC(F)(F)CC4)ncn3)c2c1";"IC50";"'='";"8.0";"nM";"8.10";"";"417929";"UO_0000065";"20.07";"0.38";"4.43";"10.63";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3953830";"";"None";"349.40";"0";"2.48";"BDBM239183";"COCCNc1cc(-c2n[nH]c3ccc(-c4cnn(C)c4)cc23)ncn1";"IC50";"'='";"14.96";"nM";"7.83";"";"417642";"UO_0000065";"22.40";"0.41";"5.35";"8.37";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3935320";"";"None";"357.39";"0";"2.78";"BDBM239212";"CC(C)Oc1cc2c(-c3cc(N4CCOCC4)ncn3)n[nH]c2cc1F";"IC50";"'='";"2.39";"nM";"8.62";"";"417673";"UO_0000065";"24.12";"0.45";"5.84";"11.32";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4108580";"";"None";"356.41";"0";"2.48";"BDBM239242";"CC(C)Oc1cc2c(-c3cc(N4CC[C@@H](N)C4)ncn3)n[nH]c2cc1F";"IC50";"'='";"7.3";"nM";"8.14";"";"417703";"UO_0000065";"22.83";"0.43";"5.66";"8.75";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3927621";"";"None";"396.45";"0";"1.71";"BDBM239296";"COCCOc1ccc2[nH]nc(-c3cc(N4CCN(C(C)=O)CC4)ncn3)c2c1";"IC50";"'='";"127.5";"nM";"6.89";"";"417755";"UO_0000065";"17.39";"0.32";"5.18";"7.15";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3966175";"";"None";"323.40";"0";"3.41";"BDBM239321";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCCC4)ncn3)c2c1";"IC50";"'='";"13.9";"nM";"7.86";"";"417789";"UO_0000065";"24.29";"0.45";"4.45";"11.74";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4743843";"";"None";"425.49";"0";"3.36";"11";"CCOc1nc(Nc2ccc(C(=O)N3CCOCC3)cc2OC(C)C)nc2[nH]ccc12";"IC50";"'='";"12.59";"nM";"7.90";"";"";"UO_0000065";"18.57";"0.35";"4.54";"7.78";"0";"CHEMBL4721243";"Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs in presence of ATP by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4715821";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2018";"None";"TIME = 2.5 hr";"INHIBITOR";""
"CHEMBL4794578";"";"None";"397.44";"0";"2.58";"7";"CCOc1nc(Nc2ccc(C(=O)N3CCOCC3)cc2OC)nc2[nH]ccc12";"IC50";"'='";"15.85";"nM";"7.80";"";"";"UO_0000065";"19.63";"0.37";"5.22";"7.68";"0";"CHEMBL4721260";"Inhibition of LRRK2 G2019S mutant in human ANK cells assessed as reduction in Ser935 phosphorylation";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"Lymphoblastoid cell";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4715821";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2018";"None";"";"INHIBITOR";""
"CHEMBL4097778";"TP-030n";"None";"458.54";"0";"1.13";"TP-030n";"CN1C(=O)[C@@H](N2CCc3cn(CC4CCS(=O)(=O)CC4)nc3C2=O)COc2ccccc21";"IC50";"";"1000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL4885502";"LRRK2(LRR2PGF1) Takeda global kinase panel";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4507327";"54";"Donated Chemical Probes - SGC Frankfurt";"";"2021";"None";"Compound concentration None 1.0 µM";"";""
"CHEMBL4451151";"";"None";"410.92";"0";"4.67";"96";"[2H]C([2H])([2H])c1cnc(Cc2nc3cnc4ccc(Cl)cc4c3n2[C@@H]2CCO[C@H](C)C2)cn1";"IC50";"'='";"3.21";"nM";"8.49";"";"";"UO_0000065";"20.82";"0.40";"3.82";"12.92";"0";"CHEMBL4334283";"Inhibition of recombinant wild-type GST-tagged LRRK2 (unknown origin) expressed in baculovirus expression system using fluorescein-labeled LRRKtide as substrate after 30 mins by Lanthascreen assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330176";"1";"Scientific Literature";"ACS Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4466740";"";"None";"430.43";"0";"4.06";"9";"C[C@@H]1C[C@H](n2c(Cc3cn(C)nn3)nc3cnc4ccc(C(F)(F)F)cc4c32)CCO1";"IC50";"'='";"11.8";"nM";"7.93";"";"";"UO_0000065";"18.42";"0.35";"3.87";"11.22";"0";"CHEMBL4334283";"Inhibition of recombinant wild-type GST-tagged LRRK2 (unknown origin) expressed in baculovirus expression system using fluorescein-labeled LRRKtide as substrate after 30 mins by Lanthascreen assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330176";"1";"Scientific Literature";"ACS Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4562596";"";"None";"378.44";"0";"3.96";"79";"N#Cc1ccc2ncc3nc(Cc4csnn4)n([C@@H]4CC[C@H](F)C4)c3c2c1";"IC50";"'='";"9.75";"nM";"8.01";"";"";"UO_0000065";"21.17";"0.41";"4.05";"9.98";"0";"CHEMBL4334284";"Inhibition of GST-tagged LRRK2 G2019S mutant (unknown origin) expressed in baculovirus expression system using fluorescein-labeled LRRKtide as substrate after 30 mins by Lanthascreen assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330176";"1";"Scientific Literature";"ACS Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4206654";"";"None";"247.27";"0";"1.97";"40, E:Z Mixture (30:70)";"O=C1Nc2ccc(F)cc2C1=NN1CCCCC1";"IC50";"'='";"1500.0";"nM";"5.82";"";"";"UO_0000065";"23.55";"0.44";"3.85";"13.03";"0";"CHEMBL4192178";"Inhibition of recombinant catalytic human GST-tagged LLRK2 (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4190250";"1";"Scientific Literature";"Eur J Med Chem";"2017";"None";"";"";""
"CHEMBL4214911";"";"None";"259.31";"0";"1.84";"43, E:Z Mixture (41:59)";"COc1ccc2c(c1)C(=NN1CCCCC1)C(=O)N2";"IC50";"'='";"760.0";"nM";"6.12";"";"";"UO_0000065";"23.60";"0.44";"4.28";"11.35";"0";"CHEMBL4192178";"Inhibition of recombinant catalytic human GST-tagged LLRK2 (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4190250";"1";"Scientific Literature";"Eur J Med Chem";"2017";"None";"";"";""
"CHEMBL4218856";"";"None";"313.36";"0";"4.18";"16, E:Z Mixture (95:5)";"O=C1Nc2ccccc2C1=NN(c1ccccc1)c1ccccc1";"IC50";"'='";"290.0";"nM";"6.54";"";"";"UO_0000065";"20.86";"0.37";"2.36";"14.63";"0";"CHEMBL4192179";"Inhibition of recombinant catalytic human GST-tagged LLRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4190250";"1";"Scientific Literature";"Eur J Med Chem";"2017";"None";"";"";""
"CHEMBL5286893";"";"None";"401.43";"0";"2.53";"25";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4ccncc4)c3c2)[C@@H](C)n2nnnc2N1C";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL5246757";"Inhibition human wild type LRRK2 expressed in human HEK293 assessed as Rab10 substrate phosphorylation at Threonine 73 residue incubated for 2 hrs by immunoblotting analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 2.0 hr";"";""
"CHEMBL3975772";"";"None";"332.41";"0";"3.24";"BDBM254924";"Cc1cc(-c2ccnc3[nH]cc(C#N)c23)ccc1CN1CCOCC1";"IC50";"'='";"620.0";"nM";"6.21";"";"443730";"UO_0000065";"18.67";"0.34";"2.97";"9.56";"0";"CHEMBL3889253";"Homogeneous Time Resolved-fluorescence Resonance Energy Transfer (TR-FRET) Assay: LRRK2 kinase activity is measured using a LanthaScreen kinase activity assay available from Invitrogen (Life Technologies Corporation). The assay is a homogeneous time resolved-fluorescence resonance energy transfer (TR-FRET) assay that measures phosphorylation of a fluorescein-labelled peptide substrate (fluorescein-LRRKtide, fluorescein-GAGRLGRDKYKTLRQIRQ) (SEQ ID NO 1) as a result of LRRK2 kinase activity. The phosphorylated peptide is recognized by a terbium-labelled phospho-specific anti-LRRKtide antibody and, subsequently, the phosphorylated LRRKtide can be quantified by the extent of TR-FRET between the terbium donor and fluorescein acceptor.The LRRK2 kinase is obtained from Invitrogen (Life Technologies Corporation) and comprises residues 970 to 2527 of the full length human wild-type LRRK2 kinase or a similar sequence with the G2019S mutation. As discussed above, this mutation increases the kinase activity relative to the wild-type. The kinase reactions are performed in a 20 uL volume in 384-well plates. The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT.Â  In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 uM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 uM fluorescein-LRRKtide. The reaction mixture (20 ul total volume) is incubated for 2 hours at 30° C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 ul). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 us) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 us. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 us time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3887011";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3907032";"";"None";"314.35";"0";"3.58";"BDBM254933";"Cn1cc(Nc2cc(-c3ccccc3)c3c(C#N)c[nH]c3n2)cn1";"IC50";"'='";"97.0";"nM";"7.01";"";"443739";"UO_0000065";"22.31";"0.40";"3.43";"8.52";"0";"CHEMBL3889253";"Homogeneous Time Resolved-fluorescence Resonance Energy Transfer (TR-FRET) Assay: LRRK2 kinase activity is measured using a LanthaScreen kinase activity assay available from Invitrogen (Life Technologies Corporation). The assay is a homogeneous time resolved-fluorescence resonance energy transfer (TR-FRET) assay that measures phosphorylation of a fluorescein-labelled peptide substrate (fluorescein-LRRKtide, fluorescein-GAGRLGRDKYKTLRQIRQ) (SEQ ID NO 1) as a result of LRRK2 kinase activity. The phosphorylated peptide is recognized by a terbium-labelled phospho-specific anti-LRRKtide antibody and, subsequently, the phosphorylated LRRKtide can be quantified by the extent of TR-FRET between the terbium donor and fluorescein acceptor.The LRRK2 kinase is obtained from Invitrogen (Life Technologies Corporation) and comprises residues 970 to 2527 of the full length human wild-type LRRK2 kinase or a similar sequence with the G2019S mutation. As discussed above, this mutation increases the kinase activity relative to the wild-type. The kinase reactions are performed in a 20 uL volume in 384-well plates. The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT.Â  In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 uM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 uM fluorescein-LRRKtide. The reaction mixture (20 ul total volume) is incubated for 2 hours at 30° C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 ul). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 us) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 us. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 us time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3887011";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL5075824";"";"None";"407.48";"0";"2.23";"40";"Cc1nn(C2COC2)cc1Nc1nc(N)c2c(C#N)c(N3CCC[C@H]3C)n(C)c2n1";"IC50";"'='";"240.0";"nM";"6.62";"";"";"UO_0000065";"16.25";"0.30";"4.39";"5.39";"0";"CHEMBL5040117";"Inhibition of LRRK2-pSer935 in LRRK2 WT expressing human HEK293 cells and measured after 48 hrs by ICW assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 48.0 hr";"INHIBITOR";""
"CHEMBL5073900";"";"None";"351.42";"0";"2.19";"33";"Cc1n[nH]cc1Nc1nc(N)c2c(C#N)c(N3CCC[C@H]3C)n(C)c2n1";"IC50";"'='";"42.0";"nM";"7.38";"";"";"UO_0000065";"20.99";"0.39";"5.19";"5.93";"0";"CHEMBL5040109";"Inhibition of recombinant human LRRK2 WT using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5092087";"";"None";"421.51";"0";"2.62";"45";"Cc1c(Nc2nc(N)c3c(C#N)c(N4CCC[C@H]4C)n(C)c3n2)cnn1[C@H]1CCOC1";"IC50";"'='";"51.0";"nM";"7.29";"";"";"UO_0000065";"17.30";"0.32";"4.67";"5.94";"0";"CHEMBL5040116";"Inhibition of LRRK2-pSer935 in LRRK2 G2019S mutant expressing human HEK293 cells and measured after 48 hrs by ICW assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 48.0 hr";"INHIBITOR";""
"CHEMBL3946828";"";"None";"416.49";"0";"4.24";"BDBM239335";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCc5nc(C6CC6)oc5C4)ncn3)c2c1";"IC50";"'='";"43.0";"nM";"7.37";"";"417804";"UO_0000065";"17.69";"0.32";"3.13";"7.92";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3934311";"";"None";"446.52";"0";"3.39";"BDBM239336";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCN(c5nnc(C6CC6)o5)CC4)ncn3)c2c1";"IC50";"'='";"14.0";"nM";"7.85";"";"417805";"UO_0000065";"17.59";"0.33";"4.46";"7.20";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3934534";"";"None";"341.39";"0";"3.36";"BDBM239341";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CC[C@H](F)C4)ncn3)c2c1";"IC50";"'='";"9.5";"nM";"8.02";"";"417810";"UO_0000065";"23.50";"0.44";"4.66";"11.99";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3977651";"";"None";"429.53";"0";"3.52";"BDBM239357";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCN(Cc5ccncc5)CC4)ncn3)c2c1";"IC50";"'='";"8.2";"nM";"8.09";"";"417825";"UO_0000065";"18.83";"0.35";"4.57";"9.74";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3937091";"";"None";"416.42";"0";"2.17";"BDBM239364";"Cn1cc(-c2cc3c(-c4cc(N5CCn6ncnc6C5)ncn4)n[nH]c3cc2F)cn1";"IC50";"'='";"63.9";"nM";"7.19";"";"417831";"UO_0000065";"17.28";"0.32";"5.02";"6.77";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4107324";"";"None";"393.43";"0";"2.38";"BDBM239367";"Cn1cc(-c2cc3c(-c4cc(N5CC[C@@H](CO)C5)ncn4)n[nH]c3cc2F)cn1";"IC50";"'='";"36.8";"nM";"7.43";"";"417834";"UO_0000065";"18.90";"0.35";"5.05";"7.76";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3984432";"";"None";"399.38";"0";"3.40";"BDBM239369";"Cn1cc(-c2cc3c(-c4cc(N5CCC(F)(F)C5)ncn4)n[nH]c3cc2F)cn1";"IC50";"'='";"70.9";"nM";"7.15";"";"417836";"UO_0000065";"17.90";"0.34";"3.75";"9.47";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4108829";"";"None";"399.38";"0";"3.06";"BDBM239377";"Cn1cc(-c2cc3c(-c4cc(N5C[C@@H](F)[C@H](F)C5)ncn4)n[nH]c3cc2F)cn1";"IC50";"'='";"29.9";"nM";"7.52";"";"417844";"UO_0000065";"18.84";"0.35";"4.46";"9.96";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3930214";"";"None";"436.50";"0";"2.06";"BDBM239388";"Cn1cc(-c2cc3c(-c4cc(N5CCN(CCCO)CC5)ncn4)n[nH]c3cc2F)cn1";"IC50";"'='";"12.6";"nM";"7.90";"";"417855";"UO_0000065";"18.10";"0.34";"5.84";"7.98";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3925366";"";"None";"389.46";"0";"2.63";"BDBM239396";"CC(O)C1CCN(c2cc(-c3n[nH]c4ccc(-c5cnn(C)c5)cc34)ncn2)C1";"IC50";"'='";"2.3";"nM";"8.64";"";"417862";"UO_0000065";"22.18";"0.41";"6.01";"9.02";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4113045";"";"None";"375.44";"0";"2.24";"BDBM239397";"Cn1cc(-c2ccc3[nH]nc(-c4cc(N5CC[C@@H](CO)C5)ncn4)c3c2)cn1";"IC50";"'='";"2.9";"nM";"8.54";"";"417863";"UO_0000065";"22.74";"0.42";"6.30";"8.92";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3941596";"";"None";"476.44";"0";"4.14";"BDBM239424";"CC(C)Oc1cc2c(-c3cc(N4CCn5nc(C(F)(F)F)nc5C4C)ncn3)n[nH]c2cc1F";"IC50";"'='";"176.0";"nM";"6.75";"";"417890";"UO_0000065";"14.18";"0.27";"2.61";"6.92";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3967666";"";"None";"387.45";"0";"3.09";"BDBM239494";"C[C@@H]1CN(c2cc(-c3n[nH]c4ccc(-c5cncnc5)cc34)ncn2)C[C@H](C)O1";"IC50";"'='";"30.3";"nM";"7.52";"";"417959";"UO_0000065";"19.41";"0.35";"4.43";"8.11";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3971024";"";"None";"416.49";"0";"3.70";"BDBM239495";"COc1ccc(-c2ccc3[nH]nc(-c4cc(N5C[C@@H](C)O[C@@H](C)C5)ncn4)c3c2)cn1";"IC50";"'='";"41.1";"nM";"7.39";"";"417960";"UO_0000065";"17.73";"0.33";"3.69";"8.29";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL2204495";"";"None";"399.43";"1";"5.11";"8i; GSK2578215 A";"O=C(Nc1cccnc1)c1cc(-c2ccnc(F)c2)ccc1OCc1ccccc1";"IC50";"'='";"10.0";"nM";"8.00";"";"";"UO_0000065";"20.03";"0.36";"2.89";"12.48";"0";"CHEMBL4058537";"Inhibition of LRRK2 (unknown origin) by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4052807";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL4077195";"";"None";"390.34";"1";"5.07";"8e";"O=C(Nc1cccnc1)c1cc(C(F)(F)F)ccc1OCc1ccc(F)cc1";"IC50";"'='";"19.95";"nM";"7.70";"";"";"UO_0000065";"19.73";"0.38";"2.63";"15.03";"0";"CHEMBL4058537";"Inhibition of LRRK2 (unknown origin) by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4052807";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL3891150";"";"None";"392.46";"0";"2.64";"BDBM223565";"CC(C)n1cc(-c2cc(-c3cccc(C(=O)N4CCOCC4)c3)cnc2N)nn1";"IC50";"'='";"650.0";"nM";"6.19";"";"390850";"UO_0000065";"15.76";"0.29";"3.55";"6.24";"0";"CHEMBL3888346";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3393346";"";"None";"263.30";"0";"2.56";"BDBM50059301";"CN(C)c1ncnc2[nH]cc(-c3cccc(C#N)c3)c12";"IC50";"'='";"5.0";"nM";"8.30";"";"334324";"UO_0000065";"31.53";"0.57";"5.74";"12.10";"1";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3964393";"";"None";"268.32";"0";"2.18";"BDBM185574";"CN(C)c1ncnc2[nH]cc(-c3cccc(CO)c3)c12";"IC50";"'='";"34.0";"nM";"7.47";"";"334329";"UO_0000065";"27.83";"0.51";"5.29";"11.48";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3890066";"";"None";"332.41";"0";"3.74";"BDBM185409";"C[C@H]1CCCN(c2ncnc3[nH]cc(-c4cnc5[nH]ccc5c4)c23)C1";"IC50";"'='";"74.0";"nM";"7.13";"";"334373";"UO_0000065";"21.45";"0.39";"3.39";"9.70";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3900759";"";"None";"335.41";"0";"2.96";"BDBM185413";"C[C@H]1CCCN(c2ncnc3[nH]cc(-c4ccc(C(N)=O)cc4)c23)C1";"IC50";"'='";"13.0";"nM";"7.89";"";"334377";"UO_0000065";"23.51";"0.43";"4.93";"8.97";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3948344";"";"None";"342.37";"0";"3.00";"BDBM185525";"COc1ccc(F)cc1-c1c[nH]c2ncnc(N3CCO[C@@H](C)C3)c12";"IC50";"'='";"19.0";"nM";"7.72";"";"334494";"UO_0000065";"22.55";"0.42";"4.72";"12.20";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3973248";"";"None";"332.77";"0";"3.25";"BDBM185439";"Fc1ccc(Cl)cc1-c1c[nH]c2ncnc(N3CCOCC3)c12";"IC50";"'='";"9.0";"nM";"8.05";"";"334408";"UO_0000065";"24.18";"0.48";"4.80";"14.89";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3890755";"";"None";"301.31";"0";"2.96";"BDBM185491";"N#Cc1cccc(-c2c[nH]c3ncnc(Nc4cn[nH]c4)c23)c1";"IC50";"'='";"69.0";"nM";"7.16";"";"334464";"UO_0000065";"23.77";"0.43";"4.20";"6.75";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3982042";"";"None";"301.38";"0";"2.23";"BDBM185538";"Cc1cc(-c2c[nH]c3ncnc(N4CCOCC4)c23)sn1";"IC50";"'='";"23.0";"nM";"7.64";"";"334505";"UO_0000065";"25.34";"0.50";"5.41";"11.41";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3958543";"";"None";"321.34";"0";"1.50";"BDBM185557";"c1cnc2c(-c3c[nH]c4ncnc(N5CCOCC5)c34)cnn2c1";"IC50";"'='";"35.6";"nM";"7.45";"";"334526";"UO_0000065";"23.18";"0.42";"5.95";"8.84";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL4453650";"";"None";"202.26";"0";"2.09";"15";"Cc1n[nH]c2ccnc(NCC3CC3)c12";"IC50";"'='";"2400.0";"nM";"5.62";"";"";"UO_0000065";"27.78";"0.51";"3.53";"10.48";"0";"CHEMBL4331900";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant catalytic domain (970 to 2527 residues) expressed in baculovirus expression system by radiometric assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330096";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4098877";"MLi-2";"None";"379.46";"0";"3.56";"EUB0000715";"C[C@@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@H](C)O1";"IC50";"";"6.3";"nM";"";"";"Active";"UO_0000065";"";"";"";"";"0";"CHEMBL4882638";"LRRK2 Biochemical Assay with 5mM ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"Additional information: LanthaScreen | Assay publication: PMID: 26407721 | Target protein type: GST-tagged truncated human mutant G2019S LRRK2";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4507291";"54";"Donated Chemical Probes - SGC Frankfurt";"";"2021";"None";"";"";""
"CHEMBL3936985";"";"None";"333.40";"0";"3.25";"BDBM223543";"CN1CCc2cc(-c3cnc(N)c(-c4nnc(C5CC5)o4)c3)ccc21";"IC50";"'='";"970.0";"nM";"6.01";"";"390828";"UO_0000065";"18.04";"0.33";"2.76";"7.42";"0";"CHEMBL3888346";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3919901";"";"None";"377.45";"0";"3.09";"BDBM223546";"Nc1ncc(-c2ccc(CN3CCOCC3)cc2)cc1-c1nnc(C2CC2)o1";"IC50";"'='";"490.0";"nM";"6.31";"";"390831";"UO_0000065";"16.72";"0.31";"3.22";"6.99";"0";"CHEMBL3888346";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4075195";"";"None";"403.49";"0";"3.85";"23";"CC(C)Oc1ccc2[nH]nc(-c3ccnc(N4CCC(n5cnnc5)CC4)c3)c2c1";"IC50";"'='";"69.0";"nM";"7.16";"";"";"UO_0000065";"17.75";"0.33";"3.31";"8.45";"0";"CHEMBL4010117";"Inhibition of recombinant human GST-tagged LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus using fluorescein-ERM as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr in presence of 5 mM ATP by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007454";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL3919862";"";"None";"343.39";"0";"3.59";"BDBM254940";"Cc1cc(-c2cc(Nc3nn(C)cc3C)nc3[nH]cc(C#N)c23)ccn1";"IC50";"'='";"215.0";"nM";"6.67";"";"443746";"UO_0000065";"19.42";"0.35";"3.08";"7.00";"0";"CHEMBL3889253";"Homogeneous Time Resolved-fluorescence Resonance Energy Transfer (TR-FRET) Assay: LRRK2 kinase activity is measured using a LanthaScreen kinase activity assay available from Invitrogen (Life Technologies Corporation). The assay is a homogeneous time resolved-fluorescence resonance energy transfer (TR-FRET) assay that measures phosphorylation of a fluorescein-labelled peptide substrate (fluorescein-LRRKtide, fluorescein-GAGRLGRDKYKTLRQIRQ) (SEQ ID NO 1) as a result of LRRK2 kinase activity. The phosphorylated peptide is recognized by a terbium-labelled phospho-specific anti-LRRKtide antibody and, subsequently, the phosphorylated LRRKtide can be quantified by the extent of TR-FRET between the terbium donor and fluorescein acceptor.The LRRK2 kinase is obtained from Invitrogen (Life Technologies Corporation) and comprises residues 970 to 2527 of the full length human wild-type LRRK2 kinase or a similar sequence with the G2019S mutation. As discussed above, this mutation increases the kinase activity relative to the wild-type. The kinase reactions are performed in a 20 uL volume in 384-well plates. The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT.Â  In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 uM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 uM fluorescein-LRRKtide. The reaction mixture (20 ul total volume) is incubated for 2 hours at 30° C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 ul). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 us) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 us. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 us time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3887011";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3969077";"";"None";"328.38";"0";"3.89";"BDBM254931";"Cc1cccc(-c2cc(Nc3ccn(C)n3)nc3[nH]cc(C#N)c23)c1";"IC50";"'='";"2.0";"nM";"8.70";"";"443714";"UO_0000065";"26.49";"0.48";"4.81";"10.57";"0";"CHEMBL3889252";"Homogeneous Time Resolved-fluorescence Resonance Energy Transfer (TR-FRET) Assay: LRRK2 kinase activity is measured using a LanthaScreen kinase activity assay available from Invitrogen (Life Technologies Corporation). The assay is a homogeneous time resolved-fluorescence resonance energy transfer (TR-FRET) assay that measures phosphorylation of a fluorescein-labelled peptide substrate (fluorescein-LRRKtide, fluorescein-GAGRLGRDKYKTLRQIRQ) (SEQ ID NO 1) as a result of LRRK2 kinase activity. The phosphorylated peptide is recognized by a terbium-labelled phospho-specific anti-LRRKtide antibody and, subsequently, the phosphorylated LRRKtide can be quantified by the extent of TR-FRET between the terbium donor and fluorescein acceptor.The LRRK2 kinase is obtained from Invitrogen (Life Technologies Corporation) and comprises residues 970 to 2527 of the full length human wild-type LRRK2 kinase or a similar sequence with the G2019S mutation. As discussed above, this mutation increases the kinase activity relative to the wild-type. The kinase reactions are performed in a 20 uL volume in 384-well plates. The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT.Â  In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 uM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 uM fluorescein-LRRKtide. The reaction mixture (20 ul total volume) is incubated for 2 hours at 30° C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 ul). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 us) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 us. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 us time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3887011";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3966624";"";"None";"405.39";"0";"2.90";"BDBM185532";"Cc1nc(C2CN(c3ncnc4[nH]cc(-c5cccc(C#N)c5F)c34)CCO2)no1";"IC50";"'='";"17.0";"nM";"7.77";"";"334501";"UO_0000065";"19.17";"0.35";"4.87";"6.65";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3963345";"";"None";"292.39";"0";"3.86";"BDBM185373";"C[C@H]1CCCN(c2ncnc3[nH]cc(-c4ccccc4)c23)C1";"IC50";"'='";"92.0";"nM";"7.04";"";"334545";"UO_0000065";"24.06";"0.44";"3.18";"15.70";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3393352";"";"None";"347.42";"0";"3.36";"BDBM50059420";"COCC1CCCN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)C1";"IC50";"'='";"219.0";"nM";"6.66";"";"334557";"UO_0000065";"19.17";"0.35";"3.30";"8.56";"1";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3898649";"";"None";"321.36";"0";"3.43";"BDBM185417";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCCC(F)C4)c23)c1";"IC50";"'='";"80.0";"nM";"7.10";"";"334592";"UO_0000065";"22.08";"0.40";"3.67";"10.35";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3941219";"";"None";"371.40";"0";"2.80";"BDBM185392";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCOC(c5cc[nH]n5)C4)c23)c1";"IC50";"'='";"208.0";"nM";"6.68";"";"334607";"UO_0000065";"17.99";"0.33";"3.88";"6.27";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3932556";"";"None";"328.35";"0";"2.09";"BDBM185440";"OCc1cccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1F";"IC50";"'='";"75.0";"nM";"7.12";"";"334620";"UO_0000065";"21.70";"0.41";"5.03";"9.59";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3973146";"";"None";"326.43";"0";"3.18";"BDBM185451";"CSc1cccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"78.0";"nM";"7.11";"";"334633";"UO_0000065";"21.77";"0.42";"3.93";"13.15";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3942417";"";"None";"294.36";"0";"2.77";"BDBM185456";"Cc1cccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"20.0";"nM";"7.70";"";"334638";"UO_0000065";"26.15";"0.48";"4.93";"14.25";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3393440";"";"None";"284.32";"0";"1.19";"BDBM50059313";"Cn1ccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)n1";"IC50";"'='";"90.0";"nM";"7.05";"";"334639";"UO_0000065";"24.78";"0.46";"5.86";"9.80";"1";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3975717";"";"None";"388.46";"0";"3.53";"BDBM185478";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCOC(c5nccs5)C4)c23)c1";"IC50";"'='";"181.0";"nM";"6.74";"";"334662";"UO_0000065";"17.36";"0.33";"3.21";"7.43";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3961632";"";"None";"248.29";"0";"2.99";"22";"Cc1cccc(-c2cc(N)nc3[nH]cc(C#N)c23)c1";"IC50";"'='";"67.61";"nM";"7.17";"";"";"UO_0000065";"28.88";"0.52";"4.18";"9.13";"0";"CHEMBL4031825";"Inhibition of human wild type LRRK2 phosphorylation at ser935 expressed in BacMam transduced HEK293 cells after 48 hrs by in-cell Western assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"CHEMBL3307715";"";"";""
"CHEMBL5276498";"";"None";"388.48";"0";"3.43";"10";"C[C@@H]1CN(c2cc(-n3ncc4ccc(-c5cnn(C)c5)cc43)ccn2)C[C@H](C)O1";"IC50";"'='";"100.0";"nM";"7.00";"";"";"UO_0000065";"18.02";"0.33";"3.57";"11.48";"0";"CHEMBL5239655";"Inhibition of GST20-tagged human LRRK2 G2019S mutant using LRRKtide peptide preincubated for 15 mins followed by substrate addition and measured after 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5236618";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL5266092";"";"None";"400.49";"0";"3.11";"20";"CC(C)(O)C12CC(C1)N(c1cc(-n3ncc4ccc(C5(C#N)CC5)cc43)ncn1)C2";"IC50";"'='";"14.0";"nM";"7.85";"";"";"UO_0000065";"19.61";"0.36";"4.74";"8.64";"0";"CHEMBL5239655";"Inhibition of GST20-tagged human LRRK2 G2019S mutant using LRRKtide peptide preincubated for 15 mins followed by substrate addition and measured after 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5236618";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL5267690";"";"None";"414.51";"0";"3.36";"21";"C[C@H]1CC1(C#N)c1ccc2cnn(-c3cc(N4CC5(C(C)(C)O)CC4C5)ncn3)c2c1";"IC50";"'='";"2.0";"nM";"8.70";"";"";"UO_0000065";"20.99";"0.38";"5.34";"9.57";"0";"CHEMBL5239655";"Inhibition of GST20-tagged human LRRK2 G2019S mutant using LRRKtide peptide preincubated for 15 mins followed by substrate addition and measured after 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5236618";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL3908300";"";"None";"396.47";"0";"3.14";"BDBM223555";"CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)c(F)c3)cnc2N)nn1";"IC50";"'='";"370.0";"nM";"6.43";"";"390811";"UO_0000065";"16.22";"0.30";"3.29";"7.84";"0";"CHEMBL3888345";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3971067";"";"None";"378.48";"0";"3.00";"BDBM223552";"CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)cc3)cnc2N)nn1";"IC50";"'='";"300.0";"nM";"6.52";"";"390837";"UO_0000065";"17.23";"0.32";"3.52";"7.95";"0";"CHEMBL3888346";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3961632";"";"None";"248.29";"0";"2.99";"22";"Cc1cccc(-c2cc(N)nc3[nH]cc(C#N)c23)c1";"IC50";"'='";"61.0";"nM";"7.21";"";"";"UO_0000065";"29.06";"0.52";"4.22";"9.19";"0";"CHEMBL4031828";"Inhibition of human LRRK2 G2019S mutant phosphorylation at ser1292 expressed in BacMam transduced HEK293 cells after 48 hrs by in-cell Western assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"CHEMBL3307715";"";"";""
"CHEMBL3911415";"";"None";"406.49";"0";"2.87";"BDBM239209";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCN(C(=O)C5CC5)CC4)ncn3)c2c1";"IC50";"'='";"4.15";"nM";"8.38";"";"417670";"UO_0000065";"20.62";"0.38";"5.51";"9.61";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3933899";"";"None";"329.37";"0";"3.28";"26";"Cc1cncc(-c2cc(Nc3ccn(C)n3)nc3[nH]cc(C#N)c23)c1";"IC50";"'='";"37.0";"nM";"7.43";"";"";"UO_0000065";"22.56";"0.41";"4.15";"7.81";"1";"CHEMBL4031821";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus using fluorescein-LRRKtide as substrate after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL3939513";"";"None";"314.35";"0";"3.58";"24";"Cn1ccc(Nc2cc(-c3ccccc3)c3c(C#N)c[nH]c3n2)n1";"IC50";"'='";"85.0";"nM";"7.07";"";"";"UO_0000065";"22.49";"0.40";"3.49";"8.59";"0";"CHEMBL4031825";"Inhibition of human wild type LRRK2 phosphorylation at ser935 expressed in BacMam transduced HEK293 cells after 48 hrs by in-cell Western assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"CHEMBL3307715";"";"";""
"CHEMBL4744428";"";"None";"433.52";"0";"3.04";"10";"CC(C)n1cnnc1-c1cccc(NC(=O)[C@H]2CN(c3ccc(C4CC4)nc3)CCO2)n1";"IC50";"'<='";"500.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL4727561";"Inhibition of recombinant human GST-tagged LRRK2 expressed in baculovirus expression system";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4725315";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2020";"None";"";"INHIBITOR";""
"CHEMBL509032";"TAE-684";"None";"614.22";"2";"5.02";"TAE684";"COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1";"IC50";"'='";"21.9";"nM";"7.66";"";"";"UO_0000065";"12.47";"0.25";"2.64";"7.44";"0";"CHEMBL2015770";"Inhibition of LRRK2 G2019S and A2016T mutant expressed in HEK293 cells using nictide and ATP as substrate";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S,A2016T";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2010643";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2012";"CHEMBL3307715";"";"";""
"CHEMBL388978";"STAUROSPORINE";"None";"466.54";"0";"4.35";"Staurosporine";"CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4";"IC50";"'='";"4.85";"nM";"8.31";"";"";"UO_0000065";"17.82";"0.32";"3.96";"11.97";"0";"CHEMBL4720678";"Inhibition of human LRRK2 using RLGRDKYKTLRQIRQ as substrate by [gamma-33P]-ATP assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4715818";"1";"Scientific Literature";"Bioorg Med Chem";"2018";"None";"";"INHIBITOR";""
"CHEMBL5277668";"";"None";"472.51";"0";"1.81";"4";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4ccnc(N5CCOCC5)c4)c3c2)Cn2nnnc2N1C";"IC50";"'<'";"0.2";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5246746";"Inhibition of N-terminal GST-fused human LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5078277";"";"None";"408.46";"0";"3.57";"7";"Cc1c(Nc2ncc3ccc(N4C(=O)OC[C@@H]4C)cc3n2)cnn1C1CCOCC1";"IC50";"'<'";"0.6";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5044129";"Inhibition of recombinant N-terminal GST-fused LRRK2 G2109S mutant (970 to 2527 residues) (unknown origin) preincubated with enzyme for 15 mins followed by fluorescein-labeled LRRKtide peptide substrate and ATP addition for 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5042510";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL4457647";"";"None";"390.44";"0";"3.14";"18";"O=C(Nc1ccnnc1)c1cc(N2CCOCC2)ccc1OCc1ccccc1";"IC50";"'='";"100.0";"nM";"7.00";"";"";"UO_0000065";"17.93";"0.33";"3.86";"9.14";"0";"CHEMBL4372261";"Inhibition of parkinson's patient-derived LRRK2 G2019S mutant";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4371037";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL3914163";"";"None";"396.50";"0";"2.58";"BDBM239090";"COCCN1CCN(c2cc(-c3n[nH]c4ccc(OC(C)C)cc34)ncn2)CC1";"IC50";"'='";"24.0";"nM";"7.62";"";"417367";"UO_0000065";"19.22";"0.36";"5.04";"9.60";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3977672";"";"None";"396.47";"0";"3.23";"BDBM239229";"CC(C)Oc1cc2c(-c3cc(N4CCN(C5CC5)CC4)ncn3)n[nH]c2cc1F";"IC50";"'='";"3.99";"nM";"8.40";"";"417690";"UO_0000065";"21.18";"0.40";"5.17";"11.97";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3931097";"";"None";"383.43";"0";"3.31";"BDBM239231";"CC(C)Oc1cc2c(-c3cc(N4CC5CCC(C4)O5)ncn3)n[nH]c2cc1F";"IC50";"'='";"14.58";"nM";"7.84";"";"417692";"UO_0000065";"20.44";"0.38";"4.53";"10.29";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3891437";"";"None";"338.37";"0";"1.35";"BDBM239276";"CCOc1ccc2[nH]nc(-c3cc(N4CCNC(=O)C4)ncn3)c2c1";"IC50";"'='";"63.85";"nM";"7.20";"";"417735";"UO_0000065";"21.26";"0.39";"5.84";"7.49";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3966268";"";"None";"352.44";"0";"2.56";"BDBM239278";"CCOc1ccc2[nH]nc(-c3cc(N4CCN(CC)CC4)ncn3)c2c1";"IC50";"'='";"12.57";"nM";"7.90";"";"417737";"UO_0000065";"22.42";"0.42";"5.34";"11.26";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3934846";"";"None";"368.40";"0";"0.98";"BDBM239289";"COCCOc1ccc2[nH]nc(-c3cc(N4CCNC(=O)C4)ncn3)c2c1";"IC50";"'='";"135.6";"nM";"6.87";"";"417748";"UO_0000065";"18.64";"0.35";"5.89";"6.52";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3910233";"";"None";"375.43";"0";"2.99";"BDBM239533";"O=C1C=C(c2ccc3[nH]nc(-c4cc(N5CCOCC5)ncn4)c3c2)CCC1";"IC50";"'='";"1.63";"nM";"8.79";"";"417996";"UO_0000065";"23.41";"0.43";"5.80";"10.46";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3917266";"";"None";"369.43";"0";"2.27";"BDBM239089";"COC[C@H](C)Oc1ccc2[nH]nc(-c3cc(N4CCOCC4)ncn3)c2c1";"IC50";"'='";"2.6";"nM";"8.59";"";"312520";"UO_0000065";"23.24";"0.43";"6.32";"10.05";"0";"CHEMBL3887174";"LanthaScreen™ Assay (Km ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 184 μM ATP solution in 1× assay buffer to all wells. d) After a 60 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3954837";"";"None";"326.38";"0";"3.57";"BDBM185505";"COc1ccccc1-c1c[nH]c2ncnc(N3CCC(F)CC3)c12";"IC50";"'='";"74.0";"nM";"7.13";"";"334690";"UO_0000065";"21.85";"0.41";"3.56";"13.20";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3943687";"";"None";"286.34";"0";"1.95";"BDBM185577";"C1=C(c2c[nH]c3ncnc(N4CCOCC4)c23)CCCO1";"IC50";"'='";"167.0";"nM";"6.78";"";"334722";"UO_0000065";"23.67";"0.44";"4.83";"10.71";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3970173";"";"None";"389.46";"0";"3.04";"BDBM239187";"COC1CCN(c2cc(-c3n[nH]c4ccc(-c5cnn(C)c5)cc34)ncn2)CC1";"IC50";"'='";"2.04";"nM";"8.69";"";"417646";"UO_0000065";"22.31";"0.41";"5.65";"10.25";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3937664";"";"None";"369.43";"0";"1.74";"BDBM239226";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4C[C@H](O)[C@@H](O)[C@@H]4C)ncn3)c2c1";"IC50";"'='";"18.13";"nM";"7.74";"";"417687";"UO_0000065";"20.96";"0.39";"6.00";"7.21";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3985545";"";"None";"394.48";"0";"2.87";"BDBM239237";"CCC(=O)N1CCN(c2cc(-c3n[nH]c4ccc(OC(C)C)cc34)ncn2)CC1";"IC50";"'='";"4.26";"nM";"8.37";"";"417698";"UO_0000065";"21.22";"0.39";"5.50";"9.59";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3964794";"";"None";"370.43";"0";"2.87";"BDBM239244";"CC(C)Oc1cc2c(-c3cc(N4C[C@H](N)C[C@@H]4C)ncn3)n[nH]c2cc1F";"IC50";"'='";"7.6";"nM";"8.12";"";"417705";"UO_0000065";"21.92";"0.41";"5.25";"8.74";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3899059";"";"None";"324.34";"0";"0.96";"BDBM239267";"COc1ccc2[nH]nc(-c3cc(N4CCNC(=O)C4)ncn3)c2c1";"IC50";"'='";"100.9";"nM";"7.00";"";"417726";"UO_0000065";"21.57";"0.40";"6.04";"7.29";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3951349";"";"None";"368.44";"0";"1.80";"BDBM239287";"COCCOc1ccc2[nH]nc(-c3cc(N4CCN(C)CC4)ncn3)c2c1";"IC50";"'='";"67.21";"nM";"7.17";"";"417746";"UO_0000065";"19.47";"0.36";"5.37";"9.03";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3922207";"";"None";"369.43";"0";"2.27";"BDBM239294";"COCCOc1ccc2[nH]nc(-c3cc(N4CCO[C@@H](C)C4)ncn3)c2c1";"IC50";"'='";"100.7";"nM";"7.00";"";"417753";"UO_0000065";"18.94";"0.35";"4.73";"8.19";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3917266";"";"None";"369.43";"0";"2.27";"BDBM239089";"COC[C@H](C)Oc1ccc2[nH]nc(-c3cc(N4CCOCC4)ncn3)c2c1";"IC50";"'='";"2.6";"nM";"8.59";"";"417759";"UO_0000065";"23.24";"0.43";"6.32";"10.05";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3923675";"";"None";"366.47";"0";"2.95";"BDBM239345";"CCN1CCN(c2cc(-c3n[nH]c4ccc(OC(C)C)cc34)ncn2)CC1";"IC50";"'='";"6.0";"nM";"8.22";"";"417813";"UO_0000065";"22.44";"0.42";"5.27";"11.72";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3975429";"";"None";"406.49";"0";"2.95";"BDBM223560";"Cc1cc(-c2cnc(N)c(-c3cn(C(C)C)nn3)c2)ccc1C(=O)N1CCOCC1";"IC50";"'='";"110.0";"nM";"6.96";"";"390816";"UO_0000065";"17.12";"0.32";"4.01";"7.02";"0";"CHEMBL3888345";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3946086";"";"None";"392.51";"0";"3.31";"BDBM223561";"Cc1cc(-c2cnc(N)c(-c3cn(C(C)C)nn3)c2)ccc1CN1CCOCC1";"IC50";"'='";"240.0";"nM";"6.62";"";"390817";"UO_0000065";"16.87";"0.31";"3.31";"8.06";"0";"CHEMBL3888345";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3919227";"";"None";"378.48";"0";"3.00";"BDBM223564";"CC(C)n1cc(-c2cc(-c3cccc(CN4CCOCC4)c3)cnc2N)nn1";"IC50";"'='";"370.0";"nM";"6.43";"";"390849";"UO_0000065";"16.99";"0.31";"3.43";"7.84";"0";"CHEMBL3888346";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3938306";"";"None";"392.46";"0";"2.64";"BDBM223568";"CC(C)n1cc(-c2cc(-c3ccc(C(=O)N4CCOCC4)cc3)cnc2N)nn1";"IC50";"'='";"370.0";"nM";"6.43";"";"390853";"UO_0000065";"16.39";"0.30";"3.79";"6.49";"0";"CHEMBL3888346";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3915706";"";"None";"433.52";"0";"3.14";"BDBM239500";"COCCn1cc(-c2ccc3[nH]nc(-c4cc(N5C[C@@H](C)O[C@@H](C)C5)ncn4)c3c2)cn1";"IC50";"'='";"1.8";"nM";"8.74";"";"417965";"UO_0000065";"20.17";"0.37";"5.60";"9.30";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3901269";"";"None";"410.48";"0";"4.17";"BDBM239504";"C[C@@H]1CN(c2cc(-c3n[nH]c4ccc(-c5ccc(C#N)cc5)cc34)ncn2)C[C@H](C)O1";"IC50";"'='";"177.4";"nM";"6.75";"";"417969";"UO_0000065";"16.45";"0.30";"2.58";"7.44";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3963291";"";"None";"347.38";"0";"2.25";"BDBM239532";"c1nc(-c2n[nH]c3ccc(-c4cn[nH]c4)cc23)cc(N2CCOCC2)n1";"IC50";"'='";"2.3";"nM";"8.64";"";"417995";"UO_0000065";"24.87";"0.45";"6.39";"9.03";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3943668";"";"None";"416.49";"0";"3.70";"BDBM239501";"COc1cc(-c2ccc3[nH]nc(-c4cc(N5C[C@@H](C)O[C@@H](C)C5)ncn4)c3c2)ccn1";"IC50";"'='";"155.1";"nM";"6.81";"";"417966";"UO_0000065";"16.35";"0.30";"3.11";"7.65";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3915912";"";"None";"375.44";"0";"3.06";"BDBM239327";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CC(n5cccn5)C4)ncn3)c2c1";"IC50";"'='";"22.6";"nM";"7.65";"";"417796";"UO_0000065";"20.37";"0.37";"4.59";"9.02";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3944894";"";"None";"432.48";"0";"3.36";"BDBM239344";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCN(C(=O)c5ccco5)CC4)ncn3)c2c1";"IC50";"'='";"8.7";"nM";"8.06";"";"417812";"UO_0000065";"18.64";"0.34";"4.70";"8.03";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4474208";"";"None";"283.74";"0";"2.17";"7";"CS(=O)(=O)Nc1cc(-c2ccncc2)cnc1Cl";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL4385145";"Inhibition of LRRK2 (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4382269";"1";"Scientific Literature";"J Med Chem";"2018";"None";"";"";""
"CHEMBL3588873";"";"None";"340.43";"0";"2.93";"Z-6583";"CC(c1ccc(NC(=O)c2cc(C3CC3)[nH]n2)cc1)N1CCOCC1";"IC50";"'='";"1900.0";"nM";"5.72";"";"";"UO_0000065";"16.81";"0.31";"2.79";"8.14";"0";"CHEMBL3592570";"Inhibition of LRRK2 G2019S mutant (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3588794";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2015";"None";"";"";""
"CHEMBL4521733";"";"None";"416.48";"0";"3.39";"24";"O=C(Nc1ccnnc1)c1cc(N2C[C@H]3COC[C@H]3C2)ccc1OCc1ccccc1";"IC50";"'='";"50.12";"nM";"7.30";"";"";"UO_0000065";"17.53";"0.32";"3.91";"9.53";"0";"CHEMBL4372253";"Inhibition of recombinant 6His-Tev-tagged LRRK2 (1326 to 2527) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-RLGRDKYKTLRQIRQGNTKQR-OH as substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs by TR-FRET assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"Sf9";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4371037";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"CHEMBL3308860";"";"";""
"CHEMBL4450254";"";"None";"396.40";"0";"3.76";"11";"O=C(Nc1ccnnc1)c1cc(N2CC(F)(F)C2)ccc1OCc1ccccc1";"IC50";"'='";"12.59";"nM";"7.90";"";"";"UO_0000065";"19.93";"0.37";"4.14";"11.73";"0";"CHEMBL4372253";"Inhibition of recombinant 6His-Tev-tagged LRRK2 (1326 to 2527) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-RLGRDKYKTLRQIRQGNTKQR-OH as substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs by TR-FRET assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"Sf9";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4371037";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"CHEMBL3308860";"";"";""
"CHEMBL3893444";"";"None";"399.45";"0";"1.63";"BDBM239466";"COC[C@H](C)Oc1ccc2[nH]nc(-c3cc(N4C[C@H](OC)[C@@H](O)C4)ncn3)c2c1";"IC50";"'='";"19.8";"nM";"7.70";"";"417931";"UO_0000065";"19.28";"0.36";"6.07";"7.29";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4632948";"";"None";"488.59";"0";"4.33";"XMD8-86";"CC(C)Oc1cc(N2CCC(O)CC2)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2C";"IC50";"'='";"160.0";"nM";"6.80";"";"";"UO_0000065";"13.91";"0.26";"2.47";"7.23";"0";"CHEMBL4612965";"Inhibition of recombinant human GST-tagged LRRK2 catalytic domain (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate measured after 1 hr by Alexa fluor-647 ADP tracer-based ADAPTA assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4610122";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL3917993";"";"None";"388.43";"0";"2.93";"BDBM239482";"COc1ncccc1-c1ccc2[nH]nc(-c3cc(N4CCOCC4)ncn3)c2c1";"IC50";"'='";"37.7";"nM";"7.42";"";"417947";"UO_0000065";"19.11";"0.35";"4.49";"8.34";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL1673056";"";"None";"494.00";"0";"3.99";"XMD10-126";"COc1cc(N2CCN(C)CC2)ccc1Nc1ncc2c(n1)N(C)c1ccc(Cl)cc1C(=O)N2C";"IC50";"'='";"1330.0";"nM";"5.88";"";"";"UO_0000065";"11.90";"0.23";"1.89";"7.62";"0";"CHEMBL4612965";"Inhibition of recombinant human GST-tagged LRRK2 catalytic domain (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate measured after 1 hr by Alexa fluor-647 ADP tracer-based ADAPTA assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4610122";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL4643632";"";"None";"515.62";"1";"3.80";"FMF-03-059-1";"CCN1C(=O)c2ccccc2N(C)c2nc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)ncc21";"IC50";"'='";"14.0";"nM";"7.85";"";"";"UO_0000065";"15.23";"0.28";"4.05";"7.63";"0";"CHEMBL4612965";"Inhibition of recombinant human GST-tagged LRRK2 catalytic domain (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate measured after 1 hr by Alexa fluor-647 ADP tracer-based ADAPTA assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4610122";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL4646882";"";"None";"529.65";"1";"4.19";"FMF-03-151-1";"COc1cc(C(=O)NC2CCN(C)CC2)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2C(C)C";"IC50";"'='";"331.0";"nM";"6.48";"";"";"UO_0000065";"12.23";"0.23";"2.29";"6.30";"0";"CHEMBL4612965";"Inhibition of recombinant human GST-tagged LRRK2 catalytic domain (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate measured after 1 hr by Alexa fluor-647 ADP tracer-based ADAPTA assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4610122";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL4060044";"";"None";"281.32";"0";"1.86";"BDBM239547";"c1ccc2c(-c3cc(N4CCOCC4)ncn3)[nH]nc2c1";"IC50";"'='";"134.3";"nM";"6.87";"";"418010";"UO_0000065";"24.43";"0.45";"5.01";"10.27";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3901271";"";"None";"371.42";"0";"3.17";"BDBM239225";"CC(C)Oc1cc2c(-c3cc(N4CCOCC4C)ncn3)n[nH]c2cc1F";"IC50";"'='";"5.54";"nM";"8.26";"";"417686";"UO_0000065";"22.23";"0.42";"5.09";"10.84";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3891150";"";"None";"392.46";"0";"2.64";"BDBM223565";"CC(C)n1cc(-c2cc(-c3cccc(C(=O)N4CCOCC4)c3)cnc2N)nn1";"IC50";"'='";"950.0";"nM";"6.02";"";"390821";"UO_0000065";"15.34";"0.28";"3.38";"6.07";"0";"CHEMBL3888345";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3977607";"";"None";"338.42";"0";"2.17";"BDBM239274";"CCOc1ccc2[nH]nc(-c3cc(N4CCN(C)CC4)ncn3)c2c1";"IC50";"'='";"26.91";"nM";"7.57";"";"417733";"UO_0000065";"22.37";"0.41";"5.40";"10.79";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3918208";"";"None";"364.45";"0";"2.70";"BDBM239275";"CCOc1ccc2[nH]nc(-c3cc(N4CCN(C5CC5)CC4)ncn3)c2c1";"IC50";"'='";"16.68";"nM";"7.78";"";"417734";"UO_0000065";"21.34";"0.39";"5.08";"11.08";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3905784";"";"None";"436.52";"0";"2.68";"BDBM239304";"COC[C@H](C)Oc1ccc2[nH]nc(-c3cc(N4CCC5(CCC(=O)N5)CC4)ncn3)c2c1";"IC50";"'='";"4.36";"nM";"8.36";"";"417764";"UO_0000065";"19.15";"0.36";"5.68";"7.94";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3953662";"";"None";"434.44";"0";"2.20";"BDBM239381";"Cn1cc(-c2cc3c(-c4cc(N5CCN6C(=O)OCC6C5)ncn4)n[nH]c3cc2F)cn1";"IC50";"'='";"64.2";"nM";"7.19";"";"417848";"UO_0000065";"16.56";"0.31";"4.99";"6.85";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3917028";"";"None";"420.43";"0";"3.39";"BDBM239382";"Cn1cc(-c2cc3c(-c4cc(N5CCC(F)(C#N)CC5)ncn4)n[nH]c3cc2F)cn1";"IC50";"'='";"39.4";"nM";"7.41";"";"417849";"UO_0000065";"17.61";"0.33";"4.01";"7.46";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3967186";"";"None";"384.46";"0";"2.90";"BDBM239085";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCN(CCF)CC4)ncn3)c2c1";"IC50";"'='";"34.0";"nM";"7.47";"";"417368";"UO_0000065";"19.43";"0.36";"4.57";"10.64";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3904862";"";"None";"434.50";"0";"2.03";"BDBM239086";"CC(C)Oc1cc2c(-c3cc(N4CCN(S(C)(=O)=O)CC4)ncn3)n[nH]c2cc1F";"IC50";"'='";"28.0";"nM";"7.55";"";"417370";"UO_0000065";"17.38";"0.34";"5.52";"7.24";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3914353";"";"None";"398.44";"0";"2.61";"BDBM239221";"CCN1CCN(c2cc(-c3n[nH]c4cc(F)c(OC(C)C)cc34)ncn2)CC1=O";"IC50";"'='";"4.16";"nM";"8.38";"";"417682";"UO_0000065";"21.03";"0.39";"5.77";"9.61";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL5085622";"";"None";"363.42";"0";"4.12";"69";"O=C1NCCCOc2ccc3[nH]nc(c3c2)-c2ccc(C3CC3)c(c2)CO1";"IC50";"'<'";"10.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5030411";"Inhibition of recombinant human LRRK2 using LRRKtide peptide and ATP as substrates incubated for 1 hrs by ADP-glo luminescent assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5029192";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5198416";"";"None";"432.92";"0";"4.16";"5.17";"N#CC1CCN(c2cc3cc(NC(=O)C4CC4c4cncnc4)ncc3cc2Cl)CC1";"IC50";"'='";"0.08128";"nM";"10.09";"";"";"UO_0000065";"23.31";"0.44";"5.93";"10.64";"0";"CHEMBL5126024";"Inhibition of GST-tagged truncated human LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition measured after 90 mins in presence of ATP by TR-FRET based LanthaScreen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5120951";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL4561692";"";"None";"462.53";"0";"1.43";"3";"COc1ncc(-c2cc3c(c(NC(=O)CN4CCOCC4)c2)COC3)cc1NS(C)(=O)=O";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL4479373";"Inhibition of LRRK2 (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4477235";"1";"Scientific Literature";"J Med Chem";"2016";"None";"";"";""
"CHEMBL4543181";"";"None";"441.46";"1";"5.03";"29";"Cc1cnc(Cc2nc3cnc4ccc(C(F)(F)F)cc4c3n2[C@@H]2CCO[C@H](C)C2)cn1";"IC50";"'='";"6.47";"nM";"8.19";"";"";"UO_0000065";"18.55";"0.35";"3.16";"12.46";"0";"CHEMBL4334283";"Inhibition of recombinant wild-type GST-tagged LRRK2 (unknown origin) expressed in baculovirus expression system using fluorescein-labeled LRRKtide as substrate after 30 mins by Lanthascreen assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330176";"1";"Scientific Literature";"ACS Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4521173";"";"None";"383.46";"0";"3.02";"6";"Cc1cc(Cc2nc3cnc4ccc(C#N)cc4c3n2[C@@H]2CCN(C)C2)ncn1";"IC50";"'='";"11.3";"nM";"7.95";"";"";"UO_0000065";"20.72";"0.37";"4.93";"9.51";"0";"CHEMBL4334284";"Inhibition of GST-tagged LRRK2 G2019S mutant (unknown origin) expressed in baculovirus expression system using fluorescein-labeled LRRKtide as substrate after 30 mins by Lanthascreen assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330176";"1";"Scientific Literature";"ACS Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4077034";"";"None";"363.81";"0";"3.94";"33";"Cc1cc(-c2cc(Nc3nn(C)cc3Cl)nc3[nH]cc(C#N)c23)ccn1";"IC50";"'='";"210.0";"nM";"6.68";"";"";"UO_0000065";"18.36";"0.35";"2.74";"7.01";"0";"CHEMBL4031826";"Inhibition of human LRRK2 G2019S mutant phosphorylation at ser935 expressed in BacMam transduced HEK293 cells after 48 hrs by in-cell Western assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"CHEMBL3307715";"";"";""
"CHEMBL2348945";"";"None";"379.39";"0";"4.42";"10";"FC(F)(F)c1cccc(Sc2ccc3nnc(-c4cncs4)n3n2)c1";"IC50";"'='";"18.0";"nM";"7.75";"";"";"UO_0000065";"20.41";"0.42";"3.32";"13.84";"0";"CHEMBL2351468";"Inhibition of LRRK2 G2019S mutant (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348971";"";"None";"305.39";"0";"1.82";"37";"CC(Sc1ccc2nnc(-c3cccs3)n2n1)C(N)=O";"IC50";"'='";"98.0";"nM";"7.01";"";"";"UO_0000065";"22.95";"0.48";"5.19";"8.13";"0";"CHEMBL2351467";"Inhibition of wild type LRRK2 (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL4092521";"";"None";"363.81";"0";"3.94";"34";"Cc1cccc(-c2cc(Nc3nn(C)cc3Cl)nc3[nH]cc(C#N)c23)n1";"IC50";"'='";"44.0";"nM";"7.36";"";"";"UO_0000065";"20.22";"0.39";"3.42";"7.73";"0";"CHEMBL4031820";"Inhibition of wild type recombinant human GST-tagged LRRK2 (970 to 2527 residues) expressed in baculovirus using fluorescein-LRRKtide as substrate after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4101218";"";"None";"343.39";"0";"3.59";"29";"Cc1cncc(-c2cc(Nc3nn(C)cc3C)nc3[nH]cc(C#N)c23)c1";"IC50";"'='";"170.0";"nM";"6.77";"";"";"UO_0000065";"19.71";"0.36";"3.18";"7.11";"0";"CHEMBL4031826";"Inhibition of human LRRK2 G2019S mutant phosphorylation at ser935 expressed in BacMam transduced HEK293 cells after 48 hrs by in-cell Western assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"CHEMBL3307715";"";"";""
"CHEMBL3978722";"";"None";"392.51";"0";"3.04";"44";"CC(C)n1cc(-c2cc(-c3ccc(CCN4CCOCC4)cc3)cnc2N)nn1";"IC50";"'='";"600.0";"nM";"6.22";"";"";"UO_0000065";"15.85";"0.29";"3.18";"7.58";"1";"CHEMBL4045604";"Inhibition of recombinant human wild type GST-tagged LRRK2 (970 to 2527 residues) preincubated for 30 mins followed by fluorescein-LRRKtide substrate addition after 2 hrs by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4043168";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL4095694";"";"None";"265.32";"0";"3.60";"18";"Cc1ccc(-c2cnc(N)c(-c3cnc(C)o3)c2)cc1";"IC50";"'='";"11000.0";"nM";"4.96";"";"";"UO_0000065";"18.69";"0.34";"1.36";"7.64";"0";"CHEMBL4045603";"Inhibition of recombinant human LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus preincubated for 30 mins followed by fluorescein-LRRKtide substrate addition after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4043168";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL3393348";"";"None";"305.34";"0";"2.33";"BDBM50059277";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"11.0";"nM";"7.96";"";"334534";"UO_0000065";"26.06";"0.47";"5.63";"10.23";"1";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3929984";"";"None";"319.37";"0";"2.64";"BDBM185573";"Cc1nc(N2CCOCC2)c2c(-c3cccc(C#N)c3)c[nH]c2n1";"IC50";"'='";"513.0";"nM";"6.29";"";"334539";"UO_0000065";"19.69";"0.36";"3.65";"8.08";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3939031";"";"None";"321.38";"0";"2.33";"BDBM185371";"NC(=O)C1CCCN(c2ncnc3[nH]cc(-c4ccccc4)c23)C1";"IC50";"'='";"39.0";"nM";"7.41";"";"334543";"UO_0000065";"23.05";"0.42";"5.08";"8.43";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3906554";"";"None";"319.37";"0";"2.46";"BDBM185372";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCC[C@H](O)C4)c23)c1";"IC50";"'='";"95.0";"nM";"7.02";"";"334544";"UO_0000065";"21.99";"0.40";"4.56";"7.91";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3986026";"";"None";"347.42";"0";"4.42";"BDBM185380";"[C-]#[N+]c1ccc(OC)c(-c2c[nH]c3ncnc(N4CCCC(C)C4)c23)c1";"IC50";"'='";"46.0";"nM";"7.34";"";"334553";"UO_0000065";"21.12";"0.39";"2.92";"12.56";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3910857";"";"None";"339.35";"0";"3.73";"BDBM185387";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCC(F)(F)CC4)c23)c1";"IC50";"'='";"333.0";"nM";"6.48";"";"334562";"UO_0000065";"19.09";"0.35";"2.75";"9.44";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3923525";"";"None";"317.40";"0";"3.73";"BDBM185397";"CC1CCCN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)C1";"IC50";"'='";"172.0";"nM";"6.76";"";"334572";"UO_0000065";"21.31";"0.38";"3.03";"9.86";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3393344";"";"None";"289.34";"0";"3.10";"BDBM50059350";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCCC4)c23)c1";"IC50";"'='";"64.0";"nM";"7.19";"";"334601";"UO_0000065";"24.86";"0.45";"4.09";"10.49";"1";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3928018";"";"None";"303.37";"0";"3.34";"BDBM185426";"CC1CCN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)C1";"IC50";"'='";"102.0";"nM";"6.99";"";"334602";"UO_0000065";"23.05";"0.42";"3.65";"10.19";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3903551";"";"None";"281.29";"0";"3.38";"BDBM185427";"[C-]#[N+]c1ccc(F)c(-c2c[nH]c3ncnc(N(C)C)c23)c1";"IC50";"'='";"190.0";"nM";"6.72";"";"334603";"UO_0000065";"23.89";"0.44";"3.34";"13.67";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3393443";"";"None";"319.37";"0";"2.72";"BDBM50059311";"C[C@@H]1CN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)CCO1";"IC50";"'='";"69.0";"nM";"7.16";"";"334610";"UO_0000065";"22.42";"0.41";"4.44";"9.20";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3908095";"";"None";"316.31";"0";"2.74";"BDBM185441";"Fc1ccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c(F)c1";"IC50";"'='";"62.0";"nM";"7.21";"";"334621";"UO_0000065";"22.79";"0.43";"4.47";"13.34";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3909357";"";"None";"328.35";"0";"2.09";"BDBM185447";"OCc1cc(-c2c[nH]c3ncnc(N4CCOCC4)c23)ccc1F";"IC50";"'='";"135.0";"nM";"6.87";"";"334629";"UO_0000065";"20.92";"0.39";"4.78";"9.25";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3948963";"";"None";"281.32";"0";"1.86";"BDBM185452";"c1cncc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"159.0";"nM";"6.80";"";"334634";"UO_0000065";"24.17";"0.44";"4.94";"10.16";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL4110249";"";"None";"298.35";"0";"1.58";"BDBM185469";"C[C@@H]1CN(c2ncnc3[nH]cc(-c4cnn(C)c4)c23)CCO1";"IC50";"'='";"31.0";"nM";"7.51";"";"334653";"UO_0000065";"25.17";"0.47";"5.93";"10.45";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3919096";"";"None";"437.41";"0";"3.27";"BDBM185477";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCOC(Cc5noc(C(F)F)n5)C4)c23)c1";"IC50";"'='";"134.0";"nM";"6.87";"";"334661";"UO_0000065";"15.71";"0.29";"3.60";"5.89";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3963430";"";"None";"413.44";"0";"3.33";"BDBM185482";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCOC(c5noc(C6CC6)n5)C4)c23)c1";"IC50";"'='";"47.0";"nM";"7.33";"";"334666";"UO_0000065";"17.72";"0.32";"4.00";"6.28";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3924549";"";"None";"362.44";"0";"2.26";"BDBM185490";"CN(C)CC1CN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)CCO1";"IC50";"'='";"110.0";"nM";"6.96";"";"334674";"UO_0000065";"19.20";"0.35";"4.70";"8.58";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3975562";"";"None";"331.38";"0";"2.72";"BDBM185547";"N#Cc1cccc(-c2c[nH]c3ncnc(N4C[C@@H]5CCO[C@@H]5C4)c23)c1";"IC50";"'='";"591.0";"nM";"6.23";"";"334728";"UO_0000065";"18.80";"0.34";"3.51";"8.00";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3906208";"";"None";"308.35";"0";"1.67";"BDBM185558";"Cn1cc(-c2c[nH]c3ncnc(N4CCOCC4)c23)cc1C#N";"IC50";"'='";"13.0";"nM";"7.89";"";"334738";"UO_0000065";"25.58";"0.47";"6.22";"9.53";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3901378";"";"None";"309.33";"0";"1.07";"BDBM185560";"Cn1cc(-c2c[nH]c3ncnc(N4CCOCC4)c23)nc1C#N";"IC50";"'='";"14.7";"nM";"7.83";"";"334741";"UO_0000065";"25.32";"0.47";"6.76";"8.19";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3964035";"";"None";"409.46";"0";"2.77";"BDBM239418";"Cn1cc(-c2ccc3[nH]nc(-c4cc(N5CCc6nccnc6C5)ncn4)c3c2)cn1";"IC50";"'='";"2.7";"nM";"8.57";"";"417884";"UO_0000065";"20.93";"0.38";"5.80";"8.46";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3904489";"";"None";"371.42";"0";"2.76";"BDBM239425";"CC(C)Oc1cc2c(-c3cc(N4CC[C@H](CO)C4)ncn3)n[nH]c2cc1F";"IC50";"'='";"10.2";"nM";"7.99";"";"417891";"UO_0000065";"21.52";"0.40";"5.23";"9.17";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4108202";"";"None";"383.45";"0";"2.66";"BDBM239447";"COC[C@H](C)Oc1ccc2[nH]nc(-c3cc(N4CCOC[C@H]4C)ncn3)c2c1";"IC50";"'='";"20.2";"nM";"7.70";"";"417912";"UO_0000065";"20.07";"0.38";"5.03";"9.01";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3935418";"";"None";"490.59";"0";"3.31";"BDBM239477";"O=S(=O)(c1ccc(-c2ccc3[nH]nc(-c4cc(N5CCOCC5)ncn4)c3c2)cc1)N1CCCC1";"IC50";"'='";"914.4";"nM";"6.04";"";"417942";"UO_0000065";"12.31";"0.24";"2.73";"5.79";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3959543";"";"None";"416.49";"0";"3.70";"BDBM239488";"COc1ncccc1-c1ccc2[nH]nc(-c3cc(N4C[C@@H](C)O[C@@H](C)C4)ncn3)c2c1";"IC50";"'='";"158.5";"nM";"6.80";"";"417953";"UO_0000065";"16.33";"0.30";"3.10";"7.64";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4114714";"";"None";"349.44";"0";"3.67";"BDBM239508";"CC(C)=Cc1ccc2[nH]nc(-c3cc(N4CCO[C@H](C)C4)ncn3)c2c1";"IC50";"'='";"16.4";"nM";"7.79";"";"417972";"UO_0000065";"22.28";"0.41";"4.12";"11.63";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3931593";"";"None";"433.52";"0";"3.05";"BDBM239184";"COCCOC1CCN(c2cc(-c3n[nH]c4ccc(-c5cnn(C)c5)cc34)ncn2)CC1";"IC50";"'='";"1.87";"nM";"8.73";"";"417643";"UO_0000065";"20.13";"0.37";"5.68";"9.29";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3950044";"";"None";"393.49";"0";"3.96";"BDBM239233";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCC5(CCCO5)CC4)ncn3)c2c1";"IC50";"'='";"4.13";"nM";"8.38";"";"417694";"UO_0000065";"21.31";"0.39";"4.42";"11.01";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3950786";"";"None";"438.52";"0";"1.50";"BDBM239081";"Cn1cc(-c2ccc3[nH]nc(-c4cc(N5CCN(S(C)(=O)=O)CC5)ncn4)c3c2)cn1";"IC50";"'='";"36.0";"nM";"7.44";"";"417364";"UO_0000065";"16.97";"0.33";"5.94";"6.59";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3928102";"";"None";"339.40";"0";"2.64";"BDBM239084";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCOCC4)ncn3)c2c1";"IC50";"'='";"96.0";"nM";"7.02";"";"417366";"UO_0000065";"20.68";"0.38";"4.38";"9.21";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3932625";"";"None";"406.49";"0";"2.91";"BDBM239087";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCC5(CCNC5=O)CC4)ncn3)c2c1";"IC50";"'='";"30.0";"nM";"7.52";"";"417373";"UO_0000065";"18.51";"0.34";"4.61";"7.83";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3967256";"";"None";"400.49";"0";"2.70";"BDBM239179";"Cn1cc(-c2ccc3[nH]nc(-c4cc(N5CCN(C6CC6)CC5)ncn4)c3c2)cn1";"IC50";"'='";"2.62";"nM";"8.58";"";"417638";"UO_0000065";"21.43";"0.39";"5.88";"10.90";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3946083";"";"None";"388.48";"0";"2.56";"BDBM239409";"CN(C)[C@H]1CCN(c2cc(-c3n[nH]c4ccc(-c5cnn(C)c5)cc34)ncn2)C1";"IC50";"'='";"4.6";"nM";"8.34";"";"417875";"UO_0000065";"21.46";"0.39";"5.78";"10.59";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3893477";"";"None";"307.40";"0";"3.56";"BDBM185408";"Cc1cncc(-c2c[nH]c3ncnc(N4CCC[C@H](C)C4)c23)c1";"IC50";"'='";"15.0";"nM";"7.82";"";"334372";"UO_0000065";"25.45";"0.46";"4.26";"13.56";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3903551";"";"None";"281.29";"0";"3.38";"BDBM185427";"[C-]#[N+]c1ccc(F)c(-c2c[nH]c3ncnc(N(C)C)c23)c1";"IC50";"'='";"37.0";"nM";"7.43";"";"334392";"UO_0000065";"26.42";"0.48";"4.05";"15.11";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3897235";"";"None";"401.44";"0";"2.80";"BDBM239431";"COCC1CN(c2cc(-c3n[nH]c4cc(F)c(OC(C)C)cc34)ncn2)CCO1";"IC50";"'='";"2.9";"nM";"8.54";"";"417897";"UO_0000065";"21.27";"0.40";"5.74";"10.00";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3930912";"";"None";"405.46";"0";"2.18";"BDBM239438";"CC(C)Oc1cc2c(-c3cc(N4CCS(=O)(=O)CC4)ncn3)n[nH]c2cc1F";"IC50";"'='";"24.0";"nM";"7.62";"";"417904";"UO_0000065";"18.79";"0.37";"5.44";"7.54";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3933137";"";"None";"369.43";"0";"2.27";"BDBM239455";"COC[C@H](C)Oc1ccc2[nH]nc(-c3cc(N4CC(OC)C4)ncn3)c2c1";"IC50";"'='";"5.6";"nM";"8.25";"";"417920";"UO_0000065";"22.34";"0.42";"5.98";"9.66";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3914163";"";"None";"396.50";"0";"2.58";"BDBM239090";"COCCN1CCN(c2cc(-c3n[nH]c4ccc(OC(C)C)cc34)ncn2)CC1";"IC50";"'='";"4.9";"nM";"8.31";"";"312516";"UO_0000065";"20.96";"0.39";"5.73";"10.47";"0";"CHEMBL3887174";"LanthaScreen™ Assay (Km ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 184 μM ATP solution in 1× assay buffer to all wells. d) After a 60 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3979762";"";"None";"361.41";"0";"2.26";"BDBM239080";"Cn1cc(-c2ccc3[nH]nc(-c4cc(N5CCOCC5)ncn4)c3c2)cn1";"IC50";"'='";"2.31";"nM";"8.64";"";"312512";"UO_0000065";"23.90";"0.44";"6.38";"10.19";"0";"CHEMBL3887174";"LanthaScreen™ Assay (Km ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 184 μM ATP solution in 1× assay buffer to all wells. d) After a 60 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3904862";"";"None";"434.50";"0";"2.03";"BDBM239086";"CC(C)Oc1cc2c(-c3cc(N4CCN(S(C)(=O)=O)CC4)ncn3)n[nH]c2cc1F";"IC50";"'='";"3.09";"nM";"8.51";"";"312519";"UO_0000065";"19.59";"0.39";"6.48";"8.16";"0";"CHEMBL3887174";"LanthaScreen™ Assay (Km ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 184 μM ATP solution in 1× assay buffer to all wells. d) After a 60 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3122117";"";"None";"449.84";"0";"3.11";"20, GNE-9605";"CNc1nc(Nc2cnn([C@H]3CCN(C4COC4)C[C@@H]3F)c2Cl)ncc1C(F)(F)F";"IC50";"'='";"18.7";"nM";"7.73";"";"";"UO_0000065";"17.18";"0.35";"4.62";"9.64";"0";"CHEMBL3124215";"Inhibition of LRRK2 (unknown origin) phosphorylation by cell-based assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3120096";"1";"Scientific Literature";"J Med Chem";"2014";"None";"";"";""
"CHEMBL3122122";"";"None";"411.43";"0";"2.82";"18";"CNc1nc(Nc2cnn(C3CCN(C4COC4)CC3)c2C)ncc1C(F)(F)F";"IC50";"'='";"20.0";"nM";"7.70";"";"";"UO_0000065";"18.71";"0.36";"4.88";"9.61";"0";"CHEMBL3124215";"Inhibition of LRRK2 (unknown origin) phosphorylation by cell-based assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3120096";"1";"Scientific Literature";"J Med Chem";"2014";"None";"";"";""
"CHEMBL3122121";"";"None";"356.35";"0";"3.14";"17";"CNc1nc(Nc2cnn(C3CCOCC3)c2C)ncc1C(F)(F)F";"IC50";"'='";"11.0";"nM";"7.96";"";"";"UO_0000065";"22.33";"0.43";"4.82";"10.35";"0";"CHEMBL3124215";"Inhibition of LRRK2 (unknown origin) phosphorylation by cell-based assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3120096";"1";"Scientific Literature";"J Med Chem";"2014";"None";"";"";""
"CHEMBL3122118";"";"None";"357.73";"0";"3.14";"14";"CNc1nc(Nc2cnn(C3(C#N)CC3)c2Cl)ncc1C(F)(F)F";"IC50";"'='";"22.0";"nM";"7.66";"";"";"UO_0000065";"21.41";"0.44";"4.52";"8.37";"0";"CHEMBL3124215";"Inhibition of LRRK2 (unknown origin) phosphorylation by cell-based assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3120096";"1";"Scientific Literature";"J Med Chem";"2014";"None";"";"";""
"CHEMBL3393360";"";"None";"306.33";"0";"1.73";"26";"N#Cc1cc(-c2c[nH]c3ncnc(N4CCOCC4)c23)ccn1";"IC50";"'='";"4514.0";"nM";"5.34";"";"";"UO_0000065";"17.45";"0.32";"3.62";"5.89";"0";"CHEMBL3395727";"Inhibition of GST-tagged truncated human recombinant LRRK2 G2019S mutant using fluorescein-labeled LRRKtide peptide substrate incubated for 90 mins";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3745885";"";"None";"467.46";"0";"3.66";"7ao; ON1231320";"Cn1c(=O)c(S(=O)(=O)c2ccc(F)cc2F)cc2cnc(Nc3ccc4[nH]ccc4c3)nc21";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL3747979";"Inhibition of human LRRK2 using [RLGRDKYKTLRQIRQ] as substrate";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3745707";"1";"Scientific Literature";"Bioorg Med Chem";"2016";"None";"";"";""
"CHEMBL2012582";"";"None";"570.70";"1";"3.44";"LRRK2IN1";"COc1cc(C(=O)N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2C";"IC50";"'='";"7.9";"nM";"8.10";"";"";"UO_0000065";"14.20";"0.26";"4.66";"8.32";"0";"CHEMBL3412556";"Inhibition of LRRK2 G2019S mutant (1326 to 252 aa) (unknown origin) stably expressed in HEK293 cell lysate using [gamma-32P] after 15 mins by Cerenkov counting method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3407393";"1";"Scientific Literature";"Eur J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL3409466";"";"None";"398.94";"0";"4.57";"25";"O=C(c1ccc(Nc2cccnc2)c(Cl)c1)N1CCC(N2CCCCC2)CC1";"IC50";"'>'";"1000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL3412556";"Inhibition of LRRK2 G2019S mutant (1326 to 252 aa) (unknown origin) stably expressed in HEK293 cell lysate using [gamma-32P] after 15 mins by Cerenkov counting method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3407393";"1";"Scientific Literature";"Eur J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL3409467";"";"None";"397.95";"1";"5.17";"26";"O=C(c1ccc(Nc2ccccc2)c(Cl)c1)N1CCC(N2CCCCC2)CC1";"IC50";"'>'";"1000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL3412556";"Inhibition of LRRK2 G2019S mutant (1326 to 252 aa) (unknown origin) stably expressed in HEK293 cell lysate using [gamma-32P] after 15 mins by Cerenkov counting method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3407393";"1";"Scientific Literature";"Eur J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL3409478";"";"None";"363.93";"0";"4.25";"37";"CCCNc1ccc(C(=O)N2CCC(N3CCCCC3)CC2)cc1Cl";"IC50";"'>'";"1000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL3412556";"Inhibition of LRRK2 G2019S mutant (1326 to 252 aa) (unknown origin) stably expressed in HEK293 cell lysate using [gamma-32P] after 15 mins by Cerenkov counting method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3407393";"1";"Scientific Literature";"Eur J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL3409480";"";"None";"414.98";"0";"4.38";"39";"Cn1cccc1CNc1ccc(C(=O)N2CCC(N3CCCCC3)CC2)cc1Cl";"IC50";"'>'";"1000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL3412556";"Inhibition of LRRK2 G2019S mutant (1326 to 252 aa) (unknown origin) stably expressed in HEK293 cell lysate using [gamma-32P] after 15 mins by Cerenkov counting method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3407393";"1";"Scientific Literature";"Eur J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL2012582";"";"None";"570.70";"1";"3.44";"LRRK2IN1";"COc1cc(C(=O)N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2C";"IC50";"'='";"13.0";"nM";"7.89";"";"";"UO_0000065";"13.82";"0.26";"4.45";"8.10";"1";"CHEMBL3412562";"Inhibition of wild-type GST-tagged LRRK2 (1326 to 2527 aa)(unknown origin) stably expressed in HEK293 cell lysate using [gamma-32P] after 15 mins by Cerenkov counting method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3407393";"1";"Scientific Literature";"Eur J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL5093627";"";"None";"475.59";"0";"4.30";"34";"O=C1NCCCOc2ccc3[nH]nc(c3c2)-c2cc(cc(N3CCC(N4CCCC4)CC3)c2)CO1";"IC50";"'<'";"10.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5030411";"Inhibition of recombinant human LRRK2 using LRRKtide peptide and ATP as substrates incubated for 1 hrs by ADP-glo luminescent assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5029192";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5193515";"";"None";"666.82";"1";"4.49";"42";"CC(C)CN(CC(=O)NCCCCCCNC(=O)c1ccc(-c2n[nH]c3ccccc23)cc1)C(=O)CNC(=O)C1COc2ccccc2C1";"IC50";"'='";"12.0";"nM";"7.92";"";"";"UO_0000065";"11.88";"0.22";"3.43";"5.44";"0";"CHEMBL5146031";"Inhibition of LRRK2 (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5143599";"1";"Scientific Literature";"J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL4439395";"";"None";"331.42";"0";"4.53";"24";"O=C(Cc1ccc(-c2ccccc2)cc1)Nc1cc(C2CCC2)[nH]n1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL4326810";"Inhibition of LRRK2 (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4325851";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2018";"None";"";"";""
"CHEMBL4740778";"";"None";"419.78";"0";"3.21";"26";"Nc1nn2cccnc2c1C(=O)Nc1c[nH]nc1-c1cc(Cl)ccc1OC(F)F";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL4666938";"Inhibition of recombinant human GST-tagged LRRK2 (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate incubated for 60 mins by Adapta assay";"A";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4665643";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"TIME = 1.0 hr";"";""
"CHEMBL4579292";"";"None";"418.48";"0";"3.06";"1";"N#CC1(c2ccc3cnn(-c4cc(N5CC[C@@H](O)[C@@H](F)C5)ncn4)c3c2)CC2(CC2)C1";"IC50";"'='";"4.4";"nM";"8.36";"";"";"UO_0000065";"19.97";"0.37";"5.30";"9.20";"0";"CHEMBL4434259";"Inhibition of GST-tagged truncated human LRRK2 G2019S mutant pre-incubated for 15 mins before fluorescein-labeled peptide substrate LRRKtide addition and measured after 90 mins by LRRK2 Km ATP LanthaScreen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4433243";"1";"Scientific Literature";"ACS Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4559776";"";"None";"426.52";"0";"3.50";"33";"CC1(O)CC2(CN(c3cc(-n4ncc5ccc(C6(C#N)CC7(CC7)C6)cc54)ncn3)C2)C1";"IC50";"'='";"1.0";"nM";"9.00";"";"";"UO_0000065";"21.10";"0.38";"5.50";"9.91";"0";"CHEMBL4434259";"Inhibition of GST-tagged truncated human LRRK2 G2019S mutant pre-incubated for 15 mins before fluorescein-labeled peptide substrate LRRKtide addition and measured after 90 mins by LRRK2 Km ATP LanthaScreen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4433243";"1";"Scientific Literature";"ACS Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4562534";"";"None";"414.51";"0";"3.36";"24";"CC(C)(O)C1CN(c2cc(-n3ncc4ccc(C5(C#N)CC6(CC6)C5)cc43)ncn2)C1";"IC50";"'='";"2.6";"nM";"8.59";"";"";"UO_0000065";"20.71";"0.38";"5.23";"9.45";"0";"CHEMBL4434259";"Inhibition of GST-tagged truncated human LRRK2 G2019S mutant pre-incubated for 15 mins before fluorescein-labeled peptide substrate LRRKtide addition and measured after 90 mins by LRRK2 Km ATP LanthaScreen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4433243";"1";"Scientific Literature";"ACS Med Chem Lett";"2019";"None";"";"";""
"CHEMBL3335345";"";"None";"425.08";"0";"4.42";"20b";"COc1ccc2c(c1)/C(=C\c1cc(Br)c(O)c(Br)c1)C(=O)N2";"IC50";"'='";"31.0";"nM";"7.51";"";"";"UO_0000065";"17.66";"0.47";"3.09";"12.82";"0";"CHEMBL3390652";"Inhibition of recombinant LRRK2 (unknown origin) using gamma-32P-ATP assessed as LRRKtide substrate phosphorylation level by autoradiography";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352815";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL5286106";"";"None";"426.52";"0";"3.50";"25";"CC(C)(O)C12CC(C1)N(c1cc(-n3ncc4ccc([C@]5(C#N)CC56CC6)cc43)ncn1)C2";"IC50";"'='";"0.3";"nM";"9.52";"";"";"UO_0000065";"22.33";"0.41";"6.02";"10.48";"0";"CHEMBL5239656";"Inhibition of GST20-tagged LRRK2 in human SH-SY5Y cells assessed as reduction in pSer935 phosphorylation incubated for 90 mins by MSD assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5236618";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 1.5 hr";"INHIBITOR";""
"CHEMBL3409481";"";"None";"414.94";"0";"4.01";"40";"O=C(Nc1ccc(C(=O)N2CCC(N3CCCCC3)CC2)cc1Cl)c1ccc[nH]1";"IC50";"'>'";"1000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL3412556";"Inhibition of LRRK2 G2019S mutant (1326 to 252 aa) (unknown origin) stably expressed in HEK293 cell lysate using [gamma-32P] after 15 mins by Cerenkov counting method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3407393";"1";"Scientific Literature";"Eur J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL3335344";"";"None";"471.15";"1";"6.08";"20a";"O=C1Nc2ccc(-c3ccccc3)cc2/C1=C\c1cc(Br)c(O)c(Br)c1";"IC50";"'='";"204.0";"nM";"6.69";"";"";"UO_0000065";"14.20";"0.35";"0.61";"13.56";"0";"CHEMBL3390652";"Inhibition of recombinant LRRK2 (unknown origin) using gamma-32P-ATP assessed as LRRKtide substrate phosphorylation level by autoradiography";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352815";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL3588873";"";"None";"340.43";"0";"2.93";"Z-6583";"CC(c1ccc(NC(=O)c2cc(C3CC3)[nH]n2)cc1)N1CCOCC1";"IC50";"'='";"4800.0";"nM";"5.32";"";"";"UO_0000065";"15.62";"0.29";"2.39";"7.57";"0";"CHEMBL3592569";"Inhibition of wild type LRRK2 (unknown origin) assessed as inhibition of LRRKtide phosphorylation after 120 mins by radiometric assay in presence of [gamma-33P]-ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3588794";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2015";"None";"";"";""
"CHEMBL3904634";"";"None";"249.28";"0";"2.54";"BDBM185420";"CNc1ncnc2[nH]cc(-c3cccc(C#N)c3)c12";"IC50";"'='";"45.0";"nM";"7.35";"";"334384";"UO_0000065";"29.47";"0.53";"4.81";"9.49";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3919118";"";"None";"238.29";"0";"2.69";"BDBM185424";"CN(C)c1ncnc2[nH]cc(-c3ccccc3)c12";"IC50";"'='";"63.0";"nM";"7.20";"";"334388";"UO_0000065";"30.22";"0.55";"4.51";"16.07";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3965800";"";"None";"328.35";"0";"2.61";"BDBM185444";"COc1ccc(F)cc1-c1c[nH]c2ncnc(N3CCOCC3)c12";"IC50";"'='";"7.0";"nM";"8.15";"";"334414";"UO_0000065";"24.84";"0.46";"5.54";"12.89";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL4060479";"";"None";"301.35";"0";"3.95";"3";"Nc1cc(-c2n[nH]c3ccc(Nc4ccccc4)cc23)ccn1";"IC50";"'='";"728.0";"nM";"6.14";"";"";"UO_0000065";"20.37";"0.36";"2.19";"7.71";"0";"CHEMBL4010150";"Inhibition of wild type human recombinant LRRK2 expressed in baculovirus using fluorescein-ERM as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007454";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4075961";"";"None";"365.44";"0";"2.69";"21";"CC(C)Oc1ccc2[nH]nc(-c3ccnc(N4CCN(C)C(=O)C4)c3)c2c1";"IC50";"'='";"59.0";"nM";"7.23";"";"";"UO_0000065";"19.78";"0.37";"4.54";"9.72";"0";"CHEMBL4010118";"Inhibition LRRK2 G2019S mutant Ser935 phosphorylation in human SH-SY5Y cells after 90 mins by Western blot analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007454";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4581712";"";"None";"203.24";"0";"2.20";"24";"Cc1n[nH]c2ccnc(OC3CCC3)c12";"IC50";"'='";"170.0";"nM";"6.77";"";"";"UO_0000065";"33.31";"0.62";"4.57";"13.33";"0";"CHEMBL4331900";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant catalytic domain (970 to 2527 residues) expressed in baculovirus expression system by radiometric assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330096";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4562596";"";"None";"378.44";"0";"3.96";"79";"N#Cc1ccc2ncc3nc(Cc4csnn4)n([C@@H]4CC[C@H](F)C4)c3c2c1";"IC50";"'='";"9.73";"nM";"8.01";"";"";"UO_0000065";"21.17";"0.41";"4.05";"9.98";"0";"CHEMBL4334283";"Inhibition of recombinant wild-type GST-tagged LRRK2 (unknown origin) expressed in baculovirus expression system using fluorescein-labeled LRRKtide as substrate after 30 mins by Lanthascreen assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330176";"1";"Scientific Literature";"ACS Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4453844";"";"None";"453.37";"0";"4.48";"75";"Cc1nc(Cc2nc3cnc4ccc(C(F)(F)F)cc4c3n2[C@@H]2CCOCC2(F)F)no1";"IC50";"'='";"25.7";"nM";"7.59";"";"";"UO_0000065";"16.74";"0.32";"3.11";"9.62";"0";"CHEMBL4334283";"Inhibition of recombinant wild-type GST-tagged LRRK2 (unknown origin) expressed in baculovirus expression system using fluorescein-labeled LRRKtide as substrate after 30 mins by Lanthascreen assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330176";"1";"Scientific Literature";"ACS Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4439241";"";"None";"354.84";"0";"4.43";"2";"CCc1nc2cnc3ccc(Cl)cc3c2n1[C@H]1CCO[C@@H](CC#N)C1";"IC50";"'='";"1530.0";"nM";"5.82";"";"";"UO_0000065";"16.39";"0.32";"1.39";"9.12";"0";"CHEMBL4334283";"Inhibition of recombinant wild-type GST-tagged LRRK2 (unknown origin) expressed in baculovirus expression system using fluorescein-labeled LRRKtide as substrate after 30 mins by Lanthascreen assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330176";"1";"Scientific Literature";"ACS Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4466740";"";"None";"430.43";"0";"4.06";"9";"C[C@@H]1C[C@H](n2c(Cc3cn(C)nn3)nc3cnc4ccc(C(F)(F)F)cc4c32)CCO1";"IC50";"'='";"5.55";"nM";"8.26";"";"";"UO_0000065";"19.18";"0.36";"4.20";"11.69";"0";"CHEMBL4334284";"Inhibition of GST-tagged LRRK2 G2019S mutant (unknown origin) expressed in baculovirus expression system using fluorescein-labeled LRRKtide as substrate after 30 mins by Lanthascreen assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330176";"1";"Scientific Literature";"ACS Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4777342";"";"None";"418.79";"0";"3.64";"21";"Cn1cc(NC(=O)c2cnn3cccnc23)c(-c2cc(Cl)ccc2OC(F)F)n1";"IC50";"'='";"81.0";"nM";"7.09";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL4666938";"Inhibition of recombinant human GST-tagged LRRK2 (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate incubated for 60 mins by Adapta assay";"A";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4665643";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL4742159";"";"None";"449.21";"0";"3.74";"46";"O=C(Nc1c[nH]nc1-c1cc(Br)ccc1OC(F)F)c1cnn2cccnc12";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL4666938";"Inhibition of recombinant human GST-tagged LRRK2 (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate incubated for 60 mins by Adapta assay";"A";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4665643";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"TIME = 1.0 hr";"";""
"CHEMBL1673057";"";"None";"494.00";"0";"3.99";"XMD10-147";"COc1cc(N2CCN(C)CC2)ccc1Nc1ncc2c(n1)N(C)c1cc(Cl)ccc1C(=O)N2C";"IC50";"'='";"3740.0";"nM";"5.43";"";"";"UO_0000065";"10.99";"0.21";"1.44";"7.04";"0";"CHEMBL4612965";"Inhibition of recombinant human GST-tagged LRRK2 catalytic domain (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate measured after 1 hr by Alexa fluor-647 ADP tracer-based ADAPTA assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4610122";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL4760562";"";"None";"404.76";"0";"3.86";"40";"O=C(Nc1c[nH]nc1-c1cc(Cl)ccc1OC(F)F)c1cncc2c[nH]nc12";"IC50";"'='";"79.0";"nM";"7.10";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL4666938";"Inhibition of recombinant human GST-tagged LRRK2 (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate incubated for 60 mins by Adapta assay";"A";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4665643";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL4646447";"";"None";"424.49";"0";"2.95";"XMD17-86";"CN1C(=O)c2ccccc2N(C)c2nc(Nc3ccc(NS(C)(=O)=O)cc3)ncc21";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL4612965";"Inhibition of recombinant human GST-tagged LRRK2 catalytic domain (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate measured after 1 hr by Alexa fluor-647 ADP tracer-based ADAPTA assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4610122";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL1673047";"";"None";"410.46";"0";"2.23";"XMD12-70-2";"CN1C(=O)c2ccccc2N(C)c2nc(Nc3ccc(S(N)(=O)=O)cc3)ncc21";"IC50";"'='";"7.0";"nM";"8.15";"";"";"UO_0000065";"19.87";"0.38";"5.92";"6.71";"0";"CHEMBL4612965";"Inhibition of recombinant human GST-tagged LRRK2 catalytic domain (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate measured after 1 hr by Alexa fluor-647 ADP tracer-based ADAPTA assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4610122";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL3905416";"";"None";"338.42";"0";"2.34";"BDBM239228";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CC[C@H](N)C4)ncn3)c2c1";"IC50";"'='";"6.68";"nM";"8.18";"";"417689";"UO_0000065";"24.16";"0.45";"5.84";"8.80";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3891819";"";"None";"351.41";"0";"2.78";"BDBM239238";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4C[C@@H]5C[C@H]4CO5)ncn3)c2c1";"IC50";"'='";"5.94";"nM";"8.23";"";"417699";"UO_0000065";"23.41";"0.43";"5.45";"10.80";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3929984";"";"None";"319.37";"0";"2.64";"BDBM185573";"Cc1nc(N2CCOCC2)c2c(-c3cccc(C#N)c3)c[nH]c2n1";"IC50";"'='";"42.0";"nM";"7.38";"";"334328";"UO_0000065";"23.10";"0.42";"4.74";"9.48";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3963345";"";"None";"292.39";"0";"3.86";"BDBM185373";"C[C@H]1CCCN(c2ncnc3[nH]cc(-c4ccccc4)c23)C1";"IC50";"'='";"91.0";"nM";"7.04";"";"334334";"UO_0000065";"24.08";"0.44";"3.18";"15.71";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3908720";"";"None";"396.45";"0";"1.71";"BDBM239454";"COC[C@H](C)Oc1ccc2[nH]nc(-c3cc(N4CCN(C)C(=O)C4)ncn3)c2c1";"IC50";"'='";"10.9";"nM";"7.96";"";"417919";"UO_0000065";"20.08";"0.37";"6.25";"8.25";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3897489";"";"None";"397.45";"0";"4.98";"BDBM239518";"FC1(F)CCN(c2cc(-c3n[nH]c4ccc(-c5ccsc5)cc34)ncn2)CC1";"IC50";"'='";"347.8";"nM";"6.46";"";"417981";"UO_0000065";"16.25";"0.32";"1.48";"11.19";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3954916";"";"None";"371.44";"0";"3.83";"BDBM239531";"Cc1ccc(-c2ccc3[nH]nc(-c4cc(N5CCOCC5)ncn4)c3c2)cc1";"IC50";"'='";"251.1";"nM";"6.60";"";"417994";"UO_0000065";"17.77";"0.32";"2.77";"9.86";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4075195";"";"None";"403.49";"0";"3.85";"23";"CC(C)Oc1ccc2[nH]nc(-c3ccnc(N4CCC(n5cnnc5)CC4)c3)c2c1";"IC50";"'='";"194.0";"nM";"6.71";"";"";"UO_0000065";"16.64";"0.31";"2.86";"7.92";"0";"CHEMBL4010118";"Inhibition LRRK2 G2019S mutant Ser935 phosphorylation in human SH-SY5Y cells after 90 mins by Western blot analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007454";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4100904";"";"None";"338.41";"0";"3.25";"17";"CC(C)Oc1ccc2[nH]nc(-c3ccnc(N4CCOCC4)c3)c2c1";"IC50";"'='";"43.0";"nM";"7.37";"";"";"UO_0000065";"21.77";"0.40";"4.12";"11.64";"0";"CHEMBL4010118";"Inhibition LRRK2 G2019S mutant Ser935 phosphorylation in human SH-SY5Y cells after 90 mins by Western blot analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007454";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4581255";"";"None";"285.31";"0";"1.91";"9";"c1cc(-c2n[nH]c3ccnc(OC4CCOCC4)c23)[nH]n1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL4331199";"Inhibition of LRRK2 G2019S mutant (unknown origin) by cell based assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330074";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL3930527";"";"None";"363.81";"0";"3.94";"BDBM254936";"Cc1ccnc(-c2cc(Nc3nn(C)cc3Cl)nc3[nH]cc(C#N)c23)c1";"IC50";"'='";"145.0";"nM";"6.84";"";"443742";"UO_0000065";"18.80";"0.36";"2.90";"7.18";"0";"CHEMBL3889253";"Homogeneous Time Resolved-fluorescence Resonance Energy Transfer (TR-FRET) Assay: LRRK2 kinase activity is measured using a LanthaScreen kinase activity assay available from Invitrogen (Life Technologies Corporation). The assay is a homogeneous time resolved-fluorescence resonance energy transfer (TR-FRET) assay that measures phosphorylation of a fluorescein-labelled peptide substrate (fluorescein-LRRKtide, fluorescein-GAGRLGRDKYKTLRQIRQ) (SEQ ID NO 1) as a result of LRRK2 kinase activity. The phosphorylated peptide is recognized by a terbium-labelled phospho-specific anti-LRRKtide antibody and, subsequently, the phosphorylated LRRKtide can be quantified by the extent of TR-FRET between the terbium donor and fluorescein acceptor.The LRRK2 kinase is obtained from Invitrogen (Life Technologies Corporation) and comprises residues 970 to 2527 of the full length human wild-type LRRK2 kinase or a similar sequence with the G2019S mutation. As discussed above, this mutation increases the kinase activity relative to the wild-type. The kinase reactions are performed in a 20 uL volume in 384-well plates. The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT.Â  In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 uM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 uM fluorescein-LRRKtide. The reaction mixture (20 ul total volume) is incubated for 2 hours at 30° C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 ul). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 us) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 us. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 us time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3887011";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4098877";"MLi-2";"None";"379.46";"0";"3.56";"19";"C[C@@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@H](C)O1";"IC50";"'='";"0.8";"nM";"9.10";"";"";"UO_0000065";"23.97";"0.44";"5.54";"11.94";"0";"CHEMBL4668318";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant catalytic domain (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate preincubated for 30 mins followed by substrate addition and measured after 1 hr by LanthaScreen assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4665673";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 0.5 hr";"DEGRADER";""
"CHEMBL3393357";"";"None";"323.33";"0";"2.47";"23";"N#Cc1cc(-c2c[nH]c3ncnc(N4CCOCC4)c23)ccc1F";"IC50";"'='";"920.0";"nM";"6.04";"";"";"UO_0000065";"18.67";"0.34";"3.57";"7.76";"0";"CHEMBL3395727";"Inhibition of GST-tagged truncated human recombinant LRRK2 G2019S mutant using fluorescein-labeled LRRKtide peptide substrate incubated for 90 mins";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3393347";"";"None";"291.36";"0";"3.34";"13";"CCN(CC)c1ncnc2[nH]cc(-c3cccc(C#N)c3)c12";"IC50";"'='";"151.0";"nM";"6.82";"";"";"UO_0000065";"23.41";"0.42";"3.48";"9.94";"0";"CHEMBL3395727";"Inhibition of GST-tagged truncated human recombinant LRRK2 G2019S mutant using fluorescein-labeled LRRKtide peptide substrate incubated for 90 mins";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3393345";"";"None";"275.32";"0";"2.71";"11";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCC4)c23)c1";"IC50";"'='";"325.0";"nM";"6.49";"";"";"UO_0000065";"23.57";"0.42";"3.78";"9.46";"0";"CHEMBL3395727";"Inhibition of GST-tagged truncated human recombinant LRRK2 G2019S mutant using fluorescein-labeled LRRKtide peptide substrate incubated for 90 mins";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3393440";"";"None";"284.32";"0";"1.19";"29";"Cn1ccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)n1";"IC50";"'='";"53.0";"nM";"7.28";"";"";"UO_0000065";"25.59";"0.47";"6.09";"10.12";"0";"CHEMBL3395726";"Inhibition of GST-tagged truncated human recombinant LRRK2 using fluorescein-labeled LRRKtide peptide substrate incubated for 2 hrs";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3393345";"";"None";"275.32";"0";"2.71";"11";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCC4)c23)c1";"IC50";"'='";"115.0";"nM";"6.94";"";"";"UO_0000065";"25.20";"0.45";"4.23";"10.12";"0";"CHEMBL3395726";"Inhibition of GST-tagged truncated human recombinant LRRK2 using fluorescein-labeled LRRKtide peptide substrate incubated for 2 hrs";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3893023";"";"None";"323.36";"0";"1.56";"11";"NC(=O)c1cccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"2360.0";"nM";"5.63";"";"";"UO_0000065";"17.40";"0.32";"4.07";"5.79";"0";"CHEMBL5043428";"Displacement of K5 tracer from full length C-terminal NanoLuc fused human LRRK2 expressed in HEK293T cells incubated for 2 hrs by NanoBRET assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293T";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5042489";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL5089935";"";"None";"369.86";"0";"3.38";"20; SBP-3264";"CC(=O)NC1CCN(c2ncnc3[nH]cc(-c4cccc(Cl)c4)c23)CC1";"IC50";"'='";"1390.0";"nM";"5.86";"";"";"UO_0000065";"15.84";"0.31";"2.48";"7.92";"0";"CHEMBL5043428";"Displacement of K5 tracer from full length C-terminal NanoLuc fused human LRRK2 expressed in HEK293T cells incubated for 2 hrs by NanoBRET assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293T";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5042489";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL3409477";"";"None";"426.00";"1";"5.35";"36";"Cc1ccc(CNc2ccc(C(=O)N3CCC(N4CCCCC4)CC3)cc2Cl)cc1";"IC50";"'>'";"1000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL3412556";"Inhibition of LRRK2 G2019S mutant (1326 to 252 aa) (unknown origin) stably expressed in HEK293 cell lysate using [gamma-32P] after 15 mins by Cerenkov counting method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3407393";"1";"Scientific Literature";"Eur J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL4436378";"";"None";"404.47";"0";"3.53";"19";"C[C@@H]1COCCN1c1ccc(OCc2ccccc2)c(C(=O)Nc2ccnnc2)c1";"IC50";"'='";"19.95";"nM";"7.70";"";"";"UO_0000065";"19.04";"0.35";"4.17";"10.05";"0";"CHEMBL4372253";"Inhibition of recombinant 6His-Tev-tagged LRRK2 (1326 to 2527) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-RLGRDKYKTLRQIRQGNTKQR-OH as substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs by TR-FRET assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"Sf9";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4371037";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"CHEMBL3308860";"";"";""
"CHEMBL4443245";"";"None";"374.44";"0";"3.91";"12";"O=C(Nc1ccnnc1)c1cc(N2CCCC2)ccc1OCc1ccccc1";"IC50";"'='";"19.95";"nM";"7.70";"";"";"UO_0000065";"20.56";"0.38";"3.79";"11.43";"0";"CHEMBL4372253";"Inhibition of recombinant 6His-Tev-tagged LRRK2 (1326 to 2527) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-RLGRDKYKTLRQIRQGNTKQR-OH as substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs by TR-FRET assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"Sf9";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4371037";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"CHEMBL3308860";"";"";""
"CHEMBL4082856";"";"None";"365.44";"0";"3.18";"26";"C[C@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)CCO1";"IC50";"'='";"3.8";"nM";"8.42";"";"";"UO_0000065";"23.04";"0.43";"5.24";"11.06";"0";"CHEMBL4010118";"Inhibition LRRK2 G2019S mutant Ser935 phosphorylation in human SH-SY5Y cells after 90 mins by Western blot analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007454";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4075961";"";"None";"365.44";"0";"2.69";"21";"CC(C)Oc1ccc2[nH]nc(-c3ccnc(N4CCN(C)C(=O)C4)c3)c2c1";"IC50";"'='";"91.0";"nM";"7.04";"";"";"UO_0000065";"19.27";"0.36";"4.35";"9.47";"0";"CHEMBL4010117";"Inhibition of recombinant human GST-tagged LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus using fluorescein-ERM as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr in presence of 5 mM ATP by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007454";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4066983";"";"None";"351.41";"0";"2.79";"25";"CC1(Oc2ccc3[nH]nc(-c4cc(N5CCOCC5)ncn4)c3c2)CC1";"IC50";"'='";"10.0";"nM";"8.00";"";"";"UO_0000065";"22.77";"0.42";"5.21";"10.50";"0";"CHEMBL4010117";"Inhibition of recombinant human GST-tagged LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus using fluorescein-ERM as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr in presence of 5 mM ATP by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007454";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4553532";"";"None";"428.54";"0";"3.75";"11";"CC(C)(O)[C@@H]1CCN(c2cc(-n3ncc4ccc(C5(C#N)CC6(CC6)C5)cc43)ncn2)C1";"IC50";"'='";"0.9";"nM";"9.05";"";"";"UO_0000065";"21.11";"0.39";"5.30";"9.96";"0";"CHEMBL4434259";"Inhibition of GST-tagged truncated human LRRK2 G2019S mutant pre-incubated for 15 mins before fluorescein-labeled peptide substrate LRRKtide addition and measured after 90 mins by LRRK2 Km ATP LanthaScreen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4433243";"1";"Scientific Literature";"ACS Med Chem Lett";"2019";"None";"";"";""
"CHEMBL388978";"STAUROSPORINE";"None";"466.54";"0";"4.35";"Staurosporine";"CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4";"IC50";"'='";"17.1";"nM";"7.77";"";"";"UO_0000065";"16.65";"0.30";"3.42";"11.18";"0";"CHEMBL4328476";"Inhibition of human LRRK2 using RLGRDKYKTLRQIRQ as substrate by [gamma-33P]-ATP assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4325871";"1";"Scientific Literature";"Eur J Med Chem";"2019";"None";"";"";""
"CHEMBL4560272";"";"None";"284.37";"0";"2.74";"15";"CCc1cc(-c2n[nH]c3ccnc(NC(C)C)c23)nn1C";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL4331199";"Inhibition of LRRK2 G2019S mutant (unknown origin) by cell based assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330074";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4460909";"";"None";"417.85";"0";"3.31";"48";"Cc1cn(Cc2nc3cnc4ccc(Cl)cc4c3n2C2CN(C)CC2(F)F)nn1";"IC50";"'='";"3.27";"nM";"8.48";"";"";"UO_0000065";"20.31";"0.40";"5.18";"13.12";"0";"CHEMBL4334283";"Inhibition of recombinant wild-type GST-tagged LRRK2 (unknown origin) expressed in baculovirus expression system using fluorescein-labeled LRRKtide as substrate after 30 mins by Lanthascreen assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330176";"1";"Scientific Literature";"ACS Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4435423";"";"None";"408.42";"0";"2.53";"4";"Cc1cnn(Cc2nc3cnc4ccc(C#N)cc4c3n2C2CN(C)CC2(F)F)n1";"IC50";"'='";"17.6";"nM";"7.75";"";"";"UO_0000065";"18.99";"0.35";"5.22";"8.77";"0";"CHEMBL4334283";"Inhibition of recombinant wild-type GST-tagged LRRK2 (unknown origin) expressed in baculovirus expression system using fluorescein-labeled LRRKtide as substrate after 30 mins by Lanthascreen assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330176";"1";"Scientific Literature";"ACS Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4460909";"";"None";"417.85";"0";"3.31";"48";"Cc1cn(Cc2nc3cnc4ccc(Cl)cc4c3n2C2CN(C)CC2(F)F)nn1";"IC50";"'='";"0.94";"nM";"9.03";"";"";"UO_0000065";"21.60";"0.43";"5.72";"13.96";"0";"CHEMBL4334284";"Inhibition of GST-tagged LRRK2 G2019S mutant (unknown origin) expressed in baculovirus expression system using fluorescein-labeled LRRKtide as substrate after 30 mins by Lanthascreen assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330176";"1";"Scientific Literature";"ACS Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4436576";"";"None";"307.40";"0";"3.15";"1";"Cc1ccc(-c2cc3nccnc3c(NCCCCN)n2)cc1";"IC50";"'='";"1258.93";"nM";"5.90";"";"";"UO_0000065";"19.19";"0.35";"2.75";"7.69";"0";"CHEMBL4433048";"Inhibition of LRRK2 (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4431389";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2016";"None";"";"";""
"CHEMBL4450014";"";"None";"455.57";"0";"3.06";"13";"C[C@H]1CN(c2cc(-n3ncc4ccc(C5(C#N)CC6(CC6)C5)cc43)ncn2)CCN1C1COC1";"IC50";"'='";"1.0";"nM";"9.00";"";"";"UO_0000065";"19.76";"0.36";"5.94";"10.83";"0";"CHEMBL4434259";"Inhibition of GST-tagged truncated human LRRK2 G2019S mutant pre-incubated for 15 mins before fluorescein-labeled peptide substrate LRRKtide addition and measured after 90 mins by LRRK2 Km ATP LanthaScreen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4433243";"1";"Scientific Literature";"ACS Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4442821";"";"None";"456.55";"0";"2.38";"48";"Cc1nc(N2CCN3CCOC[C@@H]3C2)cc(-n2ncc3cnc(C4(C#N)CC5(CC5)C4)cc32)n1";"IC50";"'='";"20.2";"nM";"7.70";"";"";"UO_0000065";"16.85";"0.31";"5.31";"8.02";"0";"CHEMBL4434259";"Inhibition of GST-tagged truncated human LRRK2 G2019S mutant pre-incubated for 15 mins before fluorescein-labeled peptide substrate LRRKtide addition and measured after 90 mins by LRRK2 Km ATP LanthaScreen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4433243";"1";"Scientific Literature";"ACS Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4521173";"";"None";"383.46";"0";"3.02";"6";"Cc1cc(Cc2nc3cnc4ccc(C#N)cc4c3n2[C@@H]2CCN(C)C2)ncn1";"IC50";"'='";"6.39";"nM";"8.19";"";"";"UO_0000065";"21.37";"0.39";"5.17";"9.81";"0";"CHEMBL4334283";"Inhibition of recombinant wild-type GST-tagged LRRK2 (unknown origin) expressed in baculovirus expression system using fluorescein-labeled LRRKtide as substrate after 30 mins by Lanthascreen assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330176";"1";"Scientific Literature";"ACS Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4453844";"";"None";"453.37";"0";"4.48";"75";"Cc1nc(Cc2nc3cnc4ccc(C(F)(F)F)cc4c3n2[C@@H]2CCOCC2(F)F)no1";"IC50";"'='";"26.5";"nM";"7.58";"";"";"UO_0000065";"16.71";"0.32";"3.10";"9.61";"0";"CHEMBL4334284";"Inhibition of GST-tagged LRRK2 G2019S mutant (unknown origin) expressed in baculovirus expression system using fluorescein-labeled LRRKtide as substrate after 30 mins by Lanthascreen assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330176";"1";"Scientific Literature";"ACS Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4465007";"";"None";"372.35";"0";"4.93";"3";"O=C(Nc1cccnc1)c1cc(C(F)(F)F)ccc1OCc1ccccc1";"IC50";"'='";"12.59";"nM";"7.90";"";"";"UO_0000065";"21.22";"0.40";"2.97";"15.42";"0";"CHEMBL4372253";"Inhibition of recombinant 6His-Tev-tagged LRRK2 (1326 to 2527) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-RLGRDKYKTLRQIRQGNTKQR-OH as substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs by TR-FRET assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"Sf9";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4371037";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"CHEMBL3308860";"";"";""
"CHEMBL2436978";"";"None";"421.55";"1";"5.13";"1, URMC-099";"CN1CCN(Cc2ccc(-c3cnc4[nH]cc(-c5ccc6[nH]ccc6c5)c4c3)cc2)CC1";"IC50";"'='";"11.0";"nM";"7.96";"";"";"UO_0000065";"18.88";"0.34";"2.83";"15.62";"0";"CHEMBL2439119";"Inhibition of human wild type LRRK2 by qPCR analysis";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2434948";"1";"Scientific Literature";"J Med Chem";"2013";"None";"";"";""
"CHEMBL4098877";"MLi-2";"None";"379.46";"0";"3.56";"1; MLi-2";"C[C@@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@H](C)O1";"IC50";"'='";"6.4";"nM";"8.19";"";"";"UO_0000065";"21.59";"0.40";"4.63";"10.76";"0";"CHEMBL4010117";"Inhibition of recombinant human GST-tagged LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus using fluorescein-ERM as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr in presence of 5 mM ATP by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007454";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL3928102";"";"None";"339.40";"0";"2.64";"24";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCOCC4)ncn3)c2c1";"IC50";"'='";"41.0";"nM";"7.39";"";"";"UO_0000065";"21.77";"0.40";"4.75";"9.70";"0";"CHEMBL4010118";"Inhibition LRRK2 G2019S mutant Ser935 phosphorylation in human SH-SY5Y cells after 90 mins by Western blot analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007454";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL407391";"DIMETHYLADENINE";"None";"163.18";"0";"0.42";"8";"CN(C)c1ncnc2nc[nH]c12";"IC50";"'='";"3355.0";"nM";"5.47";"";"";"UO_0000065";"33.55";"0.62";"5.05";"9.49";"0";"CHEMBL5040107";"Inhibition of recombinant human GST tagged truncated LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL3414584";"";"None";"350.43";"0";"2.41";"55";"NC(=O)c1ncc(N[C@@H]2CCCC[C@@H]2N)nc1-c1cc2ccccc2[nH]1";"IC50";"'='";"30.0";"nM";"7.52";"";"";"UO_0000065";"21.47";"0.40";"5.11";"6.13";"0";"CHEMBL3418522";"Inhibition of LRRK2 (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3414497";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL4592487";"";"None";"357.41";"0";"2.15";"8";"CC(C)(O)Cn1cc(-c2n[nH]c3ccnc(OC4CCOCC4)c23)cn1";"IC50";"'='";"13.0";"nM";"7.89";"";"";"UO_0000065";"22.06";"0.41";"5.74";"8.04";"0";"CHEMBL4331199";"Inhibition of LRRK2 G2019S mutant (unknown origin) by cell based assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330074";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4100294";"";"None";"401.24";"0";"4.81";"6d";"O=C(Nc1cccnc1)c1cc(Br)ccc1OCc1ccc(F)cc1";"IC50";"'='";"7.943";"nM";"8.10";"";"";"UO_0000065";"20.19";"0.44";"3.29";"15.81";"0";"CHEMBL4058537";"Inhibition of LRRK2 (unknown origin) by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4052807";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL4083585";"";"None";"416.70";"1";"5.93";"7h";"O=C(Nc1cccc(Cl)c1)c1cc(Br)ccc1OCc1ccccc1";"IC50";"'='";"25.12";"nM";"7.60";"";"";"UO_0000065";"18.24";"0.42";"1.67";"19.83";"0";"CHEMBL4058537";"Inhibition of LRRK2 (unknown origin) by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4052807";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL227491";"";"None";"222.25";"0";"2.76";"4, E:Z Mixture (83:17)";"O=C1Nc2ccccc2/C1=N/c1ccccc1";"IC50";"'='";"3650.0";"nM";"5.44";"";"";"UO_0000065";"24.47";"0.44";"2.68";"13.12";"0";"CHEMBL4192178";"Inhibition of recombinant catalytic human GST-tagged LLRK2 (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4190250";"1";"Scientific Literature";"Eur J Med Chem";"2017";"None";"";"";""
"CHEMBL1311313";"";"None";"231.25";"0";"0.68";"20, E:Z Mixture (88:12)";"O=C1Nc2ccccc2C1=NN1CCOCC1";"IC50";"'='";"1700.0";"nM";"5.77";"";"";"UO_0000065";"24.95";"0.46";"5.09";"10.70";"0";"CHEMBL4192178";"Inhibition of recombinant catalytic human GST-tagged LLRK2 (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4190250";"1";"Scientific Literature";"Eur J Med Chem";"2017";"None";"";"";""
"CHEMBL4218001";"";"None";"392.26";"0";"4.94";"36, E:Z Mixture (91:9)";"O=C1Nc2ccc(Br)cc2C1=NN(c1ccccc1)c1ccccc1";"IC50";"'='";"30.0";"nM";"7.52";"";"";"UO_0000065";"19.18";"0.41";"2.58";"16.83";"0";"CHEMBL4192179";"Inhibition of recombinant catalytic human GST-tagged LLRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4190250";"1";"Scientific Literature";"Eur J Med Chem";"2017";"None";"";"";""
"CHEMBL2204495";"";"None";"399.43";"1";"5.11";"1, GSK2578215A";"O=C(Nc1cccnc1)c1cc(-c2ccnc(F)c2)ccc1OCc1ccccc1";"IC50";"'='";"81.1";"nM";"7.09";"";"";"UO_0000065";"17.75";"0.32";"1.98";"11.06";"0";"CHEMBL2215490";"Inhibition of recombinant His6-Tev-tagged LRRK2 A2016T mutant expressed in baculovirus assessed as inhibition of LRRKtide phosphorylation by HTRF assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"A2016T";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2203081";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2012";"None";"";"";""
"CHEMBL3651804";"";"None";"327.39";"0";"2.46";"11";"CC(C)c1nc(-c2n[nH]c3ccnc(NC4CCOCC4)c23)n[nH]1";"IC50";"'='";"35.0";"nM";"7.46";"";"";"UO_0000065";"22.77";"0.42";"5.00";"7.14";"0";"CHEMBL4331199";"Inhibition of LRRK2 G2019S mutant (unknown origin) by cell based assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330074";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4460415";"";"None";"381.44";"0";"2.41";"7";"c1cc(-c2n[nH]c3ccnc(OC4CCOCC4)c23)nc(N2CCOCC2)c1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL4331199";"Inhibition of LRRK2 G2019S mutant (unknown origin) by cell based assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330074";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL3937482";"";"None";"402.48";"0";"3.54";"BDBM234865";"CCCS(=O)(=O)Nc1cccc(Nc2ncnc3cc(OC)c(OC)cc23)c1";"IC50";"'='";"121.0";"nM";"6.92";"";"409347";"UO_0000065";"17.19";"0.34";"3.38";"6.75";"0";"CHEMBL3888567";"In vitro Kinase Assay: In vitro kinase assays using LRRK WT and LRRK G2019S.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886763";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3975772";"";"None";"332.41";"0";"3.24";"BDBM254924";"Cc1cc(-c2ccnc3[nH]cc(C#N)c23)ccc1CN1CCOCC1";"IC50";"'='";"78.0";"nM";"7.11";"";"443707";"UO_0000065";"21.38";"0.39";"3.87";"10.95";"0";"CHEMBL3889252";"Homogeneous Time Resolved-fluorescence Resonance Energy Transfer (TR-FRET) Assay: LRRK2 kinase activity is measured using a LanthaScreen kinase activity assay available from Invitrogen (Life Technologies Corporation). The assay is a homogeneous time resolved-fluorescence resonance energy transfer (TR-FRET) assay that measures phosphorylation of a fluorescein-labelled peptide substrate (fluorescein-LRRKtide, fluorescein-GAGRLGRDKYKTLRQIRQ) (SEQ ID NO 1) as a result of LRRK2 kinase activity. The phosphorylated peptide is recognized by a terbium-labelled phospho-specific anti-LRRKtide antibody and, subsequently, the phosphorylated LRRKtide can be quantified by the extent of TR-FRET between the terbium donor and fluorescein acceptor.The LRRK2 kinase is obtained from Invitrogen (Life Technologies Corporation) and comprises residues 970 to 2527 of the full length human wild-type LRRK2 kinase or a similar sequence with the G2019S mutation. As discussed above, this mutation increases the kinase activity relative to the wild-type. The kinase reactions are performed in a 20 uL volume in 384-well plates. The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT.Â  In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 uM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 uM fluorescein-LRRKtide. The reaction mixture (20 ul total volume) is incubated for 2 hours at 30° C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 ul). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 us) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 us. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 us time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3887011";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3959735";"";"None";"349.44";"0";"3.50";"BDBM223544";"Cc1ccc(-c2cnc(N)c(-c3nnc(C4CCN(C)CC4)o3)c2)cc1";"IC50";"'='";"860.0";"nM";"6.07";"";"390800";"UO_0000065";"17.36";"0.32";"2.57";"7.48";"0";"CHEMBL3888345";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3902701";"";"None";"402.51";"0";"2.95";"BDBM239190";"CC(C)N1CCN(c2cc(-c3n[nH]c4ccc(-c5cnn(C)c5)cc34)ncn2)CC1";"IC50";"'='";"0.73";"nM";"9.14";"";"417649";"UO_0000065";"22.70";"0.42";"6.19";"11.60";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3977858";"";"None";"416.51";"0";"1.89";"BDBM239196";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCN(S(C)(=O)=O)CC4)ncn3)c2c1";"IC50";"'='";"7.99";"nM";"8.10";"";"417656";"UO_0000065";"19.44";"0.38";"6.21";"7.76";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4203202";"";"None";"240.24";"0";"2.90";"8, E:Z Mixture (67:33)";"O=C1Nc2ccccc2C1=Nc1ccccc1F";"IC50";"'='";"2340.0";"nM";"5.63";"";"";"UO_0000065";"23.44";"0.43";"2.73";"13.58";"0";"CHEMBL4192178";"Inhibition of recombinant catalytic human GST-tagged LLRK2 (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate after 1 hr by alexaFluor-ADP-based FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4190250";"1";"Scientific Literature";"Eur J Med Chem";"2017";"None";"";"";""
"CHEMBL4745474";"";"None";"420.38";"0";"4.13";"57";"O=C(Nc1c[nH]nc1-c1cc2ccccc2cc1OC(F)F)c1cnn2cccnc12";"IC50";"'='";"180.0";"nM";"6.75";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL4666938";"Inhibition of recombinant human GST-tagged LRRK2 (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate incubated for 60 mins by Adapta assay";"A";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4665643";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL3966726";"";"None";"317.35";"0";"3.74";"33";"Nc1ncc(-c2ccc3[nH]ccc3c2)cc1-c1nnc(C2CC2)o1";"IC50";"'='";"1300.0";"nM";"5.89";"";"";"UO_0000065";"18.55";"0.33";"2.15";"6.29";"0";"CHEMBL4045604";"Inhibition of recombinant human wild type GST-tagged LRRK2 (970 to 2527 residues) preincubated for 30 mins followed by fluorescein-LRRKtide substrate addition after 2 hrs by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4043168";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL4092594";"";"None";"278.36";"0";"3.52";"30";"CCn1cc(-c2cc(-c3ccc(C)cc3)cnc2N)cn1";"IC50";"'='";"12000.0";"nM";"4.92";"";"";"UO_0000065";"17.68";"0.32";"1.40";"8.67";"0";"CHEMBL4045604";"Inhibition of recombinant human wild type GST-tagged LRRK2 (970 to 2527 residues) preincubated for 30 mins followed by fluorescein-LRRKtide substrate addition after 2 hrs by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4043168";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL4095694";"";"None";"265.32";"0";"3.60";"18";"Cc1ccc(-c2cnc(N)c(-c3cnc(C)o3)c2)cc1";"IC50";"'='";"24000.0";"nM";"4.62";"";"";"UO_0000065";"17.41";"0.32";"1.02";"7.11";"0";"CHEMBL4045604";"Inhibition of recombinant human wild type GST-tagged LRRK2 (970 to 2527 residues) preincubated for 30 mins followed by fluorescein-LRRKtide substrate addition after 2 hrs by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4043168";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL3943181";"";"None";"351.41";"0";"1.80";"12";"NC(=O)c1ncc(N[C@@H]2CCCC[C@@H]2N)nc1-c1nc2ccccc2[nH]1";"IC50";"'='";"130.0";"nM";"6.89";"";"";"UO_0000065";"19.60";"0.36";"5.09";"5.08";"0";"CHEMBL3865679";"Inhibition of GST-tagged recombinant human LRRK2 (970 to 2527 residues) expressed in baculovirus";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3864189";"1";"Scientific Literature";"ACS Med Chem Lett";"2016";"None";"";"";""
"CHEMBL3415610";"";"None";"382.42";"0";"1.26";"17";"COc1cccc2[nH]c(-c3nc(N[C@@H]4CCOC[C@@H]4N)cnc3C(N)=O)cc12";"IC50";"'='";"33.0";"nM";"7.48";"";"";"UO_0000065";"19.56";"0.36";"6.22";"5.30";"1";"CHEMBL3865679";"Inhibition of GST-tagged recombinant human LRRK2 (970 to 2527 residues) expressed in baculovirus";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3864189";"1";"Scientific Literature";"ACS Med Chem Lett";"2016";"None";"";"";""
"CHEMBL3945284";"";"None";"422.49";"0";"2.65";"BDBM223557";"COc1cc(-c2cnc(N)c(-c3cn(C(C)C)nn3)c2)ccc1C(=O)N1CCOCC1";"IC50";"'='";"95.0";"nM";"7.02";"";"390813";"UO_0000065";"16.62";"0.31";"4.37";"6.48";"0";"CHEMBL3888345";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4550702";"";"None";"406.39";"0";"3.15";"9";"Cn1cc(-c2cnc3c(-c4csc(C(=O)NCC(F)(F)F)c4)cnn3c2)cn1";"IC50";"'<'";"10.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL4479740";"Inhibition of recombinant human GST-tagged LRRK2 catalytic domain expressed in baculovirus expression system by Adapta assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4477252";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2016";"None";"";"";""
"CHEMBL4094423";"";"None";"397.27";"1";"5.24";"6i";"CC(Oc1ccc(Br)cc1C(=O)Nc1cccnc1)c1ccccc1";"IC50";"'='";"39.81";"nM";"7.40";"";"";"UO_0000065";"18.63";"0.40";"2.16";"14.45";"0";"CHEMBL4058537";"Inhibition of LRRK2 (unknown origin) by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4052807";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL4565316";"";"None";"339.42";"0";"3.39";"5";"O=C(Nc1nc2ccccc2s1)c1ccc(N2CCOCC2)cc1";"IC50";"'='";"700.0";"nM";"6.16";"";"";"UO_0000065";"18.13";"0.35";"2.76";"11.30";"0";"CHEMBL4403862";"Inhibition of wild type human GST-tagged LRRK2 (970 to 2527 residues) expressed in baculovirus expression system assessed as reduction in ADP formation using LRRKtide as substrate measured after 1 hr in presence of ATP by Adapta assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4402549";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL4565316";"";"None";"339.42";"0";"3.39";"5";"O=C(Nc1nc2ccccc2s1)c1ccc(N2CCOCC2)cc1";"IC50";"'='";"370.0";"nM";"6.43";"";"";"UO_0000065";"18.95";"0.37";"3.04";"11.81";"0";"CHEMBL4403864";"Inhibition of human GST-tagged LRRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus expression system assessed as reduction in ADP formation using LRRKtide as substrate measured after 1 hr in presence of ATP by Adapta assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4402549";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL4452771";"";"None";"418.32";"0";"4.15";"14";"O=C(Nc1nc2ccc(Br)cc2s1)c1ccc(N2CCOCC2)cc1";"IC50";"'='";"260.0";"nM";"6.58";"";"";"UO_0000065";"15.74";"0.36";"2.44";"12.09";"0";"CHEMBL4403864";"Inhibition of human GST-tagged LRRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus expression system assessed as reduction in ADP formation using LRRKtide as substrate measured after 1 hr in presence of ATP by Adapta assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4402549";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL3951996";"";"None";"337.38";"0";"2.40";"BDBM239263";"COc1ccc2[nH]nc(-c3cc(N4CC5CCC(C4)O5)ncn3)c2c1";"IC50";"'='";"148.2";"nM";"6.83";"";"417722";"UO_0000065";"20.24";"0.37";"4.43";"8.97";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3897367";"";"None";"387.47";"0";"2.04";"BDBM239331";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CC(S(C)(=O)=O)C4)ncn3)c2c1";"IC50";"'='";"13.3";"nM";"7.88";"";"417800";"UO_0000065";"20.33";"0.40";"5.84";"7.79";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3409465";"";"None";"398.94";"0";"4.57";"24";"O=C(c1ccc(Nc2ccccn2)c(Cl)c1)N1CCC(N2CCCCC2)CC1";"IC50";"'>'";"1000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL3412556";"Inhibition of LRRK2 G2019S mutant (1326 to 252 aa) (unknown origin) stably expressed in HEK293 cell lysate using [gamma-32P] after 15 mins by Cerenkov counting method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3407393";"1";"Scientific Literature";"Eur J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL4758121";"";"None";"440.96";"0";"4.15";"6.54";"OC1(c2cncs2)CCN(c2cc3c(cnn3-c3cnn(C4CC4)c3)cc2Cl)CC1";"IC50";"'='";"97.51";"nM";"7.01";"";"";"UO_0000065";"15.90";"0.32";"2.86";"9.74";"0";"CHEMBL4689513";"Inhibition of GST-tagged truncated human LRRK2 G2019S mutant using fluorescein labeled LRRKtide peptide as substrate preincubated for 15 mins followed by substrate addition measured after 90 mins in presence of ATP at Km concentration by TR-FRET Lanthascreen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4680359";"1";"Scientific Literature";"ACS Med Chem Lett";"2021";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL4741733";"";"None";"399.45";"0";"2.61";"14";"CCOc1nc(Nc2ccc(C(=O)NCC(C)(C)O)cc2OC)nc2[nH]ccc12";"IC50";"'='";"12.59";"nM";"7.90";"";"";"UO_0000065";"19.78";"0.37";"5.29";"6.51";"0";"CHEMBL4721243";"Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs in presence of ATP by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4715821";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2018";"None";"TIME = 2.5 hr";"INHIBITOR";""
"CHEMBL4794578";"";"None";"397.44";"0";"2.58";"7";"CCOc1nc(Nc2ccc(C(=O)N3CCOCC3)cc2OC)nc2[nH]ccc12";"IC50";"'='";"158.49";"nM";"6.80";"";"";"UO_0000065";"17.11";"0.32";"4.22";"6.69";"0";"CHEMBL4721244";"Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins by Alpha Screen assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4715821";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2018";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL3982042";"";"None";"301.38";"0";"2.23";"BDBM185538";"Cc1cc(-c2c[nH]c3ncnc(N4CCOCC4)c23)sn1";"IC50";"'='";"73.0";"nM";"7.14";"";"334716";"UO_0000065";"23.68";"0.46";"4.91";"10.66";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3902903";"";"None";"391.44";"0";"1.62";"BDBM239413";"CO[C@H]1CN(c2cc(-c3n[nH]c4ccc(-c5cnn(C)c5)cc34)ncn2)C[C@@H]1O";"IC50";"'='";"6.0";"nM";"8.22";"";"417879";"UO_0000065";"21.00";"0.39";"6.60";"7.83";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3908542";"";"None";"398.44";"0";"2.43";"BDBM239218";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCN(CCF)C(=O)C4)ncn3)c2c1";"IC50";"'='";"3.3";"nM";"8.48";"";"417679";"UO_0000065";"21.29";"0.40";"6.05";"9.72";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3959561";"";"None";"436.50";"0";"1.56";"BDBM239315";"CS(=O)(=O)N1CCN(c2cc(-c3n[nH]c4ccc(-c5cnccn5)cc34)ncn2)CC1";"IC50";"'='";"19.2";"nM";"7.72";"";"417774";"UO_0000065";"17.68";"0.34";"6.16";"6.38";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3893371";"";"None";"436.52";"0";"2.54";"BDBM239306";"COC[C@H](C)Oc1ccc2[nH]nc(-c3cc(N4CCC5(CC4)CNC(=O)C5)ncn3)c2c1";"IC50";"'='";"2.85";"nM";"8.54";"";"417775";"UO_0000065";"19.58";"0.36";"6.01";"8.12";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3952572";"";"None";"359.38";"0";"3.30";"BDBM239325";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4C[C@H](F)[C@@H](F)C4)ncn3)c2c1";"IC50";"'='";"11.1";"nM";"7.96";"";"417794";"UO_0000065";"22.13";"0.42";"4.65";"11.89";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3956173";"";"None";"416.49";"0";"4.24";"BDBM239329";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCc5oc(C6CC6)nc5C4)ncn3)c2c1";"IC50";"'='";"30.1";"nM";"7.52";"";"417798";"UO_0000065";"18.06";"0.33";"3.28";"8.09";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3953967";"";"None";"373.41";"0";"4.04";"BDBM239195";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCC(F)(F)CC4)ncn3)c2c1";"IC50";"'='";"20.2";"nM";"7.70";"";"417799";"UO_0000065";"20.61";"0.39";"3.65";"11.50";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3919965";"";"None";"352.44";"0";"2.56";"BDBM239332";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCN(C)CC4)ncn3)c2c1";"IC50";"'='";"5.4";"nM";"8.27";"";"417801";"UO_0000065";"23.46";"0.43";"5.71";"11.78";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3952292";"";"None";"296.38";"0";"2.59";"BDBM185374";"C[C@H]1CCCN(c2ncnc3[nH]cc(-c4cnn(C)c4)c23)C1";"IC50";"'='";"14.0";"nM";"7.85";"";"334336";"UO_0000065";"26.50";"0.49";"5.26";"12.54";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3942388";"";"None";"302.77";"0";"3.35";"BDBM185382";"COc1ccc(Cl)cc1-c1c[nH]c2ncnc(N(C)C)c12";"IC50";"'='";"22.0";"nM";"7.66";"";"334344";"UO_0000065";"25.29";"0.50";"4.31";"14.17";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3972882";"";"None";"388.48";"0";"2.80";"BDBM185384";"CN1CCC2(CC1)CN(c1ncnc3[nH]cc(-c4cccc(C#N)c4)c13)CCO2";"IC50";"'='";"40.0";"nM";"7.40";"";"334347";"UO_0000065";"19.04";"0.35";"4.60";"9.13";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3896369";"";"None";"372.43";"0";"2.60";"BDBM185396";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCCC5(CNC(=O)C5)C4)c23)c1";"IC50";"'='";"35.0";"nM";"7.46";"";"334360";"UO_0000065";"20.02";"0.36";"4.86";"7.63";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3951477";"";"None";"332.41";"0";"3.74";"BDBM185401";"C[C@H]1CCCN(c2ncnc3[nH]cc(-c4ccc5[nH]ncc5c4)c23)C1";"IC50";"'='";"67.0";"nM";"7.17";"";"334365";"UO_0000065";"21.58";"0.39";"3.43";"9.76";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3949695";"";"None";"359.39";"0";"2.31";"BDBM239473";"c1ncc(-c2ccc3[nH]nc(-c4cc(N5CCOCC5)ncn4)c3c2)cn1";"IC50";"'='";"40.7";"nM";"7.39";"";"417938";"UO_0000065";"20.56";"0.37";"5.08";"7.97";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3950786";"";"None";"438.52";"0";"1.50";"BDBM239081";"Cn1cc(-c2ccc3[nH]nc(-c4cc(N5CCN(S(C)(=O)=O)CC5)ncn4)c3c2)cn1";"IC50";"'='";"3.28";"nM";"8.48";"";"312513";"UO_0000065";"19.35";"0.37";"6.98";"7.51";"0";"CHEMBL3887174";"LanthaScreen™ Assay (Km ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 184 μM ATP solution in 1× assay buffer to all wells. d) After a 60 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3928102";"";"None";"339.40";"0";"2.64";"BDBM239084";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCOCC4)ncn3)c2c1";"IC50";"'='";"5.95";"nM";"8.22";"";"312515";"UO_0000065";"24.24";"0.45";"5.59";"10.80";"0";"CHEMBL3887174";"LanthaScreen™ Assay (Km ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 184 μM ATP solution in 1× assay buffer to all wells. d) After a 60 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3901157";"";"None";"436.48";"0";"3.65";"BDBM185484";"N#Cc1cccc(OCC2CN(c3ncnc4[nH]cc(-c5cccc(C#N)c5)c34)CCO2)c1";"IC50";"'='";"30.0";"nM";"7.52";"";"334457";"UO_0000065";"17.24";"0.31";"3.87";"6.79";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3924549";"";"None";"362.44";"0";"2.26";"BDBM185490";"CN(C)CC1CN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)CCO1";"IC50";"'='";"45.0";"nM";"7.35";"";"334463";"UO_0000065";"20.27";"0.37";"5.09";"9.06";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3977855";"";"None";"334.38";"0";"2.39";"BDBM185386";"CN(C)C(=O)CCNc1ncnc2[nH]cc(-c3cccc(C#N)c3)c12";"IC50";"'='";"54.0";"nM";"7.27";"";"334350";"UO_0000065";"21.73";"0.40";"4.88";"7.44";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3918244";"";"None";"321.36";"0";"3.43";"BDBM185388";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCC(F)CC4)c23)c1";"IC50";"'='";"17.0";"nM";"7.77";"";"334352";"UO_0000065";"24.18";"0.44";"4.34";"11.33";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3963791";"";"None";"369.43";"0";"3.60";"BDBM185390";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCC(c5cc[nH]n5)CC4)c23)c1";"IC50";"'='";"69.0";"nM";"7.16";"";"334354";"UO_0000065";"19.38";"0.35";"3.56";"7.36";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3963473";"";"None";"336.40";"0";"3.56";"BDBM185419";"C[C@H]1CCCN(c2ncnc3[nH]cc(-c4cccc(C(=O)O)c4)c23)C1";"IC50";"'='";"55.0";"nM";"7.26";"";"334383";"UO_0000065";"21.58";"0.40";"3.70";"8.84";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3975452";"";"None";"361.45";"0";"3.99";"BDBM185421";"COc1ccc(C#N)cc1-c1c[nH]c2ncnc(N3C[C@H](C)C[C@H](C)C3)c12";"IC50";"'='";"85.0";"nM";"7.07";"";"334385";"UO_0000065";"19.56";"0.36";"3.08";"9.08";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3913617";"";"None";"347.42";"0";"3.74";"BDBM185422";"COc1ccc(C#N)cc1-c1c[nH]c2ncnc(N3CCC[C@H](C)C3)c12";"IC50";"'='";"21.0";"nM";"7.68";"";"334386";"UO_0000065";"22.10";"0.40";"3.94";"9.86";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3901817";"";"None";"349.39";"0";"2.35";"BDBM185385";"COCC1CN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)CCO1";"IC50";"'='";"12.0";"nM";"7.92";"";"334394";"UO_0000065";"22.67";"0.42";"5.57";"9.10";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3900515";"";"None";"335.37";"0";"2.34";"BDBM185465";"COc1cc(C#N)cc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"177.0";"nM";"6.75";"";"334649";"UO_0000065";"20.13";"0.37";"4.41";"7.76";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3937495";"";"None";"300.39";"0";"1.91";"BDBM185466";"Cn1cc(-c2c[nH]c3ncnc(N4CCSCC4)c23)cn1";"IC50";"'='";"51.0";"nM";"7.29";"";"334650";"UO_0000065";"24.28";"0.47";"5.38";"11.64";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3905907";"";"None";"298.35";"0";"1.32";"BDBM185467";"Cn1cc(-c2c[nH]c3ncnc(N4CCCC(O)C4)c23)cn1";"IC50";"'='";"34.0";"nM";"7.47";"";"334651";"UO_0000065";"25.03";"0.46";"6.15";"9.01";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3933433";"";"None";"328.38";"0";"3.38";"BDBM185378";"[C-]#[N+]C1CCCN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)C1";"IC50";"'='";"183.0";"nM";"6.74";"";"334551";"UO_0000065";"20.52";"0.37";"3.36";"9.23";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3393350";"";"None";"333.40";"0";"3.11";"BDBM50059422";"COC1CCCN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)C1";"IC50";"'='";"154.0";"nM";"6.81";"";"334559";"UO_0000065";"20.43";"0.37";"3.70";"8.75";"1";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3901817";"";"None";"349.39";"0";"2.35";"BDBM185385";"COCC1CN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)CCO1";"IC50";"'='";"121.0";"nM";"6.92";"";"334560";"UO_0000065";"19.80";"0.36";"4.57";"7.95";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3969062";"";"None";"307.33";"0";"3.04";"BDBM185391";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CC[C@H](F)C4)c23)c1";"IC50";"'='";"155.0";"nM";"6.81";"";"334566";"UO_0000065";"22.16";"0.40";"3.77";"9.93";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3946203";"";"None";"310.38";"0";"4.00";"BDBM185403";"C[C@H]1CCCN(c2ncnc3[nH]cc(-c4ccccc4F)c23)C1";"IC50";"'='";"122.0";"nM";"6.91";"";"334578";"UO_0000065";"22.27";"0.41";"2.91";"15.43";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3972118";"";"None";"300.34";"0";"2.30";"BDBM185433";"Cn1cc(-c2c[nH]c3ncnc(N4CCC(F)CC4)c23)cn1";"IC50";"'='";"50.0";"nM";"7.30";"";"334612";"UO_0000065";"24.31";"0.45";"5.00";"11.66";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3923604";"";"None";"298.32";"0";"2.60";"BDBM185442";"Fc1cccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"21.0";"nM";"7.68";"";"334622";"UO_0000065";"25.74";"0.48";"5.08";"14.21";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL5082941";"";"None";"312.80";"0";"4.27";"15";"Clc1cccc(-c2c[nH]c3ncnc(N4CCCCC4)c23)c1";"IC50";"'='";"1140.0";"nM";"5.94";"";"";"UO_0000065";"19.00";"0.37";"1.67";"13.26";"0";"CHEMBL5043428";"Displacement of K5 tracer from full length C-terminal NanoLuc fused human LRRK2 expressed in HEK293T cells incubated for 2 hrs by NanoBRET assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293T";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5042489";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL5093841";"";"None";"302.77";"0";"3.07";"26";"OCCCNc1ncnc2[nH]cc(-c3cccc(Cl)c3)c12";"IC50";"'='";"2490.0";"nM";"5.60";"";"";"UO_0000065";"18.51";"0.36";"2.53";"7.59";"0";"CHEMBL5043428";"Displacement of K5 tracer from full length C-terminal NanoLuc fused human LRRK2 expressed in HEK293T cells incubated for 2 hrs by NanoBRET assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293T";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5042489";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL5089834";"";"None";"271.33";"0";"0.99";"25";"C[C@@H]1CCCN1c1c(C#N)c2c(N)nc(N)nc2n1C";"IC50";"'='";"248.0";"nM";"6.61";"";"";"UO_0000065";"24.35";"0.45";"5.62";"6.02";"0";"CHEMBL5040109";"Inhibition of recombinant human LRRK2 WT using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5087055";"";"None";"421.51";"0";"2.62";"44";"Cc1c(Nc2nc(N)c3c(C#N)c(N4CCC[C@H]4C)n(C)c3n2)cnn1[C@@H]1CCOC1";"IC50";"'='";"67.0";"nM";"7.17";"";"";"UO_0000065";"17.02";"0.32";"4.55";"5.84";"0";"CHEMBL5040132";"Inhibition of LRRK2 WT expressed in human PBMCs measured by KiNativ profiling analysis";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"";"INHIBITOR";""
"CHEMBL4592565";"";"None";"443.55";"0";"3.84";"26";"CN1CC2(CCN(c3ccc(OCc4ccccc4)c(C(=O)Nc4ccnnc4)c3)CC2)C1";"IC50";"'='";"63.1";"nM";"7.20";"";"";"UO_0000065";"16.23";"0.30";"3.36";"10.20";"0";"CHEMBL4372253";"Inhibition of recombinant 6His-Tev-tagged LRRK2 (1326 to 2527) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-RLGRDKYKTLRQIRQGNTKQR-OH as substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs by TR-FRET assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"Sf9";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4371037";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"CHEMBL3308860";"";"";""
"CHEMBL4549792";"";"None";"406.46";"0";"4.25";"14";"O=C(Nc1ccnnc1)c1cc(N2CCC(F)CC2)ccc1OCc1ccccc1";"IC50";"'='";"39.81";"nM";"7.40";"";"";"UO_0000065";"18.21";"0.34";"3.15";"10.99";"0";"CHEMBL4372253";"Inhibition of recombinant 6His-Tev-tagged LRRK2 (1326 to 2527) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-RLGRDKYKTLRQIRQGNTKQR-OH as substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs by TR-FRET assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"Sf9";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4371037";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"CHEMBL3308860";"";"";""
"CHEMBL2348977";"";"None";"330.40";"0";"3.09";"44";"CC(Sc1ccc2nnc(-c3cccs3)n2n1)c1nnco1";"IC50";"'='";"384.0";"nM";"6.42";"";"";"UO_0000065";"19.42";"0.40";"3.33";"7.82";"0";"CHEMBL2351467";"Inhibition of wild type LRRK2 (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL3928607";"";"None";"225.28";"0";"3.16";"BDBM254921";"N#Cc1c[nH]c2nccc(-c3ccsc3)c12";"IC50";"'='";"851.0";"nM";"6.07";"";"443704";"UO_0000065";"26.94";"0.52";"2.91";"11.57";"0";"CHEMBL3889252";"Homogeneous Time Resolved-fluorescence Resonance Energy Transfer (TR-FRET) Assay: LRRK2 kinase activity is measured using a LanthaScreen kinase activity assay available from Invitrogen (Life Technologies Corporation). The assay is a homogeneous time resolved-fluorescence resonance energy transfer (TR-FRET) assay that measures phosphorylation of a fluorescein-labelled peptide substrate (fluorescein-LRRKtide, fluorescein-GAGRLGRDKYKTLRQIRQ) (SEQ ID NO 1) as a result of LRRK2 kinase activity. The phosphorylated peptide is recognized by a terbium-labelled phospho-specific anti-LRRKtide antibody and, subsequently, the phosphorylated LRRKtide can be quantified by the extent of TR-FRET between the terbium donor and fluorescein acceptor.The LRRK2 kinase is obtained from Invitrogen (Life Technologies Corporation) and comprises residues 970 to 2527 of the full length human wild-type LRRK2 kinase or a similar sequence with the G2019S mutation. As discussed above, this mutation increases the kinase activity relative to the wild-type. The kinase reactions are performed in a 20 uL volume in 384-well plates. The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT.Â  In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 uM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 uM fluorescein-LRRKtide. The reaction mixture (20 ul total volume) is incubated for 2 hours at 30° C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 ul). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 us) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 us. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 us time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3887011";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3928018";"";"None";"303.37";"0";"3.34";"BDBM185426";"CC1CCN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)C1";"IC50";"'='";"21.0";"nM";"7.68";"";"334391";"UO_0000065";"25.31";"0.46";"4.34";"11.19";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3975717";"";"None";"388.46";"0";"3.53";"BDBM185478";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCOC(c5nccs5)C4)c23)c1";"IC50";"'='";"45.0";"nM";"7.35";"";"334451";"UO_0000065";"18.91";"0.36";"3.82";"8.10";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL4112166";"";"None";"345.41";"0";"3.25";"BDBM185549";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCO[C@H]5CCC[C@H]54)c23)c1";"IC50";"'='";"27.2";"nM";"7.57";"";"334519";"UO_0000065";"21.90";"0.40";"4.32";"9.72";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3947266";"";"None";"294.36";"0";"3.23";"BDBM185522";"COc1ccccc1-c1c[nH]c2ncnc(N3CCCC3)c12";"IC50";"'='";"68.0";"nM";"7.17";"";"334702";"UO_0000065";"24.35";"0.44";"3.94";"13.26";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3891060";"";"None";"281.29";"0";"2.70";"BDBM185425";"CN(C)c1ncnc2[nH]cc(-c3cccc(C#N)c3F)c12";"IC50";"'='";"6.0";"nM";"8.22";"";"334389";"UO_0000065";"29.23";"0.53";"5.52";"11.99";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3393347";"";"None";"291.36";"0";"3.34";"BDBM50059348";"CCN(CC)c1ncnc2[nH]cc(-c3cccc(C#N)c3)c12";"IC50";"'='";"13.0";"nM";"7.89";"";"334393";"UO_0000065";"27.07";"0.49";"4.55";"11.50";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3940283";"";"None";"316.31";"0";"2.74";"BDBM185438";"Fc1cccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1F";"IC50";"'='";"12.0";"nM";"7.92";"";"334407";"UO_0000065";"25.04";"0.47";"5.18";"14.66";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3958751";"";"None";"308.39";"0";"3.57";"BDBM185414";"C[C@H]1CCCN(c2ncnc3[nH]cc(-c4cccc(O)c4)c23)C1";"IC50";"'='";"12.0";"nM";"7.92";"";"334589";"UO_0000065";"25.68";"0.47";"4.35";"12.18";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3928476";"";"None";"298.35";"0";"1.50";"BDBM185464";"Cc1[nH]c2ncnc(N3CCOCC3)c2c1-c1cnn(C)c1";"IC50";"'='";"89.0";"nM";"7.05";"";"334648";"UO_0000065";"23.63";"0.44";"5.55";"9.81";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL4075195";"";"None";"403.49";"0";"3.85";"23";"CC(C)Oc1ccc2[nH]nc(-c3ccnc(N4CCC(n5cnnc5)CC4)c3)c2c1";"IC50";"'='";"4.4";"nM";"8.36";"";"";"UO_0000065";"20.71";"0.38";"4.51";"9.86";"0";"CHEMBL4010109";"Inhibition of recombinant human GST-tagged LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus using fluorescein-ERM as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007454";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL3326118";"";"None";"366.41";"0";"2.75";"5";"COc1ccc(OC)c(Sc2ccc3nnc(-c4cnccn4)n3n2)c1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL3367451";"Inhibition of phosphorylation at S935 residue of wild-type full-length LRRK2 kinase (unknown origin) expressed in HEK 293 cells after 90 mins by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"CHEMBL3307715";"";"";""
"CHEMBL3326131";"";"None";"334.40";"0";"3.95";"18";"COc1cccc(Sc2ccc3nnc(-c4ccccc4)n3n2)c1";"IC50";"'='";"2110.0";"nM";"5.68";"";"";"UO_0000065";"16.97";"0.32";"1.73";"10.85";"0";"CHEMBL3367450";"Inhibition of GST-tagged truncated LRRK2 (unknown origin) using fluorescein-labeled peptide LRRKtide as substrate by LANTHA screen assay in presence of 1 mM ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL5189225";"";"None";"388.90";"0";"2.64";"3.47";"CC1NN=CC1Nc1ncc2cc(Cl)c(N3CCC(C)(O)C(C)C3)cc2n1";"IC50";"'='";"0.06457";"nM";"10.19";"";"";"UO_0000065";"26.20";"0.52";"7.55";"11.89";"0";"CHEMBL5135962";"Inhibition of GST-tagged truncated human LRRK2 G2019S mutant using fluorescein labeled LRRKtide peptide as substrate preincubated for 15 mins followed by substrate addition and measured after 90 mins in presence of ATP at Km concentration by TR-FRET Lanthascreen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131528";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL4445322";"";"None";"353.45";"0";"3.69";"8";"Cc1ccc2nc(NC(=O)c3ccc(N4CCOCC4)cc3)sc2c1";"IC50";"'='";"480.0";"nM";"6.32";"";"";"UO_0000065";"17.88";"0.35";"2.63";"11.60";"0";"CHEMBL4403862";"Inhibition of wild type human GST-tagged LRRK2 (970 to 2527 residues) expressed in baculovirus expression system assessed as reduction in ADP formation using LRRKtide as substrate measured after 1 hr in presence of ATP by Adapta assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4402549";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL4543902";"";"None";"397.50";"0";"4.17";"16";"CCCOc1ccc2nc(NC(=O)c3ccc(N4CCOCC4)cc3)sc2c1";"IC50";"'='";"3490.0";"nM";"5.46";"";"";"UO_0000065";"13.73";"0.27";"1.29";"8.57";"0";"CHEMBL4403862";"Inhibition of wild type human GST-tagged LRRK2 (970 to 2527 residues) expressed in baculovirus expression system assessed as reduction in ADP formation using LRRKtide as substrate measured after 1 hr in presence of ATP by Adapta assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4402549";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL4435096";"";"None";"295.35";"0";"2.61";"17";"c1ccc(-c2n[nH]c3ccnc(NC4CCOCC4)c23)nc1";"IC50";"'='";"41.0";"nM";"7.39";"";"";"UO_0000065";"25.01";"0.46";"4.78";"9.76";"0";"CHEMBL4331199";"Inhibition of LRRK2 G2019S mutant (unknown origin) by cell based assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330074";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4457384";"";"None";"297.37";"0";"2.45";"12";"CC(C)Nc1nccc2[nH]nc(-c3nnc(C4CC4)n3C)c12";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL4331199";"Inhibition of LRRK2 G2019S mutant (unknown origin) by cell based assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330074";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4465944";"";"None";"219.24";"0";"1.43";"25";"Cc1n[nH]c2ccnc(O[C@@H]3CCOC3)c12";"IC50";"'='";"250.0";"nM";"6.60";"";"";"UO_0000065";"30.11";"0.56";"5.17";"11.00";"0";"CHEMBL4331900";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant catalytic domain (970 to 2527 residues) expressed in baculovirus expression system by radiometric assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330096";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4516855";"";"None";"340.43";"0";"3.07";"29";"CC(C)Cn1cc(-c2n[nH]c3ccnc(NC4CCOCC4)c23)cn1";"IC50";"'='";"410.0";"nM";"6.39";"";"";"UO_0000065";"18.76";"0.35";"3.32";"7.92";"0";"CHEMBL4331900";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant catalytic domain (970 to 2527 residues) expressed in baculovirus expression system by radiometric assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330096";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL5079601";"";"None";"451.50";"0";"3.88";"4";"Cc1nn(CC(F)(F)F)cc1Nc1ncc(C2CC2)c(NCCCNC(=O)C2CCC2)n1";"IC50";"'='";"19.0";"nM";"7.72";"";"";"UO_0000065";"17.10";"0.33";"3.84";"7.98";"0";"CHEMBL5046600";"Inhibition of recombinant human LRRK2 (970 to end residues) using RLGRDKYKTLRQIRQ as substrate incubated for 40 mins in presence of [gamma-33P-ATP] by radiometric scintillation assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5046221";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 0.6667 hr";"INHIBITOR";""
"CHEMBL3335335";"";"None";"312.76";"0";"3.79";"15i";"CC(=O)Nc1ccc(/C=C2/C(=O)Nc3ccc(Cl)cc32)cc1";"IC50";"'='";"10000.0";"nM";"5.00";"";"";"UO_0000065";"15.99";"0.31";"1.21";"8.59";"0";"CHEMBL3390652";"Inhibition of recombinant LRRK2 (unknown origin) using gamma-32P-ATP assessed as LRRKtide substrate phosphorylation level by autoradiography";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352815";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL5089132";"";"None";"328.80";"0";"3.24";"16";"OC1CCN(c2ncnc3[nH]cc(-c4cccc(Cl)c4)c23)CC1";"IC50";"'='";"1340.0";"nM";"5.87";"";"";"UO_0000065";"17.86";"0.35";"2.63";"9.03";"0";"CHEMBL5043428";"Displacement of K5 tracer from full length C-terminal NanoLuc fused human LRRK2 expressed in HEK293T cells incubated for 2 hrs by NanoBRET assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293T";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5042489";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL3935021";"";"None";"395.46";"0";"2.80";"BDBM239303";"COC[C@H](C)Oc1ccc2[nH]nc(-c3cc(N4CC5CCC(C4)O5)ncn3)c2c1";"IC50";"'='";"9.93";"nM";"8.00";"";"417763";"UO_0000065";"20.24";"0.38";"5.20";"9.37";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3895733";"";"None";"359.39";"0";"2.31";"BDBM239314";"c1cnc(-c2ccc3[nH]nc(-c4cc(N5CCOCC5)ncn4)c3c2)cn1";"IC50";"'='";"34.7";"nM";"7.46";"";"417773";"UO_0000065";"20.76";"0.38";"5.15";"8.05";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3903923";"";"None";"423.52";"0";"3.58";"BDBM239309";"COC[C@H](C)Oc1ccc2[nH]nc(-c3cc(N4CCC5(CCCO5)CC4)ncn3)c2c1";"IC50";"'='";"2.02";"nM";"8.70";"";"417778";"UO_0000065";"20.53";"0.38";"5.11";"10.18";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3954935";"";"None";"375.38";"0";"2.89";"BDBM239459";"COC[C@H](C)Oc1ccc2[nH]nc(-c3cc(N4CC(F)(F)C4)ncn3)c2c1";"IC50";"'='";"7.6";"nM";"8.12";"";"417924";"UO_0000065";"21.63";"0.41";"5.23";"10.66";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3914466";"";"None";"420.47";"0";"3.29";"BDBM239462";"COC[C@H](C)Oc1ccc2[nH]nc(-c3cc(N4CCc5oc(C)nc5C4)ncn3)c2c1";"IC50";"'='";"8.4";"nM";"8.08";"";"417927";"UO_0000065";"19.21";"0.36";"4.79";"7.90";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3976073";"";"None";"417.47";"0";"3.10";"BDBM239493";"COc1cnc(-c2ccc3[nH]nc(-c4cc(N5C[C@@H](C)O[C@@H](C)C5)ncn4)c3c2)cn1";"IC50";"'='";"63.4";"nM";"7.20";"";"417958";"UO_0000065";"17.24";"0.32";"4.10";"7.06";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4457647";"";"None";"390.44";"0";"3.14";"18";"O=C(Nc1ccnnc1)c1cc(N2CCOCC2)ccc1OCc1ccccc1";"IC50";"'='";"39.81";"nM";"7.40";"";"";"UO_0000065";"18.95";"0.35";"4.26";"9.66";"0";"CHEMBL4372253";"Inhibition of recombinant 6His-Tev-tagged LRRK2 (1326 to 2527) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-RLGRDKYKTLRQIRQGNTKQR-OH as substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs by TR-FRET assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"Sf9";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4371037";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"CHEMBL3308860";"";"";""
"CHEMBL4514819";"";"None";"413.48";"0";"4.05";"17";"N#CC1CCN(c2ccc(OCc3ccccc3)c(C(=O)Nc3ccnnc3)c2)CC1";"IC50";"'='";"10.0";"nM";"8.00";"";"";"UO_0000065";"19.35";"0.35";"3.95";"8.78";"0";"CHEMBL4372253";"Inhibition of recombinant 6His-Tev-tagged LRRK2 (1326 to 2527) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-RLGRDKYKTLRQIRQGNTKQR-OH as substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs by TR-FRET assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"Sf9";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4371037";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"CHEMBL3308860";"";"";""
"CHEMBL4077195";"";"None";"390.34";"1";"5.07";"8e";"O=C(Nc1cccnc1)c1cc(C(F)(F)F)ccc1OCc1ccc(F)cc1";"IC50";"'='";"19.95";"nM";"7.70";"";"";"UO_0000065";"19.73";"0.38";"2.63";"15.03";"1";"CHEMBL4372253";"Inhibition of recombinant 6His-Tev-tagged LRRK2 (1326 to 2527) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-RLGRDKYKTLRQIRQGNTKQR-OH as substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs by TR-FRET assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"Sf9";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4371037";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"CHEMBL3308860";"";"";""
"CHEMBL4443438";"";"None";"404.47";"0";"3.27";"15";"O=C(Nc1ccnnc1)c1cc(N2CCC(O)CC2)ccc1OCc1ccccc1";"IC50";"'='";"39.81";"nM";"7.40";"";"";"UO_0000065";"18.30";"0.34";"4.13";"8.45";"0";"CHEMBL4372253";"Inhibition of recombinant 6His-Tev-tagged LRRK2 (1326 to 2527) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-RLGRDKYKTLRQIRQGNTKQR-OH as substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs by TR-FRET assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"Sf9";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4371037";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"CHEMBL3308860";"";"";""
"CHEMBL4440271";"";"None";"388.47";"0";"4.30";"13";"O=C(Nc1ccnnc1)c1cc(N2CCCCC2)ccc1OCc1ccccc1";"IC50";"'='";"25.12";"nM";"7.60";"";"";"UO_0000065";"19.56";"0.36";"3.30";"11.28";"0";"CHEMBL4372253";"Inhibition of recombinant 6His-Tev-tagged LRRK2 (1326 to 2527) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-RLGRDKYKTLRQIRQGNTKQR-OH as substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs by TR-FRET assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"Sf9";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4371037";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"CHEMBL3308860";"";"";""
"CHEMBL5172722";"";"None";"432.41";"0";"2.98";"7";"COC1CN(c2cc(NC(=O)c3cccc(-c4cnn(C)c4)n3)c(C(F)(F)F)cn2)C1";"IC50";"'='";"28.0";"nM";"7.55";"";"";"UO_0000065";"17.47";"0.33";"4.57";"8.87";"0";"CHEMBL5108135";"Inhibition of recombinant human GST20 tagged truncated LRRK2 G2019S mutant assessed as substrate phosphorylation preincubated for 15 mins followed by substrate addition and measured after 90 mins using fluorescein-labeled LRRK2tide as substrate in presence of ATP by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5107939";"1";"Scientific Literature";"RSC Med Chem";"2021";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL4437566";"";"None";"373.87";"0";"4.04";"9";"O=C(Nc1nc2ccc(Cl)cc2s1)c1ccc(N2CCOCC2)cc1";"IC50";"'='";"370.0";"nM";"6.43";"";"";"UO_0000065";"17.20";"0.35";"2.39";"11.81";"0";"CHEMBL4403862";"Inhibition of wild type human GST-tagged LRRK2 (970 to 2527 residues) expressed in baculovirus expression system assessed as reduction in ADP formation using LRRKtide as substrate measured after 1 hr in presence of ATP by Adapta assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4402549";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL2403374";"";"None";"435.48";"0";"2.28";"10";"CC(=O)Nc1ccc2c(c1)/C(=C/c1cc3c([nH]1)CCN(C(=O)N1CCOCC1)C3)C(=O)N2";"IC50";"'='";"4.0";"nM";"8.40";"";"";"UO_0000065";"19.28";"0.36";"6.12";"7.87";"0";"CHEMBL2406186";"Inhibition of human LRRK2 (1885 to 2132) using 5-Fluo-Ahx-RLGRDKYKTLRQIRQGNTK-OH as substrate after 60 mins by fluorescence assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2401634";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2403367";"";"None";"337.38";"0";"2.42";"3";"COc1ccc2c(c1)/C(=C/c1cc3c([nH]1)CCN(C(C)=O)C3)C(=O)N2";"IC50";"'='";"14.0";"nM";"7.85";"";"";"UO_0000065";"23.28";"0.43";"5.43";"10.55";"0";"CHEMBL2406186";"Inhibition of human LRRK2 (1885 to 2132) using 5-Fluo-Ahx-RLGRDKYKTLRQIRQGNTK-OH as substrate after 60 mins by fluorescence assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2401634";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL3966726";"";"None";"317.35";"0";"3.74";"33";"Nc1ncc(-c2ccc3[nH]ccc3c2)cc1-c1nnc(C2CC2)o1";"IC50";"'='";"1600.0";"nM";"5.80";"";"";"UO_0000065";"18.26";"0.33";"2.06";"6.19";"0";"CHEMBL4045603";"Inhibition of recombinant human LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus preincubated for 30 mins followed by fluorescein-LRRKtide substrate addition after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4043168";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL4103716";"";"None";"291.31";"0";"3.17";"38";"Cc1nnc(-c2cc(-c3ccc4[nH]ccc4c3)cnc2N)o1";"IC50";"'='";"3600.0";"nM";"5.44";"";"";"UO_0000065";"18.69";"0.34";"2.27";"5.81";"0";"CHEMBL4045603";"Inhibition of recombinant human LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus preincubated for 30 mins followed by fluorescein-LRRKtide substrate addition after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4043168";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL3951753";"";"None";"386.43";"0";"3.28";"BDBM234860";"C=CS(=O)(=O)Nc1cccc(Nc2ncnc3cc(OC)c(OC)cc23)c1";"IC50";"'='";"213.0";"nM";"6.67";"";"409337";"UO_0000065";"17.26";"0.34";"3.39";"6.51";"0";"CHEMBL3888566";"In vitro Kinase Assay: In vitro kinase assays using LRRK WT and LRRK G2019S.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886763";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3914888";"";"None";"436.49";"0";"4.19";"BDBM234866";"COc1cc2ncnc(Nc3cccc(NS(=O)(=O)c4ccccc4)c3)c2cc1OC";"IC50";"'='";"186.0";"nM";"6.73";"";"409341";"UO_0000065";"15.42";"0.30";"2.54";"6.57";"0";"CHEMBL3888566";"In vitro Kinase Assay: In vitro kinase assays using LRRK WT and LRRK G2019S.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886763";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3949880";"";"None";"290.37";"0";"3.47";"BDBM254925";"Cc1cc(-c2ccnc3[nH]cc(C#N)c23)ccc1CN(C)C";"IC50";"'='";"549.0";"nM";"6.26";"";"443731";"UO_0000065";"21.56";"0.39";"2.79";"11.24";"0";"CHEMBL3889253";"Homogeneous Time Resolved-fluorescence Resonance Energy Transfer (TR-FRET) Assay: LRRK2 kinase activity is measured using a LanthaScreen kinase activity assay available from Invitrogen (Life Technologies Corporation). The assay is a homogeneous time resolved-fluorescence resonance energy transfer (TR-FRET) assay that measures phosphorylation of a fluorescein-labelled peptide substrate (fluorescein-LRRKtide, fluorescein-GAGRLGRDKYKTLRQIRQ) (SEQ ID NO 1) as a result of LRRK2 kinase activity. The phosphorylated peptide is recognized by a terbium-labelled phospho-specific anti-LRRKtide antibody and, subsequently, the phosphorylated LRRKtide can be quantified by the extent of TR-FRET between the terbium donor and fluorescein acceptor.The LRRK2 kinase is obtained from Invitrogen (Life Technologies Corporation) and comprises residues 970 to 2527 of the full length human wild-type LRRK2 kinase or a similar sequence with the G2019S mutation. As discussed above, this mutation increases the kinase activity relative to the wild-type. The kinase reactions are performed in a 20 uL volume in 384-well plates. The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT.Â  In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 uM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 uM fluorescein-LRRKtide. The reaction mixture (20 ul total volume) is incubated for 2 hours at 30° C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 ul). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 us) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 us. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 us time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3887011";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3975329";"";"None";"377.37";"0";"3.79";"BDBM239427";"CC(C)Oc1cc2c(-c3cc(N4CCC(F)(F)C4)ncn3)n[nH]c2cc1F";"IC50";"'='";"6.1";"nM";"8.21";"";"417893";"UO_0000065";"21.77";"0.42";"4.42";"12.27";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3326127";"";"None";"368.42";"0";"2.69";"14";"COc1ccc(OC)c(Sc2ccc3nnc(-c4ccn(C)n4)n3n2)c1";"IC50";"'='";"2760.0";"nM";"5.56";"";"";"UO_0000065";"15.09";"0.29";"2.87";"7.00";"0";"CHEMBL3367451";"Inhibition of phosphorylation at S935 residue of wild-type full-length LRRK2 kinase (unknown origin) expressed in HEK 293 cells after 90 mins by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"CHEMBL3307715";"";"";""
"CHEMBL3326152";"";"None";"381.46";"0";"3.61";"40";"COc1ccc(OC)c(Sc2ccc3nc(C)c(-c4cnn(C)c4)n3n2)c1";"IC50";"'='";"115.0";"nM";"6.94";"";"";"UO_0000065";"18.19";"0.35";"3.33";"10.44";"0";"CHEMBL3367450";"Inhibition of GST-tagged truncated LRRK2 (unknown origin) using fluorescein-labeled peptide LRRKtide as substrate by LANTHA screen assay in presence of 1 mM ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL4090725";"";"None";"305.34";"0";"2.33";"14";"N#Cc1ccc2[nH]nc(-c3ccnc(N4CCOCC4)c3)c2c1";"IC50";"'='";"64.0";"nM";"7.19";"";"";"UO_0000065";"23.56";"0.43";"4.86";"9.24";"0";"CHEMBL4010109";"Inhibition of recombinant human GST-tagged LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus using fluorescein-ERM as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007454";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4068699";"";"None";"280.33";"0";"2.46";"8";"c1ccc2c(-c3ccnc(N4CCOCC4)c3)n[nH]c2c1";"IC50";"'='";"12.0";"nM";"7.92";"";"";"UO_0000065";"28.26";"0.52";"5.46";"14.66";"0";"CHEMBL4010109";"Inhibition of recombinant human GST-tagged LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus using fluorescein-ERM as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007454";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4581507";"";"None";"418.50";"0";"3.52";"16";"O=C(Nc1ccnnc1)c1cc(N2CCC(CO)CC2)ccc1OCc1ccccc1";"IC50";"'='";"19.95";"nM";"7.70";"";"";"UO_0000065";"18.40";"0.34";"4.18";"8.79";"0";"CHEMBL4372253";"Inhibition of recombinant 6His-Tev-tagged LRRK2 (1326 to 2527) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-RLGRDKYKTLRQIRQGNTKQR-OH as substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs by TR-FRET assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"Sf9";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4371037";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"CHEMBL3308860";"";"";""
"CHEMBL4467262";"";"None";"378.41";"0";"3.47";"10";"O=C(Nc1ccnnc1)c1cc(N2CC(F)C2)ccc1OCc1ccccc1";"IC50";"'='";"25.12";"nM";"7.60";"";"";"UO_0000065";"20.08";"0.37";"4.13";"11.28";"0";"CHEMBL4372253";"Inhibition of recombinant 6His-Tev-tagged LRRK2 (1326 to 2527) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-RLGRDKYKTLRQIRQGNTKQR-OH as substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs by TR-FRET assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"Sf9";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4371037";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"CHEMBL3308860";"";"";""
"CHEMBL4764691";"";"None";"437.98";"0";"4.35";"7.12";"CC1(N2CCC(c3cc4c(cnn4-c4cnn(C56CC(C5)C6)c4)cc3Cl)CC2)COC1";"IC50";"'='";"0.71";"nM";"9.15";"";"";"UO_0000065";"20.89";"0.40";"4.80";"19.02";"0";"CHEMBL4714711";"Inhibition of recombinant human GST tagged LRRK2 G2019S mutant catalytic domain (970 to 2527 residues) expressed in baculovirus expression system using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 90 mins by TR-FRET based Lanthascreen assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4706723";"1";"Scientific Literature";"ACS Med Chem Lett";"2021";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL3326114";"";"None";"364.43";"0";"3.96";"1";"COc1ccc(OC)c(Sc2ccc3nnc(-c4ccccc4)n3n2)c1";"IC50";"'='";"173.0";"nM";"6.76";"";"";"UO_0000065";"18.55";"0.36";"2.80";"10.99";"0";"CHEMBL3367450";"Inhibition of GST-tagged truncated LRRK2 (unknown origin) using fluorescein-labeled peptide LRRKtide as substrate by LANTHA screen assay in presence of 1 mM ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL3917197";"";"None";"387.45";"0";"2.79";"BDBM239180";"Cn1cc(-c2ccc3[nH]nc(-c4cc(N5CCOC6(CC6)C5)ncn4)c3c2)cn1";"IC50";"'='";"2.01";"nM";"8.70";"";"417639";"UO_0000065";"22.45";"0.41";"5.91";"10.26";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4098877";"MLi-2";"None";"379.46";"0";"3.56";"EUB0000715";"C[C@@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@H](C)O1";"IC50";"'='";"0.4";"nM";"9.40";"";"";"UO_0000065";"24.77";"0.46";"5.84";"12.34";"1";"CHEMBL5157023";"Inhibition of full length LRRK2 G2019S mutant (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL3936985";"";"None";"333.40";"0";"3.25";"BDBM223543";"CN1CCc2cc(-c3cnc(N)c(-c4nnc(C5CC5)o4)c3)ccc21";"IC50";"'='";"710.0";"nM";"6.15";"";"390799";"UO_0000065";"18.44";"0.34";"2.90";"7.58";"0";"CHEMBL3888345";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3935728";"";"None";"376.46";"0";"2.84";"BDBM223545";"CN1CCc2cc(-c3cnc(N)c(-c4nnc(C5CCNCC5)o4)c3)ccc21";"IC50";"'='";"2200.0";"nM";"5.66";"";"390830";"UO_0000065";"15.03";"0.28";"2.82";"6.08";"0";"CHEMBL3888346";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3954783";"";"None";"365.44";"0";"3.20";"BDBM223548";"COc1cccc(-c2cnc(N)c(-c3nnc(C4CCN(C)CC4)o3)c2)c1";"IC50";"'='";"2200.0";"nM";"5.66";"";"390833";"UO_0000065";"15.48";"0.29";"2.46";"6.27";"0";"CHEMBL3888346";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3922844";"";"None";"334.43";"0";"3.16";"BDBM223550";"CC(C)n1cc(-c2cc(-c3ccc4c(c3)CCN4C)cnc2N)nn1";"IC50";"'='";"620.0";"nM";"6.21";"";"390835";"UO_0000065";"18.56";"0.34";"3.05";"8.52";"0";"CHEMBL3888346";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL5199239";"";"None";"420.49";"0";"3.77";"34";"COc1cc(-c2c(-c3ccncc3)n[nH]c2C)ccc1-c1cccc(S(N)(=O)=O)c1";"IC50";"'='";"19.4";"nM";"7.71";"";"";"UO_0000065";"18.34";"0.35";"3.94";"6.95";"0";"CHEMBL5136368";"Inhibition of full-length LRRK2 G2019S mutant (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL3953703";"";"None";"383.45";"0";"2.66";"BDBM239461";"COC[C@H](C)Oc1ccc2[nH]nc(-c3cc(N4CCOC[C@@H]4C)ncn3)c2c1";"IC50";"'='";"6.0";"nM";"8.22";"";"417926";"UO_0000065";"21.44";"0.40";"5.56";"9.63";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3900144";"";"None";"426.48";"0";"3.34";"BDBM239487";"C[C@@H]1CN(c2cc(-c3n[nH]c4ccc(-c5ccc6ncnn6c5)cc34)ncn2)C[C@H](C)O1";"IC50";"'='";"240.1";"nM";"6.62";"";"417952";"UO_0000065";"15.52";"0.28";"3.28";"6.82";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4449552";"";"None";"242.26";"0";"3.15";"4";"Cc1n[nH]c2ccnc(Nc3ccccc3F)c12";"IC50";"'='";"150.0";"nM";"6.82";"";"";"UO_0000065";"28.17";"0.52";"3.67";"12.73";"0";"CHEMBL4331900";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant catalytic domain (970 to 2527 residues) expressed in baculovirus expression system by radiometric assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330096";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4566610";"";"None";"230.31";"0";"3.01";"39";"Cc1n[nH]c2cncc(NC3CCCCC3)c12";"IC50";"'='";"770.0";"nM";"6.11";"";"";"UO_0000065";"26.54";"0.49";"3.10";"11.41";"0";"CHEMBL4331900";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant catalytic domain (970 to 2527 residues) expressed in baculovirus expression system by radiometric assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330096";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4546504";"";"None";"555.99";"2";"5.46";"20";"C[C@@H](Oc1cc(C(=O)N(C)C)ccc1Nc1nc(O[C@H]2CC[C@@](C)(O)CC2)c2c(Cl)c[nH]c2n1)C(F)(F)F";"IC50";"'='";"0.001";"nM";"";"Outside typical range";"";"UO_0000065";"";"";"";"";"0";"CHEMBL4349096";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant catalytic domain (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate measured after 1 hr by Alexa-fluor-647 ADP tracer-based ADAPTA assay";"A";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4346709";"1";"Scientific Literature";"J Med Chem";"2019";"None";"";"";""
"CHEMBL4546504";"";"None";"555.99";"2";"5.46";"20";"C[C@@H](Oc1cc(C(=O)N(C)C)ccc1Nc1nc(O[C@H]2CC[C@@](C)(O)CC2)c2c(Cl)c[nH]c2n1)C(F)(F)F";"IC50";"'='";"0.001";"nM";"";"Outside typical range";"";"UO_0000065";"";"";"";"";"0";"CHEMBL4349101";"Inhibition of recombinant human GST-tagged LRRK2 catalytic domain (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate measured after 1 hr by Alexa fluor-647 ADP tracer-based ADAPTA assay";"A";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4346709";"1";"Scientific Literature";"J Med Chem";"2019";"None";"";"";""
"CHEMBL3939512";"";"None";"397.36";"0";"4.30";"BDBM254935";"Cc1cncc(-c2cc(Nc3nn(C)cc3C(F)(F)F)nc3[nH]cc(C#N)c23)c1";"IC50";"'='";"358.0";"nM";"6.45";"";"443741";"UO_0000065";"16.22";"0.30";"2.15";"6.77";"0";"CHEMBL3889253";"Homogeneous Time Resolved-fluorescence Resonance Energy Transfer (TR-FRET) Assay: LRRK2 kinase activity is measured using a LanthaScreen kinase activity assay available from Invitrogen (Life Technologies Corporation). The assay is a homogeneous time resolved-fluorescence resonance energy transfer (TR-FRET) assay that measures phosphorylation of a fluorescein-labelled peptide substrate (fluorescein-LRRKtide, fluorescein-GAGRLGRDKYKTLRQIRQ) (SEQ ID NO 1) as a result of LRRK2 kinase activity. The phosphorylated peptide is recognized by a terbium-labelled phospho-specific anti-LRRKtide antibody and, subsequently, the phosphorylated LRRKtide can be quantified by the extent of TR-FRET between the terbium donor and fluorescein acceptor.The LRRK2 kinase is obtained from Invitrogen (Life Technologies Corporation) and comprises residues 970 to 2527 of the full length human wild-type LRRK2 kinase or a similar sequence with the G2019S mutation. As discussed above, this mutation increases the kinase activity relative to the wild-type. The kinase reactions are performed in a 20 uL volume in 384-well plates. The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT.Â  In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 uM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 uM fluorescein-LRRKtide. The reaction mixture (20 ul total volume) is incubated for 2 hours at 30° C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 ul). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 us) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 us. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 us time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3887011";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3933899";"";"None";"329.37";"0";"3.28";"BDBM254939";"Cc1cncc(-c2cc(Nc3ccn(C)n3)nc3[nH]cc(C#N)c23)c1";"IC50";"'='";"27.0";"nM";"7.57";"";"443745";"UO_0000065";"22.98";"0.41";"4.29";"7.95";"0";"CHEMBL3889253";"Homogeneous Time Resolved-fluorescence Resonance Energy Transfer (TR-FRET) Assay: LRRK2 kinase activity is measured using a LanthaScreen kinase activity assay available from Invitrogen (Life Technologies Corporation). The assay is a homogeneous time resolved-fluorescence resonance energy transfer (TR-FRET) assay that measures phosphorylation of a fluorescein-labelled peptide substrate (fluorescein-LRRKtide, fluorescein-GAGRLGRDKYKTLRQIRQ) (SEQ ID NO 1) as a result of LRRK2 kinase activity. The phosphorylated peptide is recognized by a terbium-labelled phospho-specific anti-LRRKtide antibody and, subsequently, the phosphorylated LRRKtide can be quantified by the extent of TR-FRET between the terbium donor and fluorescein acceptor.The LRRK2 kinase is obtained from Invitrogen (Life Technologies Corporation) and comprises residues 970 to 2527 of the full length human wild-type LRRK2 kinase or a similar sequence with the G2019S mutation. As discussed above, this mutation increases the kinase activity relative to the wild-type. The kinase reactions are performed in a 20 uL volume in 384-well plates. The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT.Â  In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 uM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 uM fluorescein-LRRKtide. The reaction mixture (20 ul total volume) is incubated for 2 hours at 30° C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 ul). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 us) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 us. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 us time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3887011";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3912951";"";"None";"233.27";"0";"3.41";"BDBM254919";"Cc1cccc(-c2ccnc3[nH]cc(C#N)c23)c1";"IC50";"'='";"170.0";"nM";"6.77";"";"443725";"UO_0000065";"29.02";"0.51";"3.36";"12.90";"0";"CHEMBL3889253";"Homogeneous Time Resolved-fluorescence Resonance Energy Transfer (TR-FRET) Assay: LRRK2 kinase activity is measured using a LanthaScreen kinase activity assay available from Invitrogen (Life Technologies Corporation). The assay is a homogeneous time resolved-fluorescence resonance energy transfer (TR-FRET) assay that measures phosphorylation of a fluorescein-labelled peptide substrate (fluorescein-LRRKtide, fluorescein-GAGRLGRDKYKTLRQIRQ) (SEQ ID NO 1) as a result of LRRK2 kinase activity. The phosphorylated peptide is recognized by a terbium-labelled phospho-specific anti-LRRKtide antibody and, subsequently, the phosphorylated LRRKtide can be quantified by the extent of TR-FRET between the terbium donor and fluorescein acceptor.The LRRK2 kinase is obtained from Invitrogen (Life Technologies Corporation) and comprises residues 970 to 2527 of the full length human wild-type LRRK2 kinase or a similar sequence with the G2019S mutation. As discussed above, this mutation increases the kinase activity relative to the wild-type. The kinase reactions are performed in a 20 uL volume in 384-well plates. The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT.Â  In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 uM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 uM fluorescein-LRRKtide. The reaction mixture (20 ul total volume) is incubated for 2 hours at 30° C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 ul). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 us) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 us. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 us time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3887011";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3925092";"";"None";"311.35";"0";"4.24";"BDBM254934";"N#Cc1c[nH]c2nc(Nc3ccccn3)cc(-c3ccccc3)c12";"IC50";"'='";"527.0";"nM";"6.28";"";"443717";"UO_0000065";"20.16";"0.36";"2.04";"8.11";"0";"CHEMBL3889252";"Homogeneous Time Resolved-fluorescence Resonance Energy Transfer (TR-FRET) Assay: LRRK2 kinase activity is measured using a LanthaScreen kinase activity assay available from Invitrogen (Life Technologies Corporation). The assay is a homogeneous time resolved-fluorescence resonance energy transfer (TR-FRET) assay that measures phosphorylation of a fluorescein-labelled peptide substrate (fluorescein-LRRKtide, fluorescein-GAGRLGRDKYKTLRQIRQ) (SEQ ID NO 1) as a result of LRRK2 kinase activity. The phosphorylated peptide is recognized by a terbium-labelled phospho-specific anti-LRRKtide antibody and, subsequently, the phosphorylated LRRKtide can be quantified by the extent of TR-FRET between the terbium donor and fluorescein acceptor.The LRRK2 kinase is obtained from Invitrogen (Life Technologies Corporation) and comprises residues 970 to 2527 of the full length human wild-type LRRK2 kinase or a similar sequence with the G2019S mutation. As discussed above, this mutation increases the kinase activity relative to the wild-type. The kinase reactions are performed in a 20 uL volume in 384-well plates. The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT.Â  In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 uM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 uM fluorescein-LRRKtide. The reaction mixture (20 ul total volume) is incubated for 2 hours at 30° C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 ul). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 us) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 us. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 us time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3887011";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3939512";"";"None";"397.36";"0";"4.30";"BDBM254935";"Cc1cncc(-c2cc(Nc3nn(C)cc3C(F)(F)F)nc3[nH]cc(C#N)c23)c1";"IC50";"'='";"509.0";"nM";"6.29";"";"443718";"UO_0000065";"15.84";"0.30";"1.99";"6.61";"0";"CHEMBL3889252";"Homogeneous Time Resolved-fluorescence Resonance Energy Transfer (TR-FRET) Assay: LRRK2 kinase activity is measured using a LanthaScreen kinase activity assay available from Invitrogen (Life Technologies Corporation). The assay is a homogeneous time resolved-fluorescence resonance energy transfer (TR-FRET) assay that measures phosphorylation of a fluorescein-labelled peptide substrate (fluorescein-LRRKtide, fluorescein-GAGRLGRDKYKTLRQIRQ) (SEQ ID NO 1) as a result of LRRK2 kinase activity. The phosphorylated peptide is recognized by a terbium-labelled phospho-specific anti-LRRKtide antibody and, subsequently, the phosphorylated LRRKtide can be quantified by the extent of TR-FRET between the terbium donor and fluorescein acceptor.The LRRK2 kinase is obtained from Invitrogen (Life Technologies Corporation) and comprises residues 970 to 2527 of the full length human wild-type LRRK2 kinase or a similar sequence with the G2019S mutation. As discussed above, this mutation increases the kinase activity relative to the wild-type. The kinase reactions are performed in a 20 uL volume in 384-well plates. The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT.Â  In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 uM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 uM fluorescein-LRRKtide. The reaction mixture (20 ul total volume) is incubated for 2 hours at 30° C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 ul). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 us) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 us. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 us time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3887011";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3979676";"";"None";"249.27";"0";"3.11";"BDBM254918";"COc1cccc(-c2ccnc3[nH]cc(C#N)c23)c1";"IC50";"'='";"247.0";"nM";"6.61";"";"443724";"UO_0000065";"26.51";"0.47";"3.50";"10.71";"0";"CHEMBL3889253";"Homogeneous Time Resolved-fluorescence Resonance Energy Transfer (TR-FRET) Assay: LRRK2 kinase activity is measured using a LanthaScreen kinase activity assay available from Invitrogen (Life Technologies Corporation). The assay is a homogeneous time resolved-fluorescence resonance energy transfer (TR-FRET) assay that measures phosphorylation of a fluorescein-labelled peptide substrate (fluorescein-LRRKtide, fluorescein-GAGRLGRDKYKTLRQIRQ) (SEQ ID NO 1) as a result of LRRK2 kinase activity. The phosphorylated peptide is recognized by a terbium-labelled phospho-specific anti-LRRKtide antibody and, subsequently, the phosphorylated LRRKtide can be quantified by the extent of TR-FRET between the terbium donor and fluorescein acceptor.The LRRK2 kinase is obtained from Invitrogen (Life Technologies Corporation) and comprises residues 970 to 2527 of the full length human wild-type LRRK2 kinase or a similar sequence with the G2019S mutation. As discussed above, this mutation increases the kinase activity relative to the wild-type. The kinase reactions are performed in a 20 uL volume in 384-well plates. The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT.Â  In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 uM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 uM fluorescein-LRRKtide. The reaction mixture (20 ul total volume) is incubated for 2 hours at 30° C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 ul). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 us) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 us. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 us time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3887011";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3950909";"";"None";"318.38";"0";"2.93";"BDBM254922";"N#Cc1c[nH]c2nccc(-c3ccc(CN4CCOCC4)cc3)c12";"IC50";"'='";"5442.0";"nM";"5.26";"";"443728";"UO_0000065";"16.53";"0.30";"2.33";"8.11";"0";"CHEMBL3889253";"Homogeneous Time Resolved-fluorescence Resonance Energy Transfer (TR-FRET) Assay: LRRK2 kinase activity is measured using a LanthaScreen kinase activity assay available from Invitrogen (Life Technologies Corporation). The assay is a homogeneous time resolved-fluorescence resonance energy transfer (TR-FRET) assay that measures phosphorylation of a fluorescein-labelled peptide substrate (fluorescein-LRRKtide, fluorescein-GAGRLGRDKYKTLRQIRQ) (SEQ ID NO 1) as a result of LRRK2 kinase activity. The phosphorylated peptide is recognized by a terbium-labelled phospho-specific anti-LRRKtide antibody and, subsequently, the phosphorylated LRRKtide can be quantified by the extent of TR-FRET between the terbium donor and fluorescein acceptor.The LRRK2 kinase is obtained from Invitrogen (Life Technologies Corporation) and comprises residues 970 to 2527 of the full length human wild-type LRRK2 kinase or a similar sequence with the G2019S mutation. As discussed above, this mutation increases the kinase activity relative to the wild-type. The kinase reactions are performed in a 20 uL volume in 384-well plates. The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT.Â  In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 uM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 uM fluorescein-LRRKtide. The reaction mixture (20 ul total volume) is incubated for 2 hours at 30° C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 ul). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 us) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 us. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 us time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3887011";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3967289";"";"None";"346.43";"0";"3.50";"BDBM254926";"CCc1cc(-c2ccnc3[nH]cc(C#N)c23)ccc1CN1CCOCC1";"IC50";"'='";"149.0";"nM";"6.83";"";"443732";"UO_0000065";"19.71";"0.36";"3.33";"10.51";"0";"CHEMBL3889253";"Homogeneous Time Resolved-fluorescence Resonance Energy Transfer (TR-FRET) Assay: LRRK2 kinase activity is measured using a LanthaScreen kinase activity assay available from Invitrogen (Life Technologies Corporation). The assay is a homogeneous time resolved-fluorescence resonance energy transfer (TR-FRET) assay that measures phosphorylation of a fluorescein-labelled peptide substrate (fluorescein-LRRKtide, fluorescein-GAGRLGRDKYKTLRQIRQ) (SEQ ID NO 1) as a result of LRRK2 kinase activity. The phosphorylated peptide is recognized by a terbium-labelled phospho-specific anti-LRRKtide antibody and, subsequently, the phosphorylated LRRKtide can be quantified by the extent of TR-FRET between the terbium donor and fluorescein acceptor.The LRRK2 kinase is obtained from Invitrogen (Life Technologies Corporation) and comprises residues 970 to 2527 of the full length human wild-type LRRK2 kinase or a similar sequence with the G2019S mutation. As discussed above, this mutation increases the kinase activity relative to the wild-type. The kinase reactions are performed in a 20 uL volume in 384-well plates. The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT.Â  In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 uM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 uM fluorescein-LRRKtide. The reaction mixture (20 ul total volume) is incubated for 2 hours at 30° C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 ul). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 us) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 us. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 us time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3887011";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4111923";"";"None";"353.43";"0";"3.03";"BDBM239083";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCO[C@H](C)C4)ncn3)c2c1";"IC50";"'='";"5.09";"nM";"8.29";"";"312518";"UO_0000065";"23.47";"0.44";"5.26";"10.89";"0";"CHEMBL3887174";"LanthaScreen™ Assay (Km ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 184 μM ATP solution in 1× assay buffer to all wells. d) After a 60 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3932625";"";"None";"406.49";"0";"2.91";"BDBM239087";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCC5(CCNC5=O)CC4)ncn3)c2c1";"IC50";"'='";"2.31";"nM";"8.64";"";"312522";"UO_0000065";"21.25";"0.39";"5.73";"8.99";"0";"CHEMBL3887174";"LanthaScreen™ Assay (Km ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 184 μM ATP solution in 1× assay buffer to all wells. d) After a 60 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4473326";"";"None";"357.41";"0";"3.52";"10";"O=C(Nc1nc2ccc(F)cc2s1)c1ccc(N2CCOCC2)cc1";"IC50";"'='";"180.0";"nM";"6.75";"";"";"UO_0000065";"18.87";"0.37";"3.22";"12.38";"0";"CHEMBL4403864";"Inhibition of human GST-tagged LRRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus expression system assessed as reduction in ADP formation using LRRKtide as substrate measured after 1 hr in presence of ATP by Adapta assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4402549";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL3950909";"";"None";"318.38";"0";"2.93";"BDBM254922";"N#Cc1c[nH]c2nccc(-c3ccc(CN4CCOCC4)cc3)c12";"IC50";"'='";"1308.0";"nM";"5.88";"";"443705";"UO_0000065";"18.48";"0.33";"2.95";"9.06";"0";"CHEMBL3889252";"Homogeneous Time Resolved-fluorescence Resonance Energy Transfer (TR-FRET) Assay: LRRK2 kinase activity is measured using a LanthaScreen kinase activity assay available from Invitrogen (Life Technologies Corporation). The assay is a homogeneous time resolved-fluorescence resonance energy transfer (TR-FRET) assay that measures phosphorylation of a fluorescein-labelled peptide substrate (fluorescein-LRRKtide, fluorescein-GAGRLGRDKYKTLRQIRQ) (SEQ ID NO 1) as a result of LRRK2 kinase activity. The phosphorylated peptide is recognized by a terbium-labelled phospho-specific anti-LRRKtide antibody and, subsequently, the phosphorylated LRRKtide can be quantified by the extent of TR-FRET between the terbium donor and fluorescein acceptor.The LRRK2 kinase is obtained from Invitrogen (Life Technologies Corporation) and comprises residues 970 to 2527 of the full length human wild-type LRRK2 kinase or a similar sequence with the G2019S mutation. As discussed above, this mutation increases the kinase activity relative to the wild-type. The kinase reactions are performed in a 20 uL volume in 384-well plates. The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT.Â  In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 uM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 uM fluorescein-LRRKtide. The reaction mixture (20 ul total volume) is incubated for 2 hours at 30° C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 ul). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 us) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 us. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 us time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3887011";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL2012582";"";"None";"570.70";"1";"3.44";"2, LRRK2-IN-1";"COc1cc(C(=O)N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2C";"IC50";"'='";"6.0";"nM";"8.22";"";"";"UO_0000065";"14.41";"0.27";"4.78";"8.44";"1";"CHEMBL3607919";"Inhibition of LRRK2 (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3603772";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL4441650";"";"None";"327.39";"0";"2.39";"13";"CC(C)n1cc(-c2n[nH]c3ccnc(NC4CCOCC4)c23)nn1";"IC50";"'='";"49.0";"nM";"7.31";"";"";"UO_0000065";"22.33";"0.42";"4.92";"7.81";"0";"CHEMBL4331199";"Inhibition of LRRK2 G2019S mutant (unknown origin) by cell based assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330074";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4077195";"";"None";"390.34";"1";"5.07";"8e";"O=C(Nc1cccnc1)c1cc(C(F)(F)F)ccc1OCc1ccc(F)cc1";"IC50";"'='";"7.943";"nM";"8.10";"";"";"UO_0000065";"20.75";"0.40";"3.03";"15.81";"0";"CHEMBL4058553";"Inhibition of human LRRK2 using RLGRDKYKTLRQIRQ as substrate in presence of [gamma-33P]-ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4052807";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL3937634";"";"None";"348.41";"0";"2.94";"BDBM254927";"COc1cc(-c2ccnc3[nH]cc(C#N)c23)ccc1CN1CCOCC1";"IC50";"'='";"919.0";"nM";"6.04";"";"443733";"UO_0000065";"17.33";"0.32";"3.10";"8.14";"0";"CHEMBL3889253";"Homogeneous Time Resolved-fluorescence Resonance Energy Transfer (TR-FRET) Assay: LRRK2 kinase activity is measured using a LanthaScreen kinase activity assay available from Invitrogen (Life Technologies Corporation). The assay is a homogeneous time resolved-fluorescence resonance energy transfer (TR-FRET) assay that measures phosphorylation of a fluorescein-labelled peptide substrate (fluorescein-LRRKtide, fluorescein-GAGRLGRDKYKTLRQIRQ) (SEQ ID NO 1) as a result of LRRK2 kinase activity. The phosphorylated peptide is recognized by a terbium-labelled phospho-specific anti-LRRKtide antibody and, subsequently, the phosphorylated LRRKtide can be quantified by the extent of TR-FRET between the terbium donor and fluorescein acceptor.The LRRK2 kinase is obtained from Invitrogen (Life Technologies Corporation) and comprises residues 970 to 2527 of the full length human wild-type LRRK2 kinase or a similar sequence with the G2019S mutation. As discussed above, this mutation increases the kinase activity relative to the wild-type. The kinase reactions are performed in a 20 uL volume in 384-well plates. The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT.Â  In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 uM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 uM fluorescein-LRRKtide. The reaction mixture (20 ul total volume) is incubated for 2 hours at 30° C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 ul). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 us) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 us. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 us time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3887011";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3961481";"";"None";"343.39";"0";"3.59";"BDBM254937";"Cc1cccc(-c2cc(Nc3nn(C)cc3C)nc3[nH]cc(C#N)c23)n1";"IC50";"'='";"36.0";"nM";"7.44";"";"443743";"UO_0000065";"21.68";"0.39";"3.85";"7.82";"0";"CHEMBL3889253";"Homogeneous Time Resolved-fluorescence Resonance Energy Transfer (TR-FRET) Assay: LRRK2 kinase activity is measured using a LanthaScreen kinase activity assay available from Invitrogen (Life Technologies Corporation). The assay is a homogeneous time resolved-fluorescence resonance energy transfer (TR-FRET) assay that measures phosphorylation of a fluorescein-labelled peptide substrate (fluorescein-LRRKtide, fluorescein-GAGRLGRDKYKTLRQIRQ) (SEQ ID NO 1) as a result of LRRK2 kinase activity. The phosphorylated peptide is recognized by a terbium-labelled phospho-specific anti-LRRKtide antibody and, subsequently, the phosphorylated LRRKtide can be quantified by the extent of TR-FRET between the terbium donor and fluorescein acceptor.The LRRK2 kinase is obtained from Invitrogen (Life Technologies Corporation) and comprises residues 970 to 2527 of the full length human wild-type LRRK2 kinase or a similar sequence with the G2019S mutation. As discussed above, this mutation increases the kinase activity relative to the wild-type. The kinase reactions are performed in a 20 uL volume in 384-well plates. The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT.Â  In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 uM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 uM fluorescein-LRRKtide. The reaction mixture (20 ul total volume) is incubated for 2 hours at 30° C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 ul). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 us) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 us. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 us time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3887011";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL2170016";"";"None";"377.83";"0";"2.40";"6";"CNc1nc(Nc2ccc(C(=O)N3CCOCC3)cc2OC)ncc1Cl";"IC50";"'='";"3.2";"nM";"8.49";"";"";"UO_0000065";"22.48";"0.45";"6.09";"9.59";"1";"CHEMBL4018178";"Inhibition of LRRK2 G2019S mutant (unknown origin) using biotinylated ezrin/radaxin/meosin peptide as substrate measured after 1 hr";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4017473";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL3651766";"";"None";"365.44";"0";"3.18";"12";"c1cc(-c2n[nH]c3ccnc(OC4CCOCC4)c23)cc(N2CCCC2)n1";"IC50";"'='";"3.0";"nM";"8.52";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL4018177";"Inhibition of full length wild-type LRRK2 (unknown origin) using biotinylated ezrin/radaxin/meosin peptide as substrate measured after 1 hr";"A";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4017473";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL4111865";"";"None";"383.45";"0";"2.66";"BDBM239299";"COC[C@@H](C)Oc1ccc2[nH]nc(-c3cc(N4CCO[C@H](C)C4)ncn3)c2c1";"IC50";"'='";"35.5";"nM";"7.45";"";"417758";"UO_0000065";"19.43";"0.36";"4.79";"8.72";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3939517";"";"None";"367.45";"0";"3.42";"BDBM239346";"COC1CCCN(c2cc(-c3n[nH]c4ccc(OC(C)C)cc34)ncn2)C1";"IC50";"'='";"12.7";"nM";"7.90";"";"417814";"UO_0000065";"21.49";"0.40";"4.48";"10.37";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3916009";"";"None";"362.44";"0";"3.55";"BDBM239350";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCC(C#N)CC4)ncn3)c2c1";"IC50";"'='";"7.2";"nM";"8.14";"";"417818";"UO_0000065";"22.47";"0.41";"4.59";"8.98";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3944448";"";"None";"377.43";"0";"3.22";"BDBM239394";"Cn1cc(-c2ccc3[nH]nc(-c4cc(N5CC[C@@H](CF)C5)ncn4)c3c2)cn1";"IC50";"'='";"2.3";"nM";"8.64";"";"417860";"UO_0000065";"22.89";"0.42";"5.42";"11.44";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3900844";"";"None";"375.44";"0";"2.24";"BDBM239395";"Cn1cc(-c2ccc3[nH]nc(-c4cc(N5CC[C@H](CO)C5)ncn4)c3c2)cn1";"IC50";"'='";"2.5";"nM";"8.60";"";"417861";"UO_0000065";"22.91";"0.42";"6.36";"8.98";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3985716";"";"None";"397.48";"0";"3.05";"BDBM239460";"COC[C@H](C)Oc1ccc2[nH]nc(-c3cc(N4[C@H](C)COC[C@@H]4C)ncn3)c2c1";"IC50";"'='";"7.4";"nM";"8.13";"";"417925";"UO_0000065";"20.46";"0.38";"5.08";"9.52";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3895733";"";"None";"359.39";"0";"2.31";"BDBM239314";"c1cnc(-c2ccc3[nH]nc(-c4cc(N5CCOCC5)ncn4)c3c2)cn1";"IC50";"'='";"34.7";"nM";"7.46";"";"417782";"UO_0000065";"20.76";"0.38";"5.15";"8.05";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3952422";"";"None";"337.43";"0";"3.80";"BDBM239319";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCCCC4)ncn3)c2c1";"IC50";"'='";"10.6";"nM";"7.97";"";"417787";"UO_0000065";"23.63";"0.44";"4.17";"11.91";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3974673";"";"None";"382.47";"0";"1.92";"BDBM239323";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4C[C@H](O)[C@@H](N(C)C)C4)ncn3)c2c1";"IC50";"'='";"15.3";"nM";"7.82";"";"417791";"UO_0000065";"20.43";"0.38";"5.90";"8.65";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3970331";"";"None";"416.42";"0";"3.11";"BDBM239373";"Cn1cc(-c2cc3c(-c4cc(N5CCc6oncc6C5)ncn4)n[nH]c3cc2F)cn1";"IC50";"'='";"453.3";"nM";"6.34";"";"417840";"UO_0000065";"15.23";"0.28";"3.23";"6.25";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3955624";"";"None";"394.41";"0";"2.56";"BDBM239420";"CC(C)Oc1cc2c(-c3cc(N4CCn5ncnc5C4)ncn3)n[nH]c2cc1F";"IC50";"'='";"7.1";"nM";"8.15";"";"417886";"UO_0000065";"20.66";"0.38";"5.59";"8.35";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3911871";"";"None";"385.44";"0";"3.56";"BDBM239434";"CC(C)Oc1cc2c(-c3cc(N4CCOC(C)(C)C4)ncn3)n[nH]c2cc1F";"IC50";"'='";"6.2";"nM";"8.21";"";"417900";"UO_0000065";"21.29";"0.40";"4.65";"10.78";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3942557";"";"None";"383.42";"0";"2.79";"BDBM239469";"N#Cc1cc(-c2ccc3[nH]nc(-c4cc(N5CCOCC5)ncn4)c3c2)ccn1";"IC50";"'='";"340.1";"nM";"6.47";"";"417934";"UO_0000065";"16.87";"0.30";"3.68";"6.24";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3898450";"";"None";"382.43";"0";"3.40";"BDBM239474";"N#Cc1ccc(-c2ccc3[nH]nc(-c4cc(N5CCOCC5)ncn4)c3c2)cc1";"IC50";"'='";"149.8";"nM";"6.82";"";"417939";"UO_0000065";"17.85";"0.32";"3.42";"7.52";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3951356";"";"None";"415.50";"0";"3.71";"BDBM239498";"Cc1ncc(-c2ccc3[nH]nc(-c4cc(N5C[C@@H](C)O[C@@H](C)C5)ncn4)c3c2)nc1C";"IC50";"'='";"17.4";"nM";"7.76";"";"417963";"UO_0000065";"18.67";"0.34";"4.05";"8.37";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3949980";"";"None";"332.41";"0";"3.66";"BDBM223549";"CC(C)n1cc(-c2cc(-c3ccc4c(ccn4C)c3)cnc2N)nn1";"IC50";"'='";"550.0";"nM";"6.26";"";"390834";"UO_0000065";"18.83";"0.34";"2.60";"8.40";"0";"CHEMBL3888346";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3928119";"";"None";"426.91";"0";"3.30";"BDBM223566";"CC(C)n1cc(-c2cc(-c3cc(Cl)cc(C(=O)N4CCOCC4)c3)cnc2N)nn1";"IC50";"'='";"490.0";"nM";"6.31";"";"390851";"UO_0000065";"14.78";"0.29";"3.01";"6.36";"0";"CHEMBL3888346";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4452771";"";"None";"418.32";"0";"4.15";"14";"O=C(Nc1nc2ccc(Br)cc2s1)c1ccc(N2CCOCC2)cc1";"IC50";"'='";"510.0";"nM";"6.29";"";"";"UO_0000065";"15.04";"0.34";"2.14";"11.55";"0";"CHEMBL4403862";"Inhibition of wild type human GST-tagged LRRK2 (970 to 2527 residues) expressed in baculovirus expression system assessed as reduction in ADP formation using LRRKtide as substrate measured after 1 hr in presence of ATP by Adapta assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4402549";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL3986654";"";"None";"346.39";"0";"2.20";"BDBM185486";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCCC(C(N)=O)C4)c23)c1";"IC50";"'='";"49.0";"nM";"7.31";"";"334459";"UO_0000065";"21.10";"0.38";"5.11";"6.54";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3956541";"";"None";"383.42";"0";"2.86";"BDBM185488";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCOC(c5ccncn5)C4)c23)c1";"IC50";"'='";"79.0";"nM";"7.10";"";"334461";"UO_0000065";"18.52";"0.33";"4.24";"6.85";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3954450";"";"None";"319.37";"0";"2.72";"BDBM185499";"C[C@H]1COCCN1c1ncnc2[nH]cc(-c3cccc(C#N)c3)c12";"IC50";"'='";"44.0";"nM";"7.36";"";"334473";"UO_0000065";"23.03";"0.42";"4.64";"9.45";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3910711";"";"None";"337.36";"0";"2.78";"BDBM185500";"Cc1nc(N2CCOCC2)c2c(-c3cccc(C#N)c3F)c[nH]c2n1";"IC50";"'='";"30.0";"nM";"7.52";"";"334474";"UO_0000065";"22.30";"0.41";"4.74";"9.67";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3930716";"";"None";"339.35";"0";"3.57";"BDBM185504";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCC(F)CC4)c23)c1F";"IC50";"'='";"18.0";"nM";"7.75";"";"334478";"UO_0000065";"22.82";"0.42";"4.17";"11.29";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3930005";"";"None";"333.40";"0";"3.01";"BDBM185377";"[C-]#[N+]C1CCCN(c2ncnc3[nH]cc(-c4cccc(CO)c4)c23)C1";"IC50";"'='";"56.0";"nM";"7.25";"";"334339";"UO_0000065";"21.75";"0.40";"4.24";"10.45";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3898825";"";"None";"432.51";"0";"1.13";"BDBM239284";"COCCOc1ccc2[nH]nc(-c3cc(N4CCN(S(C)(=O)=O)CC4)ncn3)c2c1";"IC50";"'='";"64.73";"nM";"7.19";"";"417743";"UO_0000065";"16.62";"0.33";"6.06";"6.33";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4578462";"";"None";"228.26";"0";"1.74";"6";"Cc1n[nH]c2ccnc(Nc3cnn(C)c3)c12";"IC50";"'='";"830.0";"nM";"6.08";"";"";"UO_0000065";"26.64";"0.49";"4.34";"8.51";"0";"CHEMBL4331900";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant catalytic domain (970 to 2527 residues) expressed in baculovirus expression system by radiometric assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330096";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4565959";"";"None";"204.28";"0";"2.48";"16";"CC[C@H](C)Nc1nccc2[nH]nc(C)c12";"IC50";"'='";"300.0";"nM";"6.52";"";"";"UO_0000065";"31.93";"0.59";"4.04";"12.17";"0";"CHEMBL4331900";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant catalytic domain (970 to 2527 residues) expressed in baculovirus expression system by radiometric assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330096";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4097465";"";"None";"373.21";"0";"4.27";"7k";"O=C(Nc1ncco1)c1cc(Br)ccc1OCc1ccccc1";"IC50";"'='";"2511.89";"nM";"5.60";"";"";"UO_0000065";"15.00";"0.33";"1.33";"8.70";"0";"CHEMBL4058537";"Inhibition of LRRK2 (unknown origin) by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4052807";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL4089737";"";"None";"322.34";"0";"4.05";"8a";"O=C(Nc1cccnc1)c1cc(F)ccc1OCc1ccccc1";"IC50";"'='";"39.81";"nM";"7.40";"";"";"UO_0000065";"22.96";"0.42";"3.35";"14.45";"0";"CHEMBL4058537";"Inhibition of LRRK2 (unknown origin) by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4052807";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL4098650";"";"None";"384.44";"0";"4.31";"8k";"Cn1cc(-c2ccc(OCc3ccccc3)c(C(=O)Nc3cccnc3)c2)cn1";"IC50";"'='";"7.943";"nM";"8.10";"";"";"UO_0000065";"21.07";"0.38";"3.79";"11.73";"0";"CHEMBL4058537";"Inhibition of LRRK2 (unknown origin) by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4052807";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL4072195";"";"None";"388.40";"0";"4.44";"8m";"O=C(Nc1cccnc1)c1cc(-c2cn[nH]c2)ccc1OCc1ccc(F)cc1";"IC50";"'='";"10.0";"nM";"8.00";"";"";"UO_0000065";"20.60";"0.38";"3.56";"10.01";"0";"CHEMBL4058537";"Inhibition of LRRK2 (unknown origin) by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4052807";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL3896115";"";"None";"234.26";"0";"2.68";"21";"N#Cc1c[nH]c2nc(N)cc(-c3ccccc3)c12";"IC50";"'='";"140.0";"nM";"6.85";"";"";"UO_0000065";"29.26";"0.52";"4.17";"8.73";"0";"CHEMBL4031820";"Inhibition of wild type recombinant human GST-tagged LRRK2 (970 to 2527 residues) expressed in baculovirus using fluorescein-LRRKtide as substrate after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4063115";"";"None";"329.37";"0";"3.28";"27";"Cc1cc(-c2cc(Nc3ccn(C)n3)nc3[nH]cc(C#N)c23)ccn1";"IC50";"'='";"102.0";"nM";"6.99";"";"";"UO_0000065";"21.23";"0.38";"3.71";"7.34";"0";"CHEMBL4031820";"Inhibition of wild type recombinant human GST-tagged LRRK2 (970 to 2527 residues) expressed in baculovirus using fluorescein-LRRKtide as substrate after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4084769";"";"None";"329.37";"0";"3.28";"28";"Cc1cccc(-c2cc(Nc3ccn(C)n3)nc3[nH]cc(C#N)c23)n1";"IC50";"'='";"28.0";"nM";"7.55";"";"";"UO_0000065";"22.93";"0.41";"4.27";"7.93";"0";"CHEMBL4031820";"Inhibition of wild type recombinant human GST-tagged LRRK2 (970 to 2527 residues) expressed in baculovirus using fluorescein-LRRKtide as substrate after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL3919862";"";"None";"343.39";"0";"3.59";"30";"Cc1cc(-c2cc(Nc3nn(C)cc3C)nc3[nH]cc(C#N)c23)ccn1";"IC50";"'='";"215.0";"nM";"6.67";"";"";"UO_0000065";"19.42";"0.35";"3.08";"7.00";"1";"CHEMBL4031820";"Inhibition of wild type recombinant human GST-tagged LRRK2 (970 to 2527 residues) expressed in baculovirus using fluorescein-LRRKtide as substrate after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4065198";"";"None";"329.37";"0";"3.28";"25";"Cc1ccnc(-c2cc(Nc3ccn(C)n3)nc3[nH]cc(C#N)c23)c1";"IC50";"'='";"324.0";"nM";"6.49";"";"";"UO_0000065";"19.70";"0.35";"3.21";"6.82";"0";"CHEMBL4031821";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus using fluorescein-LRRKtide as substrate after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4063115";"";"None";"329.37";"0";"3.28";"27";"Cc1cc(-c2cc(Nc3ccn(C)n3)nc3[nH]cc(C#N)c23)ccn1";"IC50";"'='";"55.0";"nM";"7.26";"";"";"UO_0000065";"22.04";"0.40";"3.98";"7.62";"0";"CHEMBL4031821";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus using fluorescein-LRRKtide as substrate after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL3919862";"";"None";"343.39";"0";"3.59";"30";"Cc1cc(-c2cc(Nc3nn(C)cc3C)nc3[nH]cc(C#N)c23)ccn1";"IC50";"'='";"108.0";"nM";"6.97";"";"";"UO_0000065";"20.29";"0.37";"3.38";"7.32";"1";"CHEMBL4031821";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus using fluorescein-LRRKtide as substrate after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4084769";"";"None";"329.37";"0";"3.28";"28";"Cc1cccc(-c2cc(Nc3ccn(C)n3)nc3[nH]cc(C#N)c23)n1";"IC50";"'='";"76.0";"nM";"7.12";"";"";"UO_0000065";"21.61";"0.39";"3.84";"7.48";"0";"CHEMBL4031825";"Inhibition of human wild type LRRK2 phosphorylation at ser935 expressed in BacMam transduced HEK293 cells after 48 hrs by in-cell Western assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"CHEMBL3307715";"";"";""
"CHEMBL3919862";"";"None";"343.39";"0";"3.59";"30";"Cc1cc(-c2cc(Nc3nn(C)cc3C)nc3[nH]cc(C#N)c23)ccn1";"IC50";"'='";"580.0";"nM";"6.24";"";"";"UO_0000065";"18.16";"0.33";"2.65";"6.55";"0";"CHEMBL4031825";"Inhibition of human wild type LRRK2 phosphorylation at ser935 expressed in BacMam transduced HEK293 cells after 48 hrs by in-cell Western assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"CHEMBL3307715";"";"";""
"CHEMBL3961632";"";"None";"248.29";"0";"2.99";"22";"Cc1cccc(-c2cc(N)nc3[nH]cc(C#N)c23)c1";"IC50";"'='";"70.0";"nM";"7.16";"";"";"UO_0000065";"28.82";"0.51";"4.16";"9.12";"0";"CHEMBL4031826";"Inhibition of human LRRK2 G2019S mutant phosphorylation at ser935 expressed in BacMam transduced HEK293 cells after 48 hrs by in-cell Western assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"CHEMBL3307715";"";"";""
"CHEMBL2204495";"";"None";"399.43";"1";"5.11";"2";"O=C(Nc1cccnc1)c1cc(-c2ccnc(F)c2)ccc1OCc1ccccc1";"IC50";"'='";"10.9";"nM";"7.96";"";"";"UO_0000065";"";"";"";"";"1";"CHEMBL4018177";"Inhibition of full length wild-type LRRK2 (unknown origin) using biotinylated ezrin/radaxin/meosin peptide as substrate measured after 1 hr";"A";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4017473";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL4462258";"";"None";"190.25";"0";"2.09";"14";"Cc1n[nH]c2ccnc(NC(C)C)c12";"IC50";"'='";"880.0";"nM";"6.06";"";"";"UO_0000065";"31.83";"0.59";"3.97";"11.30";"0";"CHEMBL4331900";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant catalytic domain (970 to 2527 residues) expressed in baculovirus expression system by radiometric assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330096";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL3651817";"";"None";"232.29";"0";"1.86";"17";"Cc1[nH]nc2ccnc(NC3CCOCC3)c12";"IC50";"'='";"190.0";"nM";"6.72";"";"";"UO_0000065";"28.93";"0.54";"4.86";"10.70";"0";"CHEMBL4331900";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant catalytic domain (970 to 2527 residues) expressed in baculovirus expression system by radiometric assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330096";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4744172";"";"None";"404.76";"0";"3.63";"20";"O=C(Nc1c[nH]nc1-c1cc(Cl)ccc1OC(F)F)c1cnn2cccnc12";"IC50";"'='";"18.0";"nM";"7.75";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL4666938";"Inhibition of recombinant human GST-tagged LRRK2 (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate incubated for 60 mins by Adapta assay";"A";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4665643";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL4760344";"";"None";"425.49";"0";"3.36";"17";"CCOc1nc(Nc2ccc(C(=O)N3C[C@@H](C)O[C@@H](C)C3)cc2OC)nc2[nH]ccc12";"IC50";"'='";"63.1";"nM";"7.20";"";"";"UO_0000065";"16.92";"0.32";"3.84";"7.09";"0";"CHEMBL4721243";"Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs in presence of ATP by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4715821";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2018";"None";"TIME = 2.5 hr";"INHIBITOR";""
"CHEMBL4753216";"";"None";"438.53";"0";"3.28";"10";"CCOc1nc(Nc2ccc(C(=O)N3CCN(C)CC3)cc2OC(C)C)nc2[nH]ccc12";"IC50";"'='";"10.0";"nM";"8.00";"";"";"UO_0000065";"18.24";"0.34";"4.72";"8.37";"0";"CHEMBL4721243";"Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs in presence of ATP by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4715821";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2018";"None";"TIME = 2.5 hr";"INHIBITOR";""
"CHEMBL4784513";"";"None";"398.44";"0";"2.63";"4";"CCOc1nc(Nc2ccc(C(=O)N3CCN(C)CC3)cc2F)nc2[nH]ccc12";"IC50";"'='";"12.59";"nM";"7.90";"";"";"UO_0000065";"19.83";"0.37";"5.27";"9.15";"0";"CHEMBL4721243";"Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs in presence of ATP by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4715821";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2018";"None";"TIME = 2.5 hr";"INHIBITOR";""
"CHEMBL2436980";"";"None";"399.45";"1";"5.40";"8";"COc1cc(-c2cnc3[nH]cc(-c4ccc5[nH]ccc5c4)c3c2)cc(OC)c1OC";"IC50";"'='";"35.0";"nM";"7.46";"";"";"UO_0000065";"18.67";"0.34";"2.06";"10.33";"0";"CHEMBL2439119";"Inhibition of human wild type LRRK2 by qPCR analysis";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2434948";"1";"Scientific Literature";"J Med Chem";"2013";"None";"";"";""
"CHEMBL3978722";"";"None";"392.51";"0";"3.04";"44";"CC(C)n1cc(-c2cc(-c3ccc(CCN4CCOCC4)cc3)cnc2N)nn1";"IC50";"'='";"340.0";"nM";"6.47";"";"";"UO_0000065";"16.48";"0.30";"3.43";"7.88";"1";"CHEMBL4045603";"Inhibition of recombinant human LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus preincubated for 30 mins followed by fluorescein-LRRKtide substrate addition after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4043168";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL3971067";"";"None";"378.48";"0";"3.00";"45";"CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)cc3)cnc2N)nn1";"IC50";"'='";"160.0";"nM";"6.80";"";"";"UO_0000065";"17.96";"0.33";"3.80";"8.28";"1";"CHEMBL4045603";"Inhibition of recombinant human LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus preincubated for 30 mins followed by fluorescein-LRRKtide substrate addition after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4043168";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL3919901";"";"None";"377.45";"0";"3.09";"BDBM223546";"Nc1ncc(-c2ccc(CN3CCOCC3)cc2)cc1-c1nnc(C2CC2)o1";"IC50";"'='";"390.0";"nM";"6.41";"";"390802";"UO_0000065";"16.98";"0.31";"3.32";"7.10";"0";"CHEMBL3888345";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3949980";"";"None";"332.41";"0";"3.66";"BDBM223549";"CC(C)n1cc(-c2cc(-c3ccc4c(ccn4C)c3)cnc2N)nn1";"IC50";"'='";"540.0";"nM";"6.27";"";"390805";"UO_0000065";"18.86";"0.34";"2.61";"8.41";"0";"CHEMBL3888345";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3326123";"";"None";"382.45";"0";"2.62";"10";"COc1ccc(OC)c(Sc2ccc3nnc(Cc4cnn(C)c4)n3n2)c1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL3367451";"Inhibition of phosphorylation at S935 residue of wild-type full-length LRRK2 kinase (unknown origin) expressed in HEK 293 cells after 90 mins by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"CHEMBL3307715";"";"";""
"CHEMBL3921258";"";"None";"364.45";"0";"3.01";"BDBM223553";"CC(C)n1cc(-c2cc(-c3ccc(N4CCOCC4)cc3)cnc2N)nn1";"IC50";"'='";"340.0";"nM";"6.47";"";"390838";"UO_0000065";"17.75";"0.33";"3.46";"7.88";"0";"CHEMBL3888346";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3945284";"";"None";"422.49";"0";"2.65";"BDBM223557";"COc1cc(-c2cnc(N)c(-c3cn(C(C)C)nn3)c2)ccc1C(=O)N1CCOCC1";"IC50";"'='";"91.0";"nM";"7.04";"";"390842";"UO_0000065";"16.67";"0.31";"4.39";"6.50";"0";"CHEMBL3888346";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3326122";"";"None";"371.47";"0";"2.71";"9";"COc1ccc(OC)c(Sc2ccc3nnc(C4CCN(C)C4)n3n2)c1";"IC50";"'='";"12600.0";"nM";"4.90";"";"";"UO_0000065";"13.19";"0.26";"2.19";"7.56";"0";"CHEMBL3367450";"Inhibition of GST-tagged truncated LRRK2 (unknown origin) using fluorescein-labeled peptide LRRKtide as substrate by LANTHA screen assay in presence of 1 mM ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL4446540";"";"None";"244.34";"0";"3.04";"10";"Cc1n[nH]c2ccnc(N(C)C3CCCCC3)c12";"IC50";"'='";"1600.0";"nM";"5.80";"";"";"UO_0000065";"23.72";"0.44";"2.76";"12.93";"0";"CHEMBL4331900";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant catalytic domain (970 to 2527 residues) expressed in baculovirus expression system by radiometric assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330096";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4071631";"";"None";"402.43";"0";"4.45";"8l";"Cn1cc(-c2ccc(OCc3ccc(F)cc3)c(C(=O)Nc3cccnc3)c2)cn1";"IC50";"'='";"10.0";"nM";"8.00";"";"";"UO_0000065";"19.88";"0.36";"3.55";"11.59";"0";"CHEMBL4058537";"Inhibition of LRRK2 (unknown origin) by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4052807";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL3950567";"";"None";"335.42";"0";"2.56";"BDBM223551";"CC(C)n1cc(-c2nc(-c3ccc4c(c3)CCN4C)cnc2N)nn1";"IC50";"'='";"340.0";"nM";"6.47";"";"390807";"UO_0000065";"19.28";"0.35";"3.91";"7.54";"0";"CHEMBL3888345";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3921258";"";"None";"364.45";"0";"3.01";"BDBM223553";"CC(C)n1cc(-c2cc(-c3ccc(N4CCOCC4)cc3)cnc2N)nn1";"IC50";"'='";"280.0";"nM";"6.55";"";"390809";"UO_0000065";"17.98";"0.33";"3.54";"7.98";"0";"CHEMBL3888345";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3964094";"";"None";"412.93";"0";"3.66";"BDBM223563";"CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)c(Cl)c3)cnc2N)nn1";"IC50";"'='";"220.0";"nM";"6.66";"";"390819";"UO_0000065";"16.12";"0.31";"3.00";"8.11";"0";"CHEMBL3888345";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3919227";"";"None";"378.48";"0";"3.00";"BDBM223564";"CC(C)n1cc(-c2cc(-c3cccc(CN4CCOCC4)c3)cnc2N)nn1";"IC50";"'='";"500.0";"nM";"6.30";"";"390820";"UO_0000065";"16.65";"0.31";"3.30";"7.68";"0";"CHEMBL3888345";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3903650";"";"None";"412.93";"0";"3.66";"BDBM223567";"CC(C)n1cc(-c2cc(-c3cc(Cl)cc(CN4CCOCC4)c3)cnc2N)nn1";"IC50";"'='";"760.0";"nM";"6.12";"";"390823";"UO_0000065";"14.82";"0.29";"2.46";"7.45";"0";"CHEMBL3888345";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3938306";"";"None";"392.46";"0";"2.64";"BDBM223568";"CC(C)n1cc(-c2cc(-c3ccc(C(=O)N4CCOCC4)cc3)cnc2N)nn1";"IC50";"'='";"430.0";"nM";"6.37";"";"390824";"UO_0000065";"16.22";"0.30";"3.73";"6.42";"0";"CHEMBL3888345";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3959735";"";"None";"349.44";"0";"3.50";"BDBM223544";"Cc1ccc(-c2cnc(N)c(-c3nnc(C4CCN(C)CC4)o3)c2)cc1";"IC50";"'='";"3600.0";"nM";"5.44";"";"390829";"UO_0000065";"15.58";"0.29";"1.94";"6.71";"0";"CHEMBL3888346";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3951135";"";"None";"351.41";"0";"2.86";"BDBM223547";"COc1cccc(-c2cnc(N)c(-c3nnc(C4CCNCC4)o3)c2)c1";"IC50";"'='";"3300.0";"nM";"5.48";"";"390832";"UO_0000065";"15.60";"0.29";"2.62";"5.53";"0";"CHEMBL3888346";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3950567";"";"None";"335.42";"0";"2.56";"BDBM223551";"CC(C)n1cc(-c2nc(-c3ccc4c(c3)CCN4C)cnc2N)nn1";"IC50";"'='";"570.0";"nM";"6.24";"";"390836";"UO_0000065";"18.62";"0.34";"3.68";"7.28";"0";"CHEMBL3888346";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4111923";"";"None";"353.43";"0";"3.03";"BDBM239083";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCO[C@H](C)C4)ncn3)c2c1";"IC50";"'='";"9.2";"nM";"8.04";"";"417793";"UO_0000065";"22.74";"0.42";"5.01";"10.55";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3955813";"";"None";"393.43";"0";"2.38";"BDBM239368";"Cn1cc(-c2cc3c(-c4cc(N5CC[C@H](CO)C5)ncn4)n[nH]c3cc2F)cn1";"IC50";"'='";"37.0";"nM";"7.43";"";"417835";"UO_0000065";"18.89";"0.35";"5.05";"7.76";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3904679";"";"None";"401.47";"0";"3.18";"BDBM239406";"Cn1cc(-c2ccc3[nH]nc(-c4cc(N5CCCC6(CCO6)C5)ncn4)c3c2)cn1";"IC50";"'='";"10.9";"nM";"7.96";"";"417872";"UO_0000065";"19.83";"0.36";"4.78";"9.40";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3983531";"";"None";"410.45";"0";"2.78";"BDBM223556";"CC(C)n1cc(-c2cc(-c3ccc(C(=O)N4CCOCC4)c(F)c3)cnc2N)nn1";"IC50";"'='";"510.0";"nM";"6.29";"";"390812";"UO_0000065";"15.33";"0.29";"3.51";"6.35";"0";"CHEMBL3888345";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3969077";"";"None";"328.38";"0";"3.89";"BDBM254931";"Cc1cccc(-c2cc(Nc3ccn(C)n3)nc3[nH]cc(C#N)c23)c1";"IC50";"'='";"1.0";"nM";"9.00";"";"443737";"UO_0000065";"27.41";"0.49";"5.11";"10.93";"0";"CHEMBL3889253";"Homogeneous Time Resolved-fluorescence Resonance Energy Transfer (TR-FRET) Assay: LRRK2 kinase activity is measured using a LanthaScreen kinase activity assay available from Invitrogen (Life Technologies Corporation). The assay is a homogeneous time resolved-fluorescence resonance energy transfer (TR-FRET) assay that measures phosphorylation of a fluorescein-labelled peptide substrate (fluorescein-LRRKtide, fluorescein-GAGRLGRDKYKTLRQIRQ) (SEQ ID NO 1) as a result of LRRK2 kinase activity. The phosphorylated peptide is recognized by a terbium-labelled phospho-specific anti-LRRKtide antibody and, subsequently, the phosphorylated LRRKtide can be quantified by the extent of TR-FRET between the terbium donor and fluorescein acceptor.The LRRK2 kinase is obtained from Invitrogen (Life Technologies Corporation) and comprises residues 970 to 2527 of the full length human wild-type LRRK2 kinase or a similar sequence with the G2019S mutation. As discussed above, this mutation increases the kinase activity relative to the wild-type. The kinase reactions are performed in a 20 uL volume in 384-well plates. The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT.Â  In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 uM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 uM fluorescein-LRRKtide. The reaction mixture (20 ul total volume) is incubated for 2 hours at 30° C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 ul). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 us) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 us. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 us time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3887011";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4114347";"";"None";"397.48";"0";"3.05";"BDBM239298";"COC[C@@H](C)Oc1ccc2[nH]nc(-c3cc(N4C[C@@H](C)O[C@@H](C)C4)ncn3)c2c1";"IC50";"'='";"39.12";"nM";"7.41";"";"417757";"UO_0000065";"18.64";"0.35";"4.36";"8.68";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3912556";"";"None";"397.48";"0";"3.05";"BDBM239300";"COC[C@H](C)Oc1ccc2[nH]nc(-c3cc(N4C[C@@H](C)O[C@@H](C)C4)ncn3)c2c1";"IC50";"'='";"1.7";"nM";"8.77";"";"417760";"UO_0000065";"22.06";"0.41";"5.72";"10.27";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3930335";"";"None";"450.54";"0";"2.88";"BDBM239305";"COC[C@H](C)Oc1ccc2[nH]nc(-c3cc(N4CCC5(CC4)CC(=O)N(C)C5)ncn3)c2c1";"IC50";"'='";"2.87";"nM";"8.54";"";"417765";"UO_0000065";"18.96";"0.35";"5.66";"8.85";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3971726";"";"None";"383.45";"0";"2.66";"BDBM239307";"COC[C@H](C)Oc1ccc2[nH]nc(-c3cc(N4CC[C@@H](OC)C4)ncn3)c2c1";"IC50";"'='";"4.8";"nM";"8.32";"";"417767";"UO_0000065";"21.69";"0.41";"5.66";"9.74";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3900243";"";"None";"353.43";"0";"2.77";"BDBM239317";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCC(O)CC4)ncn3)c2c1";"IC50";"'='";"5.9";"nM";"8.23";"";"417785";"UO_0000065";"23.28";"0.43";"5.46";"9.44";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3931365";"";"None";"369.43";"0";"2.00";"BDBM239192";"CO[C@H]1CN(c2cc(-c3n[nH]c4ccc(OC(C)C)cc34)ncn2)C[C@@H]1O";"IC50";"'='";"18.6";"nM";"7.73";"";"417792";"UO_0000065";"20.93";"0.39";"5.73";"8.02";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3972965";"";"None";"404.48";"0";"2.98";"BDBM239334";"CCc1nnc2n1CCN(c1cc(-c3n[nH]c4ccc(OC(C)C)cc34)ncn1)C2";"IC50";"'='";"8.6";"nM";"8.07";"";"417803";"UO_0000065";"19.94";"0.37";"5.09";"8.26";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3926035";"";"None";"414.49";"0";"2.45";"BDBM239442";"CC(C)Oc1cc2c(-c3cc(N4CCN(CCCO)CC4)ncn3)n[nH]c2cc1F";"IC50";"'='";"3.1";"nM";"8.51";"";"417908";"UO_0000065";"20.53";"0.39";"6.06";"9.41";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3979339";"";"None";"361.41";"0";"2.26";"BDBM239481";"Cn1nccc1-c1ccc2[nH]nc(-c3cc(N4CCOCC4)ncn3)c2c1";"IC50";"'='";"45.7";"nM";"7.34";"";"417946";"UO_0000065";"20.31";"0.37";"5.08";"8.66";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3890072";"";"None";"363.47";"0";"4.06";"BDBM239512";"CC(C)=Cc1ccc2[nH]nc(-c3cc(N4C[C@@H](C)O[C@@H](C)C4)ncn3)c2c1";"IC50";"'='";"20.3";"nM";"7.69";"";"417976";"UO_0000065";"21.16";"0.39";"3.63";"11.49";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4107421";"";"None";"389.46";"0";"3.25";"BDBM239545";"Cc1n[nH]c(C)c1-c1ccc2[nH]nc(-c3cc(N4CCO[C@H](C)C4)ncn3)c2c1";"IC50";"'='";"3.2";"nM";"8.49";"";"418008";"UO_0000065";"21.81";"0.40";"5.24";"8.88";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3948671";"";"None";"365.44";"0";"3.17";"BDBM239197";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CC5CCC(C4)O5)ncn3)c2c1";"IC50";"'='";"29.2";"nM";"7.54";"";"417657";"UO_0000065";"20.62";"0.38";"4.36";"9.89";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4092537";"";"None";"253.69";"0";"3.75";"14";"N#Cc1c[nH]c2nccc(-c3ccccc3Cl)c12";"IC50";"'='";"7531.0";"nM";"5.12";"";"";"UO_0000065";"20.19";"0.39";"1.37";"9.76";"0";"CHEMBL4031820";"Inhibition of wild type recombinant human GST-tagged LRRK2 (970 to 2527 residues) expressed in baculovirus using fluorescein-LRRKtide as substrate after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4075970";"";"None";"143.15";"0";"1.43";"10";"N#Cc1c[nH]c2ncccc12";"IC50";"'='";"46522.0";"nM";"4.33";"";"";"UO_0000065";"30.26";"0.54";"2.90";"8.26";"0";"CHEMBL4031821";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus using fluorescein-LRRKtide as substrate after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL3938243";"";"None";"429.53";"0";"3.62";"BDBM239539";"COc1ccncc1-c1ccc2[nH]nc(-c3cc(N4CCN(C(C)C)CC4)ncn3)c2c1";"IC50";"'='";"1.26";"nM";"8.90";"";"418002";"UO_0000065";"20.72";"0.38";"5.28";"10.71";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4063115";"";"None";"329.37";"0";"3.28";"27";"Cc1cc(-c2cc(Nc3ccn(C)n3)nc3[nH]cc(C#N)c23)ccn1";"IC50";"'='";"700.0";"nM";"6.16";"";"";"UO_0000065";"18.69";"0.34";"2.87";"6.46";"0";"CHEMBL4031825";"Inhibition of human wild type LRRK2 phosphorylation at ser935 expressed in BacMam transduced HEK293 cells after 48 hrs by in-cell Western assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"CHEMBL3307715";"";"";""
"CHEMBL3939513";"";"None";"314.35";"0";"3.58";"24";"Cn1ccc(Nc2cc(-c3ccccc3)c3c(C#N)c[nH]c3n2)n1";"IC50";"'='";"100.0";"nM";"7.00";"";"";"UO_0000065";"22.27";"0.40";"3.42";"8.50";"0";"CHEMBL4031826";"Inhibition of human LRRK2 G2019S mutant phosphorylation at ser935 expressed in BacMam transduced HEK293 cells after 48 hrs by in-cell Western assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"CHEMBL3307715";"";"";""
"CHEMBL3919862";"";"None";"343.39";"0";"3.59";"30";"Cc1cc(-c2cc(Nc3nn(C)cc3C)nc3[nH]cc(C#N)c23)ccn1";"IC50";"'='";"210.0";"nM";"6.68";"";"";"UO_0000065";"19.45";"0.35";"3.09";"7.01";"0";"CHEMBL4031826";"Inhibition of human LRRK2 G2019S mutant phosphorylation at ser935 expressed in BacMam transduced HEK293 cells after 48 hrs by in-cell Western assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"CHEMBL3307715";"";"";""
"CHEMBL3916001";"";"None";"388.45";"0";"3.15";"BDBM234869";"CCS(=O)(=O)Nc1cccc(Nc2ncnc3cc(OC)c(OC)cc23)c1";"IC50";"'='";"334.0";"nM";"6.48";"";"409344";"UO_0000065";"16.67";"0.33";"3.33";"6.32";"0";"CHEMBL3888566";"In vitro Kinase Assay: In vitro kinase assays using LRRK WT and LRRK G2019S.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886763";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3978722";"";"None";"392.51";"0";"3.04";"BDBM223554";"CC(C)n1cc(-c2cc(-c3ccc(CCN4CCOCC4)cc3)cnc2N)nn1";"IC50";"'='";"340.0";"nM";"6.47";"";"390810";"UO_0000065";"16.48";"0.30";"3.43";"7.88";"0";"CHEMBL3888345";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3895380";"";"None";"376.42";"0";"2.46";"BDBM239338";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CC(n5cnnc5)C4)ncn3)c2c1";"IC50";"'='";"20.1";"nM";"7.70";"";"417807";"UO_0000065";"20.45";"0.38";"5.24";"7.88";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4112183";"";"None";"341.39";"0";"3.36";"BDBM239340";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CC[C@@H](F)C4)ncn3)c2c1";"IC50";"'='";"8.7";"nM";"8.06";"";"417809";"UO_0000065";"23.61";"0.44";"4.70";"12.04";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3956871";"";"None";"416.49";"0";"2.92";"BDBM239349";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCN(c5ncccn5)CC4)ncn3)c2c1";"IC50";"'='";"11.8";"nM";"7.93";"";"417817";"UO_0000065";"19.04";"0.35";"5.01";"8.26";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3951760";"";"None";"395.51";"0";"3.79";"BDBM239359";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCC(C(C)(C)O)CC4)ncn3)c2c1";"IC50";"'='";"5.4";"nM";"8.27";"";"417827";"UO_0000065";"20.90";"0.39";"4.48";"9.49";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3961170";"";"None";"427.45";"0";"2.91";"BDBM239389";"Cn1cc(-c2cc3c(-c4cc(N5CCc6nccnc6C5)ncn4)n[nH]c3cc2F)cn1";"IC50";"'='";"11.1";"nM";"7.96";"";"417856";"UO_0000065";"18.61";"0.34";"5.04";"7.85";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4110232";"";"None";"375.44";"0";"2.65";"BDBM239399";"C[C@@H]1CN(c2cc(-c3n[nH]c4ccc(-c5cnn(C)c5)cc34)ncn2)CCO1";"IC50";"'='";"1.9";"nM";"8.72";"";"417865";"UO_0000065";"23.23";"0.43";"6.07";"10.29";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3902073";"";"None";"375.44";"0";"2.65";"BDBM239400";"CO[C@H]1CCN(c2cc(-c3n[nH]c4ccc(-c5cnn(C)c5)cc34)ncn2)C1";"IC50";"'='";"2.6";"nM";"8.59";"";"417866";"UO_0000065";"22.87";"0.42";"5.94";"10.13";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4113347";"";"None";"385.44";"0";"3.56";"BDBM239443";"CC(C)Oc1cc2c(-c3cc(N4[C@H](C)COC[C@H]4C)ncn3)n[nH]c2cc1F";"IC50";"'='";"62.1";"nM";"7.21";"";"417909";"UO_0000065";"18.70";"0.35";"3.65";"9.46";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3940460";"";"None";"406.45";"0";"2.05";"BDBM239446";"COC[C@H](C)Oc1ccc2[nH]nc(-c3cc(N4CCn5ncnc5C4)ncn3)c2c1";"IC50";"'='";"20.2";"nM";"7.70";"";"417911";"UO_0000065";"18.93";"0.35";"5.64";"7.20";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3920769";"";"None";"413.48";"0";"2.29";"BDBM239458";"COCC1CN(c2cc(-c3n[nH]c4ccc(O[C@@H](C)COC)cc34)ncn2)CCO1";"IC50";"'='";"3.6";"nM";"8.44";"";"417923";"UO_0000065";"20.42";"0.38";"6.15";"8.92";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3951097";"";"None";"397.48";"0";"3.05";"BDBM239463";"COC[C@H](C)Oc1ccc2[nH]nc(-c3cc(N4CCOC(C)(C)C4)ncn3)c2c1";"IC50";"'='";"5.3";"nM";"8.28";"";"417928";"UO_0000065";"20.82";"0.39";"5.23";"9.69";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3931569";"";"None";"404.54";"0";"4.28";"BDBM239537";"CC(C)N1CCN(c2cc(-c3n[nH]c4ccc(-c5cccs5)cc34)ncn2)CC1";"IC50";"'='";"61.5";"nM";"7.21";"";"418000";"UO_0000065";"17.83";"0.34";"2.93";"11.83";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3967800";"";"None";"388.48";"0";"3.81";"BDBM239538";"CC(C)N1CCN(c2cc(-c3n[nH]c4ccc(-c5ccoc5)cc34)ncn2)CC1";"IC50";"'='";"9.03";"nM";"8.04";"";"418001";"UO_0000065";"20.71";"0.38";"4.23";"10.86";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3977482";"";"None";"365.44";"0";"3.18";"BDBM239200";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCOC5(CC5)C4)ncn3)c2c1";"IC50";"'='";"4.04";"nM";"8.39";"";"417661";"UO_0000065";"22.97";"0.42";"5.21";"11.02";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3921447";"";"None";"380.50";"0";"3.34";"BDBM239204";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCN(C(C)C)CC4)ncn3)c2c1";"IC50";"'='";"7.68";"nM";"8.12";"";"417665";"UO_0000065";"21.33";"0.40";"4.77";"11.56";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3982282";"";"None";"341.42";"0";"2.89";"BDBM239206";"COCCN(C)c1cc(-c2n[nH]c3ccc(OC(C)C)cc23)ncn1";"IC50";"'='";"66.54";"nM";"7.18";"";"417667";"UO_0000065";"21.02";"0.39";"4.29";"9.42";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3932899";"";"None";"442.55";"0";"2.42";"BDBM239210";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCN(S(=O)(=O)C5CC5)CC4)ncn3)c2c1";"IC50";"'='";"5.51";"nM";"8.26";"";"417671";"UO_0000065";"18.66";"0.36";"5.84";"7.92";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3961632";"";"None";"248.29";"0";"2.99";"22";"Cc1cccc(-c2cc(N)nc3[nH]cc(C#N)c23)c1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL4031827";"Inhibition of human LRRK2 A2016T mutant phosphorylation at ser935 expressed in BacMam transduced HEK293 cells after 48 hrs by in-cell Western assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"A2016T";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4028875";"1";"Scientific Literature";"J Med Chem";"2017";"CHEMBL3307715";"";"";""
"CHEMBL4442441";"";"None";"330.39";"0";"4.46";"1";"Cc1cc(-c2ccc3nc(Nc4ccccc4)nn3c2)cc(C)c1O";"IC50";"'='";"20.0";"nM";"7.70";"";"";"UO_0000065";"23.30";"0.42";"3.24";"12.33";"0";"CHEMBL4403862";"Inhibition of wild type human GST-tagged LRRK2 (970 to 2527 residues) expressed in baculovirus expression system assessed as reduction in ADP formation using LRRKtide as substrate measured after 1 hr in presence of ATP by Adapta assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4402549";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL3928119";"";"None";"426.91";"0";"3.30";"BDBM223566";"CC(C)n1cc(-c2cc(-c3cc(Cl)cc(C(=O)N4CCOCC4)c3)cnc2N)nn1";"IC50";"'='";"690.0";"nM";"6.16";"";"390822";"UO_0000065";"14.43";"0.28";"2.86";"6.21";"0";"CHEMBL3888345";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3910377";"";"None";"377.45";"0";"3.09";"BDBM223569";"Nc1ncc(-c2cccc(CN3CCOCC3)c2)cc1-c1nnc(C2CC2)o1";"IC50";"'='";"760.0";"nM";"6.12";"";"390825";"UO_0000065";"16.21";"0.30";"3.03";"6.78";"0";"CHEMBL3888345";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4065244";"";"None";"384.23";"0";"4.07";"7a";"O=C(Nc1ccnnc1)c1cc(Br)ccc1OCc1ccccc1";"IC50";"'='";"19.95";"nM";"7.70";"";"";"UO_0000065";"20.04";"0.44";"3.63";"12.01";"0";"CHEMBL4058537";"Inhibition of LRRK2 (unknown origin) by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4052807";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL4105171";"";"None";"412.28";"1";"5.29";"7i";"COc1cccc(NC(=O)c2cc(Br)ccc2OCc2ccccc2)c1";"IC50";"'='";"125.89";"nM";"6.90";"";"";"UO_0000065";"16.74";"0.36";"1.61";"14.51";"0";"CHEMBL4058537";"Inhibition of LRRK2 (unknown origin) by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4052807";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL4082330";"";"None";"318.38";"0";"4.22";"8c";"Cc1ccc(OCc2ccccc2)c(C(=O)Nc2cccnc2)c1";"IC50";"'='";"12.59";"nM";"7.90";"";"";"UO_0000065";"24.81";"0.45";"3.68";"15.42";"0";"CHEMBL4058537";"Inhibition of LRRK2 (unknown origin) by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4052807";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL4101126";"";"None";"381.44";"0";"4.97";"8h";"O=C(Nc1cccnc1)c1cc(-c2ccncc2)ccc1OCc1ccccc1";"IC50";"'='";"10.0";"nM";"8.00";"";"";"UO_0000065";"20.97";"0.38";"3.03";"12.48";"0";"CHEMBL4058537";"Inhibition of LRRK2 (unknown origin) by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4052807";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL4291402";"";"None";"374.48";"0";"4.33";"44; GSK2646264";"COc1cccc(OCc2cc(C)ccn2)c1-c1ccc2c(c1)CCNCC2";"IC50";"'='";"3981.07";"nM";"5.40";"";"";"UO_0000065";"14.42";"0.26";"1.07";"12.45";"0";"CHEMBL4268696";"Inhibition of LRRK2 (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4265956";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2018";"None";"";"";""
"CHEMBL3393359";"";"None";"306.33";"0";"1.73";"BDBM50059314";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)n1";"IC50";"'='";"26.0";"nM";"7.58";"";"334533";"UO_0000065";"24.76";"0.45";"5.86";"8.36";"1";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3900115";"";"None";"332.41";"0";"3.74";"BDBM185404";"C[C@H]1CCCN(c2ncnc3[nH]cc(-c4cccc5[nH]ncc45)c23)C1";"IC50";"'='";"14.0";"nM";"7.85";"";"334579";"UO_0000065";"23.63";"0.43";"4.11";"10.69";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3967579";"";"None";"317.40";"0";"3.73";"BDBM185418";"CC1CCN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)CC1";"IC50";"'='";"273.0";"nM";"6.56";"";"334593";"UO_0000065";"20.68";"0.37";"2.83";"9.57";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3963473";"";"None";"336.40";"0";"3.56";"BDBM185419";"C[C@H]1CCCN(c2ncnc3[nH]cc(-c4cccc(C(=O)O)c4)c23)C1";"IC50";"'='";"39.0";"nM";"7.41";"";"334594";"UO_0000065";"22.02";"0.40";"3.85";"9.02";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3975452";"";"None";"361.45";"0";"3.99";"BDBM185421";"COc1ccc(C#N)cc1-c1c[nH]c2ncnc(N3C[C@H](C)C[C@H](C)C3)c12";"IC50";"'='";"176.0";"nM";"6.75";"";"334596";"UO_0000065";"18.69";"0.34";"2.76";"8.68";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3930716";"";"None";"339.35";"0";"3.57";"BDBM185504";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCC(F)CC4)c23)c1F";"IC50";"'='";"86.0";"nM";"7.07";"";"334689";"UO_0000065";"20.82";"0.39";"3.50";"10.30";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3901487";"";"None";"309.37";"0";"2.29";"BDBM185508";"Cc1cncc(-c2c[nH]c3ncnc(N4CCCC(O)C4)c23)c1";"IC50";"'='";"67.0";"nM";"7.17";"";"334692";"UO_0000065";"23.19";"0.43";"4.88";"9.21";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3925893";"";"None";"405.39";"0";"2.90";"BDBM185512";"Cc1noc(C2CN(c3ncnc4[nH]cc(-c5cccc(C#N)c5F)c34)CCO2)n1";"IC50";"'='";"272.0";"nM";"6.57";"";"334696";"UO_0000065";"16.20";"0.30";"3.67";"5.62";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3975129";"";"None";"307.33";"0";"3.24";"BDBM185530";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCCC4)c23)c1F";"IC50";"'='";"82.0";"nM";"7.09";"";"334710";"UO_0000065";"23.06";"0.42";"3.85";"10.33";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL4438748";"";"None";"457.49";"0";"4.13";"12j";"CN(C)c1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)cc1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL4379383";"Inhibition of recombinant human LRRK2 (970 to end residues) using RLGRDKYKTLRQI as substrate after 40 mins in presence of [gamma-33ATP] by radiometric scintillation counting analysis";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4376834";"1";"Scientific Literature";"J Med Chem";"2019";"None";"";"";""
"CHEMBL2348983";"";"None";"356.31";"0";"4.60";"50";"FC(F)(F)c1cccc(Oc2ccc3nnc(-c4ccccc4)n3n2)c1";"IC50";"'='";"1555.0";"nM";"5.81";"";"";"UO_0000065";"16.30";"0.31";"1.21";"11.10";"0";"CHEMBL2351468";"Inhibition of LRRK2 G2019S mutant (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2348979";"";"None";"392.43";"1";"5.33";"46";"Cc1cc2nnc(-c3cccs3)n2nc1Sc1cccc(C(F)(F)F)c1";"IC50";"'='";"2068.0";"nM";"5.68";"";"";"UO_0000065";"14.49";"0.30";"0.35";"13.20";"0";"CHEMBL2351468";"Inhibition of LRRK2 G2019S mutant (unknown origin) by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346543";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL4524629";"";"None";"231.30";"0";"2.98";"18";"Cc1n[nH]c2ccnc(OC3CCCCC3)c12";"IC50";"'='";"67.0";"nM";"7.17";"";"";"UO_0000065";"31.02";"0.58";"4.19";"14.12";"0";"CHEMBL4331900";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant catalytic domain (970 to 2527 residues) expressed in baculovirus expression system by radiometric assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330096";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4552576";"";"None";"177.21";"0";"1.67";"21";"CCOc1nccc2[nH]nc(C)c12";"IC50";"'='";"440.0";"nM";"6.36";"";"";"UO_0000065";"35.87";"0.67";"4.69";"12.51";"0";"CHEMBL4331900";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant catalytic domain (970 to 2527 residues) expressed in baculovirus expression system by radiometric assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330096";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4574890";"";"None";"191.23";"0";"2.05";"22";"Cc1n[nH]c2ccnc(OC(C)C)c12";"IC50";"'='";"68.0";"nM";"7.17";"";"";"UO_0000065";"37.48";"0.70";"5.12";"14.11";"0";"CHEMBL4331900";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant catalytic domain (970 to 2527 residues) expressed in baculovirus expression system by radiometric assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330096";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4549553";"";"None";"354.84";"0";"4.43";"1";"CCc1nc2cnc3ccc(Cl)cc3c2n1[C@@H]1CCO[C@H](CC#N)C1";"IC50";"'='";"8.7";"nM";"8.06";"";"";"UO_0000065";"22.72";"0.44";"3.63";"12.65";"0";"CHEMBL4334284";"Inhibition of GST-tagged LRRK2 G2019S mutant (unknown origin) expressed in baculovirus expression system using fluorescein-labeled LRRKtide as substrate after 30 mins by Lanthascreen assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330176";"1";"Scientific Literature";"ACS Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4444592";"";"None";"419.44";"0";"3.27";"20";"Cc1cnc(Cc2nc3cnc4ccc(C#N)cc4c3n2C2CN(C)CC2(F)F)cn1";"IC50";"'='";"3.31";"nM";"8.48";"";"";"UO_0000065";"20.22";"0.37";"5.21";"10.15";"0";"CHEMBL4334284";"Inhibition of GST-tagged LRRK2 G2019S mutant (unknown origin) expressed in baculovirus expression system using fluorescein-labeled LRRKtide as substrate after 30 mins by Lanthascreen assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330176";"1";"Scientific Literature";"ACS Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4113861";"";"None";"371.42";"0";"3.17";"BDBM239224";"CC(C)Oc1cc2c(-c3cc(N4CCO[C@H](C)C4)ncn3)n[nH]c2cc1F";"IC50";"'='";"2.87";"nM";"8.54";"";"417685";"UO_0000065";"23.00";"0.43";"5.37";"11.22";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4115404";"";"None";"338.42";"0";"2.34";"BDBM239227";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CC[C@@H](N)C4)ncn3)c2c1";"IC50";"'='";"8.78";"nM";"8.06";"";"417688";"UO_0000065";"23.81";"0.44";"5.72";"8.67";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3927721";"";"None";"384.46";"0";"3.09";"BDBM239230";"CCN1CCN(c2cc(-c3n[nH]c4cc(F)c(OC(C)C)cc34)ncn2)CC1";"IC50";"'='";"2.97";"nM";"8.53";"";"417691";"UO_0000065";"22.18";"0.42";"5.44";"12.15";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3921084";"";"None";"384.46";"0";"3.09";"BDBM239234";"CC(C)Oc1cc2c(-c3cc(N4CCN(C)[C@@H](C)C4)ncn3)n[nH]c2cc1F";"IC50";"'='";"1.2";"nM";"8.92";"";"417695";"UO_0000065";"23.20";"0.44";"5.83";"12.71";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3910578";"";"None";"356.41";"0";"2.48";"BDBM239243";"CC(C)Oc1cc2c(-c3cc(N4CC[C@H](N)C4)ncn3)n[nH]c2cc1F";"IC50";"'='";"10.4";"nM";"7.98";"";"417704";"UO_0000065";"22.40";"0.42";"5.50";"8.59";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3972366";"";"None";"389.46";"0";"3.03";"BDBM239489";"C[C@@H]1CN(c2cc(-c3n[nH]c4ccc(-c5ccnn5C)cc34)ncn2)C[C@H](C)O1";"IC50";"'='";"32.1";"nM";"7.49";"";"417954";"UO_0000065";"19.24";"0.35";"4.46";"8.84";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3921038";"";"None";"435.51";"0";"2.16";"BDBM239515";"CS(=O)(=O)N1CCN(c2cc(-c3n[nH]c4ccc(-c5cccnc5)cc34)ncn2)CC1";"IC50";"'='";"7.3";"nM";"8.14";"";"417979";"UO_0000065";"18.68";"0.36";"5.98";"7.54";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL1673040";"";"None";"460.54";"0";"3.55";"XMD9-19";"COc1cc(N2CCC(O)CC2)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2C";"IC50";"'='";"14.1";"nM";"7.85";"";"";"UO_0000065";"17.05";"0.32";"4.30";"8.35";"0";"CHEMBL4612965";"Inhibition of recombinant human GST-tagged LRRK2 catalytic domain (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate measured after 1 hr by Alexa fluor-647 ADP tracer-based ADAPTA assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4610122";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL4647792";"";"None";"570.70";"1";"3.44";"XMD11-50; LRRK2-IN-1";"COc1cc(C(=O)N2CCN(C3CCN(C)CC3)CC2)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2C";"IC50";"'='";"5.0";"nM";"8.30";"";"";"UO_0000065";"14.55";"0.27";"4.86";"8.52";"0";"CHEMBL4612965";"Inhibition of recombinant human GST-tagged LRRK2 catalytic domain (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate measured after 1 hr by Alexa fluor-647 ADP tracer-based ADAPTA assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4610122";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL4636072";"";"None";"499.62";"0";"4.26";"JWG-068";"COc1cc(N2CCN(C)CC2)ccc1Nc1ncc2c(n1)N(C1CCC1)c1ccccc1C(=O)N2C";"IC50";"'='";"97.0";"nM";"7.01";"";"";"UO_0000065";"14.04";"0.26";"2.75";"9.10";"0";"CHEMBL4612965";"Inhibition of recombinant human GST-tagged LRRK2 catalytic domain (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate measured after 1 hr by Alexa fluor-647 ADP tracer-based ADAPTA assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4610122";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL1673054";"";"None";"473.58";"0";"3.65";"XMD11-34";"COc1cc(N2CCN(C)CC2)ccc1Nc1ncc2c(n1)N(C)c1ccc(C)cc1C(=O)N2C";"IC50";"'='";"928.0";"nM";"6.03";"";"";"UO_0000065";"12.74";"0.24";"2.38";"7.83";"0";"CHEMBL4612965";"Inhibition of recombinant human GST-tagged LRRK2 catalytic domain (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate measured after 1 hr by Alexa fluor-647 ADP tracer-based ADAPTA assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4610122";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL1672987";"";"None";"445.53";"0";"3.31";"XMD8-87";"COc1cc(N2CCN(C)CC2)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2";"IC50";"'='";"70.0";"nM";"7.16";"";"";"UO_0000065";"16.06";"0.30";"3.84";"8.33";"0";"CHEMBL4612965";"Inhibition of recombinant human GST-tagged LRRK2 catalytic domain (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate measured after 1 hr by Alexa fluor-647 ADP tracer-based ADAPTA assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4610122";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL3939513";"";"None";"314.35";"0";"3.58";"BDBM254930";"Cn1ccc(Nc2cc(-c3ccccc3)c3c(C#N)c[nH]c3n2)n1";"IC50";"'='";"58.0";"nM";"7.24";"";"443713";"UO_0000065";"23.02";"0.41";"3.66";"8.79";"0";"CHEMBL3889252";"Homogeneous Time Resolved-fluorescence Resonance Energy Transfer (TR-FRET) Assay: LRRK2 kinase activity is measured using a LanthaScreen kinase activity assay available from Invitrogen (Life Technologies Corporation). The assay is a homogeneous time resolved-fluorescence resonance energy transfer (TR-FRET) assay that measures phosphorylation of a fluorescein-labelled peptide substrate (fluorescein-LRRKtide, fluorescein-GAGRLGRDKYKTLRQIRQ) (SEQ ID NO 1) as a result of LRRK2 kinase activity. The phosphorylated peptide is recognized by a terbium-labelled phospho-specific anti-LRRKtide antibody and, subsequently, the phosphorylated LRRKtide can be quantified by the extent of TR-FRET between the terbium donor and fluorescein acceptor.The LRRK2 kinase is obtained from Invitrogen (Life Technologies Corporation) and comprises residues 970 to 2527 of the full length human wild-type LRRK2 kinase or a similar sequence with the G2019S mutation. As discussed above, this mutation increases the kinase activity relative to the wild-type. The kinase reactions are performed in a 20 uL volume in 384-well plates. The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT.Â  In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 uM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 uM fluorescein-LRRKtide. The reaction mixture (20 ul total volume) is incubated for 2 hours at 30° C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 ul). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 us) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 us. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 us time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3887011";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3893561";"";"None";"286.31";"0";"2.84";"BDBM185529";"COc1ccc(F)cc1-c1c[nH]c2ncnc(N(C)C)c12";"IC50";"'='";"11.0";"nM";"7.96";"";"334709";"UO_0000065";"27.80";"0.52";"5.12";"14.73";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3942875";"";"None";"317.35";"0";"2.47";"BDBM185460";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CC5CC(C4)O5)c23)c1";"IC50";"'='";"58.0";"nM";"7.24";"";"334433";"UO_0000065";"22.80";"0.41";"4.77";"9.30";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3981479";"";"None";"351.39";"0";"2.80";"BDBM185480";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCC(F)(CO)CC4)c23)c1";"IC50";"'='";"42.0";"nM";"7.38";"";"334453";"UO_0000065";"20.99";"0.39";"4.58";"8.30";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3983178";"";"None";"312.33";"0";"1.26";"BDBM185497";"COc1cncc(-c2c[nH]c3ncnc(N4CCOCC4)c23)n1";"IC50";"'='";"32.0";"nM";"7.50";"";"334471";"UO_0000065";"24.00";"0.45";"6.23";"8.42";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3908095";"";"None";"316.31";"0";"2.74";"BDBM185441";"Fc1ccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c(F)c1";"IC50";"'='";"41.0";"nM";"7.39";"";"334410";"UO_0000065";"23.35";"0.44";"4.65";"13.67";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3923604";"";"None";"298.32";"0";"2.60";"BDBM185442";"Fc1cccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"9.0";"nM";"8.05";"";"334411";"UO_0000065";"26.97";"0.50";"5.45";"14.89";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3393354";"";"None";"310.36";"0";"2.47";"BDBM50059346";"COc1cccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"28.0";"nM";"7.55";"";"334417";"UO_0000065";"24.34";"0.45";"5.08";"11.94";"1";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3965683";"";"None";"286.31";"0";"2.84";"BDBM185535";"COc1cccc(F)c1-c1c[nH]c2ncnc(N(C)C)c12";"IC50";"'='";"40.0";"nM";"7.40";"";"334503";"UO_0000065";"25.84";"0.48";"4.56";"13.69";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3935730";"";"None";"387.40";"0";"2.77";"BDBM185459";"Cc1nc(C2CN(c3ncnc4[nH]cc(-c5cccc(C#N)c5)c34)CCO2)no1";"IC50";"'='";"8.0";"nM";"8.10";"";"334507";"UO_0000065";"20.90";"0.38";"5.33";"6.94";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3901817";"";"None";"349.39";"0";"2.35";"BDBM185385";"COCC1CN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)CCO1";"IC50";"'='";"214.0";"nM";"6.67";"";"334508";"UO_0000065";"19.09";"0.35";"4.32";"7.66";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3934716";"";"None";"386.42";"0";"3.37";"BDBM185579";"Cc1cc(C2CN(c3ncnc4[nH]cc(-c5cccc(C#N)c5)c34)CCO2)on1";"IC50";"'='";"64.7";"nM";"7.19";"";"334513";"UO_0000065";"18.60";"0.34";"3.82";"6.92";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3913617";"";"None";"347.42";"0";"3.74";"BDBM185422";"COc1ccc(C#N)cc1-c1c[nH]c2ncnc(N3CCC[C@H](C)C3)c12";"IC50";"'='";"51.0";"nM";"7.29";"";"334597";"UO_0000065";"20.99";"0.38";"3.55";"9.37";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3933433";"";"None";"328.38";"0";"3.38";"BDBM185378";"[C-]#[N+]C1CCCN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)C1";"IC50";"'='";"57.0";"nM";"7.24";"";"334340";"UO_0000065";"22.06";"0.40";"3.86";"9.93";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3890755";"";"None";"301.31";"0";"2.96";"BDBM185491";"N#Cc1cccc(-c2c[nH]c3ncnc(Nc4cn[nH]c4)c23)c1";"IC50";"'='";"36.0";"nM";"7.44";"";"334675";"UO_0000065";"24.70";"0.44";"4.48";"7.02";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3983178";"";"None";"312.33";"0";"1.26";"BDBM185497";"COc1cncc(-c2c[nH]c3ncnc(N4CCOCC4)c23)n1";"IC50";"'='";"37.0";"nM";"7.43";"";"334682";"UO_0000065";"23.79";"0.44";"6.17";"8.35";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3981043";"";"None";"321.34";"0";"1.50";"BDBM185553";"c1cnn2c(-c3c[nH]c4ncnc(N5CCOCC5)c34)cnc2c1";"IC50";"'='";"6.26";"nM";"8.20";"";"334523";"UO_0000065";"25.53";"0.47";"6.70";"9.74";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3891128";"";"None";"347.42";"0";"3.10";"BDBM185406";"C[C@H]1CCCN(c2ncnc3[nH]cc(-c4ccc5c(c4)CNC5=O)c23)C1";"IC50";"'='";"33.0";"nM";"7.48";"";"334581";"UO_0000065";"21.53";"0.39";"4.38";"10.12";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3893477";"";"None";"307.40";"0";"3.56";"BDBM185408";"Cc1cncc(-c2c[nH]c3ncnc(N4CCC[C@H](C)C4)c23)c1";"IC50";"'='";"19.0";"nM";"7.72";"";"334583";"UO_0000065";"25.12";"0.46";"4.16";"13.38";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3904634";"";"None";"249.28";"0";"2.54";"BDBM185420";"CNc1ncnc2[nH]cc(-c3cccc(C#N)c3)c12";"IC50";"'='";"97.0";"nM";"7.01";"";"334595";"UO_0000065";"28.13";"0.50";"4.47";"9.06";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3393347";"";"None";"291.36";"0";"3.34";"BDBM50059348";"CCN(CC)c1ncnc2[nH]cc(-c3cccc(C#N)c3)c12";"IC50";"'='";"119.0";"nM";"6.92";"";"334604";"UO_0000065";"23.77";"0.43";"3.58";"10.09";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3914712";"";"None";"314.78";"0";"3.11";"BDBM185445";"Clc1ccccc1-c1c[nH]c2ncnc(N3CCOCC3)c12";"IC50";"'='";"33.0";"nM";"7.48";"";"334626";"UO_0000065";"23.77";"0.46";"4.37";"13.84";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3978400";"";"None";"312.35";"0";"2.91";"BDBM185446";"Cc1ccc(F)cc1-c1c[nH]c2ncnc(N3CCOCC3)c12";"IC50";"'='";"223.0";"nM";"6.65";"";"334627";"UO_0000065";"21.30";"0.39";"3.74";"12.31";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3961632";"";"None";"248.29";"0";"2.99";"BDBM254929";"Cc1cccc(-c2cc(N)nc3[nH]cc(C#N)c23)c1";"IC50";"'='";"15.0";"nM";"7.82";"";"443735";"UO_0000065";"31.51";"0.56";"4.83";"9.97";"0";"CHEMBL3889253";"Homogeneous Time Resolved-fluorescence Resonance Energy Transfer (TR-FRET) Assay: LRRK2 kinase activity is measured using a LanthaScreen kinase activity assay available from Invitrogen (Life Technologies Corporation). The assay is a homogeneous time resolved-fluorescence resonance energy transfer (TR-FRET) assay that measures phosphorylation of a fluorescein-labelled peptide substrate (fluorescein-LRRKtide, fluorescein-GAGRLGRDKYKTLRQIRQ) (SEQ ID NO 1) as a result of LRRK2 kinase activity. The phosphorylated peptide is recognized by a terbium-labelled phospho-specific anti-LRRKtide antibody and, subsequently, the phosphorylated LRRKtide can be quantified by the extent of TR-FRET between the terbium donor and fluorescein acceptor.The LRRK2 kinase is obtained from Invitrogen (Life Technologies Corporation) and comprises residues 970 to 2527 of the full length human wild-type LRRK2 kinase or a similar sequence with the G2019S mutation. As discussed above, this mutation increases the kinase activity relative to the wild-type. The kinase reactions are performed in a 20 uL volume in 384-well plates. The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT.Â  In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 uM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 uM fluorescein-LRRKtide. The reaction mixture (20 ul total volume) is incubated for 2 hours at 30° C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 ul). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 us) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 us. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 us time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3887011";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3981433";"";"None";"375.44";"0";"3.02";"BDBM239543";"C[C@@H]1CN(c2cc(-c3n[nH]c4ccc(-c5cn[nH]c5)cc34)ncn2)C[C@H](C)O1";"IC50";"'='";"1.35";"nM";"8.87";"";"418006";"UO_0000065";"23.62";"0.43";"5.85";"9.28";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3985759";"";"None";"442.42";"0";"3.69";"BDBM234868";"COc1cc2ncnc(Nc3cccc(NS(=O)(=O)CC(F)(F)F)c3)c2cc1OC";"IC50";"'='";"380.0";"nM";"6.42";"";"409343";"UO_0000065";"14.51";"0.29";"2.73";"6.27";"0";"CHEMBL3888566";"In vitro Kinase Assay: In vitro kinase assays using LRRK WT and LRRK G2019S.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886763";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3985759";"";"None";"442.42";"0";"3.69";"BDBM234868";"COc1cc2ncnc(Nc3cccc(NS(=O)(=O)CC(F)(F)F)c3)c2cc1OC";"IC50";"'='";"274.0";"nM";"6.56";"";"409351";"UO_0000065";"14.83";"0.30";"2.87";"6.41";"0";"CHEMBL3888567";"In vitro Kinase Assay: In vitro kinase assays using LRRK WT and LRRK G2019S.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886763";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3913713";"";"None";"426.91";"0";"3.30";"BDBM223562";"CC(C)n1cc(-c2cc(-c3ccc(C(=O)N4CCOCC4)c(Cl)c3)cnc2N)nn1";"IC50";"'='";"290.0";"nM";"6.54";"";"390818";"UO_0000065";"15.31";"0.30";"3.24";"6.59";"0";"CHEMBL3888345";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3905434";"";"None";"405.46";"0";"2.35";"BDBM185472";"Cc1ccc(OCC2CN(c3ncnc4[nH]cc(-c5cnn(C)c5)c34)CCO2)cn1";"IC50";"'='";"54.0";"nM";"7.27";"";"334445";"UO_0000065";"17.92";"0.33";"4.92";"7.73";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3898946";"";"None";"318.38";"0";"2.42";"BDBM185476";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCCC(N)C4)c23)c1";"IC50";"'='";"14.0";"nM";"7.85";"";"334449";"UO_0000065";"24.67";"0.45";"5.43";"8.30";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3957531";"";"None";"270.30";"0";"1.18";"BDBM185572";"c1nc(N2CCOCC2)c2c(-c3cn[nH]c3)c[nH]c2n1";"IC50";"'='";"25.0";"nM";"7.60";"";"334327";"UO_0000065";"28.12";"0.52";"6.42";"9.19";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3916251";"";"None";"293.33";"0";"3.25";"BDBM185381";"[C-]#[N+]c1ccc(OC)c(-c2c[nH]c3ncnc(N(C)C)c23)c1";"IC50";"'='";"24.0";"nM";"7.62";"";"334343";"UO_0000065";"25.98";"0.47";"4.37";"13.05";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3897065";"";"None";"369.43";"0";"3.60";"BDBM185383";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCC(c5ncc[nH]5)CC4)c23)c1";"IC50";"'='";"42.0";"nM";"7.38";"";"334345";"UO_0000065";"19.97";"0.36";"3.78";"7.58";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3901817";"";"None";"349.39";"0";"2.35";"BDBM185385";"COCC1CN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)CCO1";"IC50";"'='";"17.0";"nM";"7.77";"";"334349";"UO_0000065";"22.24";"0.41";"5.42";"8.92";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3942417";"";"None";"294.36";"0";"2.77";"BDBM185456";"Cc1cccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"13.0";"nM";"7.89";"";"334427";"UO_0000065";"26.79";"0.49";"5.12";"14.59";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3968498";"";"None";"319.37";"0";"2.46";"BDBM185457";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCC(O)CC4)c23)c1";"IC50";"'='";"52.0";"nM";"7.28";"";"334429";"UO_0000065";"22.81";"0.41";"4.82";"8.20";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3914899";"";"None";"339.79";"0";"2.99";"BDBM185461";"N#Cc1cc(Cl)cc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"77.0";"nM";"7.11";"";"334434";"UO_0000065";"20.94";"0.40";"4.12";"9.14";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL4560969";"";"None";"414.36";"1";"5.55";"7";"N#Cc1cccc(NC(=O)c2cc(C(F)(F)F)ccc2OCc2ccc(F)cc2)c1";"IC50";"'='";"7.943";"nM";"8.10";"";"";"UO_0000065";"19.55";"0.37";"2.55";"13.04";"0";"CHEMBL4372253";"Inhibition of recombinant 6His-Tev-tagged LRRK2 (1326 to 2527) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-RLGRDKYKTLRQIRQGNTKQR-OH as substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs by TR-FRET assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"Sf9";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4371037";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"CHEMBL3308860";"";"";""
"CHEMBL4452797";"";"None";"407.34";"1";"5.81";"6";"O=C(Nc1cccc(F)c1)c1cc(C(F)(F)F)ccc1OCc1ccc(F)cc1";"IC50";"'='";"31.62";"nM";"7.50";"";"";"UO_0000065";"18.41";"0.35";"1.69";"19.57";"0";"CHEMBL4372253";"Inhibition of recombinant 6His-Tev-tagged LRRK2 (1326 to 2527) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-RLGRDKYKTLRQIRQGNTKQR-OH as substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs by TR-FRET assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"Sf9";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4371037";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"CHEMBL3308860";"";"";""
"CHEMBL3930240";"";"None";"377.37";"0";"3.44";"BDBM239220";"CC(C)Oc1cc2c(-c3cc(N4C[C@H](F)[C@@H](F)C4)ncn3)n[nH]c2cc1F";"IC50";"'='";"4.78";"nM";"8.32";"";"417681";"UO_0000065";"22.05";"0.42";"4.88";"12.43";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3922307";"";"None";"381.44";"0";"3.11";"BDBM239232";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCC(C(=O)O)CC4)ncn3)c2c1";"IC50";"'='";"4.45";"nM";"8.35";"";"417693";"UO_0000065";"21.90";"0.41";"5.24";"8.01";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3936066";"";"None";"339.40";"0";"2.64";"BDBM239260";"COc1ccc2[nH]nc(-c3cc(N4C[C@@H](C)O[C@@H](C)C4)ncn3)c2c1";"IC50";"'='";"29.3";"nM";"7.53";"";"417719";"UO_0000065";"22.20";"0.41";"4.89";"9.89";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3974533";"";"None";"352.40";"0";"1.70";"BDBM239262";"COc1ccc2[nH]nc(-c3cc(N4CCN(C(C)=O)CC4)ncn3)c2c1";"IC50";"'='";"74.5";"nM";"7.13";"";"417721";"UO_0000065";"20.23";"0.37";"5.43";"8.17";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3921703";"";"None";"324.39";"0";"1.78";"BDBM239264";"COc1ccc2[nH]nc(-c3cc(N4CCN(C)CC4)ncn3)c2c1";"IC50";"'='";"28.2";"nM";"7.55";"";"417723";"UO_0000065";"23.27";"0.43";"5.77";"10.76";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3651817";"";"None";"232.29";"0";"1.86";"3";"Cc1[nH]nc2ccnc(NC3CCOCC3)c12";"IC50";"'='";"426.0";"nM";"6.37";"";"";"UO_0000065";"27.43";"0.51";"4.51";"10.14";"0";"CHEMBL4331199";"Inhibition of LRRK2 G2019S mutant (unknown origin) by cell based assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330074";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL3393451";"";"None";"319.37";"0";"2.72";"40";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCCOCC4)c23)c1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL3395728";"Inhibition of full length LRRK2 (unknown origin) expressed in HEK293 cells assessed as reduction in S935 phosphorylation incubated for 90 mins by ELISA method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL3393356";"";"None";"323.33";"0";"2.47";"22";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1F";"IC50";"'='";"20.0";"nM";"7.70";"";"";"UO_0000065";"23.81";"0.44";"5.23";"9.89";"0";"CHEMBL3395728";"Inhibition of full length LRRK2 (unknown origin) expressed in HEK293 cells assessed as reduction in S935 phosphorylation incubated for 90 mins by ELISA method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL3393349";"";"None";"318.38";"0";"2.25";"15";"CN1CCN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)CC1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL3395728";"Inhibition of full length LRRK2 (unknown origin) expressed in HEK293 cells assessed as reduction in S935 phosphorylation incubated for 90 mins by ELISA method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL3393347";"";"None";"291.36";"0";"3.34";"13";"CCN(CC)c1ncnc2[nH]cc(-c3cccc(C#N)c3)c12";"IC50";"'='";"443.0";"nM";"6.35";"";"";"UO_0000065";"21.81";"0.39";"3.01";"9.26";"0";"CHEMBL3395728";"Inhibition of full length LRRK2 (unknown origin) expressed in HEK293 cells assessed as reduction in S935 phosphorylation incubated for 90 mins by ELISA method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL3393343";"";"None";"303.37";"0";"3.49";"9";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCCCC4)c23)c1";"IC50";"'='";"182.0";"nM";"6.74";"";"";"UO_0000065";"22.22";"0.40";"3.25";"9.82";"0";"CHEMBL3395728";"Inhibition of full length LRRK2 (unknown origin) expressed in HEK293 cells assessed as reduction in S935 phosphorylation incubated for 90 mins by ELISA method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL3393342";"";"None";"317.40";"0";"3.73";"8";"C[C@@H]1CCCN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)C1";"IC50";"'='";"1579.0";"nM";"5.80";"";"";"UO_0000065";"18.28";"0.33";"2.07";"8.46";"0";"CHEMBL3395728";"Inhibition of full length LRRK2 (unknown origin) expressed in HEK293 cells assessed as reduction in S935 phosphorylation incubated for 90 mins by ELISA method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL3393359";"";"None";"306.33";"0";"1.73";"25";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)n1";"IC50";"'='";"9.0";"nM";"8.05";"";"";"UO_0000065";"26.27";"0.48";"6.32";"8.87";"0";"CHEMBL3395726";"Inhibition of GST-tagged truncated human recombinant LRRK2 using fluorescein-labeled LRRKtide peptide substrate incubated for 2 hrs";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3393356";"";"None";"323.33";"0";"2.47";"22";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1F";"IC50";"'='";"3.0";"nM";"8.52";"";"";"UO_0000065";"26.36";"0.48";"6.05";"10.95";"0";"CHEMBL3395726";"Inhibition of GST-tagged truncated human recombinant LRRK2 using fluorescein-labeled LRRKtide peptide substrate incubated for 2 hrs";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3393354";"";"None";"310.36";"0";"2.47";"20";"COc1cccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"28.0";"nM";"7.55";"";"";"UO_0000065";"24.34";"0.45";"5.08";"11.94";"0";"CHEMBL3395726";"Inhibition of GST-tagged truncated human recombinant LRRK2 using fluorescein-labeled LRRKtide peptide substrate incubated for 2 hrs";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3393342";"";"None";"317.40";"0";"3.73";"8";"C[C@@H]1CCCN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)C1";"IC50";"'='";"69.0";"nM";"7.16";"";"";"UO_0000065";"22.56";"0.41";"3.43";"10.44";"0";"CHEMBL3395726";"Inhibition of GST-tagged truncated human recombinant LRRK2 using fluorescein-labeled LRRKtide peptide substrate incubated for 2 hrs";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL4455001";"";"None";"383.47";"0";"3.78";"13";"CCOc1ccc2nc(NC(=O)c3ccc(N4CCOCC4)cc3)sc2c1";"IC50";"'='";"300.0";"nM";"6.52";"";"";"UO_0000065";"17.01";"0.33";"2.74";"10.24";"0";"CHEMBL4403862";"Inhibition of wild type human GST-tagged LRRK2 (970 to 2527 residues) expressed in baculovirus expression system assessed as reduction in ADP formation using LRRKtide as substrate measured after 1 hr in presence of ATP by Adapta assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4402549";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL4455001";"";"None";"383.47";"0";"3.78";"13";"CCOc1ccc2nc(NC(=O)c3ccc(N4CCOCC4)cc3)sc2c1";"IC50";"'='";"160.0";"nM";"6.80";"";"";"UO_0000065";"17.72";"0.34";"3.02";"10.67";"0";"CHEMBL4403864";"Inhibition of human GST-tagged LRRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus expression system assessed as reduction in ADP formation using LRRKtide as substrate measured after 1 hr in presence of ATP by Adapta assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4402549";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL212590";"";"None";"272.30";"0";"3.69";"19";"O=C(Nc1nc2ccc(F)cc2s1)c1ccccc1";"IC50";"'='";"520.0";"nM";"6.28";"";"";"UO_0000065";"23.08";"0.45";"2.59";"14.97";"0";"CHEMBL4403864";"Inhibition of human GST-tagged LRRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus expression system assessed as reduction in ADP formation using LRRKtide as substrate measured after 1 hr in presence of ATP by Adapta assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4402549";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL3953571";"";"None";"353.43";"0";"3.03";"BDBM239207";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCO[C@@H](C)C4)ncn3)c2c1";"IC50";"'='";"21.44";"nM";"7.67";"";"417668";"UO_0000065";"21.70";"0.40";"4.64";"10.07";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3975802";"";"None";"394.48";"0";"2.86";"BDBM239215";"CC(C)Oc1ccc2[nH]nc(-c3cc(N4CCN(C(C)C)C(=O)C4)ncn3)c2c1";"IC50";"'='";"5.28";"nM";"8.28";"";"417676";"UO_0000065";"20.98";"0.39";"5.42";"9.49";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3929129";"";"None";"400.46";"0";"2.06";"BDBM239246";"CC(C)Oc1cc2c(-c3cc(N4CCN(CCO)CC4)ncn3)n[nH]c2cc1F";"IC50";"'='";"1.65";"nM";"8.78";"";"417707";"UO_0000065";"21.93";"0.41";"6.72";"9.72";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3906191";"";"None";"384.42";"0";"2.22";"BDBM239254";"CC(C)Oc1cc2c(-c3cc(N4CCN(C)C(=O)C4)ncn3)n[nH]c2cc1F";"IC50";"'='";"2.19";"nM";"8.66";"";"417715";"UO_0000065";"22.53";"0.42";"6.44";"9.93";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3953035";"";"None";"331.33";"0";"2.52";"BDBM239259";"COc1ccc2[nH]nc(-c3cc(N4C[C@H](F)[C@@H](F)C4)ncn3)c2c1";"IC50";"'='";"68.6";"nM";"7.16";"";"417718";"UO_0000065";"21.62";"0.41";"4.64";"10.70";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4543181";"";"None";"441.46";"1";"5.03";"29";"Cc1cnc(Cc2nc3cnc4ccc(C(F)(F)F)cc4c3n2[C@@H]2CCO[C@H](C)C2)cn1";"IC50";"'='";"4.13";"nM";"8.38";"";"";"UO_0000065";"18.99";"0.36";"3.35";"12.76";"0";"CHEMBL4334284";"Inhibition of GST-tagged LRRK2 G2019S mutant (unknown origin) expressed in baculovirus expression system using fluorescein-labeled LRRKtide as substrate after 30 mins by Lanthascreen assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330176";"1";"Scientific Literature";"ACS Med Chem Lett";"2019";"None";"";"";""
"CHEMBL3968566";"";"None";"331.42";"0";"4.12";"BDBM185370";"CC1(C)CCCN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)C1";"IC50";"'='";"90.0";"nM";"7.05";"";"334330";"UO_0000065";"21.26";"0.38";"2.93";"10.27";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3393441";"";"None";"295.35";"0";"2.16";"BDBM50059312";"Cc1cncc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"18.0";"nM";"7.75";"";"334469";"UO_0000065";"26.22";"0.48";"5.58";"11.57";"1";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3899954";"";"None";"344.37";"0";"3.71";"BDBM185506";"COc1cc(F)cc(-c2c[nH]c3ncnc(N4CCC(F)CC4)c23)c1";"IC50";"'='";"84.0";"nM";"7.08";"";"334480";"UO_0000065";"20.55";"0.39";"3.37";"13.09";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3942307";"";"None";"330.34";"0";"3.32";"BDBM185531";"COc1ccc(F)cc1-c1c[nH]c2ncnc(N3CC[C@H](F)C3)c12";"IC50";"'='";"15.0";"nM";"7.82";"";"334500";"UO_0000065";"23.68";"0.45";"4.50";"14.48";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3918244";"";"None";"321.36";"0";"3.43";"BDBM185388";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCC(F)CC4)c23)c1";"IC50";"'='";"17.0";"nM";"7.77";"";"334353";"UO_0000065";"24.18";"0.44";"4.34";"11.33";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3393447";"";"None";"372.39";"0";"3.06";"BDBM50059310";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCOC(c5ccno5)C4)c23)c1";"IC50";"'='";"234.0";"nM";"6.63";"";"334740";"UO_0000065";"17.81";"0.32";"3.57";"6.38";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL4846169";"";"None";"470.98";"0";"4.78";"7.4";"Cc1c(Nc2ncc3cc(Cl)c(C4CCN(C5COCC5F)CC4)cc3n2)cnn1C1CC1";"IC50";"'<'";"0.631";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL4827623";"Inhibition of Kinase tracer 236 binding to GST-tagged truncated human LRRK2 G2019S (970 to 2527 residues) mutant using fluorescein labeled LRRKtide peptide as substrate preincubated for 15 mins followed by substrate addition measured after 90 mins in presence of ATP at Km concentration by TR-FRET Lanthascreen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4825716";"1";"Scientific Literature";"ACS Med Chem Lett";"2021";"None";"TIME = 1.75 hr";"";""
"CHEMBL2152709";"";"None";"217.27";"0";"2.59";"23";"Cc1[nH]nc2ccnc(OC3CCCC3)c12";"IC50";"'='";"86.0";"nM";"7.07";"";"";"UO_0000065";"32.52";"0.60";"4.48";"13.91";"0";"CHEMBL4331900";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant catalytic domain (970 to 2527 residues) expressed in baculovirus expression system by radiometric assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330096";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4756758";"";"None";"380.45";"0";"2.49";"3";"CCOc1nc(Nc2ccc(C(=O)N3CCN(C)CC3)cc2)nc2[nH]ccc12";"IC50";"'='";"79.43";"nM";"7.10";"";"";"UO_0000065";"18.66";"0.35";"4.61";"8.22";"0";"CHEMBL4721244";"Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins by Alpha Screen assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4715821";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2018";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL3928607";"";"None";"225.28";"0";"3.16";"BDBM254921";"N#Cc1c[nH]c2nccc(-c3ccsc3)c12";"IC50";"'='";"1279.0";"nM";"5.89";"";"443727";"UO_0000065";"26.16";"0.50";"2.73";"11.23";"0";"CHEMBL3889253";"Homogeneous Time Resolved-fluorescence Resonance Energy Transfer (TR-FRET) Assay: LRRK2 kinase activity is measured using a LanthaScreen kinase activity assay available from Invitrogen (Life Technologies Corporation). The assay is a homogeneous time resolved-fluorescence resonance energy transfer (TR-FRET) assay that measures phosphorylation of a fluorescein-labelled peptide substrate (fluorescein-LRRKtide, fluorescein-GAGRLGRDKYKTLRQIRQ) (SEQ ID NO 1) as a result of LRRK2 kinase activity. The phosphorylated peptide is recognized by a terbium-labelled phospho-specific anti-LRRKtide antibody and, subsequently, the phosphorylated LRRKtide can be quantified by the extent of TR-FRET between the terbium donor and fluorescein acceptor.The LRRK2 kinase is obtained from Invitrogen (Life Technologies Corporation) and comprises residues 970 to 2527 of the full length human wild-type LRRK2 kinase or a similar sequence with the G2019S mutation. As discussed above, this mutation increases the kinase activity relative to the wild-type. The kinase reactions are performed in a 20 uL volume in 384-well plates. The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT.Â  In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 uM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 uM fluorescein-LRRKtide. The reaction mixture (20 ul total volume) is incubated for 2 hours at 30° C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 ul). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 us) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 us. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 us time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3887011";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3925092";"";"None";"311.35";"0";"4.24";"BDBM254934";"N#Cc1c[nH]c2nc(Nc3ccccn3)cc(-c3ccccc3)c12";"IC50";"'='";"340.0";"nM";"6.47";"";"443740";"UO_0000065";"20.78";"0.37";"2.23";"8.36";"0";"CHEMBL3889253";"Homogeneous Time Resolved-fluorescence Resonance Energy Transfer (TR-FRET) Assay: LRRK2 kinase activity is measured using a LanthaScreen kinase activity assay available from Invitrogen (Life Technologies Corporation). The assay is a homogeneous time resolved-fluorescence resonance energy transfer (TR-FRET) assay that measures phosphorylation of a fluorescein-labelled peptide substrate (fluorescein-LRRKtide, fluorescein-GAGRLGRDKYKTLRQIRQ) (SEQ ID NO 1) as a result of LRRK2 kinase activity. The phosphorylated peptide is recognized by a terbium-labelled phospho-specific anti-LRRKtide antibody and, subsequently, the phosphorylated LRRKtide can be quantified by the extent of TR-FRET between the terbium donor and fluorescein acceptor.The LRRK2 kinase is obtained from Invitrogen (Life Technologies Corporation) and comprises residues 970 to 2527 of the full length human wild-type LRRK2 kinase or a similar sequence with the G2019S mutation. As discussed above, this mutation increases the kinase activity relative to the wild-type. The kinase reactions are performed in a 20 uL volume in 384-well plates. The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT.Â  In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 uM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 uM fluorescein-LRRKtide. The reaction mixture (20 ul total volume) is incubated for 2 hours at 30° C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 ul). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 us) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 us. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 us time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3887011";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3969370";"";"None";"533.59";"2";"5.26";"1; FMF-01-086-2";"C=CC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1";"IC50";"'='";"754.0";"nM";"6.12";"";"";"UO_0000065";"11.47";"0.21";"0.86";"5.12";"0";"CHEMBL4185649";"Inhibition of recombinant GST-tagged human LRRK2 (970 to 2527 residues) catalytic domain expressed in baculovirus expression system by ADAPTA assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4184148";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL3393353";"";"None";"280.33";"0";"2.46";"BDBM50059347";"c1ccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)cc1";"IC50";"'='";"9.0";"nM";"8.05";"";"334413";"UO_0000065";"28.70";"0.52";"5.59";"14.89";"1";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3928476";"";"None";"298.35";"0";"1.50";"BDBM185464";"Cc1[nH]c2ncnc(N3CCOCC3)c2c1-c1cnn(C)c1";"IC50";"'='";"47.0";"nM";"7.33";"";"334437";"UO_0000065";"24.56";"0.45";"5.83";"10.20";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3979061";"";"None";"362.79";"0";"3.26";"BDBM185539";"COc1ccc(F)c(Cl)c1-c1c[nH]c2ncnc(N3CCOCC3)c12";"IC50";"'='";"47.0";"nM";"7.33";"";"334506";"UO_0000065";"20.20";"0.40";"4.07";"11.58";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3907468";"";"None";"311.37";"0";"2.39";"BDBM185552";"N#Cc1ccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)s1";"IC50";"'='";"118.0";"nM";"6.93";"";"334733";"UO_0000065";"22.25";"0.43";"4.54";"8.90";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3927437";"";"None";"344.80";"0";"3.12";"BDBM185463";"COc1ccc(Cl)cc1-c1c[nH]c2ncnc(N3CCOCC3)c12";"IC50";"'='";"85.0";"nM";"7.07";"";"334436";"UO_0000065";"20.51";"0.40";"3.95";"11.18";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3900515";"";"None";"335.37";"0";"2.34";"BDBM185465";"COc1cc(C#N)cc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"77.0";"nM";"7.11";"";"334438";"UO_0000065";"21.21";"0.39";"4.77";"8.17";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3922710";"";"None";"298.35";"0";"1.58";"BDBM185468";"C[C@H]1CN(c2ncnc3[nH]cc(-c4cnn(C)c4)c23)CCO1";"IC50";"'='";"57.0";"nM";"7.24";"";"334441";"UO_0000065";"24.28";"0.45";"5.66";"10.08";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3919096";"";"None";"437.41";"0";"3.27";"BDBM185477";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCOC(Cc5noc(C(F)F)n5)C4)c23)c1";"IC50";"'='";"44.0";"nM";"7.36";"";"334450";"UO_0000065";"16.82";"0.31";"4.09";"6.30";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3933441";"";"None";"242.29";"0";"1.42";"BDBM185473";"CN(C)c1ncnc2[nH]cc(-c3cnn(C)c3)c12";"IC50";"'='";"35.0";"nM";"7.46";"";"334657";"UO_0000065";"30.77";"0.57";"6.04";"11.90";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3956541";"";"None";"383.42";"0";"2.86";"BDBM185488";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCOC(c5ccncn5)C4)c23)c1";"IC50";"'='";"193.0";"nM";"6.71";"";"334672";"UO_0000065";"17.51";"0.32";"3.85";"6.48";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3925893";"";"None";"405.39";"0";"2.90";"BDBM185512";"Cc1noc(C2CN(c3ncnc4[nH]cc(-c5cccc(C#N)c5F)c34)CCO2)n1";"IC50";"'='";"7.71";"nM";"8.11";"";"334524";"UO_0000065";"20.01";"0.37";"5.21";"6.95";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3393346";"";"None";"263.30";"0";"2.56";"BDBM50059301";"CN(C)c1ncnc2[nH]cc(-c3cccc(C#N)c3)c12";"IC50";"'='";"15.0";"nM";"7.82";"";"334535";"UO_0000065";"29.71";"0.53";"5.26";"11.41";"1";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3393444";"";"None";"319.37";"0";"2.72";"BDBM50059281";"C[C@H]1CN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)CCO1";"IC50";"'='";"37.0";"nM";"7.43";"";"334536";"UO_0000065";"23.27";"0.42";"4.71";"9.55";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3957531";"";"None";"270.30";"0";"1.18";"BDBM185572";"c1nc(N2CCOCC2)c2c(-c3cn[nH]c3)c[nH]c2n1";"IC50";"'='";"33.0";"nM";"7.48";"";"334538";"UO_0000065";"27.68";"0.51";"6.30";"9.04";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3393341";"";"None";"317.40";"0";"3.73";"BDBM50059259";"C[C@H]1CCCN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)C1";"IC50";"'='";"45.0";"nM";"7.35";"";"334546";"UO_0000065";"23.15";"0.42";"3.62";"10.71";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3952292";"";"None";"296.38";"0";"2.59";"BDBM185374";"C[C@H]1CCCN(c2ncnc3[nH]cc(-c4cnn(C)c4)c23)C1";"IC50";"'='";"12.0";"nM";"7.92";"";"334547";"UO_0000065";"26.73";"0.49";"5.33";"12.65";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL5089345";"";"None";"188.19";"0";"0.00";"14";"Cn1c(N)c(C#N)c2c(N)ncnc21";"IC50";"'='";"14381.0";"nM";"4.84";"";"";"UO_0000065";"25.73";"0.47";"None";"4.54";"0";"CHEMBL5040109";"Inhibition of recombinant human LRRK2 WT using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5089152";"";"None";"421.51";"0";"2.62";"42";"Cc1nn(C2CCOC2)cc1Nc1nc(N)c2c(C#N)c(N3CCC[C@H]3C)n(C)c2n1";"IC50";"'='";"44.0";"nM";"7.36";"";"";"UO_0000065";"17.45";"0.32";"4.74";"5.99";"0";"CHEMBL5040109";"Inhibition of recombinant human LRRK2 WT using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5092087";"";"None";"421.51";"0";"2.62";"45";"Cc1c(Nc2nc(N)c3c(C#N)c(N4CCC[C@H]4C)n(C)c3n2)cnn1[C@H]1CCOC1";"IC50";"'='";"23.0";"nM";"7.64";"";"";"UO_0000065";"18.12";"0.34";"5.02";"6.22";"0";"CHEMBL5040109";"Inhibition of recombinant human LRRK2 WT using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5094228";"";"None";"437.51";"1";"1.42";"38";"Cc1nn(CC2(O)COC2)cc1Nc1nc(N)c2c(C#N)c(N3CCC[C@H]3C)n(C)c2n1";"IC50";"'='";"250.0";"nM";"6.60";"";"";"UO_0000065";"15.09";"0.28";"5.18";"4.61";"0";"CHEMBL5040116";"Inhibition of LRRK2-pSer935 in LRRK2 G2019S mutant expressing human HEK293 cells and measured after 48 hrs by ICW assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 48.0 hr";"INHIBITOR";""
"CHEMBL3393355";"";"None";"314.78";"0";"3.11";"BDBM50059345";"Clc1cccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"13.0";"nM";"7.89";"";"334614";"UO_0000065";"25.05";"0.49";"4.78";"14.59";"1";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3931012";"";"None";"298.32";"0";"2.60";"BDBM185435";"Fc1ccccc1-c1c[nH]c2ncnc(N3CCOCC3)c12";"IC50";"'='";"30.0";"nM";"7.52";"";"334615";"UO_0000065";"25.22";"0.47";"4.92";"13.92";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3945834";"";"None";"293.33";"0";"2.57";"BDBM185494";"COc1cc(C#N)cc(-c2c[nH]c3ncnc(N(C)C)c23)c1";"IC50";"'='";"93.0";"nM";"7.03";"";"334678";"UO_0000065";"23.97";"0.44";"4.46";"9.03";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3975196";"";"None";"298.35";"0";"1.68";"BDBM185495";"CCn1cc(-c2c[nH]c3ncnc(N4CCOCC4)c23)cn1";"IC50";"'='";"92.0";"nM";"7.04";"";"334679";"UO_0000065";"23.58";"0.44";"5.36";"9.79";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3393441";"";"None";"295.35";"0";"2.16";"BDBM50059312";"Cc1cncc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"30.0";"nM";"7.52";"";"334680";"UO_0000065";"25.47";"0.47";"5.36";"11.24";"1";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3899954";"";"None";"344.37";"0";"3.71";"BDBM185506";"COc1cc(F)cc(-c2c[nH]c3ncnc(N4CCC(F)CC4)c23)c1";"IC50";"'='";"96.0";"nM";"7.02";"";"334691";"UO_0000065";"20.38";"0.38";"3.31";"12.99";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3960198";"";"None";"293.37";"0";"3.26";"BDBM185407";"C[C@H]1CCCN(c2ncnc3[nH]cc(-c4cccnc4)c23)C1";"IC50";"'='";"56.0";"nM";"7.25";"";"334371";"UO_0000065";"24.72";"0.45";"3.99";"12.57";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3393448";"";"None";"387.40";"0";"2.77";"BDBM50059290";"Cc1noc(C2CN(c3ncnc4[nH]cc(-c5cccc(C#N)c5)c34)CCO2)n1";"IC50";"'='";"20.0";"nM";"7.70";"";"334430";"UO_0000065";"19.87";"0.36";"4.93";"6.59";"1";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3925893";"";"None";"405.39";"0";"2.90";"BDBM185512";"Cc1noc(C2CN(c3ncnc4[nH]cc(-c5cccc(C#N)c5F)c34)CCO2)n1";"IC50";"'='";"38.0";"nM";"7.42";"";"334485";"UO_0000065";"18.30";"0.34";"4.52";"6.36";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3962415";"";"None";"312.35";"0";"3.18";"BDBM185521";"COc1ccccc1-c1c[nH]c2ncnc(N3CC[C@H](F)C3)c12";"IC50";"'='";"41.0";"nM";"7.39";"";"334490";"UO_0000065";"23.65";"0.44";"4.21";"13.67";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3900759";"";"None";"335.41";"0";"2.96";"BDBM185413";"C[C@H]1CCCN(c2ncnc3[nH]cc(-c4ccc(C(N)=O)cc4)c23)C1";"IC50";"'='";"9.0";"nM";"8.05";"";"334588";"UO_0000065";"23.99";"0.44";"5.09";"9.15";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3889722";"";"None";"341.85";"0";"4.22";"BDBM185415";"Cc1cnc(Cl)c(-c2c[nH]c3ncnc(N4CCC[C@H](C)C4)c23)c1";"IC50";"'='";"30.0";"nM";"7.52";"";"334590";"UO_0000065";"22.01";"0.43";"3.30";"13.04";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3940283";"";"None";"316.31";"0";"2.74";"BDBM185438";"Fc1cccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1F";"IC50";"'='";"24.0";"nM";"7.62";"";"334618";"UO_0000065";"24.09";"0.45";"4.88";"14.10";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL4552628";"";"None";"425.89";"0";"3.66";"27";"Cc1sc(C(=O)N[C@@H]2[C@H](N)CCCC2(F)F)cc1-c1cnn2cc(Cl)cnc12";"IC50";"'='";"62.0";"nM";"7.21";"";"";"UO_0000065";"16.92";"0.35";"3.55";"8.45";"0";"CHEMBL4479740";"Inhibition of recombinant human GST-tagged LRRK2 catalytic domain expressed in baculovirus expression system by Adapta assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4477252";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2016";"None";"";"";""
"CHEMBL3326134";"";"None";"377.26";"0";"3.98";"21";"Cn1cc(-c2nnc3ccc(Sc4cc(Cl)ccc4Cl)nn23)cn1";"IC50";"'='";"373.0";"nM";"6.43";"";"";"UO_0000065";"17.04";"0.37";"2.45";"10.56";"0";"CHEMBL3367450";"Inhibition of GST-tagged truncated LRRK2 (unknown origin) using fluorescein-labeled peptide LRRKtide as substrate by LANTHA screen assay in presence of 1 mM ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL3326119";"";"None";"395.44";"0";"3.36";"6";"COc1cncc(-c2nnc3ccc(Sc4cc(OC)ccc4OC)nn23)c1";"IC50";"'='";"66.0";"nM";"7.18";"";"";"UO_0000065";"18.16";"0.35";"3.82";"8.58";"0";"CHEMBL3367450";"Inhibition of GST-tagged truncated LRRK2 (unknown origin) using fluorescein-labeled peptide LRRKtide as substrate by LANTHA screen assay in presence of 1 mM ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"None";"";"";""
"CHEMBL3326142";"";"None";"386.36";"0";"2.68";"30";"COc1ccc(OC)c(C(F)(F)c2ccc3nnc(-c4cnn(C)c4)n3n2)c1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL3367451";"Inhibition of phosphorylation at S935 residue of wild-type full-length LRRK2 kinase (unknown origin) expressed in HEK 293 cells after 90 mins by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352207";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2014";"CHEMBL3307715";"";"";""
"CHEMBL2170016";"";"None";"377.83";"0";"2.40";"6";"CNc1nc(Nc2ccc(C(=O)N3CCOCC3)cc2OC)ncc1Cl";"IC50";"'='";"20.3";"nM";"7.69";"";"";"UO_0000065";"";"";"";"";"1";"CHEMBL4018177";"Inhibition of full length wild-type LRRK2 (unknown origin) using biotinylated ezrin/radaxin/meosin peptide as substrate measured after 1 hr";"A";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4017473";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL5279418";"";"None";"310.32";"0";"0.91";"1";"CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)Cn2nnnc2N1C";"IC50";"'='";"509.0";"nM";"6.29";"";"";"UO_0000065";"20.28";"0.37";"5.38";"6.02";"0";"CHEMBL5246745";"Inhibition of N-terminal GST-fused human wild type LRRK2 using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5267951";"";"None";"324.35";"0";"1.30";"14";"CCN1C(C)=C(C(=O)Nc2ccc3[nH]ncc3c2)Cn2nnnc21";"IC50";"'='";"865.0";"nM";"6.06";"";"";"UO_0000065";"18.69";"0.35";"4.76";"5.80";"0";"CHEMBL5246745";"Inhibition of N-terminal GST-fused human wild type LRRK2 using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5286615";"";"None";"372.39";"0";"2.61";"17";"CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)Cn2nnnc2N1c1ccccc1";"IC50";"'='";"5.7";"nM";"8.24";"";"";"UO_0000065";"22.14";"0.40";"5.63";"7.88";"0";"CHEMBL5246745";"Inhibition of N-terminal GST-fused human wild type LRRK2 using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5289513";"";"None";"324.35";"0";"1.47";"21";"CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)[C@@H](C)n2nnnc2N1C";"IC50";"'='";"71.0";"nM";"7.15";"";"";"UO_0000065";"22.04";"0.41";"5.68";"6.83";"0";"CHEMBL5246745";"Inhibition of N-terminal GST-fused human wild type LRRK2 using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5279816";"";"None";"338.38";"0";"1.78";"23";"CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)[C@@H](C)n2nnnc2N1C";"IC50";"'='";"20.0";"nM";"7.70";"";"";"UO_0000065";"22.75";"0.42";"5.92";"7.36";"0";"CHEMBL5246745";"Inhibition of N-terminal GST-fused human wild type LRRK2 using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5280577";"";"None";"352.40";"0";"1.96";"29";"CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)C(C)(C)n2nnnc2N1C";"IC50";"'='";"152.0";"nM";"6.82";"";"";"UO_0000065";"19.35";"0.36";"4.86";"6.52";"0";"CHEMBL5246745";"Inhibition of N-terminal GST-fused human wild type LRRK2 using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5290973";"";"None";"310.32";"0";"0.91";"34";"CC1=C(C(=O)Nc2ccc3[nH]cnc3c2)Cn2nnnc2N1C";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5246745";"Inhibition of N-terminal GST-fused human wild type LRRK2 using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"";""
"CHEMBL5279418";"";"None";"310.32";"0";"0.91";"1";"CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)Cn2nnnc2N1C";"IC50";"'='";"32.0";"nM";"7.50";"";"";"UO_0000065";"24.15";"0.45";"6.58";"7.16";"0";"CHEMBL5246746";"Inhibition of N-terminal GST-fused human LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5289675";"";"None";"486.54";"0";"2.37";"27";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4ccnc(N5CCOCC5)c4)c3c2)[C@H](C)n2nnnc2N1C";"IC50";"'<'";"0.2";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5246746";"Inhibition of N-terminal GST-fused human LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5280577";"";"None";"352.40";"0";"1.96";"29";"CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)C(C)(C)n2nnnc2N1C";"IC50";"'='";"0.8";"nM";"9.10";"";"";"UO_0000065";"25.81";"0.48";"7.14";"8.70";"0";"CHEMBL5246746";"Inhibition of N-terminal GST-fused human LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL4435423";"";"None";"408.42";"0";"2.53";"4";"Cc1cnn(Cc2nc3cnc4ccc(C#N)cc4c3n2C2CN(C)CC2(F)F)n1";"IC50";"'='";"3.31";"nM";"8.48";"";"";"UO_0000065";"20.76";"0.39";"5.95";"9.59";"0";"CHEMBL4334284";"Inhibition of GST-tagged LRRK2 G2019S mutant (unknown origin) expressed in baculovirus expression system using fluorescein-labeled LRRKtide as substrate after 30 mins by Lanthascreen assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330176";"1";"Scientific Literature";"ACS Med Chem Lett";"2019";"None";"";"";""
"CHEMBL5281154";"";"None";"486.54";"0";"2.37";"26";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4ccnc(N5CCOCC5)c4)c3c2)[C@@H](C)n2nnnc2N1C";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL5246757";"Inhibition human wild type LRRK2 expressed in human HEK293 assessed as Rab10 substrate phosphorylation at Threonine 73 residue incubated for 2 hrs by immunoblotting analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 2.0 hr";"";""
"CHEMBL5277668";"";"None";"472.51";"0";"1.81";"4";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4ccnc(N5CCOCC5)c4)c3c2)Cn2nnnc2N1C";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL5246758";"Inhibition human LRRK2 G2019S mutant expressed in human HEK293 assessed as Rab10 substrate phosphorylation at Threonine 73 residue incubated for 2 hrs by immunoblotting analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 2.0 hr";"";""
"CHEMBL2403369";"";"None";"421.50";"0";"2.24";"5";"COc1ccc2c(c1)/C(=C/c1cc3c([nH]1)CCN(C(=O)N1CCN(C)CC1)C3)C(=O)N2";"IC50";"'='";"9.0";"nM";"8.05";"";"";"UO_0000065";"19.09";"0.35";"5.81";"9.94";"0";"CHEMBL2406186";"Inhibition of human LRRK2 (1885 to 2132) using 5-Fluo-Ahx-RLGRDKYKTLRQIRQGNTK-OH as substrate after 60 mins by fluorescence assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2401634";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL5197339";"";"None";"514.55";"1";"4.93";"19";"CC(C)(O)[C@@H]1CCN(c2cnc(C(F)(F)F)c(NC(=O)c3cccc(-c4cnn(C5CCC5)c4)n3)c2)C1";"IC50";"'='";"19.0";"nM";"7.72";"";"";"UO_0000065";"15.01";"0.29";"2.79";"8.03";"0";"CHEMBL5108135";"Inhibition of recombinant human GST20 tagged truncated LRRK2 G2019S mutant assessed as substrate phosphorylation preincubated for 15 mins followed by substrate addition and measured after 90 mins using fluorescein-labeled LRRK2tide as substrate in presence of ATP by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5107939";"1";"Scientific Literature";"RSC Med Chem";"2021";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL5183621";"";"None";"339.37";"0";"3.40";"2";"Cn1cc(-c2cccc(C(=O)Nc3cnn(C4CCC4)c3)c2F)cn1";"IC50";"'='";"1647.0";"nM";"5.78";"";"";"UO_0000065";"17.04";"0.32";"2.38";"8.93";"0";"CHEMBL5108136";"Inhibition of human LRRK2 G2019S mutant expressed in human SH-SY5Y cells assessed as inhibition of tetracycline induced LRRK2 phosphorylation at Ser935 residue incubated for 90 mins by MSD assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5107939";"1";"Scientific Literature";"RSC Med Chem";"2021";"None";"TIME = 1.5 hr";"INHIBITOR";""
"CHEMBL4103352";"";"None";"358.39";"0";"3.91";"22";"CC(C)Oc1ccc2[nH]nc(-c3ccnc(N4C[C@@H](F)[C@H](F)C4)c3)c2c1";"IC50";"'='";"128.0";"nM";"6.89";"";"";"UO_0000065";"19.23";"0.36";"2.98";"12.75";"0";"CHEMBL4010117";"Inhibition of recombinant human GST-tagged LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus using fluorescein-ERM as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr in presence of 5 mM ATP by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007454";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4102839";"";"None";"310.36";"0";"2.47";"16";"COc1ccc2[nH]nc(-c3ccnc(N4CCOCC4)c3)c2c1";"IC50";"'='";"15.0";"nM";"7.82";"";"";"UO_0000065";"25.21";"0.46";"5.35";"12.37";"0";"CHEMBL4010109";"Inhibition of recombinant human GST-tagged LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus using fluorescein-ERM as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007454";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4078558";"";"None";"384.46";"0";"2.40";"15";"O=S(=O)(c1ccc2[nH]nc(-c3ccnc(N4CCOCC4)c3)c2c1)C1CC1";"IC50";"'='";"18.0";"nM";"7.75";"";"";"UO_0000065";"20.14";"0.39";"5.34";"8.78";"0";"CHEMBL4010109";"Inhibition of recombinant human GST-tagged LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus using fluorescein-ERM as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007454";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4062772";"";"None";"320.40";"0";"3.34";"13";"c1cc(-c2n[nH]c3ccc(C4CC4)cc23)cc(N2CCOCC2)n1";"IC50";"'='";"13.0";"nM";"7.89";"";"";"UO_0000065";"24.61";"0.45";"4.55";"14.59";"0";"CHEMBL4010109";"Inhibition of recombinant human GST-tagged LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus using fluorescein-ERM as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007454";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4089811";"";"None";"268.32";"0";"2.68";"7";"COCCNc1cc(-c2n[nH]c3ccccc23)ccn1";"IC50";"'='";"98.0";"nM";"7.01";"";"";"UO_0000065";"26.12";"0.48";"4.33";"11.16";"0";"CHEMBL4010109";"Inhibition of recombinant human GST-tagged LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus using fluorescein-ERM as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007454";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4078985";"";"None";"195.22";"0";"2.62";"6";"c1ccc(-c2n[nH]c3ccccc23)nc1";"IC50";"'='";"6186.0";"nM";"5.21";"";"";"UO_0000065";"26.68";"0.47";"2.59";"12.53";"0";"CHEMBL4010109";"Inhibition of recombinant human GST-tagged LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus using fluorescein-ERM as substrate preincubated for 30 mins followed by substrate addition measured after 1 hr by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007454";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4065697";"";"None";"365.44";"0";"3.18";"27";"C[C@@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)CCO1";"IC50";"'='";"5.0";"nM";"8.30";"";"";"UO_0000065";"22.72";"0.42";"5.12";"10.90";"0";"CHEMBL4010118";"Inhibition LRRK2 G2019S mutant Ser935 phosphorylation in human SH-SY5Y cells after 90 mins by Western blot analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007454";"1";"Scientific Literature";"J Med Chem";"2017";"None";"";"";""
"CHEMBL4788941";"";"None";"513.04";"1";"2.67";"12.4";"COCC12CC(n3cc(-n4ncc5cc(Cl)c(N6CCN([C@]7(C)COC[C@@H]7O)CC6)cc54)cn3)(C1)C2";"IC50";"'<'";"80.4";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL4689513";"Inhibition of GST-tagged truncated human LRRK2 G2019S mutant using fluorescein labeled LRRKtide peptide as substrate preincubated for 15 mins followed by substrate addition measured after 90 mins in presence of ATP at Km concentration by TR-FRET Lanthascreen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4680359";"1";"Scientific Literature";"ACS Med Chem Lett";"2021";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL5089102";"";"None";"438.96";"0";"4.44";"13";"Cc1c(Nc2ncc3cc(Cl)c(C4CCN(C5COC5)CC4)cc3n2)cnn1C1CC1";"IC50";"'='";"0.65";"nM";"9.19";"";"";"UO_0000065";"20.93";"0.40";"4.75";"13.49";"0";"CHEMBL5044129";"Inhibition of recombinant N-terminal GST-fused LRRK2 G2109S mutant (970 to 2527 residues) (unknown origin) preincubated with enzyme for 15 mins followed by fluorescein-labeled LRRKtide peptide substrate and ATP addition for 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5042510";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL5094228";"";"None";"437.51";"1";"1.42";"38";"Cc1nn(CC2(O)COC2)cc1Nc1nc(N)c2c(C#N)c(N3CCC[C@H]3C)n(C)c2n1";"IC50";"'='";"51.0";"nM";"7.29";"";"";"UO_0000065";"16.67";"0.31";"5.87";"5.10";"0";"CHEMBL5040107";"Inhibition of recombinant human GST tagged truncated LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5090953";"";"None";"255.32";"0";"2.02";"24";"C[C@@H]1CCCN1c1c(C#N)c2c(N)nccc2n1C";"IC50";"'='";"34.0";"nM";"7.47";"";"";"UO_0000065";"29.25";"0.54";"5.45";"10.54";"0";"CHEMBL5040109";"Inhibition of recombinant human LRRK2 WT using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5089933";"";"None";"349.44";"0";"4.11";"6";"Cc1c(Nc2ncc3cccc(C4CC4)c3n2)cnn1C1CCOCC1";"IC50";"'='";"1.0";"nM";"9.00";"";"";"UO_0000065";"25.76";"0.47";"4.89";"13.88";"0";"CHEMBL5044129";"Inhibition of recombinant N-terminal GST-fused LRRK2 G2109S mutant (970 to 2527 residues) (unknown origin) preincubated with enzyme for 15 mins followed by fluorescein-labeled LRRKtide peptide substrate and ATP addition for 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5042510";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL5076397";"";"None";"543.38";"1";"4.34";"22";"O[C@H]1COC[C@H]1N1CC[C@@H](c2cc3nc(Nc4cnn([C@@H]5CC5(F)F)c4Cl)ncc3cc2Cl)[C@H](F)C1";"IC50";"'<'";"0.6";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5044129";"Inhibition of recombinant N-terminal GST-fused LRRK2 G2109S mutant (970 to 2527 residues) (unknown origin) preincubated with enzyme for 15 mins followed by fluorescein-labeled LRRKtide peptide substrate and ATP addition for 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5042510";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL4096615";"";"None";"250.31";"0";"3.03";"28";"Cc1ccc(-c2cnc(N)c(-c3cn[nH]c3)c2)cc1";"IC50";"'='";"13000.0";"nM";"4.89";"";"";"UO_0000065";"19.52";"0.35";"1.86";"7.23";"0";"CHEMBL4045603";"Inhibition of recombinant human LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus preincubated for 30 mins followed by fluorescein-LRRKtide substrate addition after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4043168";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL4091112";"";"None";"305.34";"0";"3.42";"40";"CCc1nnc(-c2cc(-c3ccc4[nH]ccc4c3)cnc2N)o1";"IC50";"'='";"2900.0";"nM";"5.54";"";"";"UO_0000065";"18.14";"0.33";"2.12";"5.91";"0";"CHEMBL4045603";"Inhibition of recombinant human LRRK2 (970 to 2527 residues) G2019S mutant expressed in baculovirus preincubated for 30 mins followed by fluorescein-LRRKtide substrate addition after 2 hrs by TR-FRET assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4043168";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL3933441";"";"None";"242.29";"0";"1.42";"BDBM185473";"CN(C)c1ncnc2[nH]cc(-c3cnn(C)c3)c12";"IC50";"'='";"55.0";"nM";"7.26";"";"334446";"UO_0000065";"29.96";"0.55";"5.84";"11.59";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3963370";"";"None";"324.38";"0";"2.59";"BDBM185511";"COc1ccccc1-c1c[nH]c2ncnc(N3CCCC(O)C3)c12";"IC50";"'='";"58.0";"nM";"7.24";"";"334484";"UO_0000065";"22.31";"0.41";"4.65";"9.74";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3943641";"";"None";"310.36";"0";"2.47";"BDBM185450";"COc1ccccc1-c1c[nH]c2ncnc(N3CCOCC3)c12";"IC50";"'='";"14.0";"nM";"7.85";"";"334421";"UO_0000065";"25.31";"0.47";"5.38";"12.41";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3917998";"";"None";"300.34";"0";"2.30";"BDBM185470";"Cn1cc(-c2c[nH]c3ncnc(N4CCCC(F)C4)c23)cn1";"IC50";"'='";"31.0";"nM";"7.51";"";"334443";"UO_0000065";"25.00";"0.47";"5.21";"11.99";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3917780";"";"None";"348.37";"0";"2.51";"BDBM185578";"c1cc(-c2ncon2)cc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"129.0";"nM";"6.89";"";"334512";"UO_0000065";"19.78";"0.36";"4.38";"7.41";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL4435935";"";"None";"403.49";"0";"3.06";"22";"CN1CCN(c2ccc(OCc3ccccc3)c(C(=O)Nc3ccnnc3)c2)CC1";"IC50";"'='";"12.59";"nM";"7.90";"";"";"UO_0000065";"19.58";"0.36";"4.84";"11.19";"0";"CHEMBL4372253";"Inhibition of recombinant 6His-Tev-tagged LRRK2 (1326 to 2527) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-RLGRDKYKTLRQIRQGNTKQR-OH as substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs by TR-FRET assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"Sf9";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4371037";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"CHEMBL3308860";"";"";""
"CHEMBL4585874";"";"None";"418.50";"0";"3.92";"20";"C[C@@H]1CN(c2ccc(OCc3ccccc3)c(C(=O)Nc3ccnnc3)c2)C[C@H](C)O1";"IC50";"'='";"19.95";"nM";"7.70";"";"";"UO_0000065";"18.40";"0.34";"3.78";"10.05";"0";"CHEMBL4372253";"Inhibition of recombinant 6His-Tev-tagged LRRK2 (1326 to 2527) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-RLGRDKYKTLRQIRQGNTKQR-OH as substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs by TR-FRET assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"Sf9";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4371037";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"CHEMBL3308860";"";"";""
"CHEMBL4445334";"";"None";"405.80";"1";"6.19";"5";"O=C(Nc1cccc(Cl)c1)c1cc(C(F)(F)F)ccc1OCc1ccccc1";"IC50";"'='";"25.12";"nM";"7.60";"";"";"UO_0000065";"18.73";"0.37";"1.41";"19.83";"0";"CHEMBL4372253";"Inhibition of recombinant 6His-Tev-tagged LRRK2 (1326 to 2527) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-RLGRDKYKTLRQIRQGNTKQR-OH as substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs by TR-FRET assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"Sf9";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4371037";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"CHEMBL3308860";"";"";""
"CHEMBL3958751";"";"None";"308.39";"0";"3.57";"BDBM185414";"C[C@H]1CCCN(c2ncnc3[nH]cc(-c4cccc(O)c4)c23)C1";"IC50";"'='";"9.0";"nM";"8.05";"";"334378";"UO_0000065";"26.09";"0.48";"4.48";"12.37";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL5207003";"";"None";"339.40";"0";"4.67";"32";"C[C@H](Nc1ccc2[nH]nc(-c3ccncc3)c2c1)c1cccc(C#N)c1";"IC50";"'='";"67.0";"nM";"7.17";"";"";"UO_0000065";"21.14";"0.38";"2.50";"9.27";"0";"CHEMBL5157022";"Inhibition of full length wild type LRRK2 (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL2333112";"";"None";"307.36";"0";"2.61";"25";"CC(C)Nc1c(C(N)=O)nnc2cc(-c3ccncc3)ccc12";"IC50";"'='";"16.0";"nM";"7.80";"";"";"UO_0000065";"25.36";"0.46";"5.19";"8.31";"0";"CHEMBL2345527";"Inhibition of GST-tagged LRRK2 G2019S mutant (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2333126";"";"None";"384.46";"0";"2.62";"11";"CC(C)Nc1c(C(N)=O)nnc2cc(-c3ccc(S(C)(=O)=O)cc3)ccc12";"IC50";"'='";"27.0";"nM";"7.57";"";"";"UO_0000065";"19.69";"0.38";"4.95";"6.58";"0";"CHEMBL2345527";"Inhibition of GST-tagged LRRK2 G2019S mutant (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2333122";"";"None";"398.49";"0";"2.88";"35";"CNC(=O)c1nnc2cc(-c3ccc(S(C)(=O)=O)cc3)ccc2c1NC(C)C";"IC50";"'='";"412.0";"nM";"6.38";"";"";"UO_0000065";"16.02";"0.31";"3.51";"6.32";"0";"CHEMBL2345528";"Inhibition of wild type GST-tagged LRRK2 (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2333119";"";"None";"328.42";"0";"1.30";"32";"CC(C)Nc1c(C(N)=O)nnc2cc(N3CCN(C)CC3)ccc12";"IC50";"'='";"53.0";"nM";"7.28";"";"";"UO_0000065";"22.15";"0.41";"5.98";"8.33";"0";"CHEMBL2345528";"Inhibition of wild type GST-tagged LRRK2 (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL2333118";"";"None";"310.36";"0";"1.95";"31";"CC(C)Nc1c(C(N)=O)nnc2cc(-c3cnn(C)c3)ccc12";"IC50";"'='";"9.0";"nM";"8.05";"";"";"UO_0000065";"25.92";"0.48";"6.10";"8.15";"0";"CHEMBL2345528";"Inhibition of wild type GST-tagged LRRK2 (970 to 2527 amino acid residues) (unknown origin) assessed as inhibition of biotinylated-LRRKtide phosphorylation by HTRF assay in presence of ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331489";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2013";"None";"";"";""
"CHEMBL3971055";"";"None";"305.34";"0";"2.33";"BDBM185434";"N#Cc1ccccc1-c1c[nH]c2ncnc(N3CCOCC3)c12";"IC50";"'='";"95.0";"nM";"7.02";"";"334402";"UO_0000065";"23.00";"0.42";"4.69";"9.02";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3932556";"";"None";"328.35";"0";"2.09";"BDBM185440";"OCc1cccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1F";"IC50";"'='";"32.0";"nM";"7.50";"";"334409";"UO_0000065";"22.83";"0.43";"5.40";"10.09";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL4780638";"";"None";"436.52";"0";"3.03";"21";"CCOc1nc(Nc2ccc(C(=O)N3CCN4CCC[C@H]4C3)cc2OC)nc2[nH]ccc12";"IC50";"'='";"3.162";"nM";"8.50";"";"";"UO_0000065";"19.47";"0.36";"5.47";"8.89";"0";"CHEMBL4721243";"Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs in presence of ATP by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4715821";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2018";"None";"TIME = 2.5 hr";"INHIBITOR";""
"CHEMBL5091290";"";"None";"231.30";"0";"1.54";"21";"C[C@@H]1CCCN1c1cc2c(N)ncnc2n1C";"IC50";"'='";"6387.0";"nM";"5.20";"";"";"UO_0000065";"22.46";"0.42";"3.65";"8.66";"0";"CHEMBL5040107";"Inhibition of recombinant human GST tagged truncated LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5073457";"";"None";"350.43";"0";"2.49";"29";"C[C@@H]1CCCN1c1c(C#N)c2c(N)nc(Nc3ccn(C)n3)cc2n1C";"IC50";"'='";"206.0";"nM";"6.69";"";"";"UO_0000065";"19.08";"0.35";"4.20";"6.64";"0";"CHEMBL5040107";"Inhibition of recombinant human GST tagged truncated LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5078779";"";"None";"242.29";"0";"1.40";"20";"C[C@@H]1CCCN1c1[nH]c2ncnc(N)c2c1C#N";"IC50";"'='";"166.0";"nM";"6.78";"";"";"UO_0000065";"27.98";"0.51";"5.38";"7.17";"0";"CHEMBL5040109";"Inhibition of recombinant human LRRK2 WT using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5075824";"";"None";"407.48";"0";"2.23";"40";"Cc1nn(C2COC2)cc1Nc1nc(N)c2c(C#N)c(N3CCC[C@H]3C)n(C)c2n1";"IC50";"'='";"140.0";"nM";"6.85";"";"";"UO_0000065";"16.82";"0.31";"4.62";"5.58";"0";"CHEMBL5040116";"Inhibition of LRRK2-pSer935 in LRRK2 G2019S mutant expressing human HEK293 cells and measured after 48 hrs by ICW assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 48.0 hr";"INHIBITOR";""
"CHEMBL5088551";"";"None";"423.53";"0";"2.43";"37";"Cc1c(Nc2nc(N)c3c(C#N)c(N4CCC[C@H]4C)n(C)c3n2)cnn1CC(C)(C)O";"IC50";"'='";"280.0";"nM";"6.55";"";"";"UO_0000065";"15.47";"0.29";"4.12";"4.90";"0";"CHEMBL5040117";"Inhibition of LRRK2-pSer935 in LRRK2 WT expressing human HEK293 cells and measured after 48 hrs by ICW assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 48.0 hr";"INHIBITOR";""
"CHEMBL4442441";"";"None";"330.39";"0";"4.46";"1";"Cc1cc(-c2ccc3nc(Nc4ccccc4)nn3c2)cc(C)c1O";"IC50";"'='";"20.0";"nM";"7.70";"";"";"UO_0000065";"23.30";"0.42";"3.24";"12.33";"0";"CHEMBL4403864";"Inhibition of human GST-tagged LRRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus expression system assessed as reduction in ADP formation using LRRKtide as substrate measured after 1 hr in presence of ATP by Adapta assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4402549";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL5086901";"";"None";"406.42";"0";"3.54";"3";"Cc1nn(CC(F)(F)F)cc1Nc1ncc(C2CC2)c(NCCc2c[nH]cn2)n1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5046624";"Inhibition of NanoLuc-fused LRRK2 (unknown origin) expressed in HEK293 cells incubated for 2 hrs by NanoBRET assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5046221";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 2.0 hr";"";""
"CHEMBL4865136";"";"None";"452.99";"0";"4.83";"1.14";"Cc1c(Nc2ncc3cc(Cl)c(C4CCN(C5COC5)[C@@H](C)C4)cc3n2)cnn1C1CC1";"IC50";"'<'";"0.631";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL4827623";"Inhibition of Kinase tracer 236 binding to GST-tagged truncated human LRRK2 G2019S (970 to 2527 residues) mutant using fluorescein labeled LRRKtide peptide as substrate preincubated for 15 mins followed by substrate addition measured after 90 mins in presence of ATP at Km concentration by TR-FRET Lanthascreen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4825716";"1";"Scientific Literature";"ACS Med Chem Lett";"2021";"None";"TIME = 1.75 hr";"";""
"CHEMBL4444592";"";"None";"419.44";"0";"3.27";"20";"Cc1cnc(Cc2nc3cnc4ccc(C#N)cc4c3n2C2CN(C)CC2(F)F)cn1";"IC50";"'='";"4.12";"nM";"8.38";"";"";"UO_0000065";"19.99";"0.37";"5.12";"10.04";"0";"CHEMBL4334283";"Inhibition of recombinant wild-type GST-tagged LRRK2 (unknown origin) expressed in baculovirus expression system using fluorescein-labeled LRRKtide as substrate after 30 mins by Lanthascreen assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330176";"1";"Scientific Literature";"ACS Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4549553";"";"None";"354.84";"0";"4.43";"1";"CCc1nc2cnc3ccc(Cl)cc3c2n1[C@@H]1CCO[C@H](CC#N)C1";"IC50";"'='";"10.2";"nM";"7.99";"";"";"UO_0000065";"22.52";"0.44";"3.56";"12.54";"0";"CHEMBL4334283";"Inhibition of recombinant wild-type GST-tagged LRRK2 (unknown origin) expressed in baculovirus expression system using fluorescein-labeled LRRKtide as substrate after 30 mins by Lanthascreen assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330176";"1";"Scientific Literature";"ACS Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4439241";"";"None";"354.84";"0";"4.43";"2";"CCc1nc2cnc3ccc(Cl)cc3c2n1[C@H]1CCO[C@@H](CC#N)C1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL4334284";"Inhibition of GST-tagged LRRK2 G2019S mutant (unknown origin) expressed in baculovirus expression system using fluorescein-labeled LRRKtide as substrate after 30 mins by Lanthascreen assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330176";"1";"Scientific Literature";"ACS Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4527232";"";"None";"369.45";"0";"3.39";"6";"COc1ccc2nc(NC(=O)c3ccc(N4CCOCC4)cc3)sc2c1";"IC50";"'='";"440.0";"nM";"6.36";"";"";"UO_0000065";"17.21";"0.33";"2.97";"9.98";"0";"CHEMBL4403864";"Inhibition of human GST-tagged LRRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus expression system assessed as reduction in ADP formation using LRRKtide as substrate measured after 1 hr in presence of ATP by Adapta assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4402549";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL4450247";"";"None";"407.42";"0";"4.40";"7";"O=C(Nc1nc2ccc(C(F)(F)F)cc2s1)c1ccc(N2CCOCC2)cc1";"IC50";"'='";"280.0";"nM";"6.55";"";"";"UO_0000065";"16.08";"0.32";"2.15";"12.03";"0";"CHEMBL4403864";"Inhibition of human GST-tagged LRRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus expression system assessed as reduction in ADP formation using LRRKtide as substrate measured after 1 hr in presence of ATP by Adapta assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4402549";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL4445322";"";"None";"353.45";"0";"3.69";"8";"Cc1ccc2nc(NC(=O)c3ccc(N4CCOCC4)cc3)sc2c1";"IC50";"'='";"330.0";"nM";"6.48";"";"";"UO_0000065";"18.34";"0.35";"2.79";"11.90";"0";"CHEMBL4403864";"Inhibition of human GST-tagged LRRK2 G2019S mutant (970 to 2527 residues) expressed in baculovirus expression system assessed as reduction in ADP formation using LRRKtide as substrate measured after 1 hr in presence of ATP by Adapta assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4402549";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL5071164";"";"None";"341.85";"0";"3.47";"19";"CNC1CCN(c2ncnc3[nH]cc(-c4cccc(Cl)c4)c23)CC1";"IC50";"'='";"3540.0";"nM";"5.45";"";"";"UO_0000065";"15.95";"0.31";"1.98";"9.59";"0";"CHEMBL5043428";"Displacement of K5 tracer from full length C-terminal NanoLuc fused human LRRK2 expressed in HEK293T cells incubated for 2 hrs by NanoBRET assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293T";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5042489";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL5078540";"";"None";"407.48";"0";"2.23";"41";"Cc1c(Nc2nc(N)c3c(C#N)c(N4CCC[C@H]4C)n(C)c3n2)cnn1C1COC1";"IC50";"'='";"190.0";"nM";"6.72";"";"";"UO_0000065";"16.49";"0.31";"4.49";"5.47";"0";"CHEMBL5040116";"Inhibition of LRRK2-pSer935 in LRRK2 G2019S mutant expressing human HEK293 cells and measured after 48 hrs by ICW assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 48.0 hr";"INHIBITOR";""
"CHEMBL5094228";"";"None";"437.51";"1";"1.42";"38";"Cc1nn(CC2(O)COC2)cc1Nc1nc(N)c2c(C#N)c(N3CCC[C@H]3C)n(C)c2n1";"IC50";"'='";"410.0";"nM";"6.39";"";"";"UO_0000065";"14.60";"0.27";"4.97";"4.46";"0";"CHEMBL5040117";"Inhibition of LRRK2-pSer935 in LRRK2 WT expressing human HEK293 cells and measured after 48 hrs by ICW assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 48.0 hr";"INHIBITOR";""
"CHEMBL5279816";"";"None";"338.38";"0";"1.78";"23";"CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)[C@@H](C)n2nnnc2N1C";"IC50";"'='";"19.0";"nM";"7.72";"";"";"UO_0000065";"22.82";"0.42";"5.94";"7.38";"0";"CHEMBL5246755";"Inhibition of human LRRK2 G2019S mutant expressed in HEK293 cells assessed as reduction in pS1292 phosphorylation incubated for 2 hrs by MSD analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL5082872";"";"None";"491.59";"0";"3.54";"38";"O=C1NCCCOc2ccc3[nH]nc(c3c2)-c2cc(cc(N3CCC(N4CCOCC4)CC3)c2)CO1";"IC50";"'<'";"10.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5030411";"Inhibition of recombinant human LRRK2 using LRRKtide peptide and ATP as substrates incubated for 1 hrs by ADP-glo luminescent assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5029192";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5090730";"";"None";"434.50";"0";"3.47";"14";"O=C1NCCCOc2ccc3[nH]nc(c3c2)-c2cc(cc(N3CCC4(COC4)C3)c2)CO1";"IC50";"'<'";"10.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5030411";"Inhibition of recombinant human LRRK2 using LRRKtide peptide and ATP as substrates incubated for 1 hrs by ADP-glo luminescent assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5029192";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5190579";"";"None";"322.37";"0";"2.66";"4";"Cn1cc(-c2cccc(C(=O)Nc3cnn(C4CCC4)c3)n2)cn1";"IC50";"'='";"53.0";"nM";"7.28";"";"";"UO_0000065";"22.57";"0.41";"4.62";"9.37";"0";"CHEMBL5108135";"Inhibition of recombinant human GST20 tagged truncated LRRK2 G2019S mutant assessed as substrate phosphorylation preincubated for 15 mins followed by substrate addition and measured after 90 mins using fluorescein-labeled LRRK2tide as substrate in presence of ATP by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5107939";"1";"Scientific Literature";"RSC Med Chem";"2021";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL4794578";"";"None";"397.44";"0";"2.58";"7";"CCOc1nc(Nc2ccc(C(=O)N3CCOCC3)cc2OC)nc2[nH]ccc12";"IC50";"'='";"12.59";"nM";"7.90";"";"";"UO_0000065";"19.88";"0.37";"5.32";"7.78";"0";"CHEMBL4721243";"Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs in presence of ATP by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4715821";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2018";"None";"TIME = 2.5 hr";"INHIBITOR";""
"CHEMBL4760344";"";"None";"425.49";"0";"3.36";"17";"CCOc1nc(Nc2ccc(C(=O)N3C[C@@H](C)O[C@@H](C)C3)cc2OC)nc2[nH]ccc12";"IC50";"'='";"199.53";"nM";"6.70";"";"";"UO_0000065";"15.75";"0.30";"3.34";"6.59";"0";"CHEMBL4721244";"Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins by Alpha Screen assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4715821";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2018";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5182067";"";"None";"312.33";"0";"4.29";"15";"N#Cc1ccccc1Oc1ccc2[nH]nc(-c3ccncc3)c2c1";"IC50";"'='";"20.0";"nM";"7.70";"";"";"UO_0000065";"24.65";"0.44";"3.41";"10.32";"0";"CHEMBL5157022";"Inhibition of full length wild type LRRK2 (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5206337";"";"None";"329.34";"0";"4.38";"24";"N#Cc1cccc(F)c1Nc1ccc2[nH]nc(-c3ccncc3)c2c1";"IC50";"'='";"10.0";"nM";"8.00";"";"";"UO_0000065";"24.29";"0.44";"3.62";"10.34";"0";"CHEMBL5157022";"Inhibition of full length wild type LRRK2 (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5198050";"";"None";"311.35";"0";"4.24";"5";"N#Cc1ccc(Nc2ccc3[nH]nc(-c4ccncc4)c3c2)cc1";"IC50";"'='";"16.0";"nM";"7.80";"";"";"UO_0000065";"25.04";"0.44";"3.56";"10.07";"0";"CHEMBL5157023";"Inhibition of full length LRRK2 G2019S mutant (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5206958";"";"None";"341.37";"0";"4.25";"17";"COc1cccc(C#N)c1Nc1ccc2[nH]nc(-c3ccncc3)c2c1";"IC50";"'='";"54.0";"nM";"7.27";"";"";"UO_0000065";"21.29";"0.38";"3.02";"8.39";"0";"CHEMBL5157023";"Inhibition of full length LRRK2 G2019S mutant (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5207466";"";"None";"404.50";"0";"4.07";"26";"Cc1cc(-c2cccc(S(N)(=O)=O)c2)ccc1-c1c(-c2ccncc2)n[nH]c1C";"IC50";"'='";"1170.0";"nM";"5.93";"";"";"UO_0000065";"14.66";"0.28";"1.86";"5.83";"0";"CHEMBL5136367";"Inhibition of full-length wild type LRRK2 (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5172291";"";"None";"426.45";"0";"4.04";"36";"Cc1[nH]nc(-c2ccncc2)c1-c1cc(F)c(-c2cccc(S(N)(=O)=O)c2)c(F)c1";"IC50";"'='";"62.9";"nM";"7.20";"";"";"UO_0000065";"16.89";"0.33";"3.16";"7.08";"0";"CHEMBL5136367";"Inhibition of full-length wild type LRRK2 (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL3971067";"";"None";"378.48";"0";"3.00";"45";"CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)cc3)cnc2N)nn1";"IC50";"'='";"2100.0";"nM";"5.68";"";"";"UO_0000065";"15.00";"0.28";"2.68";"6.92";"0";"CHEMBL4045620";"Inhibition wild type LRRK2 (unknown origin) Ser935 phosphorylation in HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4043168";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL3393604";"";"None";"684.79";"1";"4.68";"68";"COc1ccc2c(c1)OCC(C(=O)NC(=O)N(CC(=O)NCCCCCCNC(=O)c1ccc(-c3n[nH]c4ccccc34)cc1)CC(C)C)O2";"IC50";"'='";"99.0";"nM";"7.00";"";"";"UO_0000065";"10.23";"0.19";"2.32";"4.27";"0";"CHEMBL3396751";"Inhibition of LRRK2 G2019S mutant (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393060";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL5089152";"";"None";"421.51";"0";"2.62";"42";"Cc1nn(C2CCOC2)cc1Nc1nc(N)c2c(C#N)c(N3CCC[C@H]3C)n(C)c2n1";"IC50";"'='";"140.0";"nM";"6.85";"";"";"UO_0000065";"16.26";"0.30";"4.23";"5.58";"0";"CHEMBL5040117";"Inhibition of LRRK2-pSer935 in LRRK2 WT expressing human HEK293 cells and measured after 48 hrs by ICW assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 48.0 hr";"INHIBITOR";""
"CHEMBL4098877";"MLi-2";"None";"379.46";"0";"3.56";"1; MLi-2";"C[C@@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@H](C)O1";"IC50";"'='";"1.0";"nM";"9.00";"";"";"UO_0000065";"23.72";"0.44";"5.44";"11.82";"1";"CHEMBL5157022";"Inhibition of full length wild type LRRK2 (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL4527232";"";"None";"369.45";"0";"3.39";"6";"COc1ccc2nc(NC(=O)c3ccc(N4CCOCC4)cc3)sc2c1";"IC50";"'='";"370.0";"nM";"6.43";"";"";"UO_0000065";"17.41";"0.34";"3.04";"10.10";"0";"CHEMBL4403862";"Inhibition of wild type human GST-tagged LRRK2 (970 to 2527 residues) expressed in baculovirus expression system assessed as reduction in ADP formation using LRRKtide as substrate measured after 1 hr in presence of ATP by Adapta assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4402549";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL5284086";"";"None";"325.33";"0";"0.53";"37";"CC1=C(C(=O)Nc2ccc3c(c2)CC(=O)N3)Cn2nnnc2N1C";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5246745";"Inhibition of N-terminal GST-fused human wild type LRRK2 using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"";""
"CHEMBL5280528";"";"None";"323.36";"0";"1.83";"33";"CC1=C(C(=O)Nc2ccc3[nH]cc(C)c3c2)Cn2nnnc2N1C";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5246746";"Inhibition of N-terminal GST-fused human LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"";""
"CHEMBL5286893";"";"None";"401.43";"0";"2.53";"25";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4ccncc4)c3c2)[C@@H](C)n2nnnc2N1C";"IC50";"'='";"1140.0";"nM";"5.94";"";"";"UO_0000065";"14.80";"0.27";"3.41";"5.06";"0";"CHEMBL5246748";"Inhibition of human wild type LRRK2 expressed in HEK293 cells assessed as reduction in pSer935 phosphorylation incubated for 2 hrs by HTRF analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL5288427";"";"None";"426.44";"0";"2.46";"7";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4nc5ccccc5[nH]4)c3c2)Cn2nnnc2N1C";"IC50";"'='";"21.0";"nM";"7.68";"";"";"UO_0000065";"18.00";"0.33";"5.22";"5.76";"0";"CHEMBL5246755";"Inhibition of human LRRK2 G2019S mutant expressed in HEK293 cells assessed as reduction in pS1292 phosphorylation incubated for 2 hrs by MSD analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL5268380";"";"None";"388.48";"0";"3.41";"9";"C[C@@H]1CN(c2cc(-c3ncc4ccc(-c5cnn(C)c5)cn34)ccn2)C[C@H](C)O1";"IC50";"'='";"161.0";"nM";"6.79";"";"";"UO_0000065";"17.49";"0.32";"3.38";"11.23";"0";"CHEMBL5239655";"Inhibition of GST20-tagged human LRRK2 G2019S mutant using LRRKtide peptide preincubated for 15 mins followed by substrate addition and measured after 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5236618";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL5279615";"";"None";"401.47";"0";"2.95";"14";"CC(C)(O)C12CC(C1)N(c1cc(-n3ncc4ccc(-c5ccn[nH]5)cc43)ncn1)C2";"IC50";"'='";"19.0";"nM";"7.72";"";"";"UO_0000065";"19.23";"0.35";"4.77";"8.06";"0";"CHEMBL5239656";"Inhibition of GST20-tagged LRRK2 in human SH-SY5Y cells assessed as reduction in pSer935 phosphorylation incubated for 90 mins by MSD assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5236618";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 1.5 hr";"INHIBITOR";""
"CHEMBL5266616";"";"None";"428.54";"0";"3.75";"22";"CC(C)(O)C12CC(C1)N(c1cc(-n3ncc4ccc(C5(C#N)CC5(C)C)cc43)ncn1)C2";"IC50";"'='";"610.0";"nM";"6.21";"";"";"UO_0000065";"14.50";"0.27";"2.46";"6.84";"0";"CHEMBL5239656";"Inhibition of GST20-tagged LRRK2 in human SH-SY5Y cells assessed as reduction in pSer935 phosphorylation incubated for 90 mins by MSD assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5236618";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 1.5 hr";"INHIBITOR";""
"CHEMBL3393352";"";"None";"347.42";"0";"3.36";"18";"COCC1CCCN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)C1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL3395728";"Inhibition of full length LRRK2 (unknown origin) expressed in HEK293 cells assessed as reduction in S935 phosphorylation incubated for 90 mins by ELISA method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL3393343";"";"None";"303.37";"0";"3.49";"9";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCCCC4)c23)c1";"IC50";"'='";"28.0";"nM";"7.55";"";"";"UO_0000065";"24.90";"0.45";"4.06";"11.01";"0";"CHEMBL3395727";"Inhibition of GST-tagged truncated human recombinant LRRK2 G2019S mutant using fluorescein-labeled LRRKtide peptide substrate incubated for 90 mins";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL5277668";"";"None";"472.51";"0";"1.81";"4";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4ccnc(N5CCOCC5)c4)c3c2)Cn2nnnc2N1C";"IC50";"'='";"377.0";"nM";"6.42";"";"";"UO_0000065";"13.59";"0.25";"4.61";"4.94";"0";"CHEMBL5246748";"Inhibition of human wild type LRRK2 expressed in HEK293 cells assessed as reduction in pSer935 phosphorylation incubated for 2 hrs by HTRF analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL1933288";"";"None";"458.57";"0";"3.89";"EUB0000679a";"C[C@@H]1CCNC(=O)c2cc3ccc(C(=O)Nc4nc5ccccc5n4CCCN(C)C)cc3n21";"IC50";"'='";"16.0";"nM";"7.80";"";"";"UO_0000065";"17.00";"0.31";"3.91";"9.26";"0";"CHEMBL5213147";"Selectivity interaction (SelectScreen (Invitrogen)) EUB0000679a LRRK2";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"Protein family: Protein Kinase";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5212743";"65";"Literature data from EUbOPEN Chemogenomic Library";"";"2023";"None";"Selectivity number of off-targets = 10.0 None | Selectivity number of targets = 200.0 None | Selectivity Remarks: Screened at 1 µM (in vitro) | Selectivity Source Knowledge: https://doi.org/10.1016/j.bmcl.2011.10.029";"";""
"CHEMBL5192191";"";"None";"329.34";"0";"4.38";"26";"N#Cc1cc(F)ccc1Nc1ccc2[nH]nc(-c3ccncc3)c2c1";"IC50";"'='";"13.0";"nM";"7.89";"";"";"UO_0000065";"23.95";"0.43";"3.51";"10.19";"0";"CHEMBL5157023";"Inhibition of full length LRRK2 G2019S mutant (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5187271";"";"None";"325.38";"0";"4.55";"29";"Cc1cc(-c2n[nH]c3ccc(Nc4ccccc4C#N)cc23)ccn1";"IC50";"'='";"1.0";"nM";"9.00";"";"";"UO_0000065";"27.66";"0.49";"4.45";"11.63";"0";"CHEMBL5157023";"Inhibition of full length LRRK2 G2019S mutant (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5188644";"";"None";"339.40";"0";"4.42";"31";"Cc1c(C#N)cccc1CNc1ccc2[nH]nc(-c3ccncc3)c2c1";"IC50";"'='";"11.0";"nM";"7.96";"";"";"UO_0000065";"23.45";"0.42";"3.54";"10.28";"0";"CHEMBL5157023";"Inhibition of full length LRRK2 G2019S mutant (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5208819";"";"None";"395.47";"1";"5.05";"47";"Cc1cc(-c2n[nH]c3ccc(N[C@@H]4CCOc5cc(C#N)ccc54)cc23)cc(C)n1";"IC50";"'='";"4.0";"nM";"8.40";"";"";"UO_0000065";"21.24";"0.38";"3.35";"9.70";"0";"CHEMBL5157023";"Inhibition of full length LRRK2 G2019S mutant (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL4786263";"";"None";"411.46";"0";"2.97";"9";"CCOc1cc(C(=O)N2CCOCC2)ccc1Nc1nc(OCC)c2cc[nH]c2n1";"IC50";"'='";"199.53";"nM";"6.70";"";"";"UO_0000065";"16.28";"0.31";"3.73";"6.59";"0";"CHEMBL4721244";"Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins by Alpha Screen assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4715821";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2018";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL4756244";"";"None";"410.48";"0";"2.50";"6";"CCOc1nc(Nc2ccc(C(=O)N3CCN(C)CC3)cc2OC)nc2[nH]ccc12";"IC50";"'='";"158.49";"nM";"6.80";"";"";"UO_0000065";"16.57";"0.31";"4.30";"7.11";"0";"CHEMBL4721244";"Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins by Alpha Screen assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4715821";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2018";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL4784513";"";"None";"398.44";"0";"2.63";"4";"CCOc1nc(Nc2ccc(C(=O)N3CCN(C)CC3)cc2F)nc2[nH]ccc12";"IC50";"'='";"158.49";"nM";"6.80";"";"";"UO_0000065";"17.07";"0.32";"4.17";"7.87";"0";"CHEMBL4721244";"Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins by Alpha Screen assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4715821";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2018";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL4752817";"";"None";"436.52";"0";"3.03";"22";"CCOc1nc(Nc2ccc(C(=O)N3CCN4CCC[C@@H]4C3)cc2OC)nc2[nH]ccc12";"IC50";"'='";"158.49";"nM";"6.80";"";"";"UO_0000065";"15.58";"0.29";"3.77";"7.11";"0";"CHEMBL4721244";"Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins by Alpha Screen assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4715821";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2018";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL4782722";"";"None";"468.99";"0";"2.92";"10.1";"CO[C@H]1COC[C@H]1N1CCN(c2cc3c(cnn3-c3cnn(C45CC(C4)C5)c3)cc2Cl)CC1";"IC50";"'='";"104.3";"nM";"6.98";"";"";"UO_0000065";"14.89";"0.29";"4.06";"11.52";"0";"CHEMBL4689513";"Inhibition of GST-tagged truncated human LRRK2 G2019S mutant using fluorescein labeled LRRKtide peptide as substrate preincubated for 15 mins followed by substrate addition measured after 90 mins in presence of ATP at Km concentration by TR-FRET Lanthascreen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4680359";"1";"Scientific Literature";"ACS Med Chem Lett";"2021";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL4780515";"";"None";"516.06";"1";"2.67";"12.5";"[2H]C([2H])([2H])OCC12CC(n3cc(-n4ncc5cc(Cl)c(N6CCN([C@]7(C)COC[C@@H]7O)CC6)cc54)cn3)(C1)C2";"IC50";"'='";"157.0";"nM";"6.80";"";"";"UO_0000065";"13.26";"0.26";"4.13";"8.42";"0";"CHEMBL4689513";"Inhibition of GST-tagged truncated human LRRK2 G2019S mutant using fluorescein labeled LRRKtide peptide as substrate preincubated for 15 mins followed by substrate addition measured after 90 mins in presence of ATP at Km concentration by TR-FRET Lanthascreen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4680359";"1";"Scientific Literature";"ACS Med Chem Lett";"2021";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL4797678";"";"None";"434.54";"0";"1.92";"16.2";"Cc1cc2cnn(-c3cnn(C45CC(C4)C5)c3)c2cc1N1CCN([C@@H]2COC[C@@H]2O)CC1";"IC50";"'='";"259.2";"nM";"6.59";"";"";"UO_0000065";"15.16";"0.28";"4.67";"9.20";"0";"CHEMBL4689513";"Inhibition of GST-tagged truncated human LRRK2 G2019S mutant using fluorescein labeled LRRKtide peptide as substrate preincubated for 15 mins followed by substrate addition measured after 90 mins in presence of ATP at Km concentration by TR-FRET Lanthascreen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4680359";"1";"Scientific Literature";"ACS Med Chem Lett";"2021";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL4795392";"";"None";"452.99";"0";"3.42";"19.2";"C[C@@]1(N2CCN(c3cc4c(cnn4-c4cnn(C56CC(C5)C6)c4)cc3Cl)CC2)CC[C@H]1O";"IC50";"'='";"154.0";"nM";"6.81";"";"";"UO_0000065";"15.04";"0.29";"3.39";"10.93";"0";"CHEMBL4689513";"Inhibition of GST-tagged truncated human LRRK2 G2019S mutant using fluorescein labeled LRRKtide peptide as substrate preincubated for 15 mins followed by substrate addition measured after 90 mins in presence of ATP at Km concentration by TR-FRET Lanthascreen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4680359";"1";"Scientific Literature";"ACS Med Chem Lett";"2021";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL1673041";"";"None";"446.51";"0";"3.42";"XMD13-43";"COc1cc(N2CCOCC2)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2C";"IC50";"'='";"31.0";"nM";"7.51";"";"";"UO_0000065";"16.82";"0.31";"4.09";"9.04";"0";"CHEMBL4612965";"Inhibition of recombinant human GST-tagged LRRK2 catalytic domain (970 to 2527 residues) expressed in baculovirus expression system using LRRKtide as substrate measured after 1 hr by Alexa fluor-647 ADP tracer-based ADAPTA assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4610122";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL5093047";"";"None";"296.31";"0";"2.17";"10";"Cn1c(NCc2ccccc2F)c(C#N)c2c(N)ncnc21";"IC50";"'='";"1739.0";"nM";"5.76";"";"";"UO_0000065";"19.44";"0.36";"3.59";"6.22";"0";"CHEMBL5040107";"Inhibition of recombinant human GST tagged truncated LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5090953";"";"None";"255.32";"0";"2.02";"24";"C[C@@H]1CCCN1c1c(C#N)c2c(N)nccc2n1C";"IC50";"'='";"28.0";"nM";"7.55";"";"";"UO_0000065";"29.58";"0.54";"5.53";"10.66";"0";"CHEMBL5040107";"Inhibition of recombinant human GST tagged truncated LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5091290";"";"None";"231.30";"0";"1.54";"21";"C[C@@H]1CCCN1c1cc2c(N)ncnc2n1C";"IC50";"'='";"6832.0";"nM";"5.17";"";"";"UO_0000065";"22.33";"0.41";"3.63";"8.61";"0";"CHEMBL5040109";"Inhibition of recombinant human LRRK2 WT using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5070699";"";"None";"364.46";"0";"2.80";"30";"Cc1cn(C)nc1Nc1cc2c(c(N)n1)c(C#N)c(N1CCC[C@H]1C)n2C";"IC50";"'='";"2109.0";"nM";"5.68";"";"";"UO_0000065";"15.57";"0.29";"2.88";"5.64";"0";"CHEMBL5040109";"Inhibition of recombinant human LRRK2 WT using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5089152";"";"None";"421.51";"0";"2.62";"42";"Cc1nn(C2CCOC2)cc1Nc1nc(N)c2c(C#N)c(N3CCC[C@H]3C)n(C)c2n1";"IC50";"'='";"65.0";"nM";"7.19";"";"";"UO_0000065";"17.05";"0.32";"4.57";"5.85";"0";"CHEMBL5040116";"Inhibition of LRRK2-pSer935 in LRRK2 G2019S mutant expressing human HEK293 cells and measured after 48 hrs by ICW assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 48.0 hr";"INHIBITOR";""
"CHEMBL5076098";"";"None";"302.76";"0";"2.71";"24";"CN(CCO)c1ncnc2[nH]cc(-c3cccc(Cl)c3)c12";"IC50";"'='";"1520.0";"nM";"5.82";"";"";"UO_0000065";"19.22";"0.38";"3.11";"8.95";"0";"CHEMBL5043428";"Displacement of K5 tracer from full length C-terminal NanoLuc fused human LRRK2 expressed in HEK293T cells incubated for 2 hrs by NanoBRET assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293T";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5042489";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL5206966";"";"None";"372.34";"0";"3.24";"3";"N#Cc1ccc(Nc2ccc3[nH]c(=O)n(-c4ccncc4)c3c2)c([N+](=O)[O-])c1";"IC50";"'='";"5110.0";"nM";"5.29";"";"";"UO_0000065";"14.21";"0.26";"2.05";"4.08";"0";"CHEMBL5157023";"Inhibition of full length LRRK2 G2019S mutant (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5201629";"";"None";"365.44";"0";"4.99";"34";"N#Cc1ccc2c(c1)CCC[C@H]2Nc1ccc2[nH]nc(-c3ccncc3)c2c1";"IC50";"'='";"9.0";"nM";"8.05";"";"";"UO_0000065";"22.02";"0.39";"3.06";"10.40";"0";"CHEMBL5157023";"Inhibition of full length LRRK2 G2019S mutant (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5092087";"";"None";"421.51";"0";"2.62";"45";"Cc1c(Nc2nc(N)c3c(C#N)c(N4CCC[C@H]4C)n(C)c3n2)cnn1[C@H]1CCOC1";"IC50";"'='";"140.0";"nM";"6.85";"";"";"UO_0000065";"16.26";"0.30";"4.23";"5.58";"0";"CHEMBL5040117";"Inhibition of LRRK2-pSer935 in LRRK2 WT expressing human HEK293 cells and measured after 48 hrs by ICW assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 48.0 hr";"INHIBITOR";""
"CHEMBL5188336";"";"None";"390.47";"0";"3.76";"5";"Cc1ccc(S(N)(=O)=O)cc1-c1ccc(-c2c[nH]nc2-c2ccncc2)cc1";"IC50";"'='";"260.0";"nM";"6.58";"";"";"UO_0000065";"16.86";"0.32";"2.83";"6.47";"0";"CHEMBL5136367";"Inhibition of full-length wild type LRRK2 (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5190480";"";"None";"406.47";"0";"3.46";"22";"COc1cc(-c2n[nH]cc2-c2ccc(-c3cccc(S(N)(=O)=O)c3)cc2)ccn1";"IC50";"'='";"34.7";"nM";"7.46";"";"";"UO_0000065";"18.35";"0.35";"4.00";"6.72";"0";"CHEMBL5136368";"Inhibition of full-length LRRK2 G2019S mutant (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5205763";"";"None";"328.40";"0";"2.72";"1";"Cn1cc(-c2nc(C(=O)Nc3cnn(C4CCC4)c3)cs2)cn1";"IC50";"'='";"14.0";"nM";"7.85";"";"";"UO_0000065";"23.92";"0.47";"5.13";"10.12";"0";"CHEMBL5108135";"Inhibition of recombinant human GST20 tagged truncated LRRK2 G2019S mutant assessed as substrate phosphorylation preincubated for 15 mins followed by substrate addition and measured after 90 mins using fluorescein-labeled LRRK2tide as substrate in presence of ATP by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5107939";"1";"Scientific Literature";"RSC Med Chem";"2021";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL5183621";"";"None";"339.37";"0";"3.40";"2";"Cn1cc(-c2cccc(C(=O)Nc3cnn(C4CCC4)c3)c2F)cn1";"IC50";"'='";"70.0";"nM";"7.16";"";"";"UO_0000065";"21.08";"0.39";"3.75";"11.05";"0";"CHEMBL5108135";"Inhibition of recombinant human GST20 tagged truncated LRRK2 G2019S mutant assessed as substrate phosphorylation preincubated for 15 mins followed by substrate addition and measured after 90 mins using fluorescein-labeled LRRK2tide as substrate in presence of ATP by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5107939";"1";"Scientific Literature";"RSC Med Chem";"2021";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL3920540";"";"None";"337.36";"0";"2.60";"BDBM185524";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCCC(O)C4)c23)c1F";"IC50";"'='";"42.0";"nM";"7.38";"";"334704";"UO_0000065";"21.87";"0.40";"4.78";"8.30";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3890691";"";"None";"295.35";"0";"2.16";"BDBM185534";"Cc1ccnc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"90.0";"nM";"7.05";"";"334713";"UO_0000065";"23.86";"0.44";"4.89";"10.53";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3951523";"";"None";"319.37";"0";"2.64";"BDBM185544";"Cc1c(C#N)cccc1-c1c[nH]c2ncnc(N3CCOCC3)c12";"IC50";"'='";"90.1";"nM";"7.04";"";"334725";"UO_0000065";"22.06";"0.40";"4.41";"9.05";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3910988";"";"None";"359.43";"0";"3.50";"BDBM185399";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCCC5(CCOC5)C4)c23)c1";"IC50";"'='";"34.0";"nM";"7.47";"";"334363";"UO_0000065";"20.78";"0.38";"3.97";"9.60";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3898649";"";"None";"321.36";"0";"3.43";"BDBM185417";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCCC(F)C4)c23)c1";"IC50";"'='";"12.0";"nM";"7.92";"";"334381";"UO_0000065";"24.65";"0.45";"4.49";"11.55";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3927997";"";"None";"339.35";"0";"3.73";"BDBM185475";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCCC(F)(F)C4)c23)c1";"IC50";"'='";"79.0";"nM";"7.10";"";"334448";"UO_0000065";"20.93";"0.39";"3.37";"10.35";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3926809";"";"None";"298.35";"0";"1.50";"BDBM185498";"Cc1nn(C)cc1-c1c[nH]c2ncnc(N3CCOCC3)c12";"IC50";"'='";"60.0";"nM";"7.22";"";"334472";"UO_0000065";"24.21";"0.45";"5.72";"10.05";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3979426";"";"None";"268.32";"0";"2.70";"BDBM185519";"COc1ccccc1-c1c[nH]c2ncnc(N(C)C)c12";"IC50";"'='";"43.0";"nM";"7.37";"";"334489";"UO_0000065";"27.45";"0.50";"4.67";"13.63";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3920540";"";"None";"337.36";"0";"2.60";"BDBM185524";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCCC(O)C4)c23)c1F";"IC50";"'='";"9.0";"nM";"8.05";"";"334493";"UO_0000065";"23.85";"0.44";"5.45";"9.06";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3983547";"";"None";"297.32";"0";"1.15";"BDBM185545";"O=c1cc(-c2c[nH]c3ncnc(N4CCOCC4)c23)cc[nH]1";"IC50";"'='";"11.7";"nM";"7.93";"";"334515";"UO_0000065";"26.68";"0.49";"6.78";"9.13";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3968543";"";"None";"319.37";"0";"2.64";"BDBM185570";"Cc1[nH]c2ncnc(N3CCOCC3)c2c1-c1cccc(C#N)c1";"IC50";"'='";"43.0";"nM";"7.37";"";"334532";"UO_0000065";"23.07";"0.42";"4.73";"9.46";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3905428";"";"None";"310.41";"0";"2.84";"BDBM185379";"C[C@@H]1C[C@H](C)CN(c2ncnc3[nH]cc(-c4cnn(C)c4)c23)C1";"IC50";"'='";"16.0";"nM";"7.80";"";"334552";"UO_0000065";"25.11";"0.46";"4.96";"12.45";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3960198";"";"None";"293.37";"0";"3.26";"BDBM185407";"C[C@H]1CCCN(c2ncnc3[nH]cc(-c4cccnc4)c23)C1";"IC50";"'='";"95.0";"nM";"7.02";"";"334582";"UO_0000065";"23.94";"0.44";"3.76";"12.17";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3964405";"";"None";"312.35";"0";"2.73";"BDBM185502";"OC1CCCN(c2ncnc3[nH]cc(-c4cccc(F)c4)c23)C1";"IC50";"'='";"57.0";"nM";"7.24";"";"334476";"UO_0000065";"23.19";"0.43";"4.51";"11.14";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3393447";"";"None";"372.39";"0";"3.06";"BDBM50059310";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCOC(c5ccno5)C4)c23)c1";"IC50";"'='";"37.0";"nM";"7.43";"";"334529";"UO_0000065";"19.96";"0.36";"4.37";"7.16";"1";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3942388";"";"None";"302.77";"0";"3.35";"BDBM185382";"COc1ccc(Cl)cc1-c1c[nH]c2ncnc(N(C)C)c12";"IC50";"'='";"19.0";"nM";"7.72";"";"334555";"UO_0000065";"25.50";"0.50";"4.37";"14.29";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3934457";"";"None";"369.43";"0";"3.60";"BDBM185393";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCCC(c5cc[nH]n5)C4)c23)c1";"IC50";"'='";"200.0";"nM";"6.70";"";"334568";"UO_0000065";"18.13";"0.33";"3.10";"6.89";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3910988";"";"None";"359.43";"0";"3.50";"BDBM185399";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCCC5(CCOC5)C4)c23)c1";"IC50";"'='";"244.0";"nM";"6.61";"";"334574";"UO_0000065";"18.40";"0.33";"3.11";"8.50";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3952215";"";"None";"331.38";"0";"3.01";"BDBM185453";"c1ccc2c(-c3c[nH]c4ncnc(N5CCOCC5)c34)cncc2c1";"IC50";"'='";"51.0";"nM";"7.29";"";"334635";"UO_0000065";"22.01";"0.40";"4.28";"10.90";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3972503";"";"None";"319.37";"0";"2.46";"BDBM185485";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCCC(O)C4)c23)c1";"IC50";"'='";"27.0";"nM";"7.57";"";"334669";"UO_0000065";"23.70";"0.43";"5.11";"8.52";"0";"CHEMBL3887346";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL4749895";"";"None";"367.41";"0";"2.57";"2";"CCOc1nc(Nc2ccc(C(=O)N3CCOCC3)cc2)nc2[nH]ccc12";"IC50";"'='";"7.943";"nM";"8.10";"";"";"UO_0000065";"22.05";"0.41";"5.53";"8.77";"0";"CHEMBL4721243";"Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs in presence of ATP by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4715821";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2018";"None";"TIME = 2.5 hr";"INHIBITOR";""
"CHEMBL4784679";"";"None";"414.90";"0";"3.14";"5";"CCOc1nc(Nc2ccc(C(=O)N3CCN(C)CC3)cc2Cl)nc2[nH]ccc12";"IC50";"'='";"251.19";"nM";"6.60";"";"";"UO_0000065";"15.91";"0.31";"3.46";"7.64";"0";"CHEMBL4721244";"Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins by Alpha Screen assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4715821";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2018";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5275913";"";"None";"415.55";"0";"3.58";"15";"C[C@@H]1CN(c2cc(-n3ncc4ccc(CC5(C#N)CCC5)cc43)ncn2)C[C@H](C)N1C";"IC50";"'='";"275.0";"nM";"6.56";"";"";"UO_0000065";"15.79";"0.29";"2.98";"8.88";"0";"CHEMBL5239655";"Inhibition of GST20-tagged human LRRK2 G2019S mutant using LRRKtide peptide preincubated for 15 mins followed by substrate addition and measured after 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5236618";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL5266092";"";"None";"400.49";"0";"3.11";"20";"CC(C)(O)C12CC(C1)N(c1cc(-n3ncc4ccc(C5(C#N)CC5)cc43)ncn1)C2";"IC50";"'='";"30.0";"nM";"7.52";"";"";"UO_0000065";"18.78";"0.34";"4.41";"8.28";"0";"CHEMBL5239656";"Inhibition of GST20-tagged LRRK2 in human SH-SY5Y cells assessed as reduction in pSer935 phosphorylation incubated for 90 mins by MSD assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5236618";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 1.5 hr";"INHIBITOR";""
"CHEMBL5288427";"";"None";"426.44";"0";"2.46";"7";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4nc5ccccc5[nH]4)c3c2)Cn2nnnc2N1C";"IC50";"'='";"0.53";"nM";"9.28";"";"";"UO_0000065";"21.75";"0.40";"6.82";"6.96";"0";"CHEMBL5246745";"Inhibition of N-terminal GST-fused human wild type LRRK2 using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL4450247";"";"None";"407.42";"0";"4.40";"7";"O=C(Nc1nc2ccc(C(F)(F)F)cc2s1)c1ccc(N2CCOCC2)cc1";"IC50";"'='";"2270.0";"nM";"5.64";"";"";"UO_0000065";"13.85";"0.28";"1.24";"10.36";"0";"CHEMBL4403862";"Inhibition of wild type human GST-tagged LRRK2 (970 to 2527 residues) expressed in baculovirus expression system assessed as reduction in ADP formation using LRRKtide as substrate measured after 1 hr in presence of ATP by Adapta assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4402549";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL212590";"";"None";"272.30";"0";"3.69";"19";"O=C(Nc1nc2ccc(F)cc2s1)c1ccccc1";"IC50";"'='";"520.0";"nM";"6.28";"";"";"UO_0000065";"23.08";"0.45";"2.59";"14.97";"0";"CHEMBL4403862";"Inhibition of wild type human GST-tagged LRRK2 (970 to 2527 residues) expressed in baculovirus expression system assessed as reduction in ADP formation using LRRKtide as substrate measured after 1 hr in presence of ATP by Adapta assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4402549";"1";"Scientific Literature";"J Med Chem";"2020";"None";"";"";""
"CHEMBL5194234";"";"None";"418.52";"0";"4.38";"39";"Cc1cc(-c2c(-c3ccncc3)n[nH]c2C)cc(C)c1-c1cccc(S(N)(=O)=O)c1";"IC50";"'='";"275.0";"nM";"6.56";"";"";"UO_0000065";"15.68";"0.30";"2.18";"6.45";"0";"CHEMBL5136367";"Inhibition of full-length wild type LRRK2 (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5202898";"";"None";"458.47";"0";"4.78";"32";"Cc1[nH]nc(-c2ccncc2)c1-c1ccc(-c2cccc(S(N)(=O)=O)c2)c(C(F)(F)F)c1";"IC50";"'='";"87.8";"nM";"7.06";"";"";"UO_0000065";"15.39";"0.30";"2.28";"6.94";"0";"CHEMBL5136368";"Inhibition of full-length LRRK2 G2019S mutant (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5174380";"";"None";"430.53";"0";"4.64";"37";"Cc1[nH]nc(-c2ccncc2)c1-c1ccc(-c2cccc(S(N)(=O)=O)c2)c(C2CC2)c1";"IC50";"'='";"3.1";"nM";"8.51";"";"";"UO_0000065";"19.76";"0.37";"3.87";"8.36";"0";"CHEMBL5136368";"Inhibition of full-length LRRK2 G2019S mutant (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5194234";"";"None";"418.52";"0";"4.38";"39";"Cc1cc(-c2c(-c3ccncc3)n[nH]c2C)cc(C)c1-c1cccc(S(N)(=O)=O)c1";"IC50";"'='";"16.8";"nM";"7.78";"";"";"UO_0000065";"18.58";"0.35";"3.39";"7.64";"0";"CHEMBL5136368";"Inhibition of full-length LRRK2 G2019S mutant (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5181966";"";"None";"444.56";"0";"4.95";"41";"Cc1cc(-c2n[nH]c(C)c2-c2ccc(-c3cccc(S(N)(=O)=O)c3)c(C3CC3)c2)ccn1";"IC50";"'='";"2.4";"nM";"8.62";"";"";"UO_0000065";"19.39";"0.37";"3.67";"8.47";"0";"CHEMBL5136368";"Inhibition of full-length LRRK2 G2019S mutant (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL4451151";"";"None";"410.92";"0";"4.67";"96";"[2H]C([2H])([2H])c1cnc(Cc2nc3cnc4ccc(Cl)cc4c3n2[C@@H]2CCO[C@H](C)C2)cn1";"IC50";"'='";"2.16";"nM";"8.67";"";"";"UO_0000065";"21.24";"0.41";"4.00";"13.19";"0";"CHEMBL4334284";"Inhibition of GST-tagged LRRK2 G2019S mutant (unknown origin) expressed in baculovirus expression system using fluorescein-labeled LRRKtide as substrate after 30 mins by Lanthascreen assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330176";"1";"Scientific Literature";"ACS Med Chem Lett";"2019";"None";"";"";""
"CHEMBL3122117";"";"None";"449.84";"0";"3.11";"EUB0000629a";"CNc1nc(Nc2cnn([C@H]3CCN(C4COC4)C[C@@H]3F)c2Cl)ncc1C(F)(F)F";"IC50";"'='";"19.0";"nM";"7.72";"";"";"UO_0000065";"17.16";"0.35";"4.61";"9.64";"0";"CHEMBL5210127";"Affinity On-target Cellular interaction (Cellular assay (LRRK2 phosphorylation)) EUB0000629a LRRK2";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"Mode of action: Inhibitor | Protein family: Protein Kinase | Recommended concentration = 100.0 nM";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5210121";"65";"Literature data from EUbOPEN Chemogenomic Library";"";"2023";"None";"Affinity On-target Cellular Source Knowledge: https://doi.org/10.1021/jm401654j";"INHIBITOR";""
"CHEMBL5093114";"";"None";"313.79";"0";"3.72";"32";"Clc1cccc(-c2c[nH]c3nccc(N4CCOCC4)c23)c1";"IC50";"'='";"121.0";"nM";"6.92";"";"";"UO_0000065";"22.04";"0.43";"3.20";"16.81";"0";"CHEMBL5043428";"Displacement of K5 tracer from full length C-terminal NanoLuc fused human LRRK2 expressed in HEK293T cells incubated for 2 hrs by NanoBRET assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293T";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5042489";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL5280373";"";"None";"414.47";"0";"3.31";"31; EB-42486";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4ccccc4)c3c2)C(C)(C)n2nnnc2N1C";"IC50";"'='";"6.6";"nM";"8.18";"";"";"UO_0000065";"19.74";"0.36";"4.87";"7.82";"0";"CHEMBL5246745";"Inhibition of N-terminal GST-fused human wild type LRRK2 using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5280373";"";"None";"414.47";"0";"3.31";"31; EB-42486";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4ccccc4)c3c2)C(C)(C)n2nnnc2N1C";"IC50";"'<'";"0.2";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5246746";"Inhibition of N-terminal GST-fused human LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5270706";"";"None";"500.57";"1";"2.55";"30";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4ccnc(N5CCOCC5)c4)c3c2)C(C)(C)n2nnnc2N1C";"IC50";"'='";"1.1";"nM";"8.96";"";"";"UO_0000065";"17.90";"0.33";"6.41";"6.89";"0";"CHEMBL5246749";"Inhibition of human LRRK2 G2019S mutant expressed in HEK293 cells assessed as reduction in pSer935 phosphorylation incubated for 2 hrs by HTRF analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL5281154";"";"None";"486.54";"0";"2.37";"26";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4ccnc(N5CCOCC5)c4)c3c2)[C@@H](C)n2nnnc2N1C";"IC50";"'='";"20.9";"nM";"7.68";"";"";"UO_0000065";"15.78";"0.29";"5.31";"5.91";"0";"CHEMBL5246754";"Inhibition of human wild type LRRK2 expressed in HEK293 cells assessed as reduction in pS1292 phosphorylation incubated for 2 hrs by MSD analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL5277668";"";"None";"472.51";"0";"1.81";"4";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4ccnc(N5CCOCC5)c4)c3c2)Cn2nnnc2N1C";"IC50";"'='";"9.2";"nM";"8.04";"";"";"UO_0000065";"17.01";"0.31";"6.23";"6.18";"0";"CHEMBL5246755";"Inhibition of human LRRK2 G2019S mutant expressed in HEK293 cells assessed as reduction in pS1292 phosphorylation incubated for 2 hrs by MSD analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL5277668";"";"None";"472.51";"0";"1.81";"4";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4ccnc(N5CCOCC5)c4)c3c2)Cn2nnnc2N1C";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL5246757";"Inhibition human wild type LRRK2 expressed in human HEK293 assessed as Rab10 substrate phosphorylation at Threonine 73 residue incubated for 2 hrs by immunoblotting analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 2.0 hr";"";""
"CHEMBL5288427";"";"None";"426.44";"0";"2.46";"7";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4nc5ccccc5[nH]4)c3c2)Cn2nnnc2N1C";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL5246758";"Inhibition human LRRK2 G2019S mutant expressed in human HEK293 assessed as Rab10 substrate phosphorylation at Threonine 73 residue incubated for 2 hrs by immunoblotting analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 2.0 hr";"";""
"CHEMBL5196195";"";"None";"433.44";"1";"6.00";"52";"N#Cc1ccc2c(c1)CCC[C@H]2Nc1cc2c(-c3ccncc3)n[nH]c2cc1C(F)(F)F";"IC50";"'='";"646.0";"nM";"6.19";"";"";"UO_0000065";"14.28";"0.26";"0.19";"8.00";"0";"CHEMBL5157022";"Inhibition of full length wild type LRRK2 (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5194659";"";"None";"326.36";"0";"4.60";"9";"Cc1cc(C#N)ccc1Oc1ccc2[nH]nc(-c3ccncc3)c2c1";"IC50";"'='";"50.0";"nM";"7.30";"";"";"UO_0000065";"22.37";"0.40";"2.70";"9.79";"0";"CHEMBL5157023";"Inhibition of full length LRRK2 G2019S mutant (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL3393453";"";"None";"331.38";"0";"2.72";"42";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CC5CCOC5C4)c23)c1";"IC50";"'='";"139.0";"nM";"6.86";"";"";"UO_0000065";"20.69";"0.37";"4.14";"8.81";"0";"CHEMBL3395726";"Inhibition of GST-tagged truncated human recombinant LRRK2 using fluorescein-labeled LRRKtide peptide substrate incubated for 2 hrs";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3393443";"";"None";"319.37";"0";"2.72";"32";"C[C@@H]1CN(c2ncnc3[nH]cc(-c4cccc(C#N)c4)c23)CCO1";"IC50";"'='";"18.0";"nM";"7.75";"";"";"UO_0000065";"24.25";"0.44";"5.02";"9.95";"0";"CHEMBL3395726";"Inhibition of GST-tagged truncated human recombinant LRRK2 using fluorescein-labeled LRRKtide peptide substrate incubated for 2 hrs";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3393009";"1";"Scientific Literature";"J Med Chem";"2015";"None";"";"";""
"CHEMBL3409479";"";"None";"404.00";"1";"5.18";"38";"O=C(c1ccc(NC2CCCCC2)c(Cl)c1)N1CCC(N2CCCCC2)CC1";"IC50";"'>'";"1000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL3412556";"Inhibition of LRRK2 G2019S mutant (1326 to 252 aa) (unknown origin) stably expressed in HEK293 cell lysate using [gamma-32P] after 15 mins by Cerenkov counting method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3407393";"1";"Scientific Literature";"Eur J Med Chem";"2015";"CHEMBL3307715";"";"";""
"CHEMBL5085536";"";"None";"460.37";"0";"3.73";"16";"Clc1cc2cnc(Nc3cnn(C4CC4)c3Cl)nc2cc1N1CCN(C2COC2)CC1";"IC50";"'='";"2.6";"nM";"8.59";"";"";"UO_0000065";"18.65";"0.38";"4.86";"12.03";"0";"CHEMBL5044129";"Inhibition of recombinant N-terminal GST-fused LRRK2 G2109S mutant (970 to 2527 residues) (unknown origin) preincubated with enzyme for 15 mins followed by fluorescein-labeled LRRKtide peptide substrate and ATP addition for 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5042510";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL5093254";"";"None";"335.41";"0";"3.80";"5";"c1cc(C2CC2)c2nc(Nc3cnn(C4CCOCC4)c3)ncc2c1";"IC50";"'='";"15.0";"nM";"7.82";"";"";"UO_0000065";"23.33";"0.43";"4.02";"12.06";"0";"CHEMBL5044129";"Inhibition of recombinant N-terminal GST-fused LRRK2 G2109S mutant (970 to 2527 residues) (unknown origin) preincubated with enzyme for 15 mins followed by fluorescein-labeled LRRKtide peptide substrate and ATP addition for 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5042510";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL5206767";"";"None";"395.47";"0";"4.99";"36";"COc1cc(-c2n[nH]c3ccc(N[C@@H]4CCCc5cc(C#N)ccc54)cc23)ccn1";"IC50";"'='";"637.0";"nM";"6.20";"";"";"UO_0000065";"15.67";"0.28";"1.21";"7.15";"0";"CHEMBL5157022";"Inhibition of full length wild type LRRK2 (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5198808";"";"None";"367.41";"0";"4.43";"45";"N#Cc1ccc2c(c1)OCC[C@H]2Nc1ccc2[nH]nc(-c3ccncc3)c2c1";"IC50";"'='";"189.0";"nM";"6.72";"";"";"UO_0000065";"18.30";"0.33";"2.29";"7.76";"0";"CHEMBL5157022";"Inhibition of full length wild type LRRK2 (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5186274";"";"None";"381.44";"0";"4.74";"46";"Cc1cc(-c2n[nH]c3ccc(N[C@@H]4CCOc5cc(C#N)ccc54)cc23)ccn1";"IC50";"'='";"132.0";"nM";"6.88";"";"";"UO_0000065";"18.04";"0.32";"2.14";"7.94";"0";"CHEMBL5157022";"Inhibition of full length wild type LRRK2 (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5193770";"";"None";"383.43";"1";"5.13";"51";"N#Cc1ccc2c(c1)CCC[C@H]2Nc1cc2c(-c3ccncc3)n[nH]c2cc1F";"IC50";"'='";"218.0";"nM";"6.66";"";"";"UO_0000065";"17.37";"0.31";"1.53";"8.61";"0";"CHEMBL5157022";"Inhibition of full length wild type LRRK2 (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5177346";"";"None";"379.47";"1";"5.29";"42";"Cc1cc(-c2n[nH]c3ccc(N[C@H]4CCCc5cc(C#N)ccc54)cc23)ccn1";"IC50";"'<'";"1.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5157023";"Inhibition of full length LRRK2 G2019S mutant (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5169393";"";"None";"336.36";"0";"4.11";"11";"N#Cc1ccc(Nc2ccc3[nH]nc(-c4ccncc4)c3c2)c(C#N)c1";"IC50";"'='";"6.0";"nM";"8.22";"";"";"UO_0000065";"24.44";"0.43";"4.11";"8.13";"0";"CHEMBL5157023";"Inhibition of full length LRRK2 G2019S mutant (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5195812";"";"None";"329.34";"0";"4.38";"23";"N#Cc1ccc(F)cc1Nc1ccc2[nH]nc(-c3ccncc3)c2c1";"IC50";"'='";"81.0";"nM";"7.09";"";"";"UO_0000065";"21.53";"0.39";"2.71";"9.16";"0";"CHEMBL5157023";"Inhibition of full length LRRK2 G2019S mutant (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5205363";"";"None";"376.44";"0";"3.45";"3";"NS(=O)(=O)c1cccc(-c2ccc(-c3c[nH]nc3-c3ccncc3)cc2)c1";"IC50";"'='";"24.3";"nM";"7.61";"";"";"UO_0000065";"20.23";"0.39";"4.16";"7.48";"0";"CHEMBL5136368";"Inhibition of full-length LRRK2 G2019S mutant (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5202898";"";"None";"458.47";"0";"4.78";"32";"Cc1[nH]nc(-c2ccncc2)c1-c1ccc(-c2cccc(S(N)(=O)=O)c2)c(C(F)(F)F)c1";"IC50";"'='";"853.0";"nM";"6.07";"";"";"UO_0000065";"13.24";"0.26";"1.29";"5.97";"0";"CHEMBL5136367";"Inhibition of full-length wild type LRRK2 (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5204222";"";"None";"325.38";"0";"4.55";"22";"Cc1ccc(C#N)c(Nc2ccc3[nH]nc(-c4ccncc4)c3c2)c1";"IC50";"'='";"197.0";"nM";"6.71";"";"";"UO_0000065";"20.61";"0.37";"2.16";"8.66";"0";"CHEMBL5157023";"Inhibition of full length LRRK2 G2019S mutant (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5276942";"";"None";"354.37";"0";"0.78";"39";"CC1=C(C(=O)Nc2ccc3c(c2)[nH]c(=O)n3C)[C@@H](C)n2nnnc2N1C";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5246745";"Inhibition of N-terminal GST-fused human wild type LRRK2 using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"";""
"CHEMBL5288427";"";"None";"426.44";"0";"2.46";"7";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4nc5ccccc5[nH]4)c3c2)Cn2nnnc2N1C";"IC50";"'<'";"0.2";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5246746";"Inhibition of N-terminal GST-fused human LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5288038";"";"None";"429.44";"0";"2.16";"10";"CC1=C(C(=O)Nc2ccc3[nH]nc(NC(=O)c4ccccc4)c3c2)Cn2nnnc2N1C";"IC50";"'='";"3.0";"nM";"8.52";"";"";"UO_0000065";"19.85";"0.36";"6.36";"6.37";"0";"CHEMBL5246746";"Inhibition of N-terminal GST-fused human LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5207757";"";"None";"432.55";"0";"4.69";"10";"Cc1cc(-c2n[nH]c(C)c2-c2ccc(-c3ccc(S(N)(=O)=O)c(C)c3C)cc2)ccn1";"IC50";"'='";"337.0";"nM";"6.47";"";"";"UO_0000065";"14.96";"0.29";"1.78";"6.36";"0";"CHEMBL5136367";"Inhibition of full-length wild type LRRK2 (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5172291";"";"None";"426.45";"0";"4.04";"36";"Cc1[nH]nc(-c2ccncc2)c1-c1cc(F)c(-c2cccc(S(N)(=O)=O)c2)c(F)c1";"IC50";"'='";"4.3";"nM";"8.37";"";"";"UO_0000065";"19.62";"0.38";"4.33";"8.22";"0";"CHEMBL5136368";"Inhibition of full-length LRRK2 G2019S mutant (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL4475494";"";"None";"482.52";"0";"1.88";"EUB0001558";"CC(C)(O)[C@H](F)CN1Cc2cc(NC(=O)c3cnn4cccnc34)c(N3CCOCC3)cc2C1=O";"IC50";"";"198.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL4886010";"LRRK2 Kinase panel";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4879554";"54";"Donated Chemical Probes - SGC Frankfurt";"";"2021";"None";"";"";""
"CHEMBL5279816";"";"None";"338.38";"0";"1.78";"23";"CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)[C@@H](C)n2nnnc2N1C";"IC50";"'='";"380.0";"nM";"6.42";"";"";"UO_0000065";"18.97";"0.35";"4.64";"6.14";"0";"CHEMBL5246754";"Inhibition of human wild type LRRK2 expressed in HEK293 cells assessed as reduction in pS1292 phosphorylation incubated for 2 hrs by MSD analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL5203973";"";"None";"515.05";"1";"3.16";"10.82";"CC1(C2CCOC2)CC1C(=O)Nc1cc2cc(N3CCN(C4(C)COCC4O)CC3)c(Cl)cc2cn1";"IC50";"'='";"0.1";"nM";"10.00";"";"";"UO_0000065";"19.42";"0.38";"6.84";"11.47";"0";"CHEMBL5126024";"Inhibition of GST-tagged truncated human LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition measured after 90 mins in presence of ATP by TR-FRET based LanthaScreen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5120951";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL5171075";"";"None";"512.01";"1";"2.03";"16.2";"Cn1ncc(C2CC2C(=O)Nc2cc3cc(N4CCN(C5(C)COCC5O)CC4)c(Cl)cc3cn2)n1";"IC50";"'='";"0.08128";"nM";"10.09";"";"";"UO_0000065";"19.71";"0.38";"8.06";"9.29";"0";"CHEMBL5126024";"Inhibition of GST-tagged truncated human LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition measured after 90 mins in presence of ATP by TR-FRET based LanthaScreen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5120951";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL5086513";"";"None";"256.31";"0";"1.41";"18";"C[C@@H]1CCCN1c1c(C#N)c2c(N)ncnc2n1C";"IC50";"'='";"11.0";"nM";"7.96";"";"";"UO_0000065";"31.05";"0.57";"6.55";"9.50";"0";"CHEMBL5040107";"Inhibition of recombinant human GST tagged truncated LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5078779";"";"None";"242.29";"0";"1.40";"20";"C[C@@H]1CCCN1c1[nH]c2ncnc(N)c2c1C#N";"IC50";"'='";"201.0";"nM";"6.70";"";"";"UO_0000065";"27.64";"0.51";"5.30";"7.08";"0";"CHEMBL5040107";"Inhibition of recombinant human GST tagged truncated LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5080604";"";"None";"274.33";"0";"0.64";"22";"C[C@@H]1CCCN1c1c(C(N)=O)c2c(N)ncnc2n1C";"IC50";"'='";"3192.0";"nM";"5.50";"";"";"UO_0000065";"20.03";"0.38";"4.86";"5.33";"0";"CHEMBL5040109";"Inhibition of recombinant human LRRK2 WT using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5089194";"";"None";"365.45";"0";"2.20";"31";"Cc1c(Nc2nc(N)c3c(C#N)c(N4CCC[C@H]4C)n(C)c3n2)cnn1C";"IC50";"'='";"310.0";"nM";"6.51";"";"";"UO_0000065";"17.81";"0.33";"4.31";"5.73";"0";"CHEMBL5040117";"Inhibition of LRRK2-pSer935 in LRRK2 WT expressing human HEK293 cells and measured after 48 hrs by ICW assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 48.0 hr";"INHIBITOR";""
"CHEMBL5201483";"";"None";"469.03";"1";"5.52";"4.64";"CC(C)(C)Cn1cc(Nc2ncc3cc(Cl)c(N4CCC(C5(C)COC5)CC4)cc3n2)cn1";"IC50";"'='";"0.1875";"nM";"9.73";"";"";"UO_0000065";"20.74";"0.40";"4.21";"14.28";"0";"CHEMBL5135962";"Inhibition of GST-tagged truncated human LRRK2 G2019S mutant using fluorescein labeled LRRKtide peptide as substrate preincubated for 15 mins followed by substrate addition and measured after 90 mins in presence of ATP at Km concentration by TR-FRET Lanthascreen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131528";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL5202841";"";"None";"489.60";"0";"3.91";"13";"Cc1c(-c2ccc(-c3c[nH]nc3-c3ccnc(N4CCOCC4)c3)cc2)ccc(S(N)(=O)=O)c1C";"IC50";"'='";"15.5";"nM";"7.81";"";"";"UO_0000065";"15.95";"0.30";"3.90";"6.84";"0";"CHEMBL5136368";"Inhibition of full-length LRRK2 G2019S mutant (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5208171";"";"None";"444.44";"0";"4.47";"18";"NS(=O)(=O)c1cccc(-c2ccc(-c3c(-c4ccncc4)n[nH]c3C(F)(F)F)cc2)c1";"IC50";"'='";"666.0";"nM";"6.18";"";"";"UO_0000065";"13.90";"0.27";"1.71";"6.07";"0";"CHEMBL5136368";"Inhibition of full-length LRRK2 G2019S mutant (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5190962";"";"None";"404.50";"0";"4.07";"24";"Cc1cc(-c2n[nH]cc2-c2ccc(-c3cccc(S(N)(=O)=O)c3)cc2)cc(C)n1";"IC50";"'='";"8.7";"nM";"8.06";"";"";"UO_0000065";"19.93";"0.38";"3.99";"7.92";"0";"CHEMBL5136368";"Inhibition of full-length LRRK2 G2019S mutant (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5083394";"";"None";"256.31";"0";"1.41";"19";"C[C@H]1CCCN1c1c(C#N)c2c(N)ncnc2n1C";"IC50";"'='";"3083.0";"nM";"5.51";"";"";"UO_0000065";"21.50";"0.40";"4.10";"6.58";"0";"CHEMBL5040107";"Inhibition of recombinant human GST tagged truncated LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5190480";"";"None";"406.47";"0";"3.46";"22";"COc1cc(-c2n[nH]cc2-c2ccc(-c3cccc(S(N)(=O)=O)c3)cc2)ccn1";"IC50";"'='";"275.0";"nM";"6.56";"";"";"UO_0000065";"16.14";"0.31";"3.10";"5.91";"0";"CHEMBL5136367";"Inhibition of full-length wild type LRRK2 (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5091544";"";"None";"216.25";"0";"0.49";"15";"CN(C)c1c(C#N)c2c(N)ncnc2n1C";"IC50";"'='";"4619.0";"nM";"5.33";"";"";"UO_0000065";"24.67";"0.46";"4.85";"6.37";"0";"CHEMBL5040109";"Inhibition of recombinant human LRRK2 WT using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5078540";"";"None";"407.48";"0";"2.23";"41";"Cc1c(Nc2nc(N)c3c(C#N)c(N4CCC[C@H]4C)n(C)c3n2)cnn1C1COC1";"IC50";"'='";"47.0";"nM";"7.33";"";"";"UO_0000065";"17.98";"0.33";"5.10";"5.97";"0";"CHEMBL5040109";"Inhibition of recombinant human LRRK2 WT using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5091909";"";"None";"337.39";"0";"1.88";"27";"C[C@@H]1CCCN1c1c(C#N)c2c(N)nc(Nc3cn[nH]c3)nc2n1C";"IC50";"'='";"6.0";"nM";"8.22";"";"";"UO_0000065";"24.37";"0.45";"6.34";"6.61";"0";"CHEMBL5040109";"Inhibition of recombinant human LRRK2 WT using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL3949880";"";"None";"290.37";"0";"3.47";"BDBM254925";"Cc1cc(-c2ccnc3[nH]cc(C#N)c23)ccc1CN(C)C";"IC50";"'='";"288.0";"nM";"6.54";"";"443708";"UO_0000065";"22.53";"0.41";"3.07";"11.74";"0";"CHEMBL3889252";"Homogeneous Time Resolved-fluorescence Resonance Energy Transfer (TR-FRET) Assay: LRRK2 kinase activity is measured using a LanthaScreen kinase activity assay available from Invitrogen (Life Technologies Corporation). The assay is a homogeneous time resolved-fluorescence resonance energy transfer (TR-FRET) assay that measures phosphorylation of a fluorescein-labelled peptide substrate (fluorescein-LRRKtide, fluorescein-GAGRLGRDKYKTLRQIRQ) (SEQ ID NO 1) as a result of LRRK2 kinase activity. The phosphorylated peptide is recognized by a terbium-labelled phospho-specific anti-LRRKtide antibody and, subsequently, the phosphorylated LRRKtide can be quantified by the extent of TR-FRET between the terbium donor and fluorescein acceptor.The LRRK2 kinase is obtained from Invitrogen (Life Technologies Corporation) and comprises residues 970 to 2527 of the full length human wild-type LRRK2 kinase or a similar sequence with the G2019S mutation. As discussed above, this mutation increases the kinase activity relative to the wild-type. The kinase reactions are performed in a 20 uL volume in 384-well plates. The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT.Â  In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 uM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 uM fluorescein-LRRKtide. The reaction mixture (20 ul total volume) is incubated for 2 hours at 30° C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 ul). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 us) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 us. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 us time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3887011";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL5086506";"";"None";"437.51";"1";"1.42";"39";"Cc1c(Nc2nc(N)c3c(C#N)c(N4CCC[C@H]4C)n(C)c3n2)cnn1CC1(O)COC1";"IC50";"'='";"120.0";"nM";"6.92";"";"";"UO_0000065";"15.82";"0.30";"5.50";"4.84";"0";"CHEMBL5040116";"Inhibition of LRRK2-pSer935 in LRRK2 G2019S mutant expressing human HEK293 cells and measured after 48 hrs by ICW assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 48.0 hr";"INHIBITOR";""
"CHEMBL5080937";"";"None";"385.86";"0";"2.54";"34";"C[C@@H]1CCCN1c1c(C#N)c2c(N)nc(Nc3cn(C)nc3Cl)nc2n1C";"IC50";"'='";"21.0";"nM";"7.68";"";"";"UO_0000065";"19.90";"0.39";"5.14";"6.76";"0";"CHEMBL5040107";"Inhibition of recombinant human GST tagged truncated LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5074790";"";"None";"419.42";"0";"2.91";"35";"C[C@@H]1CCCN1c1c(C#N)c2c(N)nc(Nc3cn(C)nc3C(F)(F)F)nc2n1C";"IC50";"'='";"358.0";"nM";"6.45";"";"";"UO_0000065";"15.37";"0.29";"3.54";"5.67";"0";"CHEMBL5040107";"Inhibition of recombinant human GST tagged truncated LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5088551";"";"None";"423.53";"0";"2.43";"37";"Cc1c(Nc2nc(N)c3c(C#N)c(N4CCC[C@H]4C)n(C)c3n2)cnn1CC(C)(C)O";"IC50";"'='";"35.0";"nM";"7.46";"";"";"UO_0000065";"17.60";"0.33";"5.03";"5.57";"0";"CHEMBL5040107";"Inhibition of recombinant human GST tagged truncated LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5078540";"";"None";"407.48";"0";"2.23";"41";"Cc1c(Nc2nc(N)c3c(C#N)c(N4CCC[C@H]4C)n(C)c3n2)cnn1C1COC1";"IC50";"'='";"37.0";"nM";"7.43";"";"";"UO_0000065";"18.24";"0.34";"5.20";"6.05";"0";"CHEMBL5040107";"Inhibition of recombinant human GST tagged truncated LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5093047";"";"None";"296.31";"0";"2.17";"10";"Cn1c(NCc2ccccc2F)c(C#N)c2c(N)ncnc21";"IC50";"'='";"6055.0";"nM";"5.22";"";"";"UO_0000065";"17.61";"0.32";"3.05";"5.64";"0";"CHEMBL5040109";"Inhibition of recombinant human LRRK2 WT using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL4064135";"";"None";"349.39";"0";"2.31";"17";"NC(=O)c1ccc(Nc2nc(N3CCOCC3)c3ccccc3n2)cc1";"IC50";"'='";"633.0";"nM";"6.20";"";"";"UO_0000065";"17.74";"0.33";"3.89";"6.64";"0";"CHEMBL4018178";"Inhibition of LRRK2 G2019S mutant (unknown origin) using biotinylated ezrin/radaxin/meosin peptide as substrate measured after 1 hr";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4017473";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";"None";"";"";""
"CHEMBL5283154";"";"None";"375.44";"0";"2.82";"11";"C[C@@H]1CN(c2cc(-n3ncc4ccc(-c5ccn[nH]5)cc43)ncn2)C[C@H](C)O1";"IC50";"'='";"14.0";"nM";"7.85";"";"";"UO_0000065";"20.92";"0.38";"5.03";"9.27";"0";"CHEMBL5239655";"Inhibition of GST20-tagged human LRRK2 G2019S mutant using LRRKtide peptide preincubated for 15 mins followed by substrate addition and measured after 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5236618";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL5266616";"";"None";"428.54";"0";"3.75";"22";"CC(C)(O)C12CC(C1)N(c1cc(-n3ncc4ccc(C5(C#N)CC5(C)C)cc43)ncn1)C2";"IC50";"'='";"35.0";"nM";"7.46";"";"";"UO_0000065";"17.40";"0.32";"3.71";"8.21";"0";"CHEMBL5239655";"Inhibition of GST20-tagged human LRRK2 G2019S mutant using LRRKtide peptide preincubated for 15 mins followed by substrate addition and measured after 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5236618";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL5283154";"";"None";"375.44";"0";"2.82";"11";"C[C@@H]1CN(c2cc(-n3ncc4ccc(-c5ccn[nH]5)cc43)ncn2)C[C@H](C)O1";"IC50";"'='";"24.0";"nM";"7.62";"";"";"UO_0000065";"20.30";"0.37";"4.80";"8.99";"0";"CHEMBL5239656";"Inhibition of GST20-tagged LRRK2 in human SH-SY5Y cells assessed as reduction in pSer935 phosphorylation incubated for 90 mins by MSD assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5236618";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 1.5 hr";"INHIBITOR";""
"CHEMBL5282583";"";"None";"389.46";"0";"2.80";"13";"CC(C)(O)[C@@H]1CCN(c2cc(-n3ncc4ccc(-c5ccn[nH]5)cc43)ncn2)C1";"IC50";"'='";"18.0";"nM";"7.75";"";"";"UO_0000065";"19.89";"0.36";"4.94";"8.09";"0";"CHEMBL5239656";"Inhibition of GST20-tagged LRRK2 in human SH-SY5Y cells assessed as reduction in pSer935 phosphorylation incubated for 90 mins by MSD assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5236618";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 1.5 hr";"INHIBITOR";""
"CHEMBL5285084";"";"None";"428.54";"0";"3.75";"23";"CC(C#N)(c1ccc2cnn(-c3cc(N4CC5(C(C)(C)O)CC4C5)ncn3)c2c1)C1CC1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5239656";"Inhibition of GST20-tagged LRRK2 in human SH-SY5Y cells assessed as reduction in pSer935 phosphorylation incubated for 90 mins by MSD assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5236618";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 1.5 hr";"";""
"CHEMBL5284341";"";"None";"426.52";"0";"3.50";"24";"CC(C)(O)C12CC(C1)N(c1cc(-n3ncc4ccc([C@]5(C#N)CC56CC6)cc43)ncn1)C2";"IC50";"'='";"0.4";"nM";"9.40";"";"";"UO_0000065";"22.03";"0.40";"5.90";"10.34";"0";"CHEMBL5239656";"Inhibition of GST20-tagged LRRK2 in human SH-SY5Y cells assessed as reduction in pSer935 phosphorylation incubated for 90 mins by MSD assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5236618";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 1.5 hr";"INHIBITOR";""
"CHEMBL5271437";"";"None";"350.39";"0";"1.73";"43";"CC1=C(C(=O)Nc2ccc3c(N)nccc3c2)[C@@H](C)n2nnnc2N1C";"IC50";"'='";"12.0";"nM";"7.92";"";"";"UO_0000065";"22.61";"0.42";"6.19";"6.90";"0";"CHEMBL5246746";"Inhibition of N-terminal GST-fused human LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5281154";"";"None";"486.54";"0";"2.37";"26";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4ccnc(N5CCOCC5)c4)c3c2)[C@@H](C)n2nnnc2N1C";"IC50";"'='";"65.0";"nM";"7.19";"";"";"UO_0000065";"14.77";"0.27";"4.82";"5.53";"0";"CHEMBL5246748";"Inhibition of human wild type LRRK2 expressed in HEK293 cells assessed as reduction in pSer935 phosphorylation incubated for 2 hrs by HTRF analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL5280373";"";"None";"414.47";"0";"3.31";"31; EB-42486";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4ccccc4)c3c2)C(C)(C)n2nnnc2N1C";"IC50";"'='";"1060.0";"nM";"5.97";"";"";"UO_0000065";"14.42";"0.26";"2.66";"5.71";"0";"CHEMBL5246748";"Inhibition of human wild type LRRK2 expressed in HEK293 cells assessed as reduction in pSer935 phosphorylation incubated for 2 hrs by HTRF analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL5288427";"";"None";"426.44";"0";"2.46";"7";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4nc5ccccc5[nH]4)c3c2)Cn2nnnc2N1C";"IC50";"'='";"21.0";"nM";"7.68";"";"";"UO_0000065";"18.00";"0.33";"5.22";"5.76";"0";"CHEMBL5246749";"Inhibition of human LRRK2 G2019S mutant expressed in HEK293 cells assessed as reduction in pSer935 phosphorylation incubated for 2 hrs by HTRF analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL5289513";"";"None";"324.35";"0";"1.47";"21";"CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)[C@@H](C)n2nnnc2N1C";"IC50";"'='";"189.0";"nM";"6.72";"";"";"UO_0000065";"20.73";"0.38";"5.25";"6.43";"0";"CHEMBL5246749";"Inhibition of human LRRK2 G2019S mutant expressed in HEK293 cells assessed as reduction in pSer935 phosphorylation incubated for 2 hrs by HTRF analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL5270706";"";"None";"500.57";"1";"2.55";"30";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4ccnc(N5CCOCC5)c4)c3c2)C(C)(C)n2nnnc2N1C";"IC50";"'='";"259.0";"nM";"6.59";"";"";"UO_0000065";"13.16";"0.24";"4.04";"5.07";"0";"CHEMBL5246751";"Inhibition of human wild type LRRK2 expressed in HEK293 cells assessed as reduction in pSer935 phosphorylation incubated for 2 hrs by immunoblotting analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL5280373";"";"None";"414.47";"0";"3.31";"31; EB-42486";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4ccccc4)c3c2)C(C)(C)n2nnnc2N1C";"IC50";"'='";"117.0";"nM";"6.93";"";"";"UO_0000065";"16.72";"0.31";"3.62";"6.63";"0";"CHEMBL5246754";"Inhibition of human wild type LRRK2 expressed in HEK293 cells assessed as reduction in pS1292 phosphorylation incubated for 2 hrs by MSD analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL5270706";"";"None";"500.57";"1";"2.55";"30";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4ccnc(N5CCOCC5)c4)c3c2)C(C)(C)n2nnnc2N1C";"IC50";"'='";"1.0";"nM";"9.00";"";"";"UO_0000065";"17.98";"0.33";"6.45";"6.92";"0";"CHEMBL5246755";"Inhibition of human LRRK2 G2019S mutant expressed in HEK293 cells assessed as reduction in pS1292 phosphorylation incubated for 2 hrs by MSD analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL5186450";"";"None";"357.33";"0";"4.20";"8";"N#Cc1ccc(Oc2ccc3[nH]nc(-c4ccncc4)c3c2)c([N+](=O)[O-])c1";"IC50";"'='";"26.0";"nM";"7.58";"";"";"UO_0000065";"21.23";"0.38";"3.39";"6.44";"0";"CHEMBL5157022";"Inhibition of full length wild type LRRK2 (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL3983531";"";"None";"410.45";"0";"2.78";"BDBM223556";"CC(C)n1cc(-c2cc(-c3ccc(C(=O)N4CCOCC4)c(F)c3)cnc2N)nn1";"IC50";"'='";"580.0";"nM";"6.24";"";"390841";"UO_0000065";"15.19";"0.28";"3.46";"6.29";"0";"CHEMBL3888346";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3937495";"";"None";"300.39";"0";"1.91";"BDBM185466";"Cn1cc(-c2c[nH]c3ncnc(N4CCSCC4)c23)cn1";"IC50";"'='";"71.0";"nM";"7.15";"";"334439";"UO_0000065";"23.80";"0.46";"5.24";"11.41";"0";"CHEMBL3887345";"Lantha Screen Technology Assay: LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat #PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat #PR8975A). The assay was carried out under the following protocol: 3 uL of a working solution of substrate (233 nM LRRKtide, 117 uM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCl2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half-log in DMSO 11 times. Aliquots (3.5 uL) of the 100% DMSO dose response were mixed with 46.5 uL water.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886286";"37";"BindingDB Database";"";"2015";"None";"";"";""
"CHEMBL3980263";"";"None";"375.38";"0";"2.54";"BDBM239286";"COCCOc1ccc2[nH]nc(-c3cc(N4C[C@H](F)[C@@H](F)C4)ncn3)c2c1";"IC50";"'='";"138.5";"nM";"6.86";"";"417745";"UO_0000065";"18.27";"0.35";"4.32";"9.01";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3915899";"";"None";"446.53";"0";"1.52";"BDBM239301";"COC[C@H](C)Oc1ccc2[nH]nc(-c3cc(N4CCN(S(C)(=O)=O)CC4)ncn3)c2c1";"IC50";"'='";"4.5";"nM";"8.35";"";"417761";"UO_0000065";"18.69";"0.37";"6.83";"7.35";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3907065";"";"None";"382.47";"0";"2.19";"BDBM239302";"COC[C@H](C)Oc1ccc2[nH]nc(-c3cc(N4CCN(C)CC4)ncn3)c2c1";"IC50";"'='";"2.08";"nM";"8.68";"";"417762";"UO_0000065";"22.70";"0.42";"6.49";"10.93";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3966726";"";"None";"317.35";"0";"3.74";"BDBM223542";"Nc1ncc(-c2ccc3[nH]ccc3c2)cc1-c1nnc(C2CC2)o1";"IC50";"'='";"1000.0";"nM";"6.00";"";"390798";"UO_0000065";"18.91";"0.34";"2.26";"6.41";"0";"CHEMBL3888345";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3954911";"";"None";"347.38";"0";"3.12";"BDBM239524";"c1nc(-c2n[nH]c3ccc(-c4ccoc4)cc23)cc(N2CCOCC2)n1";"IC50";"'='";"19.01";"nM";"7.72";"";"417987";"UO_0000065";"22.23";"0.41";"4.60";"9.64";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3960072";"";"None";"388.43";"0";"2.93";"BDBM239529";"COc1ccncc1-c1ccc2[nH]nc(-c3cc(N4CCOCC4)ncn3)c2c1";"IC50";"'='";"1.72";"nM";"8.76";"";"417992";"UO_0000065";"22.56";"0.41";"5.83";"9.84";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3955660";"";"None";"465.54";"0";"2.17";"BDBM239536";"COc1ccncc1-c1ccc2[nH]nc(-c3cc(N4CCN(S(C)(=O)=O)CC4)ncn3)c2c1";"IC50";"'='";"1.58";"nM";"8.80";"";"417999";"UO_0000065";"18.91";"0.36";"6.63";"7.51";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3961481";"";"None";"343.39";"0";"3.59";"BDBM254937";"Cc1cccc(-c2cc(Nc3nn(C)cc3C)nc3[nH]cc(C#N)c23)n1";"IC50";"'='";"50.0";"nM";"7.30";"";"443720";"UO_0000065";"21.26";"0.38";"3.71";"7.67";"0";"CHEMBL3889252";"Homogeneous Time Resolved-fluorescence Resonance Energy Transfer (TR-FRET) Assay: LRRK2 kinase activity is measured using a LanthaScreen kinase activity assay available from Invitrogen (Life Technologies Corporation). The assay is a homogeneous time resolved-fluorescence resonance energy transfer (TR-FRET) assay that measures phosphorylation of a fluorescein-labelled peptide substrate (fluorescein-LRRKtide, fluorescein-GAGRLGRDKYKTLRQIRQ) (SEQ ID NO 1) as a result of LRRK2 kinase activity. The phosphorylated peptide is recognized by a terbium-labelled phospho-specific anti-LRRKtide antibody and, subsequently, the phosphorylated LRRKtide can be quantified by the extent of TR-FRET between the terbium donor and fluorescein acceptor.The LRRK2 kinase is obtained from Invitrogen (Life Technologies Corporation) and comprises residues 970 to 2527 of the full length human wild-type LRRK2 kinase or a similar sequence with the G2019S mutation. As discussed above, this mutation increases the kinase activity relative to the wild-type. The kinase reactions are performed in a 20 uL volume in 384-well plates. The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT.Â  In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 uM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 uM fluorescein-LRRKtide. The reaction mixture (20 ul total volume) is incubated for 2 hours at 30° C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 ul). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 us) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 us. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 us time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3887011";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3896115";"";"None";"234.26";"0";"2.68";"BDBM254928";"N#Cc1c[nH]c2nc(N)cc(-c3ccccc3)c12";"IC50";"'='";"216.0";"nM";"6.67";"";"443734";"UO_0000065";"28.45";"0.51";"3.99";"8.49";"0";"CHEMBL3889253";"Homogeneous Time Resolved-fluorescence Resonance Energy Transfer (TR-FRET) Assay: LRRK2 kinase activity is measured using a LanthaScreen kinase activity assay available from Invitrogen (Life Technologies Corporation). The assay is a homogeneous time resolved-fluorescence resonance energy transfer (TR-FRET) assay that measures phosphorylation of a fluorescein-labelled peptide substrate (fluorescein-LRRKtide, fluorescein-GAGRLGRDKYKTLRQIRQ) (SEQ ID NO 1) as a result of LRRK2 kinase activity. The phosphorylated peptide is recognized by a terbium-labelled phospho-specific anti-LRRKtide antibody and, subsequently, the phosphorylated LRRKtide can be quantified by the extent of TR-FRET between the terbium donor and fluorescein acceptor.The LRRK2 kinase is obtained from Invitrogen (Life Technologies Corporation) and comprises residues 970 to 2527 of the full length human wild-type LRRK2 kinase or a similar sequence with the G2019S mutation. As discussed above, this mutation increases the kinase activity relative to the wild-type. The kinase reactions are performed in a 20 uL volume in 384-well plates. The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT.Â  In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 uM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 uM fluorescein-LRRKtide. The reaction mixture (20 ul total volume) is incubated for 2 hours at 30° C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 ul). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 us) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 us. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 us time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3887011";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3922655";"";"None";"374.45";"0";"2.17";"BDBM239182";"CN1CCN(c2cc(-c3n[nH]c4ccc(-c5cnn(C)c5)cc34)ncn2)CC1";"IC50";"'='";"2.85";"nM";"8.54";"";"417641";"UO_0000065";"22.82";"0.42";"6.38";"10.85";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3952812";"";"None";"402.46";"0";"2.09";"BDBM239188";"CC(=O)N1CCN(c2cc(-c3n[nH]c4ccc(-c5cnn(C)c5)cc34)ncn2)CC1";"IC50";"'='";"3.15";"nM";"8.50";"";"417647";"UO_0000065";"21.12";"0.39";"6.41";"8.87";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3922844";"";"None";"334.43";"0";"3.16";"BDBM223550";"CC(C)n1cc(-c2cc(-c3ccc4c(c3)CCN4C)cnc2N)nn1";"IC50";"'='";"350.0";"nM";"6.46";"";"390806";"UO_0000065";"19.30";"0.35";"3.30";"8.86";"0";"CHEMBL3888345";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3966726";"";"None";"317.35";"0";"3.74";"BDBM223542";"Nc1ncc(-c2ccc3[nH]ccc3c2)cc1-c1nnc(C2CC2)o1";"IC50";"'='";"570.0";"nM";"6.24";"";"390827";"UO_0000065";"19.68";"0.36";"2.50";"6.67";"0";"CHEMBL3888346";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3952893";"";"None";"394.48";"0";"2.87";"BDBM239219";"CCCN1CCN(c2cc(-c3n[nH]c4ccc(OC(C)C)cc34)ncn2)CC1=O";"IC50";"'='";"4.39";"nM";"8.36";"";"417680";"UO_0000065";"21.19";"0.39";"5.49";"9.58";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4113352";"";"None";"384.46";"0";"3.09";"BDBM239235";"CC(C)Oc1cc2c(-c3cc(N4CCN(C)[C@H](C)C4)ncn3)n[nH]c2cc1F";"IC50";"'='";"1.3";"nM";"8.89";"";"417696";"UO_0000065";"23.11";"0.43";"5.80";"12.66";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3928726";"";"None";"412.47";"0";"3.00";"BDBM239253";"CC(C)Oc1cc2c(-c3cc(N4CCN(C(C)C)C(=O)C4)ncn3)n[nH]c2cc1F";"IC50";"'='";"3.09";"nM";"8.51";"";"417714";"UO_0000065";"20.63";"0.39";"5.51";"9.75";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3941371";"";"None";"350.43";"0";"2.31";"BDBM239266";"COc1ccc2[nH]nc(-c3cc(N4CCN(C5CC5)CC4)ncn3)c2c1";"IC50";"'='";"25.9";"nM";"7.59";"";"417725";"UO_0000065";"21.65";"0.40";"5.28";"10.81";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3942624";"";"None";"366.43";"0";"2.09";"BDBM239281";"CCOc1ccc2[nH]nc(-c3cc(N4CCN(C(C)=O)CC4)ncn3)c2c1";"IC50";"'='";"18.0";"nM";"7.75";"";"417740";"UO_0000065";"21.14";"0.39";"5.65";"8.88";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL5191262";"";"None";"513.06";"1";"3.96";"10.13";"CC1(N2CCN(c3cc4cc(NC(=O)C5CC5c5cccs5)ncc4cc3Cl)CC2)COCC1O";"IC50";"'='";"0.08128";"nM";"10.09";"";"";"UO_0000065";"19.67";"0.39";"6.13";"12.95";"0";"CHEMBL5126024";"Inhibition of GST-tagged truncated human LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition measured after 90 mins in presence of ATP by TR-FRET based LanthaScreen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5120951";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL4848810";"";"None";"498.42";"0";"4.93";"4.102";"N#CC1COCC1N1CCC(c2cc3nc(Nc4cnn(C5CC5)c4Cl)ncc3cc2Cl)CC1";"IC50";"'<'";"0.631";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL4827623";"Inhibition of Kinase tracer 236 binding to GST-tagged truncated human LRRK2 G2019S (970 to 2527 residues) mutant using fluorescein labeled LRRKtide peptide as substrate preincubated for 15 mins followed by substrate addition measured after 90 mins in presence of ATP at Km concentration by TR-FRET Lanthascreen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4825716";"1";"Scientific Literature";"ACS Med Chem Lett";"2021";"None";"TIME = 1.75 hr";"";""
"CHEMBL2204495";"";"None";"399.43";"1";"5.11";"EUB0000622a";"O=C(Nc1cccnc1)c1cc(-c2ccnc(F)c2)ccc1OCc1ccccc1";"IC50";"'='";"10.9";"nM";"7.96";"";"";"UO_0000065";"19.93";"0.36";"2.85";"12.42";"0";"CHEMBL5210322";"Affinity Biochemical interaction (HTRF assay) EUB0000622a LRRK2";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"Mode of action: Inhibitor | Protein family: Protein Kinase | Recommended concentration = 1.0 µM";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5210307";"65";"Literature data from EUbOPEN Chemogenomic Library";"";"2023";"None";"Affinity Biochemical Source Knowledge: https://doi.org/10.1016/j.bmcl.2012.06.104";"INHIBITOR";""
"CHEMBL4098877";"MLi-2";"None";"379.46";"0";"3.56";"EUB0000715a";"C[C@@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@H](C)O1";"IC50";"'='";"0.76";"nM";"9.12";"";"";"UO_0000065";"24.03";"0.44";"5.56";"11.97";"0";"CHEMBL5210435";"Affinity Biochemical interaction (LanthaScreen) EUB0000715a LRRK2";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"Mode of action: Inhibitor | Negative control: MLi-2-NC | Protein family: Protein Kinase | Recommended concentration = 100.0 nM";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5210307";"65";"Literature data from EUbOPEN Chemogenomic Library";"";"2023";"None";"Affinity Biochemical Source Knowledge: https://doi.org/10.1124/jpet.115.227587";"INHIBITOR";""
"CHEMBL5196263";"";"None";"323.36";"0";"2.05";"3";"Cn1cc(-c2nccc(C(=O)Nc3cnn(C4CCC4)c3)n2)cn1";"IC50";"'='";"34.0";"nM";"7.47";"";"";"UO_0000065";"23.10";"0.42";"5.42";"8.25";"0";"CHEMBL5108135";"Inhibition of recombinant human GST20 tagged truncated LRRK2 G2019S mutant assessed as substrate phosphorylation preincubated for 15 mins followed by substrate addition and measured after 90 mins using fluorescein-labeled LRRK2tide as substrate in presence of ATP by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5107939";"1";"Scientific Literature";"RSC Med Chem";"2021";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL5187531";"";"None";"460.46";"0";"3.76";"6";"C[C@@H]1CN(c2cc(NC(=O)c3cccc(-c4cnn(C)c4)n3)c(C(F)(F)F)cn2)C[C@H](C)O1";"IC50";"'='";"4.0";"nM";"8.40";"";"";"UO_0000065";"18.24";"0.35";"4.64";"9.86";"0";"CHEMBL5108135";"Inhibition of recombinant human GST20 tagged truncated LRRK2 G2019S mutant assessed as substrate phosphorylation preincubated for 15 mins followed by substrate addition and measured after 90 mins using fluorescein-labeled LRRK2tide as substrate in presence of ATP by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5107939";"1";"Scientific Literature";"RSC Med Chem";"2021";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL5202285";"";"None";"486.50";"0";"3.89";"11";"Cn1cc(-c2cccc(C(=O)Nc3cc(N4CC5(C(C)(C)O)CC4C5)ncc3C(F)(F)F)n2)cn1";"IC50";"'='";"9.0";"nM";"8.05";"";"";"UO_0000065";"16.54";"0.31";"4.16";"8.37";"0";"CHEMBL5108135";"Inhibition of recombinant human GST20 tagged truncated LRRK2 G2019S mutant assessed as substrate phosphorylation preincubated for 15 mins followed by substrate addition and measured after 90 mins using fluorescein-labeled LRRK2tide as substrate in presence of ATP by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5107939";"1";"Scientific Literature";"RSC Med Chem";"2021";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL5181104";"";"None";"514.55";"1";"4.62";"21";"CC(C)(O)[C@@H]1CCN(c2cnc(C(F)(F)F)c(NC(=O)c3cccc(-c4cnn(CC5CC5)c4)n3)c2)C1";"IC50";"'='";"8.6";"nM";"8.07";"";"";"UO_0000065";"15.67";"0.30";"3.45";"8.39";"0";"CHEMBL5108135";"Inhibition of recombinant human GST20 tagged truncated LRRK2 G2019S mutant assessed as substrate phosphorylation preincubated for 15 mins followed by substrate addition and measured after 90 mins using fluorescein-labeled LRRK2tide as substrate in presence of ATP by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5107939";"1";"Scientific Literature";"RSC Med Chem";"2021";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL5190579";"";"None";"322.37";"0";"2.66";"4";"Cn1cc(-c2cccc(C(=O)Nc3cnn(C4CCC4)c3)n2)cn1";"IC50";"'='";"905.0";"nM";"6.04";"";"";"UO_0000065";"18.75";"0.34";"3.38";"7.78";"0";"CHEMBL5108136";"Inhibition of human LRRK2 G2019S mutant expressed in human SH-SY5Y cells assessed as inhibition of tetracycline induced LRRK2 phosphorylation at Ser935 residue incubated for 90 mins by MSD assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5107939";"1";"Scientific Literature";"RSC Med Chem";"2021";"None";"TIME = 1.5 hr";"INHIBITOR";""
"CHEMBL5208974";"";"None";"406.49";"0";"3.05";"5";"Cc1cnc(N2C[C@@H](C)O[C@@H](C)C2)cc1NC(=O)c1cccc(-c2cnn(C)c2)n1";"IC50";"'='";"24.0";"nM";"7.62";"";"";"UO_0000065";"18.75";"0.35";"4.57";"8.95";"0";"CHEMBL5108136";"Inhibition of human LRRK2 G2019S mutant expressed in human SH-SY5Y cells assessed as inhibition of tetracycline induced LRRK2 phosphorylation at Ser935 residue incubated for 90 mins by MSD assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5107939";"1";"Scientific Literature";"RSC Med Chem";"2021";"None";"TIME = 1.5 hr";"INHIBITOR";""
"CHEMBL5190679";"";"None";"418.38";"0";"2.33";"8";"Cn1cc(-c2cccc(C(=O)Nc3cc(N4CC(O)C4)ncc3C(F)(F)F)n2)cn1";"IC50";"'='";"7.5";"nM";"8.12";"";"";"UO_0000065";"19.42";"0.37";"5.79";"8.45";"0";"CHEMBL5108136";"Inhibition of human LRRK2 G2019S mutant expressed in human SH-SY5Y cells assessed as inhibition of tetracycline induced LRRK2 phosphorylation at Ser935 residue incubated for 90 mins by MSD assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5107939";"1";"Scientific Literature";"RSC Med Chem";"2021";"None";"TIME = 1.5 hr";"INHIBITOR";""
"CHEMBL5190434";"";"None";"432.41";"0";"2.72";"9";"C[C@@H]1[C@@H](O)CN1c1cc(NC(=O)c2cccc(-c3cnn(C)c3)n2)c(C(F)(F)F)cn1";"IC50";"'='";"2.0";"nM";"8.70";"";"";"UO_0000065";"20.12";"0.38";"5.98";"9.05";"0";"CHEMBL5108136";"Inhibition of human LRRK2 G2019S mutant expressed in human SH-SY5Y cells assessed as inhibition of tetracycline induced LRRK2 phosphorylation at Ser935 residue incubated for 90 mins by MSD assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5107939";"1";"Scientific Literature";"RSC Med Chem";"2021";"None";"TIME = 1.5 hr";"INHIBITOR";""
"CHEMBL5288038";"";"None";"429.44";"0";"2.16";"10";"CC1=C(C(=O)Nc2ccc3[nH]nc(NC(=O)c4ccccc4)c3c2)Cn2nnnc2N1C";"IC50";"'='";"108.0";"nM";"6.97";"";"";"UO_0000065";"16.22";"0.30";"4.81";"5.21";"0";"CHEMBL5246745";"Inhibition of N-terminal GST-fused human wild type LRRK2 using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5277180";"";"None";"324.35";"0";"1.47";"22";"CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)[C@H](C)n2nnnc2N1C";"IC50";"'='";"302.0";"nM";"6.52";"";"";"UO_0000065";"20.10";"0.37";"5.05";"6.23";"0";"CHEMBL5246745";"Inhibition of N-terminal GST-fused human wild type LRRK2 using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5289260";"";"None";"338.38";"0";"1.65";"28";"CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(C)(C)n2nnnc2N1C";"IC50";"'='";"1300.0";"nM";"5.89";"";"";"UO_0000065";"17.39";"0.32";"4.24";"5.63";"0";"CHEMBL5246745";"Inhibition of N-terminal GST-fused human wild type LRRK2 using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5285625";"";"None";"324.35";"0";"0.99";"35";"CC1=C(C(=O)Nc2ccc3cnc(C)n3c2)Cn2nnnc2N1C";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5246745";"Inhibition of N-terminal GST-fused human wild type LRRK2 using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"";""
"CHEMBL5266676";"";"None";"353.35";"0";"0.01";"9";"CC1=C(C(=O)Nc2ccc3[nH]nc(C(N)=O)c3c2)Cn2nnnc2N1C";"IC50";"'='";"6.0";"nM";"8.22";"";"";"UO_0000065";"23.27";"0.43";"8.21";"5.57";"0";"CHEMBL5246746";"Inhibition of N-terminal GST-fused human LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5267951";"";"None";"324.35";"0";"1.30";"14";"CCN1C(C)=C(C(=O)Nc2ccc3[nH]ncc3c2)Cn2nnnc21";"IC50";"'='";"58.0";"nM";"7.24";"";"";"UO_0000065";"22.31";"0.41";"5.94";"6.92";"0";"CHEMBL5246746";"Inhibition of N-terminal GST-fused human LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5277004";"";"None";"367.37";"0";"0.96";"16";"CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)Cn2nnnc2N1C(=O)N(C)C";"IC50";"'='";"53.0";"nM";"7.28";"";"";"UO_0000065";"19.80";"0.37";"6.32";"5.82";"0";"CHEMBL5246746";"Inhibition of N-terminal GST-fused human LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5289513";"";"None";"324.35";"0";"1.47";"21";"CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)[C@@H](C)n2nnnc2N1C";"IC50";"'='";"1.64";"nM";"8.79";"";"";"UO_0000065";"27.09";"0.50";"7.32";"8.40";"0";"CHEMBL5246746";"Inhibition of N-terminal GST-fused human LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5279765";"";"None";"338.38";"0";"1.78";"24";"CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)[C@H](C)n2nnnc2N1C";"IC50";"'='";"51.0";"nM";"7.29";"";"";"UO_0000065";"21.55";"0.40";"5.51";"6.97";"0";"CHEMBL5246746";"Inhibition of N-terminal GST-fused human LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5198878";"";"None";"404.50";"0";"4.07";"25";"Cc1cc(-c2c(-c3ccncc3)n[nH]c2C)ccc1-c1cccc(S(N)(=O)=O)c1";"IC50";"'='";"44.3";"nM";"7.35";"";"";"UO_0000065";"18.18";"0.35";"3.28";"7.23";"0";"CHEMBL5136367";"Inhibition of full-length wild type LRRK2 (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5198788";"";"None";"403.51";"0";"4.83";"28";"Cc1cc(-c2c(-c3ccncc3)n[nH]c2C)ccc1-c1cccc(S(C)(=O)=O)c1";"IC50";"'='";"406.0";"nM";"6.39";"";"";"UO_0000065";"15.84";"0.30";"1.56";"8.44";"0";"CHEMBL5136367";"Inhibition of full-length wild type LRRK2 (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5195211";"";"None";"418.52";"0";"4.32";"29";"CCc1cc(-c2c(-c3ccncc3)n[nH]c2C)ccc1-c1ccc(S(N)(=O)=O)cc1";"IC50";"'='";"405.0";"nM";"6.39";"";"";"UO_0000065";"15.27";"0.29";"2.07";"6.28";"0";"CHEMBL5136367";"Inhibition of full-length wild type LRRK2 (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL4576555";"T3-CLK-N";"None";"593.82";"2";"6.90";"EUB0000705a";"CN1CCN(C(=O)C(C)(C)c2ccc(C(=O)Nc3cn4cc(-c5cc(C(C)(C)C)cc(C(C)(C)C)c5)ccc4n3)cc2)CC1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5213389";"Selectivity interaction (NanoBRET assay (HEK293T cells)) EUB0000705a LRRK2";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"Protein family: Protein Kinase";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5212743";"65";"Literature data from EUbOPEN Chemogenomic Library";"";"2023";"None";"Selectivity Remarks: Cellular potency | Selectivity Source Knowledge: https://www.thesgc.org/chemical-probes/T3-CLK";"";""
"CHEMBL5200500";"";"None";"420.49";"0";"3.77";"21";"COc1cc(-c2n[nH]c(C)c2-c2ccc(-c3cccc(S(N)(=O)=O)c3)cc2)ccn1";"IC50";"'='";"19.1";"nM";"7.72";"";"";"UO_0000065";"18.36";"0.35";"3.95";"6.96";"0";"CHEMBL5136368";"Inhibition of full-length LRRK2 G2019S mutant (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5170225";"";"None";"408.46";"0";"3.90";"35";"Cc1[nH]nc(-c2ccncc2)c1-c1ccc(-c2cccc(S(N)(=O)=O)c2)c(F)c1";"IC50";"'='";"7.6";"nM";"8.12";"";"";"UO_0000065";"19.88";"0.38";"4.22";"7.98";"0";"CHEMBL5136368";"Inhibition of full-length LRRK2 G2019S mutant (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5085777";"";"None";"400.49";"0";"4.18";"10";"Cc1c(Nc2ncc3ccc(C4(C#N)CC45CC5)cc3n2)cnn1C1CCOCC1";"IC50";"'<'";"0.6";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5044129";"Inhibition of recombinant N-terminal GST-fused LRRK2 G2109S mutant (970 to 2527 residues) (unknown origin) preincubated with enzyme for 15 mins followed by fluorescein-labeled LRRKtide peptide substrate and ATP addition for 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5042510";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL5094228";"";"None";"437.51";"1";"1.42";"38";"Cc1nn(CC2(O)COC2)cc1Nc1nc(N)c2c(C#N)c(N3CCC[C@H]3C)n(C)c2n1";"IC50";"'='";"57.0";"nM";"7.24";"";"";"UO_0000065";"16.56";"0.31";"5.82";"5.06";"0";"CHEMBL5040109";"Inhibition of recombinant human LRRK2 WT using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5075824";"";"None";"407.48";"0";"2.23";"40";"Cc1nn(C2COC2)cc1Nc1nc(N)c2c(C#N)c(N3CCC[C@H]3C)n(C)c2n1";"IC50";"'='";"38.0";"nM";"7.42";"";"";"UO_0000065";"18.21";"0.34";"5.19";"6.04";"0";"CHEMBL5040109";"Inhibition of recombinant human LRRK2 WT using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5089152";"";"None";"421.51";"0";"2.62";"42";"Cc1nn(C2CCOC2)cc1Nc1nc(N)c2c(C#N)c(N3CCC[C@H]3C)n(C)c2n1";"IC50";"'='";"180.0";"nM";"6.75";"";"";"UO_0000065";"16.00";"0.30";"4.12";"5.49";"0";"CHEMBL5040116";"Inhibition of LRRK2-pSer935 in LRRK2 G2019S mutant expressing human HEK293 cells and measured after 48 hrs by ICW assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 48.0 hr";"INHIBITOR";""
"CHEMBL5080937";"";"None";"385.86";"0";"2.54";"34";"C[C@@H]1CCCN1c1c(C#N)c2c(N)nc(Nc3cn(C)nc3Cl)nc2n1C";"IC50";"'='";"54.0";"nM";"7.27";"";"";"UO_0000065";"18.83";"0.37";"4.73";"6.40";"0";"CHEMBL5040116";"Inhibition of LRRK2-pSer935 in LRRK2 G2019S mutant expressing human HEK293 cells and measured after 48 hrs by ICW assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 48.0 hr";"INHIBITOR";""
"CHEMBL5091819";"";"None";"423.53";"0";"2.43";"36";"Cc1nn(CC(C)(C)O)cc1Nc1nc(N)c2c(C#N)c(N3CCC[C@H]3C)n(C)c2n1";"IC50";"'='";"180.0";"nM";"6.75";"";"";"UO_0000065";"15.93";"0.30";"4.31";"5.04";"0";"CHEMBL5040116";"Inhibition of LRRK2-pSer935 in LRRK2 G2019S mutant expressing human HEK293 cells and measured after 48 hrs by ICW assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 48.0 hr";"INHIBITOR";""
"CHEMBL5088551";"";"None";"423.53";"0";"2.43";"37";"Cc1c(Nc2nc(N)c3c(C#N)c(N4CCC[C@H]4C)n(C)c3n2)cnn1CC(C)(C)O";"IC50";"'='";"120.0";"nM";"6.92";"";"";"UO_0000065";"16.34";"0.30";"4.49";"5.17";"0";"CHEMBL5040116";"Inhibition of LRRK2-pSer935 in LRRK2 G2019S mutant expressing human HEK293 cells and measured after 48 hrs by ICW assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 48.0 hr";"INHIBITOR";""
"CHEMBL5188644";"";"None";"339.40";"0";"4.42";"31";"Cc1c(C#N)cccc1CNc1ccc2[nH]nc(-c3ccncc3)c2c1";"IC50";"'='";"82.0";"nM";"7.09";"";"";"UO_0000065";"20.88";"0.37";"2.67";"9.16";"0";"CHEMBL5157022";"Inhibition of full length wild type LRRK2 (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5194653";"";"None";"350.39";"0";"4.14";"13";"CN(c1ccc2[nH]nc(-c3ccncc3)c2c1)c1ccc(C#N)cc1C#N";"IC50";"'='";"163.0";"nM";"6.79";"";"";"UO_0000065";"19.37";"0.34";"2.65";"7.35";"0";"CHEMBL5157023";"Inhibition of full length LRRK2 G2019S mutant (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5182227";"";"None";"450.55";"0";"4.82";"35";"N#Cc1ccc2c(c1)CCC[C@H]2Nc1ccc2[nH]nc(-c3ccnc(N4CCOCC4)c3)c2c1";"IC50";"'='";"2.0";"nM";"8.70";"";"";"UO_0000065";"19.31";"0.35";"3.88";"9.68";"0";"CHEMBL5157023";"Inhibition of full length LRRK2 G2019S mutant (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5186450";"";"None";"357.33";"0";"4.20";"8";"N#Cc1ccc(Oc2ccc3[nH]nc(-c4ccncc4)c3c2)c([N+](=O)[O-])c1";"IC50";"'='";"10.0";"nM";"8.00";"";"";"UO_0000065";"22.39";"0.40";"3.80";"6.80";"0";"CHEMBL5157023";"Inhibition of full length LRRK2 G2019S mutant (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL226345";"ADENINE";"3.0";"135.13";"0";"-0.11";"adenine";"Nc1[nH]cnc2ncnc1-2";"IC50";"'='";"15809.0";"nM";"4.80";"";"";"UO_0000065";"35.53";"0.66";"4.91";"5.97";"0";"CHEMBL5040107";"Inhibition of recombinant human GST tagged truncated LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5070699";"";"None";"364.46";"0";"2.80";"30";"Cc1cn(C)nc1Nc1cc2c(c(N)n1)c(C#N)c(N1CCC[C@H]1C)n2C";"IC50";"'='";"1287.0";"nM";"5.89";"";"";"UO_0000065";"16.16";"0.30";"3.09";"5.85";"0";"CHEMBL5040107";"Inhibition of recombinant human GST tagged truncated LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5092087";"";"None";"421.51";"0";"2.62";"45";"Cc1c(Nc2nc(N)c3c(C#N)c(N4CCC[C@H]4C)n(C)c3n2)cnn1[C@H]1CCOC1";"IC50";"'='";"14.0";"nM";"7.85";"";"";"UO_0000065";"18.63";"0.35";"5.23";"6.39";"0";"CHEMBL5040107";"Inhibition of recombinant human GST tagged truncated LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5086513";"";"None";"256.31";"0";"1.41";"18";"C[C@@H]1CCCN1c1c(C#N)c2c(N)ncnc2n1C";"IC50";"'='";"15.0";"nM";"7.82";"";"";"UO_0000065";"30.53";"0.56";"6.41";"9.34";"0";"CHEMBL5040109";"Inhibition of recombinant human LRRK2 WT using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5089194";"";"None";"365.45";"0";"2.20";"31";"Cc1c(Nc2nc(N)c3c(C#N)c(N4CCC[C@H]4C)n(C)c3n2)cnn1C";"IC50";"'='";"260.0";"nM";"6.58";"";"";"UO_0000065";"18.02";"0.33";"4.39";"5.80";"0";"CHEMBL5040116";"Inhibition of LRRK2-pSer935 in LRRK2 G2019S mutant expressing human HEK293 cells and measured after 48 hrs by ICW assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 48.0 hr";"INHIBITOR";""
"CHEMBL5185136";"";"None";"404.50";"0";"4.07";"8";"Cc1ccc(S(N)(=O)=O)cc1-c1ccc(-c2c(-c3ccncc3)n[nH]c2C)cc1";"IC50";"'='";"72.7";"nM";"7.14";"";"";"UO_0000065";"17.65";"0.34";"3.07";"7.02";"0";"CHEMBL5136367";"Inhibition of full-length wild type LRRK2 (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5202841";"";"None";"489.60";"0";"3.91";"13";"Cc1c(-c2ccc(-c3c[nH]nc3-c3ccnc(N4CCOCC4)c3)cc2)ccc(S(N)(=O)=O)c1C";"IC50";"'='";"253.0";"nM";"6.60";"";"";"UO_0000065";"13.47";"0.26";"2.69";"5.78";"0";"CHEMBL5136367";"Inhibition of full-length wild type LRRK2 (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5177578";"";"None";"475.57";"0";"3.60";"19";"Cc1[nH]nc(-c2ccnc(N3CCOCC3)c2)c1-c1ccc(-c2cccc(S(N)(=O)=O)c2)cc1";"IC50";"'='";"8.1";"nM";"8.09";"";"";"UO_0000065";"17.01";"0.33";"4.49";"7.09";"0";"CHEMBL5136367";"Inhibition of full-length wild type LRRK2 (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5170423";"";"None";"415.48";"0";"3.63";"33";"Cc1[nH]nc(-c2ccncc2)c1-c1ccc(-c2cccc(S(N)(=O)=O)c2)c(C#N)c1";"IC50";"'='";"2580.0";"nM";"5.59";"";"";"UO_0000065";"13.45";"0.25";"1.96";"4.45";"0";"CHEMBL5136367";"Inhibition of full-length wild type LRRK2 (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5191932";"";"None";"446.58";"0";"5.00";"11";"Cc1cc(-c2n[nH]c(C)c2-c2ccc(-c3ccc(S(N)(=O)=O)c(C)c3C)cc2)cc(C)n1";"IC50";"'='";"76.2";"nM";"7.12";"";"";"UO_0000065";"15.94";"0.30";"2.12";"7.00";"0";"CHEMBL5136368";"Inhibition of full-length LRRK2 G2019S mutant (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5198788";"";"None";"403.51";"0";"4.83";"28";"Cc1cc(-c2c(-c3ccncc3)n[nH]c2C)ccc1-c1cccc(S(C)(=O)=O)c1";"IC50";"'='";"95.7";"nM";"7.02";"";"";"UO_0000065";"17.40";"0.33";"2.19";"9.27";"0";"CHEMBL5136368";"Inhibition of full-length LRRK2 G2019S mutant (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5187306";"";"None";"404.50";"0";"4.02";"31";"CCc1cc(-c2c[nH]nc2-c2ccncc2)ccc1-c1cccc(S(N)(=O)=O)c1";"IC50";"'='";"6.1";"nM";"8.21";"";"";"UO_0000065";"20.31";"0.39";"4.19";"8.07";"0";"CHEMBL5136368";"Inhibition of full-length LRRK2 G2019S mutant (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5199105";"";"None";"404.50";"0";"4.07";"14";"Cc1[nH]nc(-c2ccncc2)c1-c1ccc(-c2cccc(S(N)(=O)=O)c2C)cc1";"IC50";"'='";"222.0";"nM";"6.65";"";"";"UO_0000065";"16.45";"0.31";"2.58";"6.54";"0";"CHEMBL5136367";"Inhibition of full-length wild type LRRK2 (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5188336";"";"None";"390.47";"0";"3.76";"5";"Cc1ccc(S(N)(=O)=O)cc1-c1ccc(-c2c[nH]nc2-c2ccncc2)cc1";"IC50";"'='";"49.9";"nM";"7.30";"";"";"UO_0000065";"18.70";"0.36";"3.54";"7.18";"0";"CHEMBL5136368";"Inhibition of full-length LRRK2 G2019S mutant (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5196289";"";"None";"390.47";"0";"3.76";"7";"Cc1[nH]nc(-c2ccncc2)c1-c1ccc(-c2cccc(S(N)(=O)=O)c2)cc1";"IC50";"'='";"21.3";"nM";"7.67";"";"";"UO_0000065";"19.65";"0.37";"3.91";"7.54";"0";"CHEMBL5136368";"Inhibition of full-length LRRK2 G2019S mutant (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5185136";"";"None";"404.50";"0";"4.07";"8";"Cc1ccc(S(N)(=O)=O)cc1-c1ccc(-c2c(-c3ccncc3)n[nH]c2C)cc1";"IC50";"'='";"15.1";"nM";"7.82";"";"";"UO_0000065";"19.34";"0.37";"3.75";"7.69";"0";"CHEMBL5136368";"Inhibition of full-length LRRK2 G2019S mutant (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5197009";"";"None";"503.63";"1";"4.21";"12";"Cc1[nH]nc(-c2ccnc(N3CCOCC3)c2)c1-c1ccc(-c2ccc(S(N)(=O)=O)c(C)c2C)cc1";"IC50";"'='";"33.2";"nM";"7.48";"";"";"UO_0000065";"14.85";"0.28";"3.27";"6.55";"0";"CHEMBL5136368";"Inhibition of full-length LRRK2 G2019S mutant (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5177578";"";"None";"475.57";"0";"3.60";"19";"Cc1[nH]nc(-c2ccnc(N3CCOCC3)c2)c1-c1ccc(-c2cccc(S(N)(=O)=O)c2)cc1";"IC50";"'='";"1.1";"nM";"8.96";"";"";"UO_0000065";"18.84";"0.36";"5.36";"7.84";"0";"CHEMBL5136368";"Inhibition of full-length LRRK2 G2019S mutant (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5281154";"";"None";"486.54";"0";"2.37";"26";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4ccnc(N5CCOCC5)c4)c3c2)[C@@H](C)n2nnnc2N1C";"IC50";"'<'";"0.2";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5246745";"Inhibition of N-terminal GST-fused human wild type LRRK2 using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5287404";"";"None";"324.35";"0";"0.99";"36";"CC1=C(C(=O)Nc2ccn3cnc(C)c3c2)Cn2nnnc2N1C";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5246745";"Inhibition of N-terminal GST-fused human wild type LRRK2 using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"";""
"CHEMBL5271437";"";"None";"350.39";"0";"1.73";"43";"CC1=C(C(=O)Nc2ccc3c(N)nccc3c2)[C@@H](C)n2nnnc2N1C";"IC50";"'='";"581.0";"nM";"6.24";"";"";"UO_0000065";"17.80";"0.33";"4.51";"5.43";"0";"CHEMBL5246745";"Inhibition of N-terminal GST-fused human wild type LRRK2 using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5208974";"";"None";"406.49";"0";"3.05";"5";"Cc1cnc(N2C[C@@H](C)O[C@@H](C)C2)cc1NC(=O)c1cccc(-c2cnn(C)c2)n1";"IC50";"'='";"9.0";"nM";"8.05";"";"";"UO_0000065";"19.79";"0.37";"5.00";"9.45";"0";"CHEMBL5108135";"Inhibition of recombinant human GST20 tagged truncated LRRK2 G2019S mutant assessed as substrate phosphorylation preincubated for 15 mins followed by substrate addition and measured after 90 mins using fluorescein-labeled LRRK2tide as substrate in presence of ATP by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5107939";"1";"Scientific Literature";"RSC Med Chem";"2021";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL5169732";"";"None";"446.43";"0";"3.11";"10";"C[C@@H]1[C@H](O)CCN1c1cc(NC(=O)c2cccc(-c3cnn(C)c3)n2)c(C(F)(F)F)cn1";"IC50";"'='";"5.0";"nM";"8.30";"";"";"UO_0000065";"18.59";"0.35";"5.19";"8.63";"0";"CHEMBL5108135";"Inhibition of recombinant human GST20 tagged truncated LRRK2 G2019S mutant assessed as substrate phosphorylation preincubated for 15 mins followed by substrate addition and measured after 90 mins using fluorescein-labeled LRRK2tide as substrate in presence of ATP by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5107939";"1";"Scientific Literature";"RSC Med Chem";"2021";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL5187647";"";"None";"488.51";"0";"4.23";"20";"CCn1cc(-c2cccc(C(=O)Nc3cc(N4CC[C@@H](C(C)(C)O)C4)cnc3C(F)(F)F)n2)cn1";"IC50";"'='";"40.0";"nM";"7.40";"";"";"UO_0000065";"15.14";"0.29";"3.17";"7.69";"0";"CHEMBL5108135";"Inhibition of recombinant human GST20 tagged truncated LRRK2 G2019S mutant assessed as substrate phosphorylation preincubated for 15 mins followed by substrate addition and measured after 90 mins using fluorescein-labeled LRRK2tide as substrate in presence of ATP by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5107939";"1";"Scientific Literature";"RSC Med Chem";"2021";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL5286893";"";"None";"401.43";"0";"2.53";"25";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4ccncc4)c3c2)[C@@H](C)n2nnnc2N1C";"IC50";"'='";"14.7";"nM";"7.83";"";"";"UO_0000065";"19.51";"0.36";"5.30";"6.67";"0";"CHEMBL5246749";"Inhibition of human LRRK2 G2019S mutant expressed in HEK293 cells assessed as reduction in pSer935 phosphorylation incubated for 2 hrs by HTRF analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL5267301";"";"None";"324.35";"0";"1.22";"2";"CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)Cn2nnnc2N1C";"IC50";"'='";"121.0";"nM";"6.92";"";"";"UO_0000065";"21.33";"0.39";"5.70";"6.61";"0";"CHEMBL5246745";"Inhibition of N-terminal GST-fused human wild type LRRK2 using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5277004";"";"None";"367.37";"0";"0.96";"16";"CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)Cn2nnnc2N1C(=O)N(C)C";"IC50";"'='";"888.0";"nM";"6.05";"";"";"UO_0000065";"16.47";"0.31";"5.09";"4.84";"0";"CHEMBL5246745";"Inhibition of N-terminal GST-fused human wild type LRRK2 using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL4582595";"";"None";"423.79";"1";"6.33";"4";"O=C(Nc1cccc(Cl)c1)c1cc(C(F)(F)F)ccc1OCc1ccc(F)cc1";"IC50";"'='";"12.59";"nM";"7.90";"";"";"UO_0000065";"18.64";"0.37";"1.57";"20.61";"0";"CHEMBL4372253";"Inhibition of recombinant 6His-Tev-tagged LRRK2 (1326 to 2527) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-RLGRDKYKTLRQIRQGNTKQR-OH as substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs by TR-FRET assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"Sf9";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4371037";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"CHEMBL3308860";"";"";""
"CHEMBL5070497";"";"None";"527.38";"2";"5.37";"20";"FC1CN(C2CCOC2)CCC1c1cc2nc(Nc3cnn(C4CC4(F)F)c3Cl)ncc2cc1Cl";"IC50";"'<'";"0.6";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5044129";"Inhibition of recombinant N-terminal GST-fused LRRK2 G2109S mutant (970 to 2527 residues) (unknown origin) preincubated with enzyme for 15 mins followed by fluorescein-labeled LRRKtide peptide substrate and ATP addition for 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5042510";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL3393348";"";"None";"305.34";"0";"2.33";"PF-06447475";"N#Cc1cccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"84.0";"nM";"7.08";"";"";"UO_0000065";"23.17";"0.42";"4.75";"9.09";"0";"CHEMBL5043428";"Displacement of K5 tracer from full length C-terminal NanoLuc fused human LRRK2 expressed in HEK293T cells incubated for 2 hrs by NanoBRET assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293T";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5042489";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL5073900";"";"None";"351.42";"0";"2.19";"33";"Cc1n[nH]cc1Nc1nc(N)c2c(C#N)c(N3CCC[C@H]3C)n(C)c2n1";"IC50";"'='";"27.0";"nM";"7.57";"";"";"UO_0000065";"21.54";"0.40";"5.38";"6.08";"0";"CHEMBL5040107";"Inhibition of recombinant human GST tagged truncated LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5087055";"";"None";"421.51";"0";"2.62";"44";"Cc1c(Nc2nc(N)c3c(C#N)c(N4CCC[C@H]4C)n(C)c3n2)cnn1[C@@H]1CCOC1";"IC50";"'='";"80.0";"nM";"7.10";"";"";"UO_0000065";"16.84";"0.31";"4.48";"5.78";"0";"CHEMBL5040116";"Inhibition of LRRK2-pSer935 in LRRK2 G2019S mutant expressing human HEK293 cells and measured after 48 hrs by ICW assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 48.0 hr";"INHIBITOR";""
"CHEMBL5207757";"";"None";"432.55";"0";"4.69";"10";"Cc1cc(-c2n[nH]c(C)c2-c2ccc(-c3ccc(S(N)(=O)=O)c(C)c3C)cc2)ccn1";"IC50";"'='";"101.0";"nM";"7.00";"";"";"UO_0000065";"16.17";"0.31";"2.31";"6.88";"0";"CHEMBL5136368";"Inhibition of full-length LRRK2 G2019S mutant (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5199105";"";"None";"404.50";"0";"4.07";"14";"Cc1[nH]nc(-c2ccncc2)c1-c1ccc(-c2cccc(S(N)(=O)=O)c2C)cc1";"IC50";"'='";"61.4";"nM";"7.21";"";"";"UO_0000065";"17.83";"0.34";"3.14";"7.09";"0";"CHEMBL5136368";"Inhibition of full-length LRRK2 G2019S mutant (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5206036";"";"None";"419.32";"0";"4.17";"1.38";"CC1(O)CCN(c2cc3nc(Nc4cnn(C5CC5)c4Cl)ncc3cc2Cl)C1";"IC50";"'='";"0.169";"nM";"9.77";"";"";"UO_0000065";"23.30";"0.48";"5.60";"12.35";"0";"CHEMBL5135962";"Inhibition of GST-tagged truncated human LRRK2 G2019S mutant using fluorescein labeled LRRKtide peptide as substrate preincubated for 15 mins followed by substrate addition and measured after 90 mins in presence of ATP at Km concentration by TR-FRET Lanthascreen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131528";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL5274608";"";"None";"473.50";"1";"1.21";"5";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4cc(N5CCOCC5)ncn4)c3c2)Cn2nnnc2N1C";"IC50";"'='";"0.88";"nM";"9.06";"";"";"UO_0000065";"19.12";"0.35";"7.85";"6.34";"0";"CHEMBL5246745";"Inhibition of N-terminal GST-fused human wild type LRRK2 using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5278514";"";"None";"296.29";"0";"0.52";"12";"CN1C=C(C(=O)Nc2ccc3[nH]ncc3c2)Cn2nnnc21";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5246745";"Inhibition of N-terminal GST-fused human wild type LRRK2 using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"";""
"CHEMBL4786263";"";"None";"411.46";"0";"2.97";"9";"CCOc1cc(C(=O)N2CCOCC2)ccc1Nc1nc(OCC)c2cc[nH]c2n1";"IC50";"'='";"10.0";"nM";"8.00";"";"";"UO_0000065";"19.44";"0.36";"5.03";"7.87";"0";"CHEMBL4721243";"Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs in presence of ATP by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4715821";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2018";"None";"TIME = 2.5 hr";"INHIBITOR";""
"CHEMBL4784679";"";"None";"414.90";"0";"3.14";"5";"CCOc1nc(Nc2ccc(C(=O)N3CCN(C)CC3)cc2Cl)nc2[nH]ccc12";"IC50";"'='";"12.59";"nM";"7.90";"";"";"UO_0000065";"19.04";"0.37";"4.76";"9.15";"0";"CHEMBL4721243";"Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs in presence of ATP by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4715821";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2018";"None";"TIME = 2.5 hr";"INHIBITOR";""
"CHEMBL4746922";"";"None";"450.54";"0";"3.28";"20";"CCOc1nc(Nc2ccc(C(=O)N3CCC4(CC3)CN(C)C4)cc2OC)nc2[nH]ccc12";"IC50";"'='";"63.1";"nM";"7.20";"";"";"UO_0000065";"15.98";"0.30";"3.92";"7.53";"0";"CHEMBL4721244";"Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins by Alpha Screen assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4715821";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2018";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5201248";"";"None";"379.47";"1";"5.29";"38";"Cc1cc(-c2n[nH]c3ccc(N[C@@H]4CCCc5cc(C#N)ccc54)cc23)ccn1";"IC50";"'<'";"1.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5157023";"Inhibition of full length LRRK2 G2019S mutant (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5194735";"";"None";"450.55";"0";"4.82";"44";"N#Cc1ccc2c(c1)CCC[C@@H]2Nc1ccc2[nH]nc(-c3ccnc(N4CCOCC4)c3)c2c1";"IC50";"'<'";"1.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5157023";"Inhibition of full length LRRK2 G2019S mutant (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5184816";"";"None";"341.37";"0";"4.25";"16";"COc1ccc(Nc2ccc3[nH]nc(-c4ccncc4)c3c2)c(C#N)c1";"IC50";"'='";"7.0";"nM";"8.15";"";"";"UO_0000065";"23.89";"0.43";"3.90";"9.41";"0";"CHEMBL5157023";"Inhibition of full length LRRK2 G2019S mutant (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5209350";"";"None";"325.38";"0";"4.55";"21";"Cc1cccc(C#N)c1Nc1ccc2[nH]nc(-c3ccncc3)c2c1";"IC50";"'='";"8.0";"nM";"8.10";"";"";"UO_0000065";"24.88";"0.44";"3.55";"10.46";"0";"CHEMBL5157023";"Inhibition of full length LRRK2 G2019S mutant (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5206337";"";"None";"329.34";"0";"4.38";"24";"N#Cc1cccc(F)c1Nc1ccc2[nH]nc(-c3ccncc3)c2c1";"IC50";"'='";"2.0";"nM";"8.70";"";"";"UO_0000065";"26.41";"0.48";"4.32";"11.24";"0";"CHEMBL5157023";"Inhibition of full length LRRK2 G2019S mutant (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5200822";"";"None";"329.34";"0";"4.38";"25";"N#Cc1c(F)cccc1Nc1ccc2[nH]nc(-c3ccncc3)c2c1";"IC50";"'='";"5.0";"nM";"8.30";"";"";"UO_0000065";"25.21";"0.45";"3.92";"10.73";"0";"CHEMBL5157023";"Inhibition of full length LRRK2 G2019S mutant (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL3933899";"";"None";"329.37";"0";"3.28";"BDBM254939";"Cc1cncc(-c2cc(Nc3ccn(C)n3)nc3[nH]cc(C#N)c23)c1";"IC50";"'='";"37.0";"nM";"7.43";"";"443722";"UO_0000065";"22.56";"0.41";"4.15";"7.81";"0";"CHEMBL3889252";"Homogeneous Time Resolved-fluorescence Resonance Energy Transfer (TR-FRET) Assay: LRRK2 kinase activity is measured using a LanthaScreen kinase activity assay available from Invitrogen (Life Technologies Corporation). The assay is a homogeneous time resolved-fluorescence resonance energy transfer (TR-FRET) assay that measures phosphorylation of a fluorescein-labelled peptide substrate (fluorescein-LRRKtide, fluorescein-GAGRLGRDKYKTLRQIRQ) (SEQ ID NO 1) as a result of LRRK2 kinase activity. The phosphorylated peptide is recognized by a terbium-labelled phospho-specific anti-LRRKtide antibody and, subsequently, the phosphorylated LRRKtide can be quantified by the extent of TR-FRET between the terbium donor and fluorescein acceptor.The LRRK2 kinase is obtained from Invitrogen (Life Technologies Corporation) and comprises residues 970 to 2527 of the full length human wild-type LRRK2 kinase or a similar sequence with the G2019S mutation. As discussed above, this mutation increases the kinase activity relative to the wild-type. The kinase reactions are performed in a 20 uL volume in 384-well plates. The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT.Â  In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 uM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 uM fluorescein-LRRKtide. The reaction mixture (20 ul total volume) is incubated for 2 hours at 30° C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 ul). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 us) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 us. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 us time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3887011";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3919862";"";"None";"343.39";"0";"3.59";"BDBM254940";"Cc1cc(-c2cc(Nc3nn(C)cc3C)nc3[nH]cc(C#N)c23)ccn1";"IC50";"'='";"108.0";"nM";"6.97";"";"443723";"UO_0000065";"20.29";"0.37";"3.38";"7.32";"0";"CHEMBL3889252";"Homogeneous Time Resolved-fluorescence Resonance Energy Transfer (TR-FRET) Assay: LRRK2 kinase activity is measured using a LanthaScreen kinase activity assay available from Invitrogen (Life Technologies Corporation). The assay is a homogeneous time resolved-fluorescence resonance energy transfer (TR-FRET) assay that measures phosphorylation of a fluorescein-labelled peptide substrate (fluorescein-LRRKtide, fluorescein-GAGRLGRDKYKTLRQIRQ) (SEQ ID NO 1) as a result of LRRK2 kinase activity. The phosphorylated peptide is recognized by a terbium-labelled phospho-specific anti-LRRKtide antibody and, subsequently, the phosphorylated LRRKtide can be quantified by the extent of TR-FRET between the terbium donor and fluorescein acceptor.The LRRK2 kinase is obtained from Invitrogen (Life Technologies Corporation) and comprises residues 970 to 2527 of the full length human wild-type LRRK2 kinase or a similar sequence with the G2019S mutation. As discussed above, this mutation increases the kinase activity relative to the wild-type. The kinase reactions are performed in a 20 uL volume in 384-well plates. The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT.Â  In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 uM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 uM fluorescein-LRRKtide. The reaction mixture (20 ul total volume) is incubated for 2 hours at 30° C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 ul). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 us) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 us. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 us time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3887011";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL5187271";"";"None";"325.38";"0";"4.55";"29";"Cc1cc(-c2n[nH]c3ccc(Nc4ccccc4C#N)cc23)ccn1";"IC50";"'='";"5.0";"nM";"8.30";"";"";"UO_0000065";"25.51";"0.45";"3.75";"10.73";"0";"CHEMBL5157022";"Inhibition of full length wild type LRRK2 (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5285084";"";"None";"428.54";"0";"3.75";"23";"CC(C#N)(c1ccc2cnn(-c3cc(N4CC5(C(C)(C)O)CC4C5)ncn3)c2c1)C1CC1";"IC50";"'='";"300.0";"nM";"6.52";"";"";"UO_0000065";"15.22";"0.28";"2.77";"7.18";"0";"CHEMBL5239655";"Inhibition of GST20-tagged human LRRK2 G2019S mutant using LRRKtide peptide preincubated for 15 mins followed by substrate addition and measured after 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5236618";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL5267350";"";"None";"388.48";"0";"3.64";"7";"C[C@@H]1CN(c2cc(-c3n[nH]c4ccc(-c5cnn(C)c5)cc34)ccn2)C[C@H](C)O1";"IC50";"'='";"4.0";"nM";"8.40";"";"";"UO_0000065";"21.62";"0.40";"4.76";"11.69";"0";"CHEMBL5239656";"Inhibition of GST20-tagged LRRK2 in human SH-SY5Y cells assessed as reduction in pSer935 phosphorylation incubated for 90 mins by MSD assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5236618";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 1.5 hr";"INHIBITOR";""
"CHEMBL5290520";"";"None";"388.48";"0";"3.41";"8";"C[C@@H]1CN(c2cc(-c3ncn4ccc(-c5cnn(C)c5)cc34)ccn2)C[C@H](C)O1";"IC50";"'='";"22.0";"nM";"7.66";"";"";"UO_0000065";"19.71";"0.36";"4.25";"12.66";"0";"CHEMBL5239656";"Inhibition of GST20-tagged LRRK2 in human SH-SY5Y cells assessed as reduction in pSer935 phosphorylation incubated for 90 mins by MSD assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5236618";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 1.5 hr";"INHIBITOR";""
"CHEMBL5276498";"";"None";"388.48";"0";"3.43";"10";"C[C@@H]1CN(c2cc(-n3ncc4ccc(-c5cnn(C)c5)cc43)ccn2)C[C@H](C)O1";"IC50";"'='";"120.0";"nM";"6.92";"";"";"UO_0000065";"17.82";"0.33";"3.49";"11.35";"0";"CHEMBL5239656";"Inhibition of GST20-tagged LRRK2 in human SH-SY5Y cells assessed as reduction in pSer935 phosphorylation incubated for 90 mins by MSD assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5236618";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 1.5 hr";"INHIBITOR";""
"CHEMBL5289583";"";"None";"473.98";"0";"3.90";"Cpd 23.1";"C[C@@]1(N2CC[C@@H](c3cc4cc(NC(=O)C5CC56CC6)ncc4cc3Cl)[C@H](F)C2)COC[C@@H]1O";"IC50";"'='";"0.08128";"nM";"10.09";"";"";"UO_0000065";"21.29";"0.42";"6.19";"13.51";"0";"CHEMBL5252508";"Inhibition of GST20-tagged truncated human LRRK2 G2019S mutant using fluorescein labeled LRRKtide peptide as substrate by Lantha screen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5247684";"1";"Scientific Literature";"ACS Med Chem Lett";"2023";"None";"";"INHIBITOR";""
"CHEMBL5280373";"";"None";"414.47";"0";"3.31";"31; EB-42486";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4ccccc4)c3c2)C(C)(C)n2nnnc2N1C";"IC50";"'='";"1.7";"nM";"8.77";"";"";"UO_0000065";"21.16";"0.39";"5.46";"8.38";"0";"CHEMBL5246755";"Inhibition of human LRRK2 G2019S mutant expressed in HEK293 cells assessed as reduction in pS1292 phosphorylation incubated for 2 hrs by MSD analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL5270706";"";"None";"500.57";"1";"2.55";"30";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4ccnc(N5CCOCC5)c4)c3c2)C(C)(C)n2nnnc2N1C";"IC50";"'='";"473.0";"nM";"6.33";"";"";"UO_0000065";"12.64";"0.23";"3.78";"4.87";"0";"CHEMBL5246757";"Inhibition human wild type LRRK2 expressed in human HEK293 assessed as Rab10 substrate phosphorylation at Threonine 73 residue incubated for 2 hrs by immunoblotting analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL5289513";"";"None";"324.35";"0";"1.47";"21";"CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)[C@@H](C)n2nnnc2N1C";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL5246758";"Inhibition human LRRK2 G2019S mutant expressed in human HEK293 assessed as Rab10 substrate phosphorylation at Threonine 73 residue incubated for 2 hrs by immunoblotting analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 2.0 hr";"";""
"CHEMBL5270706";"";"None";"500.57";"1";"2.55";"30";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4ccnc(N5CCOCC5)c4)c3c2)C(C)(C)n2nnnc2N1C";"IC50";"'='";"4.7";"nM";"8.33";"";"";"UO_0000065";"16.64";"0.31";"5.78";"6.41";"0";"CHEMBL5246758";"Inhibition human LRRK2 G2019S mutant expressed in human HEK293 assessed as Rab10 substrate phosphorylation at Threonine 73 residue incubated for 2 hrs by immunoblotting analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL5200500";"";"None";"420.49";"0";"3.77";"21";"COc1cc(-c2n[nH]c(C)c2-c2ccc(-c3cccc(S(N)(=O)=O)c3)cc2)ccn1";"IC50";"'='";"196.0";"nM";"6.71";"";"";"UO_0000065";"15.95";"0.31";"2.94";"6.05";"0";"CHEMBL5136367";"Inhibition of full-length wild type LRRK2 (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5198175";"";"None";"404.50";"0";"4.07";"4";"Cc1c(-c2ccc(-c3c[nH]nc3-c3ccncc3)cc2)ccc(S(N)(=O)=O)c1C";"IC50";"'='";"57.1";"nM";"7.24";"";"";"UO_0000065";"17.91";"0.34";"3.17";"7.12";"0";"CHEMBL5136368";"Inhibition of full-length LRRK2 G2019S mutant (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5173029";"";"None";"461.55";"0";"3.29";"20";"NS(=O)(=O)c1cccc(-c2ccc(-c3c[nH]nc3-c3ccnc(N4CCOCC4)c3)cc2)c1";"IC50";"'='";"2.9";"nM";"8.54";"";"";"UO_0000065";"18.50";"0.35";"5.25";"7.48";"0";"CHEMBL5136368";"Inhibition of full-length LRRK2 G2019S mutant (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5200393";"";"None";"474.99";"0";"2.52";"10.12";"CCOC1CC1C(=O)Nc1cc2cc(N3CCN(C4(C)COCC4O)CC3)c(Cl)cc2cn1";"IC50";"'='";"0.08318";"nM";"10.08";"";"";"UO_0000065";"21.22";"0.42";"7.56";"11.56";"0";"CHEMBL5126024";"Inhibition of GST-tagged truncated human LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition measured after 90 mins in presence of ATP by TR-FRET based LanthaScreen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5120951";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL4098877";"MLi-2";"None";"379.46";"0";"3.56";"18; MLi-2";"C[C@@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@H](C)O1";"IC50";"'='";"0.5";"nM";"9.30";"";"";"UO_0000065";"24.51";"0.45";"5.74";"12.21";"1";"CHEMBL5121253";"Inhibition of LRRK2 (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5120751";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2022";"None";"";"INHIBITOR";""
"CHEMBL5169732";"";"None";"446.43";"0";"3.11";"10";"C[C@@H]1[C@H](O)CCN1c1cc(NC(=O)c2cccc(-c3cnn(C)c3)n2)c(C(F)(F)F)cn1";"IC50";"'='";"3.0";"nM";"8.52";"";"";"UO_0000065";"19.09";"0.36";"5.41";"8.86";"0";"CHEMBL5108136";"Inhibition of human LRRK2 G2019S mutant expressed in human SH-SY5Y cells assessed as inhibition of tetracycline induced LRRK2 phosphorylation at Ser935 residue incubated for 90 mins by MSD assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5107939";"1";"Scientific Literature";"RSC Med Chem";"2021";"None";"TIME = 1.5 hr";"INHIBITOR";""
"CHEMBL5197547";"";"None";"542.48";"1";"4.77";"23";"CC(C)(O)[C@@H]1CCN(c2cnc(C(F)(F)F)c(NC(=O)c3cccc(-c4cnn(CC(F)(F)F)c4)n3)c2)C1";"IC50";"'='";"10.0";"nM";"8.00";"";"";"UO_0000065";"14.75";"0.29";"3.23";"8.32";"0";"CHEMBL5108135";"Inhibition of recombinant human GST20 tagged truncated LRRK2 G2019S mutant assessed as substrate phosphorylation preincubated for 15 mins followed by substrate addition and measured after 90 mins using fluorescein-labeled LRRK2tide as substrate in presence of ATP by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5107939";"1";"Scientific Literature";"RSC Med Chem";"2021";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL5187531";"";"None";"460.46";"0";"3.76";"6";"C[C@@H]1CN(c2cc(NC(=O)c3cccc(-c4cnn(C)c4)n3)c(C(F)(F)F)cn2)C[C@H](C)O1";"IC50";"'='";"1.5";"nM";"8.82";"";"";"UO_0000065";"19.16";"0.37";"5.06";"10.36";"0";"CHEMBL5108136";"Inhibition of human LRRK2 G2019S mutant expressed in human SH-SY5Y cells assessed as inhibition of tetracycline induced LRRK2 phosphorylation at Ser935 residue incubated for 90 mins by MSD assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5107939";"1";"Scientific Literature";"RSC Med Chem";"2021";"None";"TIME = 1.5 hr";"INHIBITOR";""
"CHEMBL5187647";"";"None";"488.51";"0";"4.23";"20";"CCn1cc(-c2cccc(C(=O)Nc3cc(N4CC[C@@H](C(C)(C)O)C4)cnc3C(F)(F)F)n2)cn1";"IC50";"'='";"7.0";"nM";"8.15";"";"";"UO_0000065";"16.69";"0.32";"3.92";"8.48";"0";"CHEMBL5108136";"Inhibition of human LRRK2 G2019S mutant expressed in human SH-SY5Y cells assessed as inhibition of tetracycline induced LRRK2 phosphorylation at Ser935 residue incubated for 90 mins by MSD assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5107939";"1";"Scientific Literature";"RSC Med Chem";"2021";"None";"TIME = 1.5 hr";"INHIBITOR";""
"CHEMBL5092519";"";"None";"249.28";"0";"2.09";"12";"Cn1c(-c2ccccc2)c(C#N)c2c(N)ncnc21";"IC50";"'='";"483.0";"nM";"6.32";"";"";"UO_0000065";"25.34";"0.45";"4.23";"7.84";"0";"CHEMBL5040107";"Inhibition of recombinant human GST tagged truncated LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5091909";"";"None";"337.39";"0";"1.88";"27";"C[C@@H]1CCCN1c1c(C#N)c2c(N)nc(Nc3cn[nH]c3)nc2n1C";"IC50";"'='";"6.0";"nM";"8.22";"";"";"UO_0000065";"24.37";"0.45";"6.34";"6.61";"0";"CHEMBL5040107";"Inhibition of recombinant human GST tagged truncated LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5083563";"";"None";"365.45";"0";"2.20";"32";"Cc1nn(C)cc1Nc1nc(N)c2c(C#N)c(N3CCC[C@H]3C)n(C)c2n1";"IC50";"'='";"30.0";"nM";"7.52";"";"";"UO_0000065";"20.59";"0.38";"5.32";"6.62";"0";"CHEMBL5040107";"Inhibition of recombinant human GST tagged truncated LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5087055";"";"None";"421.51";"0";"2.62";"44";"Cc1c(Nc2nc(N)c3c(C#N)c(N4CCC[C@H]4C)n(C)c3n2)cnn1[C@@H]1CCOC1";"IC50";"'='";"12.0";"nM";"7.92";"";"";"UO_0000065";"18.79";"0.35";"5.30";"6.45";"0";"CHEMBL5040107";"Inhibition of recombinant human GST tagged truncated LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5092519";"";"None";"249.28";"0";"2.09";"12";"Cn1c(-c2ccccc2)c(C#N)c2c(N)ncnc21";"IC50";"'='";"1258.0";"nM";"5.90";"";"";"UO_0000065";"23.67";"0.42";"3.81";"7.33";"0";"CHEMBL5040109";"Inhibition of recombinant human LRRK2 WT using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5083394";"";"None";"256.31";"0";"1.41";"19";"C[C@H]1CCCN1c1c(C#N)c2c(N)ncnc2n1C";"IC50";"'='";"5663.0";"nM";"5.25";"";"";"UO_0000065";"20.47";"0.38";"3.84";"6.26";"0";"CHEMBL5040109";"Inhibition of recombinant human LRRK2 WT using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5074790";"";"None";"419.42";"0";"2.91";"35";"C[C@@H]1CCCN1c1c(C#N)c2c(N)nc(Nc3cn(C)nc3C(F)(F)F)nc2n1C";"IC50";"'='";"508.0";"nM";"6.29";"";"";"UO_0000065";"15.01";"0.29";"3.38";"5.54";"0";"CHEMBL5040109";"Inhibition of recombinant human LRRK2 WT using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5078540";"";"None";"407.48";"0";"2.23";"41";"Cc1c(Nc2nc(N)c3c(C#N)c(N4CCC[C@H]4C)n(C)c3n2)cnn1C1COC1";"IC50";"'='";"300.0";"nM";"6.52";"";"";"UO_0000065";"16.01";"0.30";"4.29";"5.31";"0";"CHEMBL5040117";"Inhibition of LRRK2-pSer935 in LRRK2 WT expressing human HEK293 cells and measured after 48 hrs by ICW assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 48.0 hr";"INHIBITOR";""
"CHEMBL5270706";"";"None";"500.57";"1";"2.55";"30";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4ccnc(N5CCOCC5)c4)c3c2)C(C)(C)n2nnnc2N1C";"IC50";"'='";"0.3";"nM";"9.52";"";"";"UO_0000065";"19.02";"0.35";"6.97";"7.33";"0";"CHEMBL5246745";"Inhibition of N-terminal GST-fused human wild type LRRK2 using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5287618";"";"None";"339.36";"0";"0.84";"42";"CC1=C(C(=O)Nc2ccc3c(c2)CNC3=O)[C@@H](C)n2nnnc2N1C";"IC50";"'='";"1700.0";"nM";"5.77";"";"";"UO_0000065";"17.00";"0.32";"4.93";"5.49";"0";"CHEMBL5246745";"Inhibition of N-terminal GST-fused human wild type LRRK2 using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5285310";"";"None";"326.39";"0";"1.71";"20";"CC1=C(C(=S)Nc2ccc3[nH]ncc3c2)Cn2nnnc2N1C";"IC50";"'='";"15.3";"nM";"7.82";"";"";"UO_0000065";"23.94";"0.46";"6.11";"8.93";"0";"CHEMBL5246746";"Inhibition of N-terminal GST-fused human LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5289260";"";"None";"338.38";"0";"1.65";"28";"CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(C)(C)n2nnnc2N1C";"IC50";"'='";"12.0";"nM";"7.92";"";"";"UO_0000065";"23.41";"0.43";"6.27";"7.57";"0";"CHEMBL5246746";"Inhibition of N-terminal GST-fused human LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5086506";"";"None";"437.51";"1";"1.42";"39";"Cc1c(Nc2nc(N)c3c(C#N)c(N4CCC[C@H]4C)n(C)c3n2)cnn1CC1(O)COC1";"IC50";"'='";"10.0";"nM";"8.00";"";"";"UO_0000065";"18.29";"0.34";"6.58";"5.59";"0";"CHEMBL5040107";"Inhibition of recombinant human GST tagged truncated LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5083940";"";"None";"242.29";"0";"1.02";"17";"Cn1c(N2CCCC2)c(C#N)c2c(N)ncnc21";"IC50";"'='";"1484.0";"nM";"5.83";"";"";"UO_0000065";"24.06";"0.44";"4.81";"6.96";"0";"CHEMBL5040109";"Inhibition of recombinant human LRRK2 WT using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5074790";"";"None";"419.42";"0";"2.91";"35";"C[C@@H]1CCCN1c1c(C#N)c2c(N)nc(Nc3cn(C)nc3C(F)(F)F)nc2n1C";"IC50";"'='";"460.0";"nM";"6.34";"";"";"UO_0000065";"15.11";"0.29";"3.43";"5.58";"0";"CHEMBL5040116";"Inhibition of LRRK2-pSer935 in LRRK2 G2019S mutant expressing human HEK293 cells and measured after 48 hrs by ICW assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 48.0 hr";"INHIBITOR";""
"CHEMBL5087055";"";"None";"421.51";"0";"2.62";"44";"Cc1c(Nc2nc(N)c3c(C#N)c(N4CCC[C@H]4C)n(C)c3n2)cnn1[C@@H]1CCOC1";"IC50";"'='";"180.0";"nM";"6.75";"";"";"UO_0000065";"16.00";"0.30";"4.12";"5.49";"0";"CHEMBL5040117";"Inhibition of LRRK2-pSer935 in LRRK2 WT expressing human HEK293 cells and measured after 48 hrs by ICW assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 48.0 hr";"INHIBITOR";""
"CHEMBL5279615";"";"None";"401.47";"0";"2.95";"14";"CC(C)(O)C12CC(C1)N(c1cc(-n3ncc4ccc(-c5ccn[nH]5)cc43)ncn1)C2";"IC50";"'='";"4.0";"nM";"8.40";"";"";"UO_0000065";"20.92";"0.38";"5.45";"8.77";"0";"CHEMBL5239655";"Inhibition of GST20-tagged human LRRK2 G2019S mutant using LRRKtide peptide preincubated for 15 mins followed by substrate addition and measured after 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5236618";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL5273196";"";"None";"481.00";"0";"3.79";"Cpd 3.8";"CC1(N2CCC(c3cc4cc(NC(=O)Cc5ccncc5)ncc4cc3Cl)CC2)COCC1O";"IC50";"'='";"0.08128";"nM";"10.09";"";"";"UO_0000065";"20.98";"0.41";"6.30";"11.52";"0";"CHEMBL5252508";"Inhibition of GST20-tagged truncated human LRRK2 G2019S mutant using fluorescein labeled LRRKtide peptide as substrate by Lantha screen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5247684";"1";"Scientific Literature";"ACS Med Chem Lett";"2023";"None";"";"INHIBITOR";""
"CHEMBL5276281";"";"None";"479.62";"0";"3.63";"Cpd 15.16";"Cc1cc2cnc(NC(=O)C3CC34CCOCC4)cc2cc1C1CCN(C2(C)COCC2O)CC1";"IC50";"'='";"0.08128";"nM";"10.09";"";"";"UO_0000065";"21.04";"0.39";"6.46";"12.02";"0";"CHEMBL5252508";"Inhibition of GST20-tagged truncated human LRRK2 G2019S mutant using fluorescein labeled LRRKtide peptide as substrate by Lantha screen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5247684";"1";"Scientific Literature";"ACS Med Chem Lett";"2023";"None";"";"INHIBITOR";""
"CHEMBL4114340";"";"None";"383.45";"0";"2.66";"BDBM239312";"COC[C@H](C)Oc1ccc2[nH]nc(-c3cc(N4CCO[C@H](C)C4)ncn3)c2c1";"IC50";"'='";"2.79";"nM";"8.55";"";"417781";"UO_0000065";"22.31";"0.42";"5.89";"10.02";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL3949412";"";"None";"413.41";"0";"3.80";"BDBM239366";"Cn1cc(-c2cc3c(-c4cc(N5CCCC(F)(F)C5)ncn4)n[nH]c3cc2F)cn1";"IC50";"'='";"23.4";"nM";"7.63";"";"417833";"UO_0000065";"18.46";"0.35";"3.83";"10.10";"0";"CHEMBL3888825";"LanthaScreen™ Assay (5 mM ATP): a) 400 nl of a 1:2.15 serial dilution of test compound(98 μM top assay concentration) is spotted via Labcyte Echo to certain wells in a 384 well black, untreated plate. Control wells contain 400 nl of either DMSO or 400 nl of a known inhibitor in DMSO. b) 10 μl of a 2.5 nM LRRK2(G2019S mutation, GST-LRRK2(amino acids 970-2527)) enzyme solution in 1× assay buffer(50 mM Tris pH 8.5, 10 mM MgCl2, 0.01% Brij-35, 1.0 mM EGTA, 2 mM DTT, 0.05 mM NaVO4) is added to all wells. c) A 30 minute room temperature incubation is followed by addition of 10 μl of 800 nM fluorescein labeled LRRKtide peptide substrate and 10 mM ATP solution in 1× assay buffer to all wells. d) After a 35 minute room temperature incubation, 20 μl of TR-FRET Dilution Buffer(Invitrogen PV3756B) containing 4 nM Tb-labeled anti-phospho LRRKtide antibody and 20 mM EDTA is added to all wells. e) Plates are incubated at room temperature for 1 hour and read on an Envision™ multi-mode plate reader with LanthaScreen™ settings. Results are analysed using Assay Data Analyzer.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886204";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL4450837";"";"None";"244.34";"0";"3.02";"36";"Cc1nn(C)c2ccnc(NC3CCCCC3)c12";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL4331900";"Inhibition of recombinant human GST-tagged LRRK2 G2019S mutant catalytic domain (970 to 2527 residues) expressed in baculovirus expression system by radiometric assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4330096";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"None";"";"";""
"CHEMBL4560589";"MLi-2-NC";"None";"393.49";"0";"3.58";"EUB0000706a";"C[C@@H]1CN(c2cc(-c3nn(C)c4ccc(OC5(C)CC5)cc34)ncn2)C[C@H](C)O1";"IC50";"'='";"6480.0";"nM";"5.19";"";"";"UO_0000065";"13.19";"0.24";"1.61";"7.95";"0";"CHEMBL5210420";"Affinity Biochemical interaction (Enzymatic assay) EUB0000706a LRRK2";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"Mode of action: Negative control for MLi-2 | Protein family: Protein Kinase | Recommended concentration = 100.0 nM";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5210307";"65";"Literature data from EUbOPEN Chemogenomic Library";"";"2023";"None";"Affinity Biochemical Source Knowledge: https://www.sgc-ffm.uni-frankfurt.de/#!detailedpotencydataview/MLi-2";"";""
"CHEMBL5091544";"";"None";"216.25";"0";"0.49";"15";"CN(C)c1c(C#N)c2c(N)ncnc2n1C";"IC50";"'='";"3764.0";"nM";"5.42";"";"";"UO_0000065";"25.08";"0.46";"4.93";"6.48";"0";"CHEMBL5040107";"Inhibition of recombinant human GST tagged truncated LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5080604";"";"None";"274.33";"0";"0.64";"22";"C[C@@H]1CCCN1c1c(C(N)=O)c2c(N)ncnc2n1C";"IC50";"'='";"2240.0";"nM";"5.65";"";"";"UO_0000065";"20.59";"0.39";"5.01";"5.48";"0";"CHEMBL5040107";"Inhibition of recombinant human GST tagged truncated LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5075978";"";"None";"351.42";"0";"1.89";"26";"C[C@@H]1CCCN1c1c(C#N)c2c(N)nc(Nc3cnn(C)c3)nc2n1C";"IC50";"'='";"5.0";"nM";"8.30";"";"";"UO_0000065";"23.62";"0.44";"6.41";"7.31";"0";"CHEMBL5040107";"Inhibition of recombinant human GST tagged truncated LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5080937";"";"None";"385.86";"0";"2.54";"34";"C[C@@H]1CCCN1c1c(C#N)c2c(N)nc(Nc3cn(C)nc3Cl)nc2n1C";"IC50";"'='";"190.0";"nM";"6.72";"";"";"UO_0000065";"17.42";"0.34";"4.18";"5.92";"0";"CHEMBL5040117";"Inhibition of LRRK2-pSer935 in LRRK2 WT expressing human HEK293 cells and measured after 48 hrs by ICW assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 48.0 hr";"INHIBITOR";""
"CHEMBL5086506";"";"None";"437.51";"1";"1.42";"39";"Cc1c(Nc2nc(N)c3c(C#N)c(N4CCC[C@H]4C)n(C)c3n2)cnn1CC1(O)COC1";"IC50";"'='";"220.0";"nM";"6.66";"";"";"UO_0000065";"15.22";"0.28";"5.24";"4.65";"0";"CHEMBL5040117";"Inhibition of LRRK2-pSer935 in LRRK2 WT expressing human HEK293 cells and measured after 48 hrs by ICW assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 48.0 hr";"INHIBITOR";""
"CHEMBL5083940";"";"None";"242.29";"0";"1.02";"17";"Cn1c(N2CCCC2)c(C#N)c2c(N)ncnc21";"IC50";"'='";"1909.0";"nM";"5.72";"";"";"UO_0000065";"23.60";"0.43";"4.70";"6.83";"0";"CHEMBL5040107";"Inhibition of recombinant human GST tagged truncated LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL4547658";"";"None";"446.55";"0";"4.13";"28";"COCCN1CCC(c2ccc(OCc3ccccc3)c(C(=O)Nc3ccnnc3)c2)CC1";"IC50";"'='";"63.1";"nM";"7.20";"";"";"UO_0000065";"16.12";"0.30";"3.07";"9.40";"0";"CHEMBL4372253";"Inhibition of recombinant 6His-Tev-tagged LRRK2 (1326 to 2527) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-RLGRDKYKTLRQIRQGNTKQR-OH as substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs by TR-FRET assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"Sf9";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4371037";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"CHEMBL3308860";"";"";""
"CHEMBL4483571";"";"None";"402.50";"0";"4.12";"27";"CN1CCC(c2ccc(OCc3ccccc3)c(C(=O)Nc3ccnnc3)c2)CC1";"IC50";"'='";"19.95";"nM";"7.70";"";"";"UO_0000065";"19.13";"0.35";"3.58";"11.43";"0";"CHEMBL4372253";"Inhibition of recombinant 6His-Tev-tagged LRRK2 (1326 to 2527) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-RLGRDKYKTLRQIRQGNTKQR-OH as substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs by TR-FRET assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"Sf9";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4371037";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"CHEMBL3308860";"";"";""
"CHEMBL4532879";"";"None";"415.50";"0";"3.06";"25";"CN1CC2(C1)CN(c1ccc(OCc3ccccc3)c(C(=O)Nc3ccnnc3)c1)C2";"IC50";"'='";"25.12";"nM";"7.60";"";"";"UO_0000065";"18.29";"0.33";"4.54";"10.77";"0";"CHEMBL4372253";"Inhibition of recombinant 6His-Tev-tagged LRRK2 (1326 to 2527) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-RLGRDKYKTLRQIRQGNTKQR-OH as substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs by TR-FRET assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"Sf9";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4371037";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"CHEMBL3308860";"";"";""
"CHEMBL4448579";"";"None";"447.54";"0";"3.08";"23";"COCCN1CCN(c2ccc(OCc3ccccc3)c(C(=O)Nc3ccnnc3)c2)CC1";"IC50";"'='";"19.95";"nM";"7.70";"";"";"UO_0000065";"17.21";"0.32";"4.62";"9.65";"0";"CHEMBL4372253";"Inhibition of recombinant 6His-Tev-tagged LRRK2 (1326 to 2527) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-RLGRDKYKTLRQIRQGNTKQR-OH as substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs by TR-FRET assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"Sf9";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4371037";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"CHEMBL3308860";"";"";""
"CHEMBL4536811";"";"None";"389.46";"0";"2.72";"21";"O=C(Nc1ccnnc1)c1cc(N2CCNCC2)ccc1OCc1ccccc1";"IC50";"'='";"15.85";"nM";"7.80";"";"";"UO_0000065";"20.03";"0.37";"5.08";"9.83";"0";"CHEMBL4372253";"Inhibition of recombinant 6His-Tev-tagged LRRK2 (1326 to 2527) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-RLGRDKYKTLRQIRQGNTKQR-OH as substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs by TR-FRET assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"Sf9";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4371037";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"CHEMBL3308860";"";"";""
"CHEMBL4576899";"";"None";"373.33";"0";"4.33";"8";"O=C(Nc1ccnnc1)c1cc(C(F)(F)F)ccc1OCc1ccccc1";"IC50";"'='";"15.85";"nM";"7.80";"";"";"UO_0000065";"20.89";"0.39";"3.47";"12.17";"0";"CHEMBL4372253";"Inhibition of recombinant 6His-Tev-tagged LRRK2 (1326 to 2527) (unknown origin) expressed in baculovirus infected Sf9 insect cells using biotin-RLGRDKYKTLRQIRQGNTKQR-OH as substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs by TR-FRET assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"Sf9";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4371037";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2019";"CHEMBL3308860";"";"";""
"CHEMBL5205763";"";"None";"328.40";"0";"2.72";"1";"Cn1cc(-c2nc(C(=O)Nc3cnn(C4CCC4)c3)cs2)cn1";"IC50";"'='";"271.0";"nM";"6.57";"";"";"UO_0000065";"20.00";"0.39";"3.85";"8.46";"0";"CHEMBL5108136";"Inhibition of human LRRK2 G2019S mutant expressed in human SH-SY5Y cells assessed as inhibition of tetracycline induced LRRK2 phosphorylation at Ser935 residue incubated for 90 mins by MSD assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5107939";"1";"Scientific Literature";"RSC Med Chem";"2021";"None";"TIME = 1.5 hr";"INHIBITOR";""
"CHEMBL5182935";"";"None";"474.49";"0";"3.75";"18";"Cn1cc(-c2cccc(C(=O)Nc3cc(N4CC[C@@H](C(C)(C)O)C4)cnc3C(F)(F)F)n2)cn1";"IC50";"'='";"21.0";"nM";"7.68";"";"";"UO_0000065";"16.18";"0.31";"3.93";"7.98";"0";"CHEMBL5108136";"Inhibition of human LRRK2 G2019S mutant expressed in human SH-SY5Y cells assessed as inhibition of tetracycline induced LRRK2 phosphorylation at Ser935 residue incubated for 90 mins by MSD assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5107939";"1";"Scientific Literature";"RSC Med Chem";"2021";"None";"TIME = 1.5 hr";"INHIBITOR";""
"CHEMBL5181104";"";"None";"514.55";"1";"4.62";"21";"CC(C)(O)[C@@H]1CCN(c2cnc(C(F)(F)F)c(NC(=O)c3cccc(-c4cnn(CC5CC5)c4)n3)c2)C1";"IC50";"'='";"0.4";"nM";"9.40";"";"";"UO_0000065";"18.26";"0.35";"4.78";"9.77";"0";"CHEMBL5108136";"Inhibition of human LRRK2 G2019S mutant expressed in human SH-SY5Y cells assessed as inhibition of tetracycline induced LRRK2 phosphorylation at Ser935 residue incubated for 90 mins by MSD assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5107939";"1";"Scientific Literature";"RSC Med Chem";"2021";"None";"TIME = 1.5 hr";"INHIBITOR";""
"CHEMBL5202237";"";"None";"325.38";"0";"4.11";"33";"N#Cc1ccc(CNc2ccc3[nH]nc(-c4ccncc4)c3c2)cc1";"IC50";"'='";"43.0";"nM";"7.37";"";"";"UO_0000065";"22.64";"0.40";"3.26";"9.52";"0";"CHEMBL5157022";"Inhibition of full length wild type LRRK2 (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5208819";"";"None";"395.47";"1";"5.05";"47";"Cc1cc(-c2n[nH]c3ccc(N[C@@H]4CCOc5cc(C#N)ccc54)cc23)cc(C)n1";"IC50";"'='";"42.0";"nM";"7.38";"";"";"UO_0000065";"18.65";"0.34";"2.33";"8.52";"0";"CHEMBL5157022";"Inhibition of full length wild type LRRK2 (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5280373";"";"None";"414.47";"0";"3.31";"31; EB-42486";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4ccccc4)c3c2)C(C)(C)n2nnnc2N1C";"IC50";"'='";"2092.0";"nM";"5.68";"";"";"UO_0000065";"13.70";"0.25";"2.37";"5.43";"0";"CHEMBL5246751";"Inhibition of human wild type LRRK2 expressed in HEK293 cells assessed as reduction in pSer935 phosphorylation incubated for 2 hrs by immunoblotting analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL5270706";"";"None";"500.57";"1";"2.55";"30";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4ccnc(N5CCOCC5)c4)c3c2)C(C)(C)n2nnnc2N1C";"IC50";"'='";"33.7";"nM";"7.47";"";"";"UO_0000065";"14.93";"0.28";"4.92";"5.75";"0";"CHEMBL5246754";"Inhibition of human wild type LRRK2 expressed in HEK293 cells assessed as reduction in pS1292 phosphorylation incubated for 2 hrs by MSD analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL4098877";"MLi-2";"None";"379.46";"0";"3.56";"1; Mli-2";"C[C@@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@H](C)O1";"IC50";"'='";"1.0";"nM";"9.00";"";"";"UO_0000065";"23.72";"0.44";"5.44";"11.82";"0";"CHEMBL5136367";"Inhibition of full-length wild type LRRK2 (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5198175";"";"None";"404.50";"0";"4.07";"4";"Cc1c(-c2ccc(-c3c[nH]nc3-c3ccncc3)cc2)ccc(S(N)(=O)=O)c1C";"IC50";"'='";"1730.0";"nM";"5.76";"";"";"UO_0000065";"14.24";"0.27";"1.69";"5.66";"0";"CHEMBL5136367";"Inhibition of full-length wild type LRRK2 (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5187306";"";"None";"404.50";"0";"4.02";"31";"CCc1cc(-c2c[nH]nc2-c2ccncc2)ccc1-c1cccc(S(N)(=O)=O)c1";"IC50";"'='";"67.0";"nM";"7.17";"";"";"UO_0000065";"17.74";"0.34";"3.15";"7.05";"0";"CHEMBL5136367";"Inhibition of full-length wild type LRRK2 (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5207639";"";"None";"426.45";"0";"4.04";"40";"Cc1[nH]nc(-c2ccncc2)c1-c1ccc(-c2cccc(S(N)(=O)=O)c2)c(F)c1F";"IC50";"'='";"89.4";"nM";"7.05";"";"";"UO_0000065";"16.53";"0.32";"3.01";"6.93";"0";"CHEMBL5136367";"Inhibition of full-length wild type LRRK2 (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5174552";"";"None";"325.38";"0";"4.55";"20";"Cc1ccc(Nc2ccc3[nH]nc(-c4ccncc4)c3c2)c(C#N)c1";"IC50";"'='";"6.0";"nM";"8.22";"";"";"UO_0000065";"25.27";"0.45";"3.67";"10.62";"0";"CHEMBL5157023";"Inhibition of full length LRRK2 G2019S mutant (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5282880";"";"None";"326.32";"0";"0.21";"38";"CC1=C(C(=O)Nc2ccc3[nH]c(=O)[nH]c3c2)Cn2nnnc2N1C";"IC50";"'>'";"8600.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5246745";"Inhibition of N-terminal GST-fused human wild type LRRK2 using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"";""
"CHEMBL5284086";"";"None";"325.33";"0";"0.53";"37";"CC1=C(C(=O)Nc2ccc3c(c2)CC(=O)N3)Cn2nnnc2N1C";"IC50";"'='";"6370.0";"nM";"5.20";"";"";"UO_0000065";"15.97";"0.30";"4.67";"4.95";"0";"CHEMBL5246746";"Inhibition of N-terminal GST-fused human LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5170359";"";"None";"350.39";"0";"4.42";"28";"Cc1cc(-c2n[nH]c3ccc(Nc4ccc(C#N)cc4C#N)cc23)ccn1";"IC50";"'='";"7.0";"nM";"8.15";"";"";"UO_0000065";"23.27";"0.41";"3.73";"8.06";"0";"CHEMBL5157022";"Inhibition of full length wild type LRRK2 (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5194735";"";"None";"450.55";"0";"4.82";"44";"N#Cc1ccc2c(c1)CCC[C@@H]2Nc1ccc2[nH]nc(-c3ccnc(N4CCOCC4)c3)c2c1";"IC50";"'='";"8.0";"nM";"8.10";"";"";"UO_0000065";"17.97";"0.33";"3.28";"9.01";"0";"CHEMBL5157022";"Inhibition of full length wild type LRRK2 (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5179734";"";"None";"331.34";"0";"4.28";"6";"O=[N+]([O-])c1ccccc1Nc1ccc2[nH]nc(-c3ccncc3)c2c1";"IC50";"'='";"4.0";"nM";"8.40";"";"";"UO_0000065";"25.35";"0.46";"4.12";"8.68";"0";"CHEMBL5157023";"Inhibition of full length LRRK2 G2019S mutant (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5182227";"";"None";"450.55";"0";"4.82";"35";"N#Cc1ccc2c(c1)CCC[C@H]2Nc1ccc2[nH]nc(-c3ccnc(N4CCOCC4)c3)c2c1";"IC50";"'='";"30.0";"nM";"7.52";"";"";"UO_0000065";"16.70";"0.30";"2.70";"8.37";"0";"CHEMBL5157022";"Inhibition of full length wild type LRRK2 (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5177346";"";"None";"379.47";"1";"5.29";"42";"Cc1cc(-c2n[nH]c3ccc(N[C@H]4CCCc5cc(C#N)ccc54)cc23)ccn1";"IC50";"'='";"8.0";"nM";"8.10";"";"";"UO_0000065";"21.34";"0.38";"2.81";"10.46";"0";"CHEMBL5157022";"Inhibition of full length wild type LRRK2 (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5173860";"";"None";"345.79";"0";"4.89";"10";"N#Cc1ccc(Nc2ccc3[nH]nc(-c4ccncc4)c3c2)c(Cl)c1";"IC50";"'='";"102.0";"nM";"6.99";"";"";"UO_0000065";"20.22";"0.38";"2.10";"9.03";"0";"CHEMBL5157023";"Inhibition of full length LRRK2 G2019S mutant (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5170359";"";"None";"350.39";"0";"4.42";"28";"Cc1cc(-c2n[nH]c3ccc(Nc4ccc(C#N)cc4C#N)cc23)ccn1";"IC50";"'='";"2.0";"nM";"8.70";"";"";"UO_0000065";"24.83";"0.44";"4.28";"8.60";"0";"CHEMBL5157023";"Inhibition of full length LRRK2 G2019S mutant (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5179942";"";"None";"351.41";"0";"4.60";"50";"N#Cc1ccc2c(c1)CCC2Nc1ccc2[nH]nc(-c3ccncc3)c2c1";"IC50";"'='";"5.0";"nM";"8.30";"";"";"UO_0000065";"23.62";"0.42";"3.70";"10.73";"0";"CHEMBL5157023";"Inhibition of full length LRRK2 G2019S mutant (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL4780229";"";"None";"411.46";"0";"2.97";"15";"CCOc1nc(Nc2ccc(C(=O)N3CCOC[C@@H]3C)cc2OC)nc2[nH]ccc12";"IC50";"'='";"100.0";"nM";"7.00";"";"";"UO_0000065";"17.01";"0.32";"4.03";"6.89";"0";"CHEMBL4721244";"Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins by Alpha Screen assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4715821";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2018";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5206958";"";"None";"341.37";"0";"4.25";"17";"COc1cccc(C#N)c1Nc1ccc2[nH]nc(-c3ccncc3)c2c1";"IC50";"'='";"156.0";"nM";"6.81";"";"";"UO_0000065";"19.94";"0.36";"2.56";"7.86";"0";"CHEMBL5157022";"Inhibition of full length wild type LRRK2 (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5207998";"";"None";"393.49";"1";"5.60";"43";"Cc1cc(-c2n[nH]c3ccc(N[C@H]4CCCc5cc(C#N)ccc54)cc23)cc(C)n1";"IC50";"'='";"11.0";"nM";"7.96";"";"";"UO_0000065";"20.23";"0.36";"2.36";"10.28";"0";"CHEMBL5157022";"Inhibition of full length wild type LRRK2 (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5172598";"";"None";"325.38";"0";"4.11";"30";"N#Cc1cccc(CNc2ccc3[nH]nc(-c4ccncc4)c3c2)c1";"IC50";"'='";"21.0";"nM";"7.68";"";"";"UO_0000065";"23.60";"0.42";"3.57";"9.92";"0";"CHEMBL5157023";"Inhibition of full length LRRK2 G2019S mutant (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5179131";"";"None";"367.41";"0";"4.43";"49";"N#Cc1ccc2c(c1)OCCC2Nc1ccc2[nH]nc(-c3ccncc3)c2c1";"IC50";"'='";"4.0";"nM";"8.40";"";"";"UO_0000065";"22.86";"0.41";"3.97";"9.70";"0";"CHEMBL5157023";"Inhibition of full length LRRK2 G2019S mutant (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5197009";"";"None";"503.63";"1";"4.21";"12";"Cc1[nH]nc(-c2ccnc(N3CCOCC3)c2)c1-c1ccc(-c2ccc(S(N)(=O)=O)c(C)c2C)cc1";"IC50";"'='";"188.0";"nM";"6.73";"";"";"UO_0000065";"13.35";"0.26";"2.52";"5.89";"0";"CHEMBL5136367";"Inhibition of full-length wild type LRRK2 (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5170238";"";"None";"418.52";"0";"4.32";"30";"CCc1cc(-c2c(-c3ccncc3)n[nH]c2C)ccc1-c1cccc(S(N)(=O)=O)c1";"IC50";"'='";"19.9";"nM";"7.70";"";"";"UO_0000065";"18.40";"0.35";"3.38";"7.57";"0";"CHEMBL5136367";"Inhibition of full-length wild type LRRK2 (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5170225";"";"None";"408.46";"0";"3.90";"35";"Cc1[nH]nc(-c2ccncc2)c1-c1ccc(-c2cccc(S(N)(=O)=O)c2)c(F)c1";"IC50";"'='";"66.0";"nM";"7.18";"";"";"UO_0000065";"17.58";"0.34";"3.28";"7.06";"0";"CHEMBL5136367";"Inhibition of full-length wild type LRRK2 (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5184765";"";"None";"418.52";"0";"4.38";"9";"Cc1[nH]nc(-c2ccncc2)c1-c1ccc(-c2ccc(S(N)(=O)=O)c(C)c2C)cc1";"IC50";"'='";"278.0";"nM";"6.56";"";"";"UO_0000065";"15.66";"0.30";"2.18";"6.44";"0";"CHEMBL5136368";"Inhibition of full-length LRRK2 G2019S mutant (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5185437";"";"None";"390.47";"0";"3.76";"17";"Cc1cc(-c2n[nH]cc2-c2ccc(-c3cccc(S(N)(=O)=O)c3)cc2)ccn1";"IC50";"'='";"6.2";"nM";"8.21";"";"";"UO_0000065";"21.02";"0.40";"4.45";"8.07";"0";"CHEMBL5136368";"Inhibition of full-length LRRK2 G2019S mutant (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5195211";"";"None";"418.52";"0";"4.32";"29";"CCc1cc(-c2c(-c3ccncc3)n[nH]c2C)ccc1-c1ccc(S(N)(=O)=O)cc1";"IC50";"'='";"130.0";"nM";"6.89";"";"";"UO_0000065";"16.45";"0.31";"2.57";"6.77";"0";"CHEMBL5136368";"Inhibition of full-length LRRK2 G2019S mutant (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5267690";"";"None";"414.51";"0";"3.36";"21";"C[C@H]1CC1(C#N)c1ccc2cnn(-c3cc(N4CC5(C(C)(C)O)CC4C5)ncn3)c2c1";"IC50";"'='";"2.0";"nM";"8.70";"";"";"UO_0000065";"20.99";"0.38";"5.34";"9.57";"0";"CHEMBL5239656";"Inhibition of GST20-tagged LRRK2 in human SH-SY5Y cells assessed as reduction in pSer935 phosphorylation incubated for 90 mins by MSD assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5236618";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 1.5 hr";"INHIBITOR";""
"CHEMBL5085753";"";"None";"727.91";"2";"5.95";"25";"CCc1cccc(CC)c1N1CCn2cc(-c3nc(Nc4ccc(N5CCC(C(=O)N6CC7(CN(C)C7)C6)CC5)cc4OC)nc4[nH]ccc34)cc2C1=O";"IC50";"'='";"342.0";"nM";"6.47";"";"";"UO_0000065";"8.88";"0.16";"0.52";"5.63";"0";"CHEMBL5037547";"Inhibition of LRRK2 (unknown origin) by ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5036336";"1";"Scientific Literature";"J Med Chem";"2021";"None";"";"INHIBITOR";""
"CHEMBL5190962";"";"None";"404.50";"0";"4.07";"24";"Cc1cc(-c2n[nH]cc2-c2ccc(-c3cccc(S(N)(=O)=O)c3)cc2)cc(C)n1";"IC50";"'='";"69.7";"nM";"7.16";"";"";"UO_0000065";"17.69";"0.34";"3.09";"7.04";"0";"CHEMBL5136367";"Inhibition of full-length wild type LRRK2 (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5198203";"";"None";"432.55";"0";"4.88";"38";"Cc1[nH]nc(-c2ccncc2)c1-c1ccc(-c2cccc(S(N)(=O)=O)c2)c(C(C)C)c1";"IC50";"'='";"51.4";"nM";"7.29";"";"";"UO_0000065";"16.85";"0.32";"2.41";"7.17";"0";"CHEMBL5136367";"Inhibition of full-length wild type LRRK2 (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5173076";"";"None";"418.52";"0";"4.38";"15";"Cc1cc(S(N)(=O)=O)cc(-c2ccc(-c3c(-c4ccncc4)n[nH]c3C)cc2)c1C";"IC50";"'='";"208.0";"nM";"6.68";"";"";"UO_0000065";"15.97";"0.30";"2.30";"6.57";"0";"CHEMBL5136368";"Inhibition of full-length LRRK2 G2019S mutant (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5198203";"";"None";"432.55";"0";"4.88";"38";"Cc1[nH]nc(-c2ccncc2)c1-c1ccc(-c2cccc(S(N)(=O)=O)c2)c(C(C)C)c1";"IC50";"'='";"14.5";"nM";"7.84";"";"";"UO_0000065";"18.12";"0.35";"2.96";"7.71";"0";"CHEMBL5136368";"Inhibition of full-length LRRK2 G2019S mutant (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5277441";"";"None";"354.37";"0";"0.78";"40";"CC1=C(C(=O)Nc2ccc3[nH]c(=O)n(C)c3c2)[C@@H](C)n2nnnc2N1C";"IC50";"'='";"58.0";"nM";"7.24";"";"";"UO_0000065";"20.42";"0.38";"6.46";"6.36";"0";"CHEMBL5246746";"Inhibition of N-terminal GST-fused human LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5277051";"";"None";"353.34";"0";"0.48";"41";"CC1=C(C(=O)Nc2ccc3c(c2)C(=O)NC3=O)[C@@H](C)n2nnnc2N1C";"IC50";"'='";"55.0";"nM";"7.26";"";"";"UO_0000065";"20.55";"0.38";"6.78";"5.95";"0";"CHEMBL5246746";"Inhibition of N-terminal GST-fused human LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5277668";"";"None";"472.51";"0";"1.81";"4";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4ccnc(N5CCOCC5)c4)c3c2)Cn2nnnc2N1C";"IC50";"'='";"8.3";"nM";"8.08";"";"";"UO_0000065";"17.10";"0.32";"6.27";"6.22";"0";"CHEMBL5246749";"Inhibition of human LRRK2 G2019S mutant expressed in HEK293 cells assessed as reduction in pSer935 phosphorylation incubated for 2 hrs by HTRF analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL5288427";"";"None";"426.44";"0";"2.46";"7";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4nc5ccccc5[nH]4)c3c2)Cn2nnnc2N1C";"IC50";"'='";"242.0";"nM";"6.62";"";"";"UO_0000065";"15.51";"0.28";"4.16";"4.96";"0";"CHEMBL5246754";"Inhibition of human wild type LRRK2 expressed in HEK293 cells assessed as reduction in pS1292 phosphorylation incubated for 2 hrs by MSD analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL5289513";"";"None";"324.35";"0";"1.47";"21";"CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)[C@@H](C)n2nnnc2N1C";"IC50";"'='";"104.0";"nM";"6.98";"";"";"UO_0000065";"21.53";"0.40";"5.51";"6.67";"0";"CHEMBL5246755";"Inhibition of human LRRK2 G2019S mutant expressed in HEK293 cells assessed as reduction in pS1292 phosphorylation incubated for 2 hrs by MSD analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL5277668";"";"None";"472.51";"0";"1.81";"4";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4ccnc(N5CCOCC5)c4)c3c2)Cn2nnnc2N1C";"IC50";"'='";"74.4";"nM";"7.13";"";"";"UO_0000065";"15.09";"0.28";"5.32";"5.48";"0";"CHEMBL5246754";"Inhibition of human wild type LRRK2 expressed in HEK293 cells assessed as reduction in pS1292 phosphorylation incubated for 2 hrs by MSD analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL5286893";"";"None";"401.43";"0";"2.53";"25";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4ccncc4)c3c2)[C@@H](C)n2nnnc2N1C";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL5246758";"Inhibition human LRRK2 G2019S mutant expressed in human HEK293 assessed as Rab10 substrate phosphorylation at Threonine 73 residue incubated for 2 hrs by immunoblotting analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 2.0 hr";"";""
"CHEMBL5290520";"";"None";"388.48";"0";"3.41";"8";"C[C@@H]1CN(c2cc(-c3ncn4ccc(-c5cnn(C)c5)cc34)ccn2)C[C@H](C)O1";"IC50";"'='";"3.0";"nM";"8.52";"";"";"UO_0000065";"21.94";"0.40";"5.11";"14.09";"0";"CHEMBL5239655";"Inhibition of GST20-tagged human LRRK2 G2019S mutant using LRRKtide peptide preincubated for 15 mins followed by substrate addition and measured after 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5236618";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL5276834";"";"None";"388.48";"0";"2.73";"12";"C[C@@H]1CN(c2cc(-n3ncc4ccc(-c5ccn[nH]5)cc43)ncn2)C[C@H](C)N1C";"IC50";"'='";"21.0";"nM";"7.68";"";"";"UO_0000065";"19.76";"0.36";"4.95";"9.75";"0";"CHEMBL5239655";"Inhibition of GST20-tagged human LRRK2 G2019S mutant using LRRKtide peptide preincubated for 15 mins followed by substrate addition and measured after 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5236618";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL5284341";"";"None";"426.52";"0";"3.50";"24";"CC(C)(O)C12CC(C1)N(c1cc(-n3ncc4ccc([C@]5(C#N)CC56CC6)cc43)ncn1)C2";"IC50";"'='";"0.7";"nM";"9.15";"";"";"UO_0000065";"21.46";"0.39";"5.65";"10.08";"0";"CHEMBL5239655";"Inhibition of GST20-tagged human LRRK2 G2019S mutant using LRRKtide peptide preincubated for 15 mins followed by substrate addition and measured after 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5236618";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL5268380";"";"None";"388.48";"0";"3.41";"9";"C[C@@H]1CN(c2cc(-c3ncc4ccc(-c5cnn(C)c5)cn34)ccn2)C[C@H](C)O1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5239656";"Inhibition of GST20-tagged LRRK2 in human SH-SY5Y cells assessed as reduction in pSer935 phosphorylation incubated for 90 mins by MSD assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5236618";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 1.5 hr";"";""
"CHEMBL5091819";"";"None";"423.53";"0";"2.43";"36";"Cc1nn(CC(C)(C)O)cc1Nc1nc(N)c2c(C#N)c(N3CCC[C@H]3C)n(C)c2n1";"IC50";"'='";"42.0";"nM";"7.38";"";"";"UO_0000065";"17.42";"0.32";"4.95";"5.51";"0";"CHEMBL5040107";"Inhibition of recombinant human GST tagged truncated LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5093192";"";"None";"285.26";"0";"2.37";"13";"Cn1c(-c2cccc(F)c2F)c(C#N)c2c(N)ncnc21";"IC50";"'='";"572.0";"nM";"6.24";"";"";"UO_0000065";"21.88";"0.41";"3.87";"7.75";"0";"CHEMBL5040109";"Inhibition of recombinant human LRRK2 WT using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5089194";"";"None";"365.45";"0";"2.20";"31";"Cc1c(Nc2nc(N)c3c(C#N)c(N4CCC[C@H]4C)n(C)c3n2)cnn1C";"IC50";"'='";"75.0";"nM";"7.12";"";"";"UO_0000065";"19.50";"0.36";"4.92";"6.27";"0";"CHEMBL5040109";"Inhibition of recombinant human LRRK2 WT using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5083563";"";"None";"365.45";"0";"2.20";"32";"Cc1nn(C)cc1Nc1nc(N)c2c(C#N)c(N3CCC[C@H]3C)n(C)c2n1";"IC50";"'='";"38.0";"nM";"7.42";"";"";"UO_0000065";"20.30";"0.38";"5.22";"6.53";"0";"CHEMBL5040109";"Inhibition of recombinant human LRRK2 WT using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5087055";"";"None";"421.51";"0";"2.62";"44";"Cc1c(Nc2nc(N)c3c(C#N)c(N4CCC[C@H]4C)n(C)c3n2)cnn1[C@@H]1CCOC1";"IC50";"'='";"20.0";"nM";"7.70";"";"";"UO_0000065";"18.27";"0.34";"5.08";"6.27";"0";"CHEMBL5040109";"Inhibition of recombinant human LRRK2 WT using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5075978";"";"None";"351.42";"0";"1.89";"26";"C[C@@H]1CCCN1c1c(C#N)c2c(N)nc(Nc3cnn(C)c3)nc2n1C";"IC50";"'='";"6.0";"nM";"8.22";"";"";"UO_0000065";"23.40";"0.43";"6.33";"7.24";"0";"CHEMBL5040109";"Inhibition of recombinant human LRRK2 WT using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5171090";"";"None";"361.41";"1";"5.39";"40";"N#Cc1ccc2c(Nc3ccc4[nH]nc(-c5ccncc5)c4c3)cccc2c1";"IC50";"'='";"527.0";"nM";"6.28";"";"";"UO_0000065";"17.37";"0.31";"0.89";"8.11";"0";"CHEMBL5157022";"Inhibition of full length wild type LRRK2 (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5169946";"";"None";"365.44";"0";"4.99";"41";"N#Cc1ccc2c(c1)CCC[C@@H]2Nc1ccc2[nH]nc(-c3ccncc3)c2c1";"IC50";"'='";"40.0";"nM";"7.40";"";"";"UO_0000065";"20.24";"0.36";"2.41";"9.56";"0";"CHEMBL5157022";"Inhibition of full length wild type LRRK2 (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5179131";"";"None";"367.41";"0";"4.43";"49";"N#Cc1ccc2c(c1)OCCC2Nc1ccc2[nH]nc(-c3ccncc3)c2c1";"IC50";"'='";"61.0";"nM";"7.21";"";"";"UO_0000065";"19.64";"0.35";"2.78";"8.33";"0";"CHEMBL5157022";"Inhibition of full length wild type LRRK2 (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5207998";"";"None";"393.49";"1";"5.60";"43";"Cc1cc(-c2n[nH]c3ccc(N[C@H]4CCCc5cc(C#N)ccc54)cc23)cc(C)n1";"IC50";"'<'";"1.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5157023";"Inhibition of full length LRRK2 G2019S mutant (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5182067";"";"None";"312.33";"0";"4.29";"15";"N#Cc1ccccc1Oc1ccc2[nH]nc(-c3ccncc3)c2c1";"IC50";"'='";"8.0";"nM";"8.10";"";"";"UO_0000065";"25.92";"0.46";"3.81";"10.86";"0";"CHEMBL5157023";"Inhibition of full length LRRK2 G2019S mutant (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5206767";"";"None";"395.47";"0";"4.99";"36";"COc1cc(-c2n[nH]c3ccc(N[C@@H]4CCCc5cc(C#N)ccc54)cc23)ccn1";"IC50";"'='";"51.0";"nM";"7.29";"";"";"UO_0000065";"18.44";"0.33";"2.30";"8.42";"0";"CHEMBL5157023";"Inhibition of full length LRRK2 G2019S mutant (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5070231";"";"None";"513.35";"1";"4.98";"19";"FC1CN(C2COC2)CCC1c1cc2nc(Nc3cnn(C4CC4(F)F)c3Cl)ncc2cc1Cl";"IC50";"'<'";"0.6";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5044129";"Inhibition of recombinant N-terminal GST-fused LRRK2 G2109S mutant (970 to 2527 residues) (unknown origin) preincubated with enzyme for 15 mins followed by fluorescein-labeled LRRKtide peptide substrate and ATP addition for 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5042510";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL5082260";"";"None";"501.34";"1";"4.67";"18";"FC(F)Cn1ncc(Nc2ncc3cc(Cl)c(C4CCN(C5COC5)CC4F)cc3n2)c1Cl";"IC50";"'<'";"0.6";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5044129";"Inhibition of recombinant N-terminal GST-fused LRRK2 G2109S mutant (970 to 2527 residues) (unknown origin) preincubated with enzyme for 15 mins followed by fluorescein-labeled LRRKtide peptide substrate and ATP addition for 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5042510";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL5073571";"";"None";"491.42";"0";"4.23";"15";"CC(C)(O)Cn1ncc(Nc2ncc3cc(Cl)c(C4CCN(C5COC5)CC4)cc3n2)c1Cl";"IC50";"'='";"0.8";"nM";"9.10";"";"";"UO_0000065";"18.51";"0.38";"4.87";"10.30";"0";"CHEMBL5044129";"Inhibition of recombinant N-terminal GST-fused LRRK2 G2109S mutant (970 to 2527 residues) (unknown origin) preincubated with enzyme for 15 mins followed by fluorescein-labeled LRRKtide peptide substrate and ATP addition for 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5042510";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL5091819";"";"None";"423.53";"0";"2.43";"36";"Cc1nn(CC(C)(C)O)cc1Nc1nc(N)c2c(C#N)c(N3CCC[C@H]3C)n(C)c2n1";"IC50";"'='";"49.0";"nM";"7.31";"";"";"UO_0000065";"17.26";"0.32";"4.88";"5.46";"0";"CHEMBL5040109";"Inhibition of recombinant human LRRK2 WT using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5286893";"";"None";"401.43";"0";"2.53";"25";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4ccncc4)c3c2)[C@@H](C)n2nnnc2N1C";"IC50";"'='";"272.0";"nM";"6.57";"";"";"UO_0000065";"16.36";"0.30";"4.04";"5.59";"0";"CHEMBL5246754";"Inhibition of human wild type LRRK2 expressed in HEK293 cells assessed as reduction in pS1292 phosphorylation incubated for 2 hrs by MSD analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL5286893";"";"None";"401.43";"0";"2.53";"25";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4ccncc4)c3c2)[C@@H](C)n2nnnc2N1C";"IC50";"'='";"12.1";"nM";"7.92";"";"";"UO_0000065";"19.72";"0.36";"5.39";"6.74";"0";"CHEMBL5246755";"Inhibition of human LRRK2 G2019S mutant expressed in HEK293 cells assessed as reduction in pS1292 phosphorylation incubated for 2 hrs by MSD analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL5281154";"";"None";"486.54";"0";"2.37";"26";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4ccnc(N5CCOCC5)c4)c3c2)[C@@H](C)n2nnnc2N1C";"IC50";"'='";"1.2";"nM";"8.92";"";"";"UO_0000065";"18.34";"0.34";"6.55";"6.86";"0";"CHEMBL5246755";"Inhibition of human LRRK2 G2019S mutant expressed in HEK293 cells assessed as reduction in pS1292 phosphorylation incubated for 2 hrs by MSD analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL5280373";"";"None";"414.47";"0";"3.31";"31; EB-42486";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4ccccc4)c3c2)C(C)(C)n2nnnc2N1C";"IC50";"'='";"3924.0";"nM";"5.41";"";"";"UO_0000065";"13.04";"0.24";"2.10";"5.17";"0";"CHEMBL5246757";"Inhibition human wild type LRRK2 expressed in human HEK293 assessed as Rab10 substrate phosphorylation at Threonine 73 residue incubated for 2 hrs by immunoblotting analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL5280373";"";"None";"414.47";"0";"3.31";"31; EB-42486";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4ccccc4)c3c2)C(C)(C)n2nnnc2N1C";"IC50";"'='";"11.4";"nM";"7.94";"";"";"UO_0000065";"19.16";"0.35";"4.63";"7.59";"0";"CHEMBL5246758";"Inhibition human LRRK2 G2019S mutant expressed in human HEK293 assessed as Rab10 substrate phosphorylation at Threonine 73 residue incubated for 2 hrs by immunoblotting analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL5074790";"";"None";"419.42";"0";"2.91";"35";"C[C@@H]1CCCN1c1c(C#N)c2c(N)nc(Nc3cn(C)nc3C(F)(F)F)nc2n1C";"IC50";"'='";"910.0";"nM";"6.04";"";"";"UO_0000065";"14.40";"0.28";"3.13";"5.32";"0";"CHEMBL5040117";"Inhibition of LRRK2-pSer935 in LRRK2 WT expressing human HEK293 cells and measured after 48 hrs by ICW assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 48.0 hr";"INHIBITOR";""
"CHEMBL5091819";"";"None";"423.53";"0";"2.43";"36";"Cc1nn(CC(C)(C)O)cc1Nc1nc(N)c2c(C#N)c(N3CCC[C@H]3C)n(C)c2n1";"IC50";"'='";"280.0";"nM";"6.55";"";"";"UO_0000065";"15.47";"0.29";"4.12";"4.90";"0";"CHEMBL5040117";"Inhibition of LRRK2-pSer935 in LRRK2 WT expressing human HEK293 cells and measured after 48 hrs by ICW assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 48.0 hr";"INHIBITOR";""
"CHEMBL5287618";"";"None";"339.36";"0";"0.84";"42";"CC1=C(C(=O)Nc2ccc3c(c2)CNC3=O)[C@@H](C)n2nnnc2N1C";"IC50";"'='";"32.0";"nM";"7.50";"";"";"UO_0000065";"22.09";"0.41";"6.65";"7.14";"0";"CHEMBL5246746";"Inhibition of N-terminal GST-fused human LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5288427";"";"None";"426.44";"0";"2.46";"7";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4nc5ccccc5[nH]4)c3c2)Cn2nnnc2N1C";"IC50";"'='";"3300.0";"nM";"5.48";"";"";"UO_0000065";"12.85";"0.23";"3.02";"4.11";"0";"CHEMBL5246748";"Inhibition of human wild type LRRK2 expressed in HEK293 cells assessed as reduction in pSer935 phosphorylation incubated for 2 hrs by HTRF analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL5270706";"";"None";"500.57";"1";"2.55";"30";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4ccnc(N5CCOCC5)c4)c3c2)C(C)(C)n2nnnc2N1C";"IC50";"'='";"145.0";"nM";"6.84";"";"";"UO_0000065";"13.66";"0.25";"4.29";"5.26";"0";"CHEMBL5246748";"Inhibition of human wild type LRRK2 expressed in HEK293 cells assessed as reduction in pSer935 phosphorylation incubated for 2 hrs by HTRF analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL5279816";"";"None";"338.38";"0";"1.78";"23";"CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)[C@@H](C)n2nnnc2N1C";"IC50";"'='";"46.1";"nM";"7.34";"";"";"UO_0000065";"21.68";"0.40";"5.56";"7.01";"0";"CHEMBL5246749";"Inhibition of human LRRK2 G2019S mutant expressed in HEK293 cells assessed as reduction in pSer935 phosphorylation incubated for 2 hrs by HTRF analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL5279816";"";"None";"338.38";"0";"1.78";"23";"CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)[C@@H](C)n2nnnc2N1C";"IC50";"'='";"8743.0";"nM";"5.06";"";"";"UO_0000065";"14.95";"0.28";"3.28";"4.83";"0";"CHEMBL5246751";"Inhibition of human wild type LRRK2 expressed in HEK293 cells assessed as reduction in pSer935 phosphorylation incubated for 2 hrs by immunoblotting analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL5266676";"";"None";"353.35";"0";"0.01";"9";"CC1=C(C(=O)Nc2ccc3[nH]nc(C(N)=O)c3c2)Cn2nnnc2N1C";"IC50";"'='";"125.0";"nM";"6.90";"";"";"UO_0000065";"19.54";"0.36";"6.89";"4.67";"0";"CHEMBL5246745";"Inhibition of N-terminal GST-fused human wild type LRRK2 using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5269009";"";"None";"409.45";"0";"0.61";"15";"CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)Cn2nnnc2N1CCN1CCOCC1";"IC50";"'='";"6130.0";"nM";"5.21";"";"";"UO_0000065";"12.73";"0.24";"4.60";"4.45";"0";"CHEMBL5246745";"Inhibition of N-terminal GST-fused human wild type LRRK2 using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5289675";"";"None";"486.54";"0";"2.37";"27";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4ccnc(N5CCOCC5)c4)c3c2)[C@H](C)n2nnnc2N1C";"IC50";"'='";"1.0";"nM";"9.00";"";"";"UO_0000065";"18.50";"0.34";"6.63";"6.92";"0";"CHEMBL5246745";"Inhibition of N-terminal GST-fused human wild type LRRK2 using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5280273";"";"None";"395.43";"0";"1.65";"11";"CCCC(=O)Nc1n[nH]c2ccc(NC(=O)C3=C(C)N(C)c4nnnn4C3)cc12";"IC50";"'='";"1190.0";"nM";"5.92";"";"";"UO_0000065";"14.98";"0.28";"4.27";"4.43";"0";"CHEMBL5246746";"Inhibition of N-terminal GST-fused human LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5182935";"";"None";"474.49";"0";"3.75";"18";"Cn1cc(-c2cccc(C(=O)Nc3cc(N4CC[C@@H](C(C)(C)O)C4)cnc3C(F)(F)F)n2)cn1";"IC50";"'='";"17.0";"nM";"7.77";"";"";"UO_0000065";"16.37";"0.31";"4.02";"8.08";"0";"CHEMBL5108135";"Inhibition of recombinant human GST20 tagged truncated LRRK2 G2019S mutant assessed as substrate phosphorylation preincubated for 15 mins followed by substrate addition and measured after 90 mins using fluorescein-labeled LRRK2tide as substrate in presence of ATP by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5107939";"1";"Scientific Literature";"RSC Med Chem";"2021";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL5286106";"";"None";"426.52";"0";"3.50";"25";"CC(C)(O)C12CC(C1)N(c1cc(-n3ncc4ccc([C@]5(C#N)CC56CC6)cc43)ncn1)C2";"IC50";"'='";"0.9";"nM";"9.05";"";"";"UO_0000065";"21.21";"0.39";"5.55";"9.96";"0";"CHEMBL5239655";"Inhibition of GST20-tagged human LRRK2 G2019S mutant using LRRKtide peptide preincubated for 15 mins followed by substrate addition and measured after 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5236618";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL5189805";"";"None";"341.37";"0";"4.25";"18";"COc1ccc(C#N)c(Nc2ccc3[nH]nc(-c4ccncc4)c3c2)c1";"IC50";"'='";"866.0";"nM";"6.06";"";"";"UO_0000065";"17.76";"0.32";"1.81";"7.00";"0";"CHEMBL5157022";"Inhibition of full length wild type LRRK2 (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5195812";"";"None";"329.34";"0";"4.38";"23";"N#Cc1ccc(F)cc1Nc1ccc2[nH]nc(-c3ccncc3)c2c1";"IC50";"'='";"163.0";"nM";"6.79";"";"";"UO_0000065";"20.61";"0.37";"2.41";"8.77";"0";"CHEMBL5157022";"Inhibition of full length wild type LRRK2 (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5176421";"";"None";"311.35";"0";"4.24";"12";"N#Cc1ccccc1Nc1ccc2[nH]nc(-c3ccncc3)c2c1";"IC50";"'='";"4.0";"nM";"8.40";"";"";"UO_0000065";"26.97";"0.48";"4.16";"10.85";"0";"CHEMBL5157023";"Inhibition of full length LRRK2 G2019S mutant (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5196967";"";"None";"341.37";"0";"4.25";"27";"COc1cc(-c2n[nH]c3ccc(Nc4ccccc4C#N)cc23)ccn1";"IC50";"'='";"3.0";"nM";"8.52";"";"";"UO_0000065";"24.97";"0.45";"4.27";"9.84";"0";"CHEMBL5157023";"Inhibition of full length LRRK2 G2019S mutant (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5207003";"";"None";"339.40";"0";"4.67";"32";"C[C@H](Nc1ccc2[nH]nc(-c3ccncc3)c2c1)c1cccc(C#N)c1";"IC50";"'='";"23.0";"nM";"7.64";"";"";"UO_0000065";"22.51";"0.40";"2.97";"9.87";"0";"CHEMBL5157023";"Inhibition of full length LRRK2 G2019S mutant (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5202237";"";"None";"325.38";"0";"4.11";"33";"N#Cc1ccc(CNc2ccc3[nH]nc(-c4ccncc4)c3c2)cc1";"IC50";"'='";"48.0";"nM";"7.32";"";"";"UO_0000065";"22.49";"0.40";"3.21";"9.46";"0";"CHEMBL5157023";"Inhibition of full length LRRK2 G2019S mutant (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5196195";"";"None";"433.44";"1";"6.00";"52";"N#Cc1ccc2c(c1)CCC[C@H]2Nc1cc2c(-c3ccncc3)n[nH]c2cc1C(F)(F)F";"IC50";"'='";"163.0";"nM";"6.79";"";"";"UO_0000065";"15.66";"0.29";"0.79";"8.77";"0";"CHEMBL5157023";"Inhibition of full length LRRK2 G2019S mutant (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5089152";"";"None";"421.51";"0";"2.62";"42";"Cc1nn(C2CCOC2)cc1Nc1nc(N)c2c(C#N)c(N3CCC[C@H]3C)n(C)c2n1";"IC50";"'='";"28.0";"nM";"7.55";"";"";"UO_0000065";"17.92";"0.33";"4.93";"6.15";"0";"CHEMBL5040107";"Inhibition of recombinant human GST tagged truncated LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5199239";"";"None";"420.49";"0";"3.77";"34";"COc1cc(-c2c(-c3ccncc3)n[nH]c2C)ccc1-c1cccc(S(N)(=O)=O)c1";"IC50";"'='";"141.0";"nM";"6.85";"";"";"UO_0000065";"16.29";"0.31";"3.08";"6.17";"0";"CHEMBL5136367";"Inhibition of full-length wild type LRRK2 (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5170238";"";"None";"418.52";"0";"4.32";"30";"CCc1cc(-c2c(-c3ccncc3)n[nH]c2C)ccc1-c1cccc(S(N)(=O)=O)c1";"IC50";"'='";"2.2";"nM";"8.66";"";"";"UO_0000065";"20.69";"0.39";"4.34";"8.51";"0";"CHEMBL5136368";"Inhibition of full-length LRRK2 G2019S mutant (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL4098877";"MLi-2";"None";"379.46";"0";"3.56";"1; Mli-2";"C[C@@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@H](C)O1";"IC50";"'='";"0.4";"nM";"9.40";"";"";"UO_0000065";"24.77";"0.46";"5.84";"12.34";"0";"CHEMBL5136368";"Inhibition of full-length LRRK2 G2019S mutant (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL388593";"";"None";"135.13";"0";"-0.06";"9";"Nc1ncnc2[nH]ncc12";"IC50";"'='";"26630.0";"nM";"4.58";"";"";"UO_0000065";"33.85";"0.62";"4.63";"5.68";"0";"CHEMBL5040107";"Inhibition of recombinant human GST tagged truncated LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5093192";"";"None";"285.26";"0";"2.37";"13";"Cn1c(-c2cccc(F)c2F)c(C#N)c2c(N)ncnc21";"IC50";"'='";"159.0";"nM";"6.80";"";"";"UO_0000065";"23.83";"0.44";"4.43";"8.44";"0";"CHEMBL5040107";"Inhibition of recombinant human GST tagged truncated LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5089194";"";"None";"365.45";"0";"2.20";"31";"Cc1c(Nc2nc(N)c3c(C#N)c(N4CCC[C@H]4C)n(C)c3n2)cnn1C";"IC50";"'='";"43.0";"nM";"7.37";"";"";"UO_0000065";"20.16";"0.37";"5.17";"6.48";"0";"CHEMBL5040107";"Inhibition of recombinant human GST tagged truncated LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5089152";"";"None";"421.51";"0";"2.62";"43";"Cc1nn(C2CCOC2)cc1Nc1nc(N)c2c(C#N)c(N3CCC[C@H]3C)n(C)c2n1";"IC50";"'='";"12.0";"nM";"7.92";"";"";"UO_0000065";"18.79";"0.35";"5.30";"6.45";"0";"CHEMBL5040107";"Inhibition of recombinant human GST tagged truncated LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5080937";"";"None";"385.86";"0";"2.54";"34";"C[C@@H]1CCCN1c1c(C#N)c2c(N)nc(Nc3cn(C)nc3Cl)nc2n1C";"IC50";"'='";"34.0";"nM";"7.47";"";"";"UO_0000065";"19.36";"0.38";"4.93";"6.57";"0";"CHEMBL5040109";"Inhibition of recombinant human LRRK2 WT using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5088551";"";"None";"423.53";"0";"2.43";"37";"Cc1c(Nc2nc(N)c3c(C#N)c(N4CCC[C@H]4C)n(C)c3n2)cnn1CC(C)(C)O";"IC50";"'='";"43.0";"nM";"7.37";"";"";"UO_0000065";"17.39";"0.32";"4.94";"5.50";"0";"CHEMBL5040109";"Inhibition of recombinant human LRRK2 WT using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5086506";"";"None";"437.51";"1";"1.42";"39";"Cc1c(Nc2nc(N)c3c(C#N)c(N4CCC[C@H]4C)n(C)c3n2)cnn1CC1(O)COC1";"IC50";"'='";"16.0";"nM";"7.80";"";"";"UO_0000065";"17.82";"0.33";"6.38";"5.45";"0";"CHEMBL5040109";"Inhibition of recombinant human LRRK2 WT using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5083563";"";"None";"365.45";"0";"2.20";"32";"Cc1nn(C)cc1Nc1nc(N)c2c(C#N)c(N3CCC[C@H]3C)n(C)c2n1";"IC50";"'='";"190.0";"nM";"6.72";"";"";"UO_0000065";"18.39";"0.34";"4.52";"5.92";"0";"CHEMBL5040117";"Inhibition of LRRK2-pSer935 in LRRK2 WT expressing human HEK293 cells and measured after 48 hrs by ICW assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 48.0 hr";"INHIBITOR";""
"CHEMBL5089152";"";"None";"421.51";"0";"2.62";"43";"Cc1nn(C2CCOC2)cc1Nc1nc(N)c2c(C#N)c(N3CCC[C@H]3C)n(C)c2n1";"IC50";"'='";"260.0";"nM";"6.58";"";"";"UO_0000065";"15.62";"0.29";"3.97";"5.36";"0";"CHEMBL5040117";"Inhibition of LRRK2-pSer935 in LRRK2 WT expressing human HEK293 cells and measured after 48 hrs by ICW assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 48.0 hr";"INHIBITOR";""
"CHEMBL5267301";"";"None";"324.35";"0";"1.22";"2";"CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)Cn2nnnc2N1C";"IC50";"'='";"10.0";"nM";"8.00";"";"";"UO_0000065";"24.66";"0.46";"6.78";"7.65";"0";"CHEMBL5246746";"Inhibition of N-terminal GST-fused human LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5174552";"";"None";"325.38";"0";"4.55";"20";"Cc1ccc(Nc2ccc3[nH]nc(-c4ccncc4)c3c2)c(C#N)c1";"IC50";"'='";"18.0";"nM";"7.75";"";"";"UO_0000065";"23.80";"0.42";"3.19";"10.01";"0";"CHEMBL5157022";"Inhibition of full length wild type LRRK2 (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5209350";"";"None";"325.38";"0";"4.55";"21";"Cc1cccc(C#N)c1Nc1ccc2[nH]nc(-c3ccncc3)c2c1";"IC50";"'='";"25.0";"nM";"7.60";"";"";"UO_0000065";"23.36";"0.42";"3.05";"9.82";"0";"CHEMBL5157022";"Inhibition of full length wild type LRRK2 (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5192191";"";"None";"329.34";"0";"4.38";"26";"N#Cc1cc(F)ccc1Nc1ccc2[nH]nc(-c3ccncc3)c2c1";"IC50";"'='";"56.0";"nM";"7.25";"";"";"UO_0000065";"22.02";"0.40";"2.87";"9.37";"0";"CHEMBL5157022";"Inhibition of full length wild type LRRK2 (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5198050";"";"None";"311.35";"0";"4.24";"5";"N#Cc1ccc(Nc2ccc3[nH]nc(-c4ccncc4)c3c2)cc1";"IC50";"'='";"57.0";"nM";"7.24";"";"";"UO_0000065";"23.27";"0.41";"3.00";"9.36";"0";"CHEMBL5157022";"Inhibition of full length wild type LRRK2 (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5200012";"";"None";"356.35";"0";"4.15";"7";"N#Cc1cccc([N+](=O)[O-])c1Nc1ccc2[nH]nc(-c3ccncc3)c2c1";"IC50";"'='";"118.0";"nM";"6.93";"";"";"UO_0000065";"19.44";"0.35";"2.78";"5.75";"0";"CHEMBL5157022";"Inhibition of full length wild type LRRK2 (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5279036";"";"None";"387.41";"0";"1.97";"3";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4ccncc4)c3c2)Cn2nnnc2N1C";"IC50";"'='";"9.0";"nM";"8.05";"";"";"UO_0000065";"20.77";"0.38";"6.08";"6.85";"0";"CHEMBL5246745";"Inhibition of N-terminal GST-fused human wild type LRRK2 using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5271931";"";"None";"389.22";"0";"1.67";"8";"CC1=C(C(=O)Nc2ccc3[nH]nc(Br)c3c2)Cn2nnnc2N1C";"IC50";"'='";"96.0";"nM";"7.02";"";"";"UO_0000065";"18.03";"0.40";"5.35";"6.71";"0";"CHEMBL5246745";"Inhibition of N-terminal GST-fused human wild type LRRK2 using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5277441";"";"None";"354.37";"0";"0.78";"40";"CC1=C(C(=O)Nc2ccc3[nH]c(=O)n(C)c3c2)[C@@H](C)n2nnnc2N1C";"IC50";"'='";"2870.0";"nM";"5.54";"";"";"UO_0000065";"15.64";"0.29";"4.76";"4.87";"0";"CHEMBL5246745";"Inhibition of N-terminal GST-fused human wild type LRRK2 using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5286615";"";"None";"372.39";"0";"2.61";"17";"CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)Cn2nnnc2N1c1ccccc1";"IC50";"'='";"2.6";"nM";"8.59";"";"";"UO_0000065";"23.05";"0.42";"5.98";"8.21";"0";"CHEMBL5246746";"Inhibition of N-terminal GST-fused human LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5277180";"";"None";"324.35";"0";"1.47";"22";"CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)[C@H](C)n2nnnc2N1C";"IC50";"'='";"94.0";"nM";"7.03";"";"";"UO_0000065";"21.66";"0.40";"5.56";"6.72";"0";"CHEMBL5246746";"Inhibition of N-terminal GST-fused human LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5279816";"";"None";"338.38";"0";"1.78";"23";"CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)[C@@H](C)n2nnnc2N1C";"IC50";"'='";"0.82";"nM";"9.09";"";"";"UO_0000065";"26.85";"0.50";"7.31";"8.68";"0";"CHEMBL5246746";"Inhibition of N-terminal GST-fused human LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5286893";"";"None";"401.43";"0";"2.53";"25";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4ccncc4)c3c2)[C@@H](C)n2nnnc2N1C";"IC50";"'<'";"0.2";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5246746";"Inhibition of N-terminal GST-fused human LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5290973";"";"None";"310.32";"0";"0.91";"34";"CC1=C(C(=O)Nc2ccc3[nH]cnc3c2)Cn2nnnc2N1C";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5246746";"Inhibition of N-terminal GST-fused human LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"";""
"CHEMBL5279816";"";"None";"338.38";"0";"1.78";"23";"CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)[C@@H](C)n2nnnc2N1C";"IC50";"'='";"5220.0";"nM";"5.28";"";"";"UO_0000065";"15.61";"0.29";"3.50";"5.05";"0";"CHEMBL5246748";"Inhibition of human wild type LRRK2 expressed in HEK293 cells assessed as reduction in pSer935 phosphorylation incubated for 2 hrs by HTRF analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL5281154";"";"None";"486.54";"0";"2.37";"26";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4ccnc(N5CCOCC5)c4)c3c2)[C@@H](C)n2nnnc2N1C";"IC50";"'='";"2.4";"nM";"8.62";"";"";"UO_0000065";"17.72";"0.33";"6.25";"6.63";"0";"CHEMBL5246749";"Inhibition of human LRRK2 G2019S mutant expressed in HEK293 cells assessed as reduction in pSer935 phosphorylation incubated for 2 hrs by HTRF analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL5280373";"";"None";"414.47";"0";"3.31";"31; EB-42486";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4ccccc4)c3c2)C(C)(C)n2nnnc2N1C";"IC50";"'='";"3.1";"nM";"8.51";"";"";"UO_0000065";"20.53";"0.37";"5.20";"8.13";"0";"CHEMBL5246749";"Inhibition of human LRRK2 G2019S mutant expressed in HEK293 cells assessed as reduction in pSer935 phosphorylation incubated for 2 hrs by HTRF analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL5280373";"";"None";"414.47";"0";"3.31";"31; EB-42486";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4ccccc4)c3c2)C(C)(C)n2nnnc2N1C";"IC50";"'='";"2.5";"nM";"8.60";"";"";"UO_0000065";"20.75";"0.38";"5.29";"8.22";"0";"CHEMBL5246752";"Inhibition of human LRRK2 G2019S mutant expressed in HEK293 cells assessed as reduction in pSer935 phosphorylation incubated for 2 hrs by immunoblotting analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL5289513";"";"None";"324.35";"0";"1.47";"21";"CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)[C@@H](C)n2nnnc2N1C";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL5246757";"Inhibition human wild type LRRK2 expressed in human HEK293 assessed as Rab10 substrate phosphorylation at Threonine 73 residue incubated for 2 hrs by immunoblotting analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 2.0 hr";"";""
"CHEMBL5279816";"";"None";"338.38";"0";"1.78";"23";"CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)[C@@H](C)n2nnnc2N1C";"IC50";"'='";"9736.0";"nM";"5.01";"";"";"UO_0000065";"14.81";"0.27";"3.23";"4.79";"0";"CHEMBL5246757";"Inhibition human wild type LRRK2 expressed in human HEK293 assessed as Rab10 substrate phosphorylation at Threonine 73 residue incubated for 2 hrs by immunoblotting analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL5281154";"";"None";"486.54";"0";"2.37";"26";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4ccnc(N5CCOCC5)c4)c3c2)[C@@H](C)n2nnnc2N1C";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"0";"CHEMBL5246758";"Inhibition human LRRK2 G2019S mutant expressed in human HEK293 assessed as Rab10 substrate phosphorylation at Threonine 73 residue incubated for 2 hrs by immunoblotting analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 2.0 hr";"";""
"CHEMBL4763199";"";"None";"411.94";"0";"4.18";"2.8";"Clc1cc2cnn(-c3cnn(C4CCC4)c3)c2cc1C1CCN(C2COC2)CC1";"IC50";"'='";"0.9";"nM";"9.05";"";"";"UO_0000065";"21.96";"0.43";"4.87";"18.80";"0";"CHEMBL4714711";"Inhibition of recombinant human GST tagged LRRK2 G2019S mutant catalytic domain (970 to 2527 residues) expressed in baculovirus expression system using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 90 mins by TR-FRET based Lanthascreen assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4706723";"1";"Scientific Literature";"ACS Med Chem Lett";"2021";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL3968143";"";"None";"406.49";"0";"2.57";"BDBM223570";"CC(C)n1cc(-c2cc(-c3ccc(CC(=O)N4CCOCC4)cc3)cnc2N)nn1";"IC50";"'='";"670.0";"nM";"6.17";"";"390855";"UO_0000065";"15.19";"0.28";"3.60";"6.23";"0";"CHEMBL3888346";"Kinase Activity Assay: The kinase reaction buffer consists of 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, and 2 mM DTT. In the assay, 1 nM LRRK2 WT or 250 pM LRRK2 G2019S kinase is incubated with the test compound (typically at 0 to 30 μM) for 30 minutes before the kinase reaction is initiated by addition of 1.3 mM ATP and 0.4 μM fluorescein-LRRKtide. The reaction mixture (20 μl total volume) is incubated for 2 hours at 30 °C. before the reaction is terminated by addition of 10 mM EDTA and 1 nM terbium-labelled anti-phospho-LRRKtide antibody (final volume 20 μl). The mixture is further incubated for 30 minutes at RT. TR-FRET is measured by excitation of the terbium-donor with 340 nm light and subsequent (delay time 100 μs) measurement of terbium and fluorescein emission at 495 nm and 520 nm, respectively, over a time window of 1000 μs. The measurement is repeated 10 times for fluorescein and 10 times for terbium emission with a 2000 μs time window between repeats. TR-FRET measurements are performed on a Biomek Synergy plate. The TR-FRET signal is calculated as the emission-ratio at 520 nm over 495 nm.";"B";"BAO_0000357";"single protein format";"None";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886669";"37";"BindingDB Database";"";"2016";"None";"";"";""
"CHEMBL5283143";"";"None";"511.03";"1";"3.09";"Cpd 20.2";"Cn1ncc(C2CC2C(=O)Nc2cc3cc(C4CCN(C5(C)COCC5O)CC4)c(Cl)cc3cn2)n1";"IC50";"'='";"0.08128";"nM";"10.09";"";"";"UO_0000065";"19.74";"0.38";"7.00";"9.57";"0";"CHEMBL5252508";"Inhibition of GST20-tagged truncated human LRRK2 G2019S mutant using fluorescein labeled LRRKtide peptide as substrate by Lantha screen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5247684";"1";"Scientific Literature";"ACS Med Chem Lett";"2023";"None";"";"INHIBITOR";""
"CHEMBL5266868";"";"None";"490.58";"0";"3.84";"Cpd 8.4";"CC1(N2CCC(c3cc4cc(NC(=O)C5CC5c5ccccn5)ncc4cc3F)CC2)COCC1O";"IC50";"'='";"0.08128";"nM";"10.09";"";"";"UO_0000065";"20.57";"0.38";"6.25";"11.52";"0";"CHEMBL5252508";"Inhibition of GST20-tagged truncated human LRRK2 G2019S mutant using fluorescein labeled LRRKtide peptide as substrate by Lantha screen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5247684";"1";"Scientific Literature";"ACS Med Chem Lett";"2023";"None";"";"INHIBITOR";""
"CHEMBL5276834";"";"None";"388.48";"0";"2.73";"12";"C[C@@H]1CN(c2cc(-n3ncc4ccc(-c5ccn[nH]5)cc43)ncn2)C[C@H](C)N1C";"IC50";"'='";"82.0";"nM";"7.09";"";"";"UO_0000065";"18.24";"0.33";"4.36";"9.00";"0";"CHEMBL5239656";"Inhibition of GST20-tagged LRRK2 in human SH-SY5Y cells assessed as reduction in pSer935 phosphorylation incubated for 90 mins by MSD assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5236618";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 1.5 hr";"INHIBITOR";""
"CHEMBL5183984";"";"None";"375.45";"0";"4.06";"6";"NS(=O)(=O)c1cccc(-c2ccc(-c3c[nH]nc3-c3ccccc3)cc2)c1";"IC50";"'='";"1270.0";"nM";"5.90";"";"";"UO_0000065";"15.70";"0.30";"1.84";"6.64";"0";"CHEMBL5136367";"Inhibition of full-length wild type LRRK2 (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5184765";"";"None";"418.52";"0";"4.38";"9";"Cc1[nH]nc(-c2ccncc2)c1-c1ccc(-c2ccc(S(N)(=O)=O)c(C)c2C)cc1";"IC50";"'='";"2450.0";"nM";"5.61";"";"";"UO_0000065";"13.41";"0.26";"1.23";"5.52";"0";"CHEMBL5136367";"Inhibition of full-length wild type LRRK2 (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5204372";"";"None";"404.50";"0";"4.07";"16";"Cc1cc(-c2n[nH]c(C)c2-c2ccc(-c3cccc(S(N)(=O)=O)c3)cc2)ccn1";"IC50";"'='";"46.7";"nM";"7.33";"";"";"UO_0000065";"18.12";"0.35";"3.26";"7.21";"0";"CHEMBL5136367";"Inhibition of full-length wild type LRRK2 (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5185437";"";"None";"390.47";"0";"3.76";"17";"Cc1cc(-c2n[nH]cc2-c2ccc(-c3cccc(S(N)(=O)=O)c3)cc2)ccn1";"IC50";"'='";"77.6";"nM";"7.11";"";"";"UO_0000065";"18.21";"0.35";"3.35";"6.99";"0";"CHEMBL5136367";"Inhibition of full-length wild type LRRK2 (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5208171";"";"None";"444.44";"0";"4.47";"18";"NS(=O)(=O)c1cccc(-c2ccc(-c3c(-c4ccncc4)n[nH]c3C(F)(F)F)cc2)c1";"IC50";"'='";"2120.0";"nM";"5.67";"";"";"UO_0000065";"12.77";"0.25";"1.20";"5.58";"0";"CHEMBL5136367";"Inhibition of full-length wild type LRRK2 (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5179102";"";"None";"418.52";"0";"4.38";"23";"Cc1cc(-c2n[nH]c(C)c2-c2ccc(-c3cccc(S(N)(=O)=O)c3)cc2)cc(C)n1";"IC50";"'='";"4.0";"nM";"8.40";"";"";"UO_0000065";"20.07";"0.38";"4.02";"8.26";"0";"CHEMBL5136368";"Inhibition of full-length LRRK2 G2019S mutant (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5079796";"";"None";"545.37";"2";"5.32";"21";"FC1CN(C2COCC2F)CCC1c1cc2nc(Nc3cnn(C4CC4(F)F)c3Cl)ncc2cc1Cl";"IC50";"'<'";"0.6";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5044129";"Inhibition of recombinant N-terminal GST-fused LRRK2 G2109S mutant (970 to 2527 residues) (unknown origin) preincubated with enzyme for 15 mins followed by fluorescein-labeled LRRKtide peptide substrate and ATP addition for 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5042510";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL5086901";"";"None";"406.42";"0";"3.54";"3";"Cc1nn(CC(F)(F)F)cc1Nc1ncc(C2CC2)c(NCCc2c[nH]cn2)n1";"IC50";"'='";"89.0";"nM";"7.05";"";"";"UO_0000065";"17.35";"0.33";"3.51";"7.32";"0";"CHEMBL5046600";"Inhibition of recombinant human LRRK2 (970 to end residues) using RLGRDKYKTLRQIRQ as substrate incubated for 40 mins in presence of [gamma-33P-ATP] by radiometric scintillation assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5046221";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 0.6667 hr";"INHIBITOR";""
"CHEMBL5090739";"";"None";"459.38";"0";"4.79";"14";"Clc1cc2cnc(Nc3cnn(C4CC4)c3Cl)nc2cc1C1CCN(C2COC2)CC1";"IC50";"'<'";"0.6";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5044129";"Inhibition of recombinant N-terminal GST-fused LRRK2 G2109S mutant (970 to 2527 residues) (unknown origin) preincubated with enzyme for 15 mins followed by fluorescein-labeled LRRKtide peptide substrate and ATP addition for 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5042510";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL5207466";"";"None";"404.50";"0";"4.07";"26";"Cc1cc(-c2cccc(S(N)(=O)=O)c2)ccc1-c1c(-c2ccncc2)n[nH]c1C";"IC50";"'='";"261.0";"nM";"6.58";"";"";"UO_0000065";"16.28";"0.31";"2.51";"6.47";"0";"CHEMBL5136368";"Inhibition of full-length LRRK2 G2019S mutant (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5196263";"";"None";"323.36";"0";"2.05";"3";"Cn1cc(-c2nccc(C(=O)Nc3cnn(C4CCC4)c3)n2)cn1";"IC50";"'='";"953.0";"nM";"6.02";"";"";"UO_0000065";"18.62";"0.34";"3.97";"6.65";"0";"CHEMBL5108136";"Inhibition of human LRRK2 G2019S mutant expressed in human SH-SY5Y cells assessed as inhibition of tetracycline induced LRRK2 phosphorylation at Ser935 residue incubated for 90 mins by MSD assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5107939";"1";"Scientific Literature";"RSC Med Chem";"2021";"None";"TIME = 1.5 hr";"INHIBITOR";""
"CHEMBL5180782";"";"None";"474.49";"0";"3.75";"12";"Cn1cc(-c2cccc(C(=O)Nc3cc(N4CC[C@@H](C(C)(C)O)C4)ncc3C(F)(F)F)n2)cn1";"IC50";"'='";"2.5";"nM";"8.60";"";"";"UO_0000065";"18.13";"0.35";"4.85";"8.94";"0";"CHEMBL5108136";"Inhibition of human LRRK2 G2019S mutant expressed in human SH-SY5Y cells assessed as inhibition of tetracycline induced LRRK2 phosphorylation at Ser935 residue incubated for 90 mins by MSD assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5107939";"1";"Scientific Literature";"RSC Med Chem";"2021";"None";"TIME = 1.5 hr";"INHIBITOR";""
"CHEMBL5197339";"";"None";"514.55";"1";"4.93";"19";"CC(C)(O)[C@@H]1CCN(c2cnc(C(F)(F)F)c(NC(=O)c3cccc(-c4cnn(C5CCC5)c4)n3)c2)C1";"IC50";"'='";"1.3";"nM";"8.89";"";"";"UO_0000065";"17.27";"0.33";"3.96";"9.24";"0";"CHEMBL5108136";"Inhibition of human LRRK2 G2019S mutant expressed in human SH-SY5Y cells assessed as inhibition of tetracycline induced LRRK2 phosphorylation at Ser935 residue incubated for 90 mins by MSD assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5107939";"1";"Scientific Literature";"RSC Med Chem";"2021";"None";"TIME = 1.5 hr";"INHIBITOR";""
"CHEMBL5195441";"";"None";"476.41";"0";"4.10";"1.31";"CC(C)(O)CN1CCN(c2cc3nc(Nc4cnn(C5CC5)c4Cl)ncc3cc2Cl)CC1";"IC50";"'='";"0.07586";"nM";"10.12";"";"";"UO_0000065";"21.24";"0.43";"6.02";"12.29";"0";"CHEMBL5135962";"Inhibition of GST-tagged truncated human LRRK2 G2019S mutant using fluorescein labeled LRRKtide peptide as substrate preincubated for 15 mins followed by substrate addition and measured after 90 mins in presence of ATP at Km concentration by TR-FRET Lanthascreen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131528";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL5206966";"";"None";"372.34";"0";"3.24";"3";"N#Cc1ccc(Nc2ccc3[nH]c(=O)n(-c4ccncc4)c3c2)c([N+](=O)[O-])c1";"IC50";"'='";"10000.0";"nM";"5.00";"";"";"UO_0000065";"13.43";"0.24";"1.76";"3.86";"0";"CHEMBL5157022";"Inhibition of full length wild type LRRK2 (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5089345";"";"None";"188.19";"0";"0.00";"14";"Cn1c(N)c(C#N)c2c(N)ncnc21";"IC50";"'='";"8564.0";"nM";"5.07";"";"";"UO_0000065";"26.93";"0.49";"None";"4.76";"0";"CHEMBL5040107";"Inhibition of recombinant human GST tagged truncated LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5089834";"";"None";"271.33";"0";"0.99";"25";"C[C@@H]1CCCN1c1c(C#N)c2c(N)nc(N)nc2n1C";"IC50";"'='";"217.0";"nM";"6.66";"";"";"UO_0000065";"24.56";"0.46";"5.67";"6.07";"0";"CHEMBL5040107";"Inhibition of recombinant human GST tagged truncated LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5075824";"";"None";"407.48";"0";"2.23";"40";"Cc1nn(C2COC2)cc1Nc1nc(N)c2c(C#N)c(N3CCC[C@H]3C)n(C)c2n1";"IC50";"'='";"25.0";"nM";"7.60";"";"";"UO_0000065";"18.66";"0.35";"5.37";"6.19";"0";"CHEMBL5040107";"Inhibition of recombinant human GST tagged truncated LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5094138";"";"None";"374.45";"0";"3.79";"9";"Cc1c(Nc2ncc3ccc(C4(C#N)CC4)cc3n2)cnn1C1CCOCC1";"IC50";"'='";"0.7";"nM";"9.15";"";"";"UO_0000065";"24.45";"0.45";"5.36";"10.33";"0";"CHEMBL5044129";"Inhibition of recombinant N-terminal GST-fused LRRK2 G2109S mutant (970 to 2527 residues) (unknown origin) preincubated with enzyme for 15 mins followed by fluorescein-labeled LRRKtide peptide substrate and ATP addition for 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5042510";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL5173029";"";"None";"461.55";"0";"3.29";"20";"NS(=O)(=O)c1cccc(-c2ccc(-c3c[nH]nc3-c3ccnc(N4CCOCC4)c3)cc2)c1";"IC50";"'='";"26.9";"nM";"7.57";"";"";"UO_0000065";"16.40";"0.31";"4.28";"6.63";"0";"CHEMBL5136367";"Inhibition of full-length wild type LRRK2 (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5183984";"";"None";"375.45";"0";"4.06";"6";"NS(=O)(=O)c1cccc(-c2ccc(-c3c[nH]nc3-c3ccccc3)cc2)c1";"IC50";"'='";"114.0";"nM";"6.94";"";"";"UO_0000065";"18.49";"0.35";"2.88";"7.82";"0";"CHEMBL5136368";"Inhibition of full-length LRRK2 G2019S mutant (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5170423";"";"None";"415.48";"0";"3.63";"33";"Cc1[nH]nc(-c2ccncc2)c1-c1ccc(-c2cccc(S(N)(=O)=O)c2)c(C#N)c1";"IC50";"'='";"323.0";"nM";"6.49";"";"";"UO_0000065";"15.62";"0.30";"2.86";"5.17";"0";"CHEMBL5136368";"Inhibition of full-length LRRK2 G2019S mutant (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5279036";"";"None";"387.41";"0";"1.97";"3";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4ccncc4)c3c2)Cn2nnnc2N1C";"IC50";"'='";"0.44";"nM";"9.36";"";"";"UO_0000065";"24.15";"0.44";"7.39";"7.96";"0";"CHEMBL5246746";"Inhibition of N-terminal GST-fused human LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5283355";"";"None";"338.33";"0";"0.83";"18";"CC(=O)N1C(C)=C(C(=O)Nc2ccc3[nH]ncc3c2)Cn2nnnc21";"IC50";"'='";"513.0";"nM";"6.29";"";"";"UO_0000065";"18.59";"0.34";"5.46";"5.17";"0";"CHEMBL5246746";"Inhibition of N-terminal GST-fused human LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL3923604";"";"None";"298.32";"0";"2.60";"7";"Fc1cccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"246.0";"nM";"6.61";"";"";"UO_0000065";"22.15";"0.41";"4.01";"12.23";"0";"CHEMBL5043428";"Displacement of K5 tracer from full length C-terminal NanoLuc fused human LRRK2 expressed in HEK293T cells incubated for 2 hrs by NanoBRET assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293T";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5042489";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL5198808";"";"None";"367.41";"0";"4.43";"45";"N#Cc1ccc2c(c1)OCC[C@H]2Nc1ccc2[nH]nc(-c3ccncc3)c2c1";"IC50";"'='";"8.0";"nM";"8.10";"";"";"UO_0000065";"22.04";"0.39";"3.67";"9.35";"0";"CHEMBL5157023";"Inhibition of full length LRRK2 G2019S mutant (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5193770";"";"None";"383.43";"1";"5.13";"51";"N#Cc1ccc2c(c1)CCC[C@H]2Nc1cc2c(-c3ccncc3)n[nH]c2cc1F";"IC50";"'='";"17.0";"nM";"7.77";"";"";"UO_0000065";"20.26";"0.37";"2.64";"10.04";"0";"CHEMBL5157023";"Inhibition of full length LRRK2 G2019S mutant (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5204222";"";"None";"325.38";"0";"4.55";"22";"Cc1ccc(C#N)c(Nc2ccc3[nH]nc(-c4ccncc4)c3c2)c1";"IC50";"'='";"276.0";"nM";"6.56";"";"";"UO_0000065";"20.16";"0.36";"2.01";"8.48";"0";"CHEMBL5157022";"Inhibition of full length wild type LRRK2 (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5197876";"";"None";"368.44";"0";"4.32";"37";"Cn1cc(-c2n[nH]c3ccc(N[C@@H]4CCCc5cc(C#N)ccc54)cc23)cn1";"IC50";"'='";"69.0";"nM";"7.16";"";"";"UO_0000065";"19.44";"0.35";"2.84";"8.70";"0";"CHEMBL5157022";"Inhibition of full length wild type LRRK2 (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5171585";"";"None";"393.49";"1";"5.60";"39";"Cc1cc(-c2n[nH]c3ccc(N[C@@H]4CCCc5cc(C#N)ccc54)cc23)cc(C)n1";"IC50";"'='";"35.0";"nM";"7.46";"";"";"UO_0000065";"18.95";"0.34";"1.86";"9.63";"0";"CHEMBL5157022";"Inhibition of full length wild type LRRK2 (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5182980";"";"None";"356.35";"0";"4.15";"4";"N#Cc1ccc(Nc2ccc3[nH]nc(-c4ccncc4)c3c2)c([N+](=O)[O-])c1";"IC50";"'='";"6.2";"nM";"8.21";"";"";"UO_0000065";"23.03";"0.42";"4.06";"6.81";"0";"CHEMBL5157023";"Inhibition of full length LRRK2 G2019S mutant (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5200012";"";"None";"356.35";"0";"4.15";"7";"N#Cc1cccc([N+](=O)[O-])c1Nc1ccc2[nH]nc(-c3ccncc3)c2c1";"IC50";"'='";"54.0";"nM";"7.27";"";"";"UO_0000065";"20.39";"0.37";"3.12";"6.03";"0";"CHEMBL5157023";"Inhibition of full length LRRK2 G2019S mutant (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5169734";"";"None";"325.38";"0";"4.55";"19";"Cc1cccc(Nc2ccc3[nH]nc(-c4ccncc4)c3c2)c1C#N";"IC50";"'='";"8.0";"nM";"8.10";"";"";"UO_0000065";"24.88";"0.44";"3.55";"10.46";"0";"CHEMBL5157023";"Inhibition of full length LRRK2 G2019S mutant (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5197876";"";"None";"368.44";"0";"4.32";"37";"Cn1cc(-c2n[nH]c3ccc(N[C@@H]4CCCc5cc(C#N)ccc54)cc23)cn1";"IC50";"'='";"12.0";"nM";"7.92";"";"";"UO_0000065";"21.50";"0.39";"3.60";"9.62";"0";"CHEMBL5157023";"Inhibition of full length LRRK2 G2019S mutant (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL4747186";"";"None";"446.46";"0";"3.09";"12";"CCOc1nc(Nc2ccc(C(=O)N3CCN(C)CC3)cc2OC(F)F)nc2[nH]ccc12";"IC50";"'<'";"0.1585";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL4721243";"Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs in presence of ATP by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4715821";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2018";"None";"TIME = 2.5 hr";"";""
"CHEMBL4761952";"";"None";"350.30";"0";"2.77";"1";"NC(=O)c1ccc(Nc2nc(NCC(F)(F)F)c3cc[nH]c3n2)cc1";"IC50";"'='";"50.12";"nM";"7.30";"";"";"UO_0000065";"20.84";"0.40";"4.53";"6.71";"0";"CHEMBL4721244";"Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins by Alpha Screen assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4715821";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2018";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL4741733";"";"None";"399.45";"0";"2.61";"14";"CCOc1nc(Nc2ccc(C(=O)NCC(C)(C)O)cc2OC)nc2[nH]ccc12";"IC50";"'='";"125.89";"nM";"6.90";"";"";"UO_0000065";"17.27";"0.32";"4.29";"5.68";"0";"CHEMBL4721244";"Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins by Alpha Screen assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4715821";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2018";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL4749895";"";"None";"367.41";"0";"2.57";"2";"CCOc1nc(Nc2ccc(C(=O)N3CCOCC3)cc2)nc2[nH]ccc12";"IC50";"'='";"63.1";"nM";"7.20";"";"";"UO_0000065";"19.60";"0.36";"4.63";"7.79";"0";"CHEMBL4721244";"Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins by Alpha Screen assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4715821";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2018";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5184816";"";"None";"341.37";"0";"4.25";"16";"COc1ccc(Nc2ccc3[nH]nc(-c4ccncc4)c3c2)c(C#N)c1";"IC50";"'='";"22.0";"nM";"7.66";"";"";"UO_0000065";"22.43";"0.40";"3.41";"8.84";"0";"CHEMBL5157022";"Inhibition of full length wild type LRRK2 (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5201248";"";"None";"379.47";"1";"5.29";"38";"Cc1cc(-c2n[nH]c3ccc(N[C@@H]4CCCc5cc(C#N)ccc54)cc23)ccn1";"IC50";"'='";"14.0";"nM";"7.85";"";"";"UO_0000065";"20.70";"0.37";"2.56";"10.15";"0";"CHEMBL5157022";"Inhibition of full length wild type LRRK2 (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5186274";"";"None";"381.44";"0";"4.74";"46";"Cc1cc(-c2n[nH]c3ccc(N[C@@H]4CCOc5cc(C#N)ccc54)cc23)ccn1";"IC50";"'='";"29.0";"nM";"7.54";"";"";"UO_0000065";"19.76";"0.35";"2.80";"8.70";"0";"CHEMBL5157023";"Inhibition of full length LRRK2 G2019S mutant (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5072941";"";"None";"463.54";"0";"2.76";"15";"O=C1NCCCOc2ccc3[nH]nc(c3c2)-c2cc(cc(N3CCN(C4COC4)CC3)c2)CO1";"IC50";"'<'";"10.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5030411";"Inhibition of recombinant human LRRK2 using LRRKtide peptide and ATP as substrates incubated for 1 hrs by ADP-glo luminescent assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5029192";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5093238";"";"None";"344.40";"0";"2.74";"134";"O=C1NCCCOc2ccc3[nH]nc(c3c2)-c2csc(n2)CCO1";"IC50";"'<'";"10.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5030411";"Inhibition of recombinant human LRRK2 using LRRKtide peptide and ATP as substrates incubated for 1 hrs by ADP-glo luminescent assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5029192";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5279615";"";"None";"401.47";"0";"2.95";"14";"CC(C)(O)C12CC(C1)N(c1cc(-n3ncc4ccc(-c5ccn[nH]5)cc43)ncn1)C2";"IC50";"'='";"24.0";"nM";"7.62";"";"";"UO_0000065";"18.98";"0.35";"4.67";"7.96";"0";"CHEMBL5239717";"Inhibition of LRRK2 in human PBMCs assessed as reduction in Ser95 phosphorylation";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"PBMC";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5236618";"1";"Scientific Literature";"J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5194653";"";"None";"350.39";"0";"4.14";"13";"CN(c1ccc2[nH]nc(-c3ccncc3)c2c1)c1ccc(C#N)cc1C#N";"IC50";"'='";"346.0";"nM";"6.46";"";"";"UO_0000065";"18.44";"0.33";"2.32";"6.99";"0";"CHEMBL5157022";"Inhibition of full length wild type LRRK2 (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5205363";"";"None";"376.44";"0";"3.45";"3";"NS(=O)(=O)c1cccc(-c2ccc(-c3c[nH]nc3-c3ccncc3)cc2)c1";"IC50";"'='";"247.0";"nM";"6.61";"";"";"UO_0000065";"17.55";"0.33";"3.16";"6.49";"0";"CHEMBL5136367";"Inhibition of full-length wild type LRRK2 (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5179734";"";"None";"331.34";"0";"4.28";"6";"O=[N+]([O-])c1ccccc1Nc1ccc2[nH]nc(-c3ccncc3)c2c1";"IC50";"'='";"24.0";"nM";"7.62";"";"";"UO_0000065";"23.00";"0.42";"3.34";"7.88";"0";"CHEMBL5157022";"Inhibition of full length wild type LRRK2 (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5169393";"";"None";"336.36";"0";"4.11";"11";"N#Cc1ccc(Nc2ccc3[nH]nc(-c4ccncc4)c3c2)c(C#N)c1";"IC50";"'='";"34.0";"nM";"7.47";"";"";"UO_0000065";"22.20";"0.39";"3.36";"7.38";"0";"CHEMBL5157022";"Inhibition of full length wild type LRRK2 (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5176421";"";"None";"311.35";"0";"4.24";"12";"N#Cc1ccccc1Nc1ccc2[nH]nc(-c3ccncc3)c2c1";"IC50";"'='";"19.0";"nM";"7.72";"";"";"UO_0000065";"24.80";"0.44";"3.48";"9.98";"0";"CHEMBL5157022";"Inhibition of full length wild type LRRK2 (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5283649";"";"None";"530.46";"1";"4.65";"Cpd 1.50";"CC1(N2CCC(c3cc4cc(NC(=O)c5cnn(C6CC6)c5Cl)ncc4cc3Cl)CC2)COCC1O";"IC50";"'='";"0.08128";"nM";"10.09";"";"";"UO_0000065";"19.02";"0.38";"5.44";"10.91";"0";"CHEMBL5252508";"Inhibition of GST20-tagged truncated human LRRK2 G2019S mutant using fluorescein labeled LRRKtide peptide as substrate by Lantha screen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5247684";"1";"Scientific Literature";"ACS Med Chem Lett";"2023";"None";"";"INHIBITOR";""
"CHEMBL4868411";"";"None";"483.02";"0";"4.46";"2.26";"Cc1c(Nc2ncc3cc(Cl)c(C4CCN(C5(C)COC5)CC4)cc3n2)cnn1C1CCOC1";"IC50";"'<'";"0.631";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL4827623";"Inhibition of Kinase tracer 236 binding to GST-tagged truncated human LRRK2 G2019S (970 to 2527 residues) mutant using fluorescein labeled LRRKtide peptide as substrate preincubated for 15 mins followed by substrate addition measured after 90 mins in presence of ATP at Km concentration by TR-FRET Lanthascreen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4825716";"1";"Scientific Literature";"ACS Med Chem Lett";"2021";"None";"TIME = 1.75 hr";"";""
"CHEMBL3942417";"";"None";"294.36";"0";"2.77";"5";"Cc1cccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)c1";"IC50";"'='";"127.0";"nM";"6.90";"";"";"UO_0000065";"23.43";"0.43";"4.13";"12.76";"0";"CHEMBL5043428";"Displacement of K5 tracer from full length C-terminal NanoLuc fused human LRRK2 expressed in HEK293T cells incubated for 2 hrs by NanoBRET assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"HEK293T";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5042489";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 2.0 hr";"INHIBITOR";""
"CHEMBL5172416";"";"None";"582.55";"2";"5.55";"22";"CC(C)(O)[C@@H]1CCN(c2cnc(C(F)(F)F)c(NC(=O)c3cccc(-c4cnn(CC5(C(F)(F)F)CC5)c4)n3)c2)C1";"IC50";"'='";"8.0";"nM";"8.10";"";"";"UO_0000065";"13.90";"0.27";"2.55";"8.42";"0";"CHEMBL5108135";"Inhibition of recombinant human GST20 tagged truncated LRRK2 G2019S mutant assessed as substrate phosphorylation preincubated for 15 mins followed by substrate addition and measured after 90 mins using fluorescein-labeled LRRK2tide as substrate in presence of ATP by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5107939";"1";"Scientific Literature";"RSC Med Chem";"2021";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL5172416";"";"None";"582.55";"2";"5.55";"22";"CC(C)(O)[C@@H]1CCN(c2cnc(C(F)(F)F)c(NC(=O)c3cccc(-c4cnn(CC5(C(F)(F)F)CC5)c4)n3)c2)C1";"IC50";"'='";"0.3";"nM";"9.52";"";"";"UO_0000065";"16.35";"0.32";"3.97";"9.90";"0";"CHEMBL5108136";"Inhibition of human LRRK2 G2019S mutant expressed in human SH-SY5Y cells assessed as inhibition of tetracycline induced LRRK2 phosphorylation at Ser935 residue incubated for 90 mins by MSD assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"None";"None";"SH-SY5Y";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5107939";"1";"Scientific Literature";"RSC Med Chem";"2021";"None";"TIME = 1.5 hr";"INHIBITOR";""
"CHEMBL5284027";"";"None";"465.50";"0";"1.23";"6";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4ccc(S(N)(=O)=O)cc4)c3c2)Cn2nnnc2N1C";"IC50";"'<'";"0.2";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5246746";"Inhibition of N-terminal GST-fused human LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5278514";"";"None";"296.29";"0";"0.52";"12";"CN1C=C(C(=O)Nc2ccc3[nH]ncc3c2)Cn2nnnc21";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5246746";"Inhibition of N-terminal GST-fused human LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"";""
"CHEMBL5283711";"";"None";"324.35";"0";"1.30";"13";"CCC1=C(C(=O)Nc2ccc3[nH]ncc3c2)Cn2nnnc2N1C";"IC50";"'='";"244.0";"nM";"6.61";"";"";"UO_0000065";"20.39";"0.38";"5.31";"6.32";"0";"CHEMBL5246746";"Inhibition of N-terminal GST-fused human LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5082563";"";"None";"477.37";"0";"4.74";"17";"FC1CN(C2COC2)CCC1c1cc2nc(Nc3cnn(C4CC4)c3Cl)ncc2cc1Cl";"IC50";"'<'";"0.6";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5044129";"Inhibition of recombinant N-terminal GST-fused LRRK2 G2109S mutant (970 to 2527 residues) (unknown origin) preincubated with enzyme for 15 mins followed by fluorescein-labeled LRRKtide peptide substrate and ATP addition for 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5042510";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL5088471";"";"None";"420.90";"0";"4.52";"11";"N#CC1(c2ccc3cnc(Nc4cnn(C5CCOCC5)c4Cl)nc3c2)CC12CC2";"IC50";"'<'";"0.08";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5044129";"Inhibition of recombinant N-terminal GST-fused LRRK2 G2109S mutant (970 to 2527 residues) (unknown origin) preincubated with enzyme for 15 mins followed by fluorescein-labeled LRRKtide peptide substrate and ATP addition for 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5042510";"1";"Scientific Literature";"J Med Chem";"2022";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL5089152";"";"None";"421.51";"0";"2.62";"43";"Cc1nn(C2CCOC2)cc1Nc1nc(N)c2c(C#N)c(N3CCC[C@H]3C)n(C)c2n1";"IC50";"'='";"19.0";"nM";"7.72";"";"";"UO_0000065";"18.32";"0.34";"5.10";"6.29";"0";"CHEMBL5040109";"Inhibition of recombinant human LRRK2 WT using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL5073457";"";"None";"350.43";"0";"2.49";"29";"C[C@@H]1CCCN1c1c(C#N)c2c(N)nc(Nc3ccn(C)n3)cc2n1C";"IC50";"'='";"234.0";"nM";"6.63";"";"";"UO_0000065";"18.92";"0.35";"4.14";"6.58";"0";"CHEMBL5040109";"Inhibition of recombinant human LRRK2 WT using fluorescein-labeled LRRKtide as substrate in presence of ATP preincubated for 50 mins followed by anti-phospho-LRRKtide antibody addition and measured after 30 mins by TR-FRET based Lanthascreen kinase activity assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5038598";"1";"Scientific Literature";"J Med Chem";"2021";"None";"TIME = 1.333 hr";"INHIBITOR";""
"CHEMBL3590142";"";"None";"295.26";"0";"2.38";"2";"N#Cc1ccc(Nc2ccc3[nH]c(=O)[nH]c3c2)c([N+](=O)[O-])c1";"IC50";"'='";"3300.0";"nM";"5.48";"";"";"UO_0000065";"18.56";"0.34";"3.10";"4.30";"0";"CHEMBL5157022";"Inhibition of full length wild type LRRK2 (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5185049";"";"None";"337.34";"0";"4.16";"14";"N#Cc1ccc(Oc2ccc3[nH]nc(-c4ccncc4)c3c2)c(C#N)c1";"IC50";"'='";"38.0";"nM";"7.42";"";"";"UO_0000065";"22.00";"0.39";"3.26";"7.54";"0";"CHEMBL5157022";"Inhibition of full length wild type LRRK2 (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5200822";"";"None";"329.34";"0";"4.38";"25";"N#Cc1c(F)cccc1Nc1ccc2[nH]nc(-c3ccncc3)c2c1";"IC50";"'='";"22.0";"nM";"7.66";"";"";"UO_0000065";"23.25";"0.42";"3.28";"9.89";"0";"CHEMBL5157022";"Inhibition of full length wild type LRRK2 (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5277668";"";"None";"472.51";"0";"1.81";"4";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4ccnc(N5CCOCC5)c4)c3c2)Cn2nnnc2N1C";"IC50";"'<'";"0.2";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5246745";"Inhibition of N-terminal GST-fused human wild type LRRK2 using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5284027";"";"None";"465.50";"0";"1.23";"6";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4ccc(S(N)(=O)=O)cc4)c3c2)Cn2nnnc2N1C";"IC50";"'='";"0.7";"nM";"9.15";"";"";"UO_0000065";"19.67";"0.38";"7.92";"5.56";"0";"CHEMBL5246745";"Inhibition of N-terminal GST-fused human wild type LRRK2 using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5283355";"";"None";"338.33";"0";"0.83";"18";"CC(=O)N1C(C)=C(C(=O)Nc2ccc3[nH]ncc3c2)Cn2nnnc21";"IC50";"'='";"2540.0";"nM";"5.59";"";"";"UO_0000065";"16.54";"0.31";"4.77";"4.60";"0";"CHEMBL5246745";"Inhibition of N-terminal GST-fused human wild type LRRK2 using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5273281";"";"None";"324.35";"0";"0.94";"19";"CC1=C(C(=O)N(C)c2ccc3[nH]ncc3c2)Cn2nnnc2N1C";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5246746";"Inhibition of N-terminal GST-fused human LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"";""
"CHEMBL5270706";"";"None";"500.57";"1";"2.55";"30";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4ccnc(N5CCOCC5)c4)c3c2)C(C)(C)n2nnnc2N1C";"IC50";"'<'";"0.2";"nM";"";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5246746";"Inhibition of N-terminal GST-fused human LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5287404";"";"None";"324.35";"0";"0.99";"36";"CC1=C(C(=O)Nc2ccn3cnc(C)c3c2)Cn2nnnc2N1C";"IC50";"'='";"1350.0";"nM";"5.87";"";"";"UO_0000065";"18.10";"0.33";"4.88";"6.30";"0";"CHEMBL5246746";"Inhibition of N-terminal GST-fused human LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5207639";"";"None";"426.45";"0";"4.04";"40";"Cc1[nH]nc(-c2ccncc2)c1-c1ccc(-c2cccc(S(N)(=O)=O)c2)c(F)c1F";"IC50";"'='";"8.1";"nM";"8.09";"";"";"UO_0000065";"18.97";"0.37";"4.05";"7.95";"0";"CHEMBL5136368";"Inhibition of full-length LRRK2 G2019S mutant (unknown origin) using LRRKtide as substrate incubated for 1 hr in presence of ATP by TR-FRET based ADAPTA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131546";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.0 hr";"INHIBITOR";""
"CHEMBL5196967";"";"None";"341.37";"0";"4.25";"27";"COc1cc(-c2n[nH]c3ccc(Nc4ccccc4C#N)cc23)ccn1";"IC50";"'='";"21.0";"nM";"7.68";"";"";"UO_0000065";"22.49";"0.40";"3.43";"8.86";"0";"CHEMBL5157022";"Inhibition of full length wild type LRRK2 (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5201629";"";"None";"365.44";"0";"4.99";"34";"N#Cc1ccc2c(c1)CCC[C@H]2Nc1ccc2[nH]nc(-c3ccncc3)c2c1";"IC50";"'='";"115.0";"nM";"6.94";"";"";"UO_0000065";"18.99";"0.34";"1.95";"8.97";"0";"CHEMBL5157022";"Inhibition of full length wild type LRRK2 (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5274608";"";"None";"473.50";"1";"1.21";"5";"CC1=C(C(=O)Nc2ccc3[nH]nc(-c4cc(N5CCOCC5)ncn4)c3c2)Cn2nnnc2N1C";"IC50";"'='";"0.4";"nM";"9.40";"";"";"UO_0000065";"19.85";"0.37";"8.19";"6.58";"0";"CHEMBL5246746";"Inhibition of N-terminal GST-fused human LRRK2 G2019S mutant using fluorescein-labeled LRRKtide as substrate preincubated for 15 mins followed by substrate addition and measured after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5244270";"1";"Scientific Literature";"J Med Chem";"2020";"None";"TIME = 1.25 hr";"INHIBITOR";""
"CHEMBL5204653";"";"None";"442.91";"0";"4.23";"7.11";"Cc1c(Nc2ncc3cc(Cl)c(N4C(=O)OC[C@H]4C)cc3n2)cnn1C1CCOCC1";"IC50";"'='";"0.4508";"nM";"9.35";"";"";"UO_0000065";"21.10";"0.41";"5.12";"9.90";"0";"CHEMBL5135962";"Inhibition of GST-tagged truncated human LRRK2 G2019S mutant using fluorescein labeled LRRKtide peptide as substrate preincubated for 15 mins followed by substrate addition and measured after 90 mins in presence of ATP at Km concentration by TR-FRET Lanthascreen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5131528";"1";"Scientific Literature";"ACS Med Chem Lett";"2022";"None";"TIME = 1.75 hr";"INHIBITOR";""
"CHEMBL5172598";"";"None";"325.38";"0";"4.11";"30";"N#Cc1cccc(CNc2ccc3[nH]nc(-c4ccncc4)c3c2)c1";"IC50";"'='";"26.0";"nM";"7.58";"";"";"UO_0000065";"23.31";"0.41";"3.48";"9.80";"0";"CHEMBL5157022";"Inhibition of full length wild type LRRK2 (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5173860";"";"None";"345.79";"0";"4.89";"10";"N#Cc1ccc(Nc2ccc3[nH]nc(-c4ccncc4)c3c2)c(Cl)c1";"IC50";"'='";"227.0";"nM";"6.64";"";"";"UO_0000065";"19.21";"0.36";"1.75";"8.59";"0";"CHEMBL5157022";"Inhibition of full length wild type LRRK2 (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5189165";"";"None";"342.40";"0";"4.56";"48";"c1ccc2c(c1)OCCC2Nc1ccc2[nH]nc(-c3ccncc3)c2c1";"IC50";"'='";"154.0";"nM";"6.81";"";"";"UO_0000065";"19.90";"0.36";"2.25";"10.84";"0";"CHEMBL5157022";"Inhibition of full length wild type LRRK2 (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5169946";"";"None";"365.44";"0";"4.99";"41";"N#Cc1ccc2c(c1)CCC[C@@H]2Nc1ccc2[nH]nc(-c3ccncc3)c2c1";"IC50";"'='";"3.0";"nM";"8.52";"";"";"UO_0000065";"23.32";"0.42";"3.53";"11.01";"0";"CHEMBL5157023";"Inhibition of full length LRRK2 G2019S mutant (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5182980";"";"None";"356.35";"0";"4.15";"4";"N#Cc1ccc(Nc2ccc3[nH]nc(-c4ccncc4)c3c2)c([N+](=O)[O-])c1";"IC50";"'='";"23.0";"nM";"7.64";"";"";"UO_0000065";"21.43";"0.39";"3.49";"6.34";"0";"CHEMBL5157022";"Inhibition of full length wild type LRRK2 (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL4098877";"MLi-2";"None";"379.46";"0";"3.56";"EUB0000715";"C[C@@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@H](C)O1";"IC50";"";"3.5";"nM";"";"";"Active";"UO_0000065";"";"";"";"";"0";"CHEMBL4882639";"Cellular assay monitoring dephosphorylation of pSer935 LRRK2";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"Assay publication: PMID: 26407721 | Target protein type: LRRK2 G2019S SH-SY5Y human neuroblastoma cell line";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4507291";"54";"Donated Chemical Probes - SGC Frankfurt";"";"2021";"None";"";"";""
"CHEMBL4560589";"MLi-2-NC";"None";"393.49";"0";"3.58";"EUB0000706";"C[C@@H]1CN(c2cc(-c3nn(C)c4ccc(OC5(C)CC5)cc34)ncn2)C[C@H](C)O1";"IC50";"";"6480.0";"nM";"";"";"Not Active";"UO_0000065";"";"";"";"";"0";"CHEMBL4882637";"LRRK2 Biochemical Assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"Additional information: LanthaScreen | Assay publication: PMID: 26407721 | Target protein type: GST-tagged truncated human mutant G2019S LRRK2";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4507291";"54";"Donated Chemical Probes - SGC Frankfurt";"";"2021";"None";"";"";""
"CHEMBL4560589";"MLi-2-NC";"None";"393.49";"0";"3.58";"EUB0000706";"C[C@@H]1CN(c2cc(-c3nn(C)c4ccc(OC5(C)CC5)cc34)ncn2)C[C@H](C)O1";"IC50";"";"5439.0";"nM";"";"";"Not Active";"UO_0000065";"";"";"";"";"0";"CHEMBL4882641";"Cellular assay monitoring dephosphorylation of pSer935 LRRK2";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"Target protein type: LRRK2 G2019S SH-SY5Y human neuroblastoma cell line";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4507291";"54";"Donated Chemical Probes - SGC Frankfurt";"";"2021";"None";"";"";""
"CHEMBL5169734";"";"None";"325.38";"0";"4.55";"19";"Cc1cccc(Nc2ccc3[nH]nc(-c4ccncc4)c3c2)c1C#N";"IC50";"'='";"38.0";"nM";"7.42";"";"";"UO_0000065";"22.80";"0.41";"2.87";"9.59";"0";"CHEMBL5157022";"Inhibition of full length wild type LRRK2 (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5179942";"";"None";"351.41";"0";"4.60";"50";"N#Cc1ccc2c(c1)CCC2Nc1ccc2[nH]nc(-c3ccncc3)c2c1";"IC50";"'='";"40.0";"nM";"7.40";"";"";"UO_0000065";"21.05";"0.37";"2.80";"9.56";"0";"CHEMBL5157022";"Inhibition of full length wild type LRRK2 (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"";"";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5185049";"";"None";"337.34";"0";"4.16";"14";"N#Cc1ccc(Oc2ccc3[nH]nc(-c4ccncc4)c3c2)c(C#N)c1";"IC50";"'='";"48.0";"nM";"7.32";"";"";"UO_0000065";"21.70";"0.38";"3.16";"7.44";"0";"CHEMBL5157023";"Inhibition of full length LRRK2 G2019S mutant (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5189805";"";"None";"341.37";"0";"4.25";"18";"COc1ccc(C#N)c(Nc2ccc3[nH]nc(-c4ccncc4)c3c2)c1";"IC50";"'='";"371.0";"nM";"6.43";"";"";"UO_0000065";"18.84";"0.34";"2.18";"7.42";"0";"CHEMBL5157023";"Inhibition of full length LRRK2 G2019S mutant (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
"CHEMBL5189165";"";"None";"342.40";"0";"4.56";"48";"c1ccc2c(c1)OCCC2Nc1ccc2[nH]nc(-c3ccncc3)c2c1";"IC50";"'='";"42.0";"nM";"7.38";"";"";"UO_0000065";"21.54";"0.39";"2.82";"11.74";"0";"CHEMBL5157023";"Inhibition of full length LRRK2 G2019S mutant (unknown origin) by LRRKtide Adapta assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"None";"None";"None";"None";"";"Q5S007";"G2019S";"CHEMBL1075104";"Leucine-rich repeat serine/threonine-protein kinase 2";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL5154686";"1";"Scientific Literature";"Eur J Med Chem";"2022";"None";"";"INHIBITOR";""
